,id,ticker,title,category,content,date,provider,url,article_id
200583,422099,GILD,CDC Shipping Test Kits  Wisconsin Confirms Case  Virus Update,news," Bloomberg     The World Health Organization pushed back against suggestions of imminent breakthroughs in the development of vaccines or treatments for the coronavirus  U S  health officials began shipping kits that can test for the pathogen  and Wisconsin confirmed a 12th American case 
In China s Hubei province of 60 million people  where the outbreak is centered  scenes of chaos and despair are emerging as residents cope with the modern world s largest ever quarantine  U S  health officials are preparing for more evacuees from the region to arrive at American military bases 
Key Developments 
China death toll at 490  24 324 confirmed cases  3 219 severeStranded on ships  passengers play with balloons  singDespite global fears  the virus is still concentrated mostly in HubeiFoxconn cuts outlook  will quarantine workers  may hit Apple outputMore than 7 000 held on two luxury cruise ships as virus spreadsCathay Pacific asks staff to take unpaid leave  Airbus shuts plantBloomberg is tracking the outbreak on the terminal and online 
Wisconsin Confirms New Coronavirus Case  2 32 p m  NY 
Wisconsin public health officials confirmed the 12th U S  case of the coronavirus  The patient is an adult who had traveled to Beijing and was exposed to known cases while in China  said the state s Department of Health Services 
The person has been isolated at home and is doing well  the state said in a statement Wednesday 
CDC Begins Shipping Virus Test Kits  1 25 p m  NY 
The U S  Centers for Disease Control and Prevention started shipping new test kits that can detect the coronavirus on site to 200 laboratories in the U S  and 200 others outside the country  Previously  samples had to be sent to the agency s headquarters in Atlanta 
Each kit can process 700 to 800 samples  allowing for more than a quarter million people to get their results and potentially relieving the burden on overwhelmed health systems  said Nancy Messonnier  director of the CDC s National Center for Immunization and Respiratory Diseases  It will take a few days before widespread use can begin  she said 
 By the start of next week  we expect there to be much enhanced capacity for laboratory testing closer to our patients   Messonnier said on a briefing with reporters Wednesday 
Two U S  Wuhan Flights Arriving  Two More Expected  12 50 p m  NY 
Two evacuation flights from Wuhan to the U S  are arriving today at military bases  with two more expected tomorrow  the U S  Centers for Disease Control and Prevention told reporters on a call Wednesday 
The government has repatriating Americans from the outbreak s center in China  and putting people under mandatory quarantine for as long as two weeks when they return  CDC officials didn t say how many people were on the flights 
U S  to Receive More Virus Evacuees From Wuhan  11 30 a m  NY 
U S  health authorities are preparing for several more plane loads of evacuees from Wuhan  the city in Hubei province where the virus was first detected  They plan to quarantine them for as long as two weeks at military bases in three states 
The U S  Centers for Disease Control and Prevention said in a statement Wednesday that it will screen the passengers during their travel and give quarantine orders when they arrive  The flights will land at air bases in California  Texas and Nebraska 
On Tuesday  the U S  State Department said two more plans of evacuees were on their way  The U S  government has put in place plans to temporarily isolate hundreds of at risk people returning from the outbreak in China 
WHO Cautions on Quick Breakthrough  11 10 a m  NY 
World Health Organization officials tamped down expectations of imminent breakthroughs in the development of vaccines or treatments for the outbreak 
 There are no proven  effective therapeutics  for the novel coronavirus  Mike Ryan  executive director of the WHO s Health Emergencies Program  said Wednesday at a press conference in Geneva 
The UN agency plans a systematic review of all therapeutics  Ryan said  The organization will share clinical trial protocols around the world  he said 
An antiviral drug from  Gilead Sciences Inc   NASDAQ GILD   is expected to start testing in China on Thursday 
Gates Foundation Pledges  100 Million  9 15 a m  NY 
The Bill   Melinda Gates Foundation said Wednesday it will commit as much as  100 million to bolster the international response to the novel coronavirus 
The funding will help strengthen detection  isolation and treatment efforts  protect at risk populations  and develop vaccines  therapies and diagnostics  The new funding includes the  10 million the foundation committed to the outbreak in late January 
 Multilateral organizations  national governments  the private sector and philanthropies must work together to slow the pace of the outbreak  help countries protect their most vulnerable citizens and accelerate the development of the tools to bring this epidemic under control   Gates Foundation Chief Executive Officer Mark Suzman said in a statement 
The funds will assist the World Health Organization  Chinese frontline responders and others at the global and national levels  the foundation said 
Capri Cuts Forecast  Shuts Stores in China  7 40 a m  NY 
The company  which owns the Jimmy Choo and Michael Kors brands  cut its revenue forecast for the fiscal full year  citing the material impact of the coronavirus outbreak in China on its business 
China Offers Firms Fighting Virus Lower Rates  6 58 a m  NY 
China will eliminate fees  reduce value added taxes and support banks to offer loan rates under 1 6  to key enterprises involved in the fight against the coronavirus  according to China Central Television 
Vietnam Sees Lower GDP Growth Rate  6 47 a m  NY 
Vietnam s government expects the spread of coronavirus to slow gross domestic product growth to as low as 6 09  in 2020  even if the epidemic is under control by the second quarter  Growth may be at 6 27  if the virus is controlled within the first quarter  Mai Tien Dung  chairman of the government office  said at a briefing in Hanoi 
Babies Born With Coronavirus After Mothers Infected  6 42 p m  HK 
Two newborn babies tested positive for coronavirus in Wuhan after their mothers were infected  China Central Television reported 
Markets Gain on Chinese Report of Research Progress  5 50 p m  HK 
Stocks surged  industrial metals advanced and oil gained after Chinese television reported possible progress in the hunt for a coronavirus treatment  The report said a drug being tested by researchers at Zhejiang University in China was effective against the virus  The treatment was tested on cells outside the human body  meaning it would be a long way from any clinical trials on people  let alone approval as a marketable drug 
Separately  China kick started a clinical trial to test Gilead Sciences Inc  s Remdesivir  an antiviral developed for Ebola and SARS  China s health regulator also recommended  AbbVie Inc   NYSE ABBV   s Kaletra  already approved as an HIV medicine  as an ad hoc antiviral drug for the coronavirus 
Foxconn Cuts Outlook  Quarantines IPhone Base  5 43 p m  HK 
Hon Hai Precision Industry Co   Apple Inc  NASDAQ AAPL   s main production partner  announced plans to isolate workers for up to weeks at its main iPhone making base  The company earlier cut its 2020 revenue growth outlook after assessing the potential impact of the coronavirus outbreak 
Hon Hai  known also as Foxconn  makes the vast majority of the world s iPhones from Zhengzhou  central China  The contagion will likely disrupt Apple s carefully calibrated production chain 
Hong Kong Will Quarantine China Arrivals  4 50 p m  HK 
The city will quarantine people arriving from mainland China  including Hong Kong residents and visitors entering via its international airport  Chief Executive Carrie Lam said 
The policy will go into effect on Feb  8 at midnight  Lam also said Hong Kong will close the Kai Tak Cruise Terminal in its Victoria Harbor  and announced a HK 10 billion   1 3 billion  fund for those affected 
Cathay Pacific Asks Staff to Take Unpaid Leave  3 45 p m  HK 
The airline asked staff to take unpaid leave from March 1 to June 30 as it tries to preserve cash  Cathay has said demand dropped following the outbreak and announced deep cuts to flight capacity on Tuesday  South Korean budget carrier Tway Air also asked staff to take unpaid leave 
Separately  Airbus SE shut its plant in Tianjin that builds about six A320 series jets a month  corresponding to almost 10  of the company s global single aisle output 
Virus Cases Linked to Singapore Spur Multinational Inquiry  2 41 p m  HK 
Coronavirus cases in South Korea and Malaysia tied to a business meeting in Singapore attended by visitors from China have prompted an investigation into the infection s international spread 
A 41 year old man in Malaysia and a 38 year old man in South Korea were infected with the virus after attending a meeting at a Singapore hotel in the third week of January  health authorities said  The World Health Organization is coordinating with Singapore s Ministry of Health in relation to the event  said Olivia Lawe Davies  the agency s Manila based regional communications manager 
Hong Kong Cruise Passengers Under Quarantine  1 53 p m  HK 
Hong Kong authorities are keeping 3 600 passengers and crew members under quarantine on the cruise ship World Dream after three previous travelers were diagnosed with the novel coronavirus 
The three confirmed virus patients had disembarked in China on Jan  24  according to Chief Port Health Officer Leung Yiu hong at a briefing at the cruise terminal  The cruise ship  owned by Genting HK s Dream Cruises  docked in Hong Kong on Wednesday morning 
Health officials are collecting samples from about 30 crew members who reported symptoms including cough and fever for coronavirus tests  Three crew members who earlier reported fever will be sent to the hospital for isolation  The development follows a separate case in Japan in which 10 people on Carnival  NYSE CCL  Corp  s Diamond Princess cruise ship tested positive for the coronavirus 
China Seeks Patent for Gilead s Experimental Drug  1 01 p m  HK 
China has applied for a new patent on an experimental Gilead Sciences Inc  drug that its scientists believe might fight the coronavirus 
It has applied for a patent for the use of the drug  know as remdesivir  to treat the novel coronavirus  The move is a sign that China views Gilead s therapy as one of the most promising candidates to fight the outbreak  A patent battle may affect Gilead s control over the drug in China 
While Gilead s experimental drug isn t licensed or approved anywhere in the world  it is being rushed into human trials in China on coronavirus patients after showing early signs of being highly effective 
Trump Cites Efforts on Virus in State of the Union  11 10 a m  HK 
President Donald Trump said in his State of the Union address that the U S  is working with China to contain the coronavirus outbreak 
 We are coordinating with the Chinese government and working closely together on the coronavirus outbreak in China   Trump said   My administration will take all necessary steps to safeguard our citizens from this threat  
 Credit Suisse   SIX CSGN  Scraps Hong Kong Conference  11 05 a m  HK 
Credit Suisse Group AG scrapped its annual Asia investment conference next month  adding to a string of cancellations or delay for similar gatherings in Hong Kong and China 
The decision marks the biggest cancellation in Hong Kong s financial industry after the outbreak of the virus  The city on Tuesday reported its first confirmed death from the virus  Neighboring Macau  the world s biggest gambling hub  has asked its casinos to shut down for half a month 
 Disney  Sees Virus Hurting Profits  8 24 a m  HK 
Walt Disney  NYSE DIS  Co  is feeling the impact of the virus after temporarily closing its Shanghai and Hong Kong parks due to the outbreak 
On a call to discuss the company s earnings  Chief Financial Officer Christine McCarthy said Disney expects the Shanghai park closure alone to crimp profits in the current quarter by  135 million  assuming it is shuttered for two months  With Hong Kong closing  Disney expects the coronavirus to reduce profit there by another  40 million 
China Cases Rise Above 24 000  8 00 a m  HK 
The number of total confirmed cases of coronavirus in mainland China rose to 24 324 as of Feb  4  according to the National Health Commission  The death toll is at 490  it said in a statement 
Most of the fatalities    479    have occurred in the province of Hubei  the Chinese province at the center of the outbreak  Hubei reported 3 156 new confirmed cases  bringing the total in Hubei to 16 678 
Outside the mainland  Hong Kong reported a death on Tuesday  A man from Wuhan died in the Philippines on Feb  1 
Ten Passengers on Japan Cruise Have Virus  7 33 a m  HK 
Ten people on a Carnival Corp  cruise ship moored near Yokohama with about 3 700 crew and passengers aboard have tested positive for the new coronavirus and taken to hospital  Japan s Health Ministry announced Wednesday 
The Diamond Princess was placed under quarantine this week before it reached Japan and checks were conducted after a passenger from Hong Kong who had been on the ship tested positive for the virus  Of 31 people whose test results have come through  10 were confirmed as infected  the ministry said 
The new infections come in addition to 23 people already confirmed to have contracted the disease in Japan 
FDA Grants Emergency Use of Rapid Test for Virus  6 34 a m  HK 
The U S  Food and Drug Administration cleared the way for the widespread use of a new test to detect the novel coronavirus at laboratories across the country  removing the need for doctors to send samples out for analysis 
The test was designed by the Centers for Disease Control and Prevention and can be used at any of the agency s approved labs across the country  Until now  samples taken from patients had to be sent for analysis at the agency s laboratories in Atlanta ",2020-02-05,Bloomberg,https://www.investing.com/news/general/cdc-shipping-test-kits-wisconsin-confirms-case-virus-update-2077176,2077176
200584,422100,GILD,Drugmakers see long road ahead in coronavirus vaccine race ,news,"Novavax is one of at least a dozen drugmakers racing to find a vaccine for the new Wuhan coronavirus 
The Gaithersburg  Maryland   based company already has a vaccine in development against MERS   another type of coronavirus 
But while reports of a supposed  breakthrough  took financial markets out of their rut this week and sparked optimism that researchers could find an effective treatment  companies Reuters spoke to said not so fast   warning they have a long way to go to help those infected   
  from the outbreak of the flu like virus that has killed more than 500 people in China and shows no signs of slowing down  with thousands of new cases reported each day  
But Novavax research chief   Gregory Glenn   thinks the bio tech company is in a good position  
 Novavax  has in the past gone from getting the gene sequence  identifying the virus to starting testing in 90 days for ebola and for a pandemic potential flu vaccine  So we ve done it so everyone is very focused on trying to compress these time frames  
Johnson   Johnson and Gilead Sciences  NASDAQ GILD  are also rushing to develop treatments 
And it s no easy feat  according to health experts  to move vaccines from the lab to widespread use in patients involves a number of hurdles 
In addition to scaling up manufacturing capacity and building distribution networks  there are also regulatory hurdles that include carrying out large clinical trials  
In a process that could push back a drug s release date by a year or more   according to executives from companies involved in the effort  
And it s also pricey 
Investment costs could run as high as  800 million for a vaccine that may or may not prove profitable  
One analyst pointed out that by the time a vaccine is deemed safe   the outbreak could be abating  ",2020-02-05,Reuters,https://www.investing.com/news/general/drugmakers-see-long-road-ahead-in-coronavirus-vaccine-race-2077413,2077413
200585,422101,GILD,Top Analyst Upgrades and Downgrades  AbbVie  Biogen  Boeing  Etsy  Gilead  GoPro  Micron  Newmont  Peloton  Pfizer  Valero  Zynga and More,news,Stocks have already risen each day this week  with a 1 000 point Dow Jones industrial average recovery alone  and the major equity indexes were indicated to open slightly higher again on Thursday  All time highs have come back into focus as China lowered tariffs on  75 billion worth of U S  goods  The coronavirus cases keep rising  over 28 250 cases and 565 deaths in China   but there is some growing hope that a vaccine or treatment may be available in a few months  With global gross domestic product weighed on by China weakness  there is still much uncertainty and many ongoing and unresolved developments that investors have to digest in 2020  Many investors still have not made some of their normal portfolio changes this year either 24 7 Wall St  reviews dozens of analyst research reports each day of the week with a goal of finding new ideas for traders and long term investors alike  Some of the daily analyst calls cover stocks to buy  while some calls cover stocks to sell or to avoid We have provided these analyst calls in a quick hit summary for easy reading  and additional comments and trading data have been added on many of the calls  The consensus analyst price targets and other valuation metrics are from the Refinitiv sell side research service div connatix margin bottom  1 5em   div connatix img  margin  unset  These were the top analyst upgrades  downgrades and initiations seen for Thursday  February 6  2020 AbbVie Inc   NYSE  ABBV  was started with a Buy rating and a  96 target price at Mizuho  Shares closed up about 2 7  at  86 63 ahead of the call  with a  95 18 consensus target price Alteryx Inc   NYSE  AYX  was named as the Bull of the Day at Zacks  which said that data analysis software is in high demand and this provider makes the science accessible to a wide variety of customers  Shares most recently closed at  135 21 and have a consensus price target of  130 14 Amgen Inc   NASDAQ  AMGN  was reiterated as Buy with a  265 target price at Argus  It closed up 4 5  at  231 94 ahead of his call and has a  246 05 consensus target price Biogen Inc   NASDAQ  BIIB  closed up 17 5  at  332 87 on Wednesday after winning a key multiple sclerosis drug patent ruling over Mylan  Credit Suisse maintained its Neutral rating but raised its target price to  330 from  300  Cantor Fitzgerald reiterated its Overweight rating and raised its target price to  361 from  315 Boeing Co   NYSE  BA  was named as the Zacks Bear of the Day stock  The firm said the continued 737 Max grounding and the spread of the coronavirus signal that this company s problems are not yet over  Shares last closed at  329 55  with a consensus price target of  337 50 Cogent Communications Holding  Inc   NASDAQ  CCOI  was raised to Buy from Neutral and the  52 target was raised to  84 by Goldman Sachs  The stock closed up just four cents at  71 82 a share on Wednesday and had a  56 82 consensus target price after it rallied about 10  so far this year Etsy Inc   NASDAQ  ETSY  was started with a Hold rating and a  46 target price at Stifel  It closed down 2 2  at  49 57 on Wednesday  with a prior consensus target price of  64 75 Flagstar Bancorp Inc   NYSE  FBC  was reiterated as Outperform with a  40 target price  versus a  35 49 prior close  at Wedbush Securities  but the firm lowered its earnings estimates over higher expected loan loss provisions and higher operating costs FormFactor Inc   NASDAQ  FORM  was downgraded to Hold from Buy with a  27 target price at Stifel  The stock closed down a penny to  26 38 ahead of the call  with a  26 32 consensus target price Funko Inc   NASDAQ  FNKO  saw its shares plunge almost 40  to  9 50 after showing slower sales than expected  Merrill Lynch downgraded the shares to Underperform Buy and JPMorgan downgraded them to Underweight from Overweight  D A  Davidson also downgraded it  to Neutral from Buy  and slashed its target price from  35 to  11 General Dynamics Corp   NYSE  GD  was raised to Overweight from Neutral and the target price was raised to  225 from  210 at JPMorgan  General Dynamics closed up 2 5  at  183 97 on Wednesday  with a  210 39 consensus target price Gilead Sciences Inc   NASDAQ  GILD  was downgraded to Market Perform from Outperform with a  70 target price at Bernstein ,2020-02-06,247wallst,https://invst.ly/przl8,2077915
200586,422102,GILD,Gilead an acquisition target  Deep pockets required,news,"Jefferies  Michael Yee says investors believe that Gilead Sciences  GILD  0 6   is an acquisition target considering its near term share performance  at the same level as three years ago with some volatility thrown in  and tepid growth prospects  little or no topline increase expected this year  
He equates its current situation with Allergan  AGN  2    acquired by AbbVie  ABBV  5 2   for  63B and Celgene  CELG   acquired by Bristol Myers Squibb  BMY  1 6   for  74B  albeit it is not an  obvious  takeover target 
Any potential suitor will need deep pockets  For comparison purposes  AbbVie paid a 2 8x multiple of Allergan s trailing 12 month revenues while BMY paid 4 4x for Celgene  GILD s current market cap is   90B or 4 0x times its most recent 12 month revenues  Since management is unlikely to embrace a no premium bid  an offer would probably need to be  100B   125B  an amount very few companies could digest ",2020-02-07,Seeking Alpha,https://invst.ly/psjxd,2079427
200587,422103,GILD,Gilead Sciences  Still on the Path to Recovery,news,"Gilead Sciences  NASDAQ GILD  reported fourth quarter earnings after the market close on Feb  5 and the stock price fell 2  the following day  Although the company beat expectations at the top line  profits and earnings per share both disappointed  and guidance for 2020 underwhelmed investors 
With the stock trading close to its multi year lows  the results provided little cause for optimism that things would be turning around at any time soon 
Gilead reported another mixed set of earnings results
Both bullish and bearish investors could find some solace in the results  On the negative side  profitability suffered due to an increase in costs and expenses with non GAAP  adjusted  earnings per share falling 10  year over year versus expectations of positive 10  growth  Gilead s hepatitis C virus  HCV  franchise    historically its main profit engine    continued to suffer  with overall revenues down 15  in the quarter  And guidance for next year came in on the light side of expectations  suggesting little to no growth for 2020  For someone who holds Gilead shares  patience seems to be turning into more of a vice than a virtue 

But the long term investment thesis remains intact
At the same time  however  the results contained some silver linings for the long term bull  Revenues increased  continuing their trend over the last several quarters  and reversing the many years of declines which took the stock down close to 50   Gilead s HIV franchise continues to be industry leading  with revenues up 12  year over year  And this leadership is likely to continue  Management expects that Biktarvy    its industry leading HIV drug    will continue to be the preferred treatment option through the next decade 
Nor will expense pressures continue into next year  The margin hit that Gilead took in the fourth quarter was caused primarily by one off inventory writedowns associated with its HCV drugs  Gilead does not expect this to be repeated next year and anticipates gross margins returning to the 86  to 87  level  which was the norm in prior quarters 
The longer term investment case for Gilead remains intact  The HCV franchise will be less of a drag on earnings while Gilead continues to develop its diverse pipeline across promising hepatitis B  non alcoholic steatohepatitis  oncology  and immunology products   Management also highlighted China as an opportunity for growth  with eight products approved since 2017 and four recently approved for reimbursement in 2020  
Gilead also has been aggressive in looking externally for product opportunities and has entered into 33 strategic partnerships and investment transactions since January 2018  It has a long history of making acquisitions  and its track record in this area has been exemplary    the best example being its acquisition of Pharmasset in 2011 for  11 billion  which generated  25 billion in profits over five years  
Not only does management have the will to make the necessary changes  but it also has the means  It has net cash on its balance sheet courtesy of over  25 billion in cash and marketable securities  Free cash flow has been more than sufficient to fund dividend growth and share buybacks  Gilead announced an 8  hike in its dividend for 2020  making it five consecutive years of dividend growth  With the health stock yielding more than 4  and trading at a little more than 10 times earnings  Gilead is priced for little or no growth   It may well surprise on the upside ",2020-02-08,The Motley Fool,https://invst.ly/psrsl,2079836
200588,422104,GILD,1 Big Question to Ask Yourself Before Buying Gilead Sciences Stock,news,"Timing matters  
If you had bought shares of Gilead Sciences  NASDAQ GILD  in early 2012 and held on  you d have more than tripled your initial investment  But if you had bought the biotech stock in mid 2015 and still owned the shares  you d be sitting on a loss of more than 40  
With Gilead s share price hovering near its lowest point in the last seven years  some investors could be wondering if now is the time to jump aboard  If you re in that group  there s one big question you need to ask yourself first  How long are you prepared to hold onto Gilead Sciences stock 

Near term malaise
Gilead Sciences reported some revenue growth in its 2019 fourth quarter results  but that growth wasn t anything to write home about  More importantly  the midpoint of the company s full year 2020 product sales guidance reflected a slight decline from its full year 2019 sales 
The picture for Gilead could be even worse in the first quarter of 2020 than in the rest of the year  Gilead CFO Andrew Dickinson said in the biotech s Q4 earnings conference call that Q1 sales will decline both on a year over year basis and on a quarter over quarter basis  
There are a couple of factors at work behind the near term malaise  Gilead usually experiences negative seasonal inventory and buying patterns early in the year  The company will also feel the brunt in Q1 with year over year comparisons of sales for Ranexa and Letairis  Both cardiopulmonary drugs lost exclusivity in 2019 
Gilead s share price received a boost recently on the news that it s working with Chinese authorities to test antiviral drug remdesivir in treating the 2019 nCoV coronavirus strain that s causing worldwide concerns  However  Johanna Mercier  Gilead s Chief Commercial Officer  said that the coronavirus outbreak could cause some delays in progress with marketing hepatitis B drug Vemlidy and HIV drug Genvoya in China 
Another headwind on the way for Gilead is that a generic version of Truvada hits the U S  market later in 2020  Generics have already taken a toll on European sales of the HIV drug  
The bottom line is that if you re looking to make a quick buck  Gilead Sciences probably isn t the stock for you  The chances appear to be high that there will be more bad news than good news for the biotech over the next several months 
Long term potential
But if you re a long term investor with an investing horizon of at least five years  Gilead could be worth a serious look  The biotech s bad news should fade  while there are plenty of opportunities for good news on the way 
Let s start with Gilead s current challenges  Sure  the company will feel the pain from the losses of exclusivity for Ranexa and Letairis this year  However  year over year comparisons will improve significantly in 2021  
What about the negative impact of U S  generic competition for Truvada  It might take a couple of years for Gilead to fully move past the blow  But Biktarvy is already cannibalizing sales of Gilead s other HIV drugs  and Descovy is picking up steam as a pre exposure prophylactic for HIV 
More importantly  Gilead has new growth drivers potentially on the way  The company expects to win regulatory approvals for filgotinib in treating rheumatoid arthritis this year  Gilead believes that the drug will be the best in class JAK inhibitor and is ramping up for a major commercial launch in the U S   Europe  and Japan 
Filgotinib should be the first of 10 transformative drugs that Gilead CEO Daniel O Day is pushing the biotech to launch over the next 10 years  The company will potentially look to its partnership with Galapagos to fill in some of the other nine slots  Gilead is also counting on its long acting HIV capsid inhibitor to be the foundation of its HIV franchise of the future 
Don t ignore Gilead s opportunities to make more deals  O Day said that the company  will continue to make investments in our external pipeline including transformative partnerships such as Galapagos and small to medium size bolt on acquisitions   With a cash stockpile of more than  25 billion  Gilead shouldn t have any problems funding its business development efforts 
A question not just for Gilead
My view is that whether Gilead Sciences is a good stock to buy depends entirely on your answer to the big question posed earlier  But the question of how long you re willing to hold onto shares isn t just one for Gilead  It s not limited to just biotech stocks  either  You should ask yourself this question before you buy any stock 
The Motley Fool recently tweeted   To outperform you can be  Smarter than other investors  Luckier than other investors  More patient than other investors  The last is where the big money is made   That s exactly right 
If you re a patient investor  you can make tremendous returns over the long run  I expect this will be true for investors who buy Gilead Sciences and hold on ",2020-02-09,The Motley Fool,https://invst.ly/pszxg,2080023
200589,422105,GILD,FDA Grants a Priority Review To Gilead Sciences  Cancer Therapy,news,"Today  Gilead Sciences  NASDAQ GILD  disclosed its next cell based cancer therapy could become available this summer  The Food and Drug Administration recently granted a priority review to an application Gilead submitted a couple of months ago for KTE X19 with an expected action date of Aug  10  2019 
Not exactly new
Gilead s potential new cancer therapy isn t exactly new  It s basically Yescarta with an improved manufacturing process that the company has aimed at a small segment of non Hodgkin lymphoma patients  Yescarta and KTE X19 are both CAR T therapies made with cells harvested from patients that are trained to recognize cells with the CD19 antigen on their surface 
To get its hands on Yescarta and a handful of experimental CAR T therapies in development  Gilead Sciences acquired Kite Pharma in 2017 for  11 9 billion 

Since a new batch of Yescarta and KTE X19 must be manufactured for every patient  many of whom need to begin a new treatment regimen immediately  improvements to the process can have a big effect  This appears to be the case with KTE X19 and mantle cell lymphoma patients that have exhausted additional treatment options  During a study supporting Gilead s application  a single infusion of KTE X19 helped 67  of patients achieve complete remission 
Getting crowded 
The FDA recently approved a Bruton s tyrosine kinase  BTK  inhibitor called Brukinsa from Beigene  NASDAQ BGNE  for the treatment of mantle cell lymphoma patients who have relapsed at least once  Brukinsa itself is up against Imbruvica which has been in the second line position for mantle cell lymphoma patients since 2013 
Since just 6  of patients with non Hodgkin lymphomas are diagnosed with the mantle cell variety  this space looks like it could get crowded fast  Sales of Gilead s new therapy will probably remain limited to a very small audience that has already exhausted all available treatment options ",2020-02-10,The Motley Fool,https://invst.ly/ptfqn,2080924
200590,422106,GILD,Is Gilead Sciences an Acquisition Target ,news,"Gilead Sciences   NASDAQ GILD  latest earnings report and full year outlook didn t exactly inspire confidence among investors last week  The biotech heavyweight told the investing community a week ago today that its top line will likely dip yet again this year thanks to falling hep C drug sales and the slower than expected commercialization of its anti cancer cell therapy Yescarta 
Wall Street  for its part  is even less optimistic about the big biotech s near term prospects  The average analyst estimate has the biotech s annual sales declining for the next two full years  That s a surprising take to be sure  given the strong possibility that Gilead s blockbuster in waiting  filgotinib  will likely hit the market soon   
The big deal is that the biotech s market capitalization has been bumping up against its five year low lately thanks to this rather anemic outlook  In response  Jefferies  analyst Michael Yee published a note last week suggesting that Gilead might now be an attractive takeover target  Its large cap biopharma peers Allergan and Celgene  after all  both turned into top acquisition targets when their respective market caps bottomed out  

Is a possible takeover reason enough to buy Gilead s stock right now  Let s take a deeper look to find out 
Gilead s takeover thesis isn t compelling
The main reason shareholders should mull over this idea is that Gilead s management would obviously demand a healthy premium in a takeover scenario  In fact  it would most likely require a 30  premium    at a bare minimum    to win over the biotech s brain trust  That s a decent payday for the biotech s long suffering shareholders  to be sure  Unfortunately  we d be looking at a deal valued at no less than a monstrous  115 billion at those levels  
When it comes to acquisitions  size most definitely matters  After all  the only two American mega pharmas that could possibly swallow Gilead whole are Johnson   Johnson  NYSE JNJ  and Pfizer  NYSE PFE   While J J has some noteworthy synergies with Gilead s clinical pipeline and product portfolio  the Band Aid maker isn t exactly known for mega mergers of this size  What s more  J J is one of the few large cap biopharmas that doesn t really have a glaring hole to fill via M A  So  there s no particularly good reason to think that J J would be willing to place undue stress on its nearly pristine balance sheet in order to gobble up Gilead  
Pfizer doesn t come across as a likely suitor  either    for a multitude of reasons  Chief among them  the pharma giant recently announced plans to slim down to unlock the latent growth potential of newer products such as breast cancer medication Ibrance  Pfizer does reportedly have interest in pursuing additional bolt on acquisitions to flesh out its emerging growth portfolio  But the company seems intent on sticking to small to mid sized deals to achieve this key operational goal  Pfizer and Gilead also don t share a whole lot of clear cut synergies  As such  it s hard to imagine that Pfizer would have any serious interest in buying Gilead  either  
What s next 
Gilead is almost certainly not going to be the next Allergan or Celgene  The long and short of it is that the big biotech is still far too large to be consumed by one of its peers  despite its prolonged trough period  So  if you re hoping for a quick buck on a buyout scenario  you might want to look elsewhere  Gilead simply doesn t fit the bill ",2020-02-12,The Motley Fool,https://invst.ly/ptti6,2081837
200591,422107,GILD,New Strong Sell Stocks For February 10th,opinion,Here are 5 stocks added to the Zacks Rank  5  Strong Sell  List today Extreme Networks  Inc    NASDAQ EXTR   provides software driven networking solutions for enterprise  data center  and service provider customers  The Zacks Consensus Estimate for its current year earnings has been revised 18 3  downward over the last 30 days Funko  Inc    NASDAQ FNKO   is a pop culture consumer products company  designs  sources  and distributes licensed pop culture products  The Zacks Consensus Estimate for its current year earnings has been revised 12 4  downward over the last 30 days Capri Holdings Limited   NYSE CPRI   designs  markets  distributes  and retails branded women s and men s apparel and accessories  The Zacks Consensus Estimate for its current year earnings has been revised 7 6  downward over the last 30 days KT Corporation   NYSE KT   provides telecommunications services  The Zacks Consensus Estimate for its current year earnings has been revised 7 2  downward over the last 30 days Gilead Sciences  Inc    NASDAQ GILD   a research based biopharmaceutical company  discovers  develops  and commercializes medicines in the areas of unmet medical needs  The Zacks Consensus Estimate for its current year earnings has been revised nearly 7  downward over the last 30 days View the entire,2020-02-09,Zacks Investment Research,https://www.investing.com/analysis/new-strong-sell-stocks-for-february-10th-200506083,200506083
200592,422108,GILD,Gilead s BLA For CAR T Cell Therapy Gets FDA Acceptance,opinion,Gilead Sciences  Inc    NASDAQ GILD   announced that the FDA accepted Kite s Biologics License Application  BLA  and granted Priority Review designation to investigational chimeric antigen receptor  CAR  T cell therapy  KTE X19 The company is seeking approval of KTE X19 for the treatment of adult patients with relapsed or refractory mantle cell lymphoma  MCL  The BLA is supported by data from the single arm  open label  phase II ZUMA 2 study  which showed that 93  of patients responded to a single infusion of KTE X19  including 67  of patients achieving a complete response  as assessed by an Independent Radiologic Review Committee The FDA has set a target action date of Aug 10  2020 KTE X19 is currently in phase I II studies  being evaluated in acute lymphoblastic leukemia  ALL   MCL and chronic lymphocytic leukemia  CLL  Meanwhile  the European Medicines Agency  EMA  recently validated the Marketing Authorization Application for KTE X19 in the European Union  The candidate has been granted Breakthrough Therapy Designation  BTD  by the FDA and Priority Medicines  PRIME  designation by the EMA for relapsed or refractory MCL A potential approval will give Gilead a second cell therapy treatment in its portfolio Gilead s Yescarta was the first CAR T cell therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B cell lymphoma after two or more lines of systemic therapy  including diffuse large B cell lymphoma  DLBCL  not otherwise specified  primary mediastinal large B cell lymphoma  high grade B cell lymphoma and DLBCL arising from follicular lymphoma We note that the massive decline in sales of the HCV franchise has propelled Gilead to focus on the HIV franchise  Yescarta and other newer avenues  The rapid adoption of Biktarvy propels the HIV business amid stiff competition from the likes of GlaxoSmithKline   NYSE GSK   Gilead s stock has gained 5 5  in the past year against the  s decline of 2 2  However  the uptake of Yescarta has not been per expectations  given the exorbitant cost and competition from Novartis    NYSE NVS   Kymriah  Gilead has also collaborated with Kiniksa Pharmaceuticals  Ltd    NASDAQ KNSA   to conduct a phase II  multicenter study of mavrilimumab  which is an investigational  fully human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha  in combination with Yescarta in patients with relapsed or refractory large B cell lymphoma  Gilead s intention to foray into the inflammation market to diversify the revenue base is encouraging as well Gilead currently carries a Zacks Rank  5  Strong Sell  You can see  Zacks Top 10 Stocks for 2020In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2020 Last year s 2019 Zacks Top 10 Stocks portfolio returned gains as high as  102 7   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys ,2020-02-10,Zacks Investment Research,https://www.investing.com/analysis/gileads-bla-for-car-t-cell-therapy-gets-fda-acceptance-200506455,200506455
200593,422109,GILD,Top Stock Research Reports For AbbVie  Accenture  TOTAL   Others,opinion,"Tuesday  February 11  2020The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including AbbVie  ABBV   Accenture  NYSE ACN   ACN  and TOTAL  TOT   These research reports have been hand picked from the roughly 70 reports published by our analyst team today You can see AbbVie s shares have outperformed the Zacks Large Cap Pharmaceuticals industry in the past six months   46 8  vs   15 9    The Zacks analyst believes that AbbVie s key drug  Humira is performing well based on strong demand trends despite new competition AbbVie has been successful in expanding approvals for its cancer drugs  Imbruvica and Venclexta  Moreover  it has an impressive late stage pipeline  It gained approvals for two new drugs with significant potential  Skyrizi  risankizumab  and Rinvoq  in 2019  Both are off to a strong start The acquisition of Allergan  NYSE AGN   if successful  should diversify AbbVie s revenue base and accelerate its non Humira business  However  sales erosion due to direct biosimilar competition to Humira in international markets is a big headwind   Also  the decline in HCV sales is a concern   You can  Shares of Accenture have gained  35 7  over the past year against the Zacks Consulting industry s rise of  27 1   The Zacks analyst believes that Accenture has been steadily gaining traction in its outsourcing and consulting businesses The company has been strategically enhancing its cloud and digital marketing suite through acquisitions and partnerships  The company s strong operating cash flow has helped it reward its shareholders in the form of dividends and share repurchases  and pursue opportunities in areas that show true potential  Accenture is currently a global leader in the Salesforce implementation service space However  Accenture continues to face pricing pressure due to significant competition from strong companies like Genpact  Cognizant  NASDAQ CTSH  and Infosys  Global presence exposes Accenture to foreign currency exchange rate fluctuations  Buyout related integration risks is a concern  You can  TOTAL s shares have lost  9 7  over the past three months against the Zacks Integrated International Oil industry s fall of  11 7   The Zacks analyst believes that company has been benefiting from startups  renewable projects  its LNG portfolio and expanding upstream portfolio that has above industry average exposure to faster growing hydrocarbon producing regions Streamlining the asset portfolio and syncing the same with long term objectives are going to boost its performance and strengthen operations  Cost saving initiatives are also aiding it to boost margins However  TOTAL s operations in some politically troubled regions and increasing competition might affect profitability  Due to its global presence  the company is exposed to risks associated with pursuing business abroad  You can  Other noteworthy reports we are featuring today include Amazon com  NASDAQ AMZN   AMZN   Enbridge  ENB  and Intuit  INTU  Zacks Top 10 Stocks for 2020In addition to the stocks discussed above  would you like to know about our 10 finest buy and hold tickers for the entirety of 2020 Last year s 2019 Zacks Top 10 Stocks portfolio returned gains as high as  102 7   Now a brand new portfolio has been handpicked from over 4 000 companies covered by the Zacks Rank  Don t miss your chance to get in on these long term buys Sheraz MianDirector of ResearchNote  Sheraz Mian heads the Zacks Equity Research department and is a well regarded expert of aggregate earnings  He is frequently quoted in the print and electronic media and publishes the weekly and reports  If you want an email notification each time Sheraz publishes a new article  please 
Today s Must Read
AbbVie  ABBV  Ex U S  Humira Sales Erode  New Drugs Impress


Accenture  ACN  Continues to Benefit From Acquisitions


Production Boost from Startups  Cost Savings Aid TOTAL  TOT 


Featured Reports
Amazon  AMZN  Banks on Prime Momentum   Growing AWS Adoption
Per the Zacks analyst  Amazon is riding on expanding quick delivery services via Prime which are aiding its retail position  Also  strengthening cloud offerings are bolstering AWS adoption rate 

Enbridge  ENB  Banks on  11B Project Backlog  Debt High
The Zacks analyst expects Enbridge to generate stable cash flow from multi billion dollar worth of natural gas and oil transportation project backlog  However  its debt burden is concerning 

Intuit  INTU  Rides on Product Refresh  Higher Subscriptions
Per the Zacks analyst  Intuit is benefiting from frequent product refreshes  which help it to gain customers 

Canadian National  CNI  Rides on Dividends   Buybacks
The Zacks analyst is impressed by the company s measures to reward shareholders through dividends and repurchases 

Strength in Categories Drive Ross Stores  NASDAQ ROST  Sturdy Comps
Per the Zacks analysts  Ross Stores witnesses robust comps driven by strength across categories  except ladies apparel 

Long Term Investments  Renewable Focus Aid Xcel Energy  NASDAQ XEL 
Per the Zacks analyst disciplined investments in infrastructure projects and focus on renewable expansion will strengthen Xcel Energy s existing operations 

IHS Markit  INFO  Benefits From Ipreo Buyout Amid High Costs
The Zacks analyst believes that the Ipreo acquisition boosts IHS Markit s financial services segment  However  high acquisition related costs remain a headwind 

New Upgrades
Commercial Lines Segment Aids Cincinnati Financial  NASDAQ CINF 
Per the Zacks analyst  its Commercial Lines Insurance segment has been consistently performing well on the back of several strategic initiatives and price increases  contributing to overall growth 

Increased Contract Wins  Cash Flow Growth Aids Leidos  LDOS 
Per the Zacks Analyst  Increased contract wins for its cost effective defense solutions from the Pentagon drives the company s growth and bolster its backlog 

FormFactor  FORM  Benefits from Growing Probe Card Demand
Per the Zacks analyst  FormFactor benefits from strength in both Foundry   Logic probe cards  new design releases and solid execution  Also  DRAM demand is likely to remain solid in the long term 

New Downgrades
Competition For HIV  Pipeline Setbacks Hurt Gilead  NASDAQ GILD 
Per the Zacks analyst  stiff competition for HIV franchise hurt Gilead  Additionally  the uptake of Yescarta hasn t been impressive and the treatment faces stiff competition from Kymriah 

Conservative Oil E P Spending Hurts Baker Hughes  BKR 
Tight oil exploration and production  E P  capital spending will hurt demand for Baker Hughes  oilfield services in North America  agrees the Zacks analyst  

Weak Demand for Handsets Dampens Knowles   KN  Prospects
Per the Zacks analyst  soft trend in the Mobile market  with particular weakness in the premium portion of the Android ecosystem  is acting as a major headwind for Knowles  audio business 
undefined undefined",2020-02-11,Zacks Investment Research,https://www.investing.com/analysis/top-stock-research-reports-for-abbvie-accenture-total--others-200506615,200506615
200594,422110,GILD,Diodes  DIOD  Q4 Earnings And Revenues Top Estimates,opinion,"Diodes  DIOD  came out with quarterly earnings of  0 65 per share  beating the Zacks Consensus Estimate of  0 63 per share  This compares to earnings of  0 65 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 3 17   A quarter ago  it was expected that this semiconductor components maker would post earnings of  0 78 per share when it actually produced earnings of  0 81  delivering a surprise of 3 85  
Over the last four quarters  the company has surpassed consensus EPS estimates four times 
Diodes  which belongs to the Zacks Electronics   Semiconductors industry  posted revenues of  301 16 million for the quarter ended December 2019  surpassing the Zacks Consensus Estimate by 0 39   This compares to year ago revenues of  314 45 million  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Diodes shares have lost about 13 3  since the beginning of the year versus the S P 500 s gain of 3 8  
What s Next for Diodes 
While Diodes has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Diodes was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  0 64 on  300 million in revenues for the coming quarter and  2 90 on  1 24 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Electronics   Semiconductors is currently in the top 7  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2020-02-12,Zacks Investment Research,https://www.investing.com/analysis/diodes-diod-q4-earnings-and-revenues-top-estimates-200506658,200506658
200595,422111,GILD,VAREX IMAGING  VREX  Q1 Earnings Miss Estimates,opinion,"VAREX IMAGING  VREX  came out with quarterly earnings of  0 21 per share  missing the Zacks Consensus Estimate of  0 28 per share  This compares to earnings of  0 26 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of  25   A quarter ago  it was expected that this company would post earnings of  0 46 per share when it actually produced earnings of  0 46  delivering no surprise 
Over the last four quarters  the company has surpassed consensus EPS estimates just once 
VAREX IMAGING  which belongs to the Zacks Medical   Products industry  posted revenues of  200 10 million for the quarter ended December 2019  surpassing the Zacks Consensus Estimate by 4 87   This compares to year ago revenues of  185 70 million  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
VAREX IMAGING shares have lost about 8 3  since the beginning of the year versus the S P 500 s gain of 3 8  
What s Next for VAREX IMAGING 
While VAREX IMAGING has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for VAREX IMAGING was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  0 37 on  199 20 million in revenues for the coming quarter and  1 35 on  798 55 million in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Products is currently in the top 29  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2020-02-12,Zacks Investment Research,https://www.investing.com/analysis/varex-imaging-vrex-q1-earnings-miss-estimates-200506659,200506659
200596,422112,GILD,Western Union  WU  Q4 Earnings And Revenues Lag Estimates,opinion,"Western Union  WU  came out with quarterly earnings of  0 38 per share  missing the Zacks Consensus Estimate of  0 43 per share  This compares to earnings of  0 49 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of  11 63   A quarter ago  it was expected that this money transfer company would post earnings of  0 47 per share when it actually produced earnings of  0 49  delivering a surprise of 4 26  
Over the last four quarters  the company has surpassed consensus EPS estimates just once 
Western Union  which belongs to the Zacks Financial Transaction Services industry  posted revenues of  1 31 billion for the quarter ended December 2019  missing the Zacks Consensus Estimate by 1   This compares to year ago revenues of  1 40 billion  The company has topped consensus revenue estimates just once over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Western Union shares have added about 5 7  since the beginning of the year versus the S P 500 s gain of 3 8  
What s Next for Western Union 
While Western Union has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Western Union was unfavorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  4  Sell  for the stock  So  the shares are expected to underperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  0 45 on  1 27 billion in revenues for the coming quarter and  1 97 on  5 26 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Financial Transaction Services is currently in the top 41  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2020-02-12,Zacks Investment Research,https://www.investing.com/analysis/western-union-wu-q4-earnings-and-revenues-lag-estimates-200506660,200506660
200597,422113,GILD,Can Biotech ETFs Gain On Mixed Q4 Earnings Results ,opinion,The biotechnology market kept its promise for decent returns with the returning 13 2  in the past year  Increasing M A deals  growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market  The sector has been benefiting from a flurry of positive news  including trial results and deal activities The fast spreading coronavirus has sparked a race among biotech companies  The  has crossed 1000  with around 42 638 confirmed cases  Moreover  new cases confirming coronavirus infections are being reported from different parts of the world  Biotech players are dedicatedly working on creating vaccines that can help contain the virus  As such  these stocks could see some gains owing to elevated demand for drugs or vaccinations  read    Let s take a look at some big biotechnological earnings releases and see if these will impact ETFs exposed to the space Earnings in FocusOn Jan 30  Amgen   NASDAQ AMGN   reported fourth quarter 2019 earnings of  3 64 per share  which surpassed the Zacks Consensus Estimate of  3 44  Earnings increased 6  year over year as lower revenues and higher R D costs were offset by a lower share count  Total revenues of  6 2 billion in the quarter outpaced the Zacks Consensus Estimate of  6 billion  However  total revenues edged down 1  year over year Amgen issued its financial guidance for 2020  In the year  it expects revenues in the range of  25billion to  25 6 billion  which indicates an increase from the 2019 levels  In 2020  Amgen s base business  excluding Otezla  is expected to be stable  Adjusted earnings per share are anticipated in the  14 85  15 60 band  Shares have been up 0 6  since the earnings release  as of Feb 10  2010  On Feb 4  Gilead Sciences   NASDAQ GILD   reported mixed results for the fourth quarter  as earnings missed expectations  while sales managed to beat the same  The company reported earnings of  1 30 per share in the December end quarter  down from the prior year s  1 44 and missing the Zacks Consensus Estimate of  1 68  Total revenues of  5 88 billion outpaced the Zacks Consensus Estimate by 2 7  and rose 1 4  year over year   Gilead expects sales of  21 8  22 2 billion for 2020  Adjusted product gross margin is anticipated to be 86 87   Adjusted earnings per share are expected between  6 05 and  6 45  Including stock based compensation expenses  earnings for the ongoing year are expected to be  6 13   Moreover  the stock has gained 2 4  since reporting earnings  as of Feb 10  On Jan 30  Biogen   NASDAQ BIIB   reported fourth quarter 2019 earnings per share of  8 34  which surpassed the Zacks Consensus Estimate of  8  Earnings increased 19  year over year on higher revenues and lower operating expenses  Sales of this neuroscience focused biotech came in at  3 67 billion  up 4  from the year ago quarter  Sales also beat the Zacks Consensus Estimate of  3 54 billion  Sales growth was primarily led by higher sales of its key multiple sclerosis drugs  continued global growth of spinal muscular atrophy drug  Spinraza  and expansion of its biosimilar business  The stock has gained around 20  since the earnings release as on Feb 10 On Jan 30  Alexion Pharmaceuticals   NASDAQ ALXN   posted fourth quarter adjusted earnings per share of  2 71  which rose 26 6  from the year ago quarter s  2 14  Earnings also outpaced the Zacks Consensus Estimate of  2 37  Revenues were up 22 6  year over year to  1 38 billion and surpassed the Zacks Consensus Estimate of  1 32 billion  Revenues were led by higher sales of Soliris  Strensiq  Kanuma and Ultomiris Alexion expects adjusted earnings per share of  10 65  10 85  The company projects revenues of  5 50  5 56 billion  Combined revenues from Soliris and Ultomiris are expected to be  4 76  4 80 billion  The stock has lost 5 5  since the earnings release as on Feb 10 Biotech ETFs in FocusIn the current scenario  we believe it is prudent to discuss a few ETFs which have a relatively wider exposure to the companies discussed iSharesNasdaq Biotechnology ETF This fund seeks to provide exposure to U S  biotechnology stocks and tracks the NASDAQ Biotechnology Index  It comprises 215 holdings with the above mentioned companies taking about 25 9  of the fund  It has AUM of  7 43 billion and charges a fee of 47 basis points a year  The fund carries a Zacks ETF Rank  2  Buy   with a High risk outlook  read    VanEck Vectors Biotech ETF   LON BBH  The underlying MVIS US Listed Biotech 25 Index tracks the overall performance of companies involved in the development and production  marketing and sales of drugs based on genetic analysis and diagnostic equipment  It holds about 24 securities in its basket  with the concerned companies having 28 6  weight in the fund  Its AUM is  357 2 million and expense ratio is 0 35   The fund currently carries a Zacks ETF Rank  2  with a High risk outlook  see  here  SPDR S P Biotech  NYSE XBI  ETF The fund seeks daily investment results  before fees and expenses  which match the S P Biotechnology Select Industry Index  It holds about 123 securities in its basket and puts about 7 1  weight in the in focus companies  Its AUM is  4 41 billion and expense ratio is 0 35   The fund carries a Zacks ETF Rank  2 with a High risk outlook  read  First Trust Amex Biotechnology Index The fund measures the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services  It holds about 31 securities in its basket with Biogen and Gilead Sciences together having 7 6  weight in the fund  Its AUM is around  1 79 billion and expense ratio is 0 57   The fund carries a Zacks ETF Rank  3  Hold  with a High risk outlook  read    Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2020-02-12,Zacks Investment Research,https://www.investing.com/analysis/can-biotech-etfs-gain-on-mixed-q4-earnings-results-200506657,200506657
200603,422119,GILD,Gilead Sciences Inc  GILD  Q4 2019 Earnings Call Transcript,news,"Gilead Sciences Inc  NASDAQ GILD Q4 2019 Earnings CallFeb 4  2020  4 30 p m  ETContents 

Prepared Remarks
Questions and Answers
Call Participants

Prepared Remarks 
OperatorLadies and gentlemen  thank you for standing by  and welcome to the Gilead Sciences  Fourth Quarter 2019 Earnings Conference Call  My name is Liz  and I will be your operator today  At this time  all participants are in a listen only mode  And as a reminder  this conference call is being recorded I would now like to turn the call over to Douglas Maffei from Investor Relations  Please go ahead Douglas Maffei    Investor RelationsThank you  Liz  and good afternoon  everyone  Just after market close today  we issued a press release with earnings results for fourth quarter and full year 2019  The press release and detailed slides are available on the Investor Relations website Speakers on today s call will be Daniel O Day  Chairman and Chief Executive Officer  Andrew Dickinson  Chief Financial Officer  Johanna Mercier  Chief Commercial Officer  and Merdad Parsey  Chief Medical Officer  Also in the room are Christi Shaw  Chief Executive Officer  Kite  and Diana Brainard  Senior Vice President and Head of our HIV and Emerging Viruses Therapeutic area Before we begin with our prepared comments  let me remind you that we will be making forward looking statements  including plans and expectations with respect to products  product candidates  financial projections and the use of capital  and 2020 financial guidance  all of which involve certain assumptions  risks and uncertainties that are beyond our control and could cause actual results to differ materially from these statements  A description of these risks can be found in the earnings press release and our latest SEC disclosure documents  In addition  Gilead does not undertake any obligation to update any forward looking statements made during the call Non GAAP financial measures will be used to help you understand the company s underlying business performance  Starting in 2020  Gilead will no longer regularly exclude stock based compensation expense from its non GAAP financial information  The GAAP to non GAAP reconciliations are provided in the earnings press release as well as on our website I will now turn the call over to Dan Daniel O Day    Chairman and Chief Executive OfficerThank you  Doug and good afternoon everyone  I ll share a few opening comments before I turn the call over to Andy and then Johanna will take you through the commercial highlights of the quarter and Merdad Parsey whom as you know  joined us as Chief Medical Officer in November  will offer a few remarks before we open up the call to questions We had a very strong quarter  capping a solid year for Gilead  Our financial results in 2019 were driven in large part by the outstanding performance of our HIV franchise  It s now been almost a year since I arrived at Gilead  We made key decisions and changes that have positioned us for success  Over the past decades  the company has set a high bar and we hope to raise that high bar over the decades to come  Today  I m going to focus my comments on three areas  One  our strong base business  two  the existing pipeline opportunities  and three  our new strategy to drive innovation and growth So I ll begin by saying a few words about the strength of our core business  starting with HIV where we again achieved record revenue for both the quarter and the year  Today  approximately 80  of people living with HIV  who are on therapy in US are on a Gilead based regimen  Across the franchise  we ve seen durability and sustainability of the business  which we expect to continue in 2020 and beyond  Much of the strength is being driven by Biktarvy  Today in US  approximately one in two patients  who are new to therapy and patients who are switching therapy are initiating on Biktarvy  We re also very pleased with the early progress with Descovy for PrEP  The strength of the launch and the positive response we are seeing from patients and providers  Johanna will share more details shortly on that Looking to the future  we re focused on the potential of our capsid inhibitor as the anchor molecule for multiple long acting HIV options  We may be able to dose as frequently as twice a year  and we re working rapidly to progress this medicine for both HIV prevention and treatment  Rounding out the antiviral picture  we continue to see sustained revenue from our HCV business  since the introduction of authorized generics in the US  we ve regained market share and now hold around 60  share through Asegua and Gilead  up 18 points from the beginning of last year Finally  as we look across our core business  I d like to highlight the geographic expansion and in particular China  During the fourth quarter  we had four medicines  Vemlidy  Epclusa  Harvoni and Genvoya included in China s national reimbursement drug list  This is a significant accomplishment that will enable much broader access to these medicines in the region So beyond our core business our current pipeline include several important opportunities that I d like to cover  We have 14 late stage studies under way  four of which have received breakthrough therapy designation from the FDA  During the fourth quarter  we submitted a regulatory filing for filgotinib to the FDA and it s now under priority review for rheumatoid arthritis  Filgotinib is also under review in Japan and the EU  We re actively preparing for competitive launches globally  which Joanna will talk more about later  I m encouraged about the potential of filgotinib to be best in class among the JAK inhibitors and the strength of the team we have in place to market the medicine following approval Beyond filgotinib we are pleased with what we see in the Galapagos pipeline and believe that the partnership has the potential to drive significant future growth  We are looking forward to the ulcerative colitis data this year and we remain very optimistic about both our partnership with Galapagos as well as a promising inflammation pipeline we have in hand And cell therapy  we have a pioneering platform that is enabling us to advance new therapies  with the goal of driving long term innovation and growth  To that end  our second cell therapy treatment  Kite X19 is now under review in the US and Europe as a treatment for relapsed refractory mantle cell lymphoma  This follows the presentation of positive data at the American Society of Hematology meeting in the fourth quarter of this year  We also presented data at ASH showing the approximately half of patients treated with Yescarta for relapsed refractory large B cell lymphoma were still alive after three years of treatment in the Zuma one study confirming Yescarta is benefit risk profile in the real world setting  These long term data speak to the durability of Yescarta s treatment  Finally  in cell therapy  we look forward to sharing results from our Yescarta Phase 3 second line  DLBCL trial in the second half of this year  Merdad will offer some more color on our pipeline in just a few minutes In addition to the programs  I ve described that we have in hand  I introduced our new corporate strategy last month  This strategy will guide our work as we seek to drive innovation and growth over the next decade  Over the next 10 years  we aim to introduce 10 new transformative therapies  To help us achieve that ambition  we will expand our access to internal and external innovation We ve already been very active in business development with around 33 strategic partnerships and investment transaction since January 2018  We ll continue to pursue a broad range of opportunities with a clear focus on our core scientific areas of strength  Specifically  we will continue to make investments in our external pipeline including transformative partnerships such as Galapagos and small to medium size bolt on acquisitions  Andy will talk more in a few minutes about our capital allocation priorities including today s announcement of a further increase in our dividend and it additional share repurchase authorization and our strong financial position  which gives us the opportunity to look externally as we strengthen our pipeline Before I hand off to Andy who will delve into a more detailed financial review  I d like to say just a few words about the broadening outbreak of Coronavirus  As an organization  Gilead is committed to collaborating with global health organizations to support pandemic responses including this one  Our investigational compound  Remdesivir as demonstrated in vitro and in vivo activity in animal models against the viral pathogens  MERS and SARS  which are structurally similar to the current strain of the Coronavirus  However  there are no antiviral data that show activity against this strain  We re working with the government and non government organizations and regulatory authorities to develop a strategy to provide Remdesivir to patients with Coronavirus for emergency treatment and the absence of any approved treatment options  And to support clinical trials to determine whether it can safely and effectively be used to treat the current strain of Coronavirus  As a reminder  Remdesivir is an investigational agent  It is not approved anywhere globally and has not been demonstrated to be safe or effective for any use  I m proud of our teams and the work we ve done to offer expertise and resources to help patients and communities fighting Coronavirus In closing  I m very optimistic about where we are today and the future  Our base business is strong  durable and growing  As demonstrated by our fourth quarter numbers and year end results  the near term pipeline provide several important opportunities with readouts expected later this year with filgotinib and Yescarta  And over the long term  we ve introduced a new strategy to drive growth by growing our pipeline internally and importantly  also externally through our ongoing BD activities On behalf of the leadership team  I d like to thank all of our employees and partners around the world for the dedication and hard work that led to the success of 2019 and whose commitment is driving our success in 2020 and beyond  I remain excited about the potential of Gilead as we enter the next chapter With that  I ll turn the call over to Andy Andrew Dickinson    Chief Financial OfficerThank you  Dan  I m excited to take on the role of CFO  especially during this time as Gilead enters a new chapter  We re pleased to share our financial results for the fourth quarter and the full year 2019 and provide 2020 guidance today  I ll first review financials  followed by comments from Johanna Turning to our financials  Total revenue for the fourth quarter was  5 9 billion  with non GAAP earnings of  1 30 per diluted share  This compares to revenue of  5 8 billion  with non GAAP earnings of  1 44 per diluted share for the same period last year  Our non GAAP earnings would have been  1 77 and  1 75 in the fourth quarter of 2019 and 2018  respectively excluding unfavorable cost of goods sold impacts  These impacts were primarily driven by inventory writedowns of  500 million and  410 million  respectively for slow moving and excess raw material and work in process inventory largely due to lower long term demand for our HCV products For the full year 2019  total revenues were  22 4 billion  up 1  year over year  Non GAAP diluted earnings were  6 63 per share for the year  down from  6 67 per share for the full year of 2018  Excluding the unfavorable cost of goods impacts I mentioned previously  our non GAAP earnings would have been  7 14 per share for 2019 and  7 01 per share for the prior year As noted in our earnings press release  our full year 2019 GAAP diluted earnings of  4 22 per share included total unfavorable impact of  3 30 per share from the following items  first  pre tax up front collaboration and licensing expense of  3 9 billion associated with our global research and development collaboration agreement with Galapagos  secondly  pre tax impairment charge of  800 million recognized in the fourth quarter of 2019  primarily related to in process research and development intangible assets for the treatment of indolent non Hodgkin lymphoma  and pre tax writedowns of  547 million for slow moving and excess raw materials and work in process inventories  The unfavorable impact was partially offset by a favorable impact of  1 94 per share  due to a deferred tax benefit of  1 2 billion related to an intra entity transfer of intangible assets and gains of  1 2 billion from equity securities held for investments Now turning to our product sales  Product sales for the fourth quarter were  5 8 billion  up 5  sequentially and 2  year over year  For the full year  product sales were  22 1 billion  up 2  year over year primarily due to the continued revenue growth of our HIV franchise  partially offset by the impact of loss of exclusivity on our cardiopulmonary franchise and market dynamics of our HCV franchise In the US  product sales for the quarter were  4 5 billion  up 8  sequentially and 1  year over year  Demand for Biktarvy and Descovy for PrEP was the primary driver of the sequential growth  The seasonal inventory purchases also contributed approximately  290 million to the sequential performance  In Europe  product sales for the quarter were  840 million  up 4  sequentially and 3  year over year  Recall that both the third quarter of 2019 and the fourth quarter of 2018 were negatively impacted by unfavorable adjustment for statutory rebates Turning to cell therapy  Worldwide Yescarta sales for the fourth quarter were  122 million  up 3  sequentially and 51  year over year  The year over year increase was driven by a higher number of therapies provided to patients and Kite s continued expansion in Europe Now turning to expenses for the full year 2019  Non GAAP cost of goods sold was  3 5 billion  down 1  compared to  3 6 billion in 2018  The decrease was primarily due to lower royalty expenses  partially offset by higher inventory write downs  During 2019 and 2018  we recorded writedowns of  547 million and  440 million respectively  for slow moving and excess raw materials and work in process inventories primarily due to lower long term demand for our HCV products Non GAAP R D expense was  3 8 billion  up 7  compared to  3 5 billion in 2018  the increase was primarily due to higher personnel cost to support our cell therapy business  Non GAAP SG A expense was  4 1 billion  up 13  compared to  3 6 billion in 2018  the increase was primarily due to higher promotional expenses related to Biktarvy and Descovy for PrEP in the US and expenses associated with the expansion of our business in Japan and China Turning to our balance sheet  We generated  9 1 billion in cash from operations for the full year 2019 and  2 6 billion for the quarter  We ended the year with  25 8 billion in cash and marketable debt securities  During 2019 we paid  5 6 billion in connection with our global research and development collaboration with Galapagos and our equity investment in Galapagos  In addition  we repaid  2 8 billion of debt  We paid cash dividends of  3 2 billion and we repurchased 26 million shares of stock for  1 7 billion Earlier today  we announced an increase in our quarterly dividend from  0 63 a share to  0 68 a share  which will be effective in the first quarter of 2020  This is our fifth consecutive annual increase in our dividend  In addition  our Board authorized an additional  5 billion share repurchase program in January 2020  We now have over  8 billion of share repurchase authorization available  In 2020  our capital allocation priorities will remain unchanged  First and foremost  we are focused on investment to augment internal and external research and development  our internal research and external development pipeline  Second  we intend to grow the dividend over time  pointing out of course that any dividend increase is subject to the approval of our Board  Finally  our commitment to repurchase shares in excess of dilution from our equity compensation and at a minimum  we expect to repurchase shares in 2020 on par with our 2019 share repurchases Turning to guidance  our 2020 non GAAP financial guidance is summarized on slides 23 through 26 in the earnings presentation available on our corporate website  Before I start I d like to highlight three things that are important for you to understand  The first change is that beginning in the first quarter  we will no longer regularly exclude stock based compensation expense from our non GAAP financial information  Stock based compensation as always been an important part of how we reward our employees in a way that aligns their interests with those of our shareholders and it s an important component of our compensation structure  As such  although it s not a cash expense  we believe it to be a cost that should be included when measuring our financial performance  For comparability purposes  full year 2019 non GAAP operating income and non GAAP diluted earnings per share would have been  10 4 billion and  6 13 per share respectively had stock based compensation expense  not been exclude Our second change is that we re modifying our guidance metrics for 2020 as we will now be providing guidance for earnings and operating income  in addition to the metrics that we ve historically shared  Our guidance is aligned with how the management team and our Board evaluate our financial performance and manage our operations  Finally  our guidance excludes the impact of any future significant business development transactions  certain development milestones and any product option exercise fees as they are contingent on various future events  which have a high degree of uncertainty With that background  we expect that our product sales for 2020 will be in the range of  21 8 billion to  22 2 billion  This guidance reflects robust underlying growth in our base business of approximately  800 million to  1 billion  which is expected to offset the full year impact of loss of exclusivity for our cardiopulmonary products in 2019 and the initial entry of a generic version of Truvada in the US later this year  I would also like to highlight that as we look toward Q1 of 2020  we anticipate the total product sales will decline sequentially that quarter by a percentage similar to what we ve seen over the past three years  which has been as high as 12  to 14  primarily driven by US seasonal inventory patterns and buying patterns of public payers that negatively impact our payer mix  We also anticipate that our Q1 2020 product sales will decline in comparison to Q1 2019  primarily due to lower sales of our cardiopulmonary products  Ranexa and Letairis  As a reminder generic versions of Ranexa and Letairis were launched in the first quarter and second quarter of 2019 respectively  Despite this anticipated sequential decline in total product sales in Q1  I want to underscore our confidence in the health of our worldwide HIV business from which we expect year on year growth again in 2020 Turning to our product gross margins  Our non GAAP product gross margins are expected to be in the range of 86  to 87  in 2020  We expect that both non GAAP R D and SG A expenses will increase mid single digit percentage in support of our continued growth of Biktarvy  our Descovy for PrEP launch  preparation for competitive launches of filgotinib in RA in the US  Japan  and Europe and continued investments in our pipeline  cell therapy  and external partnerships Non GAAP operating income is expected to be in the range of  10 1 billion to  10 8 billion  For the full year  our non GAAP effective tax rate is expected to be approximately 21   Non GAAP diluted EPS is expected to be in the range of  6 05 per share to  6 45 per share  which again I ll remind you no longer exclude stock based compensation  GAAP diluted EPS is expected to be in the range of  5 15 to  5 55  Finally  our diluted EPS guidance includes repurchases largely consistent with 2019 I ll now turn the call over to Johanna Johanna Mercier    Chief Commercial OfficerThank you  Andy and good afternoon everyone  I m really pleased to share the highlights of our excellent Q4 and full year commercial performance  I wanted to begin with the continued strength of our HIV franchise  which was driven by the continued uptake of Biktarvy as well as the successful early launch of Descovy for PrEP  I ll then provide an update on HCV  touch briefly on our cardiopulmonary business and finally close with a few remarks as we look ahead to the filgotinib launch As Dan mentioned  approximately 80  of people living with HIV who are on therapy in the US are taking at least one Gilead drug  a sign of the sustained and durable strength we see across the franchise  We reached another all time high with our HIV product sales for both the full year and quarter  For 2019 HIV sales were  16 4 billion  up 12  from 2018  Global HIV sales for Q4 were  4 6 billion  up 9  sequentially and 13  year over year  This marks the seventh consecutive quarter of double digit year over year growth for the franchise US HIV product sales were  3 8 billion in Q4  up 11  sequentially and 12  year over year  The year over year increase was primarily driven by underlying prescription demand growth of 10   Within our prevention market  we re really pleased with the early progress of Descovy for PrEP  which launched in the US in Q4 2019  approximately 27  of individuals on PrEP are now taking Descovy and by Q4 2020  we expect that number will have risen to anywhere between 40  and 45   Across the prevention market  we saw growth of more than 20  in the number of individuals taking PrEP year over year  There are now more than 230 000 people taking one of our HIV prevention medicines in US and this only represents approximately 20  of those who could actually benefit from it Turning to the US HIV treatment market  Biktarvy sales were  1 4 billion in Q4  up 23  sequentially  The market is continuing to consolidate around Biktarvy  which is the number one prescribed HIV regimen in US  And as Dan noted approximately one in two of every naive and switch patients are now initiated on Biktarvy In Europe  Q4 HIV product sales were  562 million  up 1  sequentially and 10  year over year  The year over year growth was driven by the continued strength of our Biktarvy launches in Europe  declining impact of generic launches and unfavorable non recurring pricing and adjustments in Q4 of the prior year  Biktarvy is now available in 29 countries in Europe and it s number one in naive and switch in Germany  France  Spain and now Italy as well Turning to our HCV business  Q4 HCV sales were  630 million  down 7  sequentially and 15  year over year  2019 sales were  2 9 billion for the full year  down 20  primarily due to lower average net selling price and declining patient starts  US revenues for Q4 were  337 million  down 11  sequentially and 18  year over year  In the US  we now have approximately 60  market share with our Gilead branded and authorized generic partner products and are continuing to sustain revenue  In Europe  HCV product sales for Q4 were  151 million  up 36  sequentially and down 20  year over year  The sequential performance was impacted by the seasonality of product sales  Overall  the HCV market continues to see a more predictable decline in patient starts and performs in line with our expectation Before turning to filgotinib  I just wanted to make a few comments on the cardiopulmonary business where we have seen generic competition enter the market early last year  As anticipated significant volume erosion has occurred and as of last December we have seen 90  of erosion of Ranexa    erosion of Ranexa  and 65  erosion of Letairis  a trend that we expect to continue into this year So in closing  I m really excited to share with you a few words about the filgotinib launch  As Dan noted  our teams have now completed regulatory filings for rheumatoid arthritis in US where filgotinib is under priority review as well as in Europe and Japan  In December  we announced a co promotion agreement in Japan with Eisai  It is estimated that approximately 600 000 to a million people in Japan are living with RA and this agreement allows us to draw on the strengths of both companies  with the goal of bringing this important new medicines to those individuals  As you re aware  despite currently available treatment options many patients are still living with symptoms of inadequately controlled RA around the world  In fact  only one out of five patients living with RA achieve complete remission at year one  which means four to five do not  Filgotinib has a compelling and differentiated clinical profile that we believe may uniquely address the significant unmet need for patients with RA  We have highly experienced team preparing for launch later this year and our focus will be on the strength of our data and the compelling risk benefit profile observed across both tested doses of this oral medicine I look forward to working with this great team of people to deliver on the promise of these medicines  And I ll now turn the call over to Merdad Merdad Parsey    Chief Medical OfficerThank you Johanna  And good afternoon everyone  It s been a pleasure to meet some of you over the past few weeks  I m pleased to participate in the first earnings call at Gilead today  I m excited to join the team to extend Gilead story and improve the lives of patients around the world  As we implement our new corporate strategy  I m confident we can leverage our existing pipeline and to expand with internal and external approaches Building on Gilead s impressive innovation in HIV  including the launch of 11 products in 17 years  our goal is to continue to transform the lives of people affected by HIV  Our next wave of HIV innovation will be driven by long acting options for treatment and prevention  We listen to what patients want and we re committed to continuing to pursue and provide more options that meet the needs of people affected by HIV  We believe our capsid inhibitor has the potential for a truly unique profile  offering both oral and subcutaneous dosing  the potential for self administration as well as multiple dosing frequencies and options for HIV treatment and prevention  We recently presented data from two Phase 1 studies demonstrating potent antiviral activity and a potential dosing in a role of up to every six months  We ve initiated Phase II III studies  including one of the    one in heavily treatment experienced patients and we received Breakthrough Therapy designation for this use  The capsid inhibitor will be the foundation of our long acting options and we are exploring multiple partner agents to pair with it As Dan said  we ve set the ambitious goal of bringing 10 transformative medicines to patients over the next decade  The first of these 10 transformative medicines will be filgotinib  which has a potential best in class profile  I ve been impressed with the strength of the filgotinib data and speaking with key opinion leaders  there is real appreciation for the results and an excitement for the potential combination of efficacy and safety of the selective oral JAK1 inhibitor  Across the FINCH studies we ve seen consistently strong efficacy and demonstrate a safety profile that is highly favorable from a benefit risk standpoint  and this is true at both doses tested  We ve now filed for filgotinib in three regions  the US  Europe and Japan  and as Joanna mentioned we are gearing up for the launch Filgotinib has the potential for five new indication launches in the next four years  And we look forward to upcoming ulcerative colitis data this year  This timing could give filgotinib one of the first labels in ulcerative colitis for JAK inhibitor  We have also had    I ve also had the opportunity to meet the Galapagos team and discuss opportunities that are being pursued beyond filgotinib  this remarkable partnership has the potential to double our research footprint as number of programs that could add to our inflammation portfolio Turning to oncology  We have a broad portfolio today including Kite and have a total of 15 clinical stage programs  Our approach is to build transformative therapies across complementary immuno oncology platforms including both cell therapy and non cell therapy  We re actively pursuing and evaluating innovative programs and technologies externally to build our presence in oncology  In total across our current pipeline  we have 40 clinical stage programs  As Dan mentioned of these programs  14 are either being registered right now or in label enabling trials and four of these programs have breakthrough therapy designation  As we pursue external opportunities  we ll continue to build around antiviral therapies  inflammation  fibrosis  and immuno oncology I m excited to work with Dan and the entire Gilead team to expand on the great things that have been done to date and go further for people living with HIV and the patients we serve  This work  internal and external  will enable us to grow in the mid to long term  I look forward to sharing more with all of you about our progress on future calls  Thank you very much And now we ll open the call for questions  Operator Questions and Answers Operator Operator Instructions  Our first question comes from Michael Yee with Jefferies  Your line is now open Michael Yee    Jefferies    AnalystHey  guys  Thanks for the question and thanks for the color on the guidance  I guess I just wanted to ask about your perspective on guidance for 2020 and thinking about both the revenue guidance  which is seemingly flat to down ish versus  19 and EPS  you know when backing out the stock option seems to be flattish to down ish  maybe you can just comment about your perspective of 2020  Is that an investment year  is it potential to be a growth year  both on revenue and EPS  And how do you think about it  of 2020 versus say what you think about  broadly speaking for  21  Thanks Daniel O Day    Chairman and Chief Executive OfficerYeah  thanks a lot Michael for the question  And I would say again based upon the strong results coming off of 2019 that our base business  our HIV business is really robust and continues to grow and of course we need to offset as Andy mentioned in his comments  the full year effect of the cardiopulmonary franchise and just the beginning of the Truvada expiry and we feel confident in our ability to be able to do that  Our guidance reflects revenue that is essentially flat year on year and of course  we ll keep you updated as we go throughout the year based on a variety of events on the commercial side On the investment side  I would say  yes  absolutely  We feel that we need to invest on the commercial side to make sure that we are preparing ourselves well for the most recent launches that have gone out and that s Biktarvy and Descovy  but also well prepare ourselves for a very competitive launch for filgotinib  where you ve heard us say we really think we have a unique medicine  with a best in class profile and we want to make sure  as we know there is only one chance to get a launch right  We want to make sure we re well prepared for that  Now  we have obviously looked hard at our expense base on the commercial side  reallocated resources from cardiopulmonary and are well prepared to put our investments on the growth drivers  And as you can see in our qualitative guidance feel we need to increase slightly from year on year for the SG A guidance Likewise with the investments that we ve made  both in our internal pipeline  the expansion of lifecycle programs around medicines like filgotinib and others  that we need    and including external innovation that we brought in over the past two years  including 33 different collaborations and or acquisitions  We want to make sure we invest appropriately in those to take them to the next decision point and decide about future investment accordingly  And we ll continue to work on that portfolio as we move forward Andy  did you have some other things you wanted to add to that Andrew Dickinson    Chief Financial OfficerYeah  thank you  And Michael  thanks for the question  I would just add two things  Again  as many of you have heard  our primary focus is on building a predictable  sustainable top line growth profile that you would expect to see a company like Gilead so  And that at times requires investment  it has in the history of Gilead as you go back to the Pharmasset acquisition and the investments that were made following that and it will going forward  So that is our primary focus as you know  and then I d also add that we also felt that it was important to provide additional transparency and accuracy in measuring our financial performance and that s why you re seeing additional guidance that helps to give you a fuller picture of how we see the business for the coming year  And I think the guidance speaks for itself and Dan s point were right on Michael Yee    Jefferies    AnalystOkay guys  I appreciate that OperatorOur next question comes from Brian Abrahams with RBC Capital Markets  Your line is now open Brian Abrahams    RBC    AnalystHi  there  Thanks so much for taking my question  As you look across your mid stage portfolio and to new corporate strategy  I was wondering if you could elaborate a little bit more on the areas of most interest to build out or to wind down  Where do Gilead s team stand today to most optimally take advantage of external opportunities  And how do you guys balance potential versus risk as you look at investing in assets  both internally and externally  Thanks Daniel O Day    Chairman and Chief Executive OfficerGreat  Thanks a lot  Brian  I ll start and then I ll ask Merdad to comment on the portfolio  because one of the big efforts that we have under way is with Merdad coming into the organization is breadth of experience in building world class portfolios  That s exactly what he is involved in right now and really leveraging the strengths accordingly across the portfolio  So I d say a couple of things Brian  I think you know as you know we ve kind of elevated the full disclosure and openness on our portfolio  We started at a JPMorgan  you can expect us to continue to be very transparent about the portfolio  the decisions we take and we make  but I think just the very fact that we have 40 clinical stage programs  14 of which are in registrational trials is something that I think maybe under appreciated as we    from the outside Now you asked about what are the things that are most interested in  I m going to let Merdad give that as well  but I ll remind you that our strength in viral diseases will continue to be invested in and that s the discussion around capsid and really truly providing kind of next generation therapies that we think patients and customers  while we know patients and customers are asking for out there  I mean  said that I think the extension of our inflammatory disease portfolio with the Galapagos transaction is something that excites me  I think there s lots of potential shots on goals there  There is ways to think about between Gilead and Galapagos building combination purchase in the future and I think we ve really got a strength in inflammatory diseases that is building Fibrotic disease is something that we have a depth of expertise in and we understand the challenges associated with that disease state  And so as Merdad builds the portfolio  I think he ll comment  we have to make sure that we re putting the right level of investment there that makes sense for the big unmet medical need  but also the risk associated with some of the natures of those diseases  And then finally  there s been significant effort long before Merdad or I joined on oncology  Of course the Kite acquisition provide us with an immediate step up and knowledge and know how and a breadth of portfolio there  but the non Kite portfolio is something that s really built up over the past couple of years  both internally and through our collaborations we know it s early and we know that we re going to have to continue to pursue those programs and build on it  So that s my  0 02  Merdad you have a deeper    kind of a refresh view because you ve just entered  not too long ago  So it d be good to hear your reactions Merdad Parsey    Chief Medical OfficerYeah  and I won t belabor on what Dan said  I think    I think he hit on the main things which is sort of making sure the capsid molecule looks really interesting and I think we re pretty excited about that one and building a partner for that for both treatment and prevention is going to be important goal of ours  And then in inflammation  getting the filgo to launch right and then supplementing filgo    filgotinib in our pipeline is going to be an important task for us to focus on as well to build around the inflammation portfolio and to enable broader reach as we develop there  And then oncology  I think that s an area where we are going to spend time building out looking for opportunities  especially immuno oncology and working with our colleagues at Kite to make sure that we re finding the right balance and bringing the non cell therapy portfolio up to complement the cell based therapy I think more qualitatively maybe I d say  I think what you re hearing is this idea about focus for us  making sure that we re really thoughtful about where we focus and where we build our expertise so that we can build a portfolio around those areas of focus  as you ve heard me and Dan layout  And also that we find a balance to address your other question around risk to find balance around how we approach the overall portfolio so that we have a mix in there of some high risk high reward programs balanced with some other programs that are less risky and have more higher likelihood of success  And so we are going to approach the portfolio that way and broadly across the entire portfolio inclusive of oncology  inflammation  fibrosis and HIV Daniel O Day    Chairman and Chief Executive OfficerThanks  Brian  Hope  we got your question Brian Abrahams    RBC    AnalystThanks very much  Thanks  Dan  Thanks Merdad OperatorOur next question comes from Geoff Meacham with Bank of America  Your line is now open Geoff Meacham    Bank of America Merrill Lynch    AnalystAfternoon guys  Thanks so much for the question  And Andy  thanks for all the clarity on guidance  Johanna  I wanted to ask you a couple on HIV  So the Descovy in PrEP targets  what gets you there to 40   45   And how are you dealing so far with generics to grab share  Then when you look at the Biktarvy franchise  obviously pretty dominating share there  but what populations have you seen of late that are going to continue to add to the    the switched dynamic  I mean  I guess the question is how many of the switches that you ve seen thus far in the US are kind of laggards and maybe where are they re coming from  Thank you very much Johanna Mercier    Chief Commercial OfficerOkay  Thanks Geoff  So maybe I ll hit your Descovy question first and then go to Biktarvy  So we exited the year around 27  with Descovy and what we re seeing is really nice uptake  But if you recall  there is a real segment to market in    the prevention market versus the treatment market  In the treatment market  you have 3 000  4 000 prescribers  In the prevention market  it s much larger than that  like by tenfold  And so  therefore  it s really how do we get there is making sure we focus on the higher volume  which is the same folks that actually are prescribing in prevention are also prescribing in the treatment    HIV treatment world and those are physicians that truly understand the benefits of going from a TDF agent to TAF with all the bone and renal safety that comes with it  And so we believe    that we ve actually seen that share of that segment increased very rapidly  We also have another big piece of the pie that is about 20   25  of the volume that are folks that have never prescribed in HIV treatment  And so these are folks that we are visiting and obviously using different means of communication to make sure they re educated around the fact of the benefits for TAF agents like Descovy and so    so what we re seeing is that increase month to month  and we re very pleased with where we are today  after only three months of launch  Having said that  we believe that s going to continue with some challenges  potentially on the payer side and that s how we get to the 40   45  toward the end of the year in light of the fact that Truvada is losing its patent later this year in October and so some payers are already planning ahead of a little bit on that one  And so we re working with them very closely to make sure that patients get the best most appropriate compound for them  And so I guess we believe that that s where we re going to about 40   45  of conversion by October of this year  So that s the Descovy story From a Biktarvy standpoint  I think  you know what you were saying  good quarter  And I think I would say it s an excellent quarter for Biktarvy  if I do say so myself  I m very proud of the team on that front  and it s been obviously very active  very competitive in the market space as you well know  The Biktarvy is really being used for with the majority of patients and that s really the profile of Biktarvy and what it brings to the table in light of the combination of convenience  tolerability  the high barrier to antiviral resistance  And so that kind of what Biktarvy has to offer  What I would say is  as you think about all the ending the epidemic initiatives  That s were the rapid start with Biktarvy is becoming a really increasingly point of differentiation and very important one for physicians  And I think that s really helping the Biktarvy growth as well as you move forward So the fact that one out of two patients are actually starting on Biktarvy  whether that s a naive patients  or switch patients that is really where you re seeing how the market is consolidating around Biktarvy and we believe that will just continue not only in 2020  but beyond that  just because of what Biktarvy has to offer for patients Hopefully that answered your question  Geoff Geoff Meacham    Bank of America Merrill Lynch    AnalystThank you OperatorOur next question comes from Geoffrey Porges with SVBLeerink  Your line is now open Geoffrey Porges    SVBLeerink    AnalystThank you very much  I appreciate the question  I just wanted if have to ask one about Remdesivir  which is  have there been any other anecdotal reports of responses  other than the one that was in the journal over the weekend  And do you have manufacturing capacity that you could scale up quickly  And then I just wondered if Merdad could talk a little bit about fibrotic disease  You re obviously still involved in NASH  but there are lot of other fibrotic diseases  and I just wonder if you ambition span all fibrotic diseases or still pretty much confined to NASH  Sorry about the double up Merdad Parsey    Chief Medical OfficerThat s alright  Thanks for the question  On Remdesivir  we have not had any other anecdotal reports to date and so we will obviously keep an eye on that very closely and see how that progresses  In terms of manufacturing  our team has really been working night and day  it s been very impressive to watch this team over the past couple of weeks really ramp up to the extent that we can  If our capacity is going up every day  we re looking at all the options we have expecting to be prepared for what may come  Obviously  we are waiting for data both in vitro and then in people to ensure that the drug actually works  But it s important just for everyone to keep that in mind that this is still investigational and we are still waiting for more data to know  but at risk we are investing pretty heavily to make sure that we re prepared as best as we can In terms of fibrotic disease  we think of it fairly broadly  but I guess from my perspective  when I think about fibrotic disease  to your point we NASH as you know we ve had programs and diabetic kidney disease  we have a program in idiopathic pulmonary fibrosis right now  And those are biologically related and one of the things that we are always have in our mind is to think about where    where to apply particularly mechanism  which disease to apply particular mechanism and so what I would say as we    as we see the readouts on the IPF study as they come forward as we have the discussions with the agency about the NASH program and as we see novel molecules that come through  we ll do those in a gated way  Fibrosis is a challenging area and we don t underestimate how difficult that s going to be  Hope that address your question Geoffrey Geoffrey Porges    SVBLeerink    AnalystYeah  thank you  Really appreciate it Merdad OperatorOur next question comes from Matthew Harrison with Morgan Stanley  your line is now open Matthew Harrison    Morgan Stanley    AnalystGreat  Good afternoon  thanks for taking the question  I was hoping you could address what you see is the opportunity in China  you obviously mentioned that for Vemlidy and then pointed out some of your HCV medicines are approved there  but I don t think you ve talked about how big you think that could be your    how much of a contributor  you think that could be over the next couple of years  Thanks Daniel O Day    Chairman and Chief Executive OfficerThanks Matty  We ll have Johanna address that  Thanks Johanna Mercier    Chief Commercial OfficerSo in China we re excited about the fact that this is really our first opportunity with reimbursed compounds  So I think Dan mentioned which one  but just to highlight  From a hepatitis C standpoint  it s Harvoni and Epclusa and the only other product  this was a tender process in China  and the only other product approved is  Indecipherable   reimbursed I should say  And so  I mean of course  this is more of a volume opportunity than anything else  And this is one that we believe many patients are in need  And we have a real opportunity to help those patients  That s in hepatitis C In hepatitis B  Vemlidy also got reimbursement  which of course as you know for hepatitis B biggest market from a patient standpoint is also in China  And then the last one is Genvoya in HIV  which HIV is going to be the first time that actually products will get reimbursed in China  in HIV the class  And so we believe that s also one that we re cautiously optimistic that more patients can really get better treatment that they need  So  we are cautiously optimistic about our China business opportunity  you can appreciate that with everything going on right now in China  the focus is not on some of these new products that got reimbursement  the focus is really on the people and what s going on with the Coronavirus  And so we do think that might be a little bit delayed in 2020 as we see kind of that play out  but I do think from a longer term standpoint this is how we should be thinking about China and the opportunity moving forward  because of the patient pool that is so predominant in the specific disease areas that we offer potential solutions for patients Daniel O Day    Chairman and Chief Executive OfficerI think that s great  Matthew  The only other thing I would say  Joanna has captured really well is that we kind of put this into the durable base part of our strategic story and I think that s because it is a volume game  I think there is real opportunity here obviously for patients in China  but also for our business  but it helps us kind of stabilize and navigate that durable base over the course of the years to come  And it s important for patients and also for our business to build out  And then we have the inflection points on top of that  you know with Yescarta  Phonetic  business with filgotinib  with a variety of things that are in our hands right now and a larger portfolio to inflect for the    for it to provide our confidence in the mid to long term growth  Thanks OperatorOur next question comes from the line of Umer Raffat with Evercore ISI  Your line is now open Umer Raffat    Evercore ISI    AnalystHi  thanks so much for taking my question  Perhaps  First one for Johanna  Johanna  I know you worked in    in your prior role you headed a commercial organization  which was best in class in oncology and a very established organization in primary care with Eliquis  And my question to you is  as you look at Gilead where it stands today how prepared is the organization to compete with AbbVie and Pfizer  two companies very well entrenched in their    with their Jack s respectively  I m just trying to understand the level of organizational preparedness especially in light of which I think is probably something like  200 million plus or minus the year over year incremental SG A expense possibly heading into the filgotinib launch And one for Merdad  I know the filgotinib UC  Phonetic  trial selection one is due any day  I also understand that there is inadequate responders to Entyvio in there  So  those patients in particular  what percentage is that of the trial  And do you expect filgotinib to be active in Entyvio non responders  Thank you Johanna Mercier    Chief Commercial OfficerSo maybe I ll kick it off Umer  with your first part of your question  So specific to filgotinib  I think that you re right  obviously we are very well aware that it s going to be a very competitive environment  There s no doubt about that  but I think we re being really smart about it  And what I mean by that is because I think what we re thinking about is making sure where we re going to bring focus to the table  So we are going to be  we are very clear about where we want to play and where we play we win and that s about commercial excellence and medical excellence  to be honest with you  because  medical and commercial  we need to partner very closely and we are already around the clinical data and the profile of this compound  and how that really needs to be at the center of everything we do with filgotinib I would also say that you know if I take other disease areas  where we had similar competitive dynamics and similar competitors to be honest  we have done  actually quite well in that space and HCV is a great example of that where we ve regained share and now we re at 60  share in HCV across the marketplace  which I do think shows others including internally and externally that we can be very competitive when we need to be and I think that s exactly what you re going to see with filgotinib We are preparing the teams  We are making sure that we are hiring the right people and with the right level of experiences to making sure that we are absolutely ready for an expected launch later this year  And I think that I m really excited about it  to be honest with you  I think the team has really come up the line and I think we brought in some really good external talent  but we already had some very good internal talent as well and building the two together  I think will make for a very successful launch moving forward Merdad Parsey    Chief Medical OfficerAnd yeah  and so this is Merdad  maybe I ll start by clarifying the timing because I think you may have given my team a heart attack  I don t think it s any day now  I think we ve got it to a little bit later in the first half of the year  So please be patient with us as well  We ll get it out there as quickly as we can  In terms of the Entyvio non responders  you know I won t know the precise proportion until after we see the demography of the study  afterwards  after the trial has done  So I m not going to    I d be speculating as to sort of where we land on that  So I m going to beg your patience on that one as well But in terms of expectations of response  I think if you look at this    this population as you know they cycle through a variety of medications  And while the response rate when they cycle to the next medication isn t usually as robust as a naive patient there are good    there is good evidence that going from  let s say Entyvio to a TNF inhibitor or vice versa you have  you still have a good proportion of patients who respond in that  So I think our expectations are fairly realistic about what the respond    that we ll have responders in there to filgotinib Umer Raffat    Evercore ISI    AnalystThank you very much OperatorOur next question comes from Cory Kasimov with JPMorgan  Your line is now open Cory Kasimov    JPMorgan    AnalystHey  good afternoon guys  Thanks for taking the question  Wanted to ask you on the corporate strategy front  With everyone is pretty clearly waiting for the company to engage in more substantial business development  but how much of a sense of urgency do you have on this front given kind of the new management team  all coming together now and how successful do you think Gilead can be without outside help basically relying on the first two pillars of your strategy Daniel O Day    Chairman and Chief Executive OfficerYeah  thanks Corey  I ll give a start and if Andy wants to add as well  So look  I think you know  first of all  I believe we re coming at this from a position of strength  The position of strength now that we have a complete management time    team with depth of experience  Of course  we re still building experience in some of our new therapeutic areas  but we have now a team that is accomplished that understands what good looks like  that understands how to take appropriate risk and then that s relatively recent that we have this team together like this  So  it allows us  if you like when we look at external opportunities in our areas of expertise  which is not unimportant because we really decided to focus there  I think it allows us to move fast and we know that moving fast is important and being first to the table at the right time in some cases that s more risks  in some cases that s less risk  depending on the nature of what we re looking at  but I think we re well prepared to be able to pivot    to be first at the table or close to first at the table and to make things happen So we have a solid pipeline  but we have a sense of urgency of course around building this and I think we ve been clear about the areas we intend to build in  We will also be disciplined  We re not going to    we re going to take    we re going to take appropriate risks  but I think risk that will help us build the shape of the portfolio very much like Merdad mentioned before  And we ll take that into account to  So it s not just about an individual target or asset  it s also about how that fits into the complementary nature of that therapeutic area and or other therapeutic areas and that s where we ll pivot and move with  But rest assured  our sense of urgency around is high  but so is our expertise I would say as well  Andy  did you want to add to that Andrew Dickinson    Chief Financial OfficerI mean  the only thing I would add  I agree that there is a sense of urgency  we will be disciplined  I d say to some extent Cory the best proxy is just looking at the past couple of years  I mean we ve outperformed commercially the last two years  we ve given very clear guidance for 2020 obviously  we will work incredibly hard to outperform again we see opportunities  things that we can potentially do better  we would like to find external assets to supplement our pipeline  but we also feel that the durability of our existing business and our existing pipeline are both under appreciated So to answer your second question on can we compete without doing large business development deals  Absolutely  I mean    and we think that we can continue to build a sustainable business  Would we like to supplement it with outside assets especially to build our late stage pipeline  Yes  And we are actively working on that  but to reiterate what Dan said we re going to be thoughtful and disciplined in how we do it Cory Kasimov    JPMorgan    AnalystAll right  That s helpful  thanks guys Daniel O Day    Chairman and Chief Executive OfficerThanks  Cory OperatorOur next question comes from Mohit Bansal with Citi  Your line is now open Mohit Bansal    Citi    AnalystGreat  thanks for taking my question  And if you could talk a little bit about the market opportunity with the capsid inhibitor  especially in  Indecipherable  should we think about this as an incremental opportunity or do you think the portion of it could be from existing in that product  Thank you Daniel O Day    Chairman and Chief Executive OfficerCapsid inhibitor Johanna Mercier    Chief Commercial OfficerSo I think you know I can touch on it from a commercial standpoint and then maybe pass it over to Diana to touch a little bit more on its clinical profile and its offerings  From a commercial standpoint  we re thinking about the capsid in two ways  one in prevention and the other one in treatment obviously  we think there is probably an opportunity we ll see  to see if there is monotherapy and prevention and potentially    obviously we re looking for combination in the treatment  And Diana can touch on that a little bit more  In prevention  I do think with Descovy right now in prevention and the launch of what s going on  we do think that probably going to be something that could be very interesting for patients  If you think about that marketplace and thinking potentially up to six months  and that s really what patients are looking forward to have something every six months  This could be something very interesting and exciting for patients and that would be with the timing that we re thinking about for this compound  assuming all plays out then it could be actually more of a switch in the prevention market from Descovy to the capsid inhibitor Having said that in treatment that we could look very different  And I do think that s potentially a market expansion  because it would really be  if we can find combination that would really work in the treatment setting  I do think that would offer a long acting that patients actually really want and that s the biggest piece of the puzzle  What we re trying to do is making sure that we match up what the patients are telling us with our clinical development plan  And what I mean by that is as we ve done so much market research with our patient pool what they re telling us is yes  weekly oral would be interesting and potentially something that they might be interested over a daily compound  but it s not for everyone  And then when you go from weekly oral to potentially what else would they want  a rather an injectable to subcu  subcu wins out  if they d rather three months and six months  six months wins out  And so that s really where we have focused our clinical development team to make sure that we re addressing the needs of patients  And maybe with that  I ll turn it over to Diana Diana Brainard    Senior Vice President and Head of HIV and Emerging Viruses Therapeutic AreaYeah  we recognize the bar is very high because Biktarvy as really set the standard  but we also know that within the US  for example  only 85  of people with HIV are in treatment  And if we want to end the epidemic  we have to do better and the capsid inhibitor is going to be one of those tools  And we really see it as Johanna was saying as a market expander because one of the reasons that those people aren t in treatment is that the treatments right now are not amenable to their lifestyles  And so long acting is a way to make the umbrella a little bit larger  it s a complement to Biktarvy and what we have already Mohit Bansal    Citi    AnalystThat s helpful  thanks OperatorOur next question comes from Alethia Young with Cantor Fitzgerald  Your line is now open Alethia Young    Cantor Fitzgerald    AnalystHey guys  thanks for taking my question  I just wanted to ask maybe perhaps Dan and Merdad  about the    Merdad  sorry  about the NASH and hep B space  I mean I know it s one that s been pretty tough in clinical side  but obviously there s a lot of leverage to your business  since you have the sales force in place  So I guess I m just try to figure out what you guys kind of think about that going forward over the next 12 months  Thanks Daniel O Day    Chairman and Chief Executive OfficerSure  Merdad  do you want to    Merdad Parsey    Chief Medical OfficerYeah  sure happy to  Yeah  thanks  Thanks Alethia  Yeah  for NASH  I think we definitely are working hard on the results from the ATLAS trial and we ll be    we ll be talking with the regulators and looking to see what the path forward is  As you said    Daniel O Day    Chairman and Chief Executive OfficerData will be published at EASL  Speech Overlap Merdad Parsey    Chief Medical OfficerExactly  So in April we ll show the data to everyone in April at EASL and where    we have plans for sort of mid year discussion with the agency to sort of see if there is a path forward and what that might look like and make a decision based on  based on those discussions  Just a reminder that we ve been studying more HEP3 and HEP4 patients  the more severe patients than our    than most of the other competition has where they re looking at the milder patient populations  The HEP1s to HEP3s  HEP2s and HEP3s sorry  primarily  So it does pose some unique challenges  so we will continue to work there And I think that I would say the same thing for HCV  right  I think it s a HCV is a bit different in that it is a core part of our business  we have    we have therapies  We have a sales force to your    to your point on that  we re continuing to be committed to that space and working there  Our focus is on a cure  we have ongoing work with a number of programs to try to hit our move from where we are today in treatment to moving toward a cure that s going to be a challenging road  but we re committed to it and continue to work there Daniel O Day    Chairman and Chief Executive OfficerYeah  I think I couldn t agree more with Merdad s view  And the only thing I d maybe add to that Alethia is just to say the particularly in Hep B we understand at the end of the day  this is going to take partnerships  So we have to decide what do we do internally  what do we do with partners  cures significantly more difficult than treatment in this area  And so I think that gets back into some of the comments that both Merdad and I had around how much do we invest in ourselves  how much do you do with partnerships  what percentage of our total investment goes into these very  very important unmet medical needs and making sure that we also invest appropriately in other areas that we know have even greater realization potential that also have big unmet medical need  So that balance will continue to play out  The reality is we have very good expertise in both these diseases and I think we ll be able to make good decisions Alethia Young    Cantor Fitzgerald    AnalystGreat  thank you Daniel O Day    Chairman and Chief Executive OfficerThank you OperatorOur next question comes from Salim Syed with Mizuho  Your line is now open Salim Syed    Mizuho    AnalystHey  thanks so much guys for taking my question  And appreciate all the color on the guidance  Andy  Just one from me on  on sort of the long term picture here  and I m not asking for a long term guidance  maybe this is for Dan or Andy  obviously you guys provided a lot of color  Johanna you mentioned Biktarvy majority of patients through 2023  Phonetic   I mean  you guys seem relatively excited about what you have currently in the pipeline with filgotinib etc  But consensus has you modeled that  22 billion sort of flattish for the next few years  do you need M A to grow your top line or do you think you can grow your top line without any additional M A  Thanks so much Daniel O Day    Chairman and Chief Executive OfficerYeah  thanks Salim and certainly have others come in here as well  But look  I think as we ve    as we tried to build the story and as I ve come to investigate the story and some of the other colleagues around the table  I think the first answer to your question is how durable is our base business  because I think that has a very different    depending on how durable you feel it is that has a very different perspective on our confidence around the mid to long term growth  So I think we ve talked quite a bit about this  we feel very confident with the durability of our base business and this is different  by the way compared to a lot of companies in the industry  Yes  we have  as you know from our guidance we are issuing today  we ve got    we ve got some patent expiry to deal with this year and some patent expiry to deal with next year in terms of Truvada  but then as you look out in terms of time  we feel well prepared for the Descovy patent expiry in  25   26 and basically then have a very durable franchise out until 2033 so  So that s the first part of the answer into the story Then we do feel that we have growth engines internally and that s exactly why we ve tried to highlight them a bit more  give you exposure to them  be transparent about it  but also be very clear about where those inflection points are  Things that we have in our hands today  And of course some of the obvious ones you know we have on the plate with things like ulcerative colitis potentially reading out this year  second line DLBCL  capsid inhibitor coming next year  but we didn t talk about a variety of things that are coming through the Galapagos pipeline that also have optionality for us  if you like  and that s osteoarthritis the Phase 2 will come through this year and then we ll have an IPF interim next year  So there are a variety of things in our hands including other collaborations  I m not speaking out here today that are in Phase ones or label enabling Phase twos that are going to read out  And we ve given you all the exposure to the pipeline and portfolio So can we grow based upon what we have in house  Yes  I m confident we can  And I also believe that we re going to supplement that and derisk that over time  but we re going to continue to do it in the way that you ve seen us do that with proper partnerships and proper M A transactions to get to a portfolio strength that s even more obvious to everybody and even more reliable and that s going to take some time to build that and to grow it  but we are firmly committed to do that  We have the resources to be able to do it  I mean  that s what I would say  Andy  would you    Andrew Dickinson    Chief Financial OfficerNo  I think that s perfect  I don t have anything else to add Daniel O Day    Chairman and Chief Executive OfficerOkay  Does that help Salim Salim Syed    Mizuho    AnalystYeah  that s super helpful  Thanks so much guys Daniel O Day    Chairman and Chief Executive OfficerThank you OperatorOur last question comes from the line of Phil Nadeau with Cowen   Company  Your line is now open Phil Nadeau    Cowen   Company    AnalystGood afternoon  Thanks for fitting me in  One question for Andy on the 2020 guidance  just kind of maybe three moving parts that weren t mentioned on slide 25 and I was just curious to get your thoughts on whether these will materially impact revenue in 2020  So positive side  first is filgotinib  any expectations for filgotinib revenue contemplated in your guidance  And then maybe as potential headwinds in HIV  the nucleotide bearing regimens are launching  any expectation for those to gain share through the course of the year  And on HCV price has been deteriorating over the last couple of years and expectations for further declines in price again contemplated in your guidance  Thank you Andrew Dickinson    Chief Financial OfficerYeah at a high level and Johanna may want to comment on the HIV headwinds  And filgo there is limited contribution in 2020 as you d expect given the projected launch dates  So there potential upside there  if that develops  We think and spend a lot of time in the HIV market  So as you might expect our expectations for the competitive dynamic in the HIV market are built into our guidance  And then in the HCV space  We do expect there to be continued price pressure in the HCV space  If you see from the third quarter to the fourth quarter  if you look at our slides  the number of patients that were treated actually went up  Nonetheless  revenues are down given kind of the dynamic in that in that space  So obviously it s a smaller  speaking of HCV  it is a smaller piece of our business  but we    our guidance assumes continued decrease in that business over time  But it s still an important business for us  It generates a lot of cash flow and on a percentage basis although the increase is the same on a dollar basis  it s less than year over year  I mean at some point it may stabilize  but that s how I would think about it Phil at a high level  I don t know if Johanna  if you want to add anything Johanna Mercier    Chief Commercial OfficerI m totally in line with what you said  I would just add from HCV standpoint  the only thing I would add to that is it is just so much more predictable today than it was  And so    and the declines are much  much softer and so what you re going to see is still continued price erosion across US and Europe and the patient starts are a little bit less every single quarter  but having said that  it s nothing like what we ve seen in the past  So  I think much more predictable marketplace for us  In HIV  I think we have had some of those I guess headwinds  as you say from a competitor standpoint mid last year I guess or so when competition came into the marketplace  And we have been able to manage that extremely well and with very limited impact to Biktarvy and its growth trajectory  And so  we believe the same will continue throughout 2020 Phil Nadeau    Cowen   Company    AnalystThat s helpful  Thank you Daniel O Day    Chairman and Chief Executive OfficerThank you  I think that s the end of our call today Douglas Maffei    Investor RelationsOperator Operator Operator Closing Remarks Duration  73 minutesCall participants Douglas Maffei    Investor RelationsDaniel O Day    Chairman and Chief Executive OfficerAndrew Dickinson    Chief Financial OfficerJohanna Mercier    Chief Commercial OfficerMerdad Parsey    Chief Medical OfficerDiana Brainard    Senior Vice President and Head of HIV and Emerging Viruses Therapeutic AreaMichael Yee    Jefferies    AnalystBrian Abrahams    RBC    AnalystGeoff Meacham    Bank of America Merrill Lynch    AnalystGeoffrey Porges    SVBLeerink    AnalystMatthew Harrison    Morgan Stanley    AnalystUmer Raffat    Evercore ISI    AnalystCory Kasimov    JPMorgan    AnalystMohit Bansal    Citi    AnalystAlethia Young    Cantor Fitzgerald    AnalystSalim Syed    Mizuho    AnalystPhil Nadeau    Cowen   Company    Analyst
More GILD analysis
All earnings call transcripts",2020-02-04,The Motley Fool,https://invst.ly/pr5a-,2076248
200604,422120,GILD,StockBeat  Markets Surge on Hints of  Virus Drugs  Smurfit  Vestas Soar,news,"By Geoffrey Smith 
Investing com    Stock markets pushed sharply higher on Wednesday on the back of reports that scientists in China and Europe had made significant breakthroughs in developing drugs to treat the novel coronavirus outbreak 
Business surveys showing that better than expected levels of activity in the eurozone economy aslo helped  strong services readings helped IHS Markit s eurozone composite purchasing managers  index to its highest level in five months  the increase to 51 3 beating forecasts for an unchanged reading of 50 9 
The news came as a relief to markets that had been pricing in a sharp drop in Chinese economic output at least in the first quarter of this year  along with the threat of reverberations throughout the world economy   
China accounts for nearly 20  of world gross domestic product  and the implications of the outbreak on Chinese demand have sent the prices of commodities such as oil and copper into freefall  a fall that had only been broken by large scale liquidity injections by the Chinese central bank earlier in the week 
By 5 15 AM ET  1015 GMT   the benchmark Stoxx 600 index was up 1 0  at 422 58  The German DAX was up 1 1  while the FTSE 100 was up 0 7   All three were off earlier highs as the initial spike in response to the news faded 
One of the reports was sourced to Sky News  which claimed a team of researchers at Imperial College London would begin testing a quickly developed drug on animals next week  Reuters also sourced a Chinese television report saying that researchers in Zhejiang had developed a drug capable of treating the coronavirus effectively  However  those claims weren t visible on any international editions of Chinese state media 
On Tuesday  a research institute had applied for a local patent on the antiviral drug remdesivir developed by Gilead Sciences  NASDAQ GILD   which has also been used with success on coronavirus patients in the U S   The drug hasn t yet received approval from U S  regulators  however 
The news rather overshadowed a flood of earnings from Europe s blue chips on Wednesday  which were a mixed bag  Siemens  a traditional bellwether for European manufacturing  underperformed with a 1 0  rise after reporting a slump in margins across all of its businesses  while chipmaker Infineon surged 8 0  after reporting a better than expected fourth quarter report and upbeat guidance 
Elsewhere  packaging companies Smurfit Kappa  LON SKG  and DS Smith  LON SMDS  led the FTSE 100 higher with gains of 7 4  and 5 7  respectively  after the Irish based company raised its dividend on the back of strong earnings at the end of last year  The two companies are riding a wave of enthusiasm for sustainable investment  capitalizing on the shift in public opinion away from plastic packaging to cardboard 
Wind turbine maker   Vestas Wind   Systems A S  CSE VWS   another company in the Green space  also surged 3 5  in Copenhagen after forecasting another three years of steady growth  in which it expects the rising share of services in its sales mix to offset declining margins in its biggest division  the manufacture of onshore turbines 
British Airways parent IAG  LON ICAG  also surged 7 6  after underperforming in recent days on fears around the coronavirus  impact on the travel sector ",2020-02-05,Investing.com,https://www.investing.com/news/stock-market-news/stockbeat-markets-surge-on-hints-of--virus-drugs-smurfit-vestas-soar-2076434,2076434
200605,422121,GILD,3 Important Things to Know About Gilead Sciences  Q4 Results,news,"Gilead Sciences  NASDAQ GILD  made headlines in recent days after the company announced that it was working with Chinese authorities to test its Ebola drug remdesivir in treating the deadly coronavirus strain that has become an epidemic  But that wasn t the biggest news for Gilead this week 
The big biotech reported its 2019 fourth quarter and full year results after the market closed on Tuesday  Here are three important things to know about Gilead s Q4 update 

1  Better than expected revenue
Gilead endured a long stretch where its revenue declined quarter after quarter  That wasn t the case in Q4  though  The company reported Q4 revenue of  5 9 billion  up from  5 8 billion in the prior year period  This result even topped the consensus Wall Street revenue estimate of  5 71 billion 
Sure  Gilead s hepatitis C virus  HCV  franchise continued to weigh on the company s total revenue  HCV sales fell nearly 19  year over year in the fourth quarter to  630 million  But the quarter over quarter decline of only 6 5  wasn t too bad considering what Gilead has experienced in the past 
The biggest bright spot for Gilead yet again was its HIV franchise  HIV sales jumped 12  year over year in Q4 to  4 6 billion  with Biktarvy leading the way with sales of  1 57 billion  Although Descovy was the only other HIV drug in Gilead s lineup to deliver sales growth  the combination of it and Biktarvy were more than enough to offset declining sales for Truvada  Genvoya  and other HIV drugs 
Yescarta didn t pick up much momentum in Q4  though  Sales rose nearly 51  year over year in the fourth quarter to  122 million  but that was only slightly above the  118 million recorded in the third quarter 
2  A big earnings miss
While Gilead topped Wall Street s Q4 revenue estimate  it was a different story on the bottom line  The biotech posted adjusted earnings of  1 7 billion  or  1 30 per diluted share  This result was lower than the  1 9 billion  or  1 44 per diluted share  generated in the prior year period  It was also well below the average analysts  Q4 earnings estimate of  1 67 per share 
Gilead s earnings based on generally accepted accounting principles  GAAP  looked much better  though  The company reported GAAP earnings of  2 7 billion  or  2 12 per share  up significantly from GAAP earnings of only  3 million in the prior year period  However  this big improvement stemmed mainly from some positive tax effects from accounting moves related to asset transfers and net gains from equity securities 
Analysts probably weren t too bothered by Gilead s big adjusted earnings miss  It s possible that they didn t factor in some of the company s acquisition related expenses 
3  Lackluster 2020 guidance
Gilead provided what could be described as lackluster full year 2020 guidance  The company projects product sales to be between  21 8 billion and  22 billion  The midpoint of that range is lower than the  22 1 billion in product sales generated in the full year 2019 
Non GAAP adjusted earnings per share  EPS  for full year 2020 are expected to be between  6 05 and  6 45  The midpoint of this range is well below the consensus Wall Street adjusted EPS estimate for 2020 of  7 01 
At first glance  it might also appear that Gilead s adjusted EPS will decline from its full year 2019 level  However  beginning this year  the company isn t excluding stock based compensation expense from its non GAAP figures  On an apples to apples basis  Gilead s adjusted EPS outlook for 2020 reflects a year over year increase of 2  at the midpoint of the guidance range 
The bigger picture
If I had to sum up Gilead s fourth quarter results in one word  it would probably be  blah   There simply was nothing in the company s update to excite investors 
However  pipelines are more important to the prospects for biotech stocks than past quarterly results  Gilead could generate more excitement later this year if it wins FDA approval for immunology drug filgotinib in treating rheumatoid arthritis  RA   Some analysts think filgotinib could achieve peak annual sales in the ballpark of  6 billion if approved for RA and other targeted immunology indications 
Gilead also ended 2019 with cash  cash equivalents  and marketable debt securities totaling  25 8 billion  That s a big cash stockpile the company could use to bolster its pipeline  The company is also putting its ample cash flow to use in another way that should delight investors    its dividend  Gilead announced an 8  dividend increase beginning in the first quarter of 2020 ",2020-02-05,The Motley Fool,https://invst.ly/prcyy,2076559
200606,422122,GILD,Gilead Sciences  Patience Required,news,"Gilead Sciences  NASDAQ GILD  reported fourth quarter and full year results after the closing bell Tuesday  Investors were none too pleased with the big biotech s financial results or near term outlook  Immediately after disclosing its latest financial figures  Gilead s shares dropped 1 68  in after hours trading yesterday 
What s ruffling the feathers of shareholders  The core issue is Gilead s anemic top line guidance for 2020  Despite years of promising to boost sales by bringing new drugs to market  the biotech is essentially calling for revenue to slightly dip this year  
The underlying problem is that Gilead simply hasn t had much luck with the progress of its internal clinical pipeline outside of HIV and cell based cancer therapies  Last year  for instance  the biotech s nonalcoholic steatohepatitis pipeline basically went belly up  putting it well behind the front runners in the space  

Despite all this doom and gloom  Gilead s shares actually look like a buy on the heels of this latest pullback  Here s why bargain hunters might want to consider buying this underperforming large cap biotech stock soon 
Reasons for optimism
Even though Gilead s hepatitis C franchise continues to be a drag on its top line  newer products like the groundbreaking HIV treatment Biktarvy and novel anti cancer therapy Yescarta have been pulling their weight in recent quarters  Biktarvy  for instance  hauled in a whopping  1 6 billion in Q4  and Yescarta posted a respectable  122 million for the three month period  These two therapies have kept Gilead s top line afloat while its clinical pipeline and various business development activities slowly take shape   
While Gilead s homegrown pipeline candidates and recent acquisitions haven t yielded much in the way of new products lately  its external pipeline development efforts have been an unmitigated success  The biotech s sizable equity stake in Galapagos brought in the promising anti inflammatory medication filgotinib  which should eventually reach megablockbuster status  more than  5 billion in annual sales   Filgotinib  in fact  should play a central role in the biotech s growth prospects for the better part of the current decade  
Gilead s enormous cash position of  25 8 billion gives it plenty of firepower for external licensing deals  as well as small to midsize bolt on acquisitions  Keeping with this theme  the company has already stated that it will start to beef up its pipeline through licensing deals and a handful of acquisitions soon  And if any of these deals bring in another filgotinib  Gilead should be able to quickly accelerate its return to modest levels of top line growth  
Finally  Gilead has one of the best shareholder rewards programs in the entire healthcare sector  The biotech has consistently raised its dividend over the past five years  and it has literally plowed billions into share buybacks as well  As things stand now  Gilead offers a forward looking annualized yield of 3 94   That s well above the prevailing average for its large cap biotech peer group 
Time to buy 
To be frank  Gilead s stock probably isn t going to do much in 2020  Until the biotech s top line perks up  its shares will almost certainly underperform the broader biopharma industry  That said  Gilead s new management team appears intent on changing this narrative soon  Filgotinib is close to its first regulatory approval  Gilead s cell therapy subsidiary  Kite Pharma  should have its second product on the market soon with Kite X19  and the company also has a sizable war chest to spend on M A 
Bottom line  Gilead s stock has likely reached a nadir In fact  the stage is now set for the biotech to return to high growth status as soon as next year  So even though patience will definitely be required on the part of shareholders in 2020  it may indeed be time for growth investors to circle back to this name ",2020-02-05,The Motley Fool,https://invst.ly/prhm4,2076928
200607,422123,GILD,CDC Shipping Test Kits  Wisconsin Confirms Case  Virus Update,news," Bloomberg     The World Health Organization pushed back against suggestions of imminent breakthroughs in the development of vaccines or treatments for the coronavirus  U S  health officials began shipping kits that can test for the pathogen  and Wisconsin confirmed a 12th American case 
In China s Hubei province of 60 million people  where the outbreak is centered  scenes of chaos and despair are emerging as residents cope with the modern world s largest ever quarantine  U S  health officials are preparing for more evacuees from the region to arrive at American military bases 
Key Developments 
China death toll at 490  24 324 confirmed cases  3 219 severeStranded on ships  passengers play with balloons  singDespite global fears  the virus is still concentrated mostly in HubeiFoxconn cuts outlook  will quarantine workers  may hit Apple outputMore than 7 000 held on two luxury cruise ships as virus spreadsCathay Pacific asks staff to take unpaid leave  Airbus shuts plantBloomberg is tracking the outbreak on the terminal and online 
Wisconsin Confirms New Coronavirus Case  2 32 p m  NY 
Wisconsin public health officials confirmed the 12th U S  case of the coronavirus  The patient is an adult who had traveled to Beijing and was exposed to known cases while in China  said the state s Department of Health Services 
The person has been isolated at home and is doing well  the state said in a statement Wednesday 
CDC Begins Shipping Virus Test Kits  1 25 p m  NY 
The U S  Centers for Disease Control and Prevention started shipping new test kits that can detect the coronavirus on site to 200 laboratories in the U S  and 200 others outside the country  Previously  samples had to be sent to the agency s headquarters in Atlanta 
Each kit can process 700 to 800 samples  allowing for more than a quarter million people to get their results and potentially relieving the burden on overwhelmed health systems  said Nancy Messonnier  director of the CDC s National Center for Immunization and Respiratory Diseases  It will take a few days before widespread use can begin  she said 
 By the start of next week  we expect there to be much enhanced capacity for laboratory testing closer to our patients   Messonnier said on a briefing with reporters Wednesday 
Two U S  Wuhan Flights Arriving  Two More Expected  12 50 p m  NY 
Two evacuation flights from Wuhan to the U S  are arriving today at military bases  with two more expected tomorrow  the U S  Centers for Disease Control and Prevention told reporters on a call Wednesday 
The government has repatriating Americans from the outbreak s center in China  and putting people under mandatory quarantine for as long as two weeks when they return  CDC officials didn t say how many people were on the flights 
U S  to Receive More Virus Evacuees From Wuhan  11 30 a m  NY 
U S  health authorities are preparing for several more plane loads of evacuees from Wuhan  the city in Hubei province where the virus was first detected  They plan to quarantine them for as long as two weeks at military bases in three states 
The U S  Centers for Disease Control and Prevention said in a statement Wednesday that it will screen the passengers during their travel and give quarantine orders when they arrive  The flights will land at air bases in California  Texas and Nebraska 
On Tuesday  the U S  State Department said two more plans of evacuees were on their way  The U S  government has put in place plans to temporarily isolate hundreds of at risk people returning from the outbreak in China 
WHO Cautions on Quick Breakthrough  11 10 a m  NY 
World Health Organization officials tamped down expectations of imminent breakthroughs in the development of vaccines or treatments for the outbreak 
 There are no proven  effective therapeutics  for the novel coronavirus  Mike Ryan  executive director of the WHO s Health Emergencies Program  said Wednesday at a press conference in Geneva 
The UN agency plans a systematic review of all therapeutics  Ryan said  The organization will share clinical trial protocols around the world  he said 
An antiviral drug from  Gilead Sciences Inc   NASDAQ GILD   is expected to start testing in China on Thursday 
Gates Foundation Pledges  100 Million  9 15 a m  NY 
The Bill   Melinda Gates Foundation said Wednesday it will commit as much as  100 million to bolster the international response to the novel coronavirus 
The funding will help strengthen detection  isolation and treatment efforts  protect at risk populations  and develop vaccines  therapies and diagnostics  The new funding includes the  10 million the foundation committed to the outbreak in late January 
 Multilateral organizations  national governments  the private sector and philanthropies must work together to slow the pace of the outbreak  help countries protect their most vulnerable citizens and accelerate the development of the tools to bring this epidemic under control   Gates Foundation Chief Executive Officer Mark Suzman said in a statement 
The funds will assist the World Health Organization  Chinese frontline responders and others at the global and national levels  the foundation said 
Capri Cuts Forecast  Shuts Stores in China  7 40 a m  NY 
The company  which owns the Jimmy Choo and Michael Kors brands  cut its revenue forecast for the fiscal full year  citing the material impact of the coronavirus outbreak in China on its business 
China Offers Firms Fighting Virus Lower Rates  6 58 a m  NY 
China will eliminate fees  reduce value added taxes and support banks to offer loan rates under 1 6  to key enterprises involved in the fight against the coronavirus  according to China Central Television 
Vietnam Sees Lower GDP Growth Rate  6 47 a m  NY 
Vietnam s government expects the spread of coronavirus to slow gross domestic product growth to as low as 6 09  in 2020  even if the epidemic is under control by the second quarter  Growth may be at 6 27  if the virus is controlled within the first quarter  Mai Tien Dung  chairman of the government office  said at a briefing in Hanoi 
Babies Born With Coronavirus After Mothers Infected  6 42 p m  HK 
Two newborn babies tested positive for coronavirus in Wuhan after their mothers were infected  China Central Television reported 
Markets Gain on Chinese Report of Research Progress  5 50 p m  HK 
Stocks surged  industrial metals advanced and oil gained after Chinese television reported possible progress in the hunt for a coronavirus treatment  The report said a drug being tested by researchers at Zhejiang University in China was effective against the virus  The treatment was tested on cells outside the human body  meaning it would be a long way from any clinical trials on people  let alone approval as a marketable drug 
Separately  China kick started a clinical trial to test Gilead Sciences Inc  s Remdesivir  an antiviral developed for Ebola and SARS  China s health regulator also recommended  AbbVie Inc   NYSE ABBV   s Kaletra  already approved as an HIV medicine  as an ad hoc antiviral drug for the coronavirus 
Foxconn Cuts Outlook  Quarantines IPhone Base  5 43 p m  HK 
Hon Hai Precision Industry Co   Apple Inc  NASDAQ AAPL   s main production partner  announced plans to isolate workers for up to weeks at its main iPhone making base  The company earlier cut its 2020 revenue growth outlook after assessing the potential impact of the coronavirus outbreak 
Hon Hai  known also as Foxconn  makes the vast majority of the world s iPhones from Zhengzhou  central China  The contagion will likely disrupt Apple s carefully calibrated production chain 
Hong Kong Will Quarantine China Arrivals  4 50 p m  HK 
The city will quarantine people arriving from mainland China  including Hong Kong residents and visitors entering via its international airport  Chief Executive Carrie Lam said 
The policy will go into effect on Feb  8 at midnight  Lam also said Hong Kong will close the Kai Tak Cruise Terminal in its Victoria Harbor  and announced a HK 10 billion   1 3 billion  fund for those affected 
Cathay Pacific Asks Staff to Take Unpaid Leave  3 45 p m  HK 
The airline asked staff to take unpaid leave from March 1 to June 30 as it tries to preserve cash  Cathay has said demand dropped following the outbreak and announced deep cuts to flight capacity on Tuesday  South Korean budget carrier Tway Air also asked staff to take unpaid leave 
Separately  Airbus SE shut its plant in Tianjin that builds about six A320 series jets a month  corresponding to almost 10  of the company s global single aisle output 
Virus Cases Linked to Singapore Spur Multinational Inquiry  2 41 p m  HK 
Coronavirus cases in South Korea and Malaysia tied to a business meeting in Singapore attended by visitors from China have prompted an investigation into the infection s international spread 
A 41 year old man in Malaysia and a 38 year old man in South Korea were infected with the virus after attending a meeting at a Singapore hotel in the third week of January  health authorities said  The World Health Organization is coordinating with Singapore s Ministry of Health in relation to the event  said Olivia Lawe Davies  the agency s Manila based regional communications manager 
Hong Kong Cruise Passengers Under Quarantine  1 53 p m  HK 
Hong Kong authorities are keeping 3 600 passengers and crew members under quarantine on the cruise ship World Dream after three previous travelers were diagnosed with the novel coronavirus 
The three confirmed virus patients had disembarked in China on Jan  24  according to Chief Port Health Officer Leung Yiu hong at a briefing at the cruise terminal  The cruise ship  owned by Genting HK s Dream Cruises  docked in Hong Kong on Wednesday morning 
Health officials are collecting samples from about 30 crew members who reported symptoms including cough and fever for coronavirus tests  Three crew members who earlier reported fever will be sent to the hospital for isolation  The development follows a separate case in Japan in which 10 people on Carnival  NYSE CCL  Corp  s Diamond Princess cruise ship tested positive for the coronavirus 
China Seeks Patent for Gilead s Experimental Drug  1 01 p m  HK 
China has applied for a new patent on an experimental Gilead Sciences Inc  drug that its scientists believe might fight the coronavirus 
It has applied for a patent for the use of the drug  know as remdesivir  to treat the novel coronavirus  The move is a sign that China views Gilead s therapy as one of the most promising candidates to fight the outbreak  A patent battle may affect Gilead s control over the drug in China 
While Gilead s experimental drug isn t licensed or approved anywhere in the world  it is being rushed into human trials in China on coronavirus patients after showing early signs of being highly effective 
Trump Cites Efforts on Virus in State of the Union  11 10 a m  HK 
President Donald Trump said in his State of the Union address that the U S  is working with China to contain the coronavirus outbreak 
 We are coordinating with the Chinese government and working closely together on the coronavirus outbreak in China   Trump said   My administration will take all necessary steps to safeguard our citizens from this threat  
 Credit Suisse   SIX CSGN  Scraps Hong Kong Conference  11 05 a m  HK 
Credit Suisse Group AG scrapped its annual Asia investment conference next month  adding to a string of cancellations or delay for similar gatherings in Hong Kong and China 
The decision marks the biggest cancellation in Hong Kong s financial industry after the outbreak of the virus  The city on Tuesday reported its first confirmed death from the virus  Neighboring Macau  the world s biggest gambling hub  has asked its casinos to shut down for half a month 
 Disney  Sees Virus Hurting Profits  8 24 a m  HK 
Walt Disney  NYSE DIS  Co  is feeling the impact of the virus after temporarily closing its Shanghai and Hong Kong parks due to the outbreak 
On a call to discuss the company s earnings  Chief Financial Officer Christine McCarthy said Disney expects the Shanghai park closure alone to crimp profits in the current quarter by  135 million  assuming it is shuttered for two months  With Hong Kong closing  Disney expects the coronavirus to reduce profit there by another  40 million 
China Cases Rise Above 24 000  8 00 a m  HK 
The number of total confirmed cases of coronavirus in mainland China rose to 24 324 as of Feb  4  according to the National Health Commission  The death toll is at 490  it said in a statement 
Most of the fatalities    479    have occurred in the province of Hubei  the Chinese province at the center of the outbreak  Hubei reported 3 156 new confirmed cases  bringing the total in Hubei to 16 678 
Outside the mainland  Hong Kong reported a death on Tuesday  A man from Wuhan died in the Philippines on Feb  1 
Ten Passengers on Japan Cruise Have Virus  7 33 a m  HK 
Ten people on a Carnival Corp  cruise ship moored near Yokohama with about 3 700 crew and passengers aboard have tested positive for the new coronavirus and taken to hospital  Japan s Health Ministry announced Wednesday 
The Diamond Princess was placed under quarantine this week before it reached Japan and checks were conducted after a passenger from Hong Kong who had been on the ship tested positive for the virus  Of 31 people whose test results have come through  10 were confirmed as infected  the ministry said 
The new infections come in addition to 23 people already confirmed to have contracted the disease in Japan 
FDA Grants Emergency Use of Rapid Test for Virus  6 34 a m  HK 
The U S  Food and Drug Administration cleared the way for the widespread use of a new test to detect the novel coronavirus at laboratories across the country  removing the need for doctors to send samples out for analysis 
The test was designed by the Centers for Disease Control and Prevention and can be used at any of the agency s approved labs across the country  Until now  samples taken from patients had to be sent for analysis at the agency s laboratories in Atlanta ",2020-02-05,Bloomberg,https://www.investing.com/news/general/cdc-shipping-test-kits-wisconsin-confirms-case-virus-update-2077175,2077175
200608,422124,GILD,Company News For Feb 4  2020,opinion,Shares of Gilead Sciences  Inc    NASDAQ GILD   rose 5  after the company reported that its Remdesivir will undergo a trial for the CoronavirusShares of Maxar Technologies Inc    TSX MAXR   jumped 3 4  after the company announced that it would manufacture Intelsat s 40e geostationary communications satellite  which is scheduled to launch in 2022Shares of Insmed Incorporated   NASDAQ INSM   soared 40 6  after the company announced its Phase 2 WILLOW study of INS1007 met both primary and key secondary endpointsShares of Asbury Automotive Group  Inc    NYSE ABG   rose 2 9  after the company reported fourth quarter earnings of  2 53 per share  beating the Zacks Consensus Estimate of  2 35,2020-02-03,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-feb-4-2020-200504425,200504425
200609,422125,GILD,Disney  Gilead   Snap Post Mixed Quarters  Chipotle Beats,opinion,"Lots of fresh Q4 earnings results to sift through after Tuesday s closing bell  so we will dive right in with The Walt Disney Company   NYSE DIS    which beat bottom line estimates by a solid dime to  1 53 per share  on revenues of  20 8 billion  which slightly missed the Zacks consensus  The company did particularly well in its direct to consumer business  with Disney  subscribers reaching 26 5 million  compared to estimates of 20 25 million  Its Studio segment grew more than 100  on the strength of its Frozen II and Star Wars  The Rise of Skywalker offerings in the quarter  For Parks  Experiences   Products  shutdowns of Disney amusement parks in Shanghai and Hong Kong related to coronavirus concerns was the only major dent in the quarter  CEO Bob Iger mentioned he does not know exactly when the parks will be re opened  Chipotle   NYSE CMG   also outperformed estimates on its bottom line     2 86 per share versus expectations of  2 74    as well as the top   1 44 billion in sales surpassed the  1 40 billion analysts were looking for  Same store sales were up big in the company s Q4   13 4  from an estimated 9 5   Digital sales rose 78 3   thanks to the addition of  Chipotlanes     the restaurant s order ahead drive thru service  Digital sales now account for 18  of Chipotle s business  Ford Motor Company   NYSE F   posted a big miss in its Q4 earnings  12 cents per share versus 17 cents anticipated  Revenues were close to in line but a little light   36 7 billion from the  36 79 billion in the Zacks consensus  China  in particular  was down  207 million in the quarter  while guidance for full year 2020 comes in lower than the Zacks consensus  1 21 per share  This amounts to Ford s first bottom line miss in the last four quarters Gilead Sciences   NASDAQ GILD   put up mixed results in its Q4 report  posting just  1 30 per share versus expectations of  1 68  on sales that easily outpaced our consensus   5 88 billion versus  5 73 billion  Its HIV treatments brought in  4 6 billion in sales while its Hep C treatments fell short of the mark  Guidance was also light going into Q1  This is Gilead s second earnings miss in a row  and the fifth of the last 12 quarters  Finally  Snap Inc    NYSE SNAP   also had a mixed Q4  with 3 cents per share outpacing the  0 00 we had expected  and the  4 cents per share in the year ago quarter   while  561 million in revenues was a tad below expectations  Its revenue per user came in 4 cents light of estimates  though top line guidance for Q1 looks stronger than the Zacks consensus of  456 7 million  Daily Active Users were also slightly better than expected at 218 million 
7 Best Stocks for the Next 30 Days
Just released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  
Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 7  per year  So be sure to give these hand picked 7 your immediate attention ",2020-02-04,Zacks Investment Research,https://www.investing.com/analysis/disney-gilead--snap-post-mixed-quarters-chipotle-beats-200504549,200504549
200610,422126,GILD,The Zacks Analyst Blog Highlights  Disney  Chipotle  Ford  Gilead And Snap,opinion,For Immediate ReleaseChicago  IL   February 5  2020   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Walt Disney Company   NYSE DIS    Chipotle   NYSE CMG    Ford Motor Company   NYSE F    Gilead Sciences   NASDAQ GILD   and Snap Inc    NYSE SNAP   Here are highlights from Tuesday s Analyst Blog Disney  Gilead   Snap Post Mixed Quarters  Chipotle BeatsLots of fresh Q4 earnings results to sift through after Tuesday s closing bell  so we will dive right in with The Walt Disney Company  which beat bottom line estimates by a solid dime to  1 53 per share  on revenues of  20 8 billion  which slightly missed the Zacks consensus  The company did particularly well in its direct to consumer business  with Disney  subscribers reaching 26 5 million  compared to estimates of 20 25 million  Its Studio segment grew more than 100  on the strength of its Frozen II and Star Wars  The Rise of Skywalker offerings in the quarter  For Parks  Experiences   Products  shutdowns of Disney amusement parks in Shanghai and Hong Kong related to coronavirus concerns was the only major dent in the quarter  CEO Bob Iger mentioned he does not know exactly when the parks will be re opened  Chipotle also outperformed estimates on its bottom line     2 86 per share versus expectations of  2 74    as well as the top   1 44 billion in sales surpassed the  1 40 billion analysts were looking for  Same store sales were up big in the company s Q4   13 4  from an estimated 9 5   Digital sales rose 78 3   thanks to the addition of  Chipotlanes     the restaurant s order ahead drive thru service  Digital sales now account for 18  of Chipotle s business  Ford Motor Company posted a big miss in its Q4 earnings  12 cents per share versus 17 cents anticipated  Revenues were close to in line but a little light   36 7 billion from the  36 79 billion in the Zacks consensus  China  in particular  was down  207 million in the quarter  while guidance for full year 2020 comes in lower than the Zacks consensus  1 21 per share  This amounts to Ford s first bottom line miss in the last four quarters Gilead Sciences put up mixed results in its Q4 report  posting just  1 30 per share versus expectations of  1 68  on sales that easily outpaced our consensus   5 88 billion versus  5 73 billion  Its HIV treatments brought in  4 6 billion in sales while its Hep C treatments fell short of the mark  Guidance was also light going into Q1  This is Gilead s second earnings miss in a row  and the fifth of the last 12 quarters  Finally  Snap Inc  also had a mixed Q4  with 3 cents per share outpacing the  0 00 we had expected  and the  4 cents per share in the year ago quarter   while  561 million in revenues was a tad below expectations  Its revenue per user came in 4 cents light of estimates  though top line guidance for Q1 looks stronger than the Zacks consensus of  456 7 million  Daily Active Users were also slightly better than expected at 218 million 7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 7  per year  So be sure to give these hand picked 7 your immediate attention Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339  Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2020-02-05,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-disney-chipotle-ford-gilead-and-snap-200504715,200504715
200611,422127,GILD,Company News For Feb 6  2020,opinion,Coty Inc  s   NYSE COTY   shares rallied 14 5  after reporting second quarter of fiscal 2020 adjusted earnings per share of  0 27  surpassing the Zacks Consensus Estimate of  0 24 Capri Holdings Ltd    NYSE CPRI   jumped 8 3  after the company reported third quarter of fiscal 2020 adjusted earnings per share of  1 66  beating the Zacks Consensus Estimate of  1 58 Shares of Humana Inc    NYSE HUM   surged 6 4  after posting fourth quarter 2019 adjusted earnings per share of  2 28  outpacing the Zacks Consensus Estimate of  2 20 Gilead Sciences Inc    NASDAQ GILD   tanked 2 3  after the company posted fourth quarter 2019 adjusted earnings per share of  1 30  missing the Zacks Consensus Estimate of  1 68 ,2020-02-05,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-feb-6-2020-200505406,200505406
200615,422131,GILD,CDC Readies for Pandemic  Long Vaccine Timeline  Virus Update,news," Bloomberg     China may seek flexibility on its trade deal with the U S  that s supposed to take effect this month  according to people familiar with the matter  after the coronavirus outbreak has led to quarantines and travel lockdowns that have hurt business activity  The U S  Centers for Disease Control and Prevention is working to get emergency approval for a test for the virus  and says it s preparing for the disease to become a pandemic 
The death toll from the coronavirus outbreak rose past 360  total confirmed cases reached almost 17 400  A vaccine for the virus may take 12 to 18 months to develop  said a major drugmaker 
Bloomberg is tracking the outbreak on the terminal and online 
Key Developments 
 Gilead Sciences Inc   NASDAQ GILD   gains with testing of its drug  some have doubtsChina s government accused the U S  of  overreacting  in response to outbreakOutbreak puts China s commodity industry at riskU S   No Request From China on Trade Deal Changes  3 p m  NY 
A spokesman for U S  Trade Representative Robert Lighthizer said Washington hasn t received any request from China to discuss changes in Beijing s purchase commitments as part of the phase one trade deal set to take effect this month 
Chinese officials are hoping the U S  will agree to some flexibility on pledges in their pact  people familiar with the situation said  Beijing is trying to contain the coronavirus crisis  which threatens to slow domestic growth with repercussions around the world 
The trade deal has a clause that states the U S  and China will consult  in the event that a natural disaster or other unforeseeable event  delays either from complying with the agreement 
Carnival  NYSE CCL  Shares Fall as Passenger Tests Positive  1 20 p m  NY 
Carnival Corp  s Princess Cruises said a recent passenger in Asia tested positive for coronavirus  prompting Japanese health officials to delay the ship he d been on while they conduct a review of all guests and crew 
Princess said in an emailed statement Monday that the passenger embarked in Yokohama  Japan  on Jan  20 and disembarked in Hong Kong on Jan  25  The ship  Diamond Princess  then continued its round trip journey to ultimately take other passengers back to Yokohama  which is near Tokyo 
On Saturday  the passenger  who was from Hong Kong  tested positive for coronavirus at a local hospital there  according to Princess  The episode comes just days after a ship from Carnival s Costa Crociere unit was put on lockdown at a port near Rome over concerns that passengers might have had coronavirus  Those passengers were eventually diagnosed with the flu 
Carnival shares fell as much as 3 3  to  42 10  the lowest intraday level since October 
Vaccine Could Take Year or More  Glaxo Says  12 32 p m  NY 
Developing a vaccine against the coronavirus could take 12 to 18 months  Thomas Breuer  GlaxoSmithKline Plc s chief medical officer for vaccines  said in an interview with Bloomberg TV Monday 
While technology could enable researchers to come up with new vaccine candidates within a few months  they will then have to undergo human safety and efficacy trials that may last about a year  Breuer said 
Read more about efforts to develop a vaccine here 
CDC Seeks Emergency Approval for Virus Test  11 58 a m  NY 
U S  health officials are seeking emergency approval to roll out a test for the coronavirus that can be used by hospitals and state health authorities  instead of having samples shipped to the Centers for Disease Control and Prevention for analysis 
The agency is preparing for the outbreak as if it will be a pandemic that spreads widely from China to other countries  including the U S   said Nancy Messonnier  director of the CDC s National Center for Immunization and Respiratory Diseases  The goal of public health officials is to slow the virus s entry into the U S   she said 
Federal and local health authorities have been monitoring people who have displayed symptoms and have a travel history that puts them at risk  The vast majority have tested negative  There are 11 confirmed cases in the U S   and 167 people who have a negative test  It s possible that some people can test negative and then have a positive result later  depending on how far along their illness is 
The severity of the U S  cases has varied  with some people becoming more severely ill  Messonnier said  Some have needed oxygen  she said 
EU Doesn t See Need for Broad Travel Restrictions  11 19 a m  NY 
The European Union doesn t see the need for blanket travel restrictions in response to the coronavirus outbreak  Stella Kyriakides  the EU s top health official  said in an interview with Bloomberg TV  Some EU member states  such as Italy  have taken such measures 
Kyriakides  the European commissioner for health and food safety  said she has no concerns about China s response to the outbreak 
There are currently 25 coronavirus cases that have been identified in Europe  21 in the EU  two in the U K  and two in Russia  according to Andrea Ammon  the executive director of the European Centre for Disease Prevention and Control 
 For the time being the situation in Europe is under control   Ammon told members of the Euopean parliament in Brussels on Monday   The aim currently is to really confine the cases and to prevent the further spread  
China Seeks U S  Flexibility on Trade Targets  10 05 a m  NY 
Chinese officials are hoping the U S  will agree to some flexibility on pledges in their phase one trade deal  people familiar with the situation said  as Beijing tries to contain a health crisis that threatens to slow domestic growth with repercussions around the world 
The agreement sealed Jan  15 is supposed to take effect in mid February  It has a clause that states the U S  and China will consult  in the event that a natural disaster or other unforeseeable event  delays either from complying with the agreement  It s unclear whether China has formally requested such a consultation yet  but the people familiar with the matter said the plan is to ask for it at some point 
The Chinese Commerce Ministry and U S  Trade Representative didn t immediately respond to a request for comment 
Lufthansa Extends China Flight Suspension  9 02 a m  NY 
German air carrier Deutsche Lufthansa  DE LHAG  AG said it would extend a suspension of flights to and from China because of the coronavirus outbreak 
The airline will maintain a halt on service to and from Beijing and Shanghai until Feb  28  Nanjing  Shenyang and Qingdao service suspensions will be extended to March 28  the airline said in a statement  It will continue to fly to and from Hong Kong 
Last month  the airline announced it would suspend service to the Chinese mainland until Feb  9 
Over 25 000 China Flights Axed Amid Virus Disruption  7 52 a m  NY 
More than 25 000 flights to  from and within China will be canceled this week as more than two dozen airlines suspend services to the country  an unprecedented shakeup in the world s second largest aviation market 
China Considers Lowering 2020 Growth Expectations  6 30 a m  NY 
Officials are evaluating whether the target for economic growth this year should be softened as part of a broader review  Further measures to shore up the economy are being considered  including increasing the planned cap on the budget deficit to GDP ratio and selling more special government bonds 
Economists had expected China would aim for output growth of  around 6   this year after seeking a range of 6  to 6 5  in 2019 
China s Biggest LNG Buyers Consider Force Majeure  6 53 p m  HK 
China s big state owned liquefied natural gas importers are considering force majeure declarations on contracted cargo deliveries as they grapple with the impact from the novel coronavirus  according to people with knowledge of the situation 
Crop Cargoes Stuck at China Ports on Virus Controls  6 13 p m  HK 
Logistical constraints at some Chinese ports due to the coronavirus are holding up deliveries of agricultural goods from soy to palm oil cargoes  While China s economic planner said that food supply can be ensured and prices will remain stable  the port disruptions highlight the country s vulnerability 
WHO Director General Says Coronavirus Must Be Fought at Source  5 57 p m  HK 
The spread of the new virus can remain  minimal and slow  if the outbreak is fought at the source and countries cooperate  WHO Director General Tedros Adhanom Ghebreyesus said   There is no reason for any measures that unnecessarily interfere with international travel and trade   he said 
Hong Kong to Close More Checkpoints  5 23 p m  HK 
Hong Kong will close more checkpoints  including two major land ports on the border with the mainland  from midnight  Chief Executive Carrie Lam said at briefing  Only three out of the 13 checkpoints will stay open  including Shenzhen Bay port  Hong Kong Zhuhai Macau Bridge port and Hong Kong airport  Striking Hong Kong health workers had demanded that all entry points be shut 
China Lunar New Year Passenger Volume Falls 73   4 40 p m  HK 
The number of trips made in China over the Lunar New Year break plunged 73  to about 190 million from the holiday last year as people were prohibited or refrained from travel 
Indonesia to Temporarily Stop Food Imports From China  4 22 p m  HK 
The government will find alternative suppliers to replace goods from China  according to a senior official  Details of the suspension will be discussed in a coordinating meeting 
China Blasts U S  for  Overreaction   3 56 p m  HK 
China said the U S  had  inappropriately overreacted  to the deadly virus originating on the mainland and hasn t provided much help to counter the outbreak 
 The U S  government hasn t provided any substantial assistance to us  but it was the first to evacuate personnel from its consulate in Wuhan  the first to suggest partial withdrawal of its embassy staff  and the first to impose a travel ban on Chinese travelers   Chinese foreign ministry spokeswoman Hua Chunying said on Monday 
PBOC Says Stock Plunge Caused by  Herd Effect   3 46 p m  HK 
There were some  irrational  factors in Monday s stock slump  PBOC backed Financial News said in commentary published on the People s Bank of China WeChat account  The post says the impact from the epidemic on China s economy is temporary and limited 
Russia May Deport Foreigners With Coronavirus  3 45 p m  HK 
Russia may deport foreign citizens who are infected with the coronavirus as part of a national plan against the outbreak signed by Prime Minister Mikhail Mishustin 
The government will also postpone the flagship Sochi Economic Forum due to be held Feb  12 14 as a precaution  Mishustin said at a televised meeting with his deputies  Russia reported its first two cases of coronavirus on Friday 
Germany Says It s Ready for an Epidemic  3 09 p m  HK 
Germany has sufficient quarantine facilities to handle an epidemic  but the outbreak of the coronavirus is below that threshold  Health Minister Jens Spahn said in an interview with public broadcaster ARD 
Thailand Sees Results From Drug Mixture  2 44 p m  HK 
A cocktail of antiviral drugs appeared effective in treating a seriously ill coronavirus patient  a Thai health official said 
The HIV medicines lopinavir and ritonavir  which are sold by  AbbVie Inc   NYSE ABBV   as the product Kaletra  was used on three patients in conjunction with the anti flu medication oseltamivir  sold by Roche Holding  SIX ROG  AG and Chugai Pharmaceutical Co  as Tamiflu  Somkiat Lalitwongsa  director of the Rajavithi Hospital in Bangkok  told reporters 
Separately  China has kick started a clinical trial to test a drug as the nation rushes therapies for those afflicted and scours for vaccines to protect the rest  Remdesivir  a new antiviral drug by Gilead Sciences aimed at infectious diseases such Ebola and SARS  will be tested by a medical team from Beijing based China Japan Friendship Hospital for efficacy in treating the coronavirus 
U S  to Send More Evacuation Flights to China  2 31 p m  HK 
The U S  will be sending a  handful more  flights to bring citizens back from China s Hubei province  U S  Secretary of State Michael Pompeo told reporters  according to a pool report  The U S  may bring citizens from other countries as well  the report said 
Hong Kong Medical Workers Strike  2 16 p m  HK 
Hong Kong medical professionals began a five day strike Monday after the government refused their demand to shut all entry points from China  Deacons Yeung  the Hospital Authority s Director of Cluster Services  said emergency services remained normal and authorities had activated a  major incident control center  to monitor the situation 
Virus Is Most Deadly in Hubei Province  12 45 p m  HK 
The number of official cases from the coronavirus is still highly concentrated in Hubei province  Of the 17 205 confirmed infections in mainland China so far  65  are in Hubei  where the outbreak originated and where residents are in effective lockdown because of travel restrictions 
The virus also appears to be more deadly in Hubei  accounting for 97  of the 361 total deaths reported in the country 
U S  Reports Additional Cases  11 20 a m  HK 
California confirmed two new cases of coronavirus in San Benito County  bringing the total of infected patients in the U S  to 11 
The two cases are a married couple  one of whom traveled to China  Earlier Sunday  Santa Clara s public health department reported an additional coronavirus patient  The woman had traveled to Wuhan and visited the U S  on Jan  23  It s the second case in the county  which is just south of San Francisco 
Chinese Stocks  Commodities Plummet as Markets Reopen  9 38 a m  HK 
Chinese stocks plummeted the most since an equity bubble burst in 2015  with the CSI 300 Index dropping as much as 9 1   as onshore financial markets opened for the first time since Jan  23 
China s three major commodity exchanges were hit by a wave of selling as investors returned to markets gripped by fear over the impact the coronavirus will have on demand in the world s biggest consumer of raw materials  China s benchmark iron ore contract fell by its daily limit of 8   while copper  crude and palm oil also sank by the maximum allowed 
China reduced rates as it injected cash into the financial system  with the central bank seeking to ensure ample liquidity as markets plunge  It cut borrowing costs on the funds by 10 basis points 
China Virus Cases Climb Above 17 000  8 12 a m  HK 
China s death toll increased by 57 to reach 361 as of Feb  2  according to a statement from the Ministry of Health  Total confirmed infections climbed to 17 205  with the addition of 2 829 cases in the past 24 hours  There are 2 296 severe cases  the ministry said 
 An earlier version of this report corrected the timestamp on one item  ",2020-02-03,Bloomberg,https://www.investing.com/news/stock-market-news/cdc-readies-for-pandemic-long-vaccine-timeline-virus-update-2074864,2074864
200616,422132,GILD,Gilead s Ebola Drug Shows Positive Signs in Treating Coronavirus,news,"Gilead Sciences  NASDAQ GILD  shot up as much as 13  on the news that its failed Ebola drug  remdesivir  showed promising initial signs of helping patients with the coronavirus  In an official statement before the weekend  the company announced it was working together with U S  and Chinese health regulators to see whether remdesivir could improve patient symptoms  
The company stated that remdesivir saw some success in treating patients with SARS and MERS  two other viruses with similarities with the coronavirus when tested in animals  Remdesivir was also tested on one U S  coronavirus patient prior to the weekend  who showed an impressive improvement in symptoms following a single dose 

The New England Journal of Medicine reported that a U S  patient received a dose of remdesivir from doctors on a compassionate use basis  Whereas the patient had been showing signs of pneumonia  fever  and required supplemental oxygen  after remdesivir was given  all symptoms disappeared except for a cough and mucus buildup in the nasal cavity  rhinorrhea  
Further details
While impressive  further clinical tests need to be performed before Gilead s remdesivir can be recommended for widespread coronavirus treatment  Other pharmaceutical giants are also hoping to develop a treatment  with Johnson   Johnson and GlaxoSmithKline working on their own vaccines  AbbVie stated it saw positive results by mixing two HIV medications with another drug called Tamiflu 
However  the biggest winners over the past few weeks have been small cap specialty vaccine producers  Moderna and Inovio Pharmaceuticals have seen substantial swings in their stock prices as the coronavirus continues to spread  There are now 362 confirmed deaths from the outbreak so far ",2020-02-03,The Motley Fool,https://invst.ly/pqltf,2074960
200617,422133,GILD,Here s a Better Reason to Buy Gilead Sciences Stock Than a Possible Coronavirus Treatment,news,"Gilead Sciences  NASDAQ GILD  just might have moved into the pole position in the race to fight the coronavirus  On Friday  the big biotech announced that it s working with Chinese authorities on a clinical trial to evaluate remdesivir  which was unsuccessful as a treatment for Ebola  in treating the 2019 nCoV coronavirus strain that has caused serious health concerns throughout the world 
Remdesivir has previously demonstrated potential against MERS and SARS  two other coronaviruses that are similar in structure to 2019 nCoV  A study published in The New England Journal of Medicine last week reported that a man in Washington state with the coronavirus strain experienced improvement after being treated with Gilead s experimental drug 
Optimism about remdesivir fueled investors  excitement on Monday  sending Gilead s shares as much as 8 7  higher during the day  But there s an even better reason to consider buying Gilead stock now than its prospects for treating the coronavirus 

More important to Gilead s future
Perhaps the best reason to buy Gilead Sciences shares right now is the potential for the immunology drug filgotinib  There s no question that it s more important to Gilead s future than remdesivir is 
For one thing  filgotinib has already been evaluated in multiple late stage clinical studies as a treatment for rheumatoid arthritis  and demonstrated both efficacy and safety  Gilead is currently waiting for regulators in the U S   the EU  and Japan to hand down their decisions on it  By contrast  though remdesivir has shown promise as a possible treatment for coronavirus  there s no guarantee that it will be successful in clinical trials  
Then there are the drugs  relative market sizes  More than 1 3 million Americans have rheumatoid arthritis  as do up to 1  of the world s population    around 78 million people in all  And as the size of the senior adult population grows across the world  the prevalence of rheumatoid arthritis will climb since the likelihood of developing the disease increases with age 
Compare those numbers to what has been seen so far with the coronavirus  As of Feb  3  there were 17 391 confirmed cases of the virus  with more than 99  of them in China  according to the World Health Organization  WHO   The number of deaths resulting from the coronavirus 2019 nCoV strain totaled 361  with 360 of them in China 
Those are worrisome statistics  to be sure  as the number of confirmed infections is growing at an alarming rate  However  there are plenty of other diseases    including rheumatoid arthritis    that have greater health impacts globally  and which still would even if 2019 nCoV spreads significantly further 
Great expectations
There have been other coronavirus outbreaks in the past  SARS  severe acute respiratory syndrome  emerged in 2003  MERS  Middle East respiratory syndrome   made headlines in 2012  But despite initial concerns  no vaccine or antiviral drug has been approved for either virus strain  
Perhaps Gilead will make a lot of money if remdesivir proves to be effective at treating 2019 nCoV  But based on the past  there appears to be a good chance that worries will die down after this virus strain runs its course 
Meanwhile  analysts think that filgotinib will generate peak annual sales of around  3 billion in treating rheumatoid arthritis  Gilead is also evaluating the drug in several other autoimmune indications  including Crohn s disease  psoriatic arthritis  and ulcerative colitis  If filgotinib wins approval for all of those indications  it could rack up another  3 billion in annual sales 
Gilead liked the prospects for filgotinib so much that it spent  5 1 billion last year to expand its partnership with Galapagos  the biotech that initially developed it  Prior to this deal  Gilead owned the license to commercialize filgotinib  Now  the company also has an exclusive license and options rights to develop and commercialize all of Galapagos  programs everywhere outside of Europe 
More pipeline prospects
Biotech stocks rise and fall on the prospects for their pipelines  As promising as Gilead s potential coronavirus treatment may be  filgotinib is clearly the crown jewel for right now  And there are more candidates potentially on the way that make Gilead appear even more attractive 
The company has multiple phase 2 and phase 3 clinical studies underway evaluating cell therapies to treat blood cancers  One analyst thinks that experimental long acting HIV drug GS 6207  which is currently in early stage clinical testing  could eventually be Gilead s biggest winner of all  Regardless of what happens with the company s efforts to treat this coronavirus strain  the big biotech s pipeline makes it worth a serious look for long term investors ",2020-02-04,The Motley Fool,https://invst.ly/pqvr8,2075377
200618,422134,GILD,Gilead Earnings Miss  Revenue Beats In Q4,news,"Investing com   Gilead  NASDAQ GILD  reported on Tuesday fourth quarter earnings  that missed analysts  forecasts and revenue that topped expectations 
Gilead announced earnings per share of  1 3 on revenue of  5 88B  Analysts polled by Investing com anticipated EPS of  1 67 on revenue of  5 71B  That with comparison to EPS of  1 44 on revenue of  5 8B in the same period a year before  Gilead had reported EPS of  1 75 on revenue of  5 6B in the previous quarter  Analysts are expecting EPS of  1 73 and revenue of  5 56B in the upcoming quarter 
Gilead shares are up 3 79  from the beginning of the year   still down 4 01  from its 52 week high of  70 26 set on February 4  2019  They are under performing the Nasdaq 100 which is up 6 04  year to date 
Gilead shares lost 1 82  in after hours trade after the report 
Gilead follows other major Healthcare sector earnings this monthGilead s report follows an earnings beat by J J  on January 22  who reported EPS of  1 88 on revenue of  20 75B   compared to forecasts EPS of  1 87 on revenue of  20 8B 
Novartis ADR had beat expectations on January 29 with fourth quarter EPS of  1 32 on revenue of  12 4B  compared to forecast for EPS of  1 31 on revenue of  12 33B 
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2020-02-04,Investing.com,https://www.investing.com/news/stock-market-news/gilead-earnings-miss-revenue-beats-in-q4-2075951,2075951
200619,422135,GILD,Gilead Announces Q4 Financial Results  Misses EPS Target,news,"Gilead Sciences  NASDAQ GILD  announced its Q4 financial results on Tuesday afternoon  While the company ended up beating revenue expectations  Gilead s results were a little disappointing when it came to its earnings 
The biotech giant reported fourth quarter revenues of  5 88 billion  which is a 1  increase from last year  while earnings per share fell to  1 30 per share in comparison to the  1 44 reported in Q4 2018  or a 9 8  decline  Although Gilead outperformed on the  5 7 billion revenue target analysts were expecting  the biotech giant fell significantly short of the  1 67 EPS target Wall Street was anticipating 

Gilead s HIV pill  Biktarvy  remains the company s top selling product  The drug brought in  1 57 billion in revenue for the quarter  a substantial increase from the  578 million reported in Q4 2018  The company s second and third top selling products  two other HIV treatments known as Genvoya and Truvada  saw revenues of  958 million and  768 million respectively  In comparison to last year  however  both drugs have seen their revenue figures fall off a bit  with Genvoya reporting a 20 6  decline in revenue while Truvada saw a 6 7  decline over the same period 
Further details
Some of the company s smaller drugs have also seen solid revenue growth as well  Yescarta  an immunotherapy treatment used to treat B cell lymphoma  lymph node cancer   generated  122 million in sales during Q4 2019  a 50  increase from the  81 million reported a year ago  
Gilead is also one of many biotech companies working to develop a possible coronavirus vaccine  The company s Ebola drug  remdesivir  has shown some promise in reducing symptoms in patients with the condition ",2020-02-04,The Motley Fool,https://invst.ly/pr2w5,2076128
200620,422136,GILD,Gilead Sciences  GILD  Earnings Expected To Grow  Should You Buy ,opinion,"The market expects Gilead Sciences  NASDAQ GILD  to deliver a year over year increase in earnings on lower revenues when it reports results for the quarter ended December 2019  This widely known consensus outlook is important in assessing the company s earnings picture  but a powerful factor that might influence its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on February 4  2020  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This HIV and hepatitis C drugmaker is expected to post quarterly earnings of  1 68 per share in its upcoming report  which represents a year over year change of  16 7  
Revenues are expected to be  5 71 billion  down 1 4  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 89  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Gilead 
For Gilead  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  2 35  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that Gilead will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Gilead would post earnings of  1 76 per share when it actually produced earnings of  1 75  delivering a surprise of  0 57  
Over the last four quarters  the company has beaten consensus EPS estimates two times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Gilead appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2020-01-28,Zacks Investment Research,https://www.investing.com/analysis/gilead-sciences-gild-earnings-expected-to-grow-should-you-buy-200502377,200502377
200621,422137,GILD,Gilead s Mantle Cell Lymphoma Drug MAA Gets EMA Validation,opinion,Gilead Sciences Inc  s   NASDAQ GILD   company  Kite  announced that its Marketing Authorization Application  MAA  for KTE X19 has been fully validated Itis now under evaluation with the European Medicines Agency  EMA   KTE X19 is an investigational chimeric antigen receptor  CAR  T cell therapy being developed for the treatment of adult patients with relapsed or refractory mantle cell lymphoma  MCL   MCL is a rare form of non Hodgkin lymphoma  NHL  that arises from cells originating in the  mantle zone  of the lymph node The MAA is supported by data from the single arm  open label  phase II ZUMA 2 study  which demonstrated an overall response rate of 93   including 67  with complete response  as assessed by an Independent Radiologic Review Committee  IRRC  following a single infusion of KTE X19  median follow up of 12 3 months  Shares of the company have decreased 7 5  in the past year compared with the  s decline of 5 6  Kite submitted a biologics license application  BLA  for KTE X19 to the FDA on Dec 11  2019  for the treatment of adult patients with relapsed or refractory MCL  The candidate has been granted Breakthrough Therapy Designation  BTD  by the FDA and Priority Medicines  PRIME  by the EMA Apart from MCL  KTE X19 is currently in phase I II studies in acute lymphoblastic leukemia  ALL  and chronic lymphocytic leukemia  CLL  Gilead has a robust pipeline  with several development programs currently underway  ranging from phase I through phase III  Gilead Sciences  Inc  Price    Zacks Rank   Stocks to ConsiderGilead is currently a Zacks Rank  3  Hold  stock A few better ranked stocks in the biotech sector are BioDelivery Sciences International Inc    NASDAQ BDSI    Guardant Health Inc    NASDAQ GH   and Denali Therapeutics Inc    NASDAQ DNLI    all sporting a Zacks Rank  1  Strong Buy   You can see  BioDelivery s loss per share estimates have narrowed from 21 cents to 16 cents for 2019 in the past 90 days  The company delivered a positive earnings surprise in the trailing four quarters by 159 38   on average Guardant s loss per share estimates have narrowed from  1 27 to 88 cents for 2019 and from  1 29 to  1 18 for 2020 in the past 90 days  The company delivered a positive earnings surprise in the trailing four quarters by 39 21   on average Denali s loss per share estimates have narrowed from  2 04 to  2 02 for 2019 and from  2 40 to  2 39 for 2020 in the past 90 days Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2020-01-28,Zacks Investment Research,https://www.investing.com/analysis/gileads-mantle-cell-lymphoma-drug-maa-gets-ema-validation-200502707,200502707
200622,422138,GILD,Will Strong HIV Sales Drive Gilead s  GILD  Q4 Earnings ,opinion,"Biotech major Gilead Sciences Inc    NASDAQ GILD   is slated to report fourth quarter 2019 results on Feb 4  after market close Gilead has a disappointing track record  with earnings beating estimates in two of the last four quarters  the average negative surprise being 0 66   In the last reported quarter  the company s missed expectations by 0 57  Gilead Sciences  Inc  Price  Consensus and EPS Surprise
    Gilead s stock has lost 8 6  in the past year compared with the  s decline of 7 2  Let s see how things have shaped up for this announcement Why a Likely Positive SurpriseOur proven model predicts an earnings beat for Gilead this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  You can uncover the best stocks to buy or sell before they re reported with our  Earnings ESP  Earnings ESP for Gilead is  1 55  as the Zacks Consensus Estimate is pegged at  1 68  while the Most Accurate Estimate is pegged at  1 71 Zacks Rank  It currently carries a Zacks Rank  3 Factors at PlayGilead did not provide any quarterly guidance  Strong performance of the HIV franchise led to better than expected sales in the third quarter  a trend that most likely continued in the fourth quarter The HIV franchise s performance and other antiviral product sales in the fourth quarter might have been driven by the momentum of tenofovir alafenamide based products   Genvoya  Descovy and Odefsey  Biktarvy s uptake has been phenomenal in 2019 and its sales are likely to have boosted the top line in the fourth quarter  Per Gilead  Biktarvy is now the number one prescribed regimen for both treatment na ve and switch patients in the United States in the quarter  However  stiff competition from the likes of GlaxoSmithKline   NYSE GSK   might have limited market share gains  The Zacks Consensus Estimate for sales of Genvoya and Biktarvy is projected at  947 million and  1 4 billion  respectively HCV sales are likely to have declined in the fourth quarter due to competitive pressure Yescarta  axicabtagene ciloleucel  generated  118 million in sales during the third quarter of 2019 and fourth quarter sales might have experienced a sequential increase  driven by a higher number of therapies provided to patients and its continued expansion in Europe   Apart from the regular top and bottom line numbers  we expect investors to focus on the company s pipeline updates Gilead submitted a Biologics License Application  BLA  to the FDA for the investigational CAR T cell therapy  KTE X19  for the treatment of adult patients with relapsed or refractory mantle cell lymphoma  MCL   The Marketing Authorization Application  MAA  for the same has been fully validated  It is now under evaluation with the European Medicines Agency  EMA  The company also submitted a new drug application  NDA  to the FDA for JAK inhibitor candidate  filgotinib  for the treatment of adults with moderate to severe rheumatoid arthritis  RA   A priority review voucher was submitted with the NDA  which should shorten the anticipated time for review The FDA approved a label expansion of HIV treatment  Descovy  as a prevention option  The agency approved the treatment for a pre exposure prophylaxis  PrEP  indication  Descovy for PrEP is indicated to reduce the risk of sexually acquired HIV 1 infection in adults and adolescents weighing at least 35 kg  who are HIV negative and at risk for sexually acquired HIV  excluding individuals at risk from receptive vaginal sex Other Stocks to ConsiderHere are some stocks you may want to consider  as our model shows that these too have the right combination of elements to post an earnings beat this quarter Merck   NYSE MRK   has an Earnings ESP of  1 05  and a Zacks Rank  3  The company is scheduled to release results on Feb 5  You can see  Regeneron   NASDAQ REGN   has an Earnings ESP of  5 39  and a Zacks Rank  3  The company is scheduled to release results on Feb 6 
Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained and impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7  This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ",2020-01-30,Zacks Investment Research,https://www.investing.com/analysis/will-strong-hiv-sales-drive-gileads-gild-q4-earnings-200503567,200503567
200623,422139,GILD,Should You Buy Gilead  GILD  Ahead Of Earnings ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Gilead Sciences  Inc    NASDAQ GILD   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Gilead is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for GILD in this report In fact  the Most Accurate Estimate for the current quarter is currently at  1 71 per share for GILD  compared to a broader Zacks Consensus Estimate of  1 68 per share  This suggests that analysts have very recently bumped up their estimates for GILD  giving the stock a Zacks Earnings ESP of  1 55  heading into earnings season Gilead Sciences  Inc  Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that GILD has a Zacks Rank  3 and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here Clearly  recent earnings estimate revisions suggest that good things are ahead for Gilead  and that a beat might be in the cards for the upcoming report Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2020-02-02,Zacks Investment Research,https://www.investing.com/analysis/should-you-buy-gilead-gild-ahead-of-earnings-200504040,200504040
200630,422146,GILD,Gilead advancing experimental antiviral to treat coronavirus infection,news,"In a statement  Gilead Sciences  NASDAQ GILD  Chief Medical Officer Merdad Parsey  M D   Ph D   says the company has supplied experimental antiviral remdesivir to a small number of patients infected with 2019 nCoV  the coronavirus causing the current outbreak  on an emergency basis since there are no approved treatments for the respiratory ailment 
It is working with Chinese health authorities on a clinical trial to determine the safety and efficacy of the nucleotide analog  it is being developed to treat infections from Ebola and Marburg viruses   It is also expediting laboratory testing of the drug against 2019 nCoV 
The New England Journal of Medicine reported that the first U S  infected person  a man in Seattle  was treated with remdesivir on the seventh day of his hospitalization  Although he is still an in patient  all symptoms  except his cough  which has improved   have resolved  The day after he received the drug  his temperature dropped from almost 103 degrees Fahrenheit to 99 1  reaching the normal range soon thereafter ",2020-02-01,Seeking Alpha,https://invst.ly/ppujw,2073754
200631,422147,GILD,Is the Coronavirus the Kick Start Gilead Sciences Stock Needs ,news,"Gilead Sciences Inc   NASDAQ  GILD  shares moved sharply higher on Monday after the company announced that it is currently working with China to develop an effective treatment for the coronavirus  Essentially  the firm believes that remdesivir  previously developed to treat Ebola  could prove successful in combating the coronavirus Gilead noted that it is setting up a randomized  controlled trial in China as part of its plans  In the past  remdesivir has shown in vitro and in vivo activity in animal models against the viral pathogens Middle East respiratory syndrome  MERS  and severe acute respiratory syndrome  SARS   both of which are also coronaviruses On Friday  it was reported that Chinese officials reached an agreement with Gilead to test remdesivir in patients with the coronavirus  Separately  the New England Journal of Medicine reported that a man infected with the coronavirus in Washington state was given remdesivir and his condition began to improve the following day div connatix margin bottom  1 5em   div connatix img  margin  unset  There have been roughly 17 000 confirmed infections and at least 360 deaths stemming from an outbreak in Wuhan  Infections have been reported in East Asia  with Japan and Thailand leading the count  A couple of European countries have reported infections  and there have been cases in the United States and Canada as well Gilead joins the growing list of biopharma companies that are joining the fight against the new coronavirus  Some of these firms have seen their share prices triple since the beginning of January Gilead Sciences stock was up about 6  at  67 24 early Monday  in a 52 week range of  60 89 to  70 26  The share price still is down almost 6  year over year  The consensus price target is  76 39  


				ALSO READ  10 Big Stocks That Should Keep Avoiding the Coronavirus Stock Market Panic				


By Chris Lange",2020-02-03,247wallst,https://invst.ly/pqg8s,2074497
200632,422148,GILD,Why Gilead Sciences Stock Is Up 13  Today,news,"What happened
Biotech blue blood Gilead Sciences  NASDAQ GILD  saw its shares jump by as much as 13  in pre market action Monday morning  The stock perked up in response to a research agreement with Chinese authorities to begin a clinical trial of the antiviral medication remdesivir in patients infected with the novel coronavirus known as 2019 nCoV  The trial will reportedly take place in Wuhan  China  the epicenter of the current outbreak  
So what
The coronavirus has already killed 361 individuals  based on the latest figures from the World Health Organization  And it has quickly spread from China to neighboring Asia Pacific nations  North America  Europe  and the Middle East  If a viable treatment isn t identified soon  the death toll from this unique respiratory disease could skyrocket in the coming weeks 

In fact  the challenging circumstances developing in Wuhan might be skewing the actual infection rates by health authorities in the region  Put simply  this outbreak might actually be far worse than current estimates suggest  What this all means is that health authorities in China and elsewhere may be forced to take extraordinary measures soon  such as approving novel treatments like Gilead s antiviral remdesivir in record time   
Now what
Should investors take advantage of this rapidly developing healthcare story  While there s a growing chance that this may in fact be a boon for one or more biotechs at the end of the day  it s still a long shot  Gilead  or any other coronavirus player for that matter  is highly unlikely to get a marketing approval for a coronavirus treatment before the outbreak simply peters out  In short  this breaking news story is not a solid reason to buy this top biotech stock today ",2020-02-03,The Motley Fool,https://invst.ly/pqgk8,2074523
200633,422149,GILD,GILD Or EXEL  Which Is The Better Value Stock Right Now ,opinion,"Investors interested in stocks from the Medical   Biomedical and Genetics sector have probably already heard of Gilead Sciences  NASDAQ GILD  and Exelixis  EXEL   But which of these two stocks offers value investors a better bang for their buck right now  We ll need to take a closer look 
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system  The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends  while our Style Scores work to grade companies based on specific traits 
Gilead Sciences and Exelixis are sporting Zacks Ranks of  2  Buy  and  3  Hold   respectively  right now  The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates  so investors should rest assured that GILD has an improving earnings outlook  But this is only part of the picture for value investors 
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels 
Our Value category grades stocks based on a number of key metrics  including the tried and true P E ratio  the P S ratio  earnings yield  and cash flow per share  as well as a variety of other fundamentals that value investors frequently use 
GILD currently has a forward P E ratio of 9 02  while EXEL has a forward P E of 35 12  We also note that GILD has a PEG ratio of 3 69  This popular figure is similar to the widely used P E ratio  but the PEG ratio also considers a company s expected EPS growth rate  EXEL currently has a PEG ratio of 4 28 
Another notable valuation metric for GILD is its P B ratio of 3 86  The P B ratio pits a stock s market value against its book value  which is defined as total assets minus total liabilities  For comparison  EXEL has a P B of 3 87 
Based on these metrics and many more  GILD holds a Value grade of A  while EXEL has a Value grade of C 
GILD is currently sporting an improving earnings outlook  which makes it stick out in our Zacks Rank model  And  based on the above valuation metrics  we feel that GILD is likely the superior value option right now ",2020-01-16,Zacks Investment Research,https://www.investing.com/analysis/gild-or-exel-which-is-the-better-value-stock-right-now-200499741,200499741
200634,422150,GILD,Stocks Rise Yet Again  But Signs Of A Pullback Are Still On The Horizon,opinion,"Anyway  at this point  the market continues grinding higher  It is making my belief of a pullback seem less likely at this point  or the very least being wrong  But it may be too early to admit defeat  we will have to wait to see what the next day or two bring 
The chart shows the rising wedge I drew in  it also indicates that the index trading higher slightly above the uptrend line  There is also now a gap that needs to be filled at lower levels around 3 290 






Russell 2000 
The Russell also made a new 52 week high today rising just above 1700  This is a region of resistance for the index in the 1 700 to 1 710 area  We can see there is a gap to fill in the Russell back around the 1680 level 






200 Day Moving Average






Additionally  one would have to go back to 2014  to find the last time the there were this many numbers of stocks above their 200 days moving average 
Twitter  TWTR  






Twitter is moving higher to resistance  this is a stock I was bullish on  then I turned bearish on  I should have just stuck with my original thought of the stock rising 
Roku  ROKU  






Here is another stock I always seem to struggle with  Roku  The stock is at support once again at  128  and still  it manages to hold 
Gilead  NASDAQ GILD 
Since we are the topic of stocks I can t get right  we might as well keep going  Today it is Gilead  NASDAQ GILD   first I thought the stock was going lower  then I thought the stock was breaking out  now it is going the other way  It needs to hold support at  61 88 






Goldman  GS 






I am moving on  Goldman looks like it breaking out  rising above resistance  and the potential to push higher towards  263 
Blackberry  TSX BB 






Here is one that had a good day  with Blackberry  TSX BB  rising above a resistance level at  6 70  another good day tomorrow  we could result in the process of that gap fill up to  7 50 ",2020-01-17,Michael Kramer,https://www.investing.com/analysis/stocks-rise-yet-again-but-signs-of-a-pullback-are-still-on-the-horizon-200499494,200499494
200640,422156,GILD,Hookipa Pharma up 2  on advancement of Gilead partnership,news,"Thinly traded HOOKIPA Pharma  HOOK  2 1   is up  albeit on a scant 38K shares  on the heels of its announcement that collaboration partner Gilead Sciences  GILD  0 2   will advance its HBV and HIV vectors toward development  a decision that triggers another milestone payment under the HBV program 
Gilead has agreed to reserve manufacturing capacity for the vectors and has expanded the resources allocated to the partnership inked in June 2018 ",2020-01-06,Seeking Alpha,https://invst.ly/peask,2053197
200641,422157,GILD,Gilead helps Nasdaq rebound on coronavirus news,news,The Nasdaq composite is back in the green  up 0 7  from its intraday low  helped by the rally in Gilead Sciences  GILD  0 6   on 30  higher volume on reports that it is evaluating its experimental Ebola candidate  Nuc inhibitor GS 5734  for the potential treatment of 2019 nCov infection  the coronavirus causing the current outbreak in China ,2020-01-23,Seeking Alpha,https://invst.ly/pm1wj,2066474
200642,422158,GILD,Gilead Considering Ebola Drug as Potential Coronavirus Treatment,news,"As fears about the coronavirus outbreak in China continue to grow  a number of companies have started working on potential vaccines  Gilead  NASDAQ GILD  announced Thursday that it was evaluating whether its experimental Ebola treatment could be used to treat the coronavirus 
In an attempt to prevent the virus from spreading  China has imposed travel restrictions on millions of people across the two cities at the center of the outbreak  The virus has already killed 18 people and infected more than 600  And although there has only been a single diagnosed case in the U S  so far  authorities here are worried about the infection getting a foothold  

 Gilead is in active discussions with researchers and clinicians in the United States and China regarding the ongoing Wuhan coronavirus outbreak and the potential use of remdesivir as an investigational treatment   said a company spokesperson in an emailed statement according to Reuters 
The director of the U S  National Institute of Allergy and Infectious Diseases  NIAID   Anthony Fauci  also added that his department has been working with Gilead closely to test whether its Ebola candidate  an antiviral drug known as remdesivir  is effective in treating coronavirus  At the moment  there are some indications that it could be  
Further developments
Gilead isn t the only biopharma company out there working on a vaccine  Earlier on Thursday  the Coalition for Epidemic Preparedness Innovations  CEPI  announced a new agreement to develop an mRNA vaccine to combat the coronavirus  Both Inovio Pharmaceuticals and Moderna received funding from the organization to help accelerate their efforts to develop potential vaccines ",2020-01-23,The Motley Fool,https://invst.ly/pm3pe,2066626
200643,422159,GILD,An Emboldened Bristol Myers Squibb Wants  1 5 Billion From Gilead Sciences,news,"Last year  Bristol Myers Squibb  NYSE BMY  spent  74 billion for Celgene and its mixed bag of commercial and clinical stage drugs  Analysts are still arguing about whether the big pharma overpaid  but last month a jury helped tip the scales in Bristol s favor by ordering Gilead Sciences  NASDAQ GILD  to pay Bristol  752 million in damages for infringing on patents that Celgene acquired years earlier 
In a recently filed motion  Bristol Myers asked a federal judge in California to include punitive damages that would raise Gilead s penalty to  1 5 billion to include punitive damages along with compensation and a royalty rate of 27 6  on Yescarta sales  
 

Bristol Myers Squibb s argument 
According to Bristol Myers  the Kite Pharma subsidiary that Gilead acquired for  11 9 billion in 2017 willfully infringed on patents that Juno Therapeutics licensed from Memorial Sloan Kettering Cancer Center  While  752 million is a princely sum  it only covers the amount Juno might have received if Kite had agreed on a licensing arrangement for the patent Yescarta infringed upon 
Bristol Myers  would like to see Gilead pay punitive damages equal to the compensation already owed because the jury s verdict shows that Kite  and later Gilead knew Yescarta would infringe and avoided striking a costly deal with Juno and Sloan 
Gilead s defense
Gilead s subsidiary has requested a do over because it wasn t allowed sufficient time to prepare its full case to the jury and the list of grievances continues to pile up  
Kite claims the patent at the heart of the argument lacked adequate written description and enablement  Kite also wants to argue that the patent involved claims more chimeric antigen receptors than Sloan and Juno actually invented ",2020-01-24,The Motley Fool,https://invst.ly/pmj64,2067452
200644,422160,GILD,Near a 7 Year Low  Is Gilead Sciences a Buy ,news,"Buying a stock near its low can be a good way to lock in a low price and hopefully set yourself up for some stronger returns later on  In the case of Gilead Sciences  NASDAQ GILD   the stock isn t just at a 52 week low    it s trading at around the lowest it has been in seven years  While the stock has occasionally dipped lower than the  63 that it trades at today  the last time that the stock was below that mark for an extended period of time was back in 2013 when it was on its way up 
Over the past year  Gilead s stock has declined by 7   even as the Health Care Select Sector SPDR Fund has risen 17   It may be tempting to believe that Gilead has bottomed out and it s due for a rally  But it s important to first understand why the stock is struggling as badly as it is  whether it can recover  and whether the stock is a good value at its current price  or if it is only likely to decline further 
Profits and sales have been falling    fast
It s no big mystery why Gilead is struggling  The company just isn t producing the results that it once did  In 2018  sales of  22 1 billion were down more than 27  from the  30 4 billion that Gilead reported in 2016  Its margins have been shrinking as well  Through 2014 to 2016  Gilead s net profit margin didn t fall below 40   but in 2018 it was only 25     which was still an improvement from 18  the year before 

The company s product sales were down 14  in 2017 and then 16  again in 2018  Although HIV drug sales increased  2 9 billion during that time   that s not enough to offset the losses from Harvoni  Sales from the Hepatitis C drug totaled just  1 2 billion in 2018  and that s down nearly  8 billion from the  9 1 billion in revenue it generated in 2016  Gilead now offers a generic  lower priced drug for patients with Hepatitis C which will help keep sales going  but at a much lower pace  That means the company is going to need another drug to help drive future growth 
Where the company is today
With more than 100 clinical studies that Gilead is working on today  there are many opportunities for the drug manufacturer to find a way to help replace the sales it has lost over the years  The problem is that clinical trials are hit or miss  and there s no guarantee any of them will result in a drug that will be as successful as Harvoni once was 
At a minimum  the company needs to show more growth than it has been achieving thus far  During the first three quarters of the year  Gilead s product sales have risen by only 2  from the same period last year  Sales from HIV drugs remain strong and up 12  year over year  but it s the lagging drug sales from all its other products that are weighing Gilead s top line down  In the company s third quarter  sales of Ranexa and Letairis were down 83  and 50   respectively  The availability of generic drugs has led to a decline in their demand 
Developing new drugs is key  and that poses a big question mark over whether the stock is a good investment today or not 
Why the stock may be a good buy
Gilead could be a calculated risk for investors to take today  At a forward price to earnings  P E  ratio of just nine  and with the company still generating some good growth from its HIV drugs  there s reason to still be optimistic that the company can turn things around  By comparison  rivals GlaxoSmithKline and Bristol Myers Squibb trade at higher forward P E ratios of 15 and 10  respectively  
With many clinical trials in the works  the company has many opportunities to find more growth in the future  And with Gilead paying shareholders a dividend of 4  per year  investors will be well compensated for their patience ",2020-01-29,The Motley Fool,https://invst.ly/podfm,2070404
200645,422161,GILD,Better Buy  Intercept Pharmaceuticals vs  Gilead Sciences,news,"Investing in biotech stocks might just be a great idea  The industry as a whole    as measured by the SPDR S P Biotech ETF Index    provided a return of 45 5  over the past three years  narrowly outperforming the S P 500 and its 44 5  return over the same period  Of course  there are scores of biotech companies to consider investing in  but let s turn our attention to two in particular  Intercept Pharmaceuticals  NASDAQ ICPT  and Gilead Sciences  NASDAQ GILD  
There are important differences between these two companies  For instance  Gilead Sciences  portfolio of products is diverse  whereas Intercept Pharma currently has only one product on the market  However  Intercept Pharma was the better performer last year  The company s shares grew by 22 95   easily topping Gilead Sciences  3 88  return  Will Intercept Pharma continue to outpace Gilead Sciences  Let s look at both companies  businesses and find out which is the better buy 

The case for Intercept 
Intercept s only drug on the market is Ocaliva  a medicine for primary biliary cholangitis  PBC   PBC is a chronic liver disease that  if left untreated  can eventually lead to liver failure  Ocaliva is generating growing sales  During the third quarter  Intercept s total revenue was  61 9 million  The bulk of the company s revenue     61 5 million  to be exact    came from sales of Ocaliva  representing 32  year over year sales growth 
However  Ocaliva could have a more significant opportunity ahead  Intercept recently submitted a New Drug Application  NDA  to the U S  Food and Drug Administration for Ocaliva as a potential treatment for fibrosis due to nonalcoholic steatohepatitis  NASH   
The potential market for this indication is exciting  Not only are there no approved therapies for fibrosis caused by NASH  but the condition is predicted to become more prevalent in the coming years  For instance  NASH is projected to become the leading cause of liver transplant in the U S   taking the top spot from Hepatitis C  In other words  if Ocaliva gains approval for liver disease caused by NASH  Intercept s revenue could soar along with the company s stock price 
The case for Gilead Sciences
Gilead Sciences  best hopes rest on its lineup of products for the prevention and treatment of HIV  This lineup includes such products as HIV prevention drugs Truvada and Descovy  as well as HIV treatments such as Genvoya and Biktarvy  During the third quarter  Gilead Sciences  HIV product sales were  4 2 billion  13 5  higher than the year ago period  Note that HIV sales accounted for about 75  of Gilead Sciences  revenue  
Besides its HIV business  Gilead Sciences could benefit immensely from its partnership with biotech company Galapagos NV  NASDAQ GLPG   Back in July of last year  Gilead Sciences made an upfront payment of  3 95 billion to Galapagos as well as a  1 1 billion equity investment  The equity investment increased Gilead Sciences  stake in Galapagos from 12 3  to 22   
Gilead Sciences also received the right to  develop and commercialize all current and future programs in all countries outside Europe   Thus  per the agreement  Gilead Sciences acquired the rights to Galapagos  pipeline candidates  including GLPG1690  a potential treatment for idiopathic pulmonary fibrosis that is currently in phase 3 testing  Gilead Sciences  deal with Galapagos could help the company beef up its portfolio and decrease its top line exposure to its HIV business  
Profitability and valuation
Neither company was profitable during the third quarter  Intercept recorded a net loss of  84 8 million  while Gilead Sciences  net loss was  1 2 billion  But while Gilead Sciences  revenue of  5 6 billion was much higher than Intercept s  61 9 million  the latter seems to be more attractively valued when taking into account future earnings growth  Intercept s price to earnings growth ratio  PEG  is currently 1 07  while Gilead Sciences  PEG is 5 29 
Verdict
There are good arguments for both companies  If Ocaliva gets approved for fibrosis due to NASH  Intercept Pharma s shares will likely skyrocket  thus rewarding the company s shareholders  However  Gilead Sciences looks like a better long term bet as its portfolio is far more diversified  and the company s partnership with Galapagos may yield exciting products to help it keep its revenue afloat  I d personally opt for Gilead Sciences if I had to pick one  but I think both of these biotech stocks are worth considering ",2020-01-30,The Motley Fool,https://invst.ly/pov1h,2071487
200646,422162,GILD,Spring Bank  SBPH  Stops Dosing In HBV Studies  Stock Down ,opinion,Shares of clinical stage biopharmaceutical company Spring Bank Pharmaceuticals  Inc    NASDAQ SBPH   plummeted 66 8  after it stopped dosing and enrolling patients in its mid stage studies on lead product candidate  inarigivir The phase IIb CATALYST studies are evaluating inarigivir soproxil 400mg for the treatment of chronic hepatitis B virus  HBV   The candidate is designed to activate within hepatic cells retinoic acid inducible gene 1  RIG I   which has been shown to inhibit HBV viral replication and induce the intracellular interferon signaling pathways for antiviral defense However  the company decided to stop the dosing of inarigivir 400mg in the CATALYST studies after observing clinical findings from the CATALYST 2 study of virally suppressed chronic HBV patients  Three subjects participating in this study showed evidence of hepatocellular dysfunction and an elevation of alanine transaminase  ALT   potentially consistent with liver injury rather than immune flares  Spring Bank is evaluating and analyzing the data  The company is further evaluating safety data across almost 100 patients who have received inarigivir at this dose Additionally  the company has stopped dosing and enrollment in all other studies of inarigivir in subjects with chronic HBV The news disappointed investors as inarigivir is the company s lead candidate and the successful development of the same would have boosted its growth prospects  Spring Bank s stock has plunged 88 5  in the year so far compared with the  s growth of 10 3   We note that the company has entered into a clinical trial supply and collaboration agreement with Gilead Sciences  Inc    NASDAQ GILD   that has been subsequently amended  Per the deal  Gilead is funding and conducting a phase II study evaluating inarigivir  50mg  200mg and 400mg  co administered with Vemlidy 25 mg  tenofovir alafenamide  in patients infected with chronic HBV  Interim top line results were positive Other FDA approved treatments for patients with chronic HBV include Bristol Myers Squibb Company s   NYSE BMY   Baraclude  In October  Arbutus Biopharma Corporation   NASDAQ ABUS   discontinued the clinical development of AB 506  an oral capsid inhibitor for the treatment of chronic hepatitis B Apart from inarigivir  Spring Bank is developing its lead STING agonist product candidate  SB 11285  an immunotherapeutic agent for the treatment of selected cancers Spring Bank currently carries a Zacks Rank  1  Strong Buy   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-12-26,Zacks Investment Research,https://www.investing.com/analysis/spring-bank-sbph-stops-dosing-in-hbv-studies-stock-down-200495156,200495156
200647,422163,GILD,GILD Vs  TECH  Which Stock Should Value Investors Buy Now ,opinion,"Investors looking for stocks in the Medical   Biomedical and Genetics sector might want to consider either Gilead Sciences  NASDAQ GILD  or Techne  TECH   But which of these two companies is the best option for those looking for undervalued stocks  Let s take a closer look 
Everyone has their own methods for finding great value opportunities  but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank  The Zacks Rank favors stocks with strong earnings estimate revision trends  and our Style Scores highlight companies with specific traits 
Gilead Sciences has a Zacks Rank of  2  Buy   while Techne has a Zacks Rank of  3  Hold  right now  This means that GILD s earnings estimate revision activity has been more impressive  so investors should feel comfortable with its improving analyst outlook  But this is just one piece of the puzzle for value investors 
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels 
The Style Score Value grade factors in a variety of key fundamental metrics  including the popular P E ratio  P S ratio  earnings yield  cash flow per share  and a number of other key stats that are commonly used by value investors 
GILD currently has a forward P E ratio of 9 27  while TECH has a forward P E of 44 48  We also note that GILD has a PEG ratio of 3 79  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  TECH currently has a PEG ratio of 4 04 
Another notable valuation metric for GILD is its P B ratio of 3 96  The P B ratio is used to compare a stock s market value with its book value  which is defined as total assets minus total liabilities  For comparison  TECH has a P B of 7 08 
Based on these metrics and many more  GILD holds a Value grade of A  while TECH has a Value grade of D 
GILD stands above TECH thanks to its solid earnings outlook  and based on these valuation figures  we also feel that GILD is the superior value option right now ",2019-12-31,Zacks Investment Research,https://www.investing.com/analysis/gild-vs-tech-which-stock-should-value-investors-buy-now-200495818,200495818
200648,422164,GILD,Novo Nordisk s Shares Up In A Year On Pipeline Progress,opinion,"Shares of Novo Nordisk  CSE NOVOb  A S   NYSE NVO   have rallied 23 4  in the past year compared with the  s growth of 14 9  

 
Novo Nordisk has a strong presence in the Diabetes care market  with a global value share of 28 4   The company has one of the broadest diabetes portfolios in the industry  The top line is driven by the strong performance of products such as Victoza  liraglutide  
In September 2019  the FDA approved semaglutide in tablet form  which will be marketed under the brand name Rybelsus  It is approved as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus  It is the first approved glucagon like peptide 1  GLP 1  receptor agonist in a tablet form  The drug is also under review with several regulatory agencies  including the European Medicines Agency and the Japanese Pharmaceuticals and Medical Devices Agency 
Additionally  the company is making efforts to develop new treatments for diabetes  which is its core area of expertise 
In February 2019  the FDA approved Novo Nordisk s biologics license application  BLA  for Esperoct  turoctocog alfa pegol  N8 GP  for the treatment of hemophilia A in adults and children  The drug is approved for routine prophylactic to reduce the frequency of bleeding episodes  on demand treatment and control of bleeding episodes plus perioperative management of bleeding in the given patient population  In July  the European Commission granted marketing authorization to the drug for the treatment of adolescents   12 years of age  and adults with hemophilia A  
In July 2019  the first human dose trial with LA GDF15 was initiated  including both single and multiple ascending doses  Human GDF15  Growth Differentiation Factor 15  also known as MIC 1  is a stress induced cytokine with multiple effects  one being appetite regulation leading to weight loss  LA GDF15 is a long acting version of human GDF15  During the same time  Gilead Sciences   NASDAQ GILD   and Novo Nordisk initiated a phase II proof of concept study combining semaglutide and the former s cilofexor  FXR agonist  and firsocostat  ACC inhibitor  for the treatment of patients with nonalcoholic steatohepatitis  NASH  
The company has also been on track with acquisitions in order to boost its portfolio  In November 2019  Novo Nordisk and UBE Industries Ltd  announced that the former obtained an exclusive worldwide license to UBE s preclinical asset UD 014  a selective Semicarbazide Sensitive Amine Oxidase Vascular Adhesion Protein 1  SSAO VAP 1  inhibitor small molecule  which has shown promising efficacy in preclinical studies for its anti inflammatory mechanism of action and antioxidative effect on endothelial cells  and can potentially be used for the treatment of non alcoholic steatohepatitis  NASH   
In October 2019  Novo Nordisk and bluebird   NASDAQ BLUE   inked a three year research collaboration to jointly develop next generation vivo genome editing treatments for genetic diseases  including hemophilia  Per the agreement  both companies will focus on identifying a development gene therapy candidate to offer people with hemophilia A a lifetime free of factor replacement therapy 
However  Novo Nordisk faces competition as the diabetes market is already crowded with a number of drugs  Merck s   NYSE MRK   Januvia and Janumet  type II diabetes   Eli Lilly s Trulicity  type II diabetes   Sanofi s Toujeo  type I and II diabetes  are already approved 
Novo Nordisk currently has a Zacks Rank  3  Hold   You can see  
Novo Nordisk A S Price

    
7 Best Stocks for the Next 30 Days
Just released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops   Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ",2020-01-02,Zacks Investment Research,https://www.investing.com/analysis/novo-nordisks-shares-up-in-a-year-on-pipeline-progress-200496039,200496039
200649,422165,GILD,Agenus Initiates Phase I Study On Oncology Candidate AGEN1223,opinion,Agenus Inc    NASDAQ AGEN   announced that it has initiated a phase I study on AGEN1223  AGEN1223 is a novel bi specific antibody  which is designed to deplete regulatory T cells in the tumor microenvironment  Agenus is currently responsible for the development of AGEN1223  Gilead Sciences  Inc    NASDAQ GILD   has an exclusive option to license the candidate The study is designed to evaluate the maximum tolerated dose of AGEN1223 in subjects with advanced solid tumors  It will also evaluate the safety  tolerability  pharmacokinetics  PK  and pharmacodynamics PD  profiles and immunogenicity of this bi specific antibody  The first patient was dosed in December 2019 and the study is ongoing  The company also plans to initiate combinations with balstilimab  its investigational PD 1 inhibitor  in 2020 Shares of the company have rallied 13  in the past year against the  s decline of 2   Besides AGEN1223  Agenus advanced three novel discoveries to investigational new drug  IND  in 2019  which are now set for clinical trials  These include the company s next generation CTLA 4  AGEN1181  the differentiated CD137 molecule  AGEN2373  and GS 1423  a bi functional molecule Further  Agenus expects to file biologics license application  BLA  for CTLA 4 targeting antibody  zalifrelimab  AGEN1884   for the treatment of second line cervical cancer and balstilimab for the treatment of recurrent ovarian cancer in 2020  It expects to commercialize both agents by the first half of 2021  The company is pursuing balstilimab as a monotherapy and in combination with zalifrelimab in patients with relapsed refractory category cervical cancer  In the combination study  the company completed its accrual requirement for a potential BLA filing as well as interim analysis Agenus Inc  Price    Zacks Rank and Stocks to ConsiderAgenus currently carries a Zacks Rank  3  Hold   A few better ranked stocks in the medical drugs sector are Emergent Biosolutions  Inc    NYSE EBS   and Audentes Therapeutics  Inc   NASDAQ BOLD    both sporting a Zacks Rank  1  Strong Buy   You can see  Emergent s earnings per share estimates have increased from  3 39 to  3 58 for 2020 in the past 60 days Audentes  loss per share estimates have narrowed from  4 17 to  4 13 for 2019 and from  4 45 to  4 33 for 2020 in the past 60 days Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9   This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2020-01-08,Zacks Investment Research,https://www.investing.com/analysis/agenus-initiates-phase-i-study-on-oncology-candidate-agen1223-200497640,200497640
200657,422173,GILD,Gilead Earnings Miss  Revenue Inline In Q3,news,"Investing com   Gilead  NASDAQ GILD  reported third quarter earnings  that missed analysts  expectations on Thursday and revenue that was inline with forecasts 
The firm reported earnings per share of  1 75 on revenue of  5 60B  Analysts polled by Investing com anticipated EPS of  1 76 on revenue of  5 6B  That compared to EPS of  1 84 on revenue of  5 6B in the same period a year earlier  The company had reported EPS of  1 82 on revenue of  5 69B in the previous quarter 
Gilead follows other major Healthcare sector earnings this monthOn October 15  J J reported third quarter EPS of  2 12 on revenue of  20 73B  compared to forecasts of EPS of  2 01 on revenue of  20 08B 
Novartis ADR earnings beat analysts  expectations on Tuesday  with third quarter EPS of  1 41 on revenue of  12 17B  Investing com analysts expected EPS of  1 33 on revenue of  11 71B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-10-24,Investing.com,https://www.investing.com/news/stock-market-news/gilead-earnings-miss-revenue-inline-in-q3-2003645,2003645
200658,422174,GILD,Exclusive  Sanofi s strategy boss to leave as CEO readies revamp,news,By Matthias Blamont PARIS  Reuters    Sanofi s  PA SASY  most senior strategy boss is set to leave by the end of the month  according to a memo seen by Reuters  in the first major management change under new chief executive Paul Hudson as he shakes up the firm s priorities   Muzammil Mansuri  head of strategy and business development and member of the French drugmaker s executive committee  will be retiring from the company  according to the note from Hudson sent to staff on Wednesday  A spokesman for Sanofi confirmed the decision   Hudson  who took over as CEO on Sept  1  is leading a strategic review and is expected to unveil the company s plan for the coming years at an investor day in Cambridge  Massachusetts  on December 10  Mansuri had joined Sanofi in 2016 from Gilead Sciences  O GILD  where he was in charge of research and development strategy and corporate development  Hudson said in the memo that Alban de la Sabliere  currently head of business development  and Laurent Van Lerberghe  head of strategy  would take on more responsibilities as of Dec  1 and report directly to him   Even though the group s new strategy is still in the works  Hudson has made no secret that significant changes were underway   I am bringing a little sense of urgency and prioritization  I have set a tone already that we can move a little bit faster   Hudson told reporters in October    I think we have the right level of resources although perhaps not always in the right place   Sources have told Reuters Sanofi was contemplating a joint venture or an outright sale among options for its consumer healthcare unit   An initial public offering  IPO  of the business  which could be worth around  30 billion according to two sources familiar with the matter  is also potentially on the cards though they cautioned that no final decision had been made  Analysts have argued a possible divestment or spin off of Sanofi s consumer healthcare arm  whose revenue grew by 3  at constant exchange rates last year to 4 7 billion euros   5 20 billion   would enable the group to invest more in internal research  The future of Sanofi s ailing diabetes business   under constant pricing pressure in the United States  the world s largest health market   is also under the spotlight ,2019-11-22,Reuters,https://www.investing.com/news/stock-market-news/exclusive-sanofis-strategy-boss-to-leave-as-ceo-readies-revamp-2026094,2026094
200659,422175,GILD,Half of lymphoma patients alive three years after Gilead cell therapy treatment  study,news,"By Manas Mishra
 Reuters    Nearly half of lymphoma patients treated with Gilead Sciences  NASDAQ GILD  Inc s Yescarta were alive at least three years after a one time infusion of the CAR T cell therapy  according to data presented on Saturday 
Out of 101 patients teated with Yescarta for an aggressive blood cancer known as refractory large B cell lymphoma in the study  47 were still alive at least three years later  the data presented at the American Society of Hematology meeting in Orlando showed 
 We are delivering towards our goal of potentially life saving therapy for many patients who previously faced limited treatment options   Christi Shaw  chief executive of Gilead s Kite unit  said in a statement  Gilead bought Kite in 2017 for  12 billion to acquire Yescarta 
Sales of Yescarta  which won U S  approval in October 2017 and carries a list price of  373 000  were slow to take off due to a range of issues  including high hospital costs and a complicated manufacturing process 
Global sales for the first nine months of 2019 were  334 million  Analysts forecast annual sales reaching  1 billion by 2022 and climbing from there  according to Refinitiv data 
Yescarta belongs to a new class of cancer treatments called CAR T therapy  seen as potentially revolutionary due to their promise of long term survival with a one time treatment for certain deadly blood cancers  such as relapsed or refractory large B cell lymphomas 
The treatment is made by harvesting T cells from a patient s own immune system  They are then engineered to more efficiently recognize and attack the cancer cells before being infused back into the patient 
Yescarta competes with Kymriah from Novartis AG  while several companies also are developing CAR T treatments  including some that aim to be off the shelf rather than patient specific 
Gilead also reported that steroids given to one group of patients helped reduce the risk of a serious complication associated with CAR T therapy called cytokine release syndrome  CRS   which can cause a range of dangerous symptoms including fever and neurological problems 
 Early steroid intervention has the potential to reduce the rate of severe CRS and neurologic events while appearing to maintain comparably impressive efficacy for Yescarta   Dr  Max Topp  a researcher from University Hospital of Wuerzburg  Germany who worked on the study  said in a statement ",2019-12-07,Reuters,https://www.investing.com/news/general/half-of-lymphoma-patients-alive-three-years-after-gilead-cell-therapy-treatment-study-2036285,2036285
200660,422176,GILD,Bristol Myers wins  752 million in U S  patent case against Gilead,news,By Jan Wolfe  Reuters    Bristol Myers Squibb  NYSE BMY  Co on Friday said it won a  752 million jury verdict against  Gilead Sciences Inc   NASDAQ GILD  in a U S  patent dispute relating to technology for treating cancer   A jury in Los Angeles awarded the damages after finding that Yescarta  a treatment sold by Gilead s Kite Pharma unit  infringed on a patent exclusively licensed by Bristol Myers  Juno Therapeutics division  The patent at issue in the lawsuit  which Juno licenses from the Memorial Sloan Kettering Cancer Center in New York  relates to CAR T cell immunotherapy for cancer  CAR T therapy involves a process of removing T cells from a patient s immune system  engineering them to better identify and attack cancer cells and infusing them back into the patient  Bristol Myers said in a statement that it was pleased with the verdict  Gilead disagreed with the decision   We remain steadfast in our opinion that Sloan Kettering s patent is not infringed and is invalid   Gilead said in a statement   Given that Kite independently developed Yescarta and assumed all of the risk in its discovery and development  we do not believe Sloan Kettering and Juno are entitled to any level of damages   Gilead said it expected to seek to undo the verdict through post trial motions and an appeal ,2019-12-13,Reuters,https://www.investing.com/news/stock-market-news/bristolmyers-prevails-over-gilead-in-yescarta-royalty-row-bloomberg-law-2041193,2041193
200661,422177,GILD,Where s the risk  U S  fund managers bet on bull run in 2020,news,By David Randall NEW YORK  Reuters    With the UK election results giving some certainty to the Brexit process  a U S  China trade deal all but signed and the Federal Reserve signaling that it will stand steady for the foreseeable future  there are three fewer hurdles standing in the way of global equities extending their record run into 2020   Yet fund managers say that lingering issues on trade and the U S  elections in November could still weigh on returns in 2020  leaving long shunned U S  value stocks and international equities primed to outperform in the year ahead    You re going into an environment where there s a lot of good news already priced into the market  so if there s any derailing of any positive items  there s not a lot of give   said Elliot Savage  portfolio manager of the YCG Enhanced Fund  which is up nearly 40  for the year to date  By focusing on unloved areas of the market such as financials   You have a chance to pick up companies with significant pricing power that you can hold for a long time   he said   A rally in value stocks would be a boon to investors who have waited in vain during this record setting bull market for more cyclical areas like energy and financials to outperform  The benchmark S P 500  SPX  hit another record on Tuesday as investors moved out of the perceived safety of bonds  continuing a rally that has boosted it nearly 28  for the year to date   PREPPING FOR A PULL BACK The dialing down of risks hanging over the market could lead to it to become overheated  warned Charles Lemonides  portfolio manager of hedge fund ValueWorks LLC    You may get some optimism in the markets where you will see buying that is valuation non specific and you ll get a momentum trade come back into market   he said   Lemonides is focusing more closely on valuations and has been buying energy names like Tidewater Inc  N TDW  and biotechs like  Gilead Sciences Inc   O GILD     Biotechs across the board are so attractively priced given their fundamentals   he said   At the same time  the increasing focus on Washington during a presidential election year could become a drain on investor sentiment  said Lemonides    Presidential elections freeze investors on both sides of the political spectrum   he said   The fundamental conditions of the market are really good but there will be a headwind from the election    A decline in the U S  equity market could offer an opportunity to add to small caps  which have underperformed the broader market  said Steve Chiavarone  a portfolio manager of the Federated Global Allocation Fund    The market has run up so quickly that we may get a sharp pullback purely on technical reasons  but we still think that there s going to be a catch up trade in areas that haven t had the same run   he said   LOOKING AT EUROPE  The apparent resolution of Brexit will likely prompt more investor interest in European stocks  while trade issues will continue to weigh on investor sentiment for China  said Lori Calvasina  head of U S  equity strategy at RBC Capital Markets    The investors we spoke with viewed the UK election as a major step toward resolution of Brexit  but didn t see the developments in the U S  China trade war as having the same significance   she said   The Conservative majority in Parliament is widely expected to pass the Brexit Withdrawal Agreement before the current deadline of Jan  31  At the same time  the  Phase one  pact between the United States and China focuses on reducing U S  tariffs on Chinese goods in exchange for increased Chinese purchases of U S  agricultural  manufactured and energy products over the next two years    Although we re seeing tamed back rhetoric  we believe that we re still far away from an ultimate trade deal that will put this behind us  Maybe we ve just tackled the easy to solve problems   said Brian Kersmanc  deputy portfolio manager for GQG Partners  International Equity strategy   Kersmanc has been moving more of his portfolio into European stocks such as  London Stock Exchange  Group PLC  L LSE  and French aerospace company  Safran  SA  PA SAF   He is also looking into European value sectors such as industrial stocks and energy  both of which have been weighed down by concerns about the strength of the European economy    There s some really interesting opportunities in companies that no one wanted to touch   he said   Now that the market sees a Brexit resolution happening  you re going to see stocks coming off a severe discount  ,2019-12-18,Reuters,https://www.investing.com/news/economy/wheres-the-risk-us-fund-managers-bet-on-bull-run-in-2020-2043864,2043864
200662,422178,GILD,Fate  FATE  Announces Encouraging Data On Immunotherapies ,opinion,Shares of Fate Therapeutics  Inc    NASDAQ FATE   surged 41 3  after the company came out with positive data on experimental cancer candidates The company announced initial clinical data on its candidates   FT516 and FT500  Both are off the shelf  induced pluripotent stem cell  iPSC  derived natural killer  NK  cell product candidates FT516 is being investigated in an open label  multi dose phase I clinical study as a monotherapy for the treatment of acute myeloid leukemia and in combination with CD20 directed monoclonal antibodies for the treatment of advanced B cell lymphoma  The initial findings show the absence of morphologic evidence of leukemia  at day 42  along with complete neutrophil recovery in the first patient treated with FT516 monotherapy for AML following the first dosing cycle FT500 is the first iPSC derived cell product candidate from the iPSC product platform  The study on FT500 is an open label  multi dose phase I trial being conducted for the treatment of advanced solid tumors  The dose escalation stage of the study is designed to assess the safety and tolerability of three once weekly doses of FT500  without IL 2 cytokine support  as a monotherapy and in combination with one of the three FDA approved immune checkpoint inhibitor  ICI  therapies in patients who have failed prior ICI therapy Initial data showed that there were no dose limiting toxicities or FT500 related serious adverse events reported in the first 12 patients treated with the candidate for advanced solid tumors The safety  tolerability and immunogenicity profile from the phase I dose escalation stage of FT500 was favorable and provided evidence that multiple doses of iPSC derived NK cells can be delivered off the shelf and administered without patient matching Fate s stock has soared 50 6  in the year so far compared with the  s growth of 6 1  The company also announced new in vivo preclinical data for FT596  its off the shelf  multi antigen targeting NK cell product candidate derived from a clonal master engineered iPSC line FT596 as a monotherapy demonstrates comparable anti tumor activity to CAR19 T Cells in vivo in the humanized mouse model of lymphoma  The combination of FT596 with rituximab shows durable tumor clearance in the preclinical lymphoma model  The company plans to initiate enrollment of a first in human clinical study on FT596 in early 2020 The data bode well for this clinical stage biopharmaceutical company Cellular immunotherapies promise huge potential  Hence  companies like Gilead Sciences  Inc    NASDAQ GILD    bluebird bio   NASDAQ BLUE   and Bristol Myers Squibb Company   NYSE BMY   are currently focusing on the development of cellular immunotherapies for the treatment of cancer Fate currently carries a Zacks Rank  3  Hold  You can see Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through Q3 2019  while the S P 500 gained  39 6   five of our strategies returned  51 8    57 5    96 9    119 0   and even  158 9  This outperformance has not just been a recent phenomenon  From 2000   Q3 2019  while the S P averaged  5 6  per year  our top strategies averaged up to  54 1  per year ,2019-12-09,Zacks Investment Research,https://www.investing.com/analysis/fate-fate-announces-encouraging-data-on-immunotherapies-200491566,200491566
200663,422179,GILD,Gilead Teams Up With Kiniksa  Submits BLA For CAR T Therapy,opinion,Gilead Sciences  Inc  s   NASDAQ GILD   Kite and Kiniksa Pharmaceuticals  Ltd    NASDAQ KNSA   have entered a clinical collaboration to conduct a phase II  multicenter study on pipeline candidate mavrilimumab in combination with Yescarta We note that Gilead s Yescarta was the first CAR T cell therapy to be approved by the FDA for the treatment of adult patients with relapsed or refractory large B cell lymphoma after two or more lines of systemic therapy  including diffuse large B cell lymphoma  DLBCL  not otherwise specified  primary mediastinal large B cell lymphoma  and high grade B cell lymphoma and DLBCL arising from follicular lymphoma Mavrilimumab is an investigational  fully human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha  GM CSFR    The combination study will be sponsored by Kite and conducted in patients with relapsed or refractory large B cell lymphoma The objective of the study is to determine the effect of mavrilimumab on the safety of Yescarta Concurrently  Kite announced that it has submitted a Biologics License Application  BLA  to the FDA for the investigational CAR T cell therapy  KTE X19  for the treatment of adult patients with relapsed or refractory mantle cell lymphoma  MCL  The BLA was based on data from the phase II ZUMA 2 study  which demonstrated an overall response rate of 93   including 67  with complete response  as assessed by an Independent Radiologic Review Committee following a single infusion of KTE X19 We remind investors that KTE X19 has been granted Breakthrough Therapy designation by the FDA and Priority Medicines  PRIME  by the European Medicines Agency  EMA  for relapsed or refractory MCL Kite plans to submit a Marketing Authorization Application for KTE X19 in the European Union in early 2020 A potential approval will boost Gilead s portfolio even though the competition is stiff in the CAR T therapy space from the likes of Novartis    NYSE NVS   Kymriah Gilead s stock has gained 8 4  in the year so far compared with the  s growth of 6 3   The massive decline in sales of the HCV franchise has propelled the company to focus on its HIV franchise  Yescarta and other newer avenues  The rapid adoption of Biktarvy maintains momentum in the HIV space amid stiff competition from the likes of GlaxoSmithKline   NYSE GSK    Gilead s intent to foray into the inflammation market to diversify the revenue base is encouraging as well     Gilead currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-12-11,Zacks Investment Research,https://www.investing.com/analysis/gilead-teams-up-with-kiniksa-submits-bla-for-car-t-therapy-200492122,200492122
200664,422180,GILD,Gilead  GILD  Announces Top Line Results From NASH Study ,opinion,Gilead Sciences  Inc    NASDAQ GILD   announced mixed top line results from the mid stage study on combination and monotherapy investigational treatments for advanced fibrosis  F3 F4  due to nonalcoholic steatohepatitis  NASH  The 48 week  phase II ATLAS randomized  double blind  placebo controlled study evaluated the safety and efficacy of monotherapy and dual combination regimens of the nonsteroidal farnesoid X receptor  FXR  agonist cilofexor 30 mg  the acetyl CoA carboxylase  ACC  inhibitor firsocostat 20 mg and selonsertib 18 mg in patients with advanced fibrosis  F3 F4  due to NASH The results showed that the investigational regimens did not lead to a statistically significant increase in the proportion of patients who achieved the primary efficacy endpoint of a  1 stage improvement in fibrosis without worsening of NASH Nevertheless  statistically significant improvements in multiple response measures of fibrosis and liver function were observed in patients treated with the combination of firsocostat and cilofexor compared with placebo Firsocostat  cilofexor and selonsertib  as monotherapies and dual combination regimens  were generally well tolerated We remind investors that the selonsertib monotherapy treatment group was discontinued following the termination of the STELLAR studies on the candidate  In February  Gilead announced that STELLAR 4  a phase III  randomized  double blind  placebo controlled study evaluating the safety and efficacy of selonsertib in patients with compensated cirrhosis  F4  due to NASH  did not meet the pre specified week 48 primary endpoint of a   1 stage histologic improvement in fibrosis without worsening of NASH  STELLAR 3  a phase III study evaluating the safety and efficacy of the drug in patients with bridging fibrosis  F3  due to NASH  also did not meet the pre specified week 48 primary endpoint A chronic liver disease  NASH  is caused by excessive fat accumulation in the liver or steatosis  Per statistics  it affected up to 15 million people in the United States causing inflammation  hepatocellular injury  progressive fibrosis and cirrhosis  With no treatments presently approved to address this disease  the market scope is substantially huge and many companies are investing a major chunk of their R D budget in the same Gilead is advancing multiple investigational compounds for the treatment of advanced fibrosis due to NASH  evaluating single agent and combination therapy approaches against the core pathways associated with NASH   hepatocyte lipotoxicity  inflammation and fibrosis  The company also collaborated with Novo Nordisk   NYSE NVO   for a proof of concept study combining Gilead s cilofexor and firsocostat and Novo Nordisk s semaglutide  GLP 1 analogue  for the treatment of patients with NASH The frontrunner in the NASH space is Intercept Pharmaceuticals  Inc    NASDAQ ICPT    Earlier this year  Intercept announced that the FDA accepted its New Drug Application  NDA  for obeticholic acid  OCA  seeking accelerated approval for the treatment of fibrosis due to NASH  The regulatory agency also granted Priority Review to the same  The authority assigned a Prescription Drug User Fee Act  PDUFA  target action date of Mar 26  2020  to the NDA However  developing NASH treatments is a complex affair and there have been quite a few setbacks  CymaBay Therapeutics  Inc    NASDAQ CBAY   terminated its mid stage study of seladelpar for NASH based on unfavorable outcomes Gilead s stock has gained 5 7  in the year so far compared with the  s growth of 7 2  The massive decline in sales of the HCV franchise has propelled the company to focus on its HIV franchise  Yescarta and other newer avenues for growth Gilead currently carries a Zacks Rank  3  Hold   You can see  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2019-12-16,Zacks Investment Research,https://www.investing.com/analysis/gilead-gild-announces-topline-results-from-nash-study-200493127,200493127
200672,422188,GILD,Medicare to cover expensive cancer cell therapies,news,"By Deena Beasley
 Reuters    The U S  Centers for Medicare and Medicaid Services  CMS  on Wednesday said it has finalized a decision to cover expensive cancer cell therapies sold by  Gilead Sciences Inc   O GILD  and  Novartis  AG  S NOVN  
CMS  which runs Medicare   the federal government s health plan for Americans 65 and older   said it will cover the U S  Food and Drug Administration approved therapies when provided in healthcare facilities that have programs in place to track patient outcomes 
The nationwide decision clears up  a lot of confusion  about coverage and will help patients get access to the novel therapies  known as CAR T  CMS Administrator Seema Verma said during a conference call with reporters on Wednesday 
The decision follows the agency s finalization last week of a proposal to raise its maximum CAR T payment to 65  of estimated costs from 50   Some hospitals will also be eligible for supplemental payments in certain cases 
Both Gilead s Yescarta and Novartis  Kymriah were approved in 2017 for certain kinds of lymphoma and leukemia  But government and private health plans have balked at their high price of at least  373 000 for a one time treatment before hospital costs  which can bring the bill for a single patient to over a million dollars 
More than half of lymphoma patients eligible for CAR T therapy are estimated to be covered by Medicare 
The agency said it will also cover the CAR Ts for uses not approved in their labels  as long as they are recommended by CMS approved medical guidelines 
The novel treatments remove a type of immune system cells from each individual patient and re engineer them to better fight certain blood cancers  keeping nearly 40  of patients alive for more than two years  according to some studies ",2019-08-07,Reuters,https://www.investing.com/news/stock-market-news/medicare-to-cover-expensive-cancer-cell-therapies-1948695,1948695
200673,422189,GILD,Atwood says  Handmaid s Tale  got much closer to reality  prompting sequel,news,"LONDON  Reuters    Canadian author Margaret Atwood said a deterioration in women s rights in some parts of the world including in the United States prompted her to write a sequel to her best selling 1985 novel  The Handmaid s Tale   The novel  made into an award winning television series in 2017  presents a totalitarian future in the state of Gilead  NASDAQ GILD   where the few remaining fertile women are forced into sexual servitude as  handmaids  to repopulate a world facing environmental disaster   For years and years people were saying will there be a sequel  please write a sequel  tell us what happened  and I always said I can t do that   Atwood told British broadcaster the BBC in an interview   But then a couple of things happened  Instead of going away from Gilead as I thought had been happening in the 1990s  we started going back towards Gilead in a number of places in the world including the United States   Recent moves to curtail access to abortion in the United States have caused huge division and galvanised women s rights activists  U S  President Donald Trump  who was elected in 2016  has said he opposes abortions in most cases and he has joined many of his fellow Republicans in seeking to limit them   Many doctors and rights groups are fighting these efforts as harmful to women s health and in breach of a constitutional right to abortion  Atwood said she was already conceptualizing a sequel to  The Handmaid s Tale  when Trump was elected  At the time  the television series based on her novel was being filmed   The frame around the show changed  and we knew at that moment it would be viewed differently  which it was  So instead of fantasy    ha ha it will never happen    it got much closer to reality  because of the kinds of people backing Trump   Atwood said  The series helped the original novel shoot back up the bestseller lists  and made the handmaid s uniform of a long dark red cloak and large white bonnet a symbol of female protest and resistance  Fans gathered in London at midnight on Tuesday to hear Atwood read from her new book  hailing it as a timely and necessary response to an increasingly menacing world for women   The world in some ways is becoming a worse place for women and particularly in the United States and so this is very current  and very relevant and very necessary   said Anne Enith Cooper  57  who attended the launch  Another fan  40 year old Stacey Morris  said   My daughter is 12 and she s just starting to understand feminism and the importance of being a woman    I d really like for her to read this in the future and to be able to share this with her   Asked if she was nervous about the huge anticipation of her new book  Atwood told the BBC   There is that feeling that you have   a lot of fanfare  the mountain roars and out comes this mouse  Will they say  what     is that what all this fuss has been about    You do have to point out it is a book  it is not regime change  it is not something that is going to physically impact the lives of many people  it is not riots in Moscow   
 The Testaments  has already landed Atwood a nomination for one of the publishing world s top accolades  the Booker Prize ",2019-09-10,Reuters,https://www.investing.com/news/general/atwood-says-handmaids-tale-got-much-closer-to-reality-prompting-sequel-1974513,1974513
200674,422190,GILD,Rule breaking Booker judges honor Atwood  Evaristo with rare double prize,news,"By Marie Louise Gumuchian LONDON  Reuters    Margaret Atwood s  The Testaments  and Bernardine Evaristo s  Girl  Woman  Other  jointly won the Booker Prize on Monday in a surprise double award in which the literary prize recognized its oldest and first black woman winners  The authors will split the 50 000 pounds   62 800  annual prize  the judging panel said  The award honors  the best novel of the year written in English and published in the UK and Ireland   Atwood  79  previously won the prize in 2000 for  The Blind Assassin   and  The Testaments   published last month  is the sequel to the Canadian author s best selling 1985 novel   The Handmaid s Tale    Evaristo  the first black woman to win the prize  tells the stories of 12 characters  mainly female and black aged 19 to 93  living in Britain in  Girl  Woman  Other    While the prize has been jointly awarded twice previously  the rules changed in 1993 limiting the award to one author  The judges defied those rules  saying they could not agree on a winner between the two books  which were on a shortlist of six   Neither of us expected to win this   Atwood said in her acceptance speech in a televised ceremony   I would have thought that I would have been too elderly and I kind of don t need the attention so I m very glad that you re getting some     It would have been embarrassing if I had been alone here   she said to Evaristo  Atwood s book  eagerly awaited by fans  returns to the totalitarian state of Gilead  NASDAQ GILD  some 15 years after the end of  The Handmaid s Tale   telling the story of three women  Atwood has said a deterioration in women s rights in some parts of the world including in the United States prompted her to write the sequel  described as a  savage and beautiful novel  by the judging panel   In Britain  it was an immediate hit  selling just over 100 000 hardback copies in its first week of release  The bleak dystopian  The Handmaid s Tale   where women are banned from reading and writing and those that are fertile are forced into sexual servitude  was itself nominated for the Booker Prize   Girl  Woman  Other  is Evaristo s eighth book of fiction  and was described by the judges as  a must read about modern Britain and womanhood     This is incredible  I suppose a lot of people say   I never thought it would happen to me   and I will say I am the first black woman to win this prize   the British author  60  said to loud applause  
 I hope that honor doesn t last too long  I hope that other people come forwards now   she said ",2019-10-14,Reuters,https://www.investing.com/news/world-news/authors-atwood-and-evaristo-jointly-win-booker-prize-1996136,1996136
200675,422191,GILD,Biotech ETF  BBH  Hits New 52 Week High,opinion,For investors seeking momentum  VanEck Vectors Biotech ETF   LON BBH   is probably on the radar now  The fund just hit a 52 week high and is up about 32  from its 52 week low price of  103 25 share But are more gains in store for this ETF  Let s take a quick look at the fund and the near term outlook on it to get a better idea on where it might be headed BBH in FocusBBH focuses on the biotechnology segment of the U S  market and measures the performance of companies involved in the development and production  marketing and sales of drugs based on genetic analysis and diagnostic equipment  The fund has a large cap focus with key holdings in Amgen   NYSE AMG    Celgene   NASDAQ CELG   and Gilead Sciences   NASDAQ GILD    It charges investors 35 basis points a year in fees  see    Why the Move The biotech corner of the broad healthcare sector has been an area to watch lately given the astounding performance this quarter  The flurry of positive news flow  including trial results and deal activities  and better than expected corporate earnings have fueled the rally in the sector  Additionally  uncertainty over trade deal added to the strength given that the sector is non cyclical in nature  which provides a defensive tilt to the portfolio More Gains Ahead Currently  BBH has a Zacks ETF Rank  2  Buy  with a Medium risk outlook  suggesting continued outperformance in the months ahead  Further  many of the segments that make up this ETF have a strong Zacks Industry Rank  So  there is definitely some promise for those who want to ride this surging ETF a little further Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ,2019-11-20,Zacks Investment Research,https://www.investing.com/analysis/biotech-etf-bbh-hits-new-52week-high-200487026,200487026
200676,422192,GILD,Intercept  ICPT  Gains 7 5  YTD On Progress In NASH Space,opinion,Shares of Intercept Pharmaceuticals   NASDAQ ICPT   have gained 7 5  in the first eleven months of 2019 compared with the  s growth of 5 4   Notably  shares gained significantly after the company announced that the FDA accepted its New Drug Application  NDA  for obeticholic acid  OCA  seeking accelerated approval for the treatment of fibrosis due to NASH  The regulatory agency also granted Priority Review to the same  The agency assigned a Prescription Drug User Fee Act  PDUFA  target action date of Mar 26  2020  to the NDA  The agency indicated to hold an advisory committee meeting to discuss the application  However  the date is yet to be finalized and the timeline for the review is subject to change A potential approval of OCA for NASH will significantly boost Intercept s prospects  given the market opportunity in fibrosis due to NASH A chronic liver disease  NASH  is caused by excessive fat accumulation in the liver or steatosis  Per statistics  it affected up to 15 million people in the United States causing inflammation  hepatocellular injury  progressive fibrosis and cirrhosis  The ailment is anticipated to be the leading reason for liver transplantation by 2020 With no treatments presently approved to address this disease  the market scope is substantially huge and the winner so far in the race seems to be Intercept OCA is already approved under the brand name Ocaliva for the treatment of primary biliary cholangitis   PBC   in adults with an inadequate response to UDCA or as monotherapy in adults who are intolerant to UDCA   The uptake of the drug for the treatment of PBC in adults has been impressive  even though the safety and dosing issues for the same were earlier under the scanner  The company expanded its sales force to reach out to more physicians  Hence  sales have gained traction and are expected to pick up further While the lack of other candidates in the company s pipeline is a concern  we are quite positive about the company s progress to advance OCA in NASH as it is now the forerunner in the same space We remind investors that there have been quite a few setbacks in the NASH space this year  In June  Conatus Pharmaceuticals   NASDAQ CNAT   announced that top line results from the ENCORE LF clinical study of emricasan failed to meet its primary endpoint  Consequently  Conatus and partner Novartis   NYSE NVS   mutually agreed to cease the collaboration agreement for the global development and commercialization of the drug  Earlier  biotech bigwig Gilead Sciences  Inc    NASDAQ GILD   too suffered a setback with the failure of a late stage study on pipeline candidate  selonsertib  in patients with compensated cirrhosis  F4  due to NASH Intercept currently carries a Zacks Rank  3  Hold    You can see  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ,2019-12-01,Zacks Investment Research,https://www.investing.com/analysis/intercept-icpt-gains-75-ytd-on-progress-in-nash-space-200489345,200489345
200677,422193,GILD,Agenus  AGEN  Up 24 5  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Agenus  AGEN   Shares have added about 24 5  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Agenus due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  Agenus Q3 Earnings Beat Estimates  Revenues Up Y YAgenus reported third quarter 2019 loss of 33 cents per share  narrower than the Zacks Consensus Estimate of a loss of 38 cents  However  the figure was wider than the year ago quarter s loss of 29 cents The company generated revenues of  20 million  including non cash royalties  up from  13 million in the year ago quarter  Revenues beat the Zacks Consensus Estimate of  16 million Quarterly HighlightsResearch and development expenses surged 54 5  to  46 1 million  General and administrative expenses grew 16 3  to  11 1 million Pipeline UpdateAgenus is a clinical stage  immuno oncology company with a comprehensive portfolio consisting of antibody based therapeutics  adjuvants and cancer vaccine platforms The company expects to file a biologics license application  BLA  for its CTLA 4 antibody  Zalifrelimab  and PD 1 antibody  Balstilimab  in 2020  It expects to commercialize both agents in the first half of 2021 The company also anticipates initiating combination studies for NexGen CTLA 4 and PD 1 antibodies shortly Agenus advanced four novel discoveries to investigational new drug  IND  in 2019 and these are now set for clinical trials  These include the company s next generation CTLA 4  AGEN1181  the differentiated CD137 molecule  AGEN2373  the first in class Treg depleting bispecific antibody  AGEN1223  and GS 1423  a bi functional molecule  which is now exclusively licensed to Gilead Sciences Inc  NASDAQ GILD   and being developed by them GlaxoSmithKline plc s herpes zoster vaccine  Shingrix  which contains Agenus  proprietary immune adjuvant QS 21 Stimulon  achieved more than  1 6 billion in revenues in the first nine months of 2019 
How Have Estimates Been Moving Since Then 
Estimates review followed a flat path over the past two months 
VGM Scores
Currently  Agenus has a nice Growth Score of B  however its Momentum Score is doing a bit better with an A  However  the stock was allocated a grade of F on the value side  putting it in the bottom 20  quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Agenus has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-12-03,Zacks Investment Research,https://www.investing.com/analysis/agenus-agen-up-245-since-last-earnings-report-can-it-continue-200490043,200490043
200684,422200,GILD,Gilead Earnings Beat  Revenue Misses In Q1,news,"Investing com   Gilead  NASDAQ GILD  reported first quarter earnings  that Beat analysts  expectations on Thursday and revenue that fell short of forecasts 
The firm reported earnings per share of  1 76 on revenue of  5 28B  Analysts polled by Investing com expected EPS of  1 61 on revenue of  5 31B  That compared to EPS of  1 48 on revenue of  5 09B in the same period a year earlier  The company had reported EPS of  1 44 on revenue of  5 8B in the previous quarter 
Gilead shares gained 0 38  to trade at  65 55 in after hours trade following the report 
Gilead follows other major Healthcare sector earnings this month
 On April 16  J J reported first quarter EPS of  2 1 on revenue of  20 02B  compared to forecasts of EPS of  2 04 on revenue of  19 61B 
Pfizer earnings Beat analysts  expectations on Tuesday  with first quarter EPS of  0 85 on revenue of  13 12B  Investing com analysts expected EPS of  0 75 on revenue of  13B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-05-02,Investing.com,https://www.investing.com/news/stock-market-news/gilead-earnings-beat-revenue-misses-in-q1-1854944,1854944
200685,422201,GILD,New season of  Handmaid s Tale  not meant to be  torture to watch   creator says,news,By Jill Serjeant LOS ANGELES  Reuters    With its chilling portrait of a patriarchal dictatorship where women are routinely raped  mutilated and forcibly separated from their children   The Handmaid s Tale  has sometimes proved tough to stomach  But Bruce Miller  creator and executive producer of the television series based on Margaret Atwood s 1985 novel  says he is  not in the business of inventing cruelties    I don t want the show to be torture to watch  It is entertainment and you want people to be compelled by it  You don t want it to be horrible medicine   Miller said  Season three of the Emmy Award winning series arrives on streaming service Hulu on Wednesday with its portrait of life in the fictional U S  state of Gilead  NASDAQ GILD  as seemingly prescient as ever  Handmaid June  played by Elisabeth Moss   having turned down a rare the chance to escape Gilead with her newborn  decides to remain to fight back against a society where women are banned from reading and writing and forced into servitude  It follows a second season last year that contained scenes of beatings  hangings and rape that many viewers found too grim   I m not interested in putting the audience through torture  I try to only show the things that we need to see to understand where June is emotionally and mentally   said Miller   What I m trying to do is tell the story of June s survival and victory and it s a long  slow slog   Season three arrives as women in the United States  sometimes wearing the distinctive red gowns and white bonnets seen in the TV series  are protesting laws in 11 U S  states that severely restrict abortion  Last season coincided with a crackdown on illegal immigration at the U S  border with Mexico in which parents and their children were separated  Although the theme of season three is rebellion  Miller says there is no quick fix   We want to show what a hero really looks like   someone who is stubborn  They get knocked down  they get bruised  and they pick themselves up and try again   Miller said  Miller said any direct parallels between the television series and current world events are unintentional  although Atwood has said that all the events in her book were drawn from history    We try to come up with what could happen in Gilead      But  if you re going to make television that is tied to the real world  it s going to be as disquieting as the political turmoil the world seem to be going through right now   he said ,2019-06-05,Reuters,https://www.investing.com/news/general-news/new-season-of-handmaids-tale-not-meant-to-be-torture-to-watch-creator-says-1888939,1888939
200686,422202,GILD,Pharma firm Gilead to raise Galapagos stake in  5 1 billion deal,news," Reuters     Gilead Sciences Inc   O GILD  will invest  5 1 billion to raise its stake in  Galapagos  NV  AS GLPG  and partner with the Belgian Dutch biotech firm to develop and commercialize its treatments for a ten year period  the companies said on Sunday  The investment in Galapagos  which comes nearly four years after the firms partnered to develop a drug targeting inflammatory diseases  includes an upfront payment of  3 95 billion and a  1 1 billion equity investment from Gilead   Gilead gains exclusive access to all current and future compounds in Galapagos  rich pipeline while Galapagos is able to expand its research activities and build commercial infrastructure   Gilead Chief Executive Officer Daniel O Day said in a statement   The U S  drugmaker will pay 140 59 euros   158 43  per new share in Galapagos to increase its stake to 22  from 12 3   That represents a premium of nearly 10  to the close of Galapagos shares on Friday  Galapagos said it would also seek shareholder approval to allow Gilead to further increase its ownership to up to 29 9   After that  their agreement includes a 10 year standstill clause that would prevent Gilead from accumulating any additional stake  In 2015  Gilead signed a deal worth more than  2 billion with Galapagos  which included a  725 million upfront payment for the development of filgotinib  as well as an equity stake in the European firm  Filgotinib is an experimental compound being advanced for rheumatoid arthritis and inflammatory bowel disease and Gilead intends to submit its new drug application to the U S  Food and Drug Administration this year  Galapagos will now have greater involvement in filgotinib s global strategy and participate more broadly in the commercialization of the product in Europe  according to their statement on Sunday  The companies will share future development costs for filgotinib equally  replacing the 80 20 cost split provided by the original agreement  they said  Galapagos will use the proceeds to expand and speed up its research and development programs  Gilead will nominate two people to Galapagos  board   Barclays   LON BARC   Centerview Partners and Lazard acted as financial advisers to Gilead while Moelis   Co and  Morgan Stanley   NYSE MS  advised Galapagos  
The Wall Street Journal reported the deal earlier on Sunday ",2019-07-14,Reuters,https://www.investing.com/news/stock-market-news/pharma-firm-gilead-to-raise-galapagos-stake-in-51-billion-deal-1923084,1923084
200689,422205,GILD,Gilead Earnings miss  Revenue beats In Q4,news,"Investing com   Gilead  NASDAQ GILD  reported fourth quarter earnings  that missed analysts  expectations on Monday and revenue that topped forecasts 
The firm reported earnings per share of  1 44 on revenue of  5 8B  Analysts polled by Investing com forecast EPS of  1 71 on revenue of  5 51B  That compared to EPS of  1 78 on revenue of  5 95B in the same period a year earlier  The company had reported EPS of  1 84 on revenue of  5 6B in the previous quarter 
Gilead shares lost 1 07  to trade at  69 30 in after hours trade following the report 
Gilead follows other major Healthcare sector earnings this month
 On January 22  J J reported fourth quarter EPS of  1 97 on revenue of  20 39B  compared to forecasts of EPS of  1 95 on revenue of  20 2B 
Pfizer earnings beat analyst s expectations on January 29  with fourth quarter EPS of  0 64 on revenue of  13 98B  Investing com analysts expected EPS of  0 63 on revenue of  13 9B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-02-04,Investing.com,https://www.investing.com/news/stock-market-news/gilead-earnings-miss-revenue-beats-in-q4-1768842,1768842
200690,422206,GILD,Gilead s selonsertib flunks late stage NASH study,news,Gilead Sciences  NASDAQ GILD  is holding steady after hours on the heels of its announcement that its Phase 3 clinical trial  STELLAR 4  evaluating selonsertib in NASH patients with compensated cirrohosis failed to sufficiently separate from placebo The study failed to meet the primary endpoint of the proportion of participants achieving at least a one stage improvement in NASH classification after 48 weeks of treatment  Specifically  14 4  of patients receiving 18 mg of selonsertib and 12 5  of those receiving 6 mg achieved at least a one stage improvement in NASH compared to 12 8  for placebo On the plus side  selonsertib was generally safe and well tolerated Topline results from the Phase 3 STELLAR 3 study in NASH patients with bridging fibrosis and the Phase 2 ATLAS trial in NASH patients with advanced fibrosis should be available later this year Now read ,2019-02-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/gileads-selonsertib-flunks-latestage-nash-study-1776421,1776421
200691,422207,GILD,As medical costs mount  Japan to weigh cost effectiveness in setting drug prices,news,"By Takashi Umekawa TOKYO  Reuters    Japanese doctor Yasushi Goto remembers prescribing the cancer drug Opdivo to an octogenarian and wondering whether taxpayers might object to helping fund treatment  which at the time cost hundreds of thousands of dollars  for patients in their twilight years   Japanese have easy access to new medicines  whose prices are decided by the government and subsidized by the country s public health insurance system  But that may change  Japan  confronted with the ballooning cost of caring for an aging population  is introducing a cost effectiveness test for drugs as a means of capping prices  There are no plans to deny care for patients of any age  But limiting the prices of innovative but costly treatments might chase new drugs out of the  86 billion Japanese market  drugmakers say   If you ask whether it s worth prescribing an 85 year old patient Opdivo  a lot of people will say no  But patients and family members are going to say yes   said Goto  who works at the National Cancer Centre Hospital  Patients also fear more drastic changes  such as denying access to new medicines  Prime Minister Shinzo Abe s economic council in December proposed considering cost in determining whether to approve treatments    For cancer patients like us  it s not acceptable if the government applies a cost effective analysis in determining whether to approve treatments   said Yoshiyuki Majima  a director of patient advocacy group Rare Cancers Japan   SUSTAINABILITY OR ACCESS The Japanese government estimates that public medical spending could surge 75 percent to 68 5 trillion yen   624 billion  by 2040    It is obvious that Japan will face difficulties in providing social security service   said a government official involved in the discussions  declining to be named because he is not authorized to speak to media   The cost effectiveness analysis is a means to secure sustainability    The system that will be adopted in April  according to a draft published on the health ministry s website  compares the cost to the effectiveness of new treatments using an  incremental cost effectiveness ratio   or ICER  ICER  already used in countries such as Britain  considers how much it costs to give a patient one additional year of healthy life compared with existing alternatives  If that exceeds 5 million yen  for example  the government may insist on a lower price  according the policy draft   There has been little public discussion  weekly meetings so far have involved mostly Health Ministry officials  doctors  academics and drugmaker executives    If I have rheumatoid arthritis and I can t write or type  but then I get a treatment that enables me to go back to work  pay taxes  and take care of my family  that benefit is not going to be captured by the ICER   said Kevin Haninger  a vice president of Pharmaceutical Research and Manufacturers of America  a lobbying group   In an interview with Reuters  he insisted Japan should carefully consider an impact on the industry when introducing such analysis to reduce drug prices    If Japan is going to cut prices so much  I think Japan will really run a risk of losing its current position   he said   LUCRATIVE MARKET NO MORE  Drugmakers have been complaining about price cuts since 2017  when the government decided to review costs more frequently   Japan has slashed the price of Opdivo  developed by Ono Pharmaceutical Co Ltd and Bristol Myers Squibb  NYSE BMY   by more than 75 percent in the last two years  It has also lowered Gilead  NASDAQ GILD  Science s hepatitis C drug Sovaldi by 32 percent since 2016   But while drugmakers threaten to pull back from Japan  the government is prepared to call the industry s bluff  saying Japan is too lucrative a market for companies to ignore  according to two government officials  who declined to be named because they are not authorized to speak to the media   Unlike the United States  where insurers may deny claims  or the UK  where patients can be denied costly drugs  Japan is seen as a relatively predictable market because of its social insurance system  For example  Novartis  Kymriah  a type of therapy in which a patient s T cells are modified to attack cancer cells  is expected to be approved in Japan this year  The price for pediatric leukemia patients  to be set by a government panel after approval  is expected to start at about  475 000  similar to U S  prices  With an estimated 250 Japanese eligible for treatment with Kymriah  sales in Japan are a potentially lucrative addition to Novartis  bottom line  Novartis declined to comment on potential effects of a new pricing policy   Goto said the government should focus on reducing prescriptions for illnesses that are not serious  rather than costly but possibly life saving treatments for a small number of patients  
 Flu medicines  for example  can be seen to have very low cost effectiveness because they don t save people s lives  except those of infants or pregnant women  compared with cancer drugs that are critical for some patients   he said ",2019-02-18,Reuters,https://www.investing.com/news/world-news/as-medical-costs-mount-japan-to-weigh-costeffectiveness-in-setting-drug-prices-1782810,1782810
200692,422208,GILD,Gilead Sciences  GILD  Misses Q3 Earnings Estimates,opinion,"Gilead Sciences  NASDAQ GILD  came out with quarterly earnings of  1 75 per share  missing the Zacks Consensus Estimate of  1 76 per share  This compares to earnings of  1 84 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of  0 57   A quarter ago  it was expected that this HIV and hepatitis C drugmaker would post earnings of  1 74 per share when it actually produced earnings of  1 82  delivering a surprise of 4 60  
Over the last four quarters  the company has surpassed consensus EPS estimates two times 
Gilead  which belongs to the Zacks Medical   Biomedical and Genetics industry  posted revenues of  5 60 billion for the quarter ended September 2019  surpassing the Zacks Consensus Estimate by 0 10   This compares to year ago revenues of  5 60 billion  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Gilead shares have added about 6 4  since the beginning of the year versus the S P 500 s gain of 19 9  
What s Next for Gilead 
While Gilead has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Gilead was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 74 on  5 79 billion in revenues for the coming quarter and  7 04 on  22 29 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Biomedical and Genetics is currently in the top 29  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/gilead-sciences-gild-misses-q3-earnings-estimates-200477978,200477978
200693,422209,GILD,Gilead s  GILD  Earnings Miss Estimates In Q3  Sales Beat,opinion,Gilead Sciences  Inc    NASDAQ GILD   reported mixed results for the third quarter of 2019 as earnings missed expectations while sales managed to marginally surpass the same The company delivered earnings of  1 75 per share in the third quarter  declining from  1 84 in the year ago quarter and missing the Zacks Consensus Estimate by a penny Total revenues of  5 60 billion beat the Zacks Consensus Estimate by 0 1  and were roughly flat year over year HIV Franchise Maintains MomentumProduct sales came in at  5 5 billion  up 1 1  year over year HCV product sales declined 25 3  to  674 million  due to competitive dynamics HIV product sales increased 13 5  year over year to  4 2 billion  driven by higher sales volume led by the continued uptake of Biktarvy  Sales of Biktarvy were  1 2 billion  up from  386 million in the year ago quarter and  1 1 billion in the previous quarter  It was the number one prescribed regimen for both treatment na ve and switch patients in the United States in the quarter Genvoya generated sales of  978 million  down from  1 2 billion in the year ago quarter  Descovy recorded sales of  363 million  down from  406 million in the year earlier period  while Odefsey sales were  436 million  up from  423 million a year ago CAR T therapy Yescarta  axicabtagene ciloleucel  generated  118 million in sales  up from  75 million a year ago  driven by a higher number of therapies provided to patients and its continued expansion in Europe  However  sales were down from  120 million in the previous quarter Other product sales   chronic hepatitis B  HBV  drugs  cardiovascular  oncology and other categories  Vemlidy  Viread  Letairis  Ranexa  Zydelig and AmBisome    were  522 million  which decreased from  751 million in the year ago quarter due to declines in Ranexa and Letairis sales after generic entries in 2019 Adjusted product gross margin was 86 2  compared with 85 9  in the year ago period  Research   development  R D  expenses came in at  954 million  down from  844 million in the year ago quarter  Selling  general and administrative  SG A  expenses increased to  967 million from  852 million in the year ago quarter 2019 Guidance NarrowedGilead now expects sales of  21 8  22 1 billion compared with the previous guidance of  21 6  22 1 billion  Adjusted R D and adjusted SG A expenses are projected to be  3 7  3 8 billion and  4 0 4 1 billion  respectively  Adjusted product gross margin is anticipated to be 85 87  Dividend and Share RepurchaseDuring the quarter  Gilead repaid  1 5 billion of debt  paid out dividends of  804 million and spent  223 million on share buybacks Other UpdatesThe FDA approved a label expansion of HIV treatment  Descovy  as a prevention option  The agency approved the treatment for the pre exposure prophylaxis  PrEP  indication  Descovy for PrEP is indicated to reduce the risk of sexually acquired HIV 1 infection in adults and adolescents weighing at least 35 kg  who are HIV negative and at risk for sexually acquired HIV  excluding individuals at risk from receptive vaginal sex  The approval was based on the DISCOVER trial  which demonstrated that the drug is just as effective as Truvada and offers advantages in bone and renal safety parameters In August  Gilead and partner Galapagos    NASDAQ GLPG   Marketing Authorization Application for filgotinib  an investigational  oral  selective JAK1 inhibitor  for the treatment of adults with rheumatoid arthritis was validated by the European Medicines Agency   The company is on track to complete a filing in the United States by the end of the year Our TakeThe company s results in the third quarter benefited from the solid performance of the HIV franchise  driven by the rapid adoption of Biktarvy amid stiff competition from the likes of GlaxoSmithKline   NYSE GSK   While the HCV franchise declined as expected  the uptake of Yescarta  from the Kite Pharma acquisition  has been quite slow and it will take some time for the drug to contribute significantly to the company s top line  given the treatment s exorbitant cost  Moreover  Novartis    NYSE NVS   Kymriah exists in the market  posing stiff competition The stock is trading down in pre market hours on lackluster results  Gilead s stock has gained 5 5  in the year so far against the  s decline of 2 5  Nevertheless  Gilead s intent to foray into the inflammation market to diversify the revenue base is encouraging Gilead currently carries a Zacks Rank  3  Hold   You can see  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2019-10-24,Zacks Investment Research,https://www.investing.com/analysis/gileads-gild-earnings-miss-estimates-in-q3-sales-beat-200478437,200478437
200696,422212,GILD,Merck loses bid to revive  200 million Gilead verdict at U S  high court,news,"By Jan Wolfe WASHINGTON  Reuters    The U S  Supreme Court on Monday handed a defeat to Merck   Co  N MRK  by refusing to hear its appeal of a ruling that it had dishonestly obtained patent rights and could not collect a  200 million verdict against rival drugmaker  Gilead Sciences Inc   O GILD  in a dispute involving blockbuster hepatitis C drugs  A jury awarded Merck  200 million in 2016 after finding Gilead s Hepatitis C drugs Sovaldi and Harvoni infringed two of its patents  but a judge later ruled the patents unenforceable because of a pattern of misconduct by Merck including lying under oath by one of its in house lawyers  Merck had urged the Supreme Court to place limits on the doctrine of  unclean hands  that can prevent plaintiffs from winning lawsuits if they acted in bad faith  Hepatitis C  estimated to infect about 3 2 million Americans  is a viral disease that causes inflammation of the liver that can lead to liver failure  Injection drug use is among the causes of the infection   Direct acting anti viral medications like Gilead s Sovaldi and Harvoni have revolutionized treatment of hepatitis C  with cure rates of more than 90 percent  Merck holds patents that it has said cover a compound that is the foundation for all major antiviral treatments for chronic hepatitis C  A federal court jury in San Jose  California awarded Merck  200 million in 2016 after finding Sovaldi and Harvoni infringed two of its patents  A judge threw out the verdict later that year  ruling that in the process of applying for one of the patents  Merck used confidential information it obtained in 2004 while discussing a possible partnership with Pharmasset Inc  a company Gilead bought in 2011  The judge also said a Merck in house lawyer testified untruthfully in a deposition and at trial about his participation in a confidential call with Pharmasset personnel  Merck s litigation against Gilead has included several reversals of fortune  
In 2016  a jury in Delaware said Gilead infringed a related patent and ordered it to pay Merck  2 54 billion in royalties  the largest verdict ever in a patent case  But a judge threw out the verdict in February 2018  ruling that Merck s patent was invalid because it was not sufficiently detailed in its wording ",2019-01-07,Reuters,https://www.investing.com/news/stock-market-news/merck-loses-bid-to-revive-200-million-gilead-verdict-at-us-high-court-1739450,1739450
200697,422213,GILD,Gilead Sciences  GILD  Expected To Beat Earnings Estimates  Can The Stock Move Higher ,opinion,"Wall Street expects a year over year decline in earnings on higher revenues when Gilead Sciences  NASDAQ GILD  reports results for the quarter ended September 2019  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on October 24  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This HIV and hepatitis C drugmaker is expected to post quarterly earnings of  1 76 per share in its upcoming report  which represents a year over year change of  4 4  
Revenues are expected to be  5 62 billion  up 0 4  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 43  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Gilead 
For Gilead  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 91  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that Gilead will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Gilead would post earnings of  1 74 per share when it actually produced earnings of  1 82  delivering a surprise of  4 60  
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Gilead appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-10-16,Zacks Investment Research,https://www.investing.com/analysis/gilead-sciences-gild-expected-to-beat-earnings-estimates-can-the-stock-move-higher-200474632,200474632
200702,422218,GILD,Margaret Atwood writing her own  Handmaid s Tale  sequel,news, Reuters    Canadian author Margaret Atwood said on Tuesday that she is writing a sequel to her best selling dystopian novel  The Handmaid s Tale    Yes indeed to those who asked  I m writing a sequel to The  HandmaidsTale   Atwood wrote on her Twitter account  Called  The Testaments   the novel will be set 15 years after the events depicted in  The Handmaid s Tale  and will be narrated by three female characters  Atwood wrote in a Twitter posting  The book is due to be published in September 2019 by Penguin Random House  a division of Germany s Bertelsmann   The Handmaid s Tale   a bleak vision of a near future in an American society called Gilead  NASDAQ GILD  where women are banned from reading and writing  have their children taken away from them  and are forced into sexual servitude by a patriarchal dictatorship  was first published in 1985  Its adaptation for television on streaming service Hulu last year brought new acclaim and multiple Emmy awards for the performance by Elisabeth Moss as lead character Offred   Everything you ve ever asked me about Gilead and its inner workings is the inspiration for this book  Well  almost everything   Atwood wrote in a video message on Twitter   The other inspiration is the world we ve been living in   she added  without elaborating  Feminists in several nations have adopted the striking red gowns and white bonnets worn by the handmaids in the book and television series to highlight women s rights at protests and marches  Atwood  79  said her sequel will not be related to the Hulu television series of  The Handmaid s Tale   whose second season earlier this year moved beyond the author s original book ,2018-11-28,Reuters,https://www.investing.com/news/general-news/margaret-atwood-writing-her-own-handmaids-tale-sequel-1703704,1703704
200703,422219,GILD,Gilead s CAR T Yescarta shows long term benefit in lymphoma study,news,Two year data from the Phase 1 2 ZUMA 1 study evaluating Gilead Sciences   NASDAQ GILD  Yescarta  axicabtagene ciloleucel  in patients with refractory large B cell lymphoma showed a sustained treatment effect  The results were presented at ASH in San Diego  With median follow up of 27 1 months and a minimum of 24 months after a single infusion of Yescarta  39  of patients maintained their responses  The best objective response via investigator assessment was 83   n 84 101  at year 2  including 58   n 59 101  with complete responses  93  of patients who responded at month 12 continued to show responses at month 24  Median duration of response was 11 1 months  Median duration of complete response and median overall survival had not been reached  On the safety front  the incidences of serious life threatening cytokine release syndrome  CRS  and neurological events were 11  and 32   respectively  at year 2  but were generally reversible  Four patients developed new serious adverse events since the previous data cutoff on August 11  2017  but none were related to Yescarta   ASH18 Now read ,2018-12-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/gileads-cart-yescarta-shows-longterm-benefit-in-lymphoma-study-1707975,1707975
200704,422220,GILD,Gilead CAR T therapy shows sustained benefit in treatment resistant ALL patients,news,"Updated data from a Phase 1 2 clinical trial  ZUMA 3  evaluating Gilead Sciences   NASDAQ GILD  CAR T candidate KTE X19  formerly KTE C19  in adult patients with relapsed refractory acute lymphoblastic leukemia  ALL  showed a continued treatment effect  The results were presented at ASH in San Diego 
With a median follow up of 15 1 months  69   n 25 36  of patients receiving a single infusion of KTE X19 achieved complete tumor remission  All 25 had undetectable minimal residual disease  less likely to relapse    ASH18 Now read ",2018-12-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/gilead-cart-therapy-shows-sustained-benefit-in-treatmentresistant-all-patients-1709924,1709924
200705,422221,GILD,Gilead Sciences snares Roche veteran O Day as CEO,news," Reuters    Drugmaker  Gilead Sciences Inc   NASDAQ GILD  on Monday named Roche Holding  SIX ROG  AG s Daniel O Day as its new chief executive  tapping an industry veteran to fill a management vacuum  O Day  now head of Roche s pharmaceuticals business  joined the company in 1987 and held various roles in the United States before moving in 1998 to headquarters in Basel  Switzerland  O Day s hiring comes about four months after Gilead said in July that Chief Executive John Milligan and Chairman John Martin would step down at the end of the year  Jefferies analysts said in a note that O Day s three decades of oncology and global commercial expertise at Roche should help Gilead build out its own global presence  particularly in new areas it is entering including oncology and inflammation as well as through more acquisitions and in licensing deals  At Roche  O Day was a champion of bi specific antibodies that are under development as a potentially less expensive  less complicated alternative to CAR T therapy where T cells must be taken out of the body  re engineered and re infused   With Gilead s Yescarta therapy  O Day is now on the opposite side of the divide  Separately  Roche said William Anderson  current CEO of its Genentech business  would replace O Day next year  Anderson joined Roche in 2006  leading the immunology business unit in Genentech  and then took charge of oncology sales and marketing  In 2013  he became head of global product strategy based in Basel before assuming his current role at Genentech in 2017  Vontobel analyst Stefan Schneider called Anderson a  seasoned Roche manager  who played a key role in leading multiple sclerosis drug Ocrevus to success and driving double digit growth in the U S  market  Gilead said on Monday that Martin would step down from the company s board of directors  effective March 1  2019  Up to Friday s close  the company s shares have fallen nearly 14 percent since Milligan and Martin s departures were announced by Gilead in July  The Wall street Journal first reported O Day s hiring on Sunday  Gilead said its board had appointed Gregg Alton as interim chief executive for the period of January 1  2019 until O Day s start date of March 1  2019  
Roche shares were down 0 6 percent by mid morning  in line with the Stoxx European health care sector index ",2018-12-10,Reuters,https://www.investing.com/news/stock-market-news/gilead-sciences-to-hire-roche-executive-oday-as-new-ceo-source-1716131,1716131
200706,422222,GILD,ProQR announces changes to the management team and key new hires,news,ProQR Therapeutics  NASDAQ PRQR  announces changes to its management team and key hires Aniz Girach  MD  is joining ProQR in the role of Chief Medical Officer  CMO  and will be reporting to David Rodman  MD  Executive Vice President of R D  Most recently  Aniz worked as the CMO for Nightstar Therapeutics Tiffany Burt is joining in the role of Vice president  Head of Commercial  Prior to joining ProQR  she served as Vice President  Marketing at Verastem Oncology Lisa Hayes is joining as Vice President of Investor Relations and Corporate Communications  Lisa joins ProQR from Celgene  NASDAQ CELG   where she was most recently Senior Director of Investor Relations Smital Shah is promoted to Chief Business and Financial Officer  Ms  Shah joined ProQR in 2014 as CFO  Most recently she was at Gilead Sciences  NASDAQ GILD  Ren  Beukema will retire at year end 2018 as Chief Corporate Development Officer   General Counsel and management board member Robert Cornelisse  Chief People and Organization will also retire at year end 2018  Now read ,2018-12-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/proqr-announces-changes-to-the-management-team-and-key-new-hires-1720494,1720494
200707,422223,GILD,AbbVie  ABBV  Gets FDA Nod For Label Expansion Of HCV Drug,opinion,"AbbVie Inc    NYSE ABBV   announced that the FDA approved the label expansion of Mavyret  glecaprevir pibrentasvir   The agency approved the drug to shorten the once daily treatment duration from 12 to 8 weeks in treatment na ve  compensated cirrhotic  chronic hepatitis C  HCV  patients across all genotypes  GT1 6   The drug is meant to treat adults and children aged 12 years or older  Following this approval  HCV patients can be treated within 8 weeks 
The label expansion was supported by data from the phase EXPEDITION 8 study  evaluating the safety and efficacy of Mavyret in treatment naive adults with GT1 6 chronic HCV and compensated cirrhosis  In the study  an overall 98  of patients achieved a sustained virologic response 12 weeks after treatment  SVR12  
Mavyret is a pan genotypic  once daily  ribavirin free treatment that combines glecaprevir  100mg   an NS3 4A protease inhibitor  and pibrentasvir  40mg   an NS5A inhibitor  dosed as three tablets taken at the same time once daily with food  Notably  the drug received regulatory approval in the United States in August 2017  as an 8 week  pan genotypic treatment in treatment naive HCV patients without cirrhosis 
Shares of the company have lost 19 8  year to date compared with the  s decline of 0 6  

 
HCV is a disease that causes inflammation of the liver  which can lead to diminished liver functions or liver failure  There are more than 2 3 million people in the United States still living with chronic HCV  Both Gilead Sciences Inc    NASDAQ GILD   and Merck   Co    NYSE MRK   have HCV drugs in their portfolio AbbVie Inc  Price

    
Zacks Rank and A Stock to Consider
AbbVie currently has a Zacks Rank  3  Hold  
A better ranked stock in the large cap pharmaceutical sector is Novartis   NYSE NVS    carrying a Zacks Rank  2  Buy   You can see 
Novartis  earnings per share estimates increased from  5 06 to  5 15 for 2019 and from  5 71 to  5 77 for 2020 over the past 60 days  The company delivered a positive earnings surprise in two of the trailing four quarters  the average beat being 2 84      
Breakout Biotech Stocks with Triple Digit Profit Potential 
The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases 
Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-09-27,Zacks Investment Research,https://www.investing.com/analysis/abbvie-abbv-gets-fda-nod-for-label-expansion-of-hcv-drug-200468856,200468856
200728,422244,GILD,ViiV Healthcare sues Gilead for patent infringement over bictegravir,news,ViiV Healthcare has filed a patent infringement lawsuit against Gilead Sciences  NASDAQ GILD  claiming bictegravir  a component of Gilead s just approved triple combo HIV pill  infringes on ViiV s dolutegravir and other compounds Bictegravir and dolutegravir are both integrase inhibitors  Dolutegravir is the active ingredient in ViiV s TIVICAY ViiV Healthcare is the HIV focused joint venture between GlaxoSmithKline  NYSE GSK    Pfizer   NYSE PFE  and Shionogi  OTCPK SGIOF  OTCPK SGIOY  Previously  FDA OKs Gilead s BIC FTC TAF for HIV 1 infection  Feb  7 Now read ,2018-02-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/viiv-healthcare-sues-gilead-for-patent-infringement-over-bictegravir-1214509,1214509
200744,422260,GILD,Teva launches generic Viread in U S ,news,Teva Pharmaceutical Industries  TEVA  2 1   announces the U S  commercial launch of its generic version of Gilead Sciences   GILD  0 7   Viread  tenofovir disoproxil fumarate  TDF  for the treatment of HIV 1 infection in patients at least two years old and chronic hepatitis B virus  HBV  infection in patients at least 12 years old In the first three calendar quarters of 2017  Viread generated  375M in U S  sales  down 6  yoy Now read ,2017-12-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/teva-launches-generic-viread-in-us-997406,997406
200745,422261,GILD,BioDelivery Sciences announces notice of allowance of patent strengthening on BELBUCA to 2032,news,The U S  Patent and Trademark Office issues a Notice of Allowance to  BioDelivery  Sciences International s  NASDAQ BDSI  patent application  that once formally granted  will be Orange Book listed and will extend the exclusivity of BELBUCA  buprenorphine  buccal film from July 2027 to December 2032 The patent covers the method of using BioErodible MucoAdhesive for the treatment of chronic pain Shares are up 9  premarket on light volume  Now read ,2017-12-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/biodelivery-sciences-announces-notice-of-allowance-of-patent-strengthening-on-belbuca-to-2032-1003507,1003507
200746,422262,GILD,New drug approvals hit 21 year high in 2017,news,"By Ben Hirschler LONDON  Reuters    U S  drug approvals hit a 21 year high in 2017  with 46 novel medicines winning a green light    more than double the previous year    while the figure also rose in the European Union  The EU recommended 92 new drugs including generics  up from 81  and China laid out plans to speed up approvals in what is now the world s second biggest market behind the United States  Yet the world s biggest drugmakers saw average returns on their research and development spending fall  reflecting more competitive pressures and the growing share of new products now coming from younger biotech companies  Consultancy Deloitte said last month that projected returns at 12 of the world s top drugmakers were at an eight year low of only 3 2 percent  Many of the drugs receiving a green light in 2017 were for rare diseases and sub types of cancer  which often target very small populations  although they can cost hundreds of thousands of dollars     Significantly  the U S  drug tally of 46 does not include the first of a new wave of cell and gene therapies from Novartis  Gilead Sciences  NASDAQ GILD  and Spark Therapeutics that were approved in 2017 under a separate category  U S  Food and Drug Administration  FDA  Commissioner Scott Gottlieb has hailed these products as  a whole new scientific paradigm for the treatment of serious diseases   However  there is debate as to how cash strapped healthcare systems will pay for them  Under Gottlieb  the FDA has taken advantage of policy changes implemented in recent years to accelerate the drug approval process   Procedures such as the agency s  breakthrough therapy  designation have cut review times and helped to stimulate competition by adding multiple new drugs that often work in a similar way   A wide choice of medicines with the same mechanism of action can be a double edged sword for manufacturers  since it gives insurers and governments ammunition to drive down prices   Pfizer   NYSE PFE  and Merck s new diabetes drug Steglatro  for example  was the fourth product of its kind to win a green light in the United States  while Novo Nordisk s Ozempic was the sixth of its type  Both were approved in December   In cancer  AstraZeneca s Imfinzi was the fifth medicine to target a key protein found on the body s immune cells when it won approval last May  For the current year  companies have more new products waiting in the wings  although the pace of FDA approvals may be tempered by the fact that several drugs that had been expected to be cleared in the first quarter of 2018 were actually approved in 2017  
In Europe  meanwhile  the focus will be on any disruption or delays to the approval process as the European Medicines Agency prepares to relocate from London to Amsterdam as a result of Britain s decision to leave the European Union ",2018-01-02,Reuters,https://www.investing.com/news/stock-market-news/new-drug-approvals-hit-21year-high-in-2017-1050787,1050787
200754,422270,GILD,Gilead Sciences  GILD  Expected To Beat Earnings Estimates  What To Know Ahead Of Q2 Release,opinion,"Wall Street expects a year over year decline in earnings on lower revenues when Gilead Sciences  NASDAQ GILD  reports results for the quarter ended June 2019  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on July 30  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This HIV and hepatitis C drugmaker is expected to post quarterly earnings of  1 74 per share in its upcoming report  which represents a year over year change of  8 9  
Revenues are expected to be  5 53 billion  down 2  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 17  higher over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Gilead 
For Gilead  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  3 69  
On the other hand  the stock currently carries a Zacks Rank of  2 
So  this combination indicates that Gilead will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Gilead would post earnings of  1 62 per share when it actually produced earnings of  1 76  delivering a surprise of  8 64  
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Gilead appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-07-22,Zacks Investment Research,https://www.investing.com/analysis/gilead-sciences-gild-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q2-release-200443288,200443288
200772,422288,GILD,Eleven Bio reports Q3 results,news,Eleven Biotherapeutics  EBIO  Q3 results  Revenues   0  R D Expense   3 6M   28 6    SG A   1 6M   75 0    Operating Loss    9 2M   Net Loss    9 1M   Loss Per Share    0 37   Quick Assets   11 3M   55 3   Financial Guidance  The Company anticipates that cash at September 30  plus the net  7M raised in November  will fund R D programs and operations into mid 2018 Now read ,2017-11-20,Seeking Alpha,https://www.investing.com/news/stock-market-news/eleven-bio-reports-q3-results-887361,887361
200773,422289,GILD,Pluristem granted key U S  patent for Skeletal Muscle Regeneration,news,Pluristem Therapeutics   NASDAQ PSTI  announces that the U S  Patent and Trademark Office has issued a patent titled   Skeletal muscle regeneration using mesenchymal system cells  MSCs    This key patent addresses the use of MSCs used either directly after  or shortly after  post surgical muscle injury  The Company received positive feedback from the FDA and the European Medicine Agency for the proposed study design and endpoints of its Phase III trial following arthroplasty for hip fracture If successful  Pluristem plans to use the study results to achieve marketing approval in both the U S  and Europe  Now read ,2017-11-22,Seeking Alpha,https://www.investing.com/news/stock-market-news/pluristem-granted-key-us-patent-for-skeletal-muscle-regeneration-900181,900181
200774,422290,GILD,Exclusive  U S  health regulator Verma eyes new methods for drug pricing,news,"By Caroline Humer NEW YORK  Reuters    The U S  government is considering setting new payment methods aimed at curbing costs for Medicare and Medicaid coverage of breakthrough medical treatments with very high prices  particularly novel gene based therapies for cancer and other diseases  a top health official said on Thursday  Seema Verma  head of the Centers for Medicare and Medicaid Services  CMS   made the comments in an interview with Reuters on the sidelines of the Forbes Healthcare Summit in New York  CMS  part of the U S  Department of Health and Human Services  HHS   spends hundreds of billions of dollars annually on medicines for seniors  disabled people and low income households through the huge Medicare and Medicaid programs  CMS does not negotiate prices or purchase drugs  but sets ground rules for the managed care companies and state Medicaid agencies that do   We are trying to do whatever we can to increase competition and give the  health insurance  plans more tools so that they can be better negotiators on our behalf   Verma said   Roughly 125 million Americans are covered by Medicare and Medicaid  The United States is the world s most expensive market for prescription drugs  Government agencies and private sector companies are struggling to cover the costs of new medicines that have made the most progress to date in treating cancer and rare genetic disorders  some with annual price tags of nearly  500 000  Verma said one model under consideration was paying different prices for a single drug based on its success treating a particular condition  such as paying more for a therapy that works better for breast cancer than it does for lung cancer or liver cancer  A second method would be to extend the payment of an extremely expensive medicine over a longer time frame  rather than immediately after it is given to a patient  Verma added  saying both are being tested by private sector pharmacy benefit managers  That approach could be particularly useful for gene based therapies aimed at small patient populations  she said  One such treatment expected to be approved by early next year is Spark Therapeutics   O ONCE  therapy for a genetic mutation that causes blindness in around 1 000 to 2 000 patients  Some industry experts expect it to carry a list price of as much as  1 million  Earlier this year  drugmaker  Novartis   S NOVN  said it reached an agreement with CMS over its revolutionary new blood cancer drug Kymriah  which has a list price of  475 000  Novartis is paid based on the outcomes achieved among pediatric and young adult leukemia patients by the end of the first month  A similar treatment that harnesses the immune system s CAR T cells from Gilead Sciences Inc s  O GILD  Kite Pharma unit was approved last month and costs  373 000  Other companies including Juno Therapeutics  O JUNO  and BlueBird Bio  O BLUE  have similar treatments in advanced clinical trials  all of which aim to cure the disease with a one time treatment  President Donald Trump has promised to curb drug costs  but little concrete action has been taken so far  CMS has begun seeking information from insurance plans and drug companies as it considers possible changes  Verma said   Alex Azar  Trump s nominee for HHS secretary  on Wednesday promised to address drug prices if confirmed to the job  where he would be Verma s boss  Some Democratic and Republican lawmakers  as well as healthcare experts  have urged Congress to enact new laws allowing the government to negotiate drug prices directly with manufacturers  In the meantime  Verma is focusing on what she is already authorized to do  
 We are trying to do whatever we can within the regulatory structure   she said ",2017-12-01,Reuters,https://www.investing.com/news/stock-market-news/exclusive-us-health-regulator-verma-eyes-new-methods-for-drug-pricing-939825,939825
200775,422291,GILD,Blueprint prices stock offering at  81,news,Blueprint Medicines  NASDAQ BPMC  prices its public offering of  3 7M common shares at  81 per share  Underwriters over allotment is an additional  555 6K shares  Closing date is December 15 Yesterday s close was  81 98 Now read ,2017-12-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/blueprint-prices-stock-offering-at-81-986305,986305
200776,422292,GILD,Galapagos up 9  premarket on decision to co promote filgotinib in Europe,news,Galapagos NV  NASDAQ GLPG  is up 9  premarket on average volume after it decided to co promote JAK1 inhibitor filgotinib with Gilead Sciences  NASDAQ GILD  in eight European countries Previously  Galapagos elects to co promote filgotinib with Gilead in Europe  Dec  14 Now read ,2017-12-15,Seeking Alpha,https://www.investing.com/news/stock-market-news/galapagos-up-9-premarket-on-decision-to-copromote-filgotinib-in-europe-997242,997242
200787,422303,GILD,Gilead Sciences  GILD  Stock Moves  0 03   What You Should Know,opinion,"Gilead Sciences  NASDAQ GILD  closed the most recent trading day at  66 92  moving  0 03  from the previous trading session  This move was narrower than the S P 500 s daily loss of 0 65   Meanwhile  the Dow lost 0 42   and the Nasdaq  a tech heavy index  lost 0 46  
Coming into today  shares of the HIV and hepatitis C drugmaker had lost 1 85  in the past month  In that same time  the Medical sector lost 0 52   while the S P 500 gained 4 11  
Investors will be hoping for strength from GILD as it approaches its next earnings release  which is expected to be July 30  2019  On that day  GILD is projected to report earnings of  1 73 per share  which would represent a year over year decline of 9 42   Meanwhile  our latest consensus estimate is calling for revenue of  5 52 billion  down 2 24  from the prior year quarter 
GILD s full year Zacks Consensus Estimates are calling for earnings of  6 90 per share and revenue of  22 09 billion  These results would represent year over year changes of  3 45  and  0 18   respectively 
Any recent changes to analyst estimates for GILD should also be noted by investors  These revisions typically reflect the latest short term business trends  which can change frequently  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate has moved 0 05  lower  GILD is currently a Zacks Rank  3  Hold  
Investors should also note GILD s current valuation metrics  including its Forward P E ratio of 9 71  For comparison  its industry has an average Forward P E of 23 19  which means GILD is trading at a discount to the group 
Also  we should mention that GILD has a PEG ratio of 3 07  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  The Medical   Biomedical and Genetics was holding an average PEG ratio of 1 85 at yesterday s closing price 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 57  which puts it in the top 23  of all 250  industries 
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
You can find more information on all of these metrics  and much more  on Zacks com ",2019-07-17,Zacks Investment Research,https://www.investing.com/analysis/gilead-sciences-gild-stock-moves-003-what-you-should-know-200441051,200441051
200802,422318,GILD,Alpine extends research term under Kite Pharma deal,news,Alpine Immune Sciences  ALPN  0 3   extends the research term of its global research and license agreement with Gilead s  GILD  0 8   Kite Pharma  The partnership  inked two year ago  grants Kite exclusive rights to two Alpine candidates from its Transmembrane Immunomodulatory Protein  TIP  program The extension of the research term does not affect the  535M in upfront and milestone payments or the royalties in the original agreement Now read ,2017-10-23,Seeking Alpha,https://www.investing.com/news/stock-market-news/alpine-extends-research-term-under-kite-pharma-deal-545940,545940
200803,422319,GILD,Gilead s GS 0976 shows positive effect in mid stage NASH study  shares ahead 1  premarket,news,"Gilead Sciences  NASDAQ GILD  perks up 1  premarket on light volume on the heels of its announcement of positive results from a 126 subject Phase 2 clinical trial assessing GS 0976  an oral inhibitor of Acetyl CoA carboxylase  ACC   in patients with nonalcoholic steatohepatitis  NASH   The data are being presented at The Liver Meeting in Washington  D C 
Patients receiving the higher dose  20 mg once daily  of GS 0976 for 12 weeks experienced statistically significant reductions in hepatic steatosis  buildup of fat in the liver  and TIMP 1   a marker of fibrosis  compared to placebo 
ACC plays a key role in several pathways associated with the progression of NASH  Specifically  it catalyzes the first step in the synthesis of fatty acids that contribute to hepatic steatosis  leading to inflammation and liver fibrosis 
The development of GS 0976 is ongoing 
Now read ",2017-10-24,Seeking Alpha,https://www.investing.com/news/stock-market-news/gileads-gs0976-shows-positive-effect-in-midstage-nash-study-shares-ahead-1-premarket-546604,546604
200804,422320,GILD,Pfizer expects broad interest for consumer health business,news,"By Bill Berkrot NEW YORK  Reuters     Pfizer  Inc  NYSE PFE   the largest U S  drugmaker  expects no shortage of suitors for its consumer health business and said it would decide whether to sell  spin off or retain the unit next year  The business  with brands such as pain drug Advil  Centrum multivitamins and Chapstick lip balm  had sales of about  3 4 billion in 2016   We expect broad interest from potential acquirers   Chief Executive Ian Read said on Tuesday after the company reported its third quarter results  Supply problems related to sterile injectable products acquired in Pfizer s purchase of Hospira  along with steep declines in sales of off patent products  contributed to an 11 percent drop in third quarter revenue from the Essential Health unit to  5 05 billion  Pfizer said the supply challenges would have a negative impact of  several hundred million dollars  this year  moderating in 2018  Pfizer shares were off 0 7 percent at  34 90 shortly after midday  SunTrust Robinson Humphrey analyst John Boris said Essential Health was  under pressure  and that investors were concerned about new competitors grabbing sterile injectables market share before Pfizer s manufacturing challenges are fully addressed  Pfizer said all of its 2 000 Puerto Rico based employees were safe and that it had made significant progress in dealing with damage to its three manufacturing plants on the island devastated by hurricane Maria last month  Chief Financial Officer Frank D Amelio said the revenue impact from the storm was  expected to be insignificant   Innovative Health sales rose 11 percent in the quarter to  8 12 billion with strong contributions from its blockbuster pneumonia vaccine Prevnar and breast cancer drug Ibrance  Prevnar sales declined 1 percent to  1 52 billion  but topped analysts  estimates of about  1 46 billion  Ibrance sales surged nearly 60 percent to  878 million but fell short of lofty Wall Street expectations for  914 million  Sales of rheumatoid arthritis drug Xeljanz rose 48 percent to  348 million but were held back in Europe  where the company is still negotiating reimbursement with several countries  Pfizer sees additional sales growth with an expected approval in psoriatic arthritis and said it still expected new eczema cream Eucrisa to eventually reach annual sales exceeding  2 billion  It also said it hoped a potential approval for Xtandi in non metatstatic prostate cancer based on recent data would provide a new growth ramp for that key medicine from its 2016 acquisition of Medivation  The company raised the midpoint of its full year adjusted earnings forecast by 3 cents to a range of  2 58 to  2 62 per share  It tightened its 2017 revenue forecast to  52 4 billion to  53 1 billion  from  52 billion to  54 billion  Excluding items  Pfizer earned 67 cents per share for the quarter  beating analysts  average estimates by 3 cents  according to Thomson Reuters I B E S   We view these results as refreshingly boring  We think boring is a good thing right now    Credit Suisse   SIX CSGN  analyst Vamil Divan said in a client note  
The lack of drama was welcomed after several drugmakers this quarter spooked investors with new concerns over critical growth products  including Merck  NYSE MRK    Co   Celgene Corp   NASDAQ CELG  and  Gilead Sciences Inc   NASDAQ GILD  ",2017-10-31,Reuters,https://www.investing.com/news/stock-market-news/pfizers-quarterly-profit-more-than-doubles-760841,760841
200806,422322,GILD,Has Gilead Sciences  GILD  Outpaced Other Medical Stocks This Year ,opinion,"Investors interested in Medical stocks should always be looking to find the best performing companies in the group  Gilead Sciences  NASDAQ GILD  is a stock that can certainly grab the attention of many investors  but do its recent returns compare favorably to the sector as a whole  One simple way to answer this question is to take a look at the year to date performance of GILD and the rest of the Medical group s stocks 
Gilead Sciences is one of 843 companies in the Medical group  The Medical group currently sits at  4 within the Zacks Sector Rank  The Zacks Sector Rank considers 16 different sector groups  The average Zacks Rank of the individual stocks within the groups is measured  and the sectors are listed from best to worst 
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks  This system has a long record of success  and these stocks tend to be on track to beat the market over the next one to three months  GILD is currently sporting a Zacks Rank of  2  Buy  
Over the past 90 days  the Zacks Consensus Estimate for GILD s full year earnings has moved 5 91  higher  This means that analyst sentiment is stronger and the stock s earnings outlook is improving 
Based on the most recent data  GILD has returned 7 24  so far this year  In comparison  Medical companies have returned an average of 7 08   This means that Gilead Sciences is outperforming the sector as a whole this year 
Looking more specifically  GILD belongs to the Medical   Biomedical and Genetics industry  which includes 351 individual stocks and currently sits at  67 in the Zacks Industry Rank  Stocks in this group have gained about 4 30  so far this year  so GILD is performing better this group in terms of year to date returns 
GILD will likely be looking to continue its solid performance  so investors interested in Medical stocks should continue to pay close attention to the company ",2019-06-27,Zacks Investment Research,https://www.investing.com/analysis/has-gilead-sciences-gild-outpaced-other-medical-stocks-this-year-200435649,200435649
200807,422323,GILD,Regeneron Sanofi s Libtayo Gets EU Approval For Skin Cancer ,opinion,Regeneron Pharmaceuticals  Inc    NASDAQ REGN   and partner Sanofi   NASDAQ SNY   announced that the European Commission  EC  has granted conditional marketing authorization to skin cancer drug  Libtayo The drug  which is a fully human monoclonal antibody targeting the immune checkpoint receptor PD 1  programmed cell death protein 1   has been approved in the European Union for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma  CSCC   who are not candidates for curative surgery or curative radiation The EU approval is based on data from the pivotal  open label  multi center  non randomized phase II study known as EMPOWER CSCC 1  Study 1540  and supported by two advanced CSCC expansion cohorts from a multi center  open label  non randomized phase I study  Study 1423  Since the drug has been granted conditional approval  Regeneron and Sanofi will add a new patient group to EMPOWER CSCC 1 to support the benefit risk profile of Libtayo  Thereafter  the companies will submit the results to the European Medicines Agency  EMA  for a label update We note that Libtayo is already approved in the United States  Canada and Brazil for adult patients with metastatic or locally advanced CSCC  who are not candidates for curative surgery or curative radiation The initial uptake of the drug is strong  Approval in other countries will further boost sales  CSCC is one of the most commonly diagnosed skin cancers worldwide and prevalent in some European countries Meanwhile  Libtayo is being evaluated in adjuvant and neoadjuvant trials in CSCC  and potential registrational trials in non small cell lung cancer  basal cell carcinoma and cervical cancer  Additional studies include trials in squamous cell carcinoma of the head and neck  melanoma  colorectal cancer  prostate cancer  multiple myeloma  Hodgkin s lymphoma and non Hodgkin s lymphoma We are impressed with Regeneron s efforts to bring new drugs to the market and concurrently expand the label of key drugs   Eylea and Dupixent   The FDA has approved a label expansion of asthma drug  Dupixent  The drug is now approved for use with other medicines to treat chronic rhinosinusitis with nasal polyposis  CRSwNP  in adults  whose disease is not controlled  The company is working to expand the drug s label further into several other indications Label expansion of certain drugs will diversify the company s revenue base and reduce dependence on lead drug  Eylea Regeneron s stock has lost 15 3  in the year so far against the  growth of 7   The company has a deep pipeline  including fully human monoclonal antibodies generated using the VelocIimune technology  Promising candidates in the pipeline include fasinumab  among others  which is being developed in collaboration with Teva Pharmaceuticals   NYSE TEVA   Zacks Rank   A Stock to ConsiderRegeneron currently carries a Zacks Rank  3  Hold  A better ranked stock in the same space is Gilead Sciences  Inc    NASDAQ GILD    which carries a Zacks Rank  2  Buy  currently   You can see  Gilead s earnings estimates have moved up 15 cents to  6 89 for 2019 over the past 60 days This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ,2019-07-01,Zacks Investment Research,https://www.investing.com/analysis/regeneronsanofis-libtayo-gets-eu-approval-for-skin-cancer-200436438,200436438
200824,422340,GILD,Updated labeling for Gilead s Epclusa OK d in Canada,news,Health Canada approves an update to the labeling of Gilead Sciences   NASDAQ GILD  EPCLUSA  sofosbuvir velpatasvir  to include HCV patients co infected with HIV 1 The approval was based on data from the Phase 3 ASTRAL 5 study Now read ,2017-09-21,Seeking Alpha,https://www.investing.com/news/stock-market-news/updated-labeling-for-gileads-epclusa-okd-in-canada-531406,531406
200825,422341,GILD,Gilead operating chief to retire in Q1 2018,news,Gilead Sciences  NASDAQ GILD  Chief Operating Officer Kevin Young will retire in Q1 2018 and will serve in an advisory capacity thereafter  He joined the company in 2004 and retired in 2016 before returning as COO Now read ,2017-09-27,Seeking Alpha,https://www.investing.com/news/stock-market-news/gilead-operating-chief-to-retire-in-q1-2018-533787,533787
200830,422346,GILD,Gilead  GILD  Teams Up With Nurix For Cancer And Other Drugs,opinion,"Biotech major Gilead Sciences  Inc    NASDAQ GILD   collaborates with San Francisco based Nurix Therapeutics  Inc  to discover  develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases Per the deal  Nurix will receive an upfront payment of  45 million  and is also entitled to milestone payments of  2 3 billion and up to low double digit tiered royalties on net sales  For those programs that Nurix opts in to co develop and co detail  the parties will split development costs as well as profits and losses equally in the United States  Nurix will be eligible to receive royalties on ex U S  sales and reduced milestone payments While Nurix will utilize its proprietary drug discovery platform to identify novel agents that utilize E3 ligases to induce degradation of specified drug targets  Gilead will have an option to license drug candidates directed to up to five targets resulting from this discovery  Nurix will retain the option to co develop and co detail for up to two programs in the United States  However  the collaboration excludes its lead degradation program  for which Nurix retains all rights Earlier  Gilead had also collaborated with Agneus   NASDAQ AGEN   for the development and commercialization of up to five novel immuno oncology therapies Given the persistent decline in HCV sales  the company is looking to HIV and newer avenues to boost its top line  Gilead has made quite a few collaborations  of late  to strengthen and diversify its pipeline However  Gilead will have to generate substantial revenues from its HIV franchise to offset the HCV sales decline  This will be a challenging task for the company with stiff competition from the likes of GlaxoSmithKline   NYSE GSK   in the HIV market and pricing issues Meanwhile  the company is intending to foray into the non alcoholic steatohepatitis  NASH  and inflammation markets with late stage candidates  selonsertib and filgotinib  respectively  It has collaborated with big pharma companies like Novo Nordisk   NYSE NVO   for the same Gilead s stock has gained 9 1  in the year so far compared with the  s growth of 5 2  The deal bodes well for Nurix as it gets a strong partner in Gilead along with infusion of cash Zacks Rank
Gilead currently carries a Zacks Rank  2  Buy   You can see  Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-06-20,Zacks Investment Research,https://www.investing.com/analysis/gilead-gild-teams-up-with-nurix-for-cancer-and-other-drugs-200433177,200433177
200845,422361,GILD,aTyr Pharma announces  45M equity financing  shares ahead 6  premarket,news,aTyr Pharma  NASDAQ LIFE  announces that it has entered into a definitive securities purchase agreement with certain institutional and other investors including members of the Company s Board of Directors  Gross proceeds are expected to be   45 8M  Investors have agreed to purchase 5 9M shares of common stock at  2 65 per share  Viking Global Investors  one of the investors will purchase 2 3M shares of non voting Class X Preferred Stock at  13 25 per share  each of which is convertible into 5 shares of common stock upon certain conditions  Each common share  and on an as converted basis for the preferred stock  will be issued with a warrant to purchase 0 375 additional shares of aTyr s common stock at an exercise price of  4 64  representing a 75  premium to the purchase price of common stock  with an expiration date of December 31  2019  Net proceeds from the transaction will be used to advance its pipeline programs and for general corporate purposes Closing date is August 31 Shares are up 6  premarket on light volume  Now read ,2017-08-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/atyr-pharma-announces-45m-equity-financing-shares-ahead-6-premarket-522958,522958
200846,422362,GILD,Gilead plans purchase of Kite Pharma to create leader in cell technology,news,"Investing com   Shares of  Kite Pharma   NASDAQ KITE jumped on Monday after  Gilead Sciences Inc   NASDAQ GILD  made an offer to purchase the company for  11 9 billion  or  180 per share  in cash 
Gilead  a biopharmaceutical company  said the purchase of Kite  also a biopharmaceutical company  would create a company that is a global leader in cell technology  Gilead added that the purchase would diversify Gilead s portfolio and create long term shareholder value 
Gilead said the transaction is expected to be neutral to earnings by year three and accretive thereafter  If approved  the acquisition should close in the fourth quarter of 2017 
The offer price represents a 29  premium to Kite s closing value last Friday  Kite investors reacted appropriately  bidding shares up close to the offering price  Monday afternoon  Kite stock was up 28 2  at  178 28  Gilead s shares had a more muted response and moved up 1 3  ",2017-08-28,Investing.com,https://www.investing.com/news/stock-market-news/gilead-to-purchase-kite-pharma-to-create-leader-in-cell-technology-523134,523134
200847,422363,GILD,Here s why Gilead broke its dealmaking hiatus and splurged  12 billion on a cancer treatment,news,"Since its bombshell hepatitis C treatments hit the market in 2013  the company has been amassing a staggering war chest  The company ended fiscal 2016 with  32 billion in cash on its balance sheet  up from  2 6 billion at the end of fiscal 2013 
But aside from a few small deals  Gilead s  NASDAQ GILD  last major transaction was the one that fueled its current cash bonanza  the 2011 acquisition of hepatitis drugmaker Pharmasset for  11 billion 
After several quiet years of watching hepatitis C treatments Sovaldi and Harvoni generate tens of billions in revenue  Gilead made a splashy return to M A Monday  buying cancer immunotherapy firm  Kite Pharma   NASDAQ KITE  for  11 9 billion in cash  a 29  premium 
Gilead shares traded up just over 1  Monday  but Wall Street wasn t uniformly impressed  In a survey by Mizuho Securities on Monday of 112 investors  59  thought Gilead overpaid  Only 40  said they liked the deal 
Many investors are wondering  Why did Gilead finally decide to strike 
According to several people familiar with the transaction  Gilead became convinced after extensive due diligence that Kite s personalized cancer treatment   a therapy called CAR T that harnesses the body s immune system to attack cancer cells   would not just gain approval from the Food and Drug Administration  but become transformative 
The powerful trial data it s delivered in the past year was crucial 
 Gilead is a very patient  diligent party when it comes to looking at strategic transactions   said one person familiar with the matter   The primary thing was just the clinical data and the success that Kite has had developing the program  
 There just aren t a lot of assets out there like Kite that have the kind of data they ve been able to deliver   they continued 
In data Kite released in February  the company found that out of 101 patients  36  had a complete response to the treatment after six months 
The FDA is expected to decide on whether to approve Kite s CAR T therapy in November 
Some have suggested that Gilead could have waited till after Kite s treatment   which has competition from Novartis  Juno Therapeutics  and Bluebird Bio   had been approved  priced  and launched  hedging against some of the risks 
But after a lengthy due diligence process  and the revelation of the promising trial data  Gilead believed Kite s program had too much upside  and that if they waited  competition for the target would soar   along with Kite s valuation 
 Quite frankly  they thought strategically  Kite  had an edge on other companies   another person familiar with the transaction said 
By acquiring now  the people also noted  Gilead is in position to exert its financial muscle in marketing and shaping the eventual launch of the therapy  which is expected to cost hundreds of thousands per patient ",2017-08-29,Business Insider,https://www.investing.com/news/stock-market-news/heres-why-gilead-broke-its-dealmaking-hiatus-and-splurged-12-billion-on-a-cancer-treatment-523424,523424
200848,422364,GILD,Why Is Gilead  GILD  Down 3  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Gilead Sciences  NASDAQ GILD   Shares have lost about 3  in that time frame  outperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Gilead due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Gilead Earnings Beat  Revenues Miss Estimates in Q1Gilead delivered earnings of  1 76 per share in the first quarter  up from  1 48 a year ago  The bottom line also beat the Zacks Consensus Estimate of  1 62 Total revenues of  5 28 billion lagged the Zacks Consensus Estimate of  5 31 billion but inched up 3 8  year over year HIV Franchise Sustains MomentumProduct sales came in at  5 2 billion  up 3 8  year over year HCV product sales plunged 21  to  790 million  due to lower patient starts and competitive dynamics including a price decline in U S  Medicare  this year HIV product sales increased 12 5  year over year to  3 2 billion  driven by higher sales volume led by the continued uptake of Biktarvy  Sales of Biktarvy surged to  793 million  up from  35 million in the year ago quarter Genvoya generated sales of  1 billion  down from  1 1 billion in the year ago quarter  Descovy recorded sales of  342 million  down from  361 million in the year earlier period while Odefsey registered sales of  397 million  up from  342 million in the prior year quarter Biktarvy became the top selling product in the United States in the quarter under review and remains the number one prescribed regimen for both treatment na ve and switch patients  Approximately 80  of Biktarvy s U S  prescriptions comes from switches with about 25  drawn from Genvoya and another 25  obtained from dolutegravir based regimens  Overall  Descovy based regimens continue to gain share and now account for approximately 80  of Gilead s total U S  treatment prescription volume  Truvada  for its use in the pre exposure prophylaxis setting  consistently maintained a positive momentum with an estimate of 200  000 patients being administered with the drug by the first quarter end CAR T therapy Yescarta  axicabtagene ciloleucel   launched in the United States during October 2017 generated  96 million in sales  up from  81 million in the earlier reported quarter  driven by an increase in the number of therapies provided to patients   Yescarta was also approved in Europe last August 2018 Other product sales including chronic hepatitis B  HBV  drugs  cardiovascular  oncology and other categories  Vemlidy  Viread  Letairis  Ranexa  Zydelig and AmBisome  were  696 million  down from  745 million in the comparable quarter last year due to the expected decline in Ranexa sales after a generic entry in the first quarter of 2019 Adjusted product gross margin was 87 3  compared with 86 3  in the year ago period  Research   development  R D  expenses increased 7  to  871 million  Selling  general and administrative  SG A  expenses climbed 8 8  to  962 billion 2019 Guidance ReiteratedGilead continues to expect net product sales of  21 3  21 8 billion  Adjusted R D and adjusted SG A expenses are projected to be  3 6  3 8 billion and  3 9  4 1 billion  respectively  Adjusted product gross margin is anticipated to be 85 87  Dividend and Share RepurchaseDuring the quarter  Gilead generated  1 4 billion in operating cash flow  repaid  750 million of debt  paid cash dividends of  817 million and spent  834 million on share buybacks  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  The consensus estimate has shifted 8 99  due to these changes 
VGM Scores
Currently  Gilead has a subpar Growth Score of D  however its Momentum Score is doing a bit better with a C  However  the stock was allocated a grade of A on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision indicates a downward shift  Notably  Gilead has a Zacks Rank  2  Buy   We expect an above average return from the stock in the next few months ",2019-05-31,Zacks Investment Research,https://www.investing.com/analysis/why-is-gilead-gild-down-3-since-last-earnings-report-200427377,200427377
200849,422365,GILD,Gilead Presents Data On CAR T Cell Therapy Candidate At ASCO,opinion,"Gilead Sciences  Inc    NASDAQ GILD   announced encouraging results from the completed phase I of the single arm ZUMA 3 study evaluating pipeline candidate KTE X19  an investigational CD19 chimeric antigen receptor T  CAR T  cell therapy  at an oral session at the 2019 American Society of Clinical Oncology  ASCO  Annual Meeting in Chicago   The data was presented by Kite  a wholly owned company of Gilead The study is being conducted in adult patients with relapsed or refractory acute lymphoblastic leukemia  ALL  The study results provide guidance on dosing and safety management of KTE X19 for the ongoing phase II study All together  45 patients received KTE X19 at one of three different dose levels   2 x 106 cells kg  n 6   1 x 106 cells kg  n 23   or 0 5 x 106 cells kg  n 16   by the end of phase I Patients enrolled in this study were primary refractory or relapsed refractory after at least two prior lines of therapy  Of them  68  achieved complete response  CR  with incomplete hematological recovery  CRi  and 100  had undetectable minimal residual disease  MRD  among the 41 patients  who were evaluable for efficacy after a minimum two months of follow up  median follow up of 16 months   Of the 23 patients treated with the dose level that will be used in the ongoing phase II study  1 x 106cells kg   19 were evaluable for efficacy  At the time of data cut off  16 patients achieved CR or CRi  and 12 were in ongoing response However  grade  3 cytokine release syndrome  CRS  events and neurologic events occurred in 29  and 38  of patients  respectively  The company had previously reported that two patients experienced KTE X19 related grade 5 adverse events  AEs  during the study   one developed stroke in the context of CRS and neurologic events  and another experienced multi organ failure secondary to CRS Consequently  a revised AE management protocol was implemented in nine patients treated with 1 x106 cells kg of KTE X19 during the study Management was encouraged by the high response rates in this study along with the reduced incidence and severity of CRS and neurologic events observed  following implementation of the revised safety management protocol  Consequently  the company is evaluating the use of KTE X19 at the selected dose with this safety management protocol in the ongoing ZUMA 3 phase II study KTE X19 is currently in phase I II trials in ALL  mantle cell lymphoma  MCL  and chronic lymphocytic leukemia  CLL  Kite also inked a collaboration with Humanigen  Inc    OTC HGEN   to conduct a phase I II study on lenzilumab  an investigational anti GM CSF monoclonal antibody  with Yescarta  axicabtageneciloleucel  in patients with relapsed or refractory diffuse large B cell lymphoma  DLBCL   The goal of this study is to evaluate the effect of the drug on the safety of Yescarta  Kite will act as the sponsor of this study and be responsible for its conduct  The study will begin enrolling in the fourth quarter of 2019 We note that Yescarta was the first FDA approved CAR T cell therapy to for the treatment of adult patients with relapsed or refractory large B cell lymphoma after two or more lines of systemic therapy  including DLBCL not otherwise specified  primary mediastinal large B cell lymphoma  and high grade B cell lymphoma and DLBCL arising from follicular lymphoma Gilead s stock has lost 0 5  in the year so far compared to the 2 2  decline for the  Concurrent with the first quarter results  Gilead announced that Kite will become a separate business unit  going forward  The initial uptake of Yescarta  from the Kite Pharma acquisition  is also encouraging but it will take some time for its sales suite to contribute significantly to the acquired company s top line  given the treatment s exorbitant cost  Moreover  Novartis    NYSE NVS   Kymriah also exists in the market  posing a fierce rivalry for the stock Zacks Rank   Another Stock to ConsiderGilead currently carries a Zacks Rank  2  Buy  Another attractive stock in the healthcare space is Bristol Myers Squibb Co    NYSE BMY    which sports a Zacks Rank  1  Strong Buy   You can see  Bristol Myers  earnings per share estimates have increased from  4 78 to  5 03 for 2020 in the past 60 days 
Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ",2019-06-02,Zacks Investment Research,https://www.investing.com/analysis/gilead-presents-data-on-car-t-cell-therapy-candidate-at-asco-200427818,200427818
200850,422366,GILD,Model N  MODN  Down 6 5  Since Last Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for Model N  MODN   Shares have lost about 6 5  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Model N due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  Model N Tops Q2 Earnings  Raises  19 GuidanceModel N delivered second quarter fiscal 2019 non GAAP earnings of 1 cent per share beating the Zacks Consensus Estimate by 4 cents  Notably  the Zacks Consensus Estimate was pegged at a loss of 3 cents  However  the figure declined by 50  from the year ago earnings of 2 cents per share Revenues came in at  34 8 million  slightly ahead of Zacks Consensus Estimate of  34 6 million  The figure was also higher than management s guided range of  34 3 million to  34 7 million  However  the top line declined 11 2  from the year ago quarter Notably  Model N adopted ASC 606 from first quarter fiscal 2019 The company is making steady progress in its transformation to a Software as a Service  SaaS  based model Quarter in DetailModel N is reported earnings results under two business lines  namely  Subscription and Professional Services  from first quarter fiscal 2019  Notably  the company previously reported under two domains  SaaS   Maintenance and License   Implementation In second quarter fiscal 2019  Subscription revenues of almost  25 9 million grew 8 1  year over year  Notably  Model N is accelerating its transition of revenue management to cloud This has enabled the company to aid more than 60  of its customers to go live on one or more of its cloud products Management is optimistic on successful transition of Gilead Sciences  NASDAQ GILD  to a 100  SaaS model from a traditional on premise model Professional Services revenues declined 41 5  on a year over year basis to  8 9 million  primarily owing to  legacy on premise implementations  Operating DetailsNon GAAP gross profit declined 15 4  from the year ago quarter to  19 6 million  Non GAAP gross margin  adjusted for deferred revenues  contracted 270 bps from the year ago figure to 56 3  Adjusted EBITDA declined 38 8  year over year to  1 8 million Total operating expenses of  22 8 million fell 6 3  on a year over year basis  As a percentage of total revenues  the figure expanded 340 bps year over year Non GAAP income from operations declined almost 32  year over year to  1 5 million in the second quarter  Non GAAP operating margin  as a percentage of revenues before deferred revenue adjustment  contracted 140 bps to 4 3  Balance Sheet   Cash FlowModel N exited the second quarter with cash and cash equivalents of  54 1 million compared with  52 2 million reported in the previous quarter In the reported quarter  the company paid  4 8 million in debt  As of Mar 31  2019  the company had total debt  including current portion  of almost  49 million  down from  53 6 million reported in the previous quarter For six months ended Mar 31  2019  net cash generated by operating activities and free cash flow came in at  0 5 million and  0 3 million  respectively  Notably  for six months ended Mar 31  2018  Model N used approximately  5 million net cash in operating activities and reported free cash flow of   5 1million  GuidanceThe company anticipates fiscal third quarter 2019 GAAP revenues to come in the range of  33 9 million to  34 3 million Non GAAP net income is anticipated to be in between in line results to 2 cents per share for the third quarter Adjusted EBITDA is anticipated to be in the range of  1 8 million to  2 2 million For fiscal 2019  management revised guidance  Model N now expects GAAP revenues to be in the range of  138 5 million to  142 5 million  inching up slightly from the prior guided range of  138  142 million  Adoption of ASC 606 is anticipated to reduce overall fiscal 2019 revenues by 7 2 million Non GAAP earnings are expected to be in the range of 10 17 cents per share  compared with previously guided 5 17 cents Adjusted EBITDA is now projected to be in the range of  9 5 million to  12 5 million  compared with earlier predicted range of  8 5  12 5 million 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  The consensus estimate has shifted  35  due to these changes 
VGM Scores
Currently  Model N has a great Growth Score of A  a grade with the same score on the momentum front  However  the stock was allocated a grade of F on the value side  putting it in the bottom 20  quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Model N has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-06-05,Zacks Investment Research,https://www.investing.com/analysis/model-n-modn-down-65-since-last-earnings-report-can-it-rebound-200429102,200429102
200851,422367,GILD,Why Is Agenus  AGEN  Down 6 3  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Agenus  AGEN   Shares have lost about 6 3  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Agenus due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Agenus Q1 Earnings Beat Estimates  Revenues MissAgenus reported first quarter 2019 earnings of 12 cents per share against the Zacks Consensus Estimate of a loss of 30 cents and the year ago quarter s loss of 42 cents The company generated revenues of  8 6 million  which includes non cash royalties  compared with no revenues in the year ago quarter  Revenues marginally missed the Zacks Consensus Estimate of  9 million  Quarterly HighlightsResearch and development  R D  expenses rallied 36 3  to  40 1 million  General and administrative expenses increased 26 8  to  10 2 million Pipeline UpdateAgenus is a clinical stage  immuno oncology company with a comprehensive portfolio  consisting of antibody based therapeutics  adjuvants and cancer vaccine platforms In December 2018  the company inked a collaboration deal with Gilead Sciences Inc  NASDAQ GILD   to develop and commercialize up to five immuno oncology  I O  therapies  In January 2019  it announced the closing of its I O partnership deal with Gilead Agenus recently received  7 5 million in cash as a milestone payment from Gilead  after the FDA accepted the former s investigational new drug  IND  application for AGEN1423  Now GS 1423   AGEN1423 is a first in class molecule  currently being developed in partnership with Gilead as a potential treatment for cancer  Agenus also received additional milestones of  150 million from Gilead The company started first in human trial with its next generation CTLA4 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates 
VGM Scores
Currently  Agenus has a strong Growth Score of A  though it is lagging a lot on the Momentum Score front with a C  Charting a somewhat similar path  the stock was allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision indicates a downward shift  Notably  Agenus has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-06-07,Zacks Investment Research,https://www.investing.com/analysis/why-is-agenus-agen-down-63-since-last-earnings-report-200429814,200429814
200852,422368,GILD,CymaBay Down On Dismal Interim Data From Mid Stage NASH Study,opinion,"Shares of CymaBay Therapeutics  Inc    NASDAQ CBAY   plunged significantly after it announced disappointing interim data from a mid stage study on lead pipeline candidate  seladelpar  
Seladelpar is a potent and selective peroxisome proliferator activated receptor delta  PPAR   agonist currently in development for non alcoholic steatohepatitis  NASH  and primary biliary cholangitis  PBC  
The double blind  placebo controlled study randomized 181 subjects with biopsy confirmed NASH and a liver fat content  LFC  greater than 10  to receive either placebo or seladelpar 10 mg  20 mg  or 50 mg once daily  The primary endpoint was the relative change in LFC from baseline to 12 weeks 
Top line results from the ongoing 52 week phase IIb dose ranging  paired liver biopsy study of seladelpar at 12 weeks showed that treatment with seladelpar resulted in minimal reductions in liver fat that were not significant enough compared to placebo 
Nevertheless  reductions in markers of liver injury were robust and clinically meaningful  The study remains blinded and will continue to 52 weeks  with assessments including a liver biopsy  non invasive imaging evaluations  and biomarker assessments of inflammation and fibrosis 
Seladelpar demonstrated a favorable safety and tolerability profile at all doses evaluated in the study 
A chronic liver disease  NASH  is caused by excessive fat accumulation in the liver or steatosis  The ailment is anticipated to be the leading reason behind liver transplantation by 2020  Currently  NASH is the primary reason for liver transplants in people under 50 years in the United States  With no treatments currently approved to address this disease  the market opportunity is substantially huge  Thus  many companies are investing a major chunk of their R D budget on the same 
Hence  the dismal interim data disappointed investors 
CymaBay s stock has lost 23 1  in the year so far compared with 16 1  decline for the  

 
NASH is a complex disease and there have been quite a few failures of late  Conatus Pharmaceuticals    NASDAQ CNAT   phase IIb ENCORE NF study in patients with biopsy confirmed NASH and liver fibrosis also failed to achieve goals 
Earlier  biotech bigwig Gilead Sciences  Inc    NASDAQ GILD   too suffered a setback with the failure of a late stage study on pipeline candidate  selonsertib  in patients with compensated cirrhosis  F4  due to NASH 
Intercept Pharmaceuticals  Inc   NASDAQ ICPT   had earlier announced positive top line results from its pivotal phase III REGENERATE study of obeticholic acid  OCA  on patients with liver fibrosis due to NASH  While the results showed promise  investors weren t impressed with additional data 
We expect investors to focus on further updates from the study 
Zacks Rank
CymaBay currently carries a Zacks Rank  3  Hold   You can see  
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2019-06-12,Zacks Investment Research,https://www.investing.com/analysis/cymabay-down-on-dismal-interim-data-from-midstage-nash-study-200431079,200431079
200866,422382,GILD,FDA OKs AbbVie s pan genotypic HCV med Mavyret,news,The FDA approves AbbVie s  ABBV  0 3   Mavyret  glecaprevir and pibrentasvir  for the treatment of adults with genotype 1   6 chronic hepatitis C virus  HCV  infection without cirrhosis or with mild cirrhosis  including patients with moderate to severe kidney disease and those on dialysis Breakthrough Therapy tagged Mavyret is approved as a once daily  three tablet  eight week regimen in treatment naive patients with all genotypes without cirrhosis Rival Gilead Sciences  GILD  1 2   is under modest pressure on the news Now read ,2017-08-03,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-abbvies-pangenotypic-hcv-med-mavyret-514363,514363
200867,422383,GILD,Takeover rumor du jour  Gilead and Glaxo eyeing United Therapeutics  shares up 9 ,news,United Therapeutics  UTHR  8 5   is up in early trading on rumors that Gilead Sciences  GILD  1 7   and GlaxoSmithKline  GSK  0 2   are eyeing the company Now read ,2017-08-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/takeover-rumor-du-jour-gilead-and-glaxo-eyeing-united-therapeutics-shares-up-9-514819,514819
200868,422384,GILD,United Therapeutics rumored to be takeover target,news,"Investing com   United Therapeutics Corporation s  NASDAQ UTHR shares rallied on Friday on the rumor that the company may be the purchase target of a major pharmaceutical company 
According to The Evening Standard  Gilead Sciences  NASDAQ GILD   GlaxoSmithKline  and Novartis are all interested suitors  United Therapeutics has five products on the market  Four treat pulmonary arterial hypertension  the fifth is intended for pediatric cancer patients 
The company s share value has been hit due to a U S  Justice Department investigation into the company s contributions to patient assistance charity groups  United Therapeutics announced earlier this week that it has set aside  210 million for a possible settlement ",2017-08-04,Investing.com,https://www.investing.com/news/stock-market-news/united-therapeutics-rumored-to-be-takeover-target-514877,514877
200873,422389,GILD,5 Best PEG Stocks Suitable For GARP Investors,opinion,GARP  growth at a reasonable price  investment  often known as a special case of value investment  is gaining popularity among the new generation of investors  According to them  to make a long term investment more effective  the principles of both value and growth strategies need to be combined What GARPers look for is whether the stocks are somewhat undervalued and have solid sustainable growth potential  Investopedia  And here lies the importance of a not so popular fundamental metric  the price earnings growth  PEG  ratio  Although it is categorized under value investing  this strategy follows the principles of both growth and value investing The PEG ratio is defined as   Price  Earnings  Earnings Growth RateIt relates the stocks P E ratio with future earnings growth rate While P E alone only gives an idea of stocks that are trading at a discount  PEG  while adding the growth element to it  helps to identify stocks that have solid potential A lower PEG ratio  preferably less than 1  is always better for GARP investors Say for example  if a stock s P E ratio is 10 and expected long term growth rate is 15   the company s PEG will come down to 0 66  a ratio that indicates both undervaluation and future growth potential Unfortunately  this ratio is often neglected due to investors  limitation to calculate the future earnings growth rate of a stock There are some drawbacks to using the PEG ratio though  It doesn t consider the very common situation of changing growth rates such as the forecast of the first three years at very high growth rate followed by a sustainable but lower growth rate in the long term Hence  PEG based investing can turn out to be even more rewarding if some other relevant parameters are also taken into consideration Here are the screening criteria for a winning strategy PEG Ratio less than X Industry MedianP E Ratio  using F1  less than X Industry Median  For more accurate valuation purpose Zacks Rank of 1  Strong Buy  or 2  Buy   Whether good market conditions or bad  stocks with a Zacks Rank  1 or  2 have a proven history of success  Market Capitalization greater than  1 Billion  This helps us to focus on companies that have strong liquidity  Average 20 Day Volume greater than 50 000  A substantial trading volume ensures that the stock is easily tradable Percentage Change F1 Earnings Estimate Revisions  4 Weeks  greater than 5   Upward estimate revisions add to the optimism  suggesting further bullishness Value Score of less than or equal to B  Our research shows that stocks with a Style Score of A or B when combined with a Zacks Rank  1  2 or 3  Hold  offer the best upside potential  Here are five out of the seven stocks that qualified the screening Gilead Sciences  Inc    NASDAQ GILD    This biopharmaceutical company is focused on developing drugs for the treatment of human immunodeficiency virus  HIV   liver diseases  hematology oncology diseases and inflammation respiratory diseases  The stock can be an impressive value investment pick with its Zacks Rank  2 and Value Score of A  Apart from a discounted PEG and P E  the stock also has an impressive long term expected growth rate of 12 4  Jazz Pharmaceuticals plc   NASDAQ JAZZ    This is a specialty biopharmaceutical company focusing on areas of sleep and hematology oncology   The stock can also be an impressive value investment pick with its Zacks Rank  2 and Value Score of A  Apart from a discounted PEG and P E  the stock also has an impressive long term historical growth rate of 15 9  Amdocs Limited   NASDAQ DOX   is one of the leading providers of customer care  billing and order management systems for communications and Internet services The company has an impressive long term growth rate of 8 5   The stock currently has a Value Score of A and a Zacks Rank  2  You can see  Arch Capital Group Ltd    NASDAQ ACGL    This property and casualty  P C  insurer offers insurance  reinsurance and mortgage insurance across the world  Through its wholly owned subsidiaries  it provides a wide range of products and services including primary and excess casualty coverages  professional indemnity  workers compensation and umbrella liability and employers  liability insurance coverages to name a few   Apart from a discounted PEG and P E  the stock has a Value Score of B and holds a Zacks Rank  2 Legg Mason  Inc    NYSE LM    This is a global asset management firm focused on the growth and preservation of its clients  capital through its proprietary mutual funds and separately managed accounts  SMAs   The stock carries a Zacks Rank  2 and has a Value Score of A You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  Disclosure  Performance information for Zacks  portfolios and strategies are available at   ,2019-05-23,Zacks Investment Research,https://www.investing.com/analysis/5-best-peg-stocks-suitable-for-garp-investors-200424848,200424848
200874,422390,GILD,Is Gilead Sciences  GILD  Outperforming Other Medical Stocks This Year ,opinion,"Investors focused on the Medical space have likely heard of Gilead Sciences  NASDAQ GILD   but is the stock performing well in comparison to the rest of its sector peers  By taking a look at the stock s year to date performance in comparison to its Medical peers  we might be able to answer that question 
Gilead Sciences is a member of our Medical group  which includes 844 different companies and currently sits at  3 in the Zacks Sector Rank  The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors 
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks  This system has a long record of success  and these stocks tend to be on track to beat the market over the next one to three months  GILD is currently sporting a Zacks Rank of  2  Buy  
Over the past 90 days  the Zacks Consensus Estimate for GILD s full year earnings has moved 5 91  higher  This shows that analyst sentiment has improved and the company s earnings outlook is stronger 
Our latest available data shows that GILD has returned about 6 94  since the start of the calendar year  Meanwhile  the Medical sector has returned an average of 4 09  on a year to date basis  As we can see  Gilead Sciences is performing better than its sector in the calendar year 
Looking more specifically  GILD belongs to the Medical   Biomedical and Genetics industry  which includes 352 individual stocks and currently sits at  79 in the Zacks Industry Rank  On average  this group has gained an average of 2 47  so far this year  meaning that GILD is performing better in terms of year to date returns 
GILD will likely be looking to continue its solid performance  so investors interested in Medical stocks should continue to pay close attention to the company ",2019-05-26,Zacks Investment Research,https://www.investing.com/analysis/is-gilead-sciences-gild-outperforming-other-medical-stocks-this-year-200425387,200425387
200875,422391,GILD,Zacks com Featured Highlights Include  Gilead  Jazz  Amdocs  Arch Capital And Legg Mason,opinion,For Immediate ReleaseChicago  IL   May 28  2019   Stocks in this week s article are Gilead Sciences  Inc    NASDAQ GILD    Jazz Pharmaceuticals plc   NASDAQ JAZZ    Amdocs Ltd    NASDAQ DOX    Arch Capital Group Ltd    NASDAQ ACGL   and Legg Mason  Inc    NYSE LM   5 Best PEG Stocks Suitable for GARP InvestorsGARP  growth at a reasonable price  investment  often known as a special case of value investment  is gaining popularity among the new generation of investors  According to them  to make a long term investment more effective  the principles of both value and growth strategies need to be combined What GARPers look for is whether the stocks are somewhat undervalued and have solid sustainable growth potential  Investopedia  And here lies the importance of a not so popular fundamental metric  the price earnings growth  PEG  ratio  Although it is categorized under value investing  this strategy follows the principles of both growth and value investing The PEG ratio is defined as   Price  Earnings  Earnings Growth RateIt relates the stocks P E ratio with future earnings growth rate While P E alone only gives an idea of stocks that are trading at a discount  PEG  while adding the growth element to it  helps to identify stocks that have solid potential A lower PEG ratio  preferably less than 1  is always better for GARP investors Say for example  if a stock s P E ratio is 10 and expected long term growth rate is 15   the company s PEG will come down to 0 66  a ratio that indicates both undervaluation and future growth potential Unfortunately  this ratio is often neglected due to investors  limitation to calculate the future earnings growth rate of a stock There are some drawbacks to using the PEG ratio though  It doesn t consider the very common situation of changing growth rates such as the forecast of the first three years at very high growth rate followed by a sustainable but lower growth rate in the long term Hence  PEG based investing can turn out to be even more rewarding if some other relevant parameters are also taken into consideration For the rest of this Screen of the Week article please visit Zacks com at  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material About Screen of the WeekZacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine   But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has more than doubled the market from 1988 through 2016  Its average gain has been a stellar  25  per year  Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Contact  Jim GiaquintoCompany  Zacks comPhone  312 265 9268Email  Visit  Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-05-27,Zacks Investment Research,https://www.investing.com/analysis/zackscom-featured-highlights-include-gilead-jazz-amdocs-arch-capital-and-legg-mason-200425614,200425614
200876,422392,GILD,Gilead Gains 6 8  YTD As HIV Franchise Maintains Momentum ,opinion,"Shares of Gilead Sciences  Inc    NASDAQ GILD   have gained 6 9  in the year so far  outperforming the 2 1  growth for the  

It is a biopharmaceutical company  focused on developing drugs for the treatment of human immunodeficiency virus  HIV  and liver diseases 
Gilead is a dominant player in the HIV market  with an impressive portfolio for the same  The company was the first to bring to market a single tablet regimen  STR    Atripla   for the treatment of HIV  Other notable STRs for HIV in the market include Complera Eviplera and Stribild  among others 
Meanwhile  Gilead is looking to fortify its dominant position in the HIV market by developing drugs with improved long term safety profiles  The TAF based products   Genvoya  Odefsey and Descovy   are performing well  with strong adoption in the United States and Europe  Descovy based regimens continue to gain share and now account for approximately 80  of Gilead s total U S  treatment prescription volumes 
The company received a major boost  when the FDA approved its once daily single tablet regimen   STR    Biktarvy  bictegravir 50mg emtricitabine 200mg tenofovir alafenamide 25mg  BIC FTC TAF   for HIV 1 infection  The approval significantly boosts Gilead s HIV franchise  The approval of this new HIV therapy will pose stiff competition to GlaxoSmith s   NYSE GSK   existing therapies   Tivicay and Triumeq 
Gilead shifted focus to the HIV franchise  and newer avenues like CAR T therapy and NASH  owing to the declining HCV franchise  The company s efforts to diversify its revenue base is impressive as well 
Gilead acquired Kite Pharma to foray into the emerging domain of cell therapy  The approval of lead candidate  Yescarta  for the treatment of refractory aggressive non Hodgkin lymphoma  which includes diffuse large B cell lymphoma  DLBCL   transformed follicular lymphoma  TFL  and primary mediastinal B cell lymphoma  PMBCL   is a significant boost for the company 
Gilead has a robust pipeline  with several programs currently under development  ranging from phase I through phase III  Inflammation is one of the three emerging areas  and the company has been developing a pipeline targeting inflammatory diseases  Galapagos   NASDAQ GLPG   and Gilead entered a global collaboration for the development and commercialization of filgotinib in inflammatory indications 
Phase III studies on filgotinib for the treatment of rheumatoid arthritis  RA  and Crohn s disease are currently ongoing  Based on the positive data from the ongoing trials  Gilead plans to progress with filgotinib in the RA indication for regulatory approval in Europe in the second half of this year  The successful development and commercialization of the candidate will boost growth for the company 
Further  Gilead and Denmark based pharma giant Novo Nordisk  CSE NOVOb  A S   NYSE NVO   intend to collaborate to develop treatments for NASH 
Meanwhile  softness in the HCV franchise has stabilized in the first quarter 
We expect investors to focus on further pipeline updates from the company 
Zacks Rank
Gilead currently carries a Zacks Rank  2  Buy   You can see   
Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases 
Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-05-28,Zacks Investment Research,https://www.investing.com/analysis/gilead-gains-68-ytd-as-hiv-franchise-maintains-momentum-200425790,200425790
200890,422406,GILD,Gilead submits U S  marketing application for HIV 1 med BIC FTC TAF,news,Gilead Sciences  NASDAQ GILD  files its New Drug Application  NDA  with the FDA seeking approval of its once daily single tablet regimen of bictegravir 50 mg  BIC  and emtricitabine tenofovir alafenamide 200 25 mg  FTC TAF  for the treatment of HIV 1 infection in adults It plans to file its marketing application in Europe next quarter Shares are off a fraction premarket Now read ,2017-06-12,Seeking Alpha,https://www.investing.com/news/stock-market-news/gilead-submits-u.s.-marketing-application-for-hiv-1-med-bic-ftc-taf-494379,494379
200891,422407,GILD,Gilead and Sanofi eyeing TESARO   StreetInsider,news,Takeover rumors have been flying about ever since the FDA approved TESARO s  TSRO  2 3   PARP inhibitor Zejula  niraparib  in March  Interest is not one sided  The company has been reaching out to potential suitors about a deal  but supposedly interest has been muted In the latest go round   Sanofi   PA SASY   SNY  2   and Gilead Sciences  GILD  1 1   are eyeing the company  which could fetch  10B Previously  TESARO exploring sale  shares up 4  after hours  May 31 Now read ,2017-06-12,Seeking Alpha,https://www.investing.com/news/stock-market-news/gilead-and-sanofi-eyeing-tesaro---streetinsider-494501,494501
200892,422408,GILD,FDA rejects Egalet s marketing application for higher doses of Oxaydo  shares off 8 ,news,Egalet  EGLT  7 9   receives a Complete Response Letter  CRL  from the FDA related to its application to market 10 mg and 15 mg strengths of pain med OXAYDO  oxycodone HCl   It is currently offered in 5 mg and 7 5 mg doses The CRL cites the need for more information on the effect of food on the 15 mg dose and the intranasal abuse deterrent properties of both doses  The company says it will work with the regulator to address the issues Previously  FDA accepts Egalet s PAS for OXAYDO 10 15 mg  shares ahead 9  premarket  April 18 Now read ,2017-06-20,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-rejects-egalet's-marketing-application-for-higher-doses-of-oxaydo;-shares-off-8-497285,497285
200893,422409,GILD,Spring Bank teams up with Gilead in clinical study of hepatitis B combo  shares ahead 2 ,news,Spring Bank Pharmaceuticals  SBPH  1 7   announces a second clinical trial collaboration with Gilead Sciences  GILD  0 3   assessing the combination SB 9200 and Vemlidy  tenofovir alafenamide  for the treatment of hepatitis B virus  HBV  infection The Phase 2 study will be funded and conducted by Gilead while Spring Bank will supply product SB 9200 is Spring Bank s novel small molecule  orally available selective immunomodulator compound being developed as both monotherapy and combination therapy as a backbone for the treatment of chronic HBV and other viral diseases Previously  Arrowhead and Spring Bank team up in hepatitis B  Oct  6  2016 Now read ,2017-07-10,Seeking Alpha,https://www.investing.com/news/stock-market-news/spring-bank-teams-up-with-gilead-in-clinical-study-of-hepatitis-b-combo;-shares-ahead-2-503871,503871
200897,422413,GILD,Horizon Therapeutics   HZNP  Q1 Earnings Beat Estimates,opinion,"Horizon Therapeutics plc   NASDAQ HZNP    previously known as Horizon Pharma plc  reported first quarter adjusted earnings of 30 cents per share  which beat the Zacks Consensus Estimate of 10 cents and increased from 3 cents reported in the year ago quarter 
The company reported quarterly sales of  280 4 million  up 25  year over year  The top line also beat the Zacks Consensus Estimate of  237 million 
On May 2  2019  shareholders of the company approved the change of the company s name to Horizon Therapeutics  This move caters to the company s long term strategy to develop and commercialize innovative medicines addressing rare diseases with very few effective treatment options 
Horizon Therapeutics  share price surged 44 8  year to date compared with the  s growth of 3 4   

 
Quarter in Detail
The company realigned structure to operate two separate businesses  Thus  with effect from the second quarter of 2018  the company has been reporting financial results in two separate segments   the orphan and rheumatology segment  and the primary care segment  Horizon Therapeutics expects the new structure to help it better allocate resources to develop products for unmet treatment needs of patients with rare diseases 
Sales of the orphan and rheumatology segment were  185 9 million  up 8  from the prior year quarter s figure  driven by continued strong growth of Krystexxa  Ravicti  Procysbi and Rayos  Krystexxa sales increased 12  year over year to  52 3 million  Beginning January 2019  the company no longer recognizes certain ex U S  sales of Ravicti  Buphenyl and Lodotra following the divestiture of those rights in 2018  
First quarter 2019 net sales of the primary care segment were  94 5 million  up 83  year over year 
Adjusted research and development  R D  expenses were 6 1  of net sales  and adjusted SG A expenses were 52 3  of the same 
2019 Guidance
The company now expects 2019 net sales of  1 26  1 28 billion  an increase from the previous guidance of  1 23  1 25 billion
Other Updates
The company s pipeline candidate teprotumumab is being developed for the treatment of thyroid eye disease  TED   The company announced positive top line results from the phase III confirmatory study  OPTIC  evaluating teprotumumab for the treatment of active TED  The study met its primary endpoint of improving proptosis or bulging of the eye compared to placebo  with 82 9  of patients showing improvement compared to 9 5  of placebo patients 
The study also succeeded in meeting secondary endpoints and the safety profile was consistent with the phase II study of teprotumumab in TED  Share price of the company rallied about 26  in pre market trading on Feb 28 in response to the encouraging study results  The company intends to submit a biologics license application to the FDA in mid 2019 
Horizon Therapeuticsis evaluating the use of methotrexate to enhance the response rate to Krystexxa through the MIRROR studyin adults living with uncontrolled gout  The MIRROR study is designed to support the potential for registration of Krystexxa  and expected to begin in June 
The company plans to initiate a clinical trial in the second half of 2019  evaluating the effect of Krystexxa on serum uric acid levels in kidney transplant patients with uncontrolled gout 
The company used the net proceeds from an underwritten public equity offering in March together with cash in hand to repay  550 million of its  1 993 billion total principal amount of debt outstanding as of Dec 31  2018  The debt level was  1 443 billion as of May 1  2019 Horizon Pharma Public Limited Company Price  Consensus and EPS Surprise

    Zacks Rank   Stocks to Consider
Horizon Therapeutics currently has a Zacks Rank  3  Hold  
Some better ranked stocks are Gilead Sciences Inc    NASDAQ GILD    Fibrocell Science Inc    NASDAQ FCSC    and Genmab A S   All the stocks carry a Zacks Rank  1  Strong Buy   You can see  
Gilead s earnings per share estimates have increased from  6 65 to  6 72 for 2019 and from  7 00 to  7 03 for 2020 in the past 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  the average being 6 86  
Fibrocell s loss per share estimates have narrowed from  2 68 to  1 15 for 2019 and from  2 55 to 97 cents for 2020 in the past 60 days  The company delivered a positive earnings surprise in two of the trailing four quarters  the average being 28 30  
Genmab s earnings per share estimates have increased from  2 69 to  2 79 for 2019 and from  4 91 to  5 08 for 2020 in the past 60 days 
This Could Be the Fastest Way to Grow Wealth in 2019 
Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities 
These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-05-09,Zacks Investment Research,https://www.investing.com/analysis/horizon-therapeutics-hznp-q1-earnings-beat-estimates-200419815,200419815
200898,422414,GILD,Mallinckrodt Ends Enrollment In Phase III For Terlipressin,opinion,Mallinckrodt plc   NYSE MNK   announced that it has completed enrolling patients in a late stage study on its pipeline candidate  terlipressin  which is being developed for the treatment of Hepatorenal Syndrome type 1  HRS 1  The company achieved the enrollment target of 300 subjects in the ongoing phase III CONFIRM study  which will evaluate the safety and efficacy of the company s investigational agent  terlipressin  for the given indication The phase CONFIRM III program is the largest prospective analysis to be ever conducted in patients suffering the HRS 1 syndrome  The primary endpoint  Verified HRS Reversal  of the probe is to examine the renal function improvement  avoidance of dialysis and short term survival Currently  there are no treatments approved for HRS 1 in North America  Top line data from the study is expected by this year end  Mallinckrodt plans to file a new drug application  NDA  in early 2020  if results from this analysis are found to be supportive Notably  in 2016  Mallinckrodt reached an agreement with the FDA on the protocol design and data analysis of the CONFIRM study under the regulatory body s special protocol assessment  SPA  process Shares of Mallinckrodt have lost 3  so far this year  outperforming the  decline of 4 6  We would like to remind investors that last month  Stratatech  acquired by Mallinckrodt in 2016  completed enrollment in the phase III assessment of its investigational regenerative skin tissue  StrataGraft  The study is designed to evaluate the safety and efficacy of StrataGraft regenerative skin tissue for promoting autologous skin regeneration in patients with thermal burns that contain intact dermal elements  also known as deep partial thickness burns  Top line findings from this evaluation are expected by this year end  Mallinckrodt plans to file a Biologics License Application  BLA  in 2020  if outcomes from the program are found to be favorable Meanwhile  StrataGraft is also under phase II development for treating full thickness burns StrataGraft is a viable  engineered  bilayer human skin substitute  currently under development for severe burns and other complex skin defects Zacks Rank   Stocks to ConsiderMallinckrodt currently carries a Zacks Rank  3  Hold   Better ranked stocks from the healthcare sector include Merus N V    NASDAQ MRUS    Gilead Sciences  Inc    NASDAQ GILD   and Repligen Corporation   NASDAQ RGEN    all flaunting a Zacks Rank  1  Strong Buy   You can see  Merus  loss per share estimates have been narrowed 28  for 2019 and 30 7  for 2020 over the past 60 days Gilead s earnings estimates have moved 3 8  north for 2019 and 1 6  for 2020 over the past 60 days Repligen s earnings estimates have been revised 13 2  upward for 2019 and 11  for 2020 over the past 60 days  The stock has inched up 0 4  year to date Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-05-14,Zacks Investment Research,https://www.investing.com/analysis/mallinckrodt-ends-enrollment-in-phase-iii-for-terlipressin-200421749,200421749
200912,422428,GILD,New studies support functional cure of ContraVir s HBV candidate CRV431  shares ahead 8  premarket,news,"ContraVir Pharmaceuticals  NASDAQ CTRV  is up 8  premarket on light volume in response to its announcement of new study data performed at the Scripps Research Institute that clarify the mechanism of action of CRV431  one of the company s candidates for the functional cure of hepatitis B virus  HBV  infection 
Results show that CRV431 blocks the interaction between hepatitis B surface antigen  HBsAg  and a key cellular protein called cyclophilin A  High levels of HBsAg is a predictor of disease progression leading to liver fibrosis  cirrhosis and cancer 
ContraVir s  functional cure  strategy for chronic HBV infection is based on combining drugs with complementary mechanisms of action  TXL  tenofovir exalidex prodrug   for example  works by lowering infectious virus in the blood  CRV431 complements TXL s activity by targeting HBsAg  possibly increasing the likelihood that the patient s immune system can kill the virus 
Phase 2 stage TXL is a prodrug of Gilead Sciences   NASDAQ GILD  VIREAD  tenofovir disoproxil fumarate   CRV431 is a next generation cyclophilin inhibitor ",2017-04-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/new-studies-support-functional-cure-of-contravir's-hbv-candidate-crv431;-shares-ahead-8-premarket-471175,471175
200913,422429,GILD,Dosing underway in Galapagos  mid stage study of filgotinib in psoriatic arthritis   10M milestone due from development partner Gilead  shares ahead 4 ,news,Galapagos NV  GLPG  3 5   earns a  10M milestone payment from collaboration partner Gilead Sciences  GILD  0 4   triggered by the start of dosing in the Phase 2 EQUATOR study assessing filgotinib in patients psoriatic arthritis  The companies inked their global partnership to co develop the JAK1 inhibitor in January 2016 According to ClinicalTrials gov  the estimated study completion date is June 2018 ,2017-04-06,Seeking Alpha,https://www.investing.com/news/stock-market-news/dosing-underway-in-galapagos'-mid-stage-study-of-filgotinib-in-psoriatic-arthritis;-$10m-milestone-due-from-development-partner-gilead;-shares-ahead-4-472188,472188
200914,422430,GILD,How drugmakers face global push back on high prices,news,"By Ben Hirschler LONDON  Reuters    Pharmaceutical companies are under fire around the world as a wave of new treatments for cancer and other serious conditions reach the market at ever rising prices  and the pressure looks set to increase  Next week the debate on drug pricing   a particularly heated topic in the United States   will move to Amsterdam as the Dutch government hosts a forum for World Health Organization  WHO  member states to promote  fair pricing   After Donald Trump earlier this year accused drugmakers of  getting away with murder   shortly before he was inaugurated as U S  president  the May 11 event underscores the focus on medicine pricing in health ministries from Berlin to Beijing  In Europe  Germany s tough price negotiators have caused some firms to pull drugs off the market rather than accept price cuts  while Britain last month introduced new budget curbs on pricey products  China and Japan  the two biggest non Western markets for pharmaceuticals  are also bearing down on costs  and poorer countries find new drugs costing tens of thousands of dollars are simply out of reach  even with preferential pricing deals   It s great that we have these treatments but we need to find a way to make them more affordable   Andrew Rintoul  the WHO health economist organizing the drug pricing forum  told Reuters  Drugmakers know they must up their game to save their reputation   even as patients cheer the scientific advances behind their new products   and the industry is fighting to defend its corner more vigorously than ever  A major advertising campaign by the U S  Pharmaceutical Research and Manufacturers of America trade group  for example  includes accusations that insurers are failing to pass on the benefits of discounts negotiated with manufacturers  This goes to the heart of a thorny issue  On the surface  the cost of medicines may be rising steeply but the picture is distorted by off invoice discounts and rebates  which in the United States average around 30 percent  according to healthcare information firm QuintilesIMS   In Europe  such rebates amount to roughly 17 percent   I personally don t believe in the talk of drug expenditure breaking the system   Thomas Cueni  who recently took over as director general of the International Federation of Pharmaceutical Manufacturers and Associations  told Reuters   When you look at the aggregate numbers  drug spending has been pretty stable in most OECD countries at around 10 to 15 percent of healthcare spending    MORE DISCLOSURE  Still  the lack of price transparency is a major bugbear for policy experts like the WHO s Rintoul  who previously negotiated on pharmaceutical prices for the Australian government  Public sector officials see the obscurity surrounding prices as a big obstacle in efforts to negotiate effectively with pharmaceutical companies  There are also growing calls for greater disclosure on companies  R D and production costs  Transparency will be high on the agenda in Amsterdam  mirroring efforts by some U S  states to shine a light on costs  Vermont last year became the first such state to demand that companies justify drug price hikes by detailing factors behind the increase  Companies  however  are reluctant to specify exactly how they come up with drug prices and prefer to stress the value that their medicines bring to patients and society   The industry has to stand up and argue its value proposition   said Cueni  who admits he is  apprehensive  about the tone of the WHO meeting   I m not a big fan of this term  fairness  because  let s face it  fairness is in the eye of the beholder  There s no objective definition   Drugmakers like  Novartis   S NOVN  and Takeda Pharmaceutical  T 4502   which recently joined with the World Economic Forum to pilot schemes that will pay for drugs based on how well they work  would much rather the focus was on outcomes  But an expensive medicine that may be cost effective  based on a particular methodology  can still prove to be unaffordable within limited national healthcare budgets  That has been the experience in many countries recently with highly effective new hepatitis C drugs from Gilead  O GILD  and others  At the other end of the spectrum  the WHO meeting will also try to address the problem of shortages of some off patent generic medicines  which should be cheap in principle but can hit supply problems if prices fall to unsustainably low levels   
As well as tackling expensive drugs  some experts therefore believe minimum prices may be needed to keep certain vital products on the market ",2017-05-04,Reuters,https://www.investing.com/news/stock-market-news/how-drugmakers-face-global-push-back-on-high-prices-480179,480179
200915,422431,GILD,U S  hepatitis C cases soar on spike in heroin use,news," Reuters    U S  health officials said new cases of hepatitis C rose nearly 300 percent from 2010 to 2015  despite the availability of cures for the liver disease  fueled by a spike in the use of heroin and other injection drugs  according to a report released on Thursday  In 2015  the national reported rate of hepatitis C was 0 8 per 100 000 persons with nearly 34 000 new infections  according to the report by the Centers for Disease Control and Prevention  Access to clean syringes and a limit on Medicaid barriers to curative treatments for hepatitis C can reduce rates of death from the disease and transmission of the virus to others  the CDC said  New treatments for hepatitis C with a cure rate of over 95 percent from Gilead Sciences  O GILD   AbbVie  N ABBV  and other drugmakers have the ability to virtually wipe out the disease  which can lead to cirrhosis  cancer  the need for a liver transplant or death   But the opioid addiction epidemic appears to be creating tens of thousands of new cases  with unclean needles the leading cause of infections  Some experts say that one reason heroin use has soared is because the illegal drug has become much cheaper than prescription opioid painkillers and due to new limits on dispensing of the addictive legal pain medicines  The CDC conducted a state by state analysis of reported cases of the hepatitis C virus  HCV   as well as a review of laws related to access to clean needles for individuals who inject drugs  and levels of restriction on Medicaid access to treatments  In 2015  it found HCV rates in 17 states exceeded the national average   The analysis found only Massachusetts  New Mexico and Washington had both a comprehensive set of laws and a permissive Medicaid treatment policy that could help prevent the spread of HCV and provide treatment services for those who inject drugs  Twenty four states had policies that require some period of sobriety to receive HCV treatment through Medicaid  potentially limiting access to cures  compared with 16 states without such restrictions   Among the best ways of preventing spread of the virus are public health laws that allow access to clean syringes for drug users  such as needle exchange programs  decriminalization of the possession of syringes  and allowing the retail sale of syringes without a prescription  
Eighteen states had no such programs  the report found  while Maine  Nevada and Utah had the most comprehensive laws related to prevention  including syringe exchange without limitations ",2017-05-11,Reuters,https://www.investing.com/news/world-news/u.s.-hepatitis-c-cases-soar-on-spike-in-heroin-use-483331,483331
200916,422432,GILD,Minerva Neuro readies Phase 3 study of lead product candidate MIN 101,news,Minerva Neurosciences  NASDAQ NERV  plans to initiate a Phase 3 clinical trial in H2 assessing lead product candidate MIN 101 for the treatment of negative symptoms of schizophrenia The primary endpoint  of the 12 week double blind core phase will be the improvement in negative symptoms in patients with moderate to severe symptoms  An open label extension will follow  Two doses of MIN 101 will be administered as monotherapy in addition to placebo The company intends to conduct additional Phase 4 studies to expand MIN 101 s profile Management will host a conference call this morning at 10 30 am to discuss its plans Now read ,2017-05-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/minerva-neuro-readies-phase-3-study-of-lead-product-candidate-min-101-484794,484794
200921,422437,GILD,Gilead Sciences  GILD  Q1 Earnings Top Estimates,opinion,"Gilead Sciences  NASDAQ GILD  came out with quarterly earnings of  1 76 per share  beating the Zacks Consensus Estimate of  1 62 per share  This compares to earnings of  1 48 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 8 64   A quarter ago  it was expected that this HIV and hepatitis C drugmaker would post earnings of  1 70 per share when it actually produced earnings of  1 44  delivering a surprise of  15 29  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
Gilead  which belongs to the Zacks Medical   Biomedical and Genetics industry  posted revenues of  5 28 billion for the quarter ended March 2019  missing the Zacks Consensus Estimate by 0 49   This compares to year ago revenues of  5 09 billion  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Gilead shares have added about 3 7  since the beginning of the year versus the S P 500 s gain of 16 6  
What s Next for Gilead 
While Gilead has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Gilead was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 70 on  5 42 billion in revenues for the coming quarter and  6 67 on  22 03 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Biomedical and Genetics is currently in the top 30  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-05-02,Zacks Investment Research,https://www.investing.com/analysis/gilead-sciences-gild-q1-earnings-top-estimates-200416132,200416132
200922,422438,GILD,Gilead  GILD  Earnings Beat  Revenues Miss Estimates In Q1,opinion,"Shares of Gilead Sciences   NASDAQ GILD   rose in after market trading post the company s release of mixed results for the first quarter of 2019 wherein earnings surpass expectations but revenues missed the same Gilead s stock has gained 7 8  in the year so far  outperforming the  growth of 3 4  Gilead delivered earnings of  1 76 per share in the first quarter  up from  1 48 a year ago  The bottom line also beat the Zacks Consensus Estimate of  1 62 Total revenues of  5 28 billion lagged the Zacks Consensus Estimate of  5 31 billion but inched up 3 8  year over year HIV Franchise Sustains MomentumProduct sales came in at  5 2 billion  up 3 8  year over year HCV product sales plunged 21  to  790 million  due to lower patient starts and competitive dynamics including a price decline in U S  Medicare  this year HIV product sales increased 12 5  year over year to  3 2 billion  driven by higher sales volume led by the continued uptake of Biktarvy  Sales of Biktarvy surged to  793 million  up from  35 million in the year ago quarter  Genvoya generated sales of  1 billion  down from  1 1 billion in the year ago quarter  Descovy recorded sales of  342 million  down from  361 million in the year earlier period while Odefsey registered sales of  397 million  up from  342 million in the prior year quarter Biktarvy became the top selling product in the United States in the quarter under review and remains the number one prescribed regimen for both treatment na ve and switch patients  Approximately 80  of Biktarvy s U S  prescriptions comes from switches with about 25  drawn from Genvoya and another 25  obtained from dolutegravir based regimens  Overall  Descovy based regimens continue to gain share and now account for approximately 80  of Gilead s total U S  treatment prescription volume  Truvada  for its use in the pre exposure prophylaxis setting  consistently maintained a positive momentum with an estimate of 200  000 patients being administered with the drug by the first quarter end CAR T therapy Yescarta  axicabtagene ciloleucel   launched in the United States during October 2017 generated  96 million in sales  up from  81 million in the earlier reported quarter  driven by an increase in the number of therapies provided to patients   Yescarta was also approved in Europe last August 2018 Other product sales including chronic hepatitis B  HBV  drugs  cardiovascular  oncology and other categories  Vemlidy  Viread  Letairis  Ranexa  Zydelig and AmBisome  were  696 million  down from  745 million in the comparable quarter last year due to the expected decline in Ranexa sales after a generic entry in the first quarter of 2019 Adjusted product gross margin was 87 3  compared with 86 3  in the year ago period  Research   development  R D  expenses increased 7  to  871 million  Selling  general and administrative  SG A  expenses climbed 8 8  to  962 billion 2019 Guidance ReiteratedGilead continues to expect net product sales of  21 3  21 8 billion  Adjusted R D and adjusted SG A expenses are projected to be  3 6  3 8 billion and  3 9  4 1 billion  respectively  Adjusted product gross margin is anticipated to be 85 87  Dividend and Share RepurchaseDuring the quarter  Gilead generated  1 4 billion in operating cash flow  repaid  750 million of debt  paid cash dividends of  817 million and spent  834 million on share buybacks Our TakeThe sales miss was disappointing even though the company s earnings top the consensus mark in the first quarter  Nevertheless  soft HCV franchise sales stabilized as compared to the levels in prior quarters  While the HIV franchise retains momentum positive trend  attributable to the rapid adoption of Descovy based regimens and Biktarvy  Gilead will have to generate substantial revenues from its HIV franchise to offset the weak HCV sales  This will be a challenging task for the company with stiff competition from the likes of GlaxoSmithKline   NYSE GSK   in the HIV market Gilead announced that Kite will become a separate business unit going forward  The initial uptake of Yescarta  from the Kite Pharma acquisition  is also encouraging but it will take some time for its sales suite to contribute significantly to the acquired company s top line  given the treatment s exorbitant cost  Moreover  Novartis    NYSE NVS   Kymriah also exists in the market  posing a fierce rivalry for the stock Gilead s collaboration with Novo Nordisk   NYSE NVO   for NASH treatments is a step in the right direction given its recent debacles Zacks Rank
Gilead currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-05-02,Zacks Investment Research,https://www.investing.com/analysis/gilead-gild-earnings-beat-revenues-miss-estimates-in-q1-200416550,200416550
200923,422439,GILD,Is Gilead Sciences  GILD  Stock Outpacing Its Medical Peers This Year ,opinion,"For those looking to find strong Medical stocks  it is prudent to search for companies in the group that are outperforming their peers  Is Gilead Sciences  NASDAQ GILD  one of those stocks right now  By taking a look at the stock s year to date performance in comparison to its Medical peers  we might be able to answer that question 
Gilead Sciences is a member of the Medical sector  This group includes 844 individual stocks and currently holds a Zacks Sector Rank of  3  The Zacks Sector Rank considers 16 different groups  measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group 
The Zacks Rank is a successful stock picking model that emphasizes earnings estimates and estimate revisions  The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months  GILD is currently sporting a Zacks Rank of  1  Strong Buy  
Over the past three months  the Zacks Consensus Estimate for GILD s full year earnings has moved 5 97  higher  This is a sign of improving analyst sentiment and a positive earnings outlook trend 
According to our latest data  GILD has moved about 5 63  on a year to date basis  In comparison  Medical companies have returned an average of 3 85   This shows that Gilead Sciences is outperforming its peers so far this year 
To break things down more  GILD belongs to the Medical   Biomedical and Genetics industry  a group that includes 352 individual companies and currently sits at  64 in the Zacks Industry Rank  This group has gained an average of 3 46  so far this year  so GILD is performing better in this area 
Investors with an interest in Medical stocks should continue to track GILD  The stock will be looking to continue its solid performance ",2019-05-08,Zacks Investment Research,https://www.investing.com/analysis/is-gilead-sciences-gild-stock-outpacing-its-medical-peers-this-year-200419474,200419474
200924,422440,GILD,Intercept  ICPT  Q1 Earnings Miss Estimates  Revenues Beat,opinion,"Intercept Pharmaceuticals  Inc    NASDAQ ICPT   gained 3 02  after the company posted mixed results for the first quarter  The company reported a wider than expected loss  but beat on sales expectations The company incurred a loss of  3 03 per share in the first quarter  wider than the Zacks Consensus Estimate of a loss of  2 57 but narrower than the year ago loss of  3 22 Quarterly revenues were  52 2 million  up from  35 9 million in the year ago quarter  Revenues also marginally surpassed the Zacks Consensus Estimate of  52 million Quarter in DetailOcaliva recorded  51 8 million of sales  down from  52 9 million recorded in the fourth quarter of 2018 but up from  35 2 million in the year earlier quarter  Net sales in the United States came in at  38 million  while ex U S  Ocaliva net sales summed  13 8 million Ocaliva in combination with ursodeoxycholic  UDCA  was approved in the United States in 2016 for the treatment of primary biliary cholangitis   PBC   in adults with an inadequate response to UDCA or as monotherapy in adults  who are unable to endure UDCA  The drug was also granted a conditional approval by the European Commission  In February 2018  the drug s label was updated in the United States to include a boxed warning and a dosing table that reinforced the existing dosing schedule in PBC patients with Child Pugh Class B or C or decompensated cirrhosis Research and development expenses increased 19 9  year over year to  58 4 million  primarily due to more clinical development programs of Ocaliva for NASH  However  selling  general and administrative expenses increased 23 5  to  77 2 million 2019 OutlookFor 2019  Ocaliva s net sales are expected between  235 million and  245 million  Intercept continues to expect operating expenses of  470  500 million for the year Pipeline UpdateObeticholic acid  OCA  is also being evaluated for other indications  including non alcoholic steatohepatitis   NASH   and primary sclerosing cholangitis   PSC   Earlier in 2019  Intercept announced positive top line results from the pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH   The company stated that the primary endpoint of the study   fibrosis improvement without worsening of NASH at 18 months   was achieved with the 25 mg daily dose of OCA Also  a numerically greater proportion of patients in both OCA treatment arms  receiving doses of 10 mg and 25 mg  met the primary endpoint of NASH resolution with no deterioration of liver fibrosis as compared to placebo  However  this did not reach statistical significance  Nevertheless  the study was required to attain one of the two primary goals per the FDA  which it did In April 2019  additional supportive REGENERATE data were presented during the Opening Ceremony of the International Liver Congress  2019  the 54th Annual Meeting of the European Association for the Study of the Liver   EASL    The data showed that OCA demonstrated robust efficacy across a range of additional histologic and biochemical parameters Intercept plans to file for an approval of OCA as a NASH treatment both in the United States and Europe in the third and fourth quarters  respectively The REVERSE study is designed to evaluate the efficacy and safety of Ocaliva in NASH patients suffering from compensated cirrhosis  The study is currently enrolling patients  which is expected to be complete by the end of the year Our TakeIntercept s first quarter results were mixed  as earnings lagged expectations but sales beat the same  Management s efforts to increase awareness about the label update of Ocaliva in 2018 and expand sales force across the United States  thereafter  are reaping results  Solid growth in new patient enrollment is likely to drive sales in 2019 Moreover  the favorable outcomes from the REGENERATE assessment are a big boost to Intercept  This news significantly buoyed investors  sentiments  given the market potential of NASH and the fact that biotech bigwig Gilead Sciences  Inc    NASDAQ GILD   announced the failure of a late stage study on selonsertib  involving patients afflicted with compensated cirrhosis  F4  due to NASH  This  in turn  puts Intercept ahead in the race to get a drug approved for NASH Pharma giant Merck   NYSE MRK    in January 2019  exercised its option to license NGM313  an investigational monoclonal antibody agonist of the   Klotho FGFR1c receptor complex that is currently being evaluated for the treatment of NASH and type II diabetes Shares of the company have rallied 19 1  in the past year compared with the   s loss of 12 9   France based Genfit s   NASDAQ GNFT   lead candidate elafibranor  which is in late stage studies for NASH  also holds promise Zacks Rank
Intercept currently carries a Zacks Rank  3  Hold    You can see  vThis Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-05-09,Zacks Investment Research,https://www.investing.com/analysis/intercept-icpt-q1-earnings-miss-estimates-revenues-beat-200419724,200419724
200925,422441,GILD,Nektar  NKTR  Q1 Earnings   Revenues Beat  Decline Y Y ,opinion,"Nektar Therapeutics   NASDAQ NKTR   reported a loss of 68 cents per share for the first quarter of 2019  narrower than the Zacks Consensus Estimate of a loss of 71 cents  The company had recorded a loss of 21 cents per share in the year ago period 
Quarterly revenues were  28 2 million compared with the year ago figure of  38 million  The unfavorable year over year comparison was attributable to a payment of  10 million received from Takeda   NYSE TAK   upon approval of Adynovi in Europe in the first quarter of 2018  Adynovi has been developed using Nektar s proprietary technology  Captisol  The top line  however  beat the Zacks Consensus Estimate of  25 45 million 
Nektar s shares gained 1 1  in pre market trading on May 9 following the earnings release  The stock has declined 0 7  so far this year against the  s rally of 8 2  

 
Quarter in Detail
Nektar s top line comprises product sales  royalty revenues  non cash royalty revenues besides license  collaboration and other revenues 
In the first quarter  product sales declined 30 1  to  4 4 million from the year ago period   Meanwhile  non cash royalty revenues increased 20 8  to  8 2 million 
Nektar reported royalty revenues of  11 4 million in the quarter  registering an improvement of 2 8  from the year ago quarter 
License  collaboration and other revenues came in at  4 2 million compared with  13 7 million in the prior year 
Research and development  R D  expenses escalated 19 2  to  118 5 million  primarily due to investments in pipeline  including candidates bempegaldesleukin  earlier NKTR 214   NKTR 358 and NKTR 255 
General and administrative  G A  expenses were up 33 7  to  25 million in the reported quarter primarily due to costs related to commercialization initiatives to support launch of NKTR 181 upon potential approval and higher stock based compensation expenses  A new drug application seeking approval for NKTR 181 as a treatment for chronic pain is under review in the United States  A decision is expected in August 2019 
Pipeline Update
Nektar is developing several candidates across important therapeutic areas including Onzeald in breast cancer and NKTR 255 in virology indications  The company is also developing several immuno oncology candidates  with bempegaldesleukin being its primary candidate  The company also has several collaborations with large pharma companies  including Gilead Sciences   NASDAQ GILD    Bristol Myers   NYSE BMY   and Lilly to develop its pipeline candidates in combination with their drugs 
Nektar and its partner Lilly expect to initiate phase Ib studies to evaluate NKTR 358 in several auto immune disorders later this year  Currently  a multiple ascending dose study is evaluating the candidate in lupus patients 
Nektar and Bristol Myers are evaluating bempegaldesleukin plus Bristol Myers  PD L1 inhibitor Opdivo  nivolumab  in a phase III study   PIVOT 09   and a registrational study   PIVOT 10   for treating renal cell carcinoma and urothelial carcinoma  respectively  Under the PIVOT program  the companies are also developing the combination therapy for first line metastatic melanoma  renal cell carcinoma and bladder cancers and second line non small cell lung cancer  The program will also develop a triplet combination of bempegaldesleukin  Opdivo and Yervoy  ipilimumab  
Zacks Rank
Nektar currently carries a Zacks Rank  3  Hold   You can see  
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities 
These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month 
Nektar Therapeutics Price  Consensus and EPS Surprise
 

  ",2019-05-09,Zacks Investment Research,https://www.investing.com/analysis/nektar-nktr-q1-earnings--revenues-beat-decline-yy-200419719,200419719
200926,422442,GILD,Amicus   FOLD  Earnings   Revenues Miss Estimates In Q1,opinion,"Amicus Therapeutics  Inc    NASDAQ FOLD   reported loss of 39 cents per share in the first quarter of 2019  excluding loss on exchange of convertible notes   wider than the year ago loss of 28 cents and the Zacks Consensus Estimate of a loss of 31 cents 
Total revenues in the first quarter were  34 million  reflecting 104  surge from  16 7 million in the year ago quarter  The figure missed the Zacks Consensus Estimate of  38 million  The company realized revenues from commercial sales of its only marketed drug  Galafold  migalastat  
The growth was largely driven by net new patients added in the first quarter along with higher than anticipated prescriptions in the EU  Japan and the United States  and continued global compliance and adherence rates exceeding 90   Revenues were in line with management s expectations  The company expects the drug to generate revenues of  160 million  180 million  with more than 1 000 Fabry patients by the end of the year 
Share price of the company has rallied 36 8  year to date compared with the  s growth of 3 4  

Pipeline Update
Amicus expects to complete enrollment in pivotal PROPEL study for AT GAA in Pompe disease by 2019 end 
The company has two gene therapy programs in pipeline for two different types of Batten disease  It expects to release top line results from the phase I II study of the CLN6 Batten program in additional patients at two years following a one time administration of its gene therapy in the third quarter of 2019  with more detail at a scientific congress later in the year  Amicus also expects to complete enrollment in the ongoing CLN3 Batten disease phase I II study 
The company plans to establish preclinical proof of concept for Fabry and Pompe gene therapies in 2019 
2019 Guidance
For full year 2019  the company expects total Galafold revenues of  160  180 million  The upside is expected to be driven by continued growth in EU markets  further geographic expansion and success from the first full year of the drug s launch in the United States and Japan  Consistent with Galafold s adoption trends and ordering patterns seen in previous years  Amicus expects higher revenues in the second and fourth quarters of 2019 
The company expects to end 2019 with approximately  300 million of cash in hand  The current cash position is anticipated to be enough to fund ongoing operations til at least mid 2021 Amicus Therapeutics  Inc  Price  Consensus and EPS Surprise

   Zacks Rank   Stocks to Consider
Amicus currently has a Zacks Rank  3  Hold  
Some better ranked stocks are Gilead Sciences Inc    NASDAQ GILD    Fibrocell Science Inc    NASDAQ FCSC   and Genmab A S   All the stocks carry a Zacks Rank  1  Strong Buy   You can see  
Gilead s earnings per share estimates have increased from  6 65 to  6 72 for 2019 and from  7 00 to  7 03 for 2020 in the past 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters  the average being 6 86  
Fibrocell s loss per share estimates has narrowed from  2 68 to  1 15 for 2019 and from  2 55 to 97 cents for 2020 in the past 60 days  The company delivered a positive earnings surprise in two of the trailing four quarters  the average being 28 30  
Genmab s earnings per share estimates have increased from  2 69 to  2 79 for 2019 and from  4 91 to  5 08 for 2020 in the past 60 days 
This Could Be the Fastest Way to Grow Wealth in 2019 
Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities 
These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-05-09,Zacks Investment Research,https://www.investing.com/analysis/amicus-fold-earnings--revenues-miss-estimates-in-q1-200419748,200419748
200943,422459,GILD,What s In The Cards For Zynerba  ZYNE  This Earnings Season ,opinion,"In the absence of an approved product  investors  focus will be on the progress of Zynerba Pharmaceuticals  Inc  s   NASDAQ ZYNE   lead pipeline candidate when the company reports first quarter 2019 results The company s earnings beat the Zacks Consensus Estimate in two of the last four quarters and missed the same twice with the average positive surprise being 2 11  Shares of Zynerba have surged 289 2  so far this year compared with the  s rise of 6 6  In the last reported quarter  Zynerba reported a positive earnings surprise of 34 33  Let s see how things are shaping up for this announcement Things to Watch Out ForInvestors will likely focus on the progress of the company s lead pipeline candidate  Zygel  on the first quarter earnings call Zynerba is developing Zygel multiple neuropsychiatric indications including Fragile X  syndrome   FXS    and developmental and epileptic encephalopathies In March  the company initiated a phase II study to evaluate Zygel in autism spectrum disorder in pediatric patients Meanwhile  the company is looking to get an approval for Zygel for treating FXS  A pivotal study is evaluating the candidate for treating patients with FXS aged 3 to 17 years  Previously presented data from the study showed improvement in core emotional and behavioral symptoms of statistical significance  Zynerba expects to report top line data in the second half of this year and submit a new drug application next year These developments are likely to drive operating expenses higher in the soon to be reported quarter  The company has enough cash to fund its operations beyond 2020 Zynerba is focused on developing cannabinoid therapies for rare neuropsychiatric disorders Earnings WhispersOur proven model does not conclusively show that Zynerba is likely to beat estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  But that is not the case here  as you will see below Earnings ESP  Zynerba s Earnings ESP is 0 00   This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of 46 cents  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Although Zynerba s Zacks Rank  2 increases the predictive power of ESP  its 0 00  ESP makes surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4  Sell  or 5  Strong Sell  going into an earnings announcement  especially when the company is seeing negative estimate revisions Zynerba Pharmaceuticals  Inc  Price and Consensus
    Stocks That Warrant a LookHere are some stocks from the pharma sector that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  1 54  and a Zacks Rank  2  The company is scheduled to release first quarter results on May 2  You can see  Horizon Pharma   NASDAQ HZNP   has an Earnings ESP of  25 00  and a Zacks Rank  3  The company is scheduled to release first quarter results on May 8 Corbus Pharmaceuticals Holdings  Inc    NASDAQ CRBP   has an Earnings ESP of  255 56  and a Zacks Rank  3 Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-04-29,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-zynerba-zyne-this-earnings-season-200413235,200413235
200944,422460,GILD,AVEO Pharmaceuticals  AVEO  To Post Q1 Earnings  What s Up ,opinion,AVEO Pharmaceuticals  Inc    NASDAQ AVEO   will report first quarter 2019 earnings results The company s performance over the last four quarters has been mixed so far with two earnings beat as well as a couple of misses  The average negative surprise over the trailing four quarters is 24 41   In the last reported quarter  AVEO delivered a positive surprise of 50 00  Shares of AVEO have plunged 40 5  so far this year against the  increase of 4 8  Let s see  how things are shaping up for this announcement Factors to ConsiderAVEO s top line comprises collaboration and licensing revenues plus partnership royalties  Fotivda  tivozanib  is the first approved drug in the company s portfolio  It won the nod in the EU during August 2017 for the first line treatment of advanced renal cell carcinoma  RCC  However  this January  AVEO faced a major setback when it had to delay the submission of a new drug application  NDA  for Fotivda for the first line treatment of advanced RCC  The company decided not to file an NDA in the United States after the regulatory agency informed that it was not satisfied with the preliminary overall survival  OS  data reported along with the top line TIVO 3 study results on the progression free survival  PFS   last November Key Events of Q1Previously  the company intended to submit the NDA in the first half of 2019  However  it has planned a final analysis of OS come August  Data from this interim assessment will be available during the fourth quarter of 2019  We expect management to provide an update during the upcoming conference call as investors are keen to know the outcome of the same Meanwhile  last December  AVEO entered into a collaboration deal with AstraZeneca   NYSE AZN   to evaluate the safety and efficacy of the latter s Imfinzi in combination with Fotivda  This phase I II study will assess the combo for the treatment of first line hepatocellular carcinoma  HCC   It is expected to begin this year  If the outcome of the study is positive  then that should push up the stock going forward AVEO has several promising early to mid stage developing candidates in its pipeline One such candidate in AVEO s pipeline is ficlatuzumab  a hepatocyte growth factor inhibitory antibody  currently being evaluated in phase I II programs for various oncological indications  Earlier this month  AVEO along with partner Biodesix  Inc  announced favorable results from the phase Ib expansion cohort of ficlatuzumab in combination with cytarabine for addressing patients with relapsed and refractory acute myeloid leukemia  AML  We expect management to provide an update on the same during the impending call Earnings WhispersThe proven Zacks model does not conclusively show that AVEO is likely to beat estimates this to be reported quarter  This is because a stock needs to have both a positive  and a top Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here as you will see below Earnings ESP  AVEO has an Earnings ESP of 0 00   This is because the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of 5 cents each  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  AVEO currently carries a Zacks Rank  2  which increases the predictive power of ESP  However  the company s 0 00  ESP in the combination makes surprise prediction difficult for the stock this reporting cycle We caution against Sell rated stocks   4 or 5  going into an earnings announcement  especially when the company is seeing negative estimate revisions AVEO Pharmaceuticals  Inc  Price and EPS Surprise   Stocks That Warrant a LookHere are a few health care stocks worth considering as our model shows that these have the right mix of elements to beat on earnings this time around Aduro Biotech  Inc    NASDAQ ADRO   has a Zacks Rank of 2 and an Earnings ESP of  82 00   You can see  Gilead Sciences  Inc    NASDAQ GILD   is a Zacks  2 Ranked player and an Earnings ESP of  1 54   The company is scheduled to release first quarter results on May 2  after the market closes Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-04-29,Zacks Investment Research,https://www.investing.com/analysis/aveo-pharmaceuticals-aveo-to-post-q1-earnings-whats-up-200413145,200413145
200945,422461,GILD,What s In Store For ANI Pharmaceuticals  ANIP  Q1 Earnings ,opinion,ANI Pharmaceuticals Inc    NASDAQ ANIP   is gearing up to report first quarter 2019 results The company has surpassed expectations in three of the previous four quarters  the average positive earnings surprise being 2 30  ANI Pharmaceuticals  stock has surged 57 5  compared with the  s growth of 4 8  year to date  Let s see how things are shaping up for this announcement Factors to ConsiderANI Pharmaceuticals is a specialty pharmaceutical company that develops  manufactures  and markets high quality branded and generic prescription pharmaceuticals The newly launched branded and generic products are likely to have a positive impact on the company s revenues in the first quarter Contract manufacturing revenues are expected to increase in the first quarter  driven by the performance of its Canadian subsidiary  ANI Pharmaceuticals Canada Inc  Through this subsidiary  ANI Pharmaceuticalsacquired WellSpring Pharma Services Inc   a Canadian company located in Oakville  Ontario  that performs contract development and manufacturing of pharmaceutical products  in August 2018  The company continues to integrate its new Canadian operations and is working to use the facility for the tech transfer of several of its pipeline products and grow its contract manufacturing business platform The first quarter results are likely to reflect royalties from Gilead s   NASDAQ GILD   Yescarta sales  impact of product development services and laboratory services revenues from ANI Canada subsidiary What Our Model IndicatesOur proven model does not conclusively show that ANI Pharmaceuticalsis likely to beat on earnings in the to be reported quarter  This is because the stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  But that is not the case here  as you will see below Earnings ESP  ANI Pharmaceuticalshas an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  The company carries a Zacks Rank  3  which increases the predictive power of ESP  However  we need to have a positive Earnings ESP to be confident of an earnings beat Note that Sell rated stocks  Zacks Rank  4 or 5  going into an earnings announcement are best avoided ANI Pharmaceuticals  Inc  Price and EPS Surprise   Stocks That Warrant a LookHere are some stocks you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat in the quarter to be reported Glaxo SmithKline plc    NYSE GSK   has an Earnings ESP of  3 55  and a Zacks Rank  3  The company is scheduled to release first quarter 2019 results on May 1  You can see  Novo Nordisk  CO NOVOb  A S   NYSE NVO   has an Earnings ESP of  0 80  and a Zacks Rank  3  The company is scheduled to release its first quarter 2019 results on May 3 Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future ,2019-04-30,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-ani-pharmaceuticals-anip-q1-earnings-200412857,200412857
200958,422474,GILD,Gilead s former NASH pipeline candidates show treatment effect in mid stage study,news,Results from an open label Phase 2 clinical trial assessing Gilead Sciences   NASDAQ GILD  selonsertib  GS 4997  alone or combination with simtuzumab  SIM  in patients with nonalcoholic steatohepatitis  NASH  and moderate to severe liver fibrosis  stages F2 or F3  showed a treatment effect favoring the combination  The data were presented at The Liver Meeting 2016 in Boston  MA Four measures of liver disease were assessed in three groups of patients  those receiving selonsertib 18 mg with without SIM  selonsertib 6 mg with without SIM and SIM alone  There were no differences observed between the combination and selonsertib alone The proportions of subjects experiencing at least one stage improvement in fibrosis in the three groups were 43   n 13 30   30   n 8 27  and 20   n 2 10   respectively The proportions that progressed to cirrhosis were 3   n 1 30   7   n 2 27  and 20   n 2 10   respectively The proportions that experienced at least a 15  reduction in liver stiffness were 20   n 5 25   32   n 7 22  and 0   n 0 7   respectively The proportions that experienced at least a 30  reduction in liver fat were 26   n 8 31   13   n 3 24  and 10   n 1 10   respectively Headache  nausea and sinusitis were the most common selonsertib related adverse events The treatment effect of both selonsertib and SIM were not enough for Gilead  though  The company recently terminated both development programs in NASH Previously  Gilead quietly stops development of certain pipeline programs  Nov  3 ,2016-11-14,Seeking Alpha,https://www.investing.com/news/stock-market-news/gilead's-former-nash-pipeline-candidates-show-treatment-effect-in-mid-stage-study-440691,440691
200959,422475,GILD,Gilead s momelotinib matches Incyte s Jakafi in late stage myelofibrosis study  but falls short of beating best alternative therapy in another,news,Two Phase 3 clinical trials  SIMPLIFY 1 and SIMPLIFY 2  assessing Gilead Sciences   NASDAQ GILD  Janus kinase  JAK  inhibitor momelotinib compared to ruxolitinib  Incyte s  NASDAQ INCY  Jakafi  or best alternative therapy  BAT  LON BATS   in patients with myelofibrosis produced different outcomes SIMPLIFY 1 met its primary endpoint of non inferiority to ruxolitinib for splenic response rate at week 24  SRR24  defined as the percentage of patients achieving at least a 35  reduction in spleen volume  momelotinib  26 5   ruxolitinib  29 0   p 0 011  SIMPLIFY 2 failed to meet its primary endpoint of superiority compared to BAT in patients previously treated with ruxolitinib as measured by SRR24  momelotinib  6 7   BAT  5 8   p 0 90   88  of the patients randomized to the BAT arm continued to receive ruxolitinib while the remainder received chemo  interferon  corticosteroids  other therapies or a combination thereof Detailed results will be presented at future scientific conference Shares are down a fraction after hours ,2016-11-16,Seeking Alpha,"https://www.investing.com/news/stock-market-news/gilead's-momelotinib-matches-incyte's-jakafi-in-late-stage-myelofibrosis-study,-but-falls-short-of-beating-best-alternative-therapy-in-another-441564",441564
200960,422476,GILD,Leerink s Porges says Incyte back on Gilead s target list after momelotinib disappoints,news,Leerink Partners analyst Geoffrey Porges believes Incyte  NASDAQ INCY  is  again  on Gilead Sciences   NASDAQ GILD  short list of acquisition targets after momelotinib failed to beat Jakafi in a late stage study  Gilead is widely known to be looking for an acquisition to boost growth Mr  Porges says the combined company would still overlap in filgotinib and baricitinib but Incyte s passive role in the development and commercialization of baricitinib should not affect filgotinib s prospects very much INCY is up 5  premarket ,2016-11-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/leerink's-porges-says-incyte-back-on-gilead's-target-list-after-momelotinib-disappoints-441763,441763
200961,422477,GILD,Piper bullish on Gilead,news,Barron s Ben Levisohn reports that Gilead Sciences   GILD  0 9   pipeline stumbles are actually bullish for investors  citing Piper Jaffray s view that the company s development setbacks should force it into a  value creating science overhaul  including a pipeline reset and M A transactions Piper s team says Gilead s modest 6x forward P E undervalues the HIV franchise and implies no new value creation  e g   M A   They chide management for being slow to realize the inevitability of acquisitions to build out its pipeline ,2016-11-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/piper-bullish-on-gilead-441878,441878
200962,422478,GILD,Leerink agrees that Incyte an attractive buyout target,news,Echoing Piper s Josh Schimmer  Leerink s Michael Schmidt also believes Gilead s  GILD  0 8   stumble with momelotinib makes Incyte  INCY  4 9   an attractive acquisition target since Gilead s candidate is no longer a potential risk to Jakafi sales  Incyte s top seller  He has an Outperform rating on the stock and has raised the price target to  115  9  upside  from  101 ,2016-11-17,Seeking Alpha,https://www.investing.com/news/stock-market-news/leerink-agrees-that-incyte-an-attractive-buyout-target-441979,441979
200963,422479,GILD,GlobeImmune shakes up management after Gilead returns GS 4774  shares down 32 ,news,Thinly traded nano cap GlobeImmune  GBIM  32 4   slumps on increased volume in the news that Gilead Sciences  GILD  1 4   has returned HBV therapeutic vaccine candidate GS 4774 to the company It also announced changes in executive management  CEO Timothy Rodell has resigned  but remains a board member  C  Jeffery Dekker has been appointed President  Secretary and Treasurer and has been named to the board and board members J  William Freytag  Augustine Lawlor  Dan Mitchell and S  Edward Torres have resigned And finally  the company has terminated its lease for the 40K square feet of office space that served as its headquarters  laboratory and manufacturing site In July  GlobeImmune filed for voluntary delisting from the Nasdaq Capital Market ,2016-11-18,Seeking Alpha,https://www.investing.com/news/stock-market-news/globeimmune-shakes-up-management-after-gilead-returns-gs-4774;-shares-down-32-442373,442373
200964,422480,GILD,U S  health spending in 2015 rose at fastest rate since 2007,news,By Toni Clarke  Reuters    U S  health spending in 2015 rose at its fastest rate since 2007  driven by expanded access to insurance under the Affordable Care Act and high priced specialty drugs  according to government figures released on Friday  Growth rose 5 8 percent to  3 2 trillion  or  9 990 per person  according to federal data published in the independent journal Health Affairs and compiled into a report by officials with the Centers for Medicare and Medicaid Services  After five years of historically low growth between 2009 and 2013  spending picked up in 2014 and 2015 as the Affordable Care Act   sometimes referred to as Obamacare   expanded health insurance coverage through marketplace insurance plans and Medicaid  the report said  Over the two year period between 2013 and 2015 the number of people with private health insurance rose 2 5 percent on average to 9 7 million  The number of people who enrolled in Medicaid rose on average 8 4 percent to 10 3 million   The health sector experienced dramatic changes in 2014 and 2015  as the main coverage provisions of the ACA were implemented   according to the report   Over those two years the insured share of the population increased 4 9 percentage points and reached 90 9 percent   For the first time the federal government became the largest sponsor of healthcare  the report said  Its share of health spending rose to 29 percent in 2015 from 28 percent in 2014 and 26 percent in 2013   Federal health spending growth in 2015 remained high mainly because of the continuation of enrollment increases in Medicaid  as newly eligible adults are fully financed by the federal government   the report said   Federal Medicaid payments  which accounted for 37 percent of total federal health spending  increased 12 6 percent in 2015   Healthcare spending as a percentage of gross domestic product rose to 17 8 percent from 17 2 percent  driven by increases in the use of healthcare services and the high cost of prescription drugs such as Gilead Sciences Inc s  O GILD  hepatitis C drugs Sovaldi and Harvoni which in 2015 generated combined sales of nearly  20 billion  Spending for private health insurance rose 7 2 percent in 2015 to  1 1 trillion  accounting for a third of the total  Medicare spending rose 4 5 percent to  646 2 billion  or 20 percent of the total  and Medicaid spending rose 9 7 percent to  545 1 billion  or 17 percent of the total ,2016-12-02,Reuters,https://www.investing.com/news/stock-market-news/u.s.-health-spending-in-2015-rose-at-fastest-rate-since-2007-445327,445327
200970,422486,GILD,Trevena  TRVN  To Post Q1 Earnings  What Awaits The Stock ,opinion,Investor focus will be on Trevena  Inc  s   NASDAQ TRVN   efforts to support the development of its pain therapy  oliceridine injection  when the company reports first quarter 2019 earnings Trevena s performance over the last four quarters has been encouraging so far with the company s earnings surpassing expectations thrice and missing the mark just once  The average positive surprise over the trailing four quarters is 3 38   In the last reported quarter  Trevena came up with a negative earnings surprise of 66 67  Shares of Trevena have skyrocketed 239 5  in the year so far  outperforming the  increase of 2 2  Let s see how things are shaping up for the upcoming quarterly results Factors to ConsiderTrevena s top line mainly consists of license and collaboration revenues associated with the licensing agreements for oliceridine  The company has been working diligently on the development of its pain therapy candidate  oliceridine injection Oliceridine is an opioid based analgesic administered intravenous and also a G protein biased ligand of the mu receptor  which is being developed for managing moderate to severe acute pain In January this year  Trevena announced the receipt of the Type A meeting minutes from the FDA with respect to the oliceridine complete response letter  CRL   issued last November  Following this  the regulatory agency agreed with the current safety database and will support labeling at a maximum daily dose of 27 mg  Post this feedback  Trevena submitted a detailed protocol and an analysis plan to the FDA  planning to initiate a study in the first half of 2019 and a path forward to resubmit the oliceridine NDA We expect management to provide an update on the same during the upcoming investors  call Meanwhile  Trevena is also developing two G protein biased ligand candidates   TRV250 as a non narcotic treatment for migraine and a partnership with the National Institute on Drug Abuse  NIDA  for TRV734   to treat moderate to severe acute and chronic pain  Both candidates are in early stage development In the fourth quarter of 2018  Trevena unveiled its candidate TRV045   a novel S1P modulator   which is under evaluation for the non opioid treatment of chronic pain  The company plans to file an investigational new drug application on the product this year We expect investors  focus to be on the company s pipeline progress during the upcoming earnings call Earnings WhispersOur proven model does not conclusively show that Trevena is likely to beat on earnings this reporting cycle  This is because the stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here as you will see below Earnings ESP  Trevena has an Earnings ESP of 0 00   This is because the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of 9 cents each  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Trevena sports a Zacks Rank of 1  which increases the predictive power of ESP  However  a 0 00  ESP in the combination makes surprise prediction difficult for the stock this earnings season We caution against Sell rated stocks   4 or 5  going into an earnings announcement  especially when the company is seeing negative estimate revisions Trevena  Inc  Price and EPS Surprise   Stocks That Warrant a LookHere are a few health care stocks worth considering as our model shows that these have the right mix of elements to beat estimates this time around Aduro Biotech  Inc    NASDAQ ADRO   has a Zacks Rank  2 and an Earnings ESP of  82 00   You can see  Incyte Corporation   NASDAQ INCY   has an Earnings ESP of  14 47  and a Zacks Rank of 1  The company is scheduled to release first quarter results on Apr 30  before the market opens Gilead Sciences  Inc    NASDAQ GILD   has a Zacks Rank of 2 and an Earnings ESP of  1 37   The company is scheduled to release first quarter results on May 2  after the market closes Will you retire a millionaire One out of every six people retires a multimillionaire  Get smart tips you can do today to become one of them in a new Special Report   7 Things You Can Do Now to Retire a Multimillionaire  ,2019-04-23,Zacks Investment Research,https://www.investing.com/analysis/trevena-trvn-to-post-q1-earnings-what-awaits-the-stock-200410338,200410338
200971,422487,GILD,GILD Vs  ALKS  Which Stock Is The Better Value Option ,opinion,"Investors interested in stocks from the Medical   Biomedical and Genetics sector have probably already heard of Gilead Sciences  NASDAQ GILD  and Alkermes  ALKS   But which of these two companies is the best option for those looking for undervalued stocks  Let s take a closer look 
There are plenty of strategies for discovering value stocks  but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns  The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions  while our Style Scores work to identify stocks with specific traits 
Both Gilead Sciences and Alkermes have a Zacks Rank of   2  Buy  right now  The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates  so investors should rest assured that both of these companies have improving earnings outlooks  But this is just one piece of the puzzle for value investors 
Value investors also tend to look at a number of traditional  tried and true figures to help them find stocks that they believe are undervalued at their current share price levels 
The Style Score Value grade factors in a variety of key fundamental metrics  including the popular P E ratio  P S ratio  earnings yield  cash flow per share  and a number of other key stats that are commonly used by value investors 
GILD currently has a forward P E ratio of 9 45  while ALKS has a forward P E of 95 86  We also note that GILD has a PEG ratio of 0 93  This popular figure is similar to the widely used P E ratio  but the PEG ratio also considers a company s expected EPS growth rate  ALKS currently has a PEG ratio of 3 42 
Another notable valuation metric for GILD is its P B ratio of 3 77  Investors use the P B ratio to look at a stock s market value versus its book value  which is defined as total assets minus total liabilities  By comparison  ALKS has a P B of 4 61 
Based on these metrics and many more  GILD holds a Value grade of A  while ALKS has a Value grade of D 
Both GILD and ALKS are impressive stocks with solid earnings outlooks  but based on these valuation figures  we feel that GILD is the superior value option right now ",2019-04-24,Zacks Investment Research,https://www.investing.com/analysis/gild-vs-alks-which-stock-is-the-better-value-option-200410835,200410835
200972,422488,GILD,Gilead Sciences  GILD  Reports Next Week  Wall Street Expects Earnings Growth,opinion,"Wall Street expects a year over year increase in earnings on higher revenues when Gilead Sciences  NASDAQ GILD  reports results for the quarter ended March 2019  While this widely known consensus outlook is important in gauging the company s earnings picture  a powerful factor that could impact its near term stock price is how the actual results compare to these estimates 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on May 2  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This HIV and hepatitis C drugmaker is expected to post quarterly earnings of  1 61 per share in its upcoming report  which represents a year over year change of  8 8  
Revenues are expected to be  5 34 billion  up 4 9  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 64  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Gilead 
For Gilead  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  1 37  
On the other hand  the stock currently carries a Zacks Rank of  2 
So  this combination indicates that Gilead will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Gilead would post earnings of  1 70 per share when it actually produced earnings of  1 44  delivering a surprise of  15 29  
Over the last four quarters  the company has beaten consensus EPS estimates two times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Gilead appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-04-24,Zacks Investment Research,https://www.investing.com/analysis/gilead-sciences-gild-reports-next-week-wall-street-expects-earnings-growth-200410971,200410971
200973,422489,GILD,Is A Beat In Store For Glaxo  GSK  This Earnings Season ,opinion,"We expect GlaxoSmithKline plc   NYSE GSK   to beat expectations when it reports first quarter 2019 results on May 1  before market open  In the last reported quarter  the company delivered a positive earnings surprise of 12 86  Shares of Glaxo have increased 5 3  so far this year against the  s decrease of 2 6  Glaxo s earnings performance has been mixed so far  The company s earnings surpassed estimates in two of the trailing four quarters and missed the same twice with the average positive beat being 3 74  Let s see how things are shaping up for this quarter Factors to ConsiderSales in Glaxo s Pharmaceuticals segment are expected to be driven by solid sales of new HIV products  Tivicay and Triumeq  Strong uptake of the company s latest product from the HIV portfolio  Juluca  is expected to continue in the first quarter of 2019  However  sales of other HIV drugs  Epzicom Kivexa are likely to decline due to more severe generic competition  particularly inthe European market In late March  the company announced that its Respiratory category will only include sales of Ellipta products and Nucala  Sales of older respiratory products  namely Seretide Advair will be included in the Established Pharmaceuticals category from the first quarter Ellipta products have shown strong growth trend  which is likely to continue in the soon to be reported quarter  A label expansion of TrelegyEllipta approved in November last year is expected to have a positive impact on its sales  International launches and U S  market expansion for Nucala is expected to drive sales in the first quarter  However  growth in Nucala sales may slow down due to a rise in competition which has affected sales in the previous quarter  Meanwhile  older respiratory products are facing generic competition  which will likely hurt sales in the quarter Growth trend for Glaxo s immuno inflammation drugs like Benlysta isexpected to continue in the first quarter The Vaccines segment is likely to consistently benefit from sustained uptake of its successful shingles vaccine  Shingrix  Meningitis vaccines like Bexsero and Menveo  acquired from Novartis AG   NYSE NVS   enjoyed strong demand in 2018  However  Menveo faced supply constraints in European and International markets in the last reported quarter  We expect demand for these vaccines to remain strong while supply constraints may partially offset growth In Consumer Healthcare segment  sales are likely to be driven by Oral health  Wellness and Nutrition products  However  rising competition in Europe and declining sales of the Skin health category will have a negative impact The launch of a generic version of Advair and costs related to the acquisition of TESARO is likely to hurt margins in the first quarter of 2019 Key Developments in Q1In January  the company completed its acquisition of TESARO  adding the latter s PARP inhibitor  Zejula  to its oncology portfolio We expect Glaxo to provide updates on synergies related to Zejula s integration into the company s portfolio and pending divestiture of its Horlicks and other nutrition products in certain geographies  Investors may ask questions on the company s path forward for its new joint venture with Pfizer  NYSE PFE   which will create the world s largest consumer healthcare business Earnings WhispersOur proven model indicates that Glaxo is likely to beat earnings estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Earnings ESP  Earnings ESP  which represents the difference between the Most Accurate Estimate  68 cents  and the Zacks Consensus Estimate  66 cents   stands at  3 55   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Glaxo has a Zacks Rank  3  The combination of a positive Earnings ESP and a favorable Zacks Rank makes us reasonably confident of an earnings beat Conversely  we caution against the Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions GlaxoSmithKline plc Price and Consensus
 

   Other Stocks to ConsiderHere are some biotech stocks that you may also want to consider  as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases Incyte Corporation   NASDAQ INCY   has an Earnings ESP of  14 47  and a Zacks Rank  1  The company is scheduled to release first quarter results on Apr 30 Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  0 98  and a Zacks Rank  2  The company is scheduled to release first quarter results on May 2 Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-04-26,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-store-for-glaxo-gsk-this-earnings-season-200411866,200411866
200974,422490,GILD,Will HIV Franchise Sales Drive Gilead s  GILD  Q1 Earnings ,opinion,"Biotech major Gilead Sciences Inc    NASDAQ GILD   is slated to report first quarter results on May 2  after the market closes 
Gilead has a mixed track record  with earnings beating estimates in two of the last four quarters  Overall  the company delivered an average positive earnings surprise of 1 99   In the last reported quarter  the company s earnings missed expectations by 15 3  
Gilead s stock has gained 4 2  in the year so far compared with the  s growth of 4 5  

 
Why a Likely Positive Surprise 
Our proven model indicates that Gilead is likely to beat on earnings this quarter  as it has the right combination of two key ingredients   a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    to be able to beat estimates 
Earnings ESP  Earnings ESP for Gilead is  1 37    The Zacks Consensus Estimate is pegged at  1 61  while the Most Accurate Estimate is pegged at  1 63  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Gilead currently carries a Zacks Rank  2  which when combined with a positive ESP makes us confident of an earnings beat 
Note  we caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Factors Likely to Impact Q1
For the first quarter of 2019  Gilead expects product sales to decline 12 14  sequentially  primarily owing to the U S  seasonal inventory patterns and buying patterns of public payers that negatively impact payer mix 
While the company s revenues in the last reported quarter beat estimates  the year over year decline was disappointing as the magnitude of decline in hepatitis C virus  HCV  sales continued to deepen 
Nevertheless  the HIV franchise is expected to maintain momentum  Strong HIV performance and other antiviral product sales are being driven by continued uptake of tenofovir alafenamide   TAF   based products   Genvoya  Descovy and Odefsey  We expect the trend to continue in the first quarter as well  Genvoya has been listed as a preferred regimen in several HIV treatment guidelines 
Truvada  for use in the pre exposure prophylaxis setting  continued to maintain momentum with an estimated 202 000 patients using the drug by the end of the fourth quarter  We expect the momentum to continue in the first quarter  The Zacks Consensus Estimate for sales of Genvoya and Descovy are projected at  1 2 billion and  408 million 
The FDA approval of Gilead s once daily single tablet regimen   STR    Biktarvy  bictegravir 50mg emtricitabine 200mg tenofovir alafenamide 25mg  BIC FTC TAF  for HIV 1 infection has boosted the portfolio   This is expected to drive sales in the first quarter 
Apart from the regular top and bottom line numbers in the to be reported quarter  we expect investors to focus on pipeline updates  The company also submitted a supplemental New Drug Application  sNDA  to the FDA for Descovy as pre exposure prophylaxis  PrEP  to reduce the risk of sexually acquired HIV 1 infection among individuals  who are HIV negative and at risk for HIV 
Gilead intends to foray into the non alcoholic steatohepatitis  NASH  and inflammation market with late stage candidates  selonsertib and filgotinib  respectively  However  the company suffered a setback with the failure of a late stage study on NASH candidate  selonsertib 
Earlier in the month  the company announced a strategic collaboration with a privately held  data driven company  Insitro  for discovering and developing therapies targeting NASH  In addition  Gilead and Denmark based pharma giant Novo Nordisk  CO NOVOb  A S   NYSE NVO   announced that both the companies intend to collaborate to develop treatments for NASH 
Moreover  the company and partner Galapagos NV announced encouraging interim safety information from four studies on experimental candidate  filgotinib  for the treatment of rheumatoid arthritis  RA  
Other Stocks to Consider
Here are some health care stocks you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter 
Incyte Corp    NASDAQ INCY   has an Earnings ESP of  14 47  and a Zacks Rank of 1  The company is scheduled to release first quarter results on Apr 30  before the market opens  You can see  
GlaxoSmithKline plc   NYSE GSK   is scheduled to release results on May 1  The company has an Earnings ESP of  3 55  and a Zacks Rank  3 
Zacks  Top 10 Stocks for 2019
In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year 
Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-04-26,Zacks Investment Research,https://www.investing.com/analysis/will-hiv-franchise-sales-drive-gileads-gild-q1-earnings-200411899,200411899
200975,422491,GILD,Sangamo  SGMO  Q1 Earnings  What s In Store For The Stock ,opinion,Sangamo Therapeutics  Inc    NASDAQ SGMO   will report first quarter 2019 earnings results The company s performance over the last four quarters has been disappointing so far with two earnings miss  one beat and an in line result on another count  The average negative surprise over the trailing four quarters is 46 85   In the last reported quarter  Sangamo delivered a positive surprise of 5 26  Shares of Sangamo have risen 5 3  so far this year  outperforming the  increase of 5  Let s see  how things are shaping up for this announcement Factors to ConsiderWith no approved product in its portfolio at the moment  Sangamo primarily generates collaboration revenues from agreements with Pfizer   NYSE PFE    Kite Pharma   a subsidiary of Gilead   and Bioverativ  a unit of Sanofi  PA SASY   During the upcoming conference call  investor focus will be on the company s update pertaining to its main pipeline candidates Sangamo  in partnership with Pfizer is developing SB 525  its gene therapy product candidate in the phase I II Alta study for hemophilia A  Earlier this month  the companies announced encouraging interim data from the program  which showed the gene therapy candidate to hold potential Meanwhile  Sangamo s investigational new drug  IND  application for ST 920  a gene therapy candidate  was accepted by the FDA and the company plans to initiate a phase I II analysis on the same for the treatment of Fabry disease later this year Sangamo s zinc finger nuclease  ZFN  in vivo genome editing candidate  SB 913  is currently being evaluated in a phase I II CHAMPIONS study for Mucopolysaccharidosis Type II  MPS II   In February this year  the company presented interim results from the study on SB 913 at a medical conference  Additional data from the investigation is awaited later this year  which will help explain if the small increases in IDS enzyme activity observed can translate to improved outcomes in MPS II patients Another similar candidate  SB 318  is currently being examined in a phase I II EMPOWERS program for addressing MPS I  Sangamo expects to report longer term safety and biochemical measurements on the candidate any time this year The company is evaluating SB FIX  an investigational in vivo genome editing therapy in a phase I II study  for treating patients with hemophilia B  It expects to report safety data from the probe later this year Last October  Sangamo closed the previously announced acquisition of France s TxCell S A  The company plans to submit a clinical trial authorization application  CTA  in Europe this year for TxCell s first CAR Treg investigational product candidate regarding solid organ transplant and activate clinical sites by this year end Sangamo in collaboration with Sanofi is developing ST 400 and BIVV003  its gene edited cell therapies for the treatment of beta thalassemia and sickle cell disease  respectively  Earlier this April  the company announced promising early results from the phase I II THALES study on ST 400 We expect management to provide an update on the same during the upcoming conference call Earnings WhispersThe proven Zacks model does not conclusively show that Sangamo is likely to beat estimates this to be reported quarter  This is because a stock needs to have both a positive  and a top Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here as you will see below Earnings ESP  Sangamo has an Earnings ESP of 0 00   This is because both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of 27 cents each  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Sangamo currently carries a Zacks Rank  3  which increases the predictive power of ESP  However  the company s 0 00  ESP in the combination makes surprise prediction difficult for the stock this reporting cycle We caution against Sell rated stocks   4 or 5  going into an earnings announcement  especially when the company is seeing negative estimate revisions Sangamo Therapeutics  Inc  Price and EPS Surprise   Stocks That Warrant a LookHere are a few health care stocks worth considering as our model shows that these have the right mix of elements to beat estimates this time around Aduro Biotech  Inc    NASDAQ ADRO   has a Zacks Rank  2 and an Earnings ESP of  82 00   You can see  Gilead Sciences  Inc    NASDAQ GILD   has a Zacks Rank of 2 and an Earnings ESP of  1 54   The company is scheduled to release first quarter results on May 2  after the market closes Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-04-28,Zacks Investment Research,https://www.investing.com/analysis/sangamo-sgmo-q1-earnings-whats-in-store-for-the-stock-200412535,200412535
200992,422508,GILD,Gilead  Mizuho starts at Buy,news,Mizuho initiates Gilead  NASDAQ GILD  at Buy  PT of  88  Implied upside 19   While Gilead is no longer a favorite among biotech investors and has lost much of its fan club  we like the stock on valuation  Not yet a  table pounding  buy  but believes GILD will execute over long term to the benefit of its investors ,2016-11-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/gilead:-mizuho-starts-at-buy-438507,438507
200993,422509,GILD,FDA OKs Gilead s TAF for HBV,news,The FDA approves Gilead Sciences   GILD  1 2   Vemlidy  tenofovir alafenamide  TAF  25 mg for the treatment of adults with chronic hepatitis B virus  HBV  infection with compensated liver disease  The agency s action date  PDUFA  was November 11 TAF has similar efficacy to TDF  Viread  tenofovir disoproxil fumarate   but at 1 10 the dose so it is less stressful on the kidneys and bones ,2016-11-10,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-gilead's-taf-for-hbv-439681,439681
200994,422510,GILD,European advisory committee backs Gilead s TAF for HBV,news,The European Medicines Agency s Committee for Medicinal Products for Human Use  CHMP  adopts a positive opinion recommending approval of Gilead Sciences   NASDAQ GILD  Vemlidy  tenofovir alafenamide  TAF  25 mg for the treatment of adults and adolescents  at least 12 years old and 35 kg body weight  with chronic hepatitis B virus  HBV  infection  The data in the application supports the use of Vemlidy in treatment naive and treatment experienced adults and adolescents who are e antigen  HBeAg  positive and HBeAg negative A final decision from the European Commission usually takes  60 days Vemlidy was OK d in the U S  yesterday for use in adults ,2016-11-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/european-advisory-committee-backs-gilead's-taf-for-hbv-439954,439954
200998,422514,GILD,Intercept Reports Additional Positive Data From NASH Study,opinion,Intercept Pharmaceuticals  Inc    NASDAQ ICPT   announced positive additional supportive data from its pivotal phase III REGENERATE study of obeticholic acid  OCA  in patients with liver fibrosis due to nonalcoholic steatohepatitis  NASH   NASH is a serious progressive liver disease caused by excessive fat accumulation in the liver known as steatosis Shares of the company have rallied 19 7  in the past year compared with the  s growth of 11 4  The additional supportive efficacy analyses were conducted in patients who completed greater than or equal to 15 months of treatment  had a month 18 end of treatment biopsy  were on investigational product for at least 30 days immediately preceding the biopsy  and did not have any major protocol deviations The additional supportive efficacy analyses showed that about three fold more patients in the OCA 25 mg group achieved an improvement of fibrosis by  2 stages compared to placebo  In an analysis of changes in fibrosis by  1 stage  about three fold more patients in the OCA 25 mg group  38   improved versus worsened  13 1    However  in the placebo group  a similar proportion of patients improved  23 2   versus worsened  20 9    OCA showed significant improvement in patients with liver fibrosis due to NASH  and demonstrated consistent efficacy across multiple histologic and biochemical parameters In the primary efficacy analysis  as previously reported  once daily OCA 25 mg met the primary endpoint of fibrosis improvement   1 stage  without any worsening signs of NASH during the planned 18 month interim analysis  Moreover  a greater proportion of patients under both OCA treatment arms compared with placebo achieved the primary endpoint of NASH resolution  with no deterioration of liver fibrosis noticed  even though the evaluation did not reach any statistical significance Notably  REGENERATE is the largest ongoing phase III study  involving more than 2000 patients with fibrosis due to NASH The market for NASH promises potential and is expected to be one of the target areas in 2019 for most large pharma biotech companies  This market is poised to witness rapid growth unlike other lucrative yet saturated markets like cancer  Pharma giant Merck   NYSE MRK    in January 2019  exercised its option to license NGM313  an investigational monoclonal antibody agonist of the   Klotho FGFR1c receptor complex that is currently being evaluated for the treatment of NASH and type II diabetes Biotech bigwig Gilead Sciences  Inc    NASDAQ GILD   entered into a licensing and collaboration agreement with South Korea based Yuhan Corporation to co develop novel therapeutic candidates for the treatment of patients suffering from advanced fibrosis due to NASH Another Swiss pharma company  Novartis AG   NYSE NVS    entered into a clinical development agreement with Pfizer  NYSE PFE  in 2018  The agreement includes a clinical trial to evaluate the combination of tropifexor  LJN452  and one or more Pfizer compounds for the treatment of NASH  Intercept Pharmaceuticals  Inc  Price    Zacks RankIntercept Pharmaceuticals currently carries a Zacks Rank  3  Hold   You can see  Breakout Biotech Stocks with Triple Digit Profit Potential The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-04-10,Zacks Investment Research,https://www.investing.com/analysis/intercept-reports-additional-positive-data-from-nash-study-200406004,200406004
200999,422515,GILD,Gilead Sciences  Value Buy Or Trap ,opinion,"Gilead Sciences  NASDAQ  NASDAQ GILD  is a biopharmaceutical company  The company had given stellar returns to the investors when the Hepatitis C drug sales were growing  Once the generics entered the market the sales dropped and also the stock took a hit  However  earnings are expected to turn around in the next couple of years  So the stock is once again in the radar of value investors 
The company announced recently that Daniel O Day will be the new CEO of the company  He is the former CEO of Roche Pharmaceuticals  The company s chairman of the board of directors John Martin also stepped down this year  Investors are hoping that the new management could drive the company in the right direction 
During the last quarter s results revenue came at  5 8 billion  which beat the median analyst estimates by  280 million  Total revenue for 2018 came at  22 13 billion when compared to  26 10 billion for 2017  Earnings per share for the 4Q 2018 came at  1 44  For the full year  2018 earnings per share came at  6 67 compared to  8 84 for 2017  For the year 2019 analysts expect the EPS to come at  6 63 
The company has approximately  31 5 billion in cash and cash equivalents  Debt at the end of December 2018 stands at  27 50 billion  down from  33 75 billion at the end of December 2017 
The dividend yield is attractive at 3 74   The company also repurchased shares worth of  962 million in the fourth quarter of 2018 
Gilead is trying hard to lower the operating expenses  Recently  the company announced that it s laying off 150 sales which account of 20  of the total sales team  Two of the company s older drugs have lost patent protection  generics would enter the market 
UBS analyst Carter Gould upgraded the stock from Neutral to buy recently and raised the price target from  75 to  77   Following the failure of selonsertib in NASH  Gilead has rattled off two important clinical wins  positive Descovy PrEP data and filgotinib FINCH1 3 data   unlocking two  2 billion plus revenue opportunities and going far to derisk outer year  2021   growth   the analyst said 
In addition to lower than expected costs in 2019  Gould said Biktarvy Truvada demand trends have been strong  UBS raised its full year 2019 EPS estimate from  6 73 to  6 85 
The company has a strong product portfolio and also a good pipeline  GS 6207 which is currently in Phase 1 clinical studies could be a blockbuster drug for the company  RBC analyst Brian Abrahams estimates that the net present value of GS 6207 is more than  20 billion  The appeal of GS 6207 is that it could become the backbone of long acting combination HIV therapies 
For the year 2019  the product revenue guidance is  21 3 billion to  21 8 billion compared to  21 0 billion for 2018  The company could also taste success in Oncology and not to mention there are other several promising therapies due to the acquisition of Kite Pharma in 2017 
Conclusion  The Company is trading at an attractive forward P E ratio of 9 72  However  the company has been trading at a lower valuation in the past couple of years  Investors need to take note that the company has a strong pipeline for the next few years and with the new management we could see some positive action in the second half of 2019 
Original post",2019-04-12,Modest Money,https://www.investing.com/analysis/gilead-sciences-is-a-value-buy-or-a-trap-200406170,200406170
201000,422516,GILD,Why Is Agenus  AGEN  Down 13  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Agenus  AGEN   Shares have lost about 13  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Agenus due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  
Agenus Q4 Loss Wider Than Expected  Pipeline in Focus
Agenus reported fourth quarter 2018 loss of 40 cents per share  wider than the Zacks Consensus Estimate of a loss of 28 cents and the year ago loss of 35 cents 
The company generated revenues of  6 5 million  which includes non cash royalties earned  compared with  8 4 million in the year ago quarter  Revenues missed the Zacks Consensus Estimate of  7 million 
Quarterly Highlights
Research and development  R D  expenses increased 13 1  to  36 million  General and administrative expenses decreased 0 6  to  9 7 million 
Pipeline Update
Agenus is a clinical stage immuno oncology company with a comprehensive portfolio  consisting of antibody based therapeutics  adjuvants and cancer vaccine platforms 
In December 2018  Agenus inked a collaboration deal with Gilead Sciences  NASDAQ GILD  to develop and commercialize up to five immuno oncology  I O  therapies  In January 2019  Agenus announced the closing of its I O partnership deal with Gilead  Agenus recently received  7 5 million in cash as milestone payment from Gilead  after the FDA accepted the former s investigational new drug  IND  application for AGEN1423  AGEN1423 is a first in class molecule  currently developed in partnership with Gilead as a potential treatment for cancer  Agenus is also eligible to receive additional milestones from Gilead in the days ahead 
Agenus has filed the IND for AGEN1223  The company also has an IND submission planned for AGEN2373 in the first half of 2019  Agenus will be responsible for developing the option studies up to the option decision points  during which Gilead may acquire the exclusive rights to the programs on option exercise 
Lead clinical stage antibodies  CTLA 4 and PD 1 are progressing well  The company intends to file for accelerated approval by 2020 
2018 Results
The company reported a net loss  1 44 per share in 2018 compared with a net loss of  1 23 in 2017  The increase reflects reduced revenues during 2018 due to an accelerated milestone received during 2017 from Incyte  NASDAQ INCY  that went missing in 2018  Revenues were also negatively impacted by loss incurred in 2018 on early extinguishment of debt and increased non cash interest on the company s liability related to the sale of future royalties 
Revenues decreased 14 9  year over year to  19 5 million in 2018 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates  The consensus estimate has shifted 7 35  due to these changes 
VGM Scores
At this time  Agenus has a poor Growth Score of F  however its Momentum Score is doing a lot better with an A  However  the stock was allocated a grade of F on the value side  putting it in the bottom 20  quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of this revision looks promising  Notably  Agenus has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-04-12,Zacks Investment Research,https://www.investing.com/analysis/why-is-agenus-agen-down-13-since-last-earnings-report-200406497,200406497
201018,422534,GILD,Gilead Sciences names Kevin Young as new Chief Operating Officer,news,"Investing com     Gilead Sciences Inc   NASDAQ GILD  announced a host of changes to its executive management structure on Tuesday  including the appointment of Kevin Young as the company s Chief Operating Officer  welcoming back the longtime executive to its senior leadership team after a two year departure 
Young  57  spent more than 10 years with the California based drug maker from September  2004 through February  2014  before spending the last two years as a senior advisor to the company  Previously  Young headed the company s U S  inflammations division and spearheaded Gilead s re launch of its rheumatoid arthritis drug Enbrel upon the completion of its acquisition of Immunex  In his new role  Young will assume responsibility for the company s worldwide commercial organization  and facilities and operations  Gilead Sciences said in a statement 
 I am delighted to welcome Kevin back to Gilead in a full time capacity  His contributions during his previous tenure  particularly his management of the introduction of eight novel therapies across diverse geographies  made a tremendous impact on the company  I have equally valued his continued engagement and significant contributions as an advisor to Gilead over the past two years   said Dr  John F  Milligan  President and Chief Executive Officer  Gilead Sciences   Kevin s knowledge of Gilead s business  all aspects of commercial operations and our therapeutic areas of focus  his commitment to operational excellence  and his leadership capabilities make him an obvious choice for the role of Chief Operating Officer  
Separately  Gilead announced on Tuesday that Dr  Martin Silverstein has been appointed as the company s Executive Vice President  Strategy and that Paul Carter  Executive Vice President  Commercial Operations will step down from his position to pursue other opportunities  Silverstein  who previously served as Chief Strategy Officer at Anthem  will oversee Gilead s corporate development  commercial planning and alliance management functions  Gilead said 
 I m very pleased to welcome Marty to the Gilead team   Milligan added   His vast expertise in the healthcare sector  across biopharmaceuticals  pharmacy benefit management  health insurance and healthcare delivery  will be of great value to Gilead as we see the complexity of our business increase around the world  
Gilead shares inched up 0 22 or 0 26  to 86 44 in after hours trading  In the regular session  Gilead closed at 86 22  up 2 89 or 3 47  ",2016-05-24,Investing.com,https://www.investing.com/news/stock-market-news/gilead-sciences-names-kevin-young-as-new-chief-operating-officer-404239,404239
201019,422535,GILD,European stocks open higher after Yellen comments  Dax rallies 1 51 ,news,"Investing com   European stocks opened higher on Tuesday  after Federal Reserve Chair Janet Yellen gave no indications on the timing of future interest rate hikes and as higher oil prices continued to support 
During European morning trade  the EURO STOXX 50 jumped 1 19   France s CAC 40 advanced 1 05   while Germany s DAX 30 rallied 1 51  
Speaking at an event in Philadelphia on Monday  Yellen said she was optimistic about the overall U S  economic outlook and warning markets against overreacting to the disappointing U S  nonfarm payrolls report released on Friday 
The Fed Chair also said the central bank plans to raise interest rates  but gave no time frame for those hikes 
Meanwhile  oil prices remained higher after rallying on Monday  helped by supply disruptions in Nigeria 
Energy stocks were broadly higher  as French oil and gas major  Total  SA  PA TOTF  rallied 1 44  and Italy s  ENI   MI ENI  advanced 1 23   while Norwegian rival  Statoil   OL STL  climbed 0 89  
Financial stocks added to gains  as French lenders  BNP Paribas   PA BNPP  and  Societe Generale   PA SOGN  jumped 1 49  and 1 63   while Germany s Commerzbank  DE CBKG  and  Deutsche Bank   DE DBKGn  surged 1 39  and 255  
Among peripheral lenders  Italy s  Intesa Sanpaolo   MI ISP  and Unicredit  MI CRDI  soared 1 06  and 2 63  respectively  while Spanish banks BBVA  MC BBVA  and  Banco Santander   MC SAN  advanced 0 94  and 1 71  
Elsewhere  Merck  NYSE MRK  shares jumped 1 44  even after a U S  judge on Monday found a pattern of misconduct by the drugmaker  including lying under oath and other unethical practices 
The decision freed  Gilead Sciences Inc   NASDAQ GILD  from paying any damages for infringing the German company s patents with its lucrative treatments for hepatitis C  Sovaldi and Harvoni 
In London  commodity heavy FTSE 100 gained 0 71   boosted by gains in the mining sector 
Shares in  Glencore   LON GLEN  rallied 2 10  and  Anglo American   LON AAL  advanced 2 32   while BHP Billiton  LON BLT  and  Rio Tinto   LON RIO  surged 2 56  and 2 70  respectively 
Energy stocks added to gains  as  BP   LON BP  advanced 1 15  and rival Royal Dutch Shell  LON RDSa  soared 2 85  
Financial stocks werw also on the upside  with shares in  HSBC Holdings   LON HSBA  up 0 81  and the Royal Bank of Scotand rallying 1 12   while  Barclays   LON BARC  and Lloyds Banking  LON LLOY  jumped 1 30  and 1 38  respectively 
In the U S   equity markets pointed to a higher open  The Dow Jones Industrial Average futures pointed to a 0 33  rise  S P 500 futures a 0 31  gain  while the Nasdaq 100 futures indicated a 0 36  increase ",2016-06-07,Investing.com,https://www.investing.com/news/stock-market-news/european-stocks-open-higher-after-yellen-comments;-dax-rallies-1.51-406893,406893
201020,422536,GILD,Health spending in U S  to rise 5 8 percent a year through 2025  CMS,news,By Ransdell Pierson  Reuters    Healthcare spending in the United States will likely grow by an average 5 8 percent per year over the next decade  a bit faster than the past two years  due to an aging population  rising medical prices and faster economic growth  according to updated projections from the federal government released on Wednesday  The annual growth of health expenditures between 2015 and 2025 will be 1 3 percentage points faster than growth in gross domestic product  the Centers for Medicare and Medicaid Services  CMS  said in a report published in the independent journal  Health Affairs  The spending will represent 20 1 percent of the country s total economy by 2025  up from 17 5 percent in 2014  the report said  Health spending rose 2 9 percent in 2013  according to the study  but rose 5 3 percent in 2014 and is expected to have risen 5 5 percent in 2015 largely as a result of millions of Americans gaining insurance coverage in 2014 under the federal Affordable Care Act  popularly known as Obamacare  But overall U S  spending increases will be tempered beginning this year  the study said  as numbers of uninsured people enrolling in Medicaid and insurance plans offered by state insurance exchanges wane  About 8 percent of Americans are expected to be uninsured in 2025  down from about 11 percent in 2014  CMS auditors said in the report  Total health expenditures this year are expected to reach  3 2 trillion  rising to  5 6 trillion in 2025  Over the same decade  costs of hospital care are expected to jump 80 percent to  1 8 trillion  while spending on prescription drugs is seen rising 91 percent to  615 billion   There s uncertainty in a lot of our estimates  especially on prescription drug spending   Sean Keehan  a CMS economist and a lead author of the study  acknowledged in a media conference call on Wednesday  He said a single costly drug that is widely used  such as Gilead Sciences  NASDAQ GILD  Inc s two year old Sovaldi treatment for hepatitis C  can drive up overall spending on pharmaceuticals  Sovaldi  which costs  84 000 per course of treatment  and a more costly related Gilead treatment called Harvoni  together captured  4 3 billion in sales during the first quarter    The consensus is no new Sovaldi is coming out  in the near future  Keehan said  Several other drugmakers  however  including Bristol Myers Squibb and Merck  NYSE MRK    Co  have recently introduced immuno oncology treatments with list prices of about  150 000 per year  And other drugmakers aim to follow suit ,2016-07-13,Reuters,https://www.investing.com/news/stock-market-news/health-spending-in-u.s.-to-rise-5.8-percent-a-year-through-2025:-cms-414212,414212
201021,422537,GILD,Gilead Sciences Q2 EPS estimated at  3 02 on revenues of  7 83 bn ,news,Investing com   Gilead Sciences  NASDAQ GILD  Q2 EPS seen at  3 02 on revenues of  7 83 bn The U S  pharmaceutical is due to report second quarter earnings on Monday Gilead reported 2015 Q2 diluted EPS of  2 92 on revenues of  8 2 bn Gilead s blockbuster Hepatitis C treatments now face competition from AbbVie Gilead  shares closed Friday at  86 55  well off high of  123 37 in June 2014 ,2016-07-25,Investing.com,https://www.investing.com/news/stock-market-news/gilead-sciences-q2-eps-estimated-at-$3.02-on-revenues-of-$7.83-bn-416337,416337
201022,422538,GILD,Shares in Gilead Sciences plunge 3  amid disappointing Harvoni sales ,news,"Investing com    Shares in  Gilead Sciences Inc   NASDAQ GILD  fell sharply in after hours trading after sales in its popular Hepatitis C drug Harvoni tumbled 29  last quarter  dragging down company revenues overall 
Over the company s second quarter of 2016  which ended in late June  Harvoni sales plunged by nearly one third on a year over year basis to  2 56 billion  offset partially by a 5 2  gain in Solvadi revenues to  1 36 billion  At the same time Gilead said Epclusa  another Hepatitis C drug that was approved by the U S  Food and Drug Administration  FDA  last month  generated  64 million in revenues  Epclusa  which combines Solvadi with another drug called Velpatsvir  is the first drug to gain FDA clearance for all six forms of Hepatitis C  When the FDA approved Epclusa last month  Gilead priced the 12 week treatment at just under  75 000 per patient  By comparison  Solvadi and Harvoni are priced at  84 000 and  94 000 respectively 
Meanwhile  analysts expected to see Harvoni sales of  2 87 billion and sales of Solvadi of  1 19 billion for the quarter  In total  Gilead reported net profit of  3 5 billion or earnings per share of 2 58  On an adjusted per share basis  excluding acquisition and other related expenses  Gilead s earnings fell from 3 15 to 3 08  As revenues fell precipitously among Gilead s Hepatitis C drugs  overall product sales declined 5 8  to  7 65 billion 
Analysts expected to see product sales of  7 77 billion on adjusted per share earnings of 3 02 
Moving forward  Gilead reduced its annual product sales outlook from  30  31 billion to a range between  29 5 and  30 5 billion following the subdued quarter 
Shares in Gilead plunged 3 45 or 3 90  to 85 10 in after hours trading ",2016-07-25,Investing.com,https://www.investing.com/news/stock-market-news/shares-in-gilead-sciences-plunge-3-amid-disappointing-harvoni-sales-416495,416495
201025,422541,GILD,Bear Of The Day  Gilead Sciences  GILD ,opinion,"Gilead Sciences  NASDAQ GILD   GILD  is aresearch based biopharmaceutical company that discovers  develops and commercializes innovative medicines in areas of unmet medical need  The company s portfolio of products and pipeline of investigational drugs includes treatments for HIV AIDS  hepatitis C virus  HCV   liver diseases  cancer  inflammatory and respiratory diseases  and cardiovascular conditions 
Mixed Q4 Results
Adjusted earnings of  1 44 per share missed the Zacks Consensus Estimate and is down from  1 78 per reported in the year ago quarter 
Total revenues of  5 79 billion did beat our consensus but declined 2 6  year over year 
Gilead s HCV portfolio continued to weigh heavily on the company  with sales down almost 51  to  738 million  HCV sales also fell 18  from the previous quarter 
A bright spot for Gilead last quarter  however  was the company s strong performing HIV pipeline  Sales were up almost 21  year over year  with Biktarvy generating sales of  578 million during Q4  Gilead s TAF based HIV drugs also did well  and sales for Genvoya  Descovy  and Odefsy all saw double digit growth 
Falling EstimatesGilead Sciences  Inc  Price and Consensus   Analysts have since turned bearish on Gilead  with nine cutting estimates in the last 60 days for the current fiscal year  Earnings are expected to decline for the year  and the Zacks Consensus Estimate has dropped 22 cents during that same time period from  6 87 to  6 65 per share 
This sentiment has stretched into 2020  though the shifting tide hasn t been as dramatic  Our consensus estimate has dropped five cents in the past two months 
GILD is now a Zacks Rank  5  Strong Sell  
Shares of the biotech have only returned about 6 3  since January  In comparison  the S P 500 is up almost 14  year to date 
Looking Ahead
Gilead s revenue outlook for full year 2019 hit the biotech hard  and this lowered guidance indicates that this year may not generate the kind of growth investors have been hoping for  Additionally  generic versions of its cardiovascular drugs Letairis and Ranexa are set to enter the U S  market  which could negatively effect Gilead s results this year 
But  the company has a huge cash stockpile of  31 5 billion  and new CEO stepping in on May 1  Daniel O Day  He s coming from Roche Pharmaceuticals  and it will be interesting to see how he leads Gilead on its oncology focused journey 
If you re an investor interested in adding a biotech stock to your portfolio  consider Celgene Corp   CELG   Shares of Zacks Rank  1  Strong Buy  CELG  which is a company that develops treatments for cancer and immune inflammatory diseases  has gained about 42  since January 
Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-03-18,Zacks Investment Research,https://www.investing.com/analysis/bear-of-the-day-gilead-sciences-gild-200398615,200398615
201026,422542,GILD,Conatus  CNAT  Declines On Failure Of NASH Fibrosis Study ,opinion,"Shares of Conatus Pharmaceuticals Inc    NASDAQ CNAT   plunged 50 8  in after hours trading  after it announced disappointing top line results from the phase IIb ENCORE NF study 
Notably  shares of Conatus have plummeted 55 2  in the past six months compared with the  decline of 4 7  

 
Conatus is conducting three phase IIb ENCORE studies on emricasan for treating fibrosis or cirrhosis induced by nonalcoholic steatohepatitis  NASH   The programs are named ENCORE NF  for NASH fibrosis   ENCORE PH  for portal hypertension  and ENCORE LF  for liver function  
The randomized  double blind ENCORE NF study was initiated in the first quarter of 2016 in patients with biopsy confirmed NASH and liver fibrosis  The study enrolled and treated 318 patients with biopsy confirmed NASH Clinical Research Network  CRN  fibrosis stages F1 F3 at baseline 
Patients enrolled in the study were randomized 1 1 1 to receive 5 mg of emricasan  50 mg of emricasan  or placebo twice daily for 72 weeks  The trial was conducted at 87 U S  and EU sites 
The trial s primary endpoint was a  1 CRN fibrosis stage improvement without any worsening of steatohepatitis compared with placebo at week 72  However  the candidate did not meet its primary endpoint as it did not have the desired effect on these earlier stage NASH fibrosis patients 
Nevertheless  the candidate is also being evaluated in more advanced stage NASH cirrhosis patients  ENCORE LF is evaluating emricasan in approximately 210 patients with decompensated NASH cirrhosis  The trial was initiated in the second quarter of 2017 and is advancing toward an event driven analysis of clinical outcome results expected in mid 2019 
Conatus currently has a collaboration agreement with Swiss pharma giant  Novartis AG   NYSE NVS   for the development of emricasan 
The failure of the study is disappointing  given the potential in the NASH market  In December 2018  the ENCORE PH study also failed to meet the primary endpoint 
Earlier  biotech bigwig Gilead Sciences   NASDAQ GILD   also announced the failure of a late stage study on selonsertib  involving patients afflicted with compensated cirrhosis  F4  due to NASH  
Nevertheless  Intercept Pharmaceuticals  Inc    NASDAQ ICPT   seems to be winning this race  The company announced positive top line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH  Intercept stated that the primary endpoint of the study   fibrosis improvement without worsening of NASH at 18 months   was achieved with the 25 mg daily dose of OCA  The company plans to file for approval of OCA as a NASH treatment in the United States and Europe in the second half of 2019 
Zacks Rank
Conatus currently carries a Zacks Rank  3  Hold   You can see  
Breakout Biotech Stocks with Triple Digit Profit Potential
The biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases 
Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-03-22,Zacks Investment Research,https://www.investing.com/analysis/conatus-cnat-declines-on-failure-of-nash-fibrosis-study-200400375,200400375
201027,422543,GILD,Gilead   Galapagos Announce Positive Data On Arthritis Drug,opinion,"Gilead Sciences  Inc    NASDAQ GILD   and partner Galapagos NV   NASDAQ GLPG   announced encouraging interim safety information from four studies on experimental candidate  filgotinib for the treatment of rheumatoid arthritis  RA  These include 24 week results of the ongoing phase III FINCH 1  2  and 3 trials  and updated week 156 safety data from the phase IIb DARWIN 3 long term extension study in patients with RA The phase III study  FINCH 1 evaluated filgotinib in comparison with AbbVie  Inc    NYSE ABBV   s Humira or placebo on a stable background dose of methotrexate  MTX  in patients with prior inadequate response to methotrexate  The study achieved its primary endpoint for both doses of filgotinib  Filgotinib 100 mg and 200 mg doses demonstrated significantly higher ACR20 50 70 responses compared to placebo in patients with prior inadequate methotrexate response FINCH 3 evaluated filgotinib in combination with MTX and as monotherapy in MTX na ve patients  Filgotinib 100 mg and 200 mg when added to MTX demonstrated significantly higher ACR20 50 70 responses than methotrexate alone  The study achieved its primary endpoint  as higher percentage of patients achieved the primary endpoint of ACR20 response at week 24 for filgotinib 200 mg plus MTX and filgotinib 100 mg plus MTX compared with only MTX alone Meanwhile  DARWIN 3 is an ongoing multi center  open label  long term follow up safety and efficacy trial of filgotinib in subjects who completed either DARWIN 1 or DARWIN 2  The patients  739  enrolled in the study were suffering from moderate to severe RA and showed an inadequate response to MTX  The safety profile of the candidate was consistent with previous studies  We remind investors that both the companies entered into a global collaboration for the development and commercialization of filgotinib in inflammatory indications  The FINCH studies are among several clinical trials of filgotinib in inflammatory diseases  Apart from RA  the candidate is being evaluated in a phase II EQUATOR program in psoriatic arthritis  the TORTUGA study in ankylosing spondylitis  the DIVERSITY phase III program in Crohn s disease and the phase III SELECTION trial in ulcerative colitis The successful development and commercialization of the candidate will boost growth for Gilead  The stock has gained 2 8  in the year so far  lagging the s growth of 9 8   Given the persistent decline in HCV sales  the company is looking to HIV and newer avenues to boost its top line However  Gilead will have to generate substantial revenues from its HIV franchise to offset the HCV sales decline  This will be a challenging task for the company with stiff competition from the likes of GlaxoSmithKline  GSK  in the HIV market Gilead is intending to foray into the non alcoholic steatohepatitis  NASH  and inflammation markets with late stage candidates  selonsertib and filgotinib  respectively However  the company recently announced the failure of its late stage study on selonsertib  involving patients afflicted with compensated cirrhosis  F4  due to NASH Gilead also collaborated with Agneus   NASDAQ AGEN   for the development and commercialization of up to five novel immuno oncology therapies Zacks Rank
Gilead currently carries a Zacks Rank  5  Strong Sell   You can see   
Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-28,Zacks Investment Research,https://www.investing.com/analysis/gilead--galapagos-announce-positive-data-on-arthritis-drug-200402267,200402267
201028,422544,GILD,Gilead Files SNDA For Label Expansion Of HIV Therapy Descovy,opinion,"Gilead Sciences  Inc    NASDAQ GILD   announced the submission of a supplemental New Drug Application  sNDA  to the FDA for Descovy  emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets  
The company is seeking FDA approval for Descovy as pre exposure prophylaxis  PrEP  to reduce the risk of sexually acquired HIV 1 infection among individuals  who are HIV negative and at risk for HIV   While Descovy is already approved in combination with other antiretroviral agents for the treatment of HIV infection in patients weighing greater or equal to 25 kg  it is not indicated for PrEP yet 
A priority review voucher was submitted with the filing  Hence  the anticipated review time for the sNDA is expected to be six months 
The filing is based on the results of the phase III study  DISCOVER  which evaluated the safety and efficacy of Descovy compared to Truvada in men and transgender women  who sexually engage with men at high risk of contracting HIV infection   The results showed that Descovy achieved non inferiority to Truvada in study participants  who were at substantial and sustained risk of HIV acquisition 
Given the persistent decline in HCV sales  the company is looking to HIV and newer avenues to boost its top line 
The stock has gained 8 3  in the year so far  lagging the s growth of 12 2  

 
However  Gilead will have to generate substantial revenues from its HIV franchise to offset the HCV sales decline  This will be a challenging task for the company with stiff competition from the likes of GlaxoSmithKline   NYSE GSK   in the HIV market 
The company is intending to foray into the non alcoholic steatohepatitis  NASH  and inflammation markets with late stage candidates  selonsertib and filgotinib  respectively  Gilead and partner Galapagos NV   NASDAQ GLPG   announced encouraging interim safety information from four studies on filgotinib for the treatment of rheumatoid arthritis  RA  
However  the company recently announced the failure of its late stage study on selonsertib  involving patients afflicted with compensated cirrhosis  F4  due to NASH 
Gilead also collaborated with Agneus   NASDAQ AGEN   for the development and commercialization of up to five novel immuno oncology therapies 
Zacks Rank
Gilead currently carries a Zacks Rank  4  Sell   You can see  
 Is Your Investment Advisor Fumbling Your Financial Future 
See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-04-08,Zacks Investment Research,https://www.investing.com/analysis/gilead-files-snda-for-label-expansion-of-hiv-therapy-descovy-200404892,200404892
201036,422552,GILD,Seven  1 billion plus drugs seen reaching market in 2016,news,"LONDON  Reuters    Drug companies are likely to launch seven  blockbuster  drugs in 2016  each with  1 billion plus annual sales potential  led by new treatments for liver disease and HIV  according to a Thomson Reuters analysis  The assessment means the pharmaceuticals industry is on track for another productive year  although not as good as 2015  which saw the arrival of 11 new blockbusters  The two top hits of 2016 are tipped to be Intercept Pharmaceuticals   O ICPT  chronic liver disease drug obeticholic acid  with a consensus sales forecast of  2 6 billion in 2020  and Gilead Sciences   O GILD  new fixed dose HIV drug emtricitabine plus tenofovir alafenamide  on  2 0 billion  Other products expected to launch this year with forecast sales above  1 billion in 2020 include a new hepatitis C drug from Merck  N MRK  and a leukemia medicine from AbbVie  N ABBV   according to the annual  Drugs to Watch  report  
Two keenly awaited Roche  VX ROG  drugs  each with forecast sales of around  3 billion  are not on list because it is unclear if atezolizumab for cancer and ocrelizumab for multiple sclerosis will be commercially available this year or next ",2016-02-03,Reuters,https://www.investing.com/news/stock-market-news/seven-$1-billion-plus-drugs-seen-reaching-market-in-2016-383027,383027
201037,422553,GILD,Celgene  Gilead Sciences shares could rise 30 percent  Barron s,news,"NEW YORK  Reuters    The tumble in share prices for biotechnology stocks has created some buying opportunities  with drugmakers  Celgene Corp   O CELG  and Gilead Sciences  O GILD  poised for a 30 percent rise over the next year  Barron s said   Both companies currently rely on closely related medications for the bulk of their income  creating risk  but the potential for diversification either through developing new treatments or being bought out could provide substantial upside  the publication said   Celgene  which specializes in treatments for a blood plasma cell cancer called myeloma  could see double digit growth for its Revlimid drug for years to come  with significant growth potential from overseas  Barron s said   Despite negative publicity related to high prices on its hepatitis C drugs  Gilead Sciences  products often cure patients within months  the publication said   That word  cure  isn t used often enough by Big Pharma   Barron s said   
The company also expects to generate  85 billion in cumulative free cash through 2020  which the publication said it could use to buy new medicines or repurchase shares ",2016-02-07,Reuters,"https://www.investing.com/news/stock-market-news/celgene,-gilead-sciences-shares-could-rise-30-percent:-barron's-383686",383686
201042,422558,GILD,Nektar  NKTR  Q4 Earnings Beat  NKTR 181 Review Extended,opinion,"Nektar Therapeutics   NASDAQ NKTR   reported a loss of 57 cents per share for the fourth quarter of 2018  narrower than the Zacks Consensus Estimate of a loss of 70 cents  The company had recorded a loss of 21 cents per share in the year ago period Quarterly revenues were  39 8 million compared with the year ago figure of  95 5 million  The significant decrease in revenues was attributable to  60 0 million of non recurring revenues recorded in the third quarter of 2017 related to a new sublicense agreement  a contract settlement agreement and the recognition of deferred revenues  The top line  however  beat the Zacks Consensus Estimate of  25 97 million Quarter in DetailNektar s top line comprises product sales  royalty revenues  non cash royalty revenues besides license  collaboration and other revenues In the fourth quarter  product sales declined 44  to  4 4 million from the year ago period   Non cash royalty revenues also decreased 2 1  to  9 million Nektar reported royalty revenues of  12 1 million in the quarter  registering an improvement of 26 2  from  9 2 million a year ago License  collaboration and other revenues came in at  14 4 million compared with  68 9 million in the prior year Research and development  R D  expenses escalated 33 8  to  108 9 million  primarily due to investments in pipeline  including candidates bempegaldesleukin  earlier NKTR 214   NKTR 358  NKTR 262 and NKTR 255  It also included costs related to filing of a new drug application   NDA   for NKTR 181 and pre commercial manufacturing Nektar is looking to get NKTR 181  an opioid analgesic  approved for the treatment of chronic low back pain  A decision from the FDA was expected by May 29  2019  However  the company announced on its earnings call that the FDA has extended the review period by three months  A decision is now expected by Aug 29  2019  The FDA extended the review period due to submission of additional preclinical abuse liability data  which it had requested earlier General and administrative  G A  expenses were up 93 5  to  23 8 million in the reported quarter primarily due to higher stock based compensation expenses Full Year ResultsNektar reported total revenues of  1 2 billion in 2018 compared with  307 8 million in the year ago period  The significant increase was due to an upfront payment from Bristol Myers   NYSE BMY   related to a collaboration agreement  The company reported earnings of  3 78 per share in 2018 against a loss of 62 cents in 2017 Nektar s stock was down 1 3  in after market trading on Feb 28  most likely due to delay in FDA s decision on the approval of NKTR 181  Shares of Nektar have lost 54 1  in the past year 2019 GuidanceNektar provided revenue and operating expenses guidance for 2019  The company expects full year revenues to be  100  110 million  which will include  40  45 million from royalties related to Takeda s Adynovate and AstraZeneca s Movantik and  32 million in non cash royalty revenues related to UCB s Cimzia and Roche s Mircera Although the company shares research and marketing costs for its pipeline candidates with its partners  operating expenses are expected to surge in 2019 due several ongoing clinical studies  especially for NKTR 214  and commercial initiatives for NKTR 181  Research and development costs are expected to be between  500 million and  525 million while G A costs are expected to be in the range of  110  120 million The company expects to end 2019 with  1 5 billion in cash and investments  which include reimbursement of development cost from Bristol Myers  The significant cash amount boosts the prospect of Nektar as it will be able to continue developing its pipeline candidates for several years Pipeline UpdateNektar is developing several candidates across important therapeutic areas including Onzeald in breast cancer and NKTR 255 in virology indications  The company is also developing several immuno oncology candidates  with bempegaldesleukin being its primary candidate In December  the company entered into a research collaboration with Gilead Sciences   NASDAQ GILD   to develop its IL 15 agonist  NKTR 255  in combination with the latter s antiretroviral therapies  Gilead will completely fund the pre clinical studies In the same month  Nektar and partner  Bristol Myers  initiated a phase III study   PIVOT 09   and a registrational study   PIVOT 10   to evaluate bempegaldesleukin plus Opdivo  nivolumab  for treating renal cell carcinoma and urothelial carcinoma  respectively  Under the PIVOT program the companies are currently developing the combination therapy for first line metastatic melanoma  renal cell carcinoma and bladder cancers  and second line non small cell lung cancer  The program will also develop a triplet combination of bempegaldesleukin  Opdivo and Yervoy  ipilimumab  In November  the company entered into a clinical collaboration with Pfizer   NYSE PFE   to develop doublet or triplet combination therapies of bempegaldesleukin in several cancer indications including metastatic castration resistant prostate cancer and squamous cell carcinoma of the head and neck  Per the terms of the agreement  Pfizer will initiate a phase Ib II study in 2019 to evaluate combination therapies of its cancer drugs candidates Bavencio  avelumab  and talazoparib or Xtandi  enzalutamide  with bempegaldesleukin Onzeald is currently being evaluated in a phase III  ATTAIN  study for the treatment of adults with advanced breast cancer  having brain metastases Nektar Therapeutics Price  Consensus and EPS Surprise
    Zacks Rank Nektar currently has a Zacks Rank  3  Hold   You can see  This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-02-28,Zacks Investment Research,https://www.investing.com/analysis/nektar-nktr-q4-earnings-beat-nktr181-review-extended-200393992,200393992
201043,422559,GILD,Intercept  ICPT  Up On Q4 Revenue Beat  NASH Study In Focus ,opinion,"Shares of Intercept Pharmaceuticals  Inc    NASDAQ ICPT   gained 7 5  after the company posted mixed results for the fourth quarter of 2018 wherein even though earnings missed estimates  revenues beat the same 
Investors are upbeat about the company s increase in Ocaliva sales and landmark results from its REGENERATE study  which were reported earlier  
Notably  Intercept s stock has surged 8 7  in the past six months Intercept Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
 

   The company incurred a loss of  2 97 per share in the fourth quarter  wider than the Zacks Consensus Estimate of a loss of  2 42 but narrower than the year ago loss of  4 43 
Quarterly revenues were  53 3 million  up from  37 7 million in the year ago quarter  Revenues also surpassed the Zacks Consensus Estimate of  51 7 million 
Quarter in Detail
Ocaliva recorded  52 9 million of sales  up from  46 6 million recorded in the third quarter of 2018 and  37 3 million in the year earlier period  Net sales in the United States came in at  41 1 million while the ex U S  Ocaliva net sales summed  11 8 million 
Ocaliva in combination with ursodeoxycholic  UDCA  was approved in the United States during 2016 for the treatment of primary biliary cholangitis   PBC   in adults with an inadequate response to UDCA or as monotherapy in adults  who are unable to endure UDCA  The drug was also granted a conditional approval by the European Commission  In February 2018  Ocaliva s label was updated in the United States to include a boxed warning and a dosing table that reinforced the existing dosing schedule in PBC patients with Child Pugh Class B or C or decompensated cirrhosis 
Research and development expenses increased 10 1  year over year to  63 3 million  primarily driven by more clinical development programs for Ocaliva  However  selling  general and administrative expenses decreased 15 8  to  71 million 
2019 Outlook
Ocaliva s net sales are expected between  225 million and  240 million in 2019  Intercept continues to expect operating expenses to be  450  470 million in 2019 
Pipeline Update
Obeticholic acid  OCA  is also being evaluated for other indications including non alcoholic steatohepatitis   NASH   and primary sclerosing cholangitis   PSC   
Earlier in 2019  Intercept announced positive top line results from its pivotal phase III REGENERATE study of OCA on patients with liver fibrosis due to NASH   The company stated that the primary endpoint of the study   fibrosis improvement without worsening of NASH at 18 months   was achieved with the 25 mg daily dose of OCA 
Also  a numerically greater proportion of patients in both OCA treatment arms  taking doses of 10 mg and 25 mg  met the primary endpoint of NASH resolution with no deterioration of liver fibrosis as compared to placebo  However  this did not reach statistical significance  Nevertheless  the study was required to attain one of the two primary goals per the FDA which it did 
Intercept plans to file for an approval of OCA as a NASH treatment both in the United States and in Europe during the second half of 2019  The company will also release data from the REGENERATE analysis at the European Association for the Study of the Liver  EASL  conference in April 
The REVERSE study is designed to evaluate the efficacy and safety of Ocaliva on NASH patients suffering compensated cirrhosis  The probe is currently enrolling patients  which is expected to be complete by the end of 2019 
Our Take
Intercept s fourth quarter results were mixed as earnings lagged expectations but sales beat the mark  Management s efforts to increase awareness about the label update in 2018 and expansion in sales force across the United States thereafter  is reaping results  Solid growth in new patient enrollment is likely to drive stronger sales in 2019 
Moreover  the favorable outcomes from the REGENERATE assessment are a big boost to Intercept  This news significantly buoyed investor sentiments given the market potential of NASH and the fact that biotech bigwig Gilead Sciences  Inc    NASDAQ GILD   announced the failure of a late stage study on selonsertib  involving patients afflicted with compensated cirrhosis  F4  due to NASH  This in turn  puts Intercept ahead in the race to get a drug approved for NASH 
The market for NASH is expected to be one of the target areas in 2019 by most large pharma biotech companies  This market is poised to witness rapid growth unlike other lucrative yet saturated markets like cancer  With no treatments currently approved to address this disease  the market opportunity is substantially huge  In fact  many companies are investing a major chunk of the respective R D spends in the same 
Madrigal Pharmaceuticals  Inc    NASDAQ MDGL   and Viking Therapeutics  Inc  too have promising NASH candidates in the respective pipelines  Pharma giant Merck   NYSE MRK   recently exercised its option to license NGM313  an investigational monoclonal antibody agonist of the   Klotho FGFR1c receptor complex that is currently being evaluated for the treatment of NASH and type 2 diabetes 
Hence  we expect investors to focus on further updates from the NASH program  A tentative approval will be significant for Intercept 
Zacks Rank
Intercept currently carries a Zacks Rank  4  Sell    You can see  
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities 
These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-02-28,Zacks Investment Research,https://www.investing.com/analysis/intercept-icpt-up-on-q4-revenue-beat-nash-study-in-focus-200394023,200394023
201044,422560,GILD,Why Is Gilead  GILD  Down 4 9  Since Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Gilead Sciences  NASDAQ GILD   Shares have lost about 4 9  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Gilead due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  
Gilead Q4 Earnings Miss Estimates  Revenues BeatGilead reported mixed results for the fourth quarter  wherein earnings missed expectations but revenues beat on the same Gilead reported earnings of  1 44 per share in the fourth quarter  down from  1 78 in the year ago quarter and missing the Zacks Consensus Estimate of  1 70 Total revenues of  5 79 billion beat the Zacks Consensus Estimate of  5 53 billion but declined 2 6  year over year HIV Franchise Sustains MomentumProduct sales came in at  5 7 billion  down 2 7  year over year due to continued decline in legacy hepatitis C virus  HCV  franchise HCV product sales plunged 50 8  to  738 million  due to lower average net selling price and decreased sales volumes of Harvoni and Epclusa across all major markets as a result of increased competition and lower patient starts  Sales of Harvoni plunged 63 9  year over year to  232 million in the quarter   Epclusa garnered sales of  453 million  down 19 8  from the year ago quarter HIV product sales increased 20 6  year over year to  4 1 billion  primarily owing to the continued uptake of Genvoya and Odefsey  and the rapid adoption of Biktarvy  The quarter are also benefited from seasonal inventory purchases and a favorable payer mix  Genvoya generated sales of  1 2 billion  up from  1 0 billion in the year ago quarter  Descovy recorded sales of  411 million  up from  365 million a year ago  while Odefsey registered sales of  448 million  up from  325 million in the year ago quarter In the United States  77  of Gilead s total HIV treatment prescription volumes comprised Descovy based regimens  We note that Gilead received a major boost when the FDA approved the company s once daily single tablet regimen   STR    Biktarvy  bictegravir 50mg emtricitabine 200mg tenofovir alafenamide 25mg  BIC FTC TAF  for HIV 1 infection  The approval of Biktarvy in Europe boosted sales further  Bikatrvy s sales came in at  578 million   Approximately 80  of Biktarvy s U S  prescriptions came from switches  25  of which came from dolutegravir and another 25  from Genvoya   Truvada  for use in the pre exposure prophylaxis setting  continued to maintain momentum with an estimated 202  000 patients using the drug by the end of the fourth quarter  However  HIV sales were slightly down year over year in Europe  due to generic competition in several markets  During 2018  Gilead experienced slower erosion of the HIV franchise due to later generic entry in a few countries HIV treatments like Stribild and Complera Eviplera sales declined 38 3  and 43 7   respectively   Atripla sales slumped 35 2  to  258 million  while Truvada sales increased 3 3  to  823 million CAR T therapy Yescarta  axicabtagene ciloleucel   which was launched in the United States in October 2017  generated  81 million in sales  up from  75 million in the previous quarter   In August  Yescarta was approved in Europe Other product sales  which include chronic hepatitis B  HBV  drugs  cardiovascular  oncology and other categories  Vemlidy  Viread  Letairis  Ranexa  Zydelig and AmBisome   were  797 million compared with  886 million in the year ago quarter Adjusted product gross margin was 77 9  compared with 83 5  in the year ago period  Research   development  R D  expenses increased 11 1  to  939 million  Selling  general and administrative  SG A  expenses increased 11 8  to  1 0 billion 2018 ResultsRevenues came in at  22 1 billion  surpassing the Zacks Consensus Estimate of  21 8 billion  Earnings per share came in at  6 67 missing the Zacks Consensus Estimate of  6 93 2019 GuidanceGilead expects net product sales of  21 3  21 8 billion compared to the Zacks Consensus Estimate of  22 01 billion  Adjusted R D and adjusted SG A expenses are projected to be  3 6  3 8 billion and  3 9  4 1 billion  respectively  Adjusted product gross margin is expected to be 85 87  For the first quarter of 2019  Gilead expects product sales to decline sequentially by 12 14   primarily owing to the U S  seasonal inventory patterns and buying patterns of public payers that negatively impact payer mix Dividend and Share RepurchaseDuring 2018  Gilead generated  8 4 billion in operating cash flow  repaid  6 3 billion of debt  paid cash dividends of  3 0 billion and spent  2 9 billion on repurchases of 40 million shares  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  The consensus estimate has shifted  6 15  due to these changes 
VGM Scores
At this time  Gilead has a poor Growth Score of F  however its Momentum Score is doing a lot better with a B  Following the exact same course  the stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  It s no surprise Gilead has a Zacks Rank  5  Strong Sell   We expect a below average return from the stock in the next few months ",2019-03-05,Zacks Investment Research,https://www.investing.com/analysis/why-is-gilead-gild-down-49-since-last-earnings-report-200395140,200395140
201045,422561,GILD,Gilead Reports Positive Data On HIV Drugs Biktarvy   Descovy,opinion,"Gilead Sciences  Inc    NASDAQ GILD   presented a series of data at the 2019 Conference on Retroviruses and Opportunistic Infections  CROI  in Seattle 
The company announced results from two studies evaluating the resistance profile of a once daily single tablet HIV regimen  Biktarvy  bictegravir 50 mg emtricitabine 200 mg tenofovir alafenamide 25 mg tablets  BIC FTC TAF  in virologically suppressed adults switching from dolutegravir abacavir lamivudine  DTG ABC 3TC  or a boosted protease inhibitor  PI  based regimen for the treatment of HIV 1 
The results showed high rates of virologic suppression with Biktarvy in treatment experienced adults  regardless of pre existing resistance to nucleoside reverse transcriptase inhibitors  NRTIs  
We note that Biktarvy is already approved in the United States as a complete regimen for the treatment of HIV 1 infection in adults without any antiretroviral treatment history  Biktarvy is also approved to replace the current antiretroviral regimen in those adults who are virologically suppressed on a stable antiretroviral regimen for at least three months 
Gilead announced 48 week results from a phase II III study evaluating the efficacy and safety of Biktarvy in virologically suppressed adolescents and children at least 6 years of age infected with HIV   Biktarvy maintained high rates of virologic suppression with a low incidence of study drug related adverse events and no treatment emergent resistance at week 48 
Gilead also announced results from the phase III randomized  controlled  double blind study evaluating the safety and efficacy of the investigational use of once daily Descovy for HIV pre exposure prophylaxis  PrEP  compared with Truvada  in men who have sex with men and transgender women at risk of sexually acquired HIV infection  Descovy met the pre established criteria for non inferiority to Truvada using a stringent rate ratio statistical comparison 
Moreover  results showed that participants receiving Descovy have significant advantages with respect to bone and renal laboratory parameters  which were pre specified secondary endpoints  compared with those receiving Truvada  Descovy is already approved in combination with other antiretroviral agents for the treatment of HIV infection in patients weighing 35 kg or more but is not indicated for PrEP  Truvada is indicated in combination with safer sex practices for HIV PrEP to reduce the risk of sexually acquired HIV in at risk adults and adolescents weighing 35 kg or more 
Gilead plans to file regulatory applications for Descovy for the PrEP indication as a potential important new option to prevent individuals from getting infected and contribute to the achievement of national and global HIV prevention goals 
Gilead s stock has lost 12 1  in the past six months compared with the s decline of 14  

 
Gilead s HIV franchise maintains momentum  driven by the rapid adoption of Descovy based regimens and Biktarvy  However  Gilead will have to generate substantial revenues from its HIV franchise to offset the HCV sales decline  This will be a challenging task for the company with stiff competition from the likes of GlaxoSmithKline   NYSE GSK   in the HIV market 
Given the persistent decline in HCV sales  the company is looking to HIV and newer avenues to help the top line  The initial uptake of Yescarta  from the Kite Pharma acquisition  is also encouraging but it will take some time for sales to contribute significantly to the top line  given the high cost of the treatment  Moreover  Novartis    NYSE NVS   Kymriah is also there in the market  posing competition 
Gilead also collaborated with Agneus   NASDAQ AGEN   for the development and commercialization of up to five novel immuno oncology therapies 
Zacks Rank
Gilead currently carries a Zacks Rank  4  Sell    You can see  
Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-03-07,Zacks Investment Research,https://www.investing.com/analysis/gilead-reports-positive-data-on-hiv-drugs-biktarvy--descovy-200395623,200395623
201046,422562,GILD,Agenus Wins  7 5M Milestone Payment From Gilead  Stock Up,opinion,Agenus Inc    NASDAQ AGEN   announced that it has received  7 5 million in cash as milestone payment from Gilead Sciences   NASDAQ GILD   after the FDA accepted the company s investigational new drug  IND  application for AGEN1423 AGEN1423 is a first in class molecule  currently developed in partnership with Gilead as a potential treatment for cancer  Agenus is also eligible to receive additional milestones from Gilead in 2019 as well as in the future Shares of Agenus were up almost 3 5  following this news on Wednesday  In fact  the stock has rallied 24 4  in the year so far compared with the  increase of 14 5  We would like to remind investors that last December  Agenus inked a collaboration deal with Gilead to develop and commercialize up to five immuno oncology  I O  therapies  Shares of the company also soared back then post this alliance In January 2019  Agenus announced the closing of its I O partnership deal with Gilead Under the terms of the agreement  Agenus receives  150 million in connection with the completion of the contract  which includes a  120 million upfront cash payment and a  30 million equity investment  The pact also includes approximately  1 7 billion as potential future fees and milestones  Gilead received worldwide exclusive rights to AGEN1423  It also received the exclusive option to license two supplementary programs on AGEN1223 and AGEN2373 Agenus has filed the IND for AGEN1223 and has an IND submission planned for AGEN2373 in the first half of 2019   The company will be responsible for developing the option studies up to the option decision points during which Gilead may acquire the exclusive rights to the programs on option exercise  For one of the option evaluations  Agenus will have the privilege to opt for shared development and commercialization in the United States  Gilead also received the right to first negotiation for two additional  undisclosed preclinical programs We remain optimistic that the collaboration will help Agenus with the much needed infusion of cash and allow advancement of its pipeline development  Also  Gilead s global presence and commitment to disruptive therapies will enable Agenus to build a broad pipeline in I O Zacks Rank   Stocks to ConsiderAgenus currently carries a Zacks Rank  3  Hold   Better ranked stocks in the biotech sector include Celgene Corporation   NASDAQ CELG   and Trevena  Inc    NASDAQ TRVN    both sporting a Zacks Rank  1  Strong Buy   You can see  Celgene s earnings estimates have moved 3 8  north for 2019 and 3 9  for 2020 over the past 60 days  The stock has surged 36 2  so far this year Trevena s loss per share estimates has been narrowed 12 9  for 2019 and 11  for 2020 in the last 60 days  The stock has skyrocketed 232 6  year to date Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-03-13,Zacks Investment Research,https://www.investing.com/analysis/agenus-wins-75m-milestone-payment-from-gilead-stock-up-200397829,200397829
201056,422572,GILD,WHO ramps up HIV drug push with call for early treatment for all,news,"By Stephanie Nebehay GENEVA  Reuters    Everyone with HIV should be given anti retroviral drugs as soon as possible after diagnosis  meaning 37 million people worldwide should be on treatment  the World Health Organization  WHO  said on Wednesday  Recent clinical trials have confirmed that early drug use extends the lives of those with the AIDS causing virus and cuts the risk of disease transmission to partners  the WHO said in a statement setting out the new goal for its 194 member states  Under previous WHO guidelines  which limited treatment to those whose immune cell counts had fallen below a certain threshold  28 million people were deemed eligible for anti retroviral therapy  ART   All people at  substantial  risk of contracting HIV should also be given preventive ART  not just men who have sex with men  the WHO said   The new guidelines are a central plank of the United Nations agency s aim to end the AIDS epidemic by 2030   Everybody living with HIV has the right to life saving treatment  The new guidelines are a very important step towards ensuring that all people living with HIV have immediate access to anti retroviral treatment   said Michel Sidibe  executive director of UNAIDS   According to UNAIDS estimates  expanding ART to all people living with HIV and expanding prevention choices can help avert 21 million AIDS related deaths and 28 million new infections by 2030   The move will lead to a sharp increase in demand for ART medicines  which are typically given as a three drug cocktail to avoid the risk of the virus developing resistance  Major suppliers of HIV drugs include Gilead Sciences  O GILD   ViiV Healthcare  which is majority owned by GlaxoSmithKline  L GSK   and multiple Indian generic manufacturers  The medical charity Medecins Sans Frontieres  Doctors Without Borders  welcomed the WHO s  treat all  plan  which it believes will prevent many HIV positive people in poorer countries from falling through the treatment net  MSF said its experience showed that a third of people who were diagnosed with HIV  but not eligible to start treatment  never returned to the clinic  The charity also warned that making the new recommendation a reality would require dramatically increased financial support from donors and governments  The WHO estimates that by 2020 low  and lower middle income countries will need  18 4 billion annually for the expanded HIV fight  However  fast tracking the response should yield economic returns of  15 per dollar invested  based on improved health and infections averted  
Since it began spreading 30 years ago  AIDS has killed around 40 million people worldwide ",2015-09-30,Reuters,https://www.investing.com/news/stock-market-news/who-ramps-up-hiv-drug-push-with-call-for-early-treatment-for-all-363917,363917
201057,422573,GILD,Gilead Sciences shares fall mildly in spite of 38  revenue spike in 3Q,news,"Investing com    Shares in  Gilead Sciences Inc   O GILD  fell nearly 2  in after hours trading even as the prominent pharmaceutical company beat analysts  revenue and earnings forecasts on Tuesday for the third quarter of 2015  
During the third quarter of fiscal year 2015  Gilead saw its revenue surge by 38  to  8 3 billion  considerably above analysts  forecasts of net sales of  7 8 billion for the period  It came as the company s revenues for its two Hepatitis C drugs   Harvoni and Solvadi   reached  4 8 billion on the quarter  above analysts  expectations of  4 47 billion  Sales for Solvadi exceeded  1 45 billion for the three month period  also above forecasts of  1 16 billion  
Overall  Gilead reported earnings of  4 6 billion or 3 06 per share for the third quarter  up from quarterly earnings of  2 73 billion or 1 67 per share over the third quarter of 2014  Analysts expected the company to report earnings of 2 87 per share for the quarter  
In addition  Gilead reported other product sales  which included revenues from its Letairis and Ranexa drugs and AmBisome   an amphotericin B liposome injection  of  509 million  compared to  424 million for the third quarter of 2014  As of late September  Gilead also had  25 1 billion of cash  cash equivalents and marketable securities compared to  14 7 billion at the start of the quarter  primarily due to issuance of senior unsecured notes last month  
While Gilead raised its full year guidance by  1 billion on Tuesday  analysts remained concerned that increased competition from rivals such as AbbVie in the Hepatitis C prescription drug market could dent sales  Still  Gilead expects full year revenues to fall within a range of  30  31 billion for 2015  
Shares in Gilead fell 2 13 or 1 92  to 108 88 in after hours  During the general session  Gilead shares gained 2 36 or 2 17  to 110 99 ",2015-10-27,Investing.com,https://www.investing.com/news/stock-market-news/gilead-sciences-shares-fall-mildly-in-spite-of-38-revenue-spike-in-3q-368337,368337
201058,422574,GILD,U S  stocks fall sharply as ECB  Yellen trigger massive dollar sell off,news,"Investing com    U S  stocks accelerated their sell off late in Thursday s session falling sharply on the day  amid limited increases in the European Central Bank s quantitative easing program and dovish comments from Janet Yellen on the likelihood of an interest rate hike from the Federal Reserve 
The U S  dollar suffered its worst one day loss against the euro in more than six years after the ECB left several key interest rates unchanged and opted not to increase the pace of its  60 billion a month quantitative easing program  as many expected  Yellen  the chair of the Federal Reserve  told a Congressional hearing that the U S  economy needs to add fewer than 100 000 jobs a month to absorb the losses of those who fell out of the labor market in recent years  Her comments came one day before a critical U S  jobs report on Friday could pave the way for the Fed to raise short term interest rates for the first time in nearly a decade 
The Dow Jones Industrial Average plunged 252 01 or 1 42  to 17 477 67  as investors digested FBI reports that the suspect in Wednesday s shooting in Southern California appeared to be radicalized  At one point on Thursday afternoon  the Dow fell by more than 300 points extending losses from Wednesday s sell off  The NASDAQ Composite index  meanwhile  lost 85 69 or 1 67  to 5 037 53  as interest rate sensitive stocks in the Utilities and Home Building sectors took a hit following aggressive upward moves in U S  10 Year bond yields 
The S P 500 Composite fell into negative territory for the year  as stocks in all 10 sectors closed in the red on Thursday  Stocks in the Health Care  Energy and Financials industries lagged  each falling by more than 1 5  on the day  With the losses the S P 500 closed on Thursday at 2 049 62  down 29 89 or 1 44  on the session 
A Fed rate hike is viewed as bullish for the dollar  but bearish for equities  as foreign investors exit their positions and pile into U S  Treasuries in order to capitalize on higher yields  The dollar also suffered on Thursday  as investors abandoned short positions in the euro  amid expectations for a significant expansion in the ECB s bond buying program and deeper cuts in its deposit facility rate 
The top performer on the Dow was Wal Mart Stores Inc  N WMT   which gained 0 68 or 1 17  to 59 03  The worst performer was The Travelers Companies Inc  N TRV   which fell 3 44 of 3 00  to 111 27  after CEO Jay Fishman stepped down from a position he held for the last 14 years  Fishman  63  continued to work over the last 14 months since being diagnosed with the neurodegenerative condition Amyotrophic Lateral Sclerosis  commonly known as Lou Gehrig s Disease 
The biggest gainer on the NASDAQ was Avago Technologies  which rose 11 91 or 9 01  to 144 12  after topping third quarter expectations on Thursday  For the company s third quarter  which ended in early November  the Silicon Valley based chipmaker saw its revenue surge 16   amid strong growth in its wireless and device storage divisions 
The worst performer was Vertex Pharmaceuticals Inc  O VRTX   which plunged 8 59 or 6 59  to 121 82 on the session  amid concerns of regulatory pushback against the pharmaceutical industry for price gouging  On Tuesday  the US Senate finance committee issued a report accusing Gilead Sciences  O GILD  of overpricing its new hepatitis C drug at  1 000 a pill  In July  Vertex s high priced Cystic Fibrosis drug Orkambi received approval from the U S  Food and Drug Administration 
Avago was also the top performer on the S P 500  just ahead of  Newmont Mining  Corporation  N NEM  which gained 0 86 or 4 79  to 18 71  A host of commodities  including gold and copper moved higher on Thursday in reaction to the dollar s nosedive  The worst performer was Chesapeake Energy Corporation  N CHK   which plunged 0 71 or 12 77  to 4 82  Shares in the Oklahoma based energy company are down by more than 70  over the last 12 months 
On the New York Stock Exchange  declining issues outnumbered advancing ones by a 2 507 592 margin ",2015-12-03,Investing.com,"https://www.investing.com/news/stock-market-news/u.s.-stocks-fall-sharply-as-ecb,-yellen-trigger-massive-dollar-sell-off-374382",374382
201063,422579,GILD,Gilead s  GILD  Late Stage Study On Liver Disease Drug Fails ,opinion,"Shares of Gilead Sciences  Inc    NASDAQ GILD   declined in after market trading on Feb 11  after the company announced the failure of a late stage study on pipeline candidate  selonsertib  in patients with compensated cirrhosis  F4  due to nonalcoholic steatohepatitis  NASH  
Gilead s stock has declined 17 8  in the past six months compared with the  decline of 16 5  

 
STELLAR 4  a phase III  randomized  double blind  placebo controlled study  n 877  evaluated the safety and efficacy of selonsertib  which is an investigational  once daily  oral inhibitor of apoptosis signal regulating kinase 1  ASK1   in patients with compensated cirrhosis due to NASH 
However  the study did not meet the pre specified week 48 primary endpoint of a   1 stage histologic improvement in fibrosis without worsening of NASH 
Gilead is conducting an in depth analysis of the findings and data will be submitted to an upcoming scientific conference  The company is also working with the Data Monitoring Committee and investigators to conclude the STELLAR 4 study in a manner consistent with the best interests of each patient 
Meanwhile  results from the phase III STELLAR 3 trial of selonsertib in patients with bridging fibrosis  F3  due to NASH and the phase II ATLAS combination trial of selonsertib  cilofexor  GS 9674  and firsocostat  GS 0976  in patients with advanced fibrosis are expected later this year 
The failure of the STELLAR 4 study comes as a disappointment  given the significant market potential of NASH  We note that Gilead had shifted focus to its HIV franchise and newer avenues like CAR T therapy and NASH  given the persistent decline in its once market leading HCV franchise 
The market for NASH promises potential and is expected to be one of the target areas in 2019 by most large pharma biotech companies  This market is poised to witness rapid growth unlike other lucrative yet saturated markets like cancer  A chronic liver disease  NASH is caused by excessive fat accumulation in the liver  known as steatosis  Per records  it has affected up to 15 million people in the United Stated and could cause inflammation  hepatocellular injury  progressive fibrosis and cirrhosis 
With no treatments currently approved to address this disease  the market opportunity is substantially huge  In fact  many companies are investing a major chunk of their R D spend in the same 
Intercept Pharmaceuticals   NASDAQ ICPT   is evaluating its lead candidate  obeticholic acid  OCA  for treating NASH patients  Currently  a phase III study  REGENERATE  among non cirrhotic NASH patients with liver fibrosis  is ongoing 
Madrigal Pharmaceuticals  Inc    NASDAQ MDGL   and Viking Therapeutics  Inc    NASDAQ VKTX   too have promising NASH candidates in their pipeline 
Zacks Rank
Gilead currently carries a Zacks Rank  5  Strong Sell   You can see  
Zacks  Best Stock Picking Strategy
It s hard to believe  even for us at Zacks  But from 2000 2018  while the market gained  4 8  per year  our top stock picking strategy averaged  54 3  per year 
How has that screen done lately  From 2017 2018  it sextupled the market s  15 8  gain with a soaring  98 3  return ",2019-02-12,Zacks Investment Research,https://www.investing.com/analysis/gileads-gild-latestage-study-on-liver-disease-drug-fails-200387096,200387096
201064,422580,GILD,What s In Store For Sangamo  SGMO  This Earnings Season ,opinion,Sangamo Therapeutics  Inc    NASDAQ SGMO   will report fourth quarter 2018 and full year earnings results The company has a disappointing track record as its key metrics missed estimates in two of the last four reported quarters while coming in line with the same on one occasion and surpassing the mark in another  the average negative surprise being 43 99   In the last reported quarter  Sangamo matched estimates at 0 00  Shares of Sangamo have plummeted 62 3  in the past year compared with the  decrease of 16 7  Let s see  how things are shaping up for this announcement Factors to ConsiderWith no approved product in its portfolio at the moment  Sangamo primarily generates collaboration revenues from agreements with Pfizer   NYSE PFE    Kite Pharma   a subsidiary of Gilead  NASDAQ GILD    and Bioverativ  a unit of Sanofi  PA SASY   During the upcoming conference call  investor focus will be on the company s update pertaining to its main pipeline candidates Sangamo is developing SB 525  its gene therapy product candidate in the phase I II Alta study for hemophilia A  in partnership with Pfizer  Last November  the company announced that an independent Safety Monitoring Committee  SMC  recommended the continuation of the study to evaluate a higher dose following an analysis in October  The company clarified that the Committee s recommendation was based on dose dependent efficacy on serum factor levels and the favorable safety and tolerability profile of SB 525 Shares of Sangamo shed value due to the company s decision to delay data presentation rom the above mentioned study  which was expected in fourth quarter 2018 Sangamo s zinc finger nuclease  ZFN  in vivo genome editing candidate  SB 913  is currently being evaluated in a phase I II CHAMPIONS study for the treatment of Mucopolysaccharidosis Type II  MPS II   Earlier this month  the company presented interim results from the study on SB 913 at a medical conference The interim data provided preliminary evidence that in vivo genome editing occurred on treatment with SB 913 and that genome edited liver cells are able to generate active  Iduronate 2 sulfatase  IDS enzyme in patients with MPS II  Additional data from the study is awaited later this year  which will help explain if the small increases in IDS enzyme activity observed can translate into improved outcomes in MPS II patients Another similar candidate  SB 318  is currently being examined in a phase I II EMPOWERS program for treating MPS I  Earlier this month  the company also presented interim findings from the study on SB 318  Data from the same provided complementary evidence  supportive of a positive safety profile and the ZFN activity in in vivo genome editing technology  used in both SB 913 and SB 318 Last December  Sangamo treated the first patient during the phase I II study on SB FIX  an investigational in vivo genome editing therapy for patients with hemophilia B Last October  Sangamo closed the previously announced acquisition of France s TxCell S A  Notably  TxCell develops innovative platforms for personalized T cell immunotherapies to handle severe inflammatory and autoimmune diseases  The company plans to submit a clinical trial authorization application  CTA  in Europe this year for TxCell s first CAR Treg investigational product candidate regarding solid organ transplant Earnings WhispersOur proven model does not conclusively show that Sangamo is likely to beat estimates this to be reported quarter  This is because a stock needs to have both a positive  and a top Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here as you will see below Earnings ESP  Sangamo has an Earnings ESP of 0 00   This is because the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of 20 cents each  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Sangamo currently carries a Zacks Rank  3  which increases the predictive power of ESP  However  the company s 0 00  ESP in the combination makes surprise prediction difficult for the stock this reporting cycle We caution against Sell rated stocks   4 or 5  going into an earnings announcement  especially when the company is seeing negative estimate revisions Sangamo Therapeutics  Inc  Price and EPS Surprise   Stocks That Warrant a LookHere are some biotech stocks that you may want to consider as per our model  these have the right mix of elements to beat on earnings this season Aduro Biotech  Inc    NASDAQ ADRO   has a Zacks Rank  2 and an Earnings ESP of  15 23   You can see  BioDelivery Sciences International  Inc    NASDAQ BDSI   has an Earnings ESP of  38 46  and a Zacks Rank of 1 Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-02-18,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-sangamo-sgmo-this-earnings-season-200389682,200389682
201065,422581,GILD,Intercept Reports Positive Top Line Data For NASH  Shares Up ,opinion,Shares of Intercept Pharmaceuticals  Inc    NASDAQ ICPT   rose about 6 1  after the company announced positive top line results from its pivotal phase III REGENERATE study of obeticholic acid  OCA  in patients with liver fibrosis due to nonalcoholic steatohepatitis  NASH   Shares of the company have increased 93 4  in the past year against the  s decline of 15 2  The company stated that the primary endpoint of the study   fibrosis improvementwithout worsening of NASH at 18 months   was achieved with the 25 mg daily dose of OCA  Also  a numerically greater proportion of patients in both OCA treatment arms  taking doses of 10 mg and 25 mg  achieved the primary endpoint of NASH resolution with no worsening of liver fibrosis compared to placebo  However  this did not reach statistical significance Intercept plans to file for approval of OCA as a NASH treatment in the United States and Europe in the second half of 2019  The company will also report the results from the REGENERATE study at the European Association for the Study of the Liver  EASL  conference in April  OCA is already available in the United States and Europe for treating another liver disease  primary biliary cholangitis  PBC   under the brand name Ocaliva  OCA is the only investigational drug to have received Breakthrough Therapy designation from the FDA for NASH with fibrosis We remind investors that last week  Gilead Sciences  Inc    NASDAQ GILD   announced the failure of a late stage study  STELLAR 4  on pipeline candidate  selonsertib  in patients with compensated cirrhosis  F4  due to NASH  The study did not meet the pre specified 48 week primary endpoint of a   1 stage histologic improvement in fibrosis without worsening of NASH The market for NASH promises potential and is expected to be one of the target areas in 2019 by most large pharma biotech companies  This market is poised to witness rapid growth unlike other lucrative yet saturated markets like cancer  A chronic liver disease  NASH is caused by excessive fat accumulation in the liver  known as steatosis  Per records  it has affected up to 15 million people in the United Stated  and could cause inflammation  hepatocellular injury  progressive fibrosis and cirrhosis With no treatments currently approved to address this disease  the market opportunity is substantially huge  In fact  many companies are investing a major chunk of their R D spend in the same Madrigal Pharmaceuticals  Inc    NASDAQ MDGL   and Viking Therapeutics  Inc  too have promising NASH candidates in their pipeline Pharma giant Merck   NYSE MRK   recently exercised its option to license NGM313  an investigational monoclonal antibody agonist of the   Klotho FGFR1c receptor complex that is currently being evaluated for the treatment of NASH and type 2 diabetes Intercept Pharmaceuticals  Inc  Price    Zacks RankIntercept currently carries a Zacks Rank  4  Sell  You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-02-19,Zacks Investment Research,https://www.investing.com/analysis/intercept-reports-positive-topline-data-for-nash-shares-up-200390052,200390052
201075,422591,GILD,Wall Street ends sharply higher as China jitters ebb,news,"By Noel Randewich  Reuters    U S  stocks ended sharply higher on Tuesday  breaking a five day losing streak as attention shifted from trouble in Chinese equities to U S  corporate earnings and to speculation the first Federal Reserve interest rate hike may not come until December  The Dow Jones industrial average and S P 500 chalked up gains of more than 1 percent  while the Nasdaq Composite lagged slightly  After the S P sank over the past week toward the low end of a range it has traded in since February  some investors wagered the market was primed for a technical bounce back   The S P has had five down days in a row and a lot of people are starting to nibble   said Michael Matousek  head trader at U S  Global Investors Inc in San Antonio  which manages about  1 billion   Market sentiment also reflected expectations the Fed would wait until December  rather than September  to raise interest rates for the first time since 2006  Matousek added  With a two day Fed policy meeting ending on Wednesday  investors are looking for hints about the timing of that rate increase  No move on rates is expected this week   September is possible but the probability for a December rate hike is increasing   said Terry Sandven  chief equity strategist at U S  Bank Wealth Management in Minneapolis   The Dow Jones industrial average  DJI  rose 1 09 percent  to end the session at 17 630 27  The S P 500  SPX  gained 1 24 percent to 2 093 25 and the Nasdaq Composite  IXIC  added 0 98 percent to finish at 5 089 21  All the 10 major S P 500 sectors rose  with the energy index leaping  2 99 percent as oil prices recovered from near six month lows  U S  consumer confidence weakened in July to its lowest level since September  due in part to a less optimistic outlook on the labor market  Ongoing uncertainty related to China s stock market  which closed lower again on Tuesday  took a backseat to U S  corporate earnings   With second quarter reports well under way  analysts now expect overall earnings of S P 500 companies to edge up 0 3 percent and revenue to decline 4 0 percent  according to Thomson Reuters data   Earnings are growing but very slowly  The market s biggest concern is the lack of top line growth and where that growth is going to come from   said Tim Courtney  chief investment officer of Exencial Wealth Advisors  which oversees  1 3 billion  After the bell  Twitter  N TWTR  jumped 5 2 percent and Gilead Sciences  O GILD  rose 3 percent after both companies posted their second quarter results   Yelp   N YELP  slumped 13 percent after its report   During Tuesday s session  SuperValu  N SVU  jumped 10 60 percent  It said it was exploring a spinoff of its discount grocery chain Save A Lot into a publicly traded company  Advancing issues outnumbered declining ones on the NYSE by 2 7 to 1  On the Nasdaq  1 67 stocks gained for each that declined  The S P 500 racked up 15 new 52 week highs and 12 lows  The Nasdaq Composite posted 36 new highs and 163 lows   
Some 7 3 billion shares changed hands on U S  exchanges  above the daily average of 6 7 billion so far this month ",2015-07-28,Reuters,https://www.investing.com/news/stock-market-news/u.s.-stock-futures-rise-as-investors-refocus-on-earnings-353234,353234
201076,422592,GILD,Clinton proposes  250 monthly cap on prescription drug costs,news,"By Amanda Becker DES MOINES  Iowa  Reuters    U S  Democratic presidential candidate Hillary Clinton proposed on Tuesday a  250 monthly cap on out of pocket prescription drug costs and other measures to stop what she called  price gouging  by pharmaceutical companies  At a campaign stop in Iowa  Clinton rolled out a plan to encourage the development and use of generic drugs and to end pharmaceutical companies  ability to write off consumer directed advertising as a business expense  Under Clinton s plan  the monthly cap would limit what insurance companies could ask patients to pay for drugs that treat chronic or serious medical conditions   We need to protect hard working Americans here at home from excessive costs  Too often these drugs cost a fortune   she said in Des Moines  adding drug companies keep the profits for themselves while  shifting the cost to families   Clinton s comments came after the New York Times reported on how a startup biotechnology company  Turing Pharmaceuticals  raised the price of the 62 year old Daraprim treatment for a dangerous parasitic infection to  750 a tablet from  13 50 after acquiring it   That is bad actors making a fortune off people s misfortune   she said  In the face of sharp criticism of its action by patients  medical groups and Clinton  Turing s chief executive officer  Martin Shkreli  told ABC s  World News Tonight  on Tuesday that the price of Daraprim would be lowered  to a point that is more affordable    Good   tweeted Clinton in response to news of the planned price rollback  The Nasdaq Biotechnology index closed down 1 7 percent on Tuesday after falling as much as 3 5 percent during the session  It had already fallen 4 4 percent on Monday after Clinton tweeted her intent to tackle high prices of some drugs  The index  which had finished the last six years higher  is up 10 4 percent so far this year  Citi biotechnology analyst Liav Abraham said that with 2016 presidential candidates taking on steep drug pricing   companies with less differentiated  more concentrated product portfolios are likely to come under increased political scrutiny   But the rhetoric may have  more bark than bite   he said  since the reforms would require approval by a Republican dominated Congress that is unlikely to implement them  While Clinton has maintained her front runner status in the Democratic race  she has been under pressure to take more populist stances to widen her lead over U S  Senator Bernie Sanders  her second place rival who has also offered a plan to rein in prescription drug costs  CONSUMER MARKETING CONTROVERSY Critics of marketing drugs to consumers say it encourages the use of costly brand names over generics and can be confusing or misleading  A series of court decisions has determined the practice cannot be banned outright because it is a form of commercial speech protected by the U S  Constitution  Clinton said the government could get billions of dollars in additional tax revenue by no longer allowing pharmaceutical companies to deduct what they spend marketing drugs to consumers  The largest pharmaceutical companies are collectively earning  80 billion to  90 billion per year at higher margins than other industries while average Americans struggle to pay for medicine  Clinton s campaign said  Clinton also proposed a ban on  pay for delay agreements   in which the owner of a brand name drug pays a generic competitor to keep its product off the market for a period of time  usually as part of a litigation settlement  Clinton said she wanted Medicare  the U S  government s health insurance program for the elderly  to be able to negotiate with pharmaceutical companies over drug prices and require more generous rebates  Consumers would also be allowed to purchase drugs from other countries  where medicine is often less expensive  so long as sufficient safety standards are in place  Clinton said  She said her proposals would augment President Barack Obama s healthcare law known as Obamacare  High drug costs had played a role in making families feel like healthcare costs were not coming under control  she said  Clinton was expected to outline a separate set of proposals on Wednesday to address other out of pocket healthcare costs  Traditional  Big Pharma  companies have long faced criticism for steadily raising prices of their prescription medicines in the United States  often by jumps of 10 percent or more   Drugmakers are unapologetic about their five  or six digit prices on new treatments for cancer  hepatitis C and high cholesterol  Sovaldi  a treatment from  Gilead Sciences Inc   NASDAQ GILD   can cure hepatitis C but at a cost of  1 000 per pill   Even more controversial have been eye popping increases in costs for older drugs in limited supply  often after other drugmakers acquire them  They say the funds help cover research and development costs for new products  
For more on the 2016 presidential race  see the Reuters blog   Tales from the Trail     ",2015-09-22,Reuters,"https://www.investing.com/news/politics-news/clinton-aims-to-lower-drug-costs,-end-industry-'profiteering'-362712",362712
201079,422595,GILD,Gilead Sciences  GILD  Misses Q4 Earnings Estimates,opinion,"Gilead Sciences  NASDAQ GILD  came out with quarterly earnings of  1 44 per share  missing the Zacks Consensus Estimate of  1 70 per share  This compares to earnings of  1 78 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of  15 29   A quarter ago  it was expected that this HIV and hepatitis C drugmaker would post earnings of  1 66 per share when it actually produced earnings of  1 84  delivering a surprise of 10 84  
Over the last four quarters  the company has surpassed consensus EPS estimates two times 
Gilead  which belongs to the Zacks Medical   Biomedical and Genetics industry  posted revenues of  5 80 billion for the quarter ended December 2018  surpassing the Zacks Consensus Estimate by 4 81   This compares to year ago revenues of  5 95 billion  The company has topped consensus revenue estimates three times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Gilead shares have added about 12  since the beginning of the year versus the S P 500 s gain of 8  
What s Next for Gilead 
While Gilead has outperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Gilead was unfavorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  4  Sell  for the stock  So  the shares are expected to underperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 67 on  5 32 billion in revenues for the coming quarter and  6 88 on  22 05 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Biomedical and Genetics is currently in the top 24  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-02-04,Zacks Investment Research,https://www.investing.com/analysis/gilead-sciences-gild-misses-q4-earnings-estimates-200383410,200383410
201080,422596,GILD,Gilead  GILD  Q4 Earnings Miss Estimates  Revenues Beat,opinion,"Shares of Gilead Sciences   NASDAQ GILD   are trading down in after market trading  after the company reported mixed results for the fourth quarter  wherein earnings missed expectations but revenues beat on the same Gilead s stock has declined 8 5  in the last six months  against the  decline of 13    Gilead reported earnings of  1 44 per share in the fourth quarter  down from  1 78 in the year ago quarter and missing the Zacks Consensus Estimate of  1 70 Total revenues of  5 79 billion beat the Zacks Consensus Estimate of  5 53 billion but declined 2 6  year over year HIV Franchise Sustains MomentumProduct sales came in at  5 7 billion  down 2 7  year over year due to continued decline in legacy hepatitis C virus  HCV  franchise HCV product sales plunged 50 8  to  738 million  due to lower average net selling price and decreased sales volumes of Harvoni and Epclusa across all major markets as a result of increased competition and lower patient starts  Sales of Harvoni plunged 63 9  year over year to  232 million in the quarter   Epclusa garnered sales of  453 million  down 19 8  from the year ago quarter HIV product sales increased 20 6  year over year to  4 1 billion  primarily owing to the continued uptake of Genvoya and Odefsey  and the rapid adoption of Biktarvy  The quarter are also benefited from seasonal inventory purchases and a favorable payer mix  Genvoya generated sales of  1 2 billion  up from  1 0 billion in the year ago quarter  Descovy recorded sales of  411 million  up from  365 million a year ago  while Odefsey registered sales of  448 million  up from  325 million in the year ago quarter In the United States  77  of Gilead s total HIV treatment prescription volumes comprised Descovy based regimens  We note that Gilead received a major boost when the FDA approved the company s once daily single tablet regimen   STR    Biktarvy  bictegravir 50mg emtricitabine 200mg tenofovir alafenamide 25mg  BIC FTC TAF  for HIV 1 infection  The approval of Biktarvy in Europe boosted sales further  Bikatrvy s sales came in at  578 million   Approximately 80  of Biktarvy s U S  prescriptions came from switches  25  of which came from dolutegravir and another 25  from Genvoya   Truvada  for use in the pre exposure prophylaxis setting  continued to maintain momentum with an estimated 202  000 patients using the drug by the end of the fourth quarter  However  HIV sales were slightly down year over year in Europe  due to generic competition in several markets  During 2018  Gilead experienced slower erosion of the HIV franchise due to later generic entry in a few countries HIV treatments like Stribild and Complera Eviplera sales declined 38 3  and 43 7   respectively   Atripla sales slumped 35 2  to  258 million  while Truvada sales increased 3 3  to  823 million CAR T therapy Yescarta  axicabtagene ciloleucel   which was launched in the United States in October 2017  generated  81 million in sales  up from  75 million in the previous quarter   In August  Yescarta was approved in Europe Other product sales  which include chronic hepatitis B  HBV  drugs  cardiovascular  oncology and other categories  Vemlidy  Viread  Letairis  Ranexa  Zydelig and AmBisome   were  797 million compared with  886 million in the year ago quarter  Adjusted product gross margin was 77 9  compared with 83 5  in the year ago period  Research   development  R D  expenses increased 11 1  to  939 million  Selling  general and administrative  SG A  expenses increased 11 8  to  1 0 billion 2018 ResultsRevenues came in at  22 1 billion  surpassing the Zacks Consensus Estimate of  21 8 billion  Earnings per share came in at  6 67 missing the Zacks Consensus Estimate of  6 93 2019 GuidanceGilead expects net product sales of  21 3  21 8 billion compared to the Zacks Consensus Estimate of  22 01 billion  Adjusted R D and adjusted SG A expenses are projected to be  3 6  3 8 billion and  3 9  4 1 billion  respectively  Adjusted product gross margin is expected to be 85 87  For the first quarter of 2019  Gilead expects product sales to decline sequentially by 12 14   primarily owing to the U S  seasonal inventory patterns and buying patterns of public payers that negatively impact payer mix Dividend and Share RepurchaseDuring 2018  Gilead generated  8 4 billion in operating cash flow  repaid  6 3 billion of debt  paid cash dividends of  3 0 billion and spent  2 9 billion on repurchases of 40 million shares Our TakeThe earnings miss was disappointing even though the company beat on revenues in the fourth quarter  The HCV franchise sales are expected to decline further While the HIV franchise maintains momentum  driven by the rapid adoption of Descovy based regimens and Biktarvy  Gilead will have to generate substantial revenues from its HIV franchise to offset the HCV sales decline  This will be a challenging task for the company with stiff competition from the likes of GlaxoSmithKline   NYSE GSK   in the HIV market Given the persistent decline in HCV sales  the company is looking to HIV and newer avenues to help the top line  The initial uptake of Yescarta  from the Kite Pharma acquisition  is also encouraging but it will take some time for sales to contribute significantly to the top line  given the high cost of the treatment  Moreover  Novartis    NYSE NVS   Kymriah is also there in the market  posing competition Gilead has promising late stage candidates like selonsertib and filgotinib in the NASH and inflammation markets  respectively  The company also has a collaboration agreement with Sangamo Therapeutics  Inc  to use Sangamo s zinc finger nuclease technology platform for the development of next generation ex vivo cell therapies in oncology  Gilead also collaborated with Agneus   NASDAQ AGEN   for the development and commercialization of up to five novel immuno oncology therapies Meanwhile  on the earnings call  management hinted that the strong balance sheet should enable the company to go for mergers  acquisitions and partnerships to drive further growth Zacks Rank
Gilead currently carries a Zacks Rank  5  Strong Sell   
You can see  
Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-02-04,Zacks Investment Research,https://www.investing.com/analysis/gilead-gild-q4-earnings-miss-estimates-revenues-beat-200383733,200383733
201081,422597,GILD,Stocks Poised To Rise As Global Rally Marches On ,opinion,"February 5  2019
S P 500  3 6 points
10 Year Rate 2 73 
Oil  55 06
VIX 15 50
Dollar Index 95 97
International Markets
Japan  19 bps
South Korea  6 bps
China   Closed  Lunar New Year 
Hong Kong   Closed  Lunar New Year 
UK FTSE   1 43 
German Dax  1 23 
Key Events for February 5
President Trump  Sec  Mnuchin and FOMC Chair Powell had an informal dinner to discuss the economy 
President Trump to hold The State of the Union tonight 
ISM Non Manufacturing  Estimates for 57 2
Earnings
Tuesday PM
Disney
SNAP
EA
Skyworks
Wednesday AM
GM
Take Two
Wednesday PM
Chipotle
UK
It is incredibly positive that the UK FTSE continues to rally and is breaking above resistance at 7 120  If the rally can hold and the breakout and push higher  then there is a path for the index to rise to roughly 7 270 


Germany
The German DAX is also nearing a breaking out with the potential to rise to 11 535  The chart below shows what appears to be a bull flag formation 

Overall international equities continue to power higher  and that continues to be positive for US equity markets 
S P 500
The S P 500 is likely heading higher again today  with the index rising above critical resistance at 2 715 and is on its way to 2 800  I see no reason why stocks can t continue to rally today  The path to 2 800 seems fairly straight forward from here 

Semis  SMH 
The semiconductors continue to look very strong as well  with the SMH on a path to  101 

Technology  XLK 
The Technology ETF  NYSE XLK  appears headed towards  69 

Industrials  XLI 
The industrial ETF  NYSE XLI  is also nearing a pretty big break out should it rise above  73  It could be on its way back to  75 50 

Gilead  GILD 
Gilead Sciences Inc  NASDAQ GILD is falling this morning after posting disappointing results  The stock is falling back to lower support around  66 this morning 

SNAP Inc  SNAP 
Snap Inc  NYSE SNAP  reports tonight  and the stock is nearing a potential break out  Should it rise above  7 30  it could go on to advance to around  9 

Skyworks  SWKS 
Skyworks Solutions Inc  NASDAQ SWKS  broke out already and appears to be heading back towards  81 30

Advanced Micro Devices Inc  AMD 
AMD s run may be over with the stock falling below support at  24 and potentially on its way back to  21 

General Motors Company  GM 
General Motors Company  NYSE GM  has a bearish rising wedge pattern forming  and I am looking for a decline towards  35 

See you tonight 
Disclaimer  Michael Kramer and the Clients of Mott Capital own Disney and Skyworks
Original post",2019-02-05,Michael Kramer,https://www.investing.com/analysis/stocks-are-poised-to-rise-on-february-5-as-global-rally-marches-on-200383544,200383544
201082,422598,GILD,Gilead Dispenses Earnings Miss   Expect More Intermediate Term Pain,opinion,"Summary
Gilead  NASDAQ GILD  fell by as much as 4  on Tuesday morning  after the biotechnology company posted earnings that missed Wall Street expectations 
Our analysis of the stock s market cycle suggests there may be a pain in the coming months 

Gilead reported earnings per share of  1 44 and total revenue of  5 8 billion  above analyst estimates of  1 71 and  5 5 billion  Management projected revenue for the fiscal year of  21 3 21 8 billion  which was in line with the average estimate 
CFO Robin Washington further explained that  Our first guidance of the year does include downside risk  but our confidence around returning a net product revenue growth is strong  We look forward to updating you throughout the year as activities progress  
Our analysis of the market cycles for GILD is that the stock has likely begun the declining phase of its current cycle  Further  our analysis has shown the stock to be trading in negatively configured cycles  Having now failed in a key resistance zone  we believe the risks are rising for further declines  Indeed  by April  we expect a test of its December low 
For more from Slim  or to learn about cycle analysis  check out the askSlim Market Week show every Friday on our YouTube channel ",2019-02-05,Steve Miller,https://www.investing.com/analysis/gilead-dispenses-earnings-miss--expect-more-intermediate-term-pain-200383995,200383995
201100,422616,GILD,Fund managers boost bets on health care even amid high prices,news,By David Randall NEW YORK  Reuters    Last July  when Federal Reserve Chair Janet Yellen spurred a sell off in healthcare stocks by saying that valuations in shares of biotech companies looked  stretched   portfolio manager Graham Tanaka saw an opportunity   After a year long buying spree  he now has more than a quarter of his  17 million Tanaka Growth fund portfolio in healthcare companies such as  Gilead Sciences Inc   NASDAQ GILD   up from just 5 percent at the start of last year       That bet is paying off  his fund is beating the S P 500 by about 13 percentage points since the start of the year  putting Tanaka in the top 1 percent of equity fund managers tracked by Morningstar  Even with his big bet on healthcare  he s planning on adding more       With aging demographics in the US and the developed world  healthcare needs are going to grow dramatically faster than GDP   Tanaka said       In the eleven months since Yellen s warning  other fund managers have benefitted by shaking off concerns about high valuations and increasing their holdings of healthcare companies  The average U S  large cap equity fund run by a stockpicker now holds 15 8 percent of its portfolio in healthcare stocks  a position higher than any of the last 3 years  according to Lipper data       With a 10 percent rally in the sector so far this year  that outsized bet on healthcare is helping fund managers post their best performance relative to the S P 500 since 2007  the year before the financial crisis  Should the rally in healthcare continue  funds may finally be able to turn around a six year skid in which stockpickers have struggled to outperform benchmarks       Yet some market strategists and analysts said that the move to healthcare after its significant outperformance reminds them of the tech bubble of the late 1990s  when stock funds piled into the hot sector just before the dot com crash        Being negative on pharmaceuticals and biotech has not been the right move thus far in 2015  but almost all the objective data suggests that underperformance is likely in the months ahead   said Tobias Levkovich  chief U S  equity strategist at  Citigroup   NYSE C   in a note to clients Tuesday  citing a declining number of upward earnings revisions   Few investors are willing to back off what has been a very rewarding strategy  which also means that when they back away it could get somewhat messy       Still  because health spending is becoming a larger part of the economy  a broad selloff in healthcare companies akin to the popping of the tech bubble is unlikely  said Randy Gwirtzman  co portfolio manager of the  95 million Baron Discovery fund  who more than doubled his holdings of healthcare companies over the last year   Healthcare is expected to rise to 19 9 percent of U S  GDP by 2022 from 17 1 percent in 2013  according to the Office of the Actuary at the Centers for Medicare and Medicaid Services  GDP itself is expected to grow 2 4 percent this year  according to a Reuters poll of economists       Gwitzman is looking for companies that can help cut costs  rather than biotechs that offer the promise of new drugs  he said       His top holding  Foundation Medicine Inc  offers a form of cancer testing that allows doctors to offer targeted therapy more effectively  Shares of the company are up nearly 60 percent for the year after Swiss pharma giant Roche took a majority interest in the company in January        There s a lot to like in healthcare other than biotech   he said       If there is a pullback in the healthcare sector  it could be sharp  analysts such as Levkovich said  The Nasdaq Biotechnology index fell nearly 6 percent in three days after Yellen noted high valuations in July  After a subsequent rally  the biotech sector is now trading 43 percent higher than it was before she noted the high valuations          BUYING BEYOND BIOTECH     While few big name funds are significantly reducing their healthcare holdings  some top performing funds are becoming more cautious because of the extent of the rally in biotech and pharma companies  The Nasdaq Biotechnology index is up 52 percent over the last year  while the S P Pharmaceuticals index is up 33 percent over the same time  Those high prices are making it harder for fund managers to find attractive places to put their money  T  Rowe Price closed its  14 1 billion Health Sciences Fund to new investors Monday after receiving  1 1 billion in new investor dollars over the first four months of the year        We ve seen extraordinary returns from stocks like Gilead  but we haven t been taking on any new positions until we find extraordinary discounts   said Rafael Resendes  whose Toreador Core fund has bested 98 percent of other large cap funds over the last three years  Shares of Gilead are up 19 percent for the year to date  and nearly 40 percent over the last 12 months       Resendes  who still holds Gilead  expects to pare down his holdings of healthcare stocks this year because they no longer offer attractive prices      Other managers are sticking with healthcare  but branching out beyond its hottest sectors  Matthew Kaufler  a portfolio manager who oversees the  997 million Federated Clover Value fund  has been buying healthcare services companies as more baby boomers age  Kaufler owns shares in companies such as Brookdale Senior Living Inc  which runs upscale assisted living and retirement centers  Shares of the company are up 2 8 percent for the year to date       Healthcare companies overall in the S P 500 are expected to post an average earnings growth of 11 4 percent in 2015 compared with just a 0 6 percent gain among the index overall  according to S P Capital IQ ,2015-06-02,Reuters,https://www.investing.com/news/stock-market-news/fund-managers-boost-bets-on-health-care-even-amid-high-prices-344568,344568
201101,422617,GILD,AbbVie reports first revenue miss in six quarters,news, Reuters     AbbVie Inc   N ABBV  on Friday reported quarterly revenue that missed analysts  estimates for the first time in six quarters  sending its shares down 3 percent in premarket trading  Revenue rose 11 percent to  5 48 billion for the second quarter ended June 30  but missed the average analyst estimate of  5 62 billion  according to Thomson Reuters I B E S   Deutsche Bank   XETRA DBKGn  analyst Robyn Karnauskas attributed the revenue miss to smaller than expected sales of AbbVie s hepatitis C treatment  Viekira Pak  in the United States  AbbVie reported sales of  277 million for the drug in the United States  Karnauskas said the consensus expectation was  278 million  Viekira Pak  approved in December  is seen as AbbVie s next blockbuster  but the drug faces competition from Gilead Sciences Inc s  O GILD  Sovaldi and Harvoni  However  AbbVie s revenue was boosted by higher sales of its arthritis drug  Humira  and the inclusion of Pharmacyclics  blood cancer drug  Imbruvica  The company s profit jumped 24 percent to  1 37 billion  Excluding special items  Abbott earned  1 08 per share  above analysts  average estimate of  1 06 per share  AbbVie  which completed the acquisition of Pharmacyclics on May 26  backed its full year profit forecast of  4 10  4 30 per share  Up to Thursday s close of  70 52  the company s shares had gained about 8 percent this year ,2015-07-24,Reuters,https://www.investing.com/news/stock-market-news/abbvie-profit-jumps-24-percent-as-humira-sales-rise-352782,352782
201102,422618,GILD,Gilead Sciences  GILD  Outpaces Stock Market Gains  What You Should Know,opinion,"Gilead Sciences  NASDAQ GILD  closed at  68 52 in the latest trading session  marking a  1 89  move from the prior day  This move outpaced the S P 500 s daily gain of 1 07   At the same time  the Dow added 0 65   and the tech heavy Nasdaq gained 1 71  
Prior to today s trading  shares of the HIV and hepatitis C drugmaker had gained 3 27  over the past month  This has outpaced the Medical sector s loss of 2 4  and the S P 500 s loss of 0 58  in that time 
Investors will be hoping for strength from GILD as it approaches its next earnings release  which is expected to be February 4  2019  In that report  analysts expect GILD to post earnings of  1 74 per share  This would mark a year over year decline of 2 25   Our most recent consensus estimate is calling for quarterly revenue of  5 52 billion  down 7 24  from the year ago period 
It is also important to note the recent changes to analyst estimates for GILD  These recent revisions tend to reflect the evolving nature of short term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  Investors can capitalize on this by using the Zacks Rank  This model considers these estimate changes and provides a simple  actionable rating system 
Ranging from  1  Strong Buy  to  5  Strong Sell   the Zacks Rank system has a proven  outside audited track record of outperformance  with  1 stocks returning an average of  25  annually since 1988  Within the past 30 days  our consensus EPS projection remained stagnant  GILD is currently a Zacks Rank  3  Hold  
In terms of valuation  GILD is currently trading at a Forward P E ratio of 9 79  This valuation marks a discount compared to its industry s average Forward P E of 24 69 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This group has a Zacks Industry Rank of 58  putting it in the top 23  of all 250  industries 
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2019-01-15,Zacks Investment Research,https://www.investing.com/analysis/gilead-sciences-gild-outpaces-stock-market-gains-what-you-should-know-200375844,200375844
201103,422619,GILD,Analysts Estimate Gilead Sciences  GILD  To Report A Decline In Earnings  What To Look Out For,opinion,"The market expects Gilead Sciences  NASDAQ GILD  to deliver a year over year decline in earnings on lower revenues when it reports results for the quarter ended December 2018  This widely known consensus outlook is important in assessing the company s earnings picture  but a powerful factor that might influence its near term stock price is how the actual results compare to these estimates 
The earnings report  which is expected to be released on February 4  2019  might help the stock move higher if these key numbers are better than expectations  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This HIV and hepatitis C drugmaker is expected to post quarterly earnings of  1 74 per share in its upcoming report  which represents a year over year change of  2 3  
Revenues are expected to be  5 52 billion  down 7 3  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 4 14  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is subject to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Gilead 
For Gilead  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  4 72  
On the other hand  the stock currently carries a Zacks Rank of  4 
So  this combination makes it difficult to conclusively predict that Gilead will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Gilead would post earnings of  1 66 per share when it actually produced earnings of  1 84  delivering a surprise of  10 84  
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Gilead doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-01-27,Zacks Investment Research,https://www.investing.com/analysis/analysts-estimate-gilead-sciences-gild-to-report-a-decline-in-earnings-what-to-look-out-for-200380097,200380097
201115,422631,GILD,Intercept  ICPT  Benefits From Ocaliva s Recovery In 2018,opinion,"Shares of Intercept Pharmaceuticals  Inc    NASDAQ ICPT   have gained 59 2  in the year so far  against the  s decline of 25 6  

 
Intercept s focus is on treating orphan and more prevalent liver diseases with limited treatment options  The company received a significant boost with the FDA approval for lead drug Ocaliva  obeticholic acid OCA  in combination with UDCA  for the treatment of primary biliary cholangitis  PBC  in adults with an inadequate response to UDCA or as monotherapy in adults who are intolerant to UDCA in May 2016 
The FDA approved Ocaliva under its accelerated approval program based on a reduction in alkaline phosphatase  ALP   since an improvement in survival or disease related symptoms has not been established yet  Additionally  in December 2016  the European Commission granted conditional approval to Ocaliva in combination with UDCA  In May 2017  the drug was approved in Canada 
The initial uptake was encouraging  However  sales took a hit due to safety and dosing issues  Earleir  the FDA reported 19 deaths due to incorrect dosing of Ocaliva  and stated that the drug may also affect the liver  In February 2018  Ocaliva s label was updated in the United States  to include a boxed warning and a dosing table that reinforced the existing dosing schedule in PBC patients with Child Pugh Class B or C  or decompensated cirrhosis 
Nevertheless  management s efforts to increase awareness about the updated label and promote Ocaliva  thereafter  is reaping results  Ocaliva recorded  46 6 million of sales in the third quarter  up from  43 2 million recorded in the second quarter of 2018  The company has expanded its sales force to reach out to more physicians  and sales are expected to ramp up to come between  170 million and  185 million in 2018 
Meanwhile  Ocaliva is also being evaluated for other indications  including non alcoholic steatohepatitis   NASH   and primary sclerosing cholangitis   PSC    The phase III NASH program includes the REGENERATE trial among patients with advanced liver fibrosis and the REVERSE trial among patients with compensated cirrhosis 
The FDA earlier approved a redesign of the phase III REGENERATE trial on Ocaliva for the safety and efficacy in treating NASH patients with liver fibrosis  The company now needs to achieve only one co primary endpoint  either fibrosis improvement or NASH resolution compared with the earlier target of achieving both 
Top line results from the REGENERATE trial are expected in the first half of 2019  The REVERSE trial is designed to evaluate the efficacy and safety of Ocaliva in NASH patients with compensated cirrhosis 
The trial is currently enrolling 
Per estimates  NASH is expected to surpass hepatitis C as the leading reason for liver transplants in the United States and Europe  NASH market has huge potential  and a tentative approval will boost Ocaliva s prospects  further  This space has been in focus in 2018  with shares of a few companies soaring on positive data from their NASH candidates 
Gilead Sciences Inc    NASDAQ GILD   has a promising late stage NASH candidate  Israel based Galmed Pharmaceuticals   NASDAQ GLMD   earlier reported positive data on its NASH candidate  Aramchol  Madrigal Pharmaceuticals   NASDAQ MDGL   also has a promising candidate for NASH 
Zacks Rank
Intercept currently carries a Zacks Rank  2  Buy    You can see  
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2018-12-28,Zacks Investment Research,https://www.investing.com/analysis/intercept-icpt-benefits-from-ocalivas-recovery-in-2018-200371679,200371679
201116,422632,GILD,Gilead Sciences  GILD  Dips More Than Broader Markets  What You Should Know,opinion,"Gilead Sciences  NASDAQ GILD  closed the most recent trading day at  61 88  moving  1 68  from the previous trading session  This change lagged the S P 500 s 0 12  loss on the day  At the same time  the Dow lost 0 33   and the tech heavy Nasdaq gained 0 08  
Prior to today s trading  shares of the HIV and hepatitis C drugmaker had lost 9 69  over the past month  This has lagged the Medical sector s loss of 6 93  and the S P 500 s loss of 6 96  in that time 
Investors will be hoping for strength from GILD as it approaches its next earnings release  which is expected to be February 5  2019  In that report  analysts expect GILD to post earnings of  1 74 per share  This would mark a year over year decline of 2 25   Meanwhile  our latest consensus estimate is calling for revenue of  5 52 billion  down 7 26  from the prior year quarter 
For the full year  our Zacks Consensus Estimates are projecting earnings of  6 93 per share and revenue of  21 85 billion  which would represent changes of  21 61  and  16 31   respectively  from the prior year 
It is also important to note the recent changes to analyst estimates for GILD  These revisions help to show the ever changing nature of near term business trends  With this in mind  we can consider positive estimate revisions a sign of optimism about the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate remained stagnant  GILD currently has a Zacks Rank of  3  Hold  
Investors should also note GILD s current valuation metrics  including its Forward P E ratio of 9 08  Its industry sports an average Forward P E of 22 13  so we one might conclude that GILD is trading at a discount comparatively 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This group has a Zacks Industry Rank of 69  putting it in the top 27  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Be sure to follow all of these stock moving metrics  and many more  on Zacks com ",2018-12-28,Zacks Investment Research,https://www.investing.com/analysis/gilead-sciences-gild-dips-more-than-broader-markets-what-you-should-know-200371694,200371694
201117,422633,GILD,Gilead  GILD  Collaborates With Yuhan For NASH Candidates ,opinion,Gilead Sciences  Inc    NASDAQ GILD   announced that it entered into a licensing and collaboration agreement with South Korea based Yuhan Corporation Both the companies have entered into a licensing and collaboration agreement to co develop novel therapeutic candidates for the treatment of patients suffering from advanced fibrosis due to non alcoholic steatohepatitis  NASH  Per the agreement  Gilead will acquire global rights to develop and commercialize novel small molecules against two undisclosed targets in all countries  except for Republic of Korea where Yuhan will retain certain commercialization rights  While both the companies will jointly conduct preclinical research  Gilead will be responsible for global clinical development  This agreement builds on the companies  existing commercial collaboration to support the promotion of Gilead s drugs in Korea Gilead will pay Yuhan an upfront fee of  15 million  Yuhan is also entitled to receive milestone payments of  770 million Gilead was once a market outperformer  with its strong HCV franchise boasting a number of blockbuster drugs  However  the HCV franchise has been under pressure since the last three four years due to competitive pressure from the likes of AbbbVie  Inc    NYSE ABBV   Consequently  Gilead had shifted focus to its HIV franchise and newer avenues like CAR T therapy and NASH Gilead already has a late stage candidate  selonsertib  and a mid stage candidate  investigational  selective  non steroidal farnesoid X receptor  FXR  agonist  GS 9674 The market for NASH promises potential   A chronic liver disease  NASH is caused by excessive fat accumulation in the liver  which  in turn  is known as steatosis  NASH is known to affect up to 15 million people in the United States and could lead to inflammation  hepatocellular injury  progressive fibrosis and cirrhosis  It is expected to become the leading cause for liver transplantation by 2020 Patients living with NASH have limited treatment options  Hence  the successful development of its candidates will significantly boost Gilead Gilead s stock has lost 9 5  in the past six months compared with the s decline of 17 6   Given the prospects of the NASH market  quite a few companies are developing candidates for the same  Intercept Pharmaceuticals  Inc    NASDAQ ICPT   is presently evaluating lead drug Ocaliva in non cirrhotic NASH patients with liver fibrosis   Merck   NYSE MRK   recently exercised its option to license NGM313  an investigational monoclonal antibody agonist of the   Klotho FGFR1c receptor complex that is currently being evaluated for the treatment of NASH and type 2 diabetes Zacks RankGilead currently carries a Zacks Rank  3  Hold   You can see  3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2019-01-06,Zacks Investment Research,https://www.investing.com/analysis/gilead-gild-collaborates-with-yuhan-for-nash-candidates-200373327,200373327
201118,422634,GILD,Gilead Sciences  GILD  Gains But Lags Market  What You Should Know,opinion,"Gilead Sciences  NASDAQ GILD  closed the most recent trading day at  68 56  moving  0 45  from the previous trading session  This change lagged the S P 500 s 0 7  gain on the day  Meanwhile  the Dow gained 0 42   and the Nasdaq  a tech heavy index  added 1 26  
Prior to today s trading  shares of the HIV and hepatitis C drugmaker had lost 2 76  over the past month  This has was narrower than the Medical sector s loss of 6 76  and the S P 500 s loss of 6 13  in that time 
Investors will be hoping for strength from GILD as it approaches its next earnings release  which is expected to be February 5  2019  On that day  GILD is projected to report earnings of  1 74 per share  which would represent a year over year decline of 2 25   Meanwhile  our latest consensus estimate is calling for revenue of  5 52 billion  down 7 24  from the prior year quarter 
Any recent changes to analyst estimates for GILD should also be noted by investors  These recent revisions tend to reflect the evolving nature of short term business trends  As such  positive estimate revisions reflect analyst optimism about the company s business and profitability 
Research indicates that these estimate revisions are directly correlated with near term share price momentum  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate remained stagnant  GILD is currently a Zacks Rank  3  Hold  
Digging into valuation  GILD currently has a Forward P E ratio of 9 93  Its industry sports an average Forward P E of 22 64  so we one might conclude that GILD is trading at a discount comparatively 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This group has a Zacks Industry Rank of 58  putting it in the top 23  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
Make sure to utilize Zacks  Com to follow all of these stock moving metrics  and more  in the coming trading sessions ",2019-01-07,Zacks Investment Research,https://www.investing.com/analysis/gilead-sciences-gild-gains-but-lags-market-what-you-should-know-200373443,200373443
201119,422635,GILD,Is Eventide Gilead Fund N  ETGLX  A Strong Mutual Fund Pick Right Now ,opinion,"If you have been looking for Mid Cap Growth funds  it would not be wise to start your search with Eventide Gilead  NASDAQ GILD  Fund N  ETGLX   ETGLX holds a Zacks Mutual Fund Rank of 5  Strong Sell   which is based on nine forecasting factors like size  cost  and past performance 
Objective
Zacks categorizes ETGLX as Mid Cap Growth  a segment packed with options  Mid Cap Growth mutual funds aim to target companies with a market capitalization between  2 billion and  10 billion that are also expected to exhibit more extensive growth opportunities for investors than their peers  A firm is typically considered to be a growth stock if it consistently posts impressive sales and or earnings growth 
History of Fund Manager
ETGLX is a part of the Eventide family of funds  a company based out of Willow Grove  PA  Eventide Gilead Fund N made its debut in July of 2008  and since then  ETGLX has accumulated about  412 39 million in assets  per the most up to date date available  The fund is currently managed by Finny Kuruvilla who has been in charge of the fund since July of 2008 
Performance
Obviously  what investors are looking for in these funds is strong performance relative to their peers  This fund carries a 5 year annualized total return of 10 8   and is in the top third among its category peers  If you re interested in shorter time frames  do not dismiss looking at the fund s 3 year annualized total return of 12 03   which places it in the top third during this time frame 
When looking at a fund s performance  it is also important to note the standard deviation of the returns  The lower the standard deviation  the less volatility the fund experiences  Over the past three years  ETGLX s standard deviation comes in at 16 18   compared to the category average of 9 45   The standard deviation of the fund over the past 5 years is 15 83  compared to the category average of 9 54   This makes the fund more volatile than its peers over the past half decade 
Risk Factors
It s always important to be aware of the downsides to any future investment  so one should not discount the risks that come with this segment 
Nevertheless  investors should also note that the fund has a 5 year beta of 1 22  which means it is hypothetically more volatile than the market at large  Alpha is an additional metric to take into consideration  since it represents a portfolio s performance on a risk adjusted basis relative to a benchmark  which in this case  is the S P 500  The fund has produced a negative alpha over the past 5 years of  1 76  which shows that managers in this portfolio find it difficult to pick securities that generate better than benchmark returns 
Holdings
Exploring the equity holdings of a mutual fund is also a valuable exercise  This can show us how the manager is applying their stated methodology  as well as if there are any inherent biases in their approach  For this particular fund  the focus is largely on equities that are traded in the United States 
Currently  this mutual fund is holding 91 16  stock in stocks  and these companies have an average market capitalization of  16 84 billion  The fund has the heaviest exposure to the following market sectors  Other Technology Health Retail Trade Industrial Cyclical Turnover is 24   which means this fund makes fewer trades than its comparable peers Expenses
For investors  taking a closer look at cost related metrics is key  since costs are increasingly important for mutual fund investing  Competition is heating up in this space  and a lower cost product will likely outperform its otherwise identical counterpart  all things being equal  In terms of fees  ETGLX is a no load fund  It has an expense ratio of 1 39  compared to the category average of 1 21   From a cost perspective  ETGLX is actually more expensive than its peers 
Investors should also note that the minimum initial investment for the product is  1 000 and that each subsequent investment needs to be at  50 
Bottom Line
Overall  Eventide Gilead Fund N   ETGLX   has a low Zacks Mutual Fund rank  and in conjunction with its comparatively strong performance  worse downside risk  and higher fees  this fund looks like a poor potential choice for investors right now 
Your research on the Mid Cap Growth segment doesn t have to stop here  You can check out all the great mutual fund tools we have to offer by going to  to see the additional features we offer as well for additional information  And don t forget  Zacks has all of your needs covered on the equity side too  Make sure to check out Zacks com for more information on our screening capabilities  Rank  and all our articles as well ",2019-01-11,Zacks Investment Research,https://www.investing.com/analysis/is-eventide-gilead-fund-n-etglx-a-strong-mutual-fund-pick-right-now-200374684,200374684
201130,422646,GILD,Bristol Myers  Label Expansion Of Sprycel Gets CHMP Nod,opinion,"Bristol Myers Squibb Company   NYSE BMY   announced that the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency has given a positive opinion on the label expansion of oncology drug Sprycel 
The CHMP recommended approval of the drug in combination with chemotherapy  to include the treatment of pediatric patients with newly diagnosed Philadelphia chromosome positive  Ph   acute lymphoblastic leukemia  ALL   The positive opinion includes the tablet form of Sprycel and the powder for oral suspension formulation  which was first approved by the European Commission  EC  in July 2018  making Sprycel the only tyrosine kinase inhibitor with a formulation developed for administration in pediatric patients and patients who cannot swallow tablets 
The EC will now review the recommendation but is not bound by it 
The CHMP recommendation will now be reviewed by the EC  which has the authority to approve medicines for the European Union  EU  
The company s supplemental Biologics License Application  sBLA  for the same indication is under review in the United States  The FDA action date is Dec 29  2018 
We note that Sprycel is already approved in the United States for the treatment of adults with Ph  chronic myeloid leukemia  CML  in chronic phase  CP   The drug also received the FDA approval for adults with Ph  ALL who are resistant to or intolerant of prior therapy  The FDA also approved Sprycel s label expansion to include pediatric patients with Ph  CML CP in November 2017 and the European Commission approved the same in July 2018 
Concurrently  Bristol Myers Squibb  Eisai Co   Ltd  and its U S  based precision medicine research   development subsidiary H3 Biomedicine  Inc  announced a multi year research collaboration  The companies will focus on novel therapeutics generating from H3 s RNA splicing platform and evaluate if these can provide a more powerful response against cancer 
The collaboration will explore modulating RNA splicing to develop potential first in class therapies that would direct the immune system to target cancer cells and help more patients experience the benefits of immunotherapy 
Per the terms  H3 and Bristol Myers will jointly conduct the research  focusing on developing immune therapies using H3 s RNA splicing platform  While the former will be responsible for development and commercialization of selected compounds  the latter is entitled to receive an upfront payment along with development  regulatory and sales milestones  and certain royalties according to sales revenue after launch  On the other hand  Eisai retains an option to co develop and co commercialize certain compounds that emerge from the collaborative research effort 
Moreover  Bristol Myers announced a multi year joint research study with Boston Medical Center to identify and analyze potential sensitivity and resistance markers in patients treated with standard of care checkpoint inhibitors  The study will primarily focus on uncovering mechanisms associated with lack of response to Immuno Oncology  I O  therapies 
Approval of new drugs and label expansion of existing drugs bode well for Bristol Myers  Bristol Myers  stock has decreased 13 1  in the year so far  against the  growth of 6 3  

 
While its blockbuster drug  Opdivo continues to perform well and the label expansion of the drug will further boost the top line  pricing concerns and stiff competition in the immuno oncology space are major concerns  In particular  Merck s   NYSE MRK   Keytruda and Roche s   OTC RHHBY   Tecentriq pose stiff competition 
Hence  the label expansion of other drugs of the company should maintain the top line momentum 
Another drug of Bristol Myers  Eliquis is also expected to drive further growth  driven by increases in market share in the novel oral anticoagulant  NOAC  market 
Zacks Rank   Other Key Pick
Bristol Myers currently carries a Zacks Rank  1  Strong Buy   Another top ranked stock from the same space is Gilead Sciences  Inc    NASDAQ GILD    which carries the same rank as Bristol Myers  You can see  
Gilead s earnings per share estimates increased from  6 65 to  6 93 for 2018 over the past 60 days  Estimates for 2019 are also up by 30 cents 
3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ",2018-12-19,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-label-expansion-of-sprycel-gets-chmp-nod-200369333,200369333
201131,422647,GILD,Gilead Partners With Scholar Rock For Fibrotic Disease Drugs,opinion,"Gilead Sciences  Inc    NASDAQ GILD   announced that it entered into a strategic collaboration with clinical stage biopharmaceutical company Scholar Rock Holding Corp    NASDAQ SRRK   to discover and develop highly specific inhibitors of transforming growth factor beta  TGF   activation for the treatment of fibrotic diseases 
Financial Value of the Transaction
Scholar Rock will receive  80 million in upfront payments  comprised of  50 million cash and  30 million purchase of Scholar Rock Holding Corporation common stock  Gilead will also pay Scholar Rock a one time milestone payment of  25 million upon the successful completion of specific preclinical studies and be eligible to receive up to an additional  1 425 million in potential payments aggregated across all three programs based on the successful achievement of certain research  development  regulatory and commercialization milestones 
In addition  Scholar Rock would also receive high single digit to low double digit tiered royalties on sales of potential future products originating from the collaboration 
Strategic Value of the Transaction  
Per the agreement  Gilead obtained exclusive options to license worldwide rights to product candidates that emerge from three Scholar Rock TGF  programs   inhibitors targeting activation of latent TGF 1 with high affinity and specificity  inhibitors selectively targeting activation of latent TGF 1 localized to extracellular matrix  and a third TGF  discovery program 
On the other hand  Scholar Rock is responsible for antibody discovery and preclinical research through product candidate nomination  If Gilead chooses to exercise the option  the company will be responsible for the program s preclinical and clinical development and commercialization 
Scholar Rock retains exclusive worldwide rights to discover  develop and commercialize certain TGF  inhibitors for oncology and cancer immunotherapy  Moreover  Scholar Rock would also receive high single digit to low double digit tiered royalties on sales of potential future products originating from the collaboration 
Our Take
Gilead is making efforts to develop its pipeline in the fibrotic disease sphere  which includes non alcoholic steatohepatitis  NASH  and diabetic kidney disease 
Gilead s stock has lost 8 8  in the past six months compared with the s decline of 20 1  

 
Gilead was once a market outperformer  with its strong HCV franchise boasting a number of blockbuster drugs  However  the HCV franchise has been under pressure since the last three four years due to competitive pressure from the likes of AbbbVie  Inc    NYSE ABBV   
Consequently  Gilead had shifted focus on its HIV franchise and newer avenues like CAR T therapy 
Gilead has been trying to revive its portfolio of late  Gilead has promising late stage candidates   selonsertib and filgotinib   in the NASH and inflammation markets  The company also has a collaboration agreement with Sangamo Therapeutics  Inc    NASDAQ SGMO   to use Sangamo s zinc finger nuclease technology platform for the development of next generation ex vivo cell therapies in oncology 
Zacks Rank
Gilead currently carries a Zacks Rank  1  Strong Buy   You can see  
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6  and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-12-20,Zacks Investment Research,https://www.investing.com/analysis/gilead-partners-with-scholar-rock-for-fibrotic-disease-drugs-200370029,200370029
201132,422648,GILD,Bristol Myers To Sell French Consumer Health Unit For  1 6B,opinion,"Bristol Myers Squibb Company   NYSE BMY   announced that it has received an offer from an over the counter  OTC  drug company in Japan  Taisho Pharmaceutical Holdings Co   Ltd  to purchase the former s consumer health business in France  UPSA for  1 6 billion 
Financial Terms of the Transaction
The potential sale is expected to be completed in the first half of 2019  subject to regulatory approvals and meeting of certain other customary closing conditions  Per the terms  the offer is subject to Bristol Myers  exercise of the put option 
Once the put option is exercised  Bristol Myers and Taisho would execute a definitive stock and assets purchase agreement  Thereafter  Taisho would acquire all of the issued and outstanding shares of capital stock of UPSA SAS as well as Bristol Myers  assets and liabilities related to the UPSA product portfolio  Assuming completion  Bristol Myers estimates the potential transaction to be dilutive to the bottom line by 4 cents in 2019  
Strategic Aspect of the Transaction
UPSA  a French pharmaceutical company and a brand owned by Bristol Myers  develops drugs and supplements for day to day ailments  Its portfolio covers a wide range of therapeutic areas like pain  cough   cold  vitamins and supplements  gastrointestinal and sleep 
However  the UPSA business no longer fits in Bristol Myers  core focus area of drugs  and hence the company has decided to divest the same  The company has been looking for potential sale options for the business since June 2018 
Taisho had earlier purchased PT Squibb Indonesia from Bristol Myers  and subsequently entered the OTC market in certain Asian countries 
Our Take
Bristol Myers is in the process of realigning its portfolio to focus better on drugs for patients facing serious diseases 
While its blockbuster drug  Opdivo continues to perform well and the label expansion of the same will further boost the top line  pricing concerns and stiff competition in the immuno oncology space are major concerns  In particular  Merck s   NYSE MRK   Keytruda and Roche s   OTC RHHBY   Tecentriq pose stiff competition 
Bristol Myers s stock has decreased 15 6  in the year so far  against the  growth of 4 9  

 
The company recently announced a multi year research collaboration with Eisai Co   Ltd  and its U S  based precision medicine research   development subsidiary H3 Biomedicine  Inc  to focus on novel therapeutics generating from H3 s RNA splicing platform and evaluate if these can provide a more powerful response against cancer 
Moreover  Bristol Myers announced a multi year joint research study with Boston Medical Center to identify and analyze potential sensitivity and resistance markers in patients treated with standard of care checkpoint inhibitors  The study will primarily focus on uncovering mechanisms associated with lack of response to Immuno Oncology  I O  therapies 
Zacks Rank   Other Key Pick
Bristol Myers currently carries a Zacks Rank  1  Strong Buy   Another top ranked stock from the same space is Gilead Sciences  Inc    NASDAQ GILD    which carries the same rank as Bristol Myers  You can see  
Gilead s earnings per share estimates increased from  6 65 to  6 93 for 2018 over the past 60 days  Estimates for 2019 are also up by 19 cents 
Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-12-20,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-to-sell-french-consumer-health-unit-for-16b-200370027,200370027
201133,422649,GILD,Biotech Stock Roundup  ALXN  ACOR Drugs  Get FDA Nod  AGEN Up On GILD Deal,opinion,"It was a busy week for the biotech sector with regulatory updates  The FDA approved Alexion s  PNH drug  Ultomiris  ahead of scheduled date and Acorda Therapeutics    NASDAQ ACOR   PD therapy   Meanwhile  Agenus soared on a deal with bigwig Gilead Sciences  Inc    NASDAQ GILD   Recap of the Week s Top Stories Alexion Gets Approval For Blood Disorder Drug   Alexion announced that the FDA has approved long acting C5 complement inhibitor Ultomiris for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria  PNH  to be administered every eight weeks  The FDA approval comes well ahead of its action date set for Feb 18  2019  The FDA approval was supported by results from two phase III studies  which included 441 patients  who had either never been treated with a complement inhibitor before or who had been stable on Alexion s lead drug Soliris  eculizumab   The studies showed that the efficacy of Ultomiris  administered every eight weeks  was non inferior to the efficacy of Soliris  administered every two weeks on all 11 endpoints   The safety profile of Ultomiris was similar to that of Soliris  The approval will complement Alexion s existing drug Soliris Agenus Soars on Deal With Gilead  Shares of Agenus  Inc    NASDAQ AGEN   soared after the company stuck a partnership deal with biotech bigwig Gilead  Both companies have entered into an immuno oncology  I O  partnership focused on the development and commercialization of up to five novel immuno oncology therapies  Per the agreement  Agenus will get an upfront  120 million cash payment and a  30 million equity investment  The company is also eligible for about  1 7 billion in potential future fees and milestones On the other hand  Gilead will receive worldwide exclusive rights to AGEN1423 and an exclusive option to license two additional programs  AGEN1223 and AGEN2373   The company has filed the IND for AGEN1223 and has a planned IND filing for AGEN2373 in the first half of 2019   Agenus will be responsible for developing the option programs up to the option decision points  at which time the latter can exercise its option and acquire exclusive rights to the programs on option exercise   For one of the option programs  Agenus will have the right to opt in to shared development and commercialization in the United States   Gilead will also receive the right of first negotiation for two additional  undisclosed preclinical programs  Gilead Partners with Scholar Rock for Fibrotic Disease Drugs  Gilead announced that it entered into a strategic collaboration with clinical stage biopharmaceutical company Scholar Rock Holding Corp    NASDAQ SRRK   to discover and develop highly specific inhibitors of transforming growth factor beta  TGF   activation for the treatment of fibrotic diseases  Scholar Rock will receive  80 million in upfront payments  comprising  50 million cash and  30 million purchase of Scholar Rock Holding Corporation common stock  Gilead will also pay Scholar Rock a one time milestone payment of  25 million upon the successful completion of specific preclinical studies and be eligible to receive up to an additional  1 425 million in potential payments aggregated across all three programs based on the successful achievement of certain research  development  regulatory and commercialization milestones In addition  Scholar Rock would also receive high single digit to low double digit tiered royalties on sales of potential future products originating from the collaboration  Per the agreement  Gilead obtained exclusive options to license worldwide rights to product candidates that emerge from three Scholar Rock TGF  programs   inhibitors targeting activation of latent TGF 1 with high affinity and specificity  inhibitors selectively targeting activation of latent TGF 1 localized to extracellular matrix  and a third TGF  discovery program  On the other hand  Scholar Rock is responsible for antibody discovery and preclinical research through product candidate nomination  If Gilead chooses to exercise the option  the company will be responsible for the program s preclinical and clinical development and commercialization Gilead currently carries a Zacks Rank  2  Buy   You can see  Acorda Gets FDA Nod ForParkinson s Disease Drug  Acorda announced that the FDA has approved its Parkinson s disease  PD  drug Inbrija  levodopa inhalation powder   The product was approved for treating OFF periods  return of Parkinson s symptoms that result from low levels of dopamine between doses of oral carbidopa levodopa  in PD patients  who are receiving carbidopa   levodopa regimen  Inbrija is expected to be launched during the first quarter of 2019  The FDA was expected to make its decision on Inbrija in October  However  in September the FDA delayed its verdict by three months and set an action date of Jan 5  2019  The FDA approval thus comes slightly earlier than expected FDA Approves Stemline s Drug  Stemline Therapeutics  Inc   NASDAQ STML   received FDA approval for its CD123 targeted therapy  Elzonris  tagraxofusp erzs  SL 401  for the treatment of blastic plasmacytoid dendritic cell neoplasm  BPDCN  in adult and pediatric patients two years and older  in both treatment na ve and previously treated populations  The therapy will be available in early 2019  BPDCN is an aggressive hematologic malignancy  The therapy is also under review in the United States PerformanceMedical   Biomedical and Genetics Industry 5YR   Return
 The NASDAQ Biotechnology index lost 8 79  in the last four trading sessions  Among the major biotech stocks  Alexion lost 11 4   Over the past six months  shares of Regeneron have rallied 4 14   while Alexion has dropped 24 7    See the last biotech stock roundup here   What s Next in Biotech Stay tuned for more regulatory and pipeline updates Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-12-25,Zacks Investment Research,https://www.investing.com/analysis/biotech-stock-roundup-alxn-acor-drugs-get-fda-nod-agen-up-on-gild-deal-200370990,200370990
201148,422664,GILD,Merck Expands Hep C Drug Market Reach With Idenix Acquisition,news,"By    Merck   Co  NYSE MRK  announced Monday that it will acquire Idenix Pharmaceuticals  NASDAQ IDIX  for  3 85 billion  to establish a stronger foothold in the market for hepatitis C drugs 
New Jersey based vaccine maker Merck said that it will pay  24 50 a share in cash  which is 3 4 times the value of Idenix stock  which closed at  7 23 on Friday  The deal will allow the  169 billion company to add an Idenix product to two of its own hepatitis C drugs  and help move the drugs to market within the next two years and directly compete with Gilead Sciences Inc  NASDAQ GILD   which makes Sovaldi  the current leader in hepatitis C treatment  and has been accused of patent infringement by Idenix and Merck separately 
 Idenix has established a promising portfolio of hepatitis C candidates   Roger Perlmutter  president of Merck Research Laboratories said  in a company statement released Monday  adding   Idenix s investigational hepatitis C candidates complement our promising therapies in development and will help advance our work to develop a highly effective  once daily  all oral  ribavirin free  pan genotypic regimen that has a duration of treatment as short as possible for millions of patients in need around the world  
The deal is expected to close in the third quarter and help reduce the treatment period for hepatitis C to between eight to 12 weeks  down from the current year long treatment regimen  More than 150 million people worldwide suffer from hepatitis C  for which no vaccine is currently available  while three million Americans suffer from the disease  which primarily affects the liver 
Last year  Merck announced that it is conducting third stage clinical trials for two of its mixed drugs for hepatitis C  and is trying to get them to market in the next two years  And  access to the Idenix drug will reportedly allow Merck to devise a treatment that will keep different versions of the virus in check for more than four weeks  and limit dosage to once a day  Perlmutter told the New York Times s DealBook blog 

 My belief is that a three drug regimen will work even faster   Perlmutter said  according to the Times  adding   We are betting  I m betting  that through this transaction we will be able to demonstrate superiority to any other regimen  
Last week  German pharmaceuticals major Bayer decided to buy Merck s consumer care business for  14 2 billion and expects to close the transaction by the end of this year  Merck  which stands to lose exclusivity on a number of its patents  eliminated 8 500 jobs last October 
While Massachusetts based Idenix s shares were up 229 05 percent in after hours trading on NASDAQ on Monday  Merck s stock ended almost flat  ending 0 16 percent up  in trading on the New York Stock Exchange ",2014-06-10,International Business Times,https://www.investing.com/news/stock-market-news/merck-expands-hep-c-drug-market-reach-with-idenix-acquisition-288784,288784
201152,422668,GILD,Gilead Sciences  GILD  Stock Moves  0 69   What You Should Know,opinion,"In the latest trading session  Gilead Sciences  NASDAQ GILD  closed at  65 12  marking a  0 69  move from the previous day  This change was narrower than the S P 500 s 2 08  loss on the day  Meanwhile  the Dow lost 2 11   and the Nasdaq  a tech heavy index  lost 2 27  
Prior to today s trading  shares of the HIV and hepatitis C drugmaker had lost 6 03  over the past month  This has lagged the Medical sector s loss of 1 48  and the S P 500 s loss of 3 6  in that time 
GILD will be looking to display strength as it nears its next earnings release  which is expected to be February 5  2019  In that report  analysts expect GILD to post earnings of  1 74 per share  This would mark a year over year decline of 2 25   Our most recent consensus estimate is calling for quarterly revenue of  5 52 billion  down 7 26  from the year ago period 
Looking at the full year  our Zacks Consensus Estimates suggest analysts are expecting earnings of  6 93 per share and revenue of  21 85 billion  These totals would mark changes of  21 61  and  16 31   respectively  from last year 
It is also important to note the recent changes to analyst estimates for GILD  These revisions help to show the ever changing nature of near term business trends  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  To benefit from this  we have developed the Zacks Rank  a proprietary model which takes these estimate changes into account and provides an actionable rating system 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Over the past month  the Zacks Consensus EPS estimate remained stagnant  GILD currently has a Zacks Rank of  1  Strong Buy  
Looking at its valuation  GILD is holding a Forward P E ratio of 9 46  Its industry sports an average Forward P E of 21 68  so we one might conclude that GILD is trading at a discount comparatively 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 63  which puts it in the top 25  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow GILD in the coming trading sessions  be sure to utilize Zacks com ",2018-12-17,Zacks Investment Research,https://www.investing.com/analysis/gilead-sciences-gild-stock-moves-069-what-you-should-know-200368891,200368891
201153,422669,GILD,Puma Biotech s Nerlynx Ups Survival In Third Line Breast Cancer,opinion,Puma Biotechnology  Inc    NASDAQ PBYI   announced positive top line results from the phase III NALA study  evaluating its only marketed drug  Nerlynx  neratinib   for the treatment of third line hormone receptor positive  HER2 positive  metastatic breast cancer We would like to remind investors that in September this year  Puma Biotech received the EU approval for Nerlynx as an extended adjuvant treatment of early stage HER2 positive breast cancer in patients  previously treated with Roche s Herceptin based adjuvant therapy  The drug was approved for the same indication in the United States in July 2017 The NALA study evaluated a combination of Nerlynx and Roche s   OTC RHHBY   Xeloda  capecitabine  as compared to Novartis    NYSE NVS   Tykerb  lapatinib  plus Xeloda in patients with HER2 positive metastatic breast cancer  who have failed two or more prior lines of HER2 directed treatments The study enrolled 621 patients  The co primary endpoints of the same are centrally confirmed progression free survival  PFS  and overall survival  OS   Notably  the study was to be considered positive if either of the co primary endpoints were found to be positive Data from the study showed that patients  who received Nerlynx   Xeloda  experienced a statistically significant improvement in centrally confirmed PFS compared with those who were administered with Tykerb   Xeloda  However  the combo regime of Nerlynx   Xeloda led to an improved OS but failed to achieve a statistical significance Puma Biotech will submit the study s full and final results to global health and regulatory authorities and present the same at a future medical conference in 2019  If the company gets an approval to include the NALA study outcome on Nerlynx s label  it will be eligible to treat a broader breast cancer population  which can drive sales higher Shares of Puma Biotech have plummeted 78 3  so far this year  significantly wider than the  decline of 20 7  In the first nine months of 2018  Nerlynx generated sales of  139 4 million  However  the metric in the third quarter of 2018 fell below expectations due to higher patient discontinuation Apart from the HER2 positive breast cancer indication  Puma Biotech believes that Nerlynx holds great potential for treating multiple cancers including NSCLC and other tumor types  which over express or have a mutation in HER2  Several additional assessments on Nerlynx targeting different types of breast cancer patient population and in earlier line settings are currently underway  The drug s label expansion will allow it to treat and access an extended patient population Zacks Rank   Stock to ConsiderPuma Biotech currently carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector is Gilead Sciences  Inc    NASDAQ GILD    which sports a Zacks Rank  1  Strong Buy   You can see  Gilead s earnings estimates have moved 4 2  north for 2018 and 2 9  for 2019 over the past 60 days 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-12-17,Zacks Investment Research,https://www.investing.com/analysis/puma-biotechs-nerlynx-ups-survival-in-thirdline-breast-cancer-200369150,200369150
201154,422670,GILD,Evofem Shares Up As Birth Control Gel Succeeds In Phase III ,opinion,"Shares of clinical stage biotechnological company Evofem Biosciences  Inc    NASDAQ EVFM   soared after the company announced that its late stage trial AMPOWER on lead candidate Amphora for the prevention of pregnancy was successful Amphora is a non hormonal  on demand  woman controlled prescription birth control vaginal gel The phase III study assessed the efficacy  safety and subject satisfaction with Amphora in approximately 1 400 healthy women aged 18 35 years at 112 centers  The primary endpoint of the study was the pregnancy rate over seven cycles of use  one cycle   21 35 days  as assessed by the Kaplan Meier statistical method  The data from the study showed a cumulative pregnancy rate of 14 0  over seven cycles of use  which corresponds to an efficacy rate of 86   Consequently  the study met its primary endpoint  The efficacy went up to 98 7  with the cumulative pregnancy rate of 1 3  over seven cycles of use when Amphora was used as directed  Evofem is developing two proprietary Multipurpose Vaginal pH Regulator  MVP R  product candidates for multiple potential indications  including prevention of pregnancy  prevention of sexually transmitted infections  STIs   and reduction of recurrent bacterial vaginosis  BV   The lead MVP R product candidate is Amphora The company plans to submit the New Drug Application to the FDA for Amphora in the second quarter of 2019 and also analyse the data further  Assuming approval  the company will commercialize this first in class MVP R for birth control in January 2020 The FDA will also review the number of pregnancies and evaluable cycles included in Evofem s calculation of the pregnancy rate using the Kaplan Meier method Meanwhile  data from the study also included an exploratory secondary endpoint of sexual satisfaction  This data will be submitted for presentation at upcoming scientific conferences and for publication in peer reviewed journals following further analyses Evofem shares are down 68 9  in the year so far compared to the  s decline of 21 4  A potential approval will boost growth prospects of the company  The company earlier suffered a setback when it had submitted an NDA to the FDA for Amphora in 2015  However  the agency had issued a Complete Response Letter  CRL  in April 2016  citing the difference in results between the United States and Russian cohorts Amphora is also being evaluated in a phase IIb trial  AMPREVENCE  for the prevention of urogenital transmission of chlamydia and gonorrhea in women  Evofem s pipeline also includes an MVP R product candidate for reduction of recurrent BV  The company is currently planning a phase II clinical trial in this indication  based on positive phase I results However  the market for drugs gels indicated for the prevention of pregnancy is crowded  Competition is stiff from the likes of Merck s   NYSE MRK   NuvaRing  among others  Moreover  the contraception products come with its set of risks  In July 2018  Bayer   OTC BAYRY   announced that it will discontinue the sales of Essure  a female contraceptive implant  by Dec 31 due to health risks Zacks Rank   Key Picks
Evofem currently carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector is Gilead Sciences  Inc    NASDAQ GILD    which sports a Zacks Rank  1  Strong Buy   You can see  Gilead s earnings per share estimates increased from  6 65 to  6 93 for 2018 over the past 60 days  Estimates for 2019 are also up by 19 cents 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ",2018-12-18,Zacks Investment Research,https://www.investing.com/analysis/evofem-shares-up-as-birth-control-gel-succeeds-in-phase-iii-200369240,200369240
201170,422686,GILD,US STOCKS SNAPSHOT Wall St extends losses  biotechs drag Nasdaq,news,"NEW YORK  Aug 6  Reuters    U S  stocks extended declines
on Thursday  with the Nasdaq briefly dropping 1 percent 
weighed down by declines in biotech companies such as Celgene
Corp and Gilead Sciences Inc 
   The Dow Jones industrial average dropped 38 24 points  or
0 41 percent  to 9 242 73  The Standard   Poor s 500 Index
dropped 5 95 points  or 0 59 percent  to 996 77  The Nasdaq
Composite Index dropped 16 52 points  or 0 83 percent  to
1 976 53 ",2009-08-06,Reuters,https://www.investing.com/news/equities-news/us-stocks-snapshot-wall-st-extends-losses;-biotechs-drag-nasdaq-77097,77097
201172,422688,GILD,TESARO Shares Rally On Glaxo s  5 1 Billion Buyout Offer,opinion,"TESARO  Inc    NASDAQ TSRO   announced that it has entered into a definitive agreement with GlaxoSmithKline   NYSE GSK   per which the latter will acquire TESARO s outstanding shares and net debt for  5 1 billion   4 0 billion Glaxo has offered TESARO s investors  75 for each share in cash  which represents a 110  premium on the 30 day volume weighted average price of  35 67  Reportedly  TESARO had been on a lookout for a prospective buyer since last month and   Although  Gilead  NASDAQ GILD  was a front runner among prospective buyer  Glaxo s offer comes as a surprise A tender offer will be made to acquire all of the issued and outstanding shares of TESARO common stock in the next 10 days  The deal is expected to be closed in the first quarter of 2019 subject to clearance from regulatory authorities  Shares of TESARO rallied 58 5  on Dec 3  following announcement of the news  Shares of the company recovered significantly following the news  with the stock down 11 3  compared with the  s decline of 7 6  in the year so far  Shares of the company have been declining owing to rising competition in the PARP inhibitor segment where TESARO sells its sole marketed drug  Zejula  The drug  a PARP inhibitor  is approved as a second line maintenance treatment for ovarian cancer irrespective of BRCA mutation  The buyout offer is a significant relief for its investors as they can sell their stake in the company at a higher price Although the drug has seen strong uptake since its launch  rising competition and stagnating market share of PARP inhibitors in the ovarian cancer market are concerns  AstraZeneca   NYSE AZN   and Merck s Lynparza and Clovis Oncology s   NASDAQ CLVS   Rubraca compete with Zejula in the PARP inhibitor segment  In October  Pfizer  NYSE PFE  received approval for its PARP inihibitor  Talzenna  for treating breast cancer  Meanwhile  several other companies are also developing their PARP inhibitor candidates  including AbbVie s veliparib  suggesting that competition will increase going forward Glaxo s strong balance sheet should help to accelerate Zejula development and enable it to compete better with Lynparza  which is being developed by two of the large cap pharmaceuticals companies  Although Clovis  Rubraca may now be at a disadvantage due to limited availability of funds  its shares increased 10  probably on speculation of a potential buyout following TESARO s acquisition offer The acquisition offer was made as part of Glaxo s strategic review to boost its pharmaceutical business and its oncology pipeline  Earlier this week  Glaxo sold its Horlicks brand to London based consumer giant Unilever  LON ULVR  for  3 8 billion to focus on pharma business We note that Glaxo s investors were not happy with the acquisition offer for TESARO as it seemed expensive with respect to Zejula s future prospects  It also adds to the company s debt  which is likely to put pressure on its margins TESARO  Inc  Price
    Zacks RankTESARO currently carries a Zacks Rank  3  Hold   You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-12-03,Zacks Investment Research,https://www.investing.com/analysis/tesaro-shares-rally-on-glaxos-51-billion-buyout-offer-200364755,200364755
201173,422689,GILD,Gilead  GILD  Announces Data On CAR T Therapy Candidate ,opinion,"Kite  a Gilead Sciences   NASDAQ GILD   company  announced updated results from a phase I II study  ZUMA 3  on experimental candidate KTE X19 at the Annual Meeting of the American Society of Hematology  ASH  
KTE C19 is a CD19 chimeric antigen receptor T  CAR T  cell therapy being evaluated in adult patients with relapsed or refractory acute lymphoblastic leukemia  ALL   ZUMA 3 is an ongoing multicenter  registrational phase I II study in adult patients   18  with ALL 
In the study  69  of evaluable patients  n 25 36  achieved complete tumor remission  defined as complete remission  CR  or CR with incomplete hematological recovery  CRi   with a median follow up of 15 1 months  range 3 7   28 6 months  following a single infusion of KTE X19  The rate of undetectable minimal residual disease  MRD  in patients who achieved complete tumor remission was 100  
Adverse events were consistent with the known toxicities of CD19 CAR T treatment  including Grade 3 or higher cytokine release syndrome  CRS  and neurologic events in 23   n 10 44  and 39   n 17 44  of patients  respectively  However  two patients died due to adverse events 
Based on these data  Gilead initiated a phase II study  evaluating KTE X19 in a larger set of adult patients with ALL 
We note that the candidate was added to Gilead s portfolio following the acquisition of Kite Pharma in 2017  Kite is a pioneer in cell therapy  having developed engineered cell therapies that express either a CAR or an engineered T cell receptor  TCR  depending on the type of cancer 
The approval of lead candidate Yescarta for the treatment of refractory aggressive non Hodgkin lymphoma  which includes diffuse large B cell lymphoma  DLBCL   transformed follicular lymphoma  TFL  and primary mediastinal B cell lymphoma  PMBCL   was a significant boost for Gilead 
Gilead s stock has gained 2 7  in the past six months  worse than the s decline of 6 5  

 
Given the persistent decline in HCV sales  Gilead is banking on HIV and newer avenues to help the top line  The initial uptake of Yescarta is also encouraging but it will take some time for sales to contribute significantly to the top line  given the high cost of treatment  Moreover  Novartis    NYSE NVS   Kymriah is also in the market  posing competition 
Going forward  Gilead will have to generate substantial revenues from its HIV franchise to offset the HCV sales decline  This will be a challenging task for the company with stiff competition from the likes of GlaxoSmithKline   NYSE GSK   in the HIV market  Gilead has promising late stage candidates   selonsertib and filgotinib   in the NASH and inflammation markets  The company also has a collaboration agreement with Sangamo Therapeutics  Inc    NASDAQ SGMO   to use Sangamo s zinc finger nuclease technology platform for the development of next generation ex vivo cell therapies in oncology 
Zacks Rank
Gilead currently carries a Zacks Rank  1  Strong Buy   You can see  
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6  and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-12-04,Zacks Investment Research,https://www.investing.com/analysis/gilead-gild-announces-data-on-car-t-therapy-candidate-200365019,200365019
201174,422690,GILD,Gilead s  GILD  Harvoni And Descovy Get Approval In China ,opinion,"Gilead Sciences  Inc    NASDAQ GILD   announced that the National Medical Products Administration  NMPA  has approved its hepatitis C virus  HCV  drug  Harvoni  in China 
The drug has been approved for the treatment of HCV infection genotype 1 6 infection in adults and adolescents aged 12 18 years 
The approval should boost sales of the dwindling HCV franchise due to competitive pressure from the likes of AbbVie   NYSE ABBV   
Concurrently  Gilead announced that the NMPA has also approved Descovy  emtricitabine 200 mg tenofovir alafenamide 10 mg and emtricitabine 200 mg tenofovir alafenamide 25 mg  F TAF   a fixed dose combination for the treatment of HIV  Descovy is approved in combination with other antiretroviral agents for the treatment of HIV 1 in adults and adolescents  aged 12 years or older with at least 35 kg body weight   The therapy is already approved in the United States 
Gilead is a dominant player in the HIV market with an impressive product portfolio  The company was the first to bring to market a single tablet regimen  STR    Atripla   for the treatment of HIV  Additional STRs for HIV in the market include Complera Eviplera and Stribild  among others  TAF based products like Genvoya  Odefsey and Descovy are performing well with strong adoption both in the United States and Europe 
The company received a major boost when the FDA approved its once daily STR  Biktarvy  bictegravir 50mg emtricitabine 200mg tenofovir alafenamide 25mg  BIC FTC TAF  for HIV 1 infection  The approval  which comes ahead of the PDUFA date of Feb 12  2018  significantly boosts Gilead s HIV franchise  Biktarvy combines the novel  unboosted integrase strand transfer inhibitor   INSTI   bictegravir  with the demonstrated safety and efficacy profile of Descovy  FTC TAF   The approval of this new HIV therapy will pose stiff competition to GlaxoSmith s   NYSE GSK   existing therapies  Tivicay and Triumeq 
Gilead s stock has gained 0 9  in the past six months  worse than the s decline of 9 2  

 
Given the persistent decline in HCV sales  the company is looking to HIV and newer avenues to help the top line  The initial uptake of Yescarta  from the Kite Pharma acquisition  is slow but encouraging 
Moreover  Gilead has promising late stage candidates   selonsertib and filgotinib   in the NASH and inflammation markets  respectively  The company also has a collaboration agreement with Sangamo Therapeutics  Inc    NASDAQ SGMO   to use Sangamo s zinc finger nuclease technology platform for the development of next generation ex vivo cell therapies in oncology 
Zacks Rank
Gilead currently carries a Zacks Rank  1  Strong Buy   You can see  
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-12-05,Zacks Investment Research,https://www.investing.com/analysis/gileads-gild-harvoni-and-descovy-get-approval-in-china-200365420,200365420
201175,422691,GILD,Roche s Tecentriq Gets FDA Approval For First Line NSCLC,opinion,"Roche   OTC RHHBY   announced that the FDA has approved a label expansion of its immuno oncology drug  Tecentriq The drug has been approved in combination with Avastin  bevacizumab   paclitaxel and carboplatin  chemotherapy  for the first line treatment of patients suffering from metastatic non squamous non small cell lung cancer  NSCLC  with no EGFR or ALK genomic tumour aberrations The approval was based on positive results from the phase III IMpower150 study  which showed that Tecentriq combined with Avastin and chemotherapy helped patients live significantly longer compared to Avastin and chemotherapy Meanwhile  Roche is working with the FDA on post marketing commitments  PMCs  to determine the potential effects of Tecentriq related anti drug antibodies  ADAs  and neutralising antibodies  NAbs  across all studies We remind investors that Tecentriq is already approved in the Unites States for the treatment of patients suffering from metastatic NSCLC who have disease progression during or following platinum containing chemotherapy  and have progressed on an appropriate FDA approved targeted therapy if their tumour has EGFR or ALK genetic alterations The drug is also approved for the treatment of patients with previously treated metastatic NSCLC and also for those with advanced or metastatic urothelial cancer  mUC  who are not eligible for cisplatin chemotherapy  or have had disease progression during or following platinum containing therapy Shares of Roche have gained 2 9  so far this year compared with the industry s growth of 10 3   Roche is working to expand the drug s label further  The company currently has nine phase III studies evaluating Tecentriq alone or in combination with other drugs Tecentriq sales came in at CHF 524 million in the first nine months of 2018  up 49   A label expansion of the drug in the NSCLC market will further boost sales  given the potential of the same However  competition is stiff in the first line NSCLC market  Merck s   NYSE MRK   Keytruda is already approved for the first line treatment of NSCLC Bristol Myers Squibb Company s   NYSE BMY   Opdivo is also in the race for the first line NSCLC treatment  However  the FDA extended the review period of the company s application by three months and set a target action date of May 20  2019 Zacks Rank   Other Stock to Consider
Roche currently carries a Zacks Rank  2  Buy   Another well positioned stock in the healthcare sector is Gilead Sciences  Inc    NASDAQ GILD    which sports a Zacks Rank  1  Strong Buy   You can see  Gilead s earnings per share estimates increased from  6 64 to  6 93 for 2018 over the past 60 days  Estimates for 2019 are also up by 30 cents Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-12-10,Zacks Investment Research,https://www.investing.com/analysis/roches-tecentriq-gets-fda-approval-for-firstline-nsclc-200366752,200366752
201176,422692,GILD,Gilead Sciences  GILD  Appoints Daniel O Day As New CEO ,opinion,"Gilead Sciences  Inc    NASDAQ GILD   announced that its board of directors has appointed Daniel O Day as the company s Chairman and Chief Executive Officer  CEO  
O Day will take over the reins on Mar 1  2019  Meanwhile  the board appointed Gregg Alton as interim CEO for the period of Jan 1 to Mar 1  2019 
O Day is the CEO of the pharmaceutical arm of Roche Holdings   OTC RHHBY   since 2012  Prior to 2012  O Day was heading Roche Diagnostics 
The appointment of a veteran leader like O Day should relieve wary investors as the new CEO will bring leadership experience across multiple therapeutic areas  which is much needed at Gilead 
Gilead has been facing turbulent times lately  and hence O Day has a tough job in his hands  Gilead s stock has lost 4 4  in the past six months  against the s decline of 12 7  

 
Gilead was once a market outperformer  with its strong HCV franchise boasting a number of blockbuster drugs  However  the HCV franchise has been under pressure since the last three four years due to competitive pressure from the likes of AbbbVie  Inc    NYSE ABBV   
Consequently  Gilead had turned focus on its HIV franchise and newer avenues like CAR T therapy  Gilead was the first to bring to market a single tablet regimen  STR    Atripla   for the treatment of HIV  Other STRs for HIV in the market include Complera Eviplera and Stribild  TAF based products like Genvoya  Odefsey and Descovy are performing well with strong adoption both in the United States and Europe  The company received a major boost when the FDA approved its once daily STR  Biktarvy 
Due to the dwindling HCV sales  Gilead acquired Kite Pharma in 2017  Kite is a pioneer in cell therapy  having developed engineered cell therapies that express either a CAR or an engineered T cell receptor  TCR  depending on the type of cancer  The approval of lead candidate Yescarta for the treatment of refractory aggressive non Hodgkin lymphoma and the initial uptake of the therapy have been encouraging 
Nevertheless  Gilead has been trying to revive its portfolio of late  and with a new CEO  we expect a more concrete and focused approach  Gilead has promising late stage candidates   selonsertib and filgotinib   in the NASH and inflammation markets  The company also has a collaboration agreement with Sangamo Therapeutics  Inc    NASDAQ SGMO   to use Sangamo s zinc finger nuclease technology platform for the development of next generation ex vivo cell therapies in oncology 
Zacks Rank
Gilead currently carries a Zacks Rank  1  Strong Buy   You can see  
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2018-12-11,Zacks Investment Research,https://www.investing.com/analysis/gilead-sciences-gild-appoints-daniel-oday-as-new-ceo-200367154,200367154
201195,422711,GILD,Catalyst s Firdapse Receives FDA Approval For Rare Disease ,opinion,Catalyst Pharmaceuticals Inc  s   NASDAQ CPRX   Firdapse  amifampridine  tablets obtained FDA approval for the treatment of Lambert Eaton Myasthenic Syndrome  LEMS  in adults  Firdapse becomes the first FDA approved treatment for LEMS So far this year  Catalyst s shares have lost 19 9  compared with the  s 9 6  decline LEMS is a rare automimmune disorder that affects the connection between nerves and muscles  and causes weakness and other symptoms in affected patients  LEMS is an ultra rare disease and the prevalence of LEMS is estimated to be three per million individuals worldwide  The market  therefore  represents significant potential for the drug  LEMS may be associated with other autoimmune diseases  but more commonly occurs in patients with cancers like small cell lung cancer  where its onset precedes or coincides with the diagnosis of cancer  The efficacy of Firdapse was studied in two studies where the adult patients received Firdapse or placebo  The studies measured the Quantitative Myasthenia Gravis score  a scale assessing muscle weakness  and the Subject Global Impression  a seven point scale  on which patients rated their overall impression of the effects of the study treatment on their physical well being   For both measures  patients receiving Firdapse experienced a greater benefit than those on placebo   In March 2018  Catalyst submitted a new drug application  NDA  to the FDA  which addressed the two issues raised in the 2016 Refusal to File letter against the previous NDA submission  The letter included all additional information requested by the FDA  The NDA was accepted by the FDA in May 2018 and the agency granted Priority Review  Firdapse also received Orphan Drug status in the United States for the treatment of congenital myasthenic syndromes  CMS  and myasthenia gravis  MG  Meanwhile  the company is also working on developing Firdapse for additional indications  Catalyst initiated an investigator sponsored phase II III study on Firdapse for the symptomatic treatment of MuSK antibody positive MG in February 2016  In March 2017  the company reported top line data from the study  In April 2018  the company enrolled the first patient in its phase III study for MuSK antibody positive myasthenia gravis  The company expects to announce top line results in the second half of 2019 Firdapse is the first approved product for Catalyst and thus is a big boost for the company  With the approval  the company will start generating revenues Catalyst Pharmaceuticals  Inc  Price    Zacks Rank   Stocks to ConsiderCatalyst is a Zacks Rank  3  Hold  stock Some better ranked stocks worth considering are Bristol Myers Squibb Company   NYSE BMY    Gilead Sciences Inc    NASDAQ GILD   and Merck   Co    NYSE MRK    While Bristol Myers and Gilead sport a Zacks Rank  1  Strong Buy   Merck carries a Zacks Rank  2  Buy   You can see  Bristol Myers  earnings per share estimates have increased from  3 62 to  3 87 for 2018 and from  3 82 to  4 08 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with average of 11 99  Gilead s earnings per share estimates have increased from  6 60 to  6 93 for 2018 and from  6 53 to  6 83 for 2019 over the past 60 days  The company delivered a positive earnings surprise in three of the trailing four quarters with average of 6 99  Merck s earnings per share estimates have increased from  4 27 to  4 34 for 2018 and from  4 63 to  4 71 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all of the trailing four quarters with average of 3 96   Shares of the company have increased 40 5  year to date The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-11-28,Zacks Investment Research,https://www.investing.com/analysis/catalysts-firdapse-receives-fda-approval-for-rare-disease-200363503,200363503
201196,422712,GILD,Roche  RHHBY  To Acquire Jecure And Enter The NASH Space,opinion,Swiss pharma giant Roche Holdings   OTC RHHBY   entered into a definitive agreement to acquire biotechnology company Jecure Therapeutics  Inc Roche s subsidiary  Genentech will obtain full rights to Jecure s entire preclinical portfolio of NLRP3 inhibitors  The latter began operating in 2015 following a seed financing from founding investor Versant Ventures   It has raised  20 million in a Series A round from Versant in 2017 to continue to develop and advance its portfolio of NLRP3 inhibitors Jecure Therapeutics is focused on the discovery of novel therapeutics for the treatment of non alcoholic steatohepatitis  NASH  and liver fibrosis  Jecure s lead program has identified small molecule inhibitors of the NLRP3 inflammasome  a novel target and pro inflammatory driver of NASH The financial terms of the acquisition were not disclosed The acquisition will enable Roche to foray into the promising NASH space  which has been the focus of late Most recently  another Swiss pharma  Novartis AG   NYSE NVS   entered into a clinical development agreement with Pfizer   NYSE PFE    The agreement includes a clinical trial to evaluate the combination of tropifexor  LJN452  and one or more Pfizer compounds for the treatment of NASH  The compounds include an Acetyl CoA Carboxylase  ACC  Inhibitor  PF 05221304   a Diacylglycerol O Acyltransferase 2  DGAT2  Inhibitor  PF 06865571   and a Ketohexokinase  KHK  Inhibitor  PF 06835919  Shares of Roche have gained 4 4  so far this year compared with the  growth of 12 8   Meanwhile  Roche has been quite active on the acquisition front  Being a leading health care company  Roche focuses on developing and commercializing innovative diagnostic and therapeutic products and services  which help in early detection and prevention of diseases as well as their treatment and monitoring During the first quarter of 2018  Roche acquired Flatiron Health and Ignyta  Inc  While Flatiron Health will help accelerate development and delivery of breakthrough medicines for oncology patients  Ignyta s lead molecule  entrectinib targets tumors with one of the two genetically defined gene rearrangements   ROS1 fusions in NSCLC and NTRK fusions across a broad range of solid tumors  The candidate is currently being evaluated in an ongoing phase II trial  which  if successful  will support NDA submission   The deal will further strengthen the company s strong pipeline  In July 2018  Roche acquired Foundation Medicine Inc  to broaden its healthcare portfolio  and aims to further advance molecular insights and the broad availability of high quality comprehensive genomic profiling  both key enablers for the development of new cancer treatments and optimal patient care Zacks Rank   Key PickRoche carries a Zacks Rank  3  Hold  A better ranked stock in the healthcare sector is Gilead Sciences  Inc    NASDAQ GILD    which sports a Zacks Rank  1  Strong Buy   You can see  Gilead s earnings per share estimates increased from  6 60 to  6 93 for 2018 over the past 60 days  Estimates for 2019 are also up by 30 cents The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-11-28,Zacks Investment Research,https://www.investing.com/analysis/roche-rhhby-to-acquire-jecure-and-enter-the-nash-space-200363498,200363498
201197,422713,GILD,Bayer  BAYRY  To Restructure Business   Reduce Headcount ,opinion,"Bayer AG  DE BAYGN    OTC BAYRY   announced a restructuring plan to streamline business and improve efficiency The company plans to exit its Animal Health business  and management is currently assessing various options for this business  The decision to exit this business comes as part of the company s plan to focus on its core businesses of Pharmaceuticals  Consumer Health and Crop Science The company is making efforts to revive its Consumer Health division to target market growth in the coming years and improve profitability  The measures include a planned exit from product categories  which were not suiting the company s business model  In addition to the previously announced divestment of prescription dermatology products  Bayer will review its strategic options in the coming months and most likely exit its sun care  Coppertone  and foot care  Dr  Scholl s  product lines  The company intends to focus on driving growth in its core Consumer Health categories Bayer is also planning to divest its 60  interest in German site services provider Currenta  as this business does not align with its existing model anymore  given the carve out of Covestro Bayer expects annual savings of  2 6 billion from 2022 as a result of its planned efficiency and structural measures  including the synergies expected from the acquisition of Monsanto  NYSE MON   We remind investors that in June 2018  Bayer acquired Monsanto for  63 million  The combined business is expected to boost Bayer s Crop Science business Concurrently  the company plans to reduce its headcount by 12 000 118 200 by 2021  Majority of these job cuts will be in Germany Of these  approximately 900 jobs in R D will be cut in the Pharmaceuticals business along with 350 positions in the factor VIII facility in Wuppertal  1 100 jobs associated with the reorganization at Consumer Health  around 4 100 positions at Crop Science as the result of integrating the acquired agriculture business and 5 500 to 6 000 jobs at Corporate Functions  supporting functions  Business Services and country platforms are likely to be cut  Bayer has decided not to utilize the factor VIII facility in Wuppertal  Germany  and to focus on all recombinant factor VIII production in Berkeley  United States Total one time costs related to these measures are expected at a factor of 1 7 times the annual contributions  The company plans to invest a total of around  35 billion in the long run  with research and development  R D  accounting for over two thirds of this figure and capital expenditures for just below one third As a result of the above mentioned factors  the company expects core earnings per share of  6 80 in 2019  2018   5 70 to  5 90   with a target of around  10 in 2022  Bayer s stock has declined 40 4  year to date  against the  s growth of 13 3   The company is currently facing generic competition for many of its products  including the Yaz franchise  oral contraceptives   Hence  investors will focus on the execution of the restructuring plan  which should boost the top and bottom lines 
Zacks Rank   Stocks to ConsiderBayer is a Zacks Rank  5  Strong Sell  stock Some better ranked stocks worth considering are Bristol Myers Squibb Company   NYSE BMY    Gilead Sciences   NASDAQ GILD   and Merck   Co    NYSE MRK    While Bristol Myers and Gilead Sciences sport a Zacks Rank  1  Strong Buy   Merck carries a Zacks Rank  2  Buy   You can see   Bristol Myers  earnings per share estimates have increased from  3 62 to  3 87 for 2018 and from  3 82 to  4 08 for 2019 over the past 60 days Gilead s earnings per share estimates increased from  6 60 to  6 93 for 2018 over the past 60 days  Estimates for 2019 are also up by 30 cents Merck s earnings per share estimates have increased from  4 27 to  4 34 for 2018 and from  4 63 to  4 71 for 2019 over the past 60 days 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ",2018-11-29,Zacks Investment Research,https://www.investing.com/analysis/bayer-bayry-to-restructure-business--reduce-headcount-200363915,200363915
201198,422714,GILD,Gilead Sciences  GILD  Stock Sinks As Market Gains  What You Should Know,opinion,"Gilead Sciences  NASDAQ GILD  closed at  70 86 in the latest trading session  marking a  1 5  move from the prior day  This change lagged the S P 500 s 1 09  gain on the day  At the same time  the Dow added 1 13   and the tech heavy Nasdaq gained 1 51  
Coming into today  shares of the HIV and hepatitis C drugmaker had gained 2 32  in the past month  In that same time  the Medical sector gained 4 8   while the S P 500 gained 1 92  
Wall Street will be looking for positivity from GILD as it approaches its next earnings report date  This is expected to be February 5  2019  On that day  GILD is projected to report earnings of  1 74 per share  which would represent a year over year decline of 2 25   Meanwhile  the Zacks Consensus Estimate for revenue is projecting net sales of  5 52 billion  down 7 26  from the year ago period 
For the full year  our Zacks Consensus Estimates are projecting earnings of  6 93 per share and revenue of  21 85 billion  which would represent changes of  21 61  and  16 31   respectively  from the prior year 
Investors should also note any recent changes to analyst estimates for GILD  These revisions typically reflect the latest short term business trends  which can change frequently  As a result  we can interpret positive estimate revisions as a good sign for the company s business outlook 
Based on our research  we believe these estimate revisions are directly related to near team stock moves  We developed the Zacks Rank to capitalize on this phenomenon  Our system takes these estimate changes into account and delivers a clear  actionable rating model 
The Zacks Rank system ranges from  1  Strong Buy  to  5  Strong Sell   It has a remarkable  outside audited track record of success  with  1 stocks delivering an average annual return of  25  since 1988  Within the past 30 days  our consensus EPS projection remained stagnant  GILD is currently sporting a Zacks Rank of  1  Strong Buy  
Valuation is also important  so investors should note that GILD has a Forward P E ratio of 10 37 right now  For comparison  its industry has an average Forward P E of 24 65  which means GILD is trading at a discount to the group 
The Medical   Biomedical and Genetics industry is part of the Medical sector  This industry currently has a Zacks Industry Rank of 73  which puts it in the top 28  of all 250  industries 
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups  Our research shows that the top 50  rated industries outperform the bottom half by a factor of 2 to 1 
To follow GILD in the coming trading sessions  be sure to utilize Zacks com ",2018-12-03,Zacks Investment Research,https://www.investing.com/analysis/gilead-sciences-gild-stock-sinks-as-market-gains-what-you-should-know-200364624,200364624
201208,422724,GILD,TESARO Shares Rally On Rumors Of Potential Acquisition Offer,opinion,"Shares of TESARO  Inc    NASDAQ TSRO   rallied more than 15  on Tuesday on rumors that it may have received a buyout offer  According to a Bloomberg  published on Nov 16  the company is working with financial advisers for a potential sale by designing a deal and pursuing prospective suitors  The acquisition rumors were strengthened further by TESARO s announcement yesterday that it will not attend an upcoming conference  as stated in a Motley Fool   Generally  companies cancel participation at important events if there are some potential strategic activities underway like a possible sale The Bloomberg report also states that the consistent decline in the share price of TESARO has made it significantly cheaper  Consequently  any company with focus on oncology will be able to make a buyout offer  Gilead Sciences  NASDAQ GILD  is being looked at as a potential buyer  TESARO s market valuation stands at  2 3 billion as of Nov 20 TESARO s shares have slumped 49 4  so far this year compared with the  s decline of 6 2   Shares of the company have been declining owing to rising competition in the PARP inhibitor segment  TESARO s marketed product portfolio consist of a single product  Zejula  It is a PARP inhibitor which is approved as maintenance treatment for ovarian cancer irrespective of BRCA mutation  Although the drug has seen strong uptake since its launch  the rising competition and the stagnating market share of PARP inhibitors in the ovarian cancer market is a concern  AstraZeneca   NYSE AZN   and Merck s   NYSE MRK   Lynparza and Clovis Oncology s   NASDAQ CLVS   Rubraca compete with Zejula in the PARP inhibitor segment With these four companies duking it out for market share in the segment  all of them are trying to develop their respective drugs in additional indications  This increases the operating expenses for these companies  consequently hurting margins  However  we note that Lynparza is being developed by two of the large cap pharmaceuticals companies which have a huge capital to continue clinical studies in several indications  Meanwhile  Clovis and TESARO have a single product in their marketed portfolio and depend on it for revenues  This is likely to impact their cash position significantly if the drugs cannot perform well  High cash burn and low revenues will continue to hurt these companies over the long haul We remind investors that AstraZeneca s label expansion application for Lynparza in first line maintenance treatment for advanced ovarian cancer  the largest ovarian cancer market  received priority review earlier this month  Although the other two companies are also developing their drugs in the first line setting  they will fall behind Lynparza as their studies are expected to complete in 2019 or beyond  This is likely to make gaining market share in the first line setting more competitive for these two drugs Moreover  Clovis and TESARO have to pay royalties on the sales of their drugs to Pfizer  NYSE PFE  and Merck  respectively  under a license agreement  Any modification to these agreements can also hamper the prospect of these companies Consequently  a buyout offer from any large pharmaceutical company for TESARO will be a significant relief for its investors as they can sell their stake in the company at a higher price  Any buyout offer gives a premium to the current stock price as we have seen in several blockbuster deals concluded in 2018 Any confirmed offer for TESARO is likely to boost buyout potential of Clovis which may fuel a rally in the latter s stock price as well  Investors should remain focused on news on these two companies to see how things pan out TESARO  Inc  Price
    Zacks RankTESARO currently carries a Zacks Rank  3  Hold   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-20,Zacks Investment Research,https://www.investing.com/analysis/tesaro-shares-rally-on-rumors-of-potential-acquisition-offer-200361412,200361412
201209,422725,GILD,Should Value Investors Consider Gilead  GILD  Stock Now ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Gilead Sciences  Inc    NASDAQ GILD   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Gilead has a trailing twelve months PE ratio of 10 5  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 17 5  If we focus on the long term PE trend  Gilead s current PE level puts it slightly above its midpoint over the past five years Further  the stock s PE also compares favorably with the industry s trailing twelve months PE ratio  which stands at 45 8  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that Gilead has a forward PE ratio  price relative to this year s earnings  of just 9 9  so it is fair to say that a slightly more value oriented path may be ahead for Gilead stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  Gilead has a P S ratio of about 4 0  While this is a bit higher than the S P 500 average  which comes in at 3 1 right now  this is well below the highs for this stock in particular over the past few years If anything  GILD is in the lower end of its range in the time period from a P S metric  suggesting some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  Gilead currently has a Zacks Value Style Score of A  putting it into the top 20  of all stocks we cover from this look  This makes Gilead a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  its P CF ratio  another great indicator of value  comes in at 7 1  which is far better than the industry average of 15 1  Clearly  GILD is a solid choice on the value front from multiple angles What About the Stock Overall Though Gilead might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of F and a Momentum score of F  This gives GILD a Zacks VGM score or its overarching fundamental grade of D   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been mostly trending higher  The current quarter has seen eight estimates go higher in the past sixty days compared to two lower  while the full year estimate has seen eleven upward and one downward revision in the same time period As a result  the current quarter consensus estimate has risen by 8 1  in the past two months  while the full year estimate has increased 4 4   You can see the consensus estimate trend and recent price action for the stock in the chart below Gilead Sciences  Inc  Price and Consensus    This bullish trend is why the stock boasts a Zacks Rank  1  Strong Buy  and why we are expecting outperformance from the company in the near term Bottom LineGilead is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Furthermore  a robust industry rank  among the Top 35   and a top Zacks Rank instills investor confidence However  it is hard to get too excited about this company overall as over the past two years  the industry has underperformed the broader market  as you can see below Despite the poor past performance of the industry  a good industry rank signals that the stock is likely to benefit from favorable broader factors in the immediate future  Add to this the positive estimate revisions and robust value metrics  and we believe that we have a strong value contender in Gilead Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-20,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-consider-gilead-gild-stock-now-200361448,200361448
201210,422726,GILD,Novartis Gets Approval For Gene Therapy Luxturna In Europe,opinion,"Novartis AG   NYSE NVS   announced that the European Commission  EC  approved Luxturna  a one time gene therapy  for the treatment of patients suffering from vision loss due to a genetic mutation in both copies of the RPE65gene and who have enough viable retinal cells The EC decision was based on positive CHMP opinion  Data from a phase I clinical trial  its follow up trial  and the first randomized  controlled phase III gene therapy trial for an inherited disease supported the decision   Data from the phase III trial showed that vision improvement was recorded as early as 30 days following the treatment We remind investors that Luxturna was developed and is commercialized in the United States by Spark Therapeutics  Novartis and Spark Therapeutics entered into a licensing and supply agreement in January 2018 for the development  registration and commercialization rights to Luxturna in markets outside the United States  Per the agreement  Novartis can commercialize Luxturna in the EU EEA  The company already owns exclusive rights to development  registration and commercialization of the gene therapy in all other countries outside the United States  and Spark Therapeutics will supply it to Novartis The FDA approved Luxturna for the same indication in December 2017 Gene therapy has gained a lot of attention of late  and is set to become one of the most promising spaces  Earlier this year  Novartis acquired gene therapy company  AveXis  Inc   AveXis  lead product candidate  AVXS 101 is being evaluated as a one time gene replacement therapy for spinal muscular atrophy  SMA   a disease that results in early death or life long disability with considerable healthcare costs  Regulatory submissions of AVXS 101 have been made in the United States  EU and Japan  for type 1 SMA  based on the phase I data and select data from the ongoing phase III study  STR1VE  Novartis plans to launch AVXS 101 by mid 2019 Other companies like Axovant Sciences   NASDAQ AXON   and uniQure N V    NASDAQ QURE   have been steadily developing their pipeline candidates using gene therapy Approval of new drugs and label expansion of existing drugs bode well for Novartis as its key drugs are facing generic competition The company s shares have gained 9 9  in the year so far on par with the  s  growth  Of late  Novartis is redirecting its focus to core areas of growth  Earlier  the company announced that it intends to spin off its ophthalmology division  Alcon  into a separately traded standalone company to grow as a medicines company solely Zacks Rank   Key Pick
Novartis carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector is Gilead Sciences  Inc    NASDAQ GILD    which sports a Zacks Rank  1  Strong Buy   You can see  Gilead s earnings per share estimates increased from  6 60 to  6 91 for 2018 over the past 60 days  Estimates for 2019 are also up by 29 cents Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2018-11-23,Zacks Investment Research,https://www.investing.com/analysis/novartis-gets-approval-for-gene-therapy-luxturna-in-europe-200361936,200361936
201211,422727,GILD,Bristol Myers  Opdivo Yervoy Combo Fails In Lung Cancer Trial,opinion,"Bristol Myers Squibb Company   NYSE BMY   announced that the phase III CheckMate 451 study on immuno oncology drug Opdivo in combination with Yervoy was unsuccessful 
The global  double blind  randomized phase III study evaluated the Opdivo Yervoy combination and Opdivo monotherapy versus placebo as a maintenance therapy in patients with extensive stage small cell lung cancer  SCLC  without disease progression after completion of first line platinum based chemotherapy 
The study did not meet primary endpoint of overall survival  OS   However  no new safety signals were observed 
We remind investors that Opdivo is already approved for the treatment of patients with metastatic SCLC with progression after platinum based chemotherapy and at least one other line of therapy 
A potential label expansion of the drug would have boosted sales  Bristol Myers  stock has decreased 11 7   against the  growth of 10 4  

 
Nevertheless  Opdivo is already approved in the United States for RCC  The drug is approved for several indications in the United States and Europe  It became the first PD 1 inhibitor to be approved for a hematological malignancy   classical Hodgkin lymphoma  Opdivo obtained the FDA approval for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck   SCCHN   with disease progression on or after platinum based therapy 
The European Commission   EC   also approved Opdivo as a monotherapy for the treatment of SCCHN in adults progressing on or after platinum based therapy in April 2017  The drug has been performing impressively  owing to demand resulting from the rapid commercial acceptance for several indications  including melanoma  renal cell carcinoma and second line non small cell lung cancer   NSCLC    The FDA also approved the drug for intravenous use in patients with hepatocellular carcinoma   HCC   who have been previously treated with Nexavar 
However  Opdivo faces stiff competition from Merck s   NYSE MRK   anti PD 1 therapy  Keytruda  which is approved in the first line lung cancer setting  Also  Roche s   OTC RHHBY   anti PDL1 immunotherapy  Tecentriq is approved for the treatment of metastatic NSCLC 
In October  the FDA extended the action date by three months for a supplemental Biologics License Application  sBLA  seeking approval of Opdivo Yervoy as a treatment for first line NSCLC with tumor mutational burden  10 mutations megabase  The Committee for Medicinal Products for Human Use also requested additional data to review a regulatory application for a similar indication 
Zacks Rank   Other Key Pick
Bristol Myers currently carries a Zacks Rank  1  Strong Buy   Another top ranked stock from the same space is Gilead Sciences  Inc    NASDAQ GILD    which carries the same rank as Bristol Myers  You can see   
Gilead s earnings per share estimates increased from  6 60 to  6 93 for 2018 over the past 60 days  Estimates for 2019 are also up by 30 cents 
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-27,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-opdivoyervoy-combo-fails-in-lung-cancer-trial-200362806,200362806
201223,422739,GILD,Bristol Myers  Opdivo Receives Positive CHMP Opinion For RCC,opinion,"Bristol Myers Squibb Company   NYSE BMY   announced that the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency adopted a positive opinion for the Odpivo plus low dose Yervoy combination for yet another indication 
The committee recommended approval of the combination for the first line treatment for patients with intermediate  and poor risk advanced renal cell carcinoma  RCC  
The recommendation will be reviewed by the European Commission  EC  
The recommendation was based on positive data from the phase III trial  CheckMate  214  We remind investors that the trial was stopped half way following a planned interim analysis  wherein the combination of Opdivo 3 mg kg plus Yervoy 1 mg kg demonstrated a significant increase in overall survival  OS  with a 37  decreased risk of death in intermediate  and poor risk patients  regardless of PD L1 expression level  compared to a current standard of care  Sutent 
An approval in Europe for RCC will further boost sales 
Bristol Myers  stock has decreased 10 8   against the  growth of 10 5  

 
Opdivo is already approved in the United States for RCC 
Opdivo is approved for several indications in the United States and Europe  It became the first PD 1 inhibitor to be approved for a hematological malignancy   classical Hodgkin lymphoma  Opdivo obtained FDA approval for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck   SCCHN   with disease progression on or after platinum based therapy  
The European Commission   EC   also approved Opdivo as a monotherapy for the treatment of SCCHN in adults progressing on or after platinum based therapy in April 2017  The drug has been performing impressively  owing to demand resulting from the rapid commercial acceptance for several indications  including melanoma  renal cell carcinoma and second line non small cell lung cancer   NSCLC   
The FDA also approved the drug for intravenous use in patients with hepatocellular carcinoma   HCC   who have been previously treated with Nexavar  In fact  Opdivo has rapidly penetrated the second line HCC market 
However  Opdivo faces stiff competition from Merck s   NYSE MRK   anti PD 1 therapy  Keytruda  which is approved in the first line lung cancer setting  Also  Roche s   OTC RHHBY   anti PDL1 immunotherapy  Tecentriq is approved for the treatment of metastatic NSCLC 
Zacks Rank   Other Key Pick
Bristol Myers currently carries a Zacks Rank  1  Strong Buy   Another top ranked stock from the same space is Gilead Sciences  Inc    NASDAQ GILD    which carries the same rank as Bristol Myers  You can see  
Gilead s earnings per share estimates increased from  6 58 to  6 87 for 2018 over the past 60 days  Estimates for 2019 are also up by 27 cents 
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-16,Zacks Investment Research,https://www.investing.com/analysis/bristolmyers-opdivo-receives-positive-chmp-opinion-for-rcc-200360160,200360160
201224,422740,GILD,Novartis  NVS  Gets FDA Nod For Label Expansion Of Promacta,opinion,"Novartis AG   NYSE NVS   announced that the FDA has expanded the label of Promacta  eltrombopag  to include first line treatment for adults and pediatric patients aged two years and older with severe aplastic anemia  SAA   in combination with standard immunosuppressive therapy  IST  
We note that the drug is already approved for SAA for patients who have had an insufficient response to IST 
The drug is marketed as Revolade in most countries outside the United States  Promacta is already approved for adults and children with chronic immune thrombocytopenia  ITP  who are refractory to other treatments  and for the treatment of thrombocytopenia in patients with chronic hepatitis C virus  HCV  infection 
The approval was based on encouraging results from a study sponsored by the National Heart  Lung and Blood Institute  NHLBI  Division of Intramural Research Program and conducted under a Cooperative Research and Development Agreement  CRADA  
In addition  Novartis submitted a type II variation application for Revolade as a first line SAA treatment to the European Medicines Agency in April 2018  A decision is expected in 2019 
Moreover  the FDA also granted Promacta Breakthrough Therapy designation as a counter measure for hematopoietic sub syndrome of acute radiation syndrome  H ARS  
Concurrently  Novartis announced that the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  has adopted a positive opinion for the label expansion of breast cancer drug Kisqali 
The CHMP recommended Kisqali for the treatment of women with hormone receptor positive  human epidermal growth factor receptor 2 negative  HR  HER2   locally advanced or metastatic breast cancer in combination with AstraZeneca s   NYSE AZN   Faslodex as initial endocrine based therapy  and for women who have received prior endocrine therapy 
The positive opinion also recommended approval of Kisqali in combination with endocrine therapy and a luteinising hormone release hormone agonist  LHRH  for pre  and perimenopausal women 
Approval of new drugs and label expansion of existing drugs bode well for Novartis whose key drugs are facing generic competition 
The company s shares have gained 8 3  in the year so far compared with the  s growth of 11 5  

 
Of late  Novartis is redirecting its focus to its core areas of growth  Earlier  the company announced that it intends to spin off its ophthalmology division  Alcon  into a separately traded standalone company to grow as a medicines company solely 
The Alcon business was not performing per management s expectations  Although it did witness some recovery  the company decided to spin off the same to focus better on its legacy drug business  The company also exited its antibacterial business  Earlier  Novartis had divested its stake in the OTC joint venture with GlaxoSmithKline   NYSE GSK   for  13 billion 
Zacks Rank   Key Pick
Novartis carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector is Gilead Sciences  Inc    NASDAQ GILD    which sports a Zacks Rank  1  Strong Buy   You can see  
Gilead s earnings per share estimates increased from  6 58 to  6 87 for 2018 over the past 60 days  Estimates for 2019 are also up by 27 cents 
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-19,Zacks Investment Research,https://www.investing.com/analysis/novartis-nvs-gets-fda-nod-for-label-expansion-of-promacta-200360729,200360729
201225,422741,GILD,Gilead s Vemlidy Gets Approval In China For HBV Infection ,opinion,"Gilead Sciences  Inc    NASDAQ GILD   announced that the China National Medical Products Administration  NMPA  has approved Vemlidy  tenofovir alafenamide  TAF  25 mg  a once daily treatment for chronic hepatitis B in adults and adolescents  aged 12 years or older with body weight at least 35 kg  
The approval was supported by data from two international phase III studies  Studies 108 and 110  among 1 632 treatment naive and treatment experienced adult patients with HBeAg negative and HBeAg positive HBV disease  Importantly  Vemlidy  a targeted prodrug of tenofovir  has demonstrated antiviral efficacy similar to Viread 300 mg but at one tenth of the dose  The drug has greater plasma stability and delivers tenofovir more efficiently to hepatocytes compared to Viread 
Vemlidy demonstrated improved renal and bone laboratory safety parameters compared to Viread 
We remind investors that Vemlidy is already approved by the FDA and in Japan  The drug was approved in European Commission in 2017 
The market potential in China is quite significant  Per the market  an estimated 20 million patients meet current guidelines for therapy  accounting for almost one third of all patients currently requiring therapy worldwide  Approximately 300 000 people in China die from cirrhosis of the liver related to HBV each year 
Last month  Gilead reported third quarter earnings  which beat estimates  However  earnings and revenues declined year over year as the magnitude of decline in hepatitis C virus  HCV  sales continues to deepen 
While the company plans to launch authorized generic versions of Epclusa and Harvoni in the United States in January 2019 through a newly created subsidiary  Asegua Therapeutics LLC  the HCV franchise sales are expected to decline further 
Given the persistent decline in HCV sales  the company is looking to HIV and newer avenues to help the top line  The initial uptake of Yescarta  from the Kite Pharma acquisition  is also encouraging but it will take some time for sales to contribute significantly to the top line  given the high cost of treatment  Moreover  Novartis    NYSE NVS   Kymriah is also there in the market  posing competition 
Gilead s stock has gained 3 9  in the past six months  compare to the  s decline of 10 1  

 
Gilead has promising late stage candidates in the NASH and inflammation market  like selonsertib and filgotinib  The company also has a collaboration agreement with Sangamo Therapeutics  Inc    NASDAQ SGMO   to use Sangamo s zinc finger nuclease technology platform for the development of next generation ex vivo cell therapies in oncology 
Going forward  Gilead will have to generate substantial revenues from its HIV franchise  to offset the HCV sales decline  This will be a challenging task for the company with stiff competition from the likes of GlaxoSmithKline   NYSE GSK   in the HIV market 
Zacks Rank
Gilead currently carries a Zacks Rank  1  Strong Buy   You can see  
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2018-11-20,Zacks Investment Research,https://www.investing.com/analysis/gileads-vemlidy-gets-approval-in-china-for-hbv-infection-200361208,200361208
201247,422763,GILD,Agios  AGIO  Q3 Earnings Beat  Tibsovo Sales Drive Stock,opinion,Agios Pharmaceuticals Inc    NASDAQ AGIO   incurred third quarter 2018 loss of  1 63 per share  narrower than the Zacks Consensus Estimate of a loss of  1 69 but wider than the year ago loss of  1 59 Total revenues in the reported quarter were  15 2 million  higher than the Zacks Consensus Estimate of  14 million as well as the year ago top line count of  11 million The year over year rise in Agios  revenues can be attributed to sales registered by its first wholly owned precision medicine  Tibsovo  ivosidenib   in the very first quarter following its FDA nod  The drug received an approval in July 2018  a month ahead of the scheduled action date of Aug 21  2018 Royalty revenues earned from Celgene   NASDAQ CELG   on the back of an increase of  1 3 million in Idhifa  enasidenib  net sales in the reported quarter  which was offset by a decrease in collaboration revenues received under the collaboration agreement with Celgene Shares of Agios have rallied 19 8  year to date versus the  decrease of 0 9  Quarter in DetailResearch   development expenses were up 13 2  year over year to  82 5 million  largely due to the start up cost for AG 348 pivotal pipeline program in pyruvate kinase  PK  deficiency  the investigational new drug  IND  application for AG 636  the DHODH inhibitor and the cost associated with Agios  ongoing research for discovery platform programs General and administrative expenses escalated 78 2  year over year to  31 1 million on higher investments to support the commercial launch of Tibsovo Agios ended the third quarter with cash  cash equivalents and marketable securities of  878 million  lower than the sequential quarter s tally of  937 million  The company expects this cash balance as well as revenues recognized from Tibsovo to effectively fund its current operating plans for at least through 2020 Agios  first wholly owned drug  Tibsovo  was approved for the treatment of patients with relapsed or refractory acute myeloid leukemia  AML  with an isocitrate dehydrogenase 1 IDH 1  mutation  The drug generated sales of  4 5 million in the very first partial quarter since its launch in July  A regulatory filing for Tibsovo in the EU is expected in the fourth quarter for the same indication Agios plans to submit a supplemental new drug application  sNDA  for Tibsovo as a monotherapy for the first line treatment of IDH1m AML patients  who are not eligible for any standard treatment by the end of January 2019 Tibsovo is also being evaluated in combination with Celgene s Vidaza for treating newly diagnosed AML patients  who are ineligible for intensive chemotherapy  The company plans to complete enrollment in this phase III AGILE study during 2020  which was previously supposed to be closed by 2021 with a newly modified primary endpoint of event free survival  EFS   Idhifa  developed by Agios  is owned by its partner Celgene Corporation  The company receive royalties on the drugs  net sales  Idhifa is also under review in the EU Pipeline UpdateAgios plans to initiate a phase III HOVON 150 study on Idhifa in combination with Tibsovo for frontline AML patients with an IDH1 or IDH2 mutation by the year end  The study will help the subjects receive either IDH inhibitor as a single agent or as a combination under a two year maintenance phase Agios  lead pipeline candidate  mitapivat  AG 348   is being developed to treat patients with Pyruvate kinase  PK  deficiency  During the first quarter of 2018  the company initiated the phase III ACTIVATE study on the candidate to treat adult patients with PK deficiency  who do not receive regular blood transfusions  AG 348 is also being evaluated in a phase III study  ACTIVATE T  on PK deficiency patients  who take regular blood transfusions  The company plans to complete enrollment in the study in 2019 Agios also aims to initiate a phase II proof of concept study on AG 348 for thalassemia by this year end During the quarter undre review  Agios submitted an IND application for another candidate  AG 636  an inhibitor of the metabolic enzyme dihydroorotate dehydrogenase  DHODH  to treat hematologic malignancies Agios Pharmaceuticals  Inc  Price  Consensus and EPS Surprise   Zacks Rank   Stocks to ConsiderAgios currently carries a Zacks Rank  3  Hold   Two better ranked stocks in the healthcare sector are Gilead Sciences  Inc    NASDAQ GILD   and Caladrius Biosciences  Inc    NASDAQ CLBS    both sporting a Zacks Rank  1  Strong Buy   You can see  Gilead Sciences  earnings estimates have been revised 4 4  upward for 2018 and 4 2  for 2019 over the past 60 days Caladrius  loss per share estimates has been narrowed 5 7  for 2018 and 1 6  for 2019 in the last 60 days  The stock has surged 37 9  year to date Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-11-02,Zacks Investment Research,https://www.investing.com/analysis/agios-agio-q3-earnings-beat-tibsovo-sales-drive-stock-200354199,200354199
201248,422764,GILD,Prothena  PRTA  Reports Narrower Than Expected Loss In Q3,opinion,"Shares of Prothena Corporation   NASDAQ PRTA   gained 1 6   following the company s third quarter results  Prothena reported loss of 70 cents per share for third quarter 2018  narrower than the Zacks Consensus Estimate of a loss of  1 05 and the year ago loss of  1 37 Quarterly revenues came in at  0 25 million  missing the Zacks Consensus by 2 67   However  revenues reported were up from  0 22 million in the year ago quarter  Revenues mainly came from the company s collaboration with Roche Holdings   OTC RHHBY   The company s shares have lost 65 3  in the year so far  worse than the industry s decline of 15 9  Quarter in DetailR D expenses were  18 5 million  down 55 2  year over year  primarily due to lower product manufacturing expenses and lesser extent lower clinical trial costs General and administrative  G A  expenses came in at  9 2 million  down from  12 4 million in the year ago quarter As of Sep 30  2018  Prothena had  455 6 million in cash  cash equivalents and restricted cash Pipeline UpdatesProthena is evaluating prasinezumab  PRX002 RG7935  in collaboration with Roche for the treatment of Parkinson s disease  A phase II study  PASADENA  which is being conducted by Roche among patients suffering from Parkinson s disease  is continuing enrollment  Data from the study is expected in 2020 Also  Prothena initiated a phase I study on PRX004 in patients with ATTR amyloidosis in the second quarter of 2018  The study continues to enroll patients  The company expects pharmacodynamic data from the lower doses of this study in 2019 Prothena has a global neuroscience research   development collaboration with Celgene Corporation   NASDAQ CELG   to develop new therapies for a broad range of neurodegenerative diseases  The collaboration is focused on three targets implicated in the pathogenesis of several neurodegenerative diseases  inducing tau  TDP 43 and a third that is undisclosed  Per the terms  Prothena received a  100 million upfront payment and a  50 million equity investment from Celgene  The company is eligible to receive future potential exercise payments and milestone payments for each licensed program  Prothena is also eligible to receive additional royalties on net sales of any resulting marketed products  The preclinical tau program is expected to initiate cell line development of a lead candidate in 2019  In addition  the preclinical A   Amyloid beta  program is also likely to initiate cell line development of a lead candidate in 2019 Prothena entered into a multi target license and option agreement with Bioasis Technologies Inc  Per the terms  Prothena will make an upfront payment of  1 million to Bioasis  In exchange  Prothena will explore the application of Bioasis s xB3 platform technology to increase the delivery of therapeutics across the blood brain barrier  BBB  for neuroscience disorders  Moreover  the company has the option to exercise exclusive worldwide rights to additional therapeutic products incorporating Bioasis s BBB technology for neuroscience targets Our TakeThe narrower than expected loss in the third quarter was encouraging  We expect investors  focus to remain on pipeline updates as the company has no approved product in its portfolio yet Prothena has discontinued the development of its lead pipeline candidate  NEOD001  The decision came as a major blow to the investors as the company has a very limited number of candidates in its pipeline and NEOD001 was a lead one  Hence  investors will now focus on the ongoing phase II study on prasinezumab  though results from the mid stage study on this candidate is not expected before 2020 Zacks Rank   Stock to ConsiderProthena carries a Zacks Rank  3  Hold  
A better ranked stock in the healthcare sector is Gilead Sciences  Inc    NASDAQ GILD     which sports a Zacks Rank  1  Strong Buy   You can see  Gilead s earnings per share estimates increased from  6 58 to  6 87 for 2018 over the past 60 days  Estimates for 2019 are also up by 27 cents Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-07,Zacks Investment Research,https://www.investing.com/analysis/prothena-prta-reports-narrowerthanexpected-loss-in-q3-200356895,200356895
201249,422765,GILD,Aerie  AERI  Q3 Earnings Miss  Rhopressa Gains Traction,opinion,"Shares of Aerie Pharmaceuticals  Inc    NASDAQ AERI   lost 6 4   following the company s third quarter results 
Aerie s shares have lost 16 5  in the year so far compared with the  s  s decline of 2 4  

 
Aerie reported third quarter 2018 loss of  1 73 per share  wider than both the Zacks Consensus Estimate of a loss of  1 33 and the year ago loss of 71 cents  The wider than expected loss was on account of higher operating costs related to the launch of lead drug  Rhopressa 
Quarter in Detail
In December 2017  Rhopressa was approved by the FDA for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension  This approval came two months ahead of the scheduled Prescription Drug User Fee Act date of Feb 28  2018  The drug was launched by the end of April 
Rhopressa s revenues came in at  7 3 million  beating the Zacks Consensus Estimate by 29 8  
In the reported quarter  research and development expenses more than doubled to  28 5 million  Selling  general and administrative expenses surged to  39 9 million from  19 8 million in the year ago quarter 
Also  operating expenses were higher in the reported quarter  primarily due to increased activities associated with the expansion of the employee base to support growth of operations and activities associated with Rhopressa commercialization efforts 
Aerie is securing formulary contracts to enable commercial coverage in 2018 and Medicare Part D coverage in 2019  As of Oct 1  2018  Rhopressa s market access increased to approximately 85   up from 80  as last reported  of commercial lives  including 45  in Tier 3 and 40  in preferred brand Tier 2  Medicare Part D coverage is now 40  in Tier 2 
Pipeline Updates
Aerie s New Drug Application  NDA  for its second product candidate  Rocklatan  netarsudil latanoprost ophthalmic solution  0 02  0 005   which is a fixed dose combination of Rhopressa and Pfizer s  PFE  Xalatan  was submitted to the FDA in May 2018  The agency has completed its initial 60 day review of the NDA and determined that the application is sufficiently complete to permit a substantive review  The PDUFA  Prescription Drug User Fee Act  goal date for the completion of the FDA s review of the Rocklatan NDA is set for Mar 14  2019 
In early October 2018  the European Medicines Agency  EMA  accepted for review the Marketing Authorisation Application  MAA  for Rhokiinsa  marketed as Rhopressa in the United States   An opinion on approval is expected in the second half of 2019 
Earlier  the company initiated a phase III trial  Mercury 3  in the third quarter of 2017 to prepare for a regulatory submission in Europe  The trial is a non inferiority trial comparing Roclatan with prescribed fixed dose combination of Ganfort 
Pre IND activities are well underway for further development of Aerie s retina program candidates  including AR 13503  Rho kinase and Protein kinase C inhibitor implant  and AR 1105  dexamethasone steroid implant   Both are expected to enter clinic in 2019 
Outlook Reiterated
Aerie expects Rhopressa s revenues to be  20  30 million in 2018 
Our Take
The wider Q3 loss was primarily due to higher expenses as the company strives to commercialize Rhopressa  Nevertheless  Rhopressa sales comfortably beat estimates  The solid uptake in prescription volumes should propel sales further as glaucoma is one of the largest segments in the global ophthalmic market  even though competition is stiff from the likes of Bausch Health s  BHC  Vyzulta  among others 
Finally  a tentative approval of Rocklatan  early next year  will further boost prospects of the company 
Zacks Rank   Other Key Pick
Aerie carries a Zacks Rank  2  Buy  
Another attractive stock in the healthcare sector is Gilead Sciences  Inc    NASDAQ GILD    which sports a Zacks Rank  1  Strong Buy   You can see   
Gilead s earnings per share estimates increased from  6 10 to  6 57 for 2018 over the past 60 days  Estimates for 2019 are also up by 14 cents 
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-11-08,Zacks Investment Research,https://www.investing.com/analysis/aerie-aeri-q3-earnings-miss-rhopressa-gains-traction-200357181,200357181
201250,422766,GILD,Endo  ENDP  Stock Declines Despite Q3 Earnings   Revenue Beat,opinion,"Shares of Endo International plc   NASDAQ ENDP   fell 17 7  even after the company reported better than expected results for the third quarter 2018 results and raised its annual guidance 
The year over year decline continues to deepen  Moreover  investors were also disappointed with the company s plans to launch its cellulite treatment in 2020 
Nevertheless  Endo s stock has gained 70 2  in the year so far  against the  s 3 8  decline 

 
Earnings from continuing operations were 71 cents per share  which beat the Zacks Consensus Estimate of 59 cents  However  earnings declined from 91 cents recorded in the year ago quarter 
Revenues came in at  745 million in the quarter  surpassing the Zacks Consensus Estimate of  696 9 million  However  the top line was down 5  year over year due to competitive pressures and product discontinuations in the U S  Generic Pharmaceutical segment  divestiture of the company s Mexican business named Somar  and the voluntary market withdrawal of OpanaER 
Quarterly Highlights
Endo now has four reportable business segments   1  U S  Generic Pharmaceuticals   2  U S  Branded   Specialty   Established Pharmaceuticals   3  U S  Branded Sterile Injectables and  4  International Pharmaceuticals 
U S  Generic Pharmaceuticals recorded sales of  258 million in the quarter  down 12  due to competitive pressures in the generic business and previously announced product discontinuations  partially offset by the launch of colchicine tablets  We note that in July 2018  Endo launched colchicine tablets  the authorized generic of Colcrys 
U S  Branded Pharmaceuticals  Specialty   Established Pharmaceuticals  sales were down 6  to  220 1 million due to cessation of product shipments of Opana ER in the third quarter of 2017  Specialty Products revenues increased 13   driven by strong performance of Xiaflex   Xiaflex sales increased 22  year over year  reflecting strong volume growth of the product for the indication of Dupuytren s Contracture and Peyronie s Disease 
The company also reported positive results from two phase III trials of collagenase clostridium histolyticum  CCH  for the treatment of cellulite in the buttocks  The results demonstrated that subjects receiving CCH showed highly statistically significant levels of improvement in the appearance of cellulite with treatment  as measured by the trial s primary endpoint 
Additionally  the RELEASE 1 study passed all the eight key secondary endpoints and the RELEASE 2 study passed seven out of eight key secondary endpoints  Regulatory and pre commercialization activities are already underway and the company targets a market launch in the second half of 2020 
U S  Branded Sterile Injectables  sales of  237 1 million was up 17   driven by strong growth of Adrenalin  up 40   and Vasostrict  up 6    In July  the segment launched ertapenem for injection  the authorized generic of Merck s   NYSE MRK   Invanz  which boosted sales 
In April  Endo entered into definitive agreements to acquire Somerset Therapeutics  LLC  a specialty pharmaceutical company that develops and markets sterile injectable and ophthalmic drugs for the U S  market  and the business of its affiliate Wintac Limited  which operates as Somerset Therapeutics  contract developer and manufacturer  The acquisitions will close in the first quarter of 2019  
Endo also entered into an exclusive licensing agreement with Nevakar  a specialty pharmaceutical company developing multiple assets in the ophthalmic and injectable areas  Both companies have collaborated for the development of five differentiated  sterile injectable products in the United States and Canada  While Nevakar will develop and seek FDA approval for these products  Endo s Par Pharmaceuticals Sterile Products division will launch and distribute them upon approval 
The International Pharmaceuticals division generated sales of  30 2 million  down from  56 4 million in the year ago quarter due to recent divestitures  Endo sold Mexican subsidiary Somar to Advent International in October 2017  Endo also sold its South African subsidiary  Litha Healthcare Group in July 2017 
2018 Outlook Updated
Endo now expects revenues between  2 87 billion and  2 92 billion in 2018  earlier estimate   2 75 billion and  2 85 billion   The company expects Xiaflex s full year revenue growth to be in the low 20s  earlier estimate  high teens percentage range  
Branded Sterile Injectables revenues are now expected to grow in the low 20  range  U S  Generics revenues for 2018 are projected to decline in the mid 30s percentage range  International Pharmaceuticals is estimated to decline approximately 40  
The company anticipates earnings from continuing operations to be  2 65  2 75 per share  earlier estimate   2 50  2 60  
Our Take
Endo s third quarter results were driven by continued momentum in Xiaflex and sterile injectables  Xiaflex s performance was outstanding  propelled by demand  The company is in the process of redefining its business  given the persistent decline in the Generic business  which is expected to face challenges 
The focus now is on sterile injectables and Xiaflex  The U S  Branded Sterile Injectables and U S  Generics Pharmaceuticals segments collectively launched 10 new products year to date 
However  investors were not much impressed with the year over year decline in earnings and revenues  The huge level of debt is a concern   Moreover  response rates from the CCH trials did not impress the investors either 
Zacks Rank   Stocks to Consider
Endo currently carries a Zacks Rank  3  Hold  
A couple of better ranked stocks in the healthcare sector are Gilead Sciences Inc    NASDAQ GILD   and Bristol Myers Squibb Co    NYSE BMY    Both sport a Zacks Rank  1  Strong Buy    You can see  
Gilead s earnings per share estimates increased from  6 58 to  6 87 for 2018 over the past 60 days  Estimates for 2019 are also up by 27 cents 
Bristol Myers  earnings per share estimates have increased from  3 59 to  3 84 for 2018 and from  3 83 to  4 07 for 2019 over the past 60 days 
The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-09,Zacks Investment Research,https://www.investing.com/analysis/endo-endp-stock-declines-despite-q3-earnings--revenue-beat-200357780,200357780
201266,422782,GILD,Bluebird  BLUE  Q3 Loss Narrower Than Expected  Revenues Beat ,opinion,"bluebird bio  Inc    NASDAQ BLUE   reported loss of  2 73 per share in the third quarter of 2018  narrower than the Zacks Consensus Estimate of loss of  2 88 but wider than the year ago quarter s loss of  1 73  The wider than expected year over year loss was due to higher research   development  R D   and general   administrative  G A  expenses on lower revenues Revenues of  11 5 million beat the Zacks Consensus Estimate of  8 3 million  Revenues were also up from  7 7 million recorded in the year ago quarter bluebird s stock has lost 28 3  in the year so far  wider than 15 6  decline registered by the    Quarter in DetailR D expenses escalated to  116 7 million in the third quarter of 2018 from  61 5 million a year ago  driven by costs incurred from the advancement and expansion of the company s pipeline G A expenses of  44 5 million were up 93 5  in the year ago quarter due to increases in employee related costs as headcount increased to support overall growth In July 2018  bluebird raised approximately  600 6 million in net proceeds through a public equity offering  In August 2018  bluebird announced that Regeneron   NASDAQ REGN   will make a  100 million investment in the company s common stock at a price of  238 10 per share  The overall increase in cash  cash equivalents and marketable securities was offset by  40 0 million paid to Gritstone Pipeline Developmentbluebird s pipeline candidates for severe genetic diseases include LentiGlobin for the treatment of transfusion dependent   thalassemia  TDT  and severe sickle cell disease  SCD   and Lenti D for the treatment of cerebral adrenoleukodystrophy  CALD   The oncology pipeline includes CAR T cell product candidates   bb2121 and bb21217   for the treatment of multiple myeloma  The company is co developing and co promoting bb2121 in the United States with Celgene Corporation   NASDAQ CELG   The pipeline progress in the third quarter was encouraging In the last month  bluebird announced that the European Medicines Agency   EMA   accepted the company s marketing authorization application  MAA  for its investigational LentiGlobin gene therapy for the treatment of adolescents and adults  with transfusion dependent   thalassemia  TDT  and a non  0  0 genotype  We remind investors that LentiGlobin was previously granted an accelerated assessment by the Committee for Medicinal Products for Human Use   CHMP   of the EMA in July 2018  which  in turn  should reduce the EMA s active review time of MAA from 210 days to 150 days Meanwhile  based on ongoing discussions with the FDA  bluebird bio is modifying and expanding its clinical development plans to explore efficacy endpoints that may allow the company to pursue a more accelerated development path in the United States for the treatment of patients with SCD  who have a history of vaso occlusive events  VOEs  In September 2018  bluebird announced updated results from phase II III Starbeam study  ALD 102   evaluating its investigational Lenti D gene therapy in boys aged 17 years or below with CALD  The company also announced initial results from the ongoing observational ALD 103 study of outcomes from allogeneic hematopoietic stem cell transplant  allo HSCT  in boys aged 17 years or below with CALD  Meanwhile  bluebird entered a collaboration agreement with Gritstone Oncology  Inc  to research  develop and commercialize products for the treatment of cancer by using cell therapy Our Takebluebird s progress with its pipeline is encouraging  bluebird has an impressive pipeline of gene therapies for genetic diseases and cancer   LentiGlobin looks promising  We are also positive on the company s collaboration with Regeneron as it provides the company with funds The company is also developing CAR T therapies in collaboration with Celgene for myeloma  The CAR T market holds potential and the successful development of the candidates will positively impact the company s results  Celgene is expected to initiate a phase III study on bb2121 in third line multiple myeloma shortly  Hence  we expect investors to focus on pipeline updates from the company Zacks Rank
bluebird currently carries a Zacks Rank  4  Sell   A better ranked stock in the healthcare sector is Gilead Sciences  Inc    NASDAQ GILD    which presently sports a Zacks Rank  1  Strong Buy    You can see  Gilead s earnings per share estimates increased from  6 58 to  6 87 for 2018 and from  6 47 to  6 75 for 2019 over the last thirty days Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-01,Zacks Investment Research,https://www.investing.com/analysis/bluebird-blue-q3-loss-narrower-than-expected-revenues-beat-200354061,200354061
201267,422783,GILD,Conatus   CNAT  Q3 Loss In Line  Revenues Lag Estimates,opinion,Conatus Pharmaceuticals  Inc    NASDAQ CNAT   incurred a loss of 15 cents per share for the third quarter of 2018  meeting the Zacks Consensus Estimate  However  the figure was wider than the year ago quarter s loss of 13 cents per share Revenues came in at  7 7 million  down 23  year over year due to lower reimbursement from partner Novartis   NYSE NVS   for the costs incurred to support development of Conatus  lead pipeline candidate  emricasan  Moreover  the top line marginally missed the Zacks Consensus Estimate of  9 7 million Conatus has no approved product in its portfolio at the moment  The revenues generated by the company are all related to its collaboration with Novartis for the worldwide development and commercialization of emricasan Shares of Conatus have lost 7 4  so far this year against the  increase of 1 3  In the third quarter  research and development expenses were  9 7 million  down 13 4  from the year ago period s figure  mainly owing to lower spending associated with the ongoing ENCORE  NF and ENCORE PH studies on emricasan  This was partially offset by higher spending in the ENCORE LF study on the same candidate General and administrative expenses were  2 7 million  marginally up from the year ago quarter s  2 4 million on higher personnel costs Emricasan in FocusEmricasan  a caspase inhibitor  is being developed for the treatment of patients with fibrosis or cirrhosis caused by nonalcoholic steatohepatitis  NASH   Conatus acquired the worldwide rights to emricasan from Pfizer   NYSE PFE   in July 2010 The company is conducting three ongoing phase IIb ENCORE studies on emricasan for treating fibrosis or cirrhosis induced by nonalcoholic steatohepatitis  NASH   The programs are namely  ENCORE NF  for NASH fibrosis   ENCORE PH  for portal hypertension  and ENCORE LF  for liver function  Top line data from the ENCORE PH evaluation is expected later this year while top line outcomes from the ENCORE NF study are awaited in the first half of 2019 However  top line data from the ENCORE LF study will now be presented in mid 2019  much earlier than the previously estimated timeline of the second half of 2019 The company remains focused on the development of emricasan as positive results from these analyses will pave the way for a phase III efficacy and safety assessment on the candidate for the given disease Apart from emricasan  another candidate in the company s portfolio is IDN 7314  which is currently undergoing a phase II study for the treatment of primary sclerosing cholangitis  PSC   a chronic liver disease GuidanceConatus continues to expect its 2018 year end cash balance between  35 million and  40 million However  with Novartis sharing half of Conatus  development costs for investigations on emricasan  the latter expects its current financial resources to be sufficient for funding operations through the end of 2019 Conatus Pharmaceuticals Inc  Price  Consensus and EPS Surprise   Zacks Rank   Stock to ConsiderConatus carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector is Gilead Sciences  Inc    NASDAQ GILD    which sports a Zacks Rank  1  Strong Buy   You can see  Gilead Sciences  earnings estimates have been revised 4 4  upward for 2018 and 4 2  for 2019 over the past 60 days Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-11-02,Zacks Investment Research,https://www.investing.com/analysis/conatus-cnat-q3-loss-in-line-revenues-lag-estimates-200354143,200354143
201268,422784,GILD,Emergent  EBS  Q3 Earnings And Revenues Fall Shy Of Estimates,opinion,Emergent BioSolutions Inc    NYSE EBS   delivered third quarter 2018 earnings of 55 cents per share  missing the Zacks Consensus Estimate of 62 cents  Earnings were also lower than the year ago bottom line figure of 73 cents Revenues in the reported quarter increased 16 3  from the year earlier period s level to  173 7 million  primarily backed by high product sales  However  the top line lagged the Zacks Consensus Estimate of  188 million Shares of Emergent have surged 37 5  year to date against the  decline of 16 2  Quarter in DetailTotal product sales rose 16 7  to  133 3 million from the year earlier quarter s tally Notably  BioThrax s sales declined 45  in the reported quarter to  45 9 million  Other product sales improved to  87 4 million from  30 8 million in the comparable quarter last year The increase in other product sales is almost entirely courtesy of the incremental contribution of ACAM2000 and raxibacumab  which did not generate sales in the prior year period  Notably  raxibacumab and ACAM2000 were acquired by Emergent from GlaxoSmithkline   NYSE GSK   and Sanofi   NYSE SNY    respectively  in the fourth quarter of 2017 Contracts  grants and collaboration revenues increased 12  year over year to  18 2 million  primarily owing to greater R D activities  associated with certain development funding programs Contract manufacturing revenues jumped 17  to  22 2 million compared with the year ago tally  This upside was primarily on the completion of certain contract manufacturing services at the company s Camden site Research and development  R D  expenses were  37 million  up 63  from the level in the comparable period a year ago  This downside was caused by higher costs associated with contract development services Selling  general and administrative  SG A  expenses were  42 1 million  up 22  from the level in the comparable quarter last year  This downside was due to higher cost incurred from the acquisition of PaxVax and Adapt Pharma 2018 OutlookEmergent raised its previously issued revenue guidance of  715  755 million to  770  800 million in 2018  This upped guidance was fueled by a strong organic sales growth performance year to date as well as an expected contribution from the recent buyouts of PaxVax and Adapt Pharma However  the company lowered its view of adjusted net income to  105  115 million from the previous figure of  110  125 million Other UpdatesEmergent completed two integrations in October and remains optimistic that the transactions will add more value to the current trends in its business The acquisition of Adapt Pharma will add its Narcan nasal spray to Emergent s portfolio  thereby expanding the company s presence in the public health threats market  Total purchase consideration was up to  735 million  which included an upfront payment of  635 million in cash and Emergent s common stock Emergent also completed the consolidation of specialty vaccine company  PaxVax  for an all cash consideration of  270 million with a combination of cash in hand and borrowings under its existing credit facility With the PaxVax deal  Emergent acquired two marketed vaccines  namely Vivotif  the only oral vaccine licensed by the FDA for preventing typhoid fever  and Vaxchora  the only FDA licensed vaccine for the prevention of cholera In July  Emergent initiated a phase I study for its pipeline candidate  ZIKV IG  currently being developed as a therapeutic intervention against Zika virus disease  The company aims to make this complete study data available during the first quarter of 2019 Emergent Biosolutions Inc  Price  Consensus and EPS Surprise   Zacks Rank   Stock to ConsiderEmergent currently carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector is Gilead Sciences  Inc    NASDAQ GILD    sporting a Zacks Rank  1  Strong Buy   You can see  Gilead Sciences  earnings estimates have moved 4 4  north for 2018 and 4 2  for 2019 over the past 60 days Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2018-11-02,Zacks Investment Research,https://www.investing.com/analysis/emergent-ebs-q3-earnings-and-revenues-fall-shy-of-estimates-200354202,200354202
201290,422806,GILD,Novartis Announces Positive Data On CAR T Therapy  Kymriah ,opinion,"Novartis AG   NYSE NVS   announced encouraging results from the JULIET trial on Kymriah after 14 months  wherein it was observed that ongoing durable responses are achievable with Kymriah when administered to adult patients with relapsed or refractory  r r  diffuse large B cell lymphoma  DLBCL  These data were also presented at the 23rd Annual Congress of the European Hematology Association The results from the trial showed overall response rate  ORR  of 52  among 93 evaluable patients  who were followed for at least three months or discontinued earlier  In addition  a complete response  CR  was achieved in 40  of patients and 12  achieved a partial response  PR   Of the total patients who had experienced CR at three months  83  remained on the same at month 12  Moreover  the relapse free probability at 12 months  after a patient s first response  was 65   which was encouraging The results further emphasize Kymriah s efficacy with durable responses  and a predictable and consistent safety profile for more than a year  after infused in patients with advanced DLBCL With eight months of additional follow up  response rates remained consistent with previous reports with no emergence of new safety signals Kymriah  formerly CTL019  is the first chimeric antigen receptor T cell  CAR T  therapy  approved by the FDA for the treatment of patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia  ALL  that is refractory or in second or later relapse  The FDA also approved Kymriah for the treatment of adult patients with r r large B cell lymphoma  after two or more lines of systemic therapy including DLBCL  high grade B cell lymphoma and DLBCL arising from follicular lymphoma  based on data from the JULIET study in May 2018 Meanwhile  Novartis  Marketing Authorization Application  MAA  for Kymriah  for the treatment of children and young adults with r r B cell acute lymphoblastic leukemia  ALL  and for adult patients with r r DLBCL  is currently under review in Europe Novartis has a strong oncology portfolio of drugs like Afinitor  Exjade  Jakavi  Zykadia  Tasigna  Jadenu and Kisqali  which continue to boost its sales  The approval of Kymriah for acute lymphoblastic leukemia is a major boost  given the potential in the CAR T therapy space  Novartis  shares have declined 7 7  in the last six months compared with the  s decline of 2 6  Earlier in 2018  Novartis announced a licensing agreement with Spark Therapeutics   NASDAQ ONCE    covering development  registration and commercialization rights to voretigene neparvovec  outside the United States Competition is increasing in the gene therapy space  Gilead s   NASDAQ GILD   Yescarta was another CAR T therapy  approved to treat adult patients with certain types of large B cell lymphoma  who have not responded to or have relapsed after at least two other kinds of treatment uniQure   NASDAQ QURE   is another gene therapy company  which is advancing a pipeline of proprietary and partnered gene therapies to treat patients with liver metabolic  central nervous system and cardiovascular diseases The approval of new drugs bode well for Novartis as the company is facing the loss of patent protection for some of the key drugs Novartis also announced results from a new comparison study showing that Jakavi  treated patients with polycythemia vera  PV   who were resistant or intolerant to hydroxyurea  HU   had a significantly reduced risk of thrombosis  blood clots  and death compared to PV patients  who received best available therapy Zacks Rank
Novartis carries a Zacks Rank  4  Sell  
You can see   Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-06-17,Zacks Investment Research,https://www.investing.com/analysis/novartis-announces-positive-data-on-cart-therapy-kymriah-200325746,200325746
201291,422807,GILD,CRISPR Science And Stocks  Knowing Enough To Invest ,opinion,"By far the most exciting real time revolution unfolding in Biotechnology is CRISPR gene editing  And the past few months have provided plenty of excitement for Biotech investors as the three public companies who are pure play manifestations of the technology have made some dramatic moves    on good news and bad 
For instance  on June 11  two scientific research studies were published that suggested CRISPR gene editing could actually enable cancer growth  Shares of the biggest of the three companies  CRISPR Therapeutics   NASDAQ CRSP    dropped over 20  on that scary news of  gene editing gone wrong  
After reading scientist  analyst  and company reactions to understand the controversy and its implications  I decided it was actually a buying opportunity for investors who follow my picks in Zacks Healthcare Innovators  where we also own the other two players Editas Medicine   NASDAQ EDIT   and Intellia Therapeutics   NASDAQ NTLA   
For a good explanation of why I saw that fear driven reaction as an excellent opportunity for investors who appreciate a good calculated risk  check out the video I made on June 18   

From  Revolutionary Breakthrough  to  Dangerous Science 
And this is not the first time a news or research scare has made the stock go from over loved to well hated  In January  there were papers being debated about whether CRISPR could cause  off target  edits  accidentally modifying other genes not related to a given targeted disease 
But this  collateral damage  view was found within a few months to be based on inconclusive research 
Beyond the scientific unknowns of this  power of God  technology  there is another landmine for investors  the three companies  and their respective partner research institutions or universities  are all in a giant patent dispute over who discovered what  and when  and who lays claim to which new developments 
What Exactly is CRISPR 
In the video that accompanies this article  I go over some of the basic scientific facts and assumptions of CRISPR that make it such a revolutionary discovery for potentially curing thousands of genetic diseases 
What s so fascinating about CRISPR is that it wasn t invented in a lab like some pharmaceutical drug  It was discovered in nature 
Rather than try to explain it in my own words and probably butcher it  let s hear from one of the experts  CRISPR Therapeutics  from their website    
CRISPR Cas9 is a rapid and easy to use gene editing technology that can selectively delete  modify or correct a disease causing abnormality in a specific DNA segment 
CRISPR refers to Clustered Regularly Interspaced Short Palindromic Repeats occurring in the genome of certain bacteria  from which the system was discovered  Cas9 is a CRISPR associated endonuclease  an enzyme   the  molecular scissors  that are easily programmed to cut and edit  or correct  disease associated DNA in a patient s cell 
The clustered repeats of CRISPR were discovered by accident in 1987 by researchers studying bacterial defense mechanisms  specifically how bacteria deal with foreign plasmids and phages  Bacteria have the ability to open and alter the genomes of invading viruses with a nuclease called Cas9  inactivating them in the process  The clustered repeats were given the name CRISPR in 2002 and multiple CRISPR associated  Cas  genes were discovered adjacent to the repeat elements in that same year 
A New Science for Treating Disease  Courtesy of Good Ole Bacteria
CRISPR could be summed up as simply as this  a protein named Cas9 found in the streptococcus bacteria attacks the DNA of an invading virus by slicing it up  In essence  the prey becomes the predator  Mother nature worked on this for billions of years  She must know something 
That is the crux of what you want to remember here about CRISPR Cas  scientists have learned from bacteria    nature s warriors of survival and her ninjas of adaptation    how they utilize proteins to alter the genetic structure of invading viruses  and thereby how we can use Cas9 to  edit  genetic material 
Because of its ability to modify a cell s DNA with amazing precision  CRISPR and its evolving variations    a new enzyme called Cas13 was recently discovered that could be less error prone    will be a hot arena for science and medical innovation for decades to come 
Mother nature indeed knows things  In fact  most scientists believe we are just scratching the surface of what will be discovered this century  So it may be premature to call CRISPR  the discovery of the century  when we ve got over 80 years left 
And investors should also be aware of different types of gene editing  Last July  I gave Zacks Confidential subscribers a special report on  Gene Editing  How to Invest   There we picked Sangamo Therapeutics   NASDAQ SGMO   as a potential winner with its technology called zinc finger nuclease  ZFN   We rode SGMO to 155  gains this year after Gilead Sciences   NASDAQ GILD   and its KITE subsidiary created a  3 billion R D partnership with Sangamo 
For my latest report on gene editing from April titled   you can email  and one of our account reps will help you out 
That report gives more background on all the companies plus a peek at the new Cas13 threat 
Disclosure  I own shares of CRSP  NTLA  EDIT  SGMO  and GILD for the  portfolio  While it is designed as a long term portfolio  I may occasionally swing trade in or out of some highly volatile stocks 
Kevin Cook is a Senior Stock Strategist for Zacks Investment Research where he runs the Healthcare Innovators service  Click Follow Author above to receive his latest stock research and macro analysis 
Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-06-20,Zacks Investment Research,https://www.investing.com/analysis/crispr-science-and-stocks-knowing-enough-to-invest-200326566,200326566
201292,422808,GILD,Gilead Sciences Stock Ripe For A Pre Earnings Options Trade,opinion,"Earnings season is kicking into high gear  with several blue chips on tap to report this week  Stocks have the tendency to make volatile moves after a company s earnings report  and those looking for a potential trading opportunity may want to consider hepatitis specialist Gilead Sciences  Inc   NASDAQ GILD   which has tended to exceed volatility expectations over the past year    a boon to would be premium buyers 
Taking a quick step back  GILD is scheduled to report second quarter earnings after the market closes next Wednesday  July 25  Over the past eight quarters  the drug stock has averaged a single session post earnings move of 4 3   regardless of direction  Overall  though  most of these reactions have been unfavorable  with six of those post earnings returns being negative over the two year time frame 
Those contemplating a pre earnings options trade on GILD may want to consider a premium buying strategy  such as a straddle  This is based on the stock s elevated Schaeffer s Volatility Scorecard  SVS  reading of 83  out of a possible 100  This means the equity has made outsized moves relative to what the options market has expected  looking back 12 months 
What s more  options on Gilead Sciences stock are relatively cheap at the moment  from a historical standpoint  The equity s Schaeffer s Volatility Index  SVI  was last seen at 28     in the 27th percentile of its annual range  In other words  short term options are pricing in relatively low volatility expectations at the moment 
Looking at the charts  GILD shares have been trending higher since their May 3 annual low of  64 27  up 19   Along the way  the stock filled its early May bear gap  and is now trading back above its 200 day moving average    which served as support late last year  Nevertheless  the security is down 0 6  today at  76 98  after Leerink struck a cautious tone on biotech earnings  but said Gilead Sciences is in a strong position to beat estimates ",2018-07-17,Schaeffer's Investment Research,https://www.investing.com/analysis/gilead-sciences-stock-ripe-for-a-preearnings-options-trade-200331221,200331221
201293,422809,GILD,CEO Departure At Gilead Sciences Upstages Good Second Quarter Results,opinion,"The big biotech announced great momentum for its new HIV drug  a hint at HCV sales stabilization  and news that its CEO is stepping down 
As Gilead Sciences   NASDAQ GILD  announcement of its second quarter earnings approached  there were three big things investors were looking to see  One was any sign that the company s hepatitis C virus  HCV  franchise sales might have begun to stabilize  Another was how well new HIV drug Biktarvy performed  And investors also hoped that the rest of the big biotech s HIV lineup held up against the competition 
Gilead answered all those questions when it provided an update of its second quarter performance after the market closed on Wednesday  but it also raised a new question  Here are the highlights from the company s second quarter results 

What happened with Gilead Sciences this quarter 
Although Gilead s HCV revenue fell more than 65  year over year to  1 billion  the more important comparison to look at is second quarter sales versus first quarter sales  The quarter over quarter decline was only 4 4     much better than the 30  quarter over quarter drop that Gilead reported in May 2018  It looks as if the long awaited stabilization in HCV revenue might be very close 
The brightest spot in Gilead s second quarter results was the performance of Biktarvy  Gilead s new HIV drug raked in  185 million in its first full quarter on the market  and all but  2 million of that total was made in the United States  As European sales also ramp up  Gilead should soon have its next blockbuster HIV drug 
Thanks in part to Biktarvy s successful launch  the biotech s total HIV sales in the second quarter increased 15 6  year over year to  3 7 billion  But Gilead s other TAF based HIV drugs also helped tremendously  Sales for Genvoya jumped 35  from the prior year period to  1 16 billion  Percentage sales growth for Descovy and Odefsey was even more impressive  with sales for Descovy increasing nearly 41  year over year to  403 million and sales for Odefsey jumping 49  year over year to  385 million 
Gilead s older HIV drugs  including Truvada  Atripla  and Stribild  saw sales drop from the prior year period  However  these declines were expected with generic competition in Europe and the ascendence of the company s own TAF based drugs 
Yescarta  the chimeric antigen receptor T cell therapy picked up with Gilead s acquisition of Kite Pharma last year  generated revenue of  68 million during the second quarter  That s up from  40 million in sales for Yescarta in the first quarter of 2018 
Revenue from Gilead s other drugs fell 13 4  year over year to  807 million  The primary factor behind this decline was significantly lower sales for hepatitis B virus drug Viread 
Gilead s other big news
Overall  Gilead s second quarter results were pretty good despite the poor comparisons with the prior year period  However  investors might have reeled a bit from the company s other news  CEO John Milligan is stepping down at the end of 2018 
Milligan was named CEO of Gilead in March 2016 and has been with the company for 28 years  A tenure of fewer than three years at the helm was definitely unexpected 
Milligan stated   It has been an honor to work at Gilead for my entire professional career  and now that the company is on solid footing for the future  the board and I have agreed it is a good time to turn the reins over to a new leader   He added   I m looking forward to a well deserved break and will then move on to new and different opportunities  
In addition  John Martin  former Gilead CEO and current chairman of the board  announced that he will step down from the company s board of directors at the end of the year  Martin felt that  this would be a natural transition point from his successive roles as CEO  executive chairman  and chairman   according to Gilead s press release about Milligan s upcoming departure 
Looking forward
In Gilead s first quarter conference call  CFO Robin Washington said 2018 would be a  trough year  for the company  The biotech s second quarter results hint that Gilead might now begin moving past the bottom of the trough on its way to renewed growth 
Investors can look forward to continued momentum for Biktarvy and Gilead s newer HIV drugs  It now seems that the worst for the company s HCV franchise could be over  Gilead also should report results for its promising immunology drug  filgotinib  in the near future 
But probably the biggest thing to watch now is whom Gilead will hire as its new CEO  Regardless of who it is  the person should inherit a company with better prospects than would have been the case a year ago 
Gilead Sciences is not on our top  Buy  list  but these 10 stocks areInvesting geniuses David and Tom Gardner just released their best stocks to buy now    and it could pay to listen  Especially when you consider their average stock pick is up 353  vs  a mere 81  for the S P 500 ",2018-07-29,Keith Speights,https://www.investing.com/analysis/ceo-departure-at-gilead-sciences-upstages-good-secondquarter-results-200334301,200334301
201311,422827,GILD,Why Is Gilead Sciences  GILD  Down 7 2  Since Its Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Gilead Sciences  Inc    NASDAQ GILD    Shares have lost about 7 2  n that time frame 
Will the recent negative trend continue leading up to its next earnings release  or is GILD due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers Gilead Q1 Earnings   Sales Miss Estimates on Weak HCVGilead reported dismal results for the first quarter of 2018 wherein both earnings and revenues missed expectations due to a wider than expected decline in the hepatitis C virus  HCV  franchise The company s first quarter earnings of  1 48 per share missed the Zacks Consensus Estimate of  1 66  Earnings were also below the year ago quarter figure of  2 23 per share Moreover  total revenues of  5 1 billion also missed the Zacks Consensus Estimate of  5 42 billion  Further  revenues declined 21 8  year over year Harvoni   Sovaldi Plunge FurtherProduct sales came in at  5 0 billion  down 21 6  year over year due to accelerated decline in HCV sales Antiviral product sales  which include Gilead s HIV and liver disease portfolio  came in at  4 4 billion in the quarter  down 24 1  from the year ago quarter Research   development  R D  expenses declined 8 4  to  814 million  Selling  general and administrative  SG A  expenses increased 9 5  to  884 million HCV product sales  which include Harvoni  Sovaldi  Epclusa and Vosevi  were  1 0 billion  down from  2 6 billion reported in the year ago quarter  The downside was mainly due to lower sales of Harvoni and Sovaldi across all major markets and lower sales of Epclusa in the United States as a result of increased competition Sales of Harvoni plunged 74 7  year over year to  348 million in the quarter   Epclusa garnered sales of  536 million in the quarter  down from the year ago period figure of  892 million Meanwhile  HIV and HBV product sales came in at  3 3 billion  up 1 9  year over year  The increase was primarily driven by continuous strong uptake of tenofoviral afenamide  TAF  based products such as Genvoya  which generated sales of  1 082 million  up from  769 million in the year ago quarter  Descovy  which recorded sales of  361 million  up from  251 million  and Odefsey  which registered sales of  342 million  up from  227 million  Entry of generics and greater U S  inventory drawdown than in the prior year quarter somewhat impacted sales  However  HIV treatments like Stribild and Complera Eviplera sales declined 43 7  and 24 9  respectively  Viread sales were down at  97 million  down 62 7  Atripla sales tanked 30 5  to  314 million  while Truvada sales fell 8 7  to  652 million Other products like Letairis  Ranexa  AmBisome and Zydelig recorded sales of  204 million  down 3 3     195 million  up 27 4     107 million  up 16 3   and  33 million  respectively  Adjusted product gross margin was 86 3  compared to 88 3  in the year ago period 2018 Guidance ReiteratedGilead continues to expect net product sales in the range of  20  21 billion  Adjusted R D expenses and adjusted SG A expenses are projected in the range of  3 4  3 6 billion and  3 4  3 6 billion  respectively  Adjusted product gross margin is expected in the range of 85 87  AcquisitionsThe company acquired Kite Pharma in 2017  The FDA approval for Yescarta  a CAR T therapy for the treatment of adult patients with relapsed or refractory large B cell lymphoma after two or more lines of systemic therapy should Gilead s prospects  The company also acquired Cell Design Labs to expand further in the CAR T space Yescarta sales came in at  40 million in the quarter Dividend and Share RepurchaseGilead declared a cash dividend of  0 57 per share of common stock for second quarter 2018  The dividend is payable on Jun 28 to stockholders of record at the close of business on Jun 15  During the quarter  the company paid cash dividends of  253 million and repurchased shares for  1 0 billion 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  There have been seven revisions lower for the current quarter Gilead Sciences  Inc  Price and Consensus    VGM Scores
At this time  GILD has a poor Growth Score of F  Its Momentum is doing a bit better with a D  The stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
The company s stock is suitable solely for value based on our styles scores 
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift  Notably  GILD has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-05-30,Zacks Investment Research,https://www.investing.com/analysis/why-is-gilead-sciences-gild-down-72-since-its-last-earnings-report-200320897,200320897
201312,422828,GILD,Gilead   Galapagos Announce Positive Data On Filgotinib,opinion,Gilead Sciences  Inc    NASDAQ GILD   and Galapagos NV   NASDAQ GLPG   announced that the phase II study  EQUATOR  on pipeline candidate  filgotinib achieved its primary endpoint of improvement in the signs and symptoms of psoriatic arthritis at Week 16  as assessed by the American College of Rheumatology 20 percent improvement score  ACR20  The EQUATOR trial  initiated by Galapagos in April 2017  is a multicenter randomized  double blind  placebo controlled trial to assess the safety and efficacy of the selective JAK1 inhibitor filgotinib in adult patients with moderately to severely active psoriatic arthritis The data from the study depicted an ACR20 response of 80  for filgotinib versus 33  for placebo  Additionally  the ACR50 and ACR70 responses at Week 16 were also significantly higher for filgotinib than placebo   Filgotinib was generally well tolerated in the trial and no new safety signals were observed  However  there was one serious infection in the filgotinib group where a patient who experienced pneumonia with a fatal outcome and one other patient receiving filgotinib developed herpes zoster Both the companies plan to report the detailed results from the EQUATOR trial at a future scientific conference Concurrently  Gilead and Galapagos also announced that an independent Data Monitoring Committee  DMC  conducted a planned interim futility analysis of the phase IIb IIII study  SELECTION  on filgotinib for the treatment of ulcerative colitis  The analysis was conducted after 350 patients completed the induction period in the phase IIb portion of the study  The DMC recommended that the study should go on as planned into phase III at both the 100 mg and 200 mg once daily dose level in biologic experienced and biologic na ve patients  The multicenter  randomized  double blind  placebo controlled study to assess the safety and efficacy of the selective JAK1 inhibitor filgotinib in adult patients  with moderately to severely active ulcerative colitis was initiated by Gilead in late 2016  Consequently  Gilead will pay  15 million to Galapagos for this progression from phase II to phase III in the SELECTION trial   The trial will enroll a total of 1 300 patients  targeted to be randomized to receive filgotinib 100 mg  200 mg  or placebo once daily administered for 58 weeks  The primary objective of SELECTION is to evaluate the efficacy of filgotinib as compared to placebo in establishing EBS  endoscopy  bleeding  stool  remission at Week 10 Both Galapagos and Gilead entered into a global collaboration for the development and commercialization of filgotinib in inflammatory indications  The candidate is also being evaluated in the ongoing phase III program  FINCH in rheumatoid arthritis  the phase III trial  DIVERSITY for Crohn s disease  also small bowel and fistulizing Crohn s disease phase II studies  among others Given the persistent decline in HCV sales  Gilead is looking to newer avenues to help its top line   Gilead s stock has lost 8 2  in the last six months as against the  s loss of 8 1   Gilead s HCV franchise witnessed slowdown across key markets  including the United States and Europe  reflecting lower sales of Harvoni and Sovaldi as a result of competitive and pricing pressure  The franchise saw a significant plunge in sales due to new competition and fewer patient starts   Pricing has largely stabilized and market share will stabilize by mid 2018  while patient starts are expected to decline further  We note that Harvoni  Sovaldi and Epclusa face competition from AbbVie s   NYSE ABBV   Viekira Pak and Mayret  and Merck s   NYSE MRK   Zepatier among others Gilead is looking to solidify its presence in the gene therapy space  The initial uptake of Yescarta is also encouraging  Gilead is also intending to foray into the NASH market with pipeline candidates   selonsertib and filgotinib Zacks RankGilead currently carries a Zacks Rank  3  Hold  You can see   Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-05-30,Zacks Investment Research,https://www.investing.com/analysis/gilead--galapagos-announce-positive-data-on-filgotinib-200320952,200320952
201313,422829,GILD,Gilead Collaborates With Hookipa For HBV And HIV Therapies,opinion,"Gilead Sciences   NASDAQ GILD   entered into a research collaboration and license agreement with Hookipa Biotech AG  Per the agreement  Gilead will own exclusive rights to Hookipa s TheraT and Vaxwave arenavirus vector based immunization technologies for two major chronic infectious disease indications  hepatitis B virus  HBV  and human immunodeficiency virus  HIV   While research work will be carried out by both  Hookipa will manufacture arenavirus based vectors for clinical development by Gilead 
In exchange  Gilead will provide an upfront payment of  10 million  In addition  Hookipa will be eligible to receive payments up to a total of more than  400 million based upon the achievement of specified development  regulatory and commercial milestones  Moreover  Gilead will fund all research and development activities  Hookipa will also be eligible to receive tiered royalties on net sales 
The agreement further expands the relationship between Hookipa and Gilead following Gilead s participation in Hookipa s Series C financing in Dec 2017   Hookipa s unique therapeutic vaccine technology demonstrated excellent safety and immunogenicity in phase I studies 
Gilead is banking on its HIV franchise to drive growth in future  given the persistent decline in HCV sales  Gilead s stock has lost 3 0  in the last six months as against the s loss of 5 2  

 
Gilead s HCV franchise witnessed slowdown across key markets  including the United States and Europe  reflecting lower sales of Harvoni and Sovaldi as a result of competitive and pricing pressure  The franchise saw a significant plunge in sales due to new competition and fewer patient starts  
Pricing has largely stabilized and market share will stabilize by mid 2018  while patient starts are expected to decline further  We note that Harvoni  Sovaldi and Epclusa face competition from AbbVie s   NYSE ABBV   Viekira Pak and Mayret  and Merck s   NYSE MRK   Zepatier among others 
Meanwhile  Gilead is looking to newer avenues to help its top line by solidifying its presence in the gene therapy space  The initial uptake of Yescarta is also encouraging  Gilead is also intending to foray into the NASH market with pipeline candidates   selonsertib and filgotinib 
During the first quarter  Gilead announced an agreement with Sangamo Therapeutics  Inc    NASDAQ SGMO   to use Sangamo s zinc finger nuclease technology platform for the development of next generation ex vivo cell therapies in oncology 
Zacks Rank
Gilead currently carries a Zacks Rank  3  Hold  
You can see   
Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6  and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-06-06,Zacks Investment Research,https://www.investing.com/analysis/gilead-collaborates-with-hookipa-for-hbv-and-hiv-therapies-200322714,200322714
201314,422830,GILD,Galmed  GLMD  Soars On Positive NASH Data On Aramchol,opinion,Shares of Israel based Galmed Pharmaceuticals Ltd    NASDAQ GLMD   soared 149 5  after the company announced positive top line results on its lead candidate  Aramchol  for the treatment of non alcoholic steatohepatitis  NASH  at 52 weeks Consequent of this gain  Galmed shares have gained 94 5  in the last six months compared with the s growth of 8 0   Shares are up in pre market trading as well  Patients enrolled in the phase IIb study  ARREST  underwent Magnetic Resonance Spectroscopy  MRS  and biopsy at baseline and week 52  Patients with biopsy proven NASH  who were overweight or obese and had pre diabetes or type II diabetes mellitus  were randomized in a ratio of 2 2 1  600mg  400mg and placebo  The primary endpoint of the study was the change from baseline to end of study  in liver triglycerides ratio as measured by MRS  Aramchol 600mg compared to placebo  A statistically significant reduction in liver fat was demonstrated by MRS  in patients who had completed 52 weeks of treatment with Aramchol 400mg as compared to placebo  In addition to this  the post hoc analysis of MRS responders  defined by a reduction of  5  absolute change from baseline  also demonstrated a clinically and statistically significant effect of Aramchol 600mg compared to placebo Moreover  a larger number of patients treated with Aramchol 600mg showed NASH resolution without worsening of fibrosis in the 52 week biopsy  Aramchol 600 mg also resulted in at least one point improvement in fibrosis score without worsening of NASH  in a higher proportion of patients  as compared to placebo Further  statistically significant reductions in live enzymes alanine transaminase  ALT  and aspartate transaminase  AST  were also seen in both Aramchol arms as compared to placebo  p 0 0002  and  p 0 001   respectively These results indicate that Aramchol 400mg is probably sufficient for fat reduction but  biologically  a higher dose is needed for achieving more stringent histological endpoints  such as NASH resolution and fibrosis reversal  The data strongly support advancing Aramchol 600mg to phase III Per estimates  NASH impacts approximately 3 5  of people in the United States and approximately 2 4  globally  NASH is also one of the fastest growing causes of liver cancer and liver transplant in the United States  due to the rise in obesity Hence  the successful development and commercialization of Aramchol will be a significant boost for the clinical stage biopharmaceutical company Galmed  given its potential in the market Other companies like Gilead Sciences   NASDAQ GILD    Intercept Pharmaceuticals   NASDAQ ICPT   and Novartis   NYSE NVS   also have promising NASH candidates in their pipelines Zacks RankGalmed currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-06-12,Zacks Investment Research,https://www.investing.com/analysis/galmed-glmd-soars-on-positive-nash-data-on-aramchol-200324534,200324534
201315,422831,GILD,NASH Space In Focus As Galmed  GLMD  Posts Positive Data ,opinion,The NASH or the non alcoholic steatohepatitis space is back in focus as Israel based Galmed Pharmaceuticals   NASDAQ GLMD   reported positive data on its candidate  Aramchol  The candidate demonstrated statistically significant reduction in liver fat at 52 weeks  A larger number of patients treated with Aramchol 600mg showed NASH resolution without worsening of fibrosis in the 52 week biopsy   This encouraging data boosted investor sentiment  leading to the stock s significant surge Of late  the NASH space has been under the spotlight given its market potential   The market for NASH is poised to witness rapid growth unlike other lucrative yet saturated markets like cancer What is NASH A chronic liver disease  NASH is caused by excessive fat accumulation in the liver  known as steatosis  Per records  it has affected up to 15 million people in the United Stated and could cause inflammation  hepatocellular injury  progressive fibrosis and cirrhosis  The ailment is anticipated to be the leading reason behind liver transplantation by 2020  Currently  NASH induces the biggest basis for liver transplants in people under 50 in the United States  Such patients also suffer obesity and type II diabetes With no treatments currently approved to address this disease  the market opportunity is substantially huge and many companies are investing a major chunk of their R D spend in the same Let us consider the companies with potential candidates presently being evaluated for the treatment of NASH 5 Stocks With Promising NASH Candidates in Their PipelineMadrigal Pharmaceuticals   NASDAQ MDGL    Shares of Madrigal Pharmaceuticals soared last month after the company reported positive top line  36 week results from a phase II trial on patients with biopsy proven NASH  The program evaluated the lead pipeline candidate  MGL 3196  a first in class  oral  once daily  liver directed  thyroid hormone receptor  THR    selective agonist  Data from the study showed that MGL 3196 achieved higher reduction in NAFLD activity score  NAS  and greater NASH resolution in patients with 30  or more liver fat reduction achievement at week 12  The candidate had met the primary endpoint of 30  or more reduction in liver fat at week 12 last December  The company will advance the candidate to a phase III study following a regulatory agreement on its design Madrigal s stock has skyrocketed 303 3  in the last six months  outperforming the  s rise of 9 2   The company currently has a Zacks Rank  3  Hold   You can see    Gilead Sciences Inc     NASDAQ GILD     Biotech bigwig Gilead is also foraying into the emerging NASH domain with its late stage candidate  selonsertib  to combat the persistent decline in its one time lucrative HCV business  In April 2018  the company announced encouraging data from a proof of concept study of experimental combination therapies for patients with advanced fibrosis due to NASH  Apoptosis signal regulating kinase 1  ASK1  inhibitor  selonsertib  was combined with either the Acetyl CoA carboxylase  ACC  inhibitor  GS 0976  or the selective  non steroidal Farnesoid X receptor  FXR  agonist  GS 9674  as therapies  Gilead s NASH pipeline includes selonsertib  GS 9674 and GS 0976  alone and in combination with one other  Favorable results suggest that the combination therapy with selonsertib and either GS 0976 or GS 9674 can be evaluated further in patients with NASH and F3 and F4 fibrosis  Gilead s stock has lost 3 5  in the last six months compared with the s decline of 6 2   Intercept Pharmaceuticals  Inc    NASDAQ ICPT    Intercept is another company  pumping its resources into the NASH space  The company is evaluating its lead candidate  obeticholic acid  OCA   for treating NASH  OCA achieved the primary endpoint in a phase IIb trial  FLINT   Currently  a phase III study  REGENERATE  among non cirrhotic NASH patients with liver fibrosis is ongoing  Top line results from its interim analysis are expected in the first half of 2019  Intercept also initiated a phase III trial  REVERSE  on OCA   The randomized phase III study will examine the efficacy and safety of OCA on subjects with compensated cirrhosis due to NASH in approximately 540 patients with a biopsy confirmed diagnosis of cirrhosis  Intercept expects to submit marketing authorization for OCA as a treatment option for NASH patients with compensated cirrhosis in the United States and international markets on the basis of the positive results from the study  A subsequent outcome trial is also in the cards to confirm the clinical benefit on a post marketing basis across a broader population of NASH patients with cirrhosis  OCA is already approved as Ocaliva in combination with ursodeoxycholic  UDCA  for the therapy of primary biliary cholangitis  PBC  in adults with an inadequate response to UDCA or as a monotherapy in adults unable to recuperate with UDCA Intercept s stock has surged 32 6  over a year versus the s decline of 6 2   Conatus Pharmaceuticals Inc    NASDAQ CNAT    Conatus also has a promising NASH candidate in its pipeline  The company is developing emricasan  a first in class  orally active pan caspase protease inhibitor  for the treatment of patients with chronic liver disease  Conatus currently has three ongoing studies  namely ENCORE PH  ENCORE NF and ENCORE LF  evaluating emricasan for NASH patients  The company has a collaboration agreement with Swiss major Novartis for the global development and commercialization of products containing emricasan either as a single active ingredient or in combination with other Novartis compounds for liver cirrhosis or liver fibrosis  Although emricasan failed in a phase IIB study   POLT HCV SVR   when it did not achieve the primary endpoint in patients with fibrosis or cirrhosis undergoing liver transplant  investors will still keenly follow data from multiple NASH studies   Data from the ongoing trials are likely to be received by this year end and 2019  A positive outcome will surely boost growth prospects for the company The company currently carries a Zacks Rank  3  Hold   Conatus  stock has rallied 25 7  in the last six months  outperforming the 11 3  increase recorded by the    Galectin Therapeutics Inc    NASDAQ GALT   is another company with a late stage NASH candidate  GR MD 02  The candidate is a carbohydrate based drug inhibiting the galectin 3 protein  directly involved in multiple inflammatory  fibrotic and malignant diseases  The lead development program is in NASH with cirrhosis  the most advanced form of NASH related fibrosis  In May  the company announced that it will initiate a phase III trial with its galectin 3 inhibitor GR MD 02 in NASH cirrhosis  incorporating advice and guidance obtained from a meeting with the FDA   The target population of the trial comprises patients with NASH cirrhosis without esophageal varices Galectin currently carries a Zacks Rank  3  Hold   Its stock has gained by a staggering 227 2  in the last six months  outperforming the  s growth of 9 4   Bottom LineRiding high on the vast market potential  other big multiple pharma and biotech companies too produce pipeline candidates for the treatment of NASH  Hence  we expect a lot of activity in this specific space going forward  A potential approval of any drug for NASH will attract more players 5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ,2018-06-13,Zacks Investment Research,https://www.investing.com/analysis/nash-space-in-focus-as-galmed-glmd-posts-positive-data-200324949,200324949
201339,422855,GILD,Celgene  CELG  Q1 Earnings   Sales Beat On Revlimid Strength,opinion,"Celgene Corporation   NASDAQ CELG   reported encouraging first quarter 2018 results wherein both earnings and sales topped expectations The company reported adjusted earnings of  2 05 per share which beat the Zacks Consensus Estimate of  2 00  up from  1 67 in the year ago quarter Celgene Corporation Price  Consensus and EPS Surprise
    Total revenues grew 19 4  to  3 54 billion in the quarter and beat the Zacks Consensus Estimate of  3 50 billion  Revenues were boosted by consistent performance of the company s key growth driver  Revlimid Revlimid   Key CatalystNet product sales increased 20  year over year to  3 5 billion  Net sales of Revlimid came in at  2 2 billion  reflecting 19  year over year growth  The drug performed well both in the United States  up 21   and international markets  up 15    Growth in the quarter was driven by increased volume as a result of increases in duration of treatment and market share Net sales of another cancer drug  Abraxane increased 11  to  262 million as sales benefited from buying patterns   Pomalyst Imnovid came in at  453 million  up 24   Sales were driven by increased volume due to increase in market share and duration Otezla sales were  353 million in the quarter  up 46   Sales in the United States were primarily volume driven due to increasing demand and improved access pull through in contracted health plans while sales in international markets were driven primarily by increasing adoption in key ex U S  markets All other product sales  including Istodax  Thalomid  Vidaza and an authorized generic version of Vidaza in the United States  totaled  229 million in the quarter  up from  226 million from the year ago quarter Adjusted research and development expenses increased 16 6  to  694 million due to higher spending related to drug discovery and clinical trial activity while adjusted selling  general and administrative expenses decreased 24 5  to  671 million Pipeline UpdateCelgene acquired acquire Juno Therapeutics  Inc  for approximately  9 billion in March 2018  In February 2018  the company also acquired Impact Biomedicines and added a late stage candidate  fedratinib  a highly selective JAK2 kinase inhibitor  to its pipeline Celgene announced a global collaboration with Prothena   NASDAQ PRTA   in March 2018 to develop new therapies for a broad range of neurodegenerative diseases primarily focused on three proteins implicated in the pathogenesis of several neurodegenerative diseases  including tau  TDP 43 and an undisclosed target Celgene s partner bluebird bio   NASDAQ BLUE   opted to co develop and co promote bb2121  an experimental anti BCMA CAR T cell therapy for the treatment of patients with RRMM in the United States in March 2018  Both companies had originally entered into a broad  global strategic research collaboration in 2013 to discover  develop and commercialize novel therapies in oncology  which included bb2121  The agreement was amended in 2015 However  Celgene suffered a setback when it received a Refusal To File letter from the FDA regarding the New Drug Application  NDA  for ozanimod in relapsing multiple sclerosis  RMS   Celegne now plans to resubmit the NDA in the first quarter of 2019 following a Type A meeting with the FDA in early April  The company also plans to submit a Marketing Authorization Application   MAA   for ozanimod in RMS in the first quarter of 2019 2018 Outlook UpdatedCelgene now anticipates earnings per share of  8 45 in 2018 compared to the earlier estimate of  8 70  8 90  The Zacks Consensus Estimate for earnings is  8 44 per share   Net revenues are now estimated around  14 8 billion  at the high end of the previously projected range of  14 4  14 8 billion  while the Zacks Consensus Estimate for the same is pegged at  14 84 billion  The numbers include the impact of dilution from the Juno acquisition Revlimid sales are now projected at  9 5 billion  up from  9 4 billion estimated earlier  Abraxane sales are estimated to be around  1 billion  Pomalyst s revenues are now projected at around  2 0 billion  previous projection   1 9 billion   Otezla sales continued to be projected at  1 5 billion Our TakeCelgene s first quarter results were encouraging as the company beat on both sales and earnings  Revlimid sales were impressive yet again along with Pomalyst and Otezla The results come as a breather for investors who bore the brunt of the decline in share price due to series of setbacks over the last few months  Celgene s stock has lost 16  in the last six months compared with the  s decline of 12 6   Nevertheless  shares of the company are up in the pre market trading due to an earnings beat Celgene suffered a series of setbacks over the last few months  The company suffered a setback when a late stage study on its lead cancer drug Revlimid in combination with Rituxan failed  The threat of generic competition is also looming large on Revlimid which loses patent protection in 2022 forcing Celgene to look for acquisitions  The stock was hit earlier after a phase III trial  REVOLVE   CD 002  on pipeline candidate GED 0301 in Crohn s disease and the extension trial  SUSTAIN  CD 004  was discontinued  The company also suffered a setback with its RMS candidate  ozanimod Celgene was on the look out of new deals and acquisitions given a lacklustre 2017 and the Juno acquisition was on the same track  We note that the slowdown in mature products compelled prominent biotechs to acquire smaller ones with promising pipelines  Gilead Sciences   NASDAQ GILD   acquired Kite Pharma and subsequently obtained FDA approval of Yescarta  axicabtagene ciloleucel   the latter s chimeric CAR T therapy candidate Zacks RankCelgene is a Zacks Rank  2  Buy  stock  You can see  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-05-03,Zacks Investment Research,https://www.investing.com/analysis/celgene-celg-q1-earnings--sales-beat-on-revlimid-strength-200313065,200313065
201356,422872,GILD,What s In The Cards For Conatus  CNAT  This Earnings Season ,opinion,Conatus Pharmaceuticals Inc    NASDAQ CNAT  is slated to report first quarter 2018 results on May 2  after the market closes The company s earnings history has been disappointing so far  having missed expectations on two occasions  missed in one and registered in line results in another with an average negative surprise of 55 24   Last reported quarter  the company delivered a positive surprise of 11 76  Shares of Conatus have plunged 61  in a year s time versus the  s 12 6  rally  Let s see  how things are shaping up for the upcoming release Factors at PlayWith no approved product in Conatus  portfolio at the moment  the company is yet to generate revenues  Hence  investors  focus will be on the company s progress with respect to the lead candidate  emricasan  an orally active pan caspase protease inhibitor Emricasan is under evaluation in various phase IIb studies for the treatment of chronic liver disease including NASH fibrosis  There are now four ongoing emricasan phase IIb trials  which consist of three other ENCORE programs on patients with fibrosis or cirrhosis caused by nonalcoholic steatohepatitis  NASH  in various patient populations  Data from these analyses are expected between 2018 and 2019 The company also plans to initiate a new study called ENCORE XT  a planned extension trial on patients  who completed the ENCORE PH or ENCORE LF studies with continued monitoring for efficacy  safety  clinical outcomes and a healthy quality of life Apart from emricasan  the company s portfolio has IDN 7314  presently undergoing a phase II study for treatment of primary sclerosing cholangitis  We expect an update on the same on first quarter conference call Emricasan has also been extensively profiled in in vitro tests and studied in many preclinical models of human disease  In April  Conatus announced positive results from both in vitro and in vivo studies  demonstrating reductions of hepatic tissue factor driven coagulation It is important to note that Conatus has an exclusive option  collaboration and license agreement with Novartis AG   NYSE NVS   for the worldwide development and commercialization of emricasan  With Novartis sharing half the development costs related to Conatus  phase IIb studies on emricasan  the company now anticipates lower spending on in licensing and internal pipeline Earnings WhispersOur proven model does not conclusively show that Conatus is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here as you will see below Zacks ESP  Conatus has an Earnings ESP of 0 00  as both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 17 cents  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Conatus carries a Zacks Rank  3  which increases the predictive power of ESP  However  a company s 0 00  Earnings ESP makes surprise prediction difficult   We caution against the Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Conatus Pharmaceuticals Inc  Price and EPS Surprise    Stocks That Warrant a LookHere are some health care stocks with the right combination of elements to beat estimates this time around Gilead Sciences  Inc    NASDAQ GILD   is scheduled to report first quarter 2018 financial numbers on May 1  The company has an Earnings ESP of  0 32  and a Zacks Rank  2  You can see  Celgene Corporation   NASDAQ CELG   is scheduled to release first quarter results on May 4  The company has an Earnings ESP of  0 63  and a Zacks Rank of 3 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-04-26,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-conatus-cnat-this-earnings-season-200310306,200310306
201357,422873,GILD,HIV Segment To Aid Gilead  GILD  Beat Q1 Earnings Estimates ,opinion,"Biotech bigwig Gilead Sciences Inc    NASDAQ GILD   develops drugs for the treatment of human immunodeficiency virus   HIV    liver diseases such as chronic hepatitis C virus   HCV   infection and chronic hepatitis B virus   HBV   infection  cardiovascular  hematology oncology and inflammation respiratory diseases 
The HCV franchise boasts drugs like Sovaldi and Harvoni and the recently launched Epclusa  However  the HCV franchise continues to grapple with competitive and pricing pressure leading to a massive decline in Harvoni and Sovaldi sales  Harvoni and Sovaldi have been facing competition from AbbVie s   NYSE ABBV   Viekira Pak and Merck s   NYSE MRK   Zepatier  among others 
Gilead is a dominant player in the HIV market with an impressive portfolio for the same  The company was the first to bring to market a single tablet regimen   STR   for the treatment of HIV   Atripla  STRs for HIV in the market include Complera Eviplera and Stribild among others 
The newly launched tenofovir alafenamide  TAF  based products Genvoya  Odefsey and Descovy are performing well with strong adoption in both the United States and Europe  Genvoya has already become the most prescribed regimen for both treatment na ve and switch patients since its launch in November 2015 
Also  Genvoya has been listed as a preferred regimen in several HIV treatment guidelines  The TAF based regimens now represent 62  of total Gilead HIV prescription volume following the launch of Genvoya and the launches of Odefsey and Descovy in 2016  The Zacks Consensus Estimate for sales of Genvoya is  1074 million 
Truvada  for use in the pre exposure prophylaxis setting  also put up a strong performance  The company saw a significant uptick in PrEP usage in 2017 with approximately 153 000 patients using Truvada by the end of 2017   We note that HIV is one of the primary areas of focus for Gilead and the company is working to bring new HIV treatments to market to further boost sales of the franchise 
The company received a major boost when the FDA approved the company s once daily STR  Biktarvy  bictegravir 50mg emtricitabine 200mg tenofovir alafenamide 25mg  BIC FTC TAF  for HIV 1 infection  The approval provides a major boost to Gilead s HIV franchise 
Biktarvy combines the novel  unboosted integrase strand transfer inhibitor   INSTI   bictegravir  with the demonstrated safety and efficacy profile of the Descovy   FTC TAF  dual nucleoside reverse transcriptase inhibitor   NRTI   backbone and is the smallest INSTI based triple therapy STR available  The approval of this new HIV therapy will pose stiff competition to GlaxoSmith s   NYSE GSK   existing therapies  Tivicay and Triumeq 
Gilead s stock has returned 10 9  in the last twelve months compared with the   loss of 8 9  

 
Gilead has a decent track record  with the company s earnings beating estimates in three of the last four while missing in one  In the last reported quarter  the company s earnings beat expectations by 4 7   Overall  the company recorded an average positive earnings surprise of 7 5   We expect the strength in the HIV franchise to offset the HCV franchise weakness making it highly likely for the company to beat on earnings in the first quarter   Read more   
Zacks Rank
Gilead currently carries a Zacks Rank  2  Buy  
You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2018-04-27,Zacks Investment Research,https://www.investing.com/analysis/hiv-segment-to-aid-gilead-gild-beat-q1-earnings-estimates-200310407,200310407
201358,422874,GILD,Will Agenus  AGEN  Disappoint Investors This Earnings Season ,opinion,Agenus Inc    NASDAQ AGEN   is expected to report first quarter 2018 on May 3 In the last reported quarter  the company reported a negative earnings surprise of 25   In the last four quarters the company delivered an average positive earnings surprise of 7 44  Notably  Agenus  shares have outperformed the industry over a year  The stock has rallied 10 4   as against the  s fall of 8 9  Let s see how things are shaping up for the company this quarter Factors at PlayAgenus  collaboration agreements with several companies  not only help it to procure funds in the form of upfront and milestone payments and future royalties but also validate its proprietary product platform  Agenus has collaborated with Merck   NYSE MRK   and Incyte to discover and develop multiple checkpoint antibodies  Under the Incyte collaboration  Agenus is evaluating the latter s anti GITR checkpoint antibody   INCAGN1876   in a phase I II study  its anti OX40 agonist antibody   INCAGN1949   in a phase I II study and its anti CTLA 4 antibody   AGEN1884   in a phase II study  All three candidates are being evaluated for the treatment of solid tumors  In January 2018  the company announced the launch of its combination phase I II study with AGEN1884 and anti PD1  AGEN2034  antibodies  Agenus has no approved product in its portfolio  With only a few candidates in mid stages of development  including Prophage Series vaccine  the company is still a few years away from bringing a product to market  Any hiccup in the development process of these candidates may weigh on the stock In October 2017  Agenus established a separate business entity to advance its cell therapy program which is designed to be self funded  The cell therapy company  AgenTus  will focus on the discovery  development  and commercialization of breakthrough  living drugs  to advance cures for cancer patients  The company took this decision to form smaller teams that can entirely focus on getting the products approved  The company expects the combined value of the separate companies to exceed the perceived value under one roof In the first quarter the company will focus on its pipeline candidates and provide updates on them What Our Model IndicatesOur proven model does not show an earnings beat for Agenus this quarter  This is because a stock needs to have both   a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    for this to happen  However  that is not the case here as you will see below Zacks ESP  Agenus has an Earnings ESP of 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 28 cents  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Agenus has a Zacks Rank  4  Sell   which decreases the predictive power of ESP  Note that we caution against stocks with a Zacks Rank  4 or 5  Strong Sell  going into an earnings announcement  Stocks That Warrant a LookHere are some biotech stocks that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Pfizer Inc    NYSE PFE   is scheduled to release quarterly results on May 1  The company has an Earnings ESP of  1 36  and a Zacks Rank  2  You can see  Gilead Sciences  Inc    NASDAQ GILD   is scheduled to release quarterly results on May 1  The company has an Earnings ESP of  0 32  and a Zacks Rank  2  Agenus Inc  Price and EPS Surprise    The Hottest Tech Mega Trend of All Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-04-29,Zacks Investment Research,https://www.investing.com/analysis/will-agenus-agen-disappoint-investors-this-earnings-season-200310876,200310876
201359,422875,GILD,What s In Store For ImmunoGen  IMGN  This Earnings Season ,opinion,ImmunoGen  Inc    NASDAQ IMGN   is scheduled to report first quarter 2018 results on May 4 before the market opens  In the last reported quarter  the company delivered a negative earnings surprise of 42 86  ImmunoGen s earnings performance has been a mixed bag in the recent past  The company surpassed expectations in two of the last four quarters  missing the same in the other two  Overall  ImmunoGen pulled off an average negative surprise of 0 50  Shares of ImmunoGen have significantly outperformed the   so far this year  The stock has skyrocketed 71 1  against the industry s decrease of 2 1   Let s see  how things are shaping up for this quarter Factors at PlayIn absence of an approved product in ImmunoGen s portfolio  investors  focus should remain on the company s progress with its lead pipeline candidate  mirvetuximab soravtansine  and other programs ImmunoGen has significantly advanced with respect to mirvetuximab soravtansine  Recently  the company successfully completed the interim analysis of a phase III study  FORWARD I   evaluating the candidate as a single agent therapy for treating patients with platinum resistant ovarian cancer  whose tumors express high or medium levels of FR alpha  The company has also finished full enrollment of the trial two months ahead of schedule and expects top line results from the program during the first half of 2019 Also  combination regimens with mirvetuximab soravtansine to address ovarian cancer are in phase Ib II FORWARD II study  The trial consists of cohorts assessing mirvetuximab soravtansine in combination with Roche s   OTC RHHBY   Avastin and Merck s Keytruda  Initial findings from the study demonstrated that the candidate has potential to complement all available therapies for the indication  Updated outcomes from the program are expected in the first half of 2018 Apart from mirvetuximab soravtansine  ImmunoGen is working to develop a couple of early stage candidates including IMGN779 and IMGN632  Last December  the company presented positive results from the ongoing phase I study  evaluating IMGN779 on patients with relapsed or refractory adult acute myeloid leukemia  AML  at the annual meeting of American Society of Hematology  Moreover  this January  the company moved IMGN632 into phase I study to treat hematological malignancies including AML Per fourth quarter 2017 earnings call  the company issued its cash guidance for 2018  anticipating cash and cash equivalents in the range of  115  120 million by the end of December 2018  ImmunoGen had then stated that it hoards enough funds to run its operations through the fourth quarter of 2019 What the Model IndicatesOur proven model does not conclusively show that ImmunoGen is likely to beat estimates this reporting cycle  This is because a stock needs to have both a positive  and a solid Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here as you will see below Zacks ESP  ImmunoGen has an Earnings ESP of  3 07   representing the percentage difference between the Most Accurate estimate of a loss of 28 cents and the Zacks Consensus Estimate of a loss of 27 cents  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  ImmunoGen has a Zacks Rank  3  which increases the predictive power of ESP  However  the company needs a positive ESP to be confident about an earnings surprise  Hence  this combination leaves surprise prediction inconclusive We caution against Sell rated stocks   4 or 5  going into an earnings announcement  especially when the company is seeing negative estimate revisions ImmunoGen  Inc  Price and EPS Surprise    Stocks to ConsiderTwo health care stocks with the right combination of elements to beat estimates this time around are as follows Gilead Sciences  Inc    NASDAQ GILD   is scheduled to report first quarter financial numbers on May 1  The company has an Earnings ESP of  0 32  and a Zacks Rank  2  You can see  Celgene Corporation   NASDAQ CELG   is scheduled to release first quarter results on May 4  The company has an Earnings ESP of  0 63  and a Zacks Rank of 3 The Hottest Tech Mega Trend of All      Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-04-29,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-immunogen-imgn-this-earnings-season-200311097,200311097
201360,422876,GILD,Is A Beat In The Cards For Agios  AGIO  In Q1 Earnings ,opinion,We expect Agios Pharmaceuticals  Inc    NASDAQ AGIO   to surpass expectations when it reports first quarter 2018 results on May 4  before the market opens  Last reported quarter  the company delivered a negative earnings surprise of 9 70  Shares of Agios have soared 67 7  in a year s time  comparing favorably with the  s increase of 12 5   The company s earnings track record shows mixed results with the company having outpaced estimates twice in the trailing four quarters and missed the same in the other two  Overall  Agios came up with an average negative surprise of 1 34  Let s see  how things are shaping up for this quarter Factors at PlayAgios  only marketed drug is Idhifa  enasidenib   which received an FDA approval last August for treatment of patients with relapsed or refractory acute myeloid leukemia  R R AML  having an isocitrate dehydrogenase 2  IDH2  mutation  Per the last report  the drug generated strong sales and we expect encouraging revenues in the first quarter as well Moreover  Agios  progress with the pipeline has been quite impressive  In fact  investors  focus will remain on the same in the to be reported quarter  Two interesting candidates in the company s cancer portfolio are IDH1 mutant inhibitor  AG 120  ivosidenib  and a pan IDH mutant inhibitor  AG 881 Ivosidenib is under priority review in the United States for treating patients with R R AML with an IDH1 mutation  An approval for ivosidenib is expected in the third quarter of 2018  Additionally  the company anticipates a regulatory filing for the candidate in the EU during the fourth quarter of 2018 for the same indication Ivosidenib is also being evaluated in phase I study for addressing advanced hematologic malignancies and combined with Celgene s   NASDAQ CELG   Vidaza  it is under assessment in phase I II  for the cure of newly diagnosed AML patients  who are not eligible for an intensive chemotherapy Meanwhile  Agios is conducting phase I programs on AG 881 for treating patients with advanced IDH1 or IDH2 mutant positive solid tumors including glioma  In the second half of 2017  the company announced positive findings from the study Notably  the company also plans to initiate a perioperative window trial to analyze ivosidenib and AG 881 in low grade glioma for investigating the effects on brain tumor tissue in the first half of 2018 The company has another interesting candidate in its portfolio  Its lead rare genetic diseases candidate  AG 348  is under evaluation in a phase II trial on adult  transfusion independent patients with Pyruvate kinase deficiency  Agios reported positive data from the program in June 2017  The FDA granted a fast track designation to the candidate for the given indication  As the RGD market still remains unexplored  newer therapies in this area hold huge potential Nonetheless  this March  Agios announced commencement of a phase I study  evaluating its first in class methionine adenosyltransferase 2a  MAT2A  inhibitor  AG 270  for patients with solid tumors or lymphoma with deletion of the MTAP  We expect management to produce an update on the same in first quarter earnings release Earnings WhispersOur proven model shows that Agios is likely to beat on earnings this reporting cycle because it has the right combination of the two key ingredients   a positive  and a favorable Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    for this to happen Zacks ESP  Agios has an Earnings ESP of  1 72   representing the percentage difference between the Most Accurate estimate  loss of  1 57 per share  and the Zacks Consensus Estimate  loss of  1 60   A positive ESP indicates a likely earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Agios has a Zacks Rank  3  which increases the predictive power of ESP and together with a positive ESP  chances of an earnings beat in the stock s upcoming release are pegged higher We caution against all Sell rated stocks   4 or 5  going into an earnings announcement  especially when the company is seeing negative estimate revisions Agios Pharmaceuticals  Inc  Price and EPS Surprise    Other Stocks to ConsiderHere are some other health care stocks worth considering with the right combination of elements to beat estimates this time around Gilead Sciences  Inc    NASDAQ GILD   is scheduled to report first quarter 2018 financial numbers on May 1  The company has an Earnings ESP of  0 32  and a Zacks Rank  2  You can see  Pfizer Inc    NYSE PFE   is scheduled to release quarterly results on May 1  The company has an Earnings ESP of  1 36  and a Zacks Rank of 2 The Hottest Tech Mega Trend of All      Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-04-29,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-the-cards-for-agios-agio-in-q1-earnings-200311088,200311088
201371,422887,GILD,Celgene Loses 17 8  In 3 Months  Time To Reshuffle Portfolio ,opinion,Celgene Corporation   NASDAQ CELG   is taking desperate attempts to bolster its portfolio and reduce dependence on lead drug  Revlimid   However  things do not seem to be working in favor of the company   Celgene s stock has lost 17 8  in the last three months  worse than the  s decline of 5 6  Last month  Celgene suffered yet another setback when it received Refusal to File letter from the FDA regarding its New Drug Application   NDA   for multiple sclerosis candidate ozanimod  The candidate is being developed for the treatment of patients with relapsing forms of multiple sclerosis   MS    The FDA stated that the nonclinical and clinical pharmacology sections in the NDA were inadequate to allow a complete review  Hence  Celgene will request a Type A meeting with the FDA to ascertain the additional information needed for resubmission of the NDA  The news comes as a great disappointment for investors given the potential the MS market holds Notably  things have been on the downturn for the company since last October after Celgene announced a phase III trial  REVOLVE   CD 002  on pipeline candidate GED 0301 in Crohn s disease and the extension trial  SUSTAIN  CD 004  have been discontinued following a recommendation from the Data Monitoring Committee  which assessed overall benefit risk during a recent interim futility analysis In December 2017  a late stage study on its lead cancer drug Revlimid in combination with Roche Holdings    OTC RHHBY   Rituxan failed  The study evaluated Revlimid plus Rituxan  R2  followed by R2 maintenance compared with the standard of care featuring Rituxan plus chemotherapy  R CHOP  R bendamustine or R VN CVP  followed by Rituxan maintenance for previously untreated follicular lymphoma  However  the R2 treatment arm could not achieve superiority in the co primary endpoints of complete response or unconfirmed complete response CR CRu  at 120 weeks and in terms of progression free survival observed during the pre planned analysis Celgene s key growth engine is Revlimid  While Revlimid sales continue to be impressive  we are concerned about the company s dependence on the product for growth  The drug is set to lose patent exclusivity soon and hence Celgene is desperately trying to revive its portfolio Celgene was on the look out of new deals and acquisitions given a lacklustre 2017 just like Gilead Sciences   NASDAQ GILD   which acquired Kite Pharma   The Juno acquisition added JCAR017  lisocabtagene maraleucel  liso cel  to Celgene s lymphoma pipeline  JCAR017 is a best in class CD19 directed CAR T candidate  currently in a pivotal program for relapsed and or refractory diffuse large B cell lymphoma   The candidate is expected to obtain regulatory approval in the United States in 2019 and generate sales of approximately  3 billion   While the acquisition of Juno will surely boost Celgene s growth prospects given the immense potential in the CAR T therapy space  it might be a risky proposition for Celgene as Juno has faced setbacks with its pipeline candidate  JCAR015 Hence  we expect investors to stay on the side lines for the time being and observe how the revival story for Celgene plays out Zacks Rank   Key PickCelgene currently carries a Zacks Rank  4  Sell  A better ranked stock from the same space is Regeneron Pharmaceuticals   NASDAQ REGN    which sports a Zacks Rank  1  Strong Buy   You can see  Regeneron s earnings per share estimates have moved up from  18 65 to  18 68 for 2018 in the last 30 days  The company pulled off a positive earnings surprise in three of the last four quarters  with an average beat of 9 15  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-03-27,Zacks Investment Research,https://www.investing.com/analysis/celgene-loses-178-in-3-months-time-to-reshuffle-portfolio-200301550,200301550
201372,422888,GILD,Ready For The Next Wave Of The Biotech Bull ,opinion,"At the start of 2017  I called for a resurgence in the biotechnology bull market that was slowly attempting to recover from its 40  bear market of the prior two years 
In response  my team and I here at Zacks worked to design a new type of portfolio  Healthcare Innovators  to capitalize on the long term trends I saw that would sustain the return of the bull 
What we got was a 34  surge in the Nasdaq Biotech Index  IBB  to January 29 this year  This explosive rally gave us gains like 155  in Sangamo  SGMO   119  in Sarepta  SRPT   and 98  in Juno  JUNO  in a matter of months 
But the current market correction has shown no mercy to any sector and so the volatility and uncertainty prompted me to dig further into the current state of the biotech bull market 
What I found is that the same long term drivers are still in place  As I outlined earlier this week  I call them my  4 megatrends  of healthcare investing   1  an aging population living longer and requiring more care   2  an explosion of scientific discovery from the  genome goldmine  to battle disease   3  powerful earnings leverage from life enhancing technologies  and  4  the highly motivated forces of M A by big BioPharma to acquire new scientific assets and revenue streams 
Continued      
                                                                                                      

Today a  4 trillion dollar industry is being revolutionized by explosive medical advances  the needs of an aging population  demands from insurance companies for alternatives to costly surgical procedures  and more 
Already in 2018  healthcare megatrends like these have led Zacks to wins of  155 6    119 1    75 6   and  98 1  in as little as 5 weeks 
Want to see our next predicted breakouts just as market pullbacks are giving us some exceptional entry points  Special opportunity ends at midnight Sunday  April 8 

                                                                                                      
4 Keys to Play the Biotech Bull
My conclusion remains that the Biotech bull still has a lot more room to go over the next 2 years  And once in a lifetime wealth building opportunities await investors who play the right industries and companies over the next decade  But the rules are different this time in this second big wave of the Bio Bull  You can t simply ride the next hot tip or momentum play  Your research and stock selection must have certain discipline  or else you ll get burned 
Here I share 4 keys in my research process and why they are so important 
1  Investment Bank Research
I read dozens of research reports every week from Wall Street s top investment analysts  Of course  we all know that these analysts are conflicted occasionally as one side of the company is providing advisory or capital underwriting services for a fee  while the  pure research  side is not supposed to be influenced by that business 
But for the most part  there are many good and un conflicted analysts devoted to their research  Many are PhDs in the life sciences  or even have medical degrees  and they care about the quality of their analysis  Reading their reports every week gives me an edge on understanding the most complicated investing in the world 
The payoff here was greater confidence in my thesis to buy Sangamo Therapeutics last year  This was a low risk high reward bet that they would be a game changer in the exciting field of gene editing  We took 155  gains in SGMO in February after Gilead Sciences  NASDAQ GILD  created a partnership worth as much as  3 billion to the company as its pipeline developed 
2  Big Brother Partnerships
How do you build a billion dollar business in medicine  Sometimes it takes a few hundred million dollars in R D  That s where big Pharma companies come in to help emerging ones with drug pipeline clinical trials that keep the FDA happy  The big firms are constantly looking for exciting new R D  often before it even leaves university labs 
When I see a big company    whether from traditional Pharma or Biotech    team up with a little guy  I know something good is in the pipeline and I start paying more attention to that potential breakthrough  If  big brother  helps get my target through Phase 2 clinical trials with positive results  the stock may already be on the launch pad 
Knowing the long term commitment of partner Celgene  NASDAQ CELG  to the emerging field of  immuno oncology  gave me the conviction to buy Juno Therapeutics last year in the low  20s  We ended up swing trading JUNO once for 70  gains in August and then made another 98  on Celgene s buyout in January 
3  Medical Journals  Company Presentations  and KOL Circles
There are many great places that new research can be found and company presentations are some of the best  Company scientists know they can t just  pull the wool  over the eyes of Wall Street analysts  When they publish in peer reviewed academic journals or make presentations at industry conferences  there are just as many doctors in the room as number crunchers 
And those presentations often are placed on company websites where I can see the entire slide deck and watch video recordings  This is a great way to not only understand new science but also to be tuned in to the criticism from scientific peers  You can t really understand an R D thesis unless you can also point out its potential flaws 
This brings up a class of expert known as the KOL  or Key Opinion Leader  In BioPharma especially  there are hundreds of doctors and researchers involved at all levels of drug and disease R D whose opinions are widely respected in the global medical community  For doctors at the front lines taking care of their patients  who don t always have time to stay up to date on the latest research  the view of a KOL can often be an important influence in their decision to try a new treatment option 
And it s how I decided to pull the trigger on Sarepta Therapeutics last May as they tackle a unique disease called Duchenne muscular dystrophy  SRPT s progress in crossing regulatory hurdles and advancing its pipeline handed us a gain of 119  in March 
4  Institutional Buying and Selling
Lastly  I still like to pay attention to what the big money is doing  There are many fund managers running tens of billions in investment war chests that are ear marked solely for the healthcare field    and some are focused entirely on biotech  like the  15 billion Baker Brothers funds run by the fabulous  real life brothers Julian and Felix 
Many of these managers are some of the most serious and disciplined of medical sector investors  So  I pay attention to what they are buying and selling and I don t mind following their money trail if enough of my other criteria are in line 
My two most fascinating places to  follow the money  right now are in the exciting fields of immuno oncology and gene editing  especially with the CRISPR companies  In my Healthcare Innovators service  I currently own a leader in each field that both saw open portfolio gains of over 100  
During the correction  these two stocks have both given back a chunk of those open profits  But I will continue to hold and accumulate them because their scientific and commercial promise is so strong 
And if there is one thing I have learned from the big and smart money it is this  holding on through volatility is how long term wealth is built in Biotech 
Focus on the Long Term Drivers
To pursue the  megatrends  of healthcare investing  I invite you to join me inside Zacks  investment portfolio  
It s designed to capitalize on those long term drivers  And I am confident that the next wave of the Biotech bull market is about to roll in 
But not all boats will rise with this tide  Using the 4 keys of my research process  we are picking powerful scientific assets  brands  and cash flow franchises that will come out on top for strategic healthcare investors 
That is how  already in 2018  we have closed wins of  155 6    119 1    75 6   and  98 1  in as little as 5 weeks 
Of course  picking the best stocks in this sector requires a considerable amount of research  But you don t have to follow FDA filings or subscribe to medical journals  That s my job  Healthcare Innovators enables you to piggy back on my research  and we ll go after exceptional longer term gains together 
There couldn t be a better time to get started than right now  Recent market pullbacks offer us excellent entry points for stocks with massive gain potential 
Plus  if you check out Healthcare Innovators before midnight Sunday  April 8  you ll get access to Zacks  special report  Making Money on Marijuana  It includes 6 ways to cash in on medical sales in this niche that are expected to nearly triple by 2020  surpassing  13 billion in revenue 

Good Investing 
Kevin Cook
Kevin  Senior Stock Strategist at Zacks  is a leading expert in biotech and medical stocks  He provides commentary and recommendations for Zacks  investment portfolio ",2018-04-06,Zacks Investment Research,https://www.investing.com/analysis/ready-for-the-next-wave-of-the-biotech-bull-200303762,200303762
201373,422889,GILD,Gilead  GILD  Presents Encouraging Data On NASH Therapies,opinion,Gilead Sciences  Inc    NASDAQ GILD   announced encouraging data from a proof of concept study of experimental combination therapies for patients with advanced fibrosis due to nonalcoholic steatohepatitis   NASH    The data were presented at The International Liver Congress 2018 in Paris Apoptosis signal regulating kinase 1  ASK1  inhibitor selonsertib was combined with either the Acetyl CoA carboxylase   ACC   inhibitor GS 0976 or the selective  non steroidal Farnesoid X receptor   FXR   agonist GS 9674 as therapies Patients diagnosed with NASH and liver fibrosis stages F2 to F3 based on biopsy  or by magnetic resonance elastography   MRE   and MRI proton density fat fraction  MRI PDFF  enrolled in the study  They were treated with either selonsertib 18 mg plus GS 0976 20 mg  n 20   selonsertib 18 mg plus GS 9674 30 mg  n 20   or each monotherapy  n 10 per group  once daily for 12 weeks Post treatment the most notable change that were observed was the decrease in liver fat content  measured by MRI PDFF   which occurred in regimens containing GS 0976  The results also showed improvements in liver biochemistry and or markers of fibrosis across both combination arms of the study compared to baseline   Moreover  patients treated with selonsertib plus GS 0976  kinetic labeling showed reduction in the fractional synthesis rate of lumican  a marker of fibrogenesis Hence  the favorable results suggest that combination therapy with selonsertib and either GS 0976 or GS 9674 can be evaluated further in patients with NASH and F3 and F4 fibrosis Gilead also announced completion of enrolment in the phase III trials  STELLAR selonsertib   Gilead s NASH pipeline include selonsertib  GS 9674 and GS 0976  alone and in combinationConcurrently  Gilead presented data from a pre clinical study of another combination treatment approach for NASH  evaluating GS 9674 and GS 0976 together and as single agents in rodent models of NASH and liver fibrosis  The data indicate that combining agents had greater anti fibrotic and anti steatotic effects and led to improvements in liver biochemistry and fibrosis markers  compared with either agent alone As a result  Gilead has initiated a larger phase IIb study in combination treatment with selonsertib  and or GS 0976  and or GS 9674 in patients with advanced fibrosis due to NASH Given the persistent decline in the HCV franchise  Gilead is looking to foray into markets like NASH and CAR T as they hold great potential  Per estimates  NASH is expected to surpass hepatitis C as the leading reason for liver transplants in the United States and Europe   Gilead s stock has lost 4 6  in the last six months as against the s decline of 15 5  Intercept Pharmaceuticals   NASDAQ ICPT   is also evaluating its lead candidate  obeticholic acid  in a phase III study in subjects with compensated cirrhosis due to NASH  Bristol Myers Squibb   NYSE BMY   has a mid stage candidate in the NASH space  BMS 986036  an investigational pegylated analogue of human fibroblast growth factor 21  FGF21   a key regulator of metabolism  in patients with biopsy confirmed NASH  F1 F3  achieved its primary endpoint of significant reduction in liver fat versus placebo Swiss major Novartis   NYSE NVS   is conducting a phase IIb involving the combination of a Novartis FXR agonist and cenicriviroc with for the treatment of NASH Zacks RankGilead currently carries a Zacks Rank  4  Sell  You can see   Investor Alert  Breakthroughs PendingA medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ,2018-04-15,Zacks Investment Research,https://www.investing.com/analysis/gilead-gild-presents-encouraging-data-on-nash-therapies-200305848,200305848
201374,422890,GILD,Is A Beat In Store For Bristol Myers  BMY  In Q1 Earnings ,opinion,"We expect Bristol Myers Squibb Company   NYSE BMY   to beat expectations when it reports first quarter 2018 results on Apr 26  before market open Bristol Myers  shares have decreased 16 5  so far this year compared with the  s decline of 4 7  Bristol Myers  track record has been mixed so far  The company delivered positive earnings surprise in three of the last four quarters and missed expectations once  The average positive earnings surprise in the last four quarters is 4 23   In the last reported quarter  Bristol Myers delivered a positive surprise of 1 49  Let s see how things are shaping up for this quarter  What Will Drive Growth in Q1 Bristol Myers  blockbuster immuno oncology drug  Opdivo is expected to remain the main sales driver in the first quarter  following several line extensions in 2017  In the soon to be reported quarter  the company announced encouraging results from a phase III study evaluating Opdivo in first line non small cell lung cancer  Opdivo in combination with Yervoy significantly improved progression free survival in patients compared to chemotherapy  A potential approval in this indication will be a significant boost for the drug  given the immense scope in the lung cancer market  The Zacks Consensus Estimate for the drug s sales in the first quarter is pegged at  1 38 billion In January 2018  the European Commission approved the label expansion of Yervoy injection in pediatric patients 12 years of age and older with unresectable or metastatic melanoma  The FDA approved the drug for this indication in July 2017  The Zacks Consensus Estimate for the drug s sales in this quarter is  291 million In November 2017  the FDA approved line extension of Sprycel in pediatric patients with Ph  chronic myeloid leukemia in chronic phase  The drug  which registered growth of 6 7  in the previous quarter  is expected to receive a boost this quarter due to the expanded label  The Zacks Consensus Estimate for Sprycel sales stands at  507 million  Cardiovascular drug  Eliquis  came up with a strong performance in 2017  with sales growing 44  year over year  Sales are expected to remain robust in the first quarter too  The Zacks Consensus Estimate for Eliquis sales is pegged at  1 43 billion On the other hand  the decline in Hepatitis C franchise is expected to continue due to intense competition from multiple drugs including Epclusa as its label was expanded to include HIV co infection in August  Moreover  the HIV business continues to face competitive pressure  Recent launches by other companies in the same space are expected to further impact the Sustiva franchise  The Zacks Consensus Estimate for Hepatitis C franchise sales is pegged at  52 million this quarter  down 67 9  from the year ago quarter actual figure ConclusionSeveral label expansions of Bristol Myers  blockbuster cancer drug  Opdivo  drove the company s sales last year and are expected do so this year as well  Moreover  cardiovascular drug  Eliquis  also demonstrated strong performance in 2017  We expect this trend to continue this quarter  Label expansion of leukemia drug  Sprycel  approved in November 2017  should bring in more sales for the drug  Moreover  continued strong performance of Yervoy and Orencia will have a favorable impact However  genericization of Plavix  Avapro Avalide and Baraclude in the United States due to loss of exclusivity is significantly hurting the company s top line  The company also faces stiff competition in the immuno oncology space  The HIV business continues to face competitive pressure The Zacks Consensus Estimate for sales and earnings for Q1 is pegged at  5 17 billion and 84 cents  respectively Why a Likely Positive Surprise Our proven model indicates that Bristol Myers is likely to beat earnings estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen Zacks ESP Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  stands at  0 82   This is a leading indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank Bristol Myers has a Zacks Rank  3  The combination of a positive Earnings ESP and a favorable Zacks Rank makes us reasonably confident of an earnings beat Conversely  we caution against the Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Bristol Myers Squibb Company Price and EPS Surprise
    Other Stocks to ConsiderHere are some biotech stocks that you may also want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Pfizer Inc    NYSE PFE   is scheduled to release its results on May 1  The company has an Earnings ESP of  1 36  and a Zacks Rank  2  You can see  AbbVie Inc    NYSE ABBV   is scheduled to release its results on Apr 26  The company has an Earnings ESP of  0 06  and a Zacks Rank  3 Gilead Sciences  Inc    NASDAQ GILD   is scheduled to release its results on May 1  The company has an Earnings ESP of  0 32  and a Zacks Rank  2 Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-04-22,Zacks Investment Research,https://www.investing.com/analysis/is-a-beat-in-store-for-bristolmyers-bmy-in-q1-earnings-200307850,200307850
201384,422900,GILD,Gilead Sciences  GILD  Down 3 4  Since Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for Gilead Sciences  Inc    NASDAQ GILD    Shares have lost about 3 35   in that time frame 
Will the recent negative trend continue leading up to its next earnings release  or is GILD due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers Gilead s HCV Sales Weak  Earnings BeatGilead reported fourth quarter 2017 results wherein both earnings and revenues surpassed expectations  However  management issued a bleak view for 2018 The company s fourth quarter earnings of  1 78 per share beat the Zacks Consensus Estimate of  1 70  However  earnings were below the year ago quarter figure of  2 70 per share Moreover  total revenues of  5 9 billion topped the Zacks Consensus Estimate of  5 8 billion  However  revenues declined 18 7  year over year Harvoni   Sovaldi Plunge FurtherProduct sales came in at  5 8 billion  down 19 1  year over year  The decline was due to lower HCV sales  partially offset by higher sales across HIV and other therapeutic areas Antiviral product sales  which include Gilead s HIV and liver disease portfolio  came in at  5 2 billion in the quarter  down 21 2  HCV product sales  which include Harvoni  Sovaldi  Epclusa and Vosevi  were  1 5 billion  down from  3 2 billion reported in the year ago quarter  The downside was mainly attributed to lower sales of Harvoni and Sovaldi across all major markets Sales of Harvoni declined 60 7  year over year to  644 million in the quarter  Further  Sovaldi sales recorded a steep year over year decline of 78 4  to  117 million Epclusa garnered sales of  565 million in the quarter  down from the year ago figure of  1 0 billion Meanwhile  HIV and HBV product sales came in at  3 7 billion  up 8 8  year over year  The increase was primarily driven by continuous strong uptake of tenofoviral afenamide  TAF  based products such as Genvoya  which generated sales of  1 060 million  up from  563 million in the year ago quarter  Descovy  which recorded sales of  365 million  up from  149 million  and Odefsey  which registered sales of  325 million  up from  155 million  HIV treatments like Stribild and Complera Eviplera sales declined 42 6  and 25 2  respectively  Viread sales were down at  212 million  down 34 6  Atripla sales tanked 27 5  to  440 million  while Truvada sales fell 8 2  to  797 million Other products like Letairis  Ranexa  AmBisome and Zydelig recorded sales of  233 million  up 3 1     200 million  down 4 7     90 million  down 4 4   and  39 million  respectively Research   development  R D  expenses declined 11 9  to  845 million due to the 2016 impact of ongoing milestone payments  Selling  general and administrative  SG A  expenses decreased 1 6  to  923 million  Adjusted product gross margin was 83 5  compared to 88 1  in the year ago period 2017 ResultsRevenues in 2017 came in at  26 1 billion  down from  30 4 billion in 2016 and surpassed Zacks Consensus Estimate of  25 9 billion  Earnings per share came in at  8 84  down from  11 57 in 2016 and beat the Zacks Consensus Estimate of  8 73 2018 GuidanceGilead now expects net product sales in the range of  20  21 billion  Adjusted R D expenses and adjusted SG A expenses are projected in the range of  3 4  3 6 billion and  3 4  3 6 billion  respectively  Adjusted product gross margin is expected in the range of 85 87  AcquisitionsThe company acquired Kite Pharma in 2017  The FDA approval for Yescarta  a CAR T therapy for the treatment of adult patients with relapsed or refractory large B cell lymphoma after two or more lines of systemic therapy should Gilead s prospects The company recently announced that it will acquire Cell Design Labs to expand further in the CAR T space Dividend and Share Repurchase
Concurrently  Gilead declared a cash dividend of 57 cents per share of common stock for first quarter 2018  an increase of 10   The dividend is payable on Mar 29 to stockholders of record at the close of business on Mar 16  During 2017  the company paid cash dividends of  2 7 billion and repurchased shares for  954 million  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  There has been one revision higher for the current quarter compared to three lower 
Gilead Sciences  Inc  Price and Consensus   VGM Scores
At this time  GILD has a poor Growth Score of F  however its Momentum is doing a lot better with a C  Charting a somewhat similar path  the stock was allocated a grade of B on the value side  putting it in the second quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Our style scores indicate that the stock is more suitable for value investors than momentum investors 
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift  Notably  GILD has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-03-07,Zacks Investment Research,https://www.investing.com/analysis/gilead-sciences-gild-down-34-since-earnings-report-can-it-rebound-200296700,200296700
201392,422908,GILD,FDA Approves Gilead  GILD  HIV Triple Therapy  Stock Up,opinion,Gilead Sciences  Inc    NASDAQ GILD   received a major boost when the FDA approved the company s once daily single tablet regimen   STR    Biktarvy  bictegravir 50mg emtricitabine 200mg tenofovir alafenamide 25mg  BIC FTC TAF  for HIV 1 infection The approval  which comes ahead of the PDUFA date of Feb 12  2018  provides a major boost to Gilead s HIV franchise Though the company topped both earnings and revenue estimates in the fourth quarter  the magnitude of the decline in HCV sales was wider than expected  The HCV franchise has been under pressure for a while due to lower patient starts and increased competition form AbbVie s   NYSE ABBV   The company s guidance for 2018 also lacks lustre and we expect sales of the same to decline further   Amid such a scenario  the approval of this latest triple HIV therapy is likely to provide an impetus to the stock as Gilead is now banking on its HIV franchise and newer avenues like the CAR T therapy post the Kite acquisition and promising NASH candidates for growth  Following the news of the approval  shares of the company moved up 3 8   Gilead s stock has gained 14 4  in the last six months as against the  decline of 3 6  Biktarvy  Gilead s latest triple therapy  is approved as a complete regimen for the treatment of HIV 1 infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed  HIV 1 RNA  50 c mL  on a stable antiretroviral regimen for at least three months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy Meanwhile  the HIV franchise continues to gain traction on the back of rapid adoption of TAF based regimens in the United States and EU  The TAF based regimens now represent 62  of total Gilead HIV prescription volume following the launch of Genvoya along with Odefsey and Descovy in 2016 Biktarvy combines the novel  unboosted integrase strand transfer inhibitor   INSTI   bictegravir  with the demonstrated safety and efficacy profile of the Descovy   FTC TAF  dual nucleoside reverse transcriptase inhibitor   NRTI   backbone  and is the smallest INSTI based triple therapy STR available The approval of Biktarvy was supported by encouraging data from four ongoing studies  Studies 1489 and 1490 in treatment na ve HIV 1 infected adults  and Studies 1844 and 1878 in virologically suppressed adults  Biktarvy met its primary objective of non inferiority at 48 weeks across all four studies However  Biktarvy has a Boxed Warning in its product label regarding the risk of post treatment acute exacerbation of hepatitis B The approval of this new HIV therapy will pose stiff competition to GlaxoSmith s   NYSE GSK   existing therapies  Tivicay and Triumeq On the other hand  per a report from Reuters  ViiV Healthcare  a joint venture majority owned by GlaxoSmith with Pfizer   NYSE PFE   and Shionogi Ltd has filed a lawsuit against Gilead alleging patent infringement on ViiV s dolutegravir  a component of the venture s triple drug HIV treatment Triumeq Zacks RankGilead currently carries a Zacks Rank  4  Sell  You can see  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research  It s not the one you think ,2018-02-07,Zacks Investment Research,https://www.investing.com/analysis/fda-approves-gilead-gild-hiv-triple-therapy-stock-up-200288375,200288375
201393,422909,GILD,Intercept Starts OCA Trial For NASH Patients With Cirrhosis ,opinion,"Intercept Pharmaceuticals  Inc    NASDAQ ICPT   initiated a phase III trial  REVERSE  on obeticholic acid   OCA   The randomized phase III study will evaluate the efficacy and safety of OCA  in subjects with compensated cirrhosis due to non alcoholic steatohepatitis   NASH   in approximately 540 patients with a biopsy confirmed diagnosis of cirrhosis The primary endpoint of the study is the percentage of subjects with histological improvement in fibrosis by at least one stage using the NASH Clinical Research Network   CRN   scoring system after 12 months of treatment  Patients enrolled in the trial are being randomized in a 1 1 1 ratio to one of the three treatment arms   once daily dosing of OCA 10 mg  once daily OCA 10 mg with titration to 25 mg at three months  or placebo  The patients who successfully complete the double blind phase of REVERSE will be enrolled in an open label extension phase for up to 12 additional months Intercept expects  to submit marketing authorization for OCA as a treatment option for NASH patients with compensated cirrhosis  in the United States and international markets on the basis of the positive results from the study  A subsequent outcome trial is also in the cards to confirm the clinical benefit on a post marketing basis in a broader population of NASH patients with cirrhosis We note that OCA is already approved as Ocaliva in combination with ursodeoxycholic   UDCA    for the treatment of primary biliary cholangitis   PBC   in adults with an inadequate response to UDCA or as a monotherapy in adults unable to recuperate with UDCA  The initial uptake of Ocaliva has been encouraging  However  there has been a lot of debates regarding the drug s safety  Prescription demand softened following the Dear Health Care Provider letter and the FDA safety communication on Ocaliva Intercept is also evaluating OCA to treat a variety of other non viral progressive liver diseases such as NASH  primary sclerosing cholangitis and biliary atresia   Intercept s stock has lost 47 9  in the last six months compared with the  s decline of 5    In particular  the company s shares have plunged significantly due to safety issues regarding the approved drug Ocaliva The company initiated a phase III study  REGENERATE  on Ocaliva for the treatment of non cirrhotic NASH in patients with advanced liver fibrosis  Enrollment for the interim analysis cohort in the REGENERATE trial was completed  CONTROL study is being conducted to evaluate the effect of Ocaliva in combination with statin therapy on lipid metabolism in patients with NASH   Results from AESOP revealed that OCA met the primary endpoint of statistically significant reduction in alkaline phosphatase while results from CONTROL showed that the company achieved its objective in demonstrating that the lowest available dose of atorvastatin rapidly reverses OCA associated LDL changes to below baseline levels in NASH patients with fibrosis or cirrhosis Given the challenges faced by the drug in recent times  the label expansion of OCA will boost the growth prospects Per estimates  NASH is expected to surpass hepatitis C as the leading reason for liver transplants in the United States and Europe  NASH market has huge potential and a tentative approval will boost Ocaliva s prospects   However  bigwigs like Novartis AG   NYSE NVS   and Gilead Sciences   NASDAQ GILD   have FXR agonists in phase II or earlier stages of clinical or preclinical development that can be used to treat PBC  NASH and the other liver diseases Zacks Rank   Key PickIntercept currently carries a Zacks Rank  3  Hold  
A better ranked stock in the healthcare sector is Exelixis   NASDAQ EXEL   which currently carries a Zacks Rank  2  Buy    You can see  Exelixis  earnings per share estimates increased from 72 cents to 77 cents for 2018 over the last 60 days The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-02-12,Zacks Investment Research,https://www.investing.com/analysis/intercept-starts-oca-trial-for-nash-patients-with-cirrhosis-200289927,200289927
201394,422910,GILD,Intercept  ICPT  Q4 Earnings   Sales Lag On Dull Ocaliva ,opinion,"Intercept Pharmaceuticals  Inc    NASDAQ ICPT   reported disappointing results for fourth quarter 2017 on account of drab Ocaliva sales  The company reported a loss of  4 43 per share in the fourth quarter  wider than the Zacks Consensus Estimate of  3 57 but narrower than the year ago loss of  4 84 Intercept Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
     
Quarterly revenues were  37 7 million  up significantly from  13 8 million in the year ago quarter but missed the Zacks Consensus Estimate of  38 3 million Quarter in DetailIn fourth quarter 2017 Ocaliva recorded  37 3 million of sales  down from  40 9 million recorded in third quarter 2017  Revenues from international markets were  5 3 million  Ocaliva was approved in the United States  in combination with ursodeoxycholic   UDCA   for the treatment of primary biliary cholangitis   PBC   in adults with an inadequate response to UDCA  or as monotherapy in adults who are unable to endure UDCA in 2016  The drug was also granted conditional approval by the European Commission Sales from the United States markets came in at  32 0 million  down from  36 2 million recorded in the third quarter as prescriptions continue to grow Research and development expenses increased 6 8  year over year to  57 5 million primarily driven by increases in clinical development programs for Obeticholic acid   OCA   and infrastructure to support such programs Selling  general and administrative expenses increased to  84 3 million  up from  73 9 million in the year ago quarter 2017 ResultsSales came in at  130 9 million in 2017  missing the Zacks Consensus Estimate of  132 4 million  Ocaliva sales came in at  129 2 million in 2017  Loss per share came in at  14 38  wider than the Zacks Consensus Estimate of  13 52 2018 OutlookIntercept expects operating expenses in the range of  390  410 million in 2018  The company believes that continued commercialization of Ocaliva in PBC in the United States and other markets  Pipeline UpdateOCA is being evaluated for other indications including non alcoholic steatohepatitis   NASH   and primary sclerosing cholangitis   PSC   The FDA has earlier approved a redesign of the phase III trial  REGENERATE on OCA for the safety and efficacy in treating NASH patients with liver fibrosis  The company now needs to achieve only one co primary endpoint  either fibrosis improvement or NASH resolution as compared with the earlier target of achieving both  Enrolment of the interim analysis cohort was completed in the trial and results are expected in the first half of 2019 Earlier in the month  Intercept initiated a phase III trial  REVERSE  on OCA  The randomized phase III study will evaluate the efficacy and safety of OCA  in subjects with compensated cirrhosis due to NASH in approximately 540 patients with a biopsy confirmed diagnosis of cirrhosis  The primary endpoint of the study is the percentage of subjects with histological improvement in fibrosis by at least one stage using the NASH Clinical Research Network   CRN   scoring system after 12 months of treatment  Patients enrolled in the trial are being randomized in a 1 1 1 ratio to one of the three treatment arms   once daily dosing of OCA 10 mg  once daily OCA 10 mg with titration to 25 mg at three months  or placebo  The patients who successfully complete the double blind phase of REVERSE will be enrolled in an open label extension phase for up to 12 additional months Intercept expects to submit marketing authorization for OCA as a treatment option for NASH patients with compensated cirrhosis  in the United States and international markets based on the positive results from the study  A subsequent outcome trial is also in the cards to confirm the clinical benefit on a post marketing basis in a broader population of NASH patients with cirrhosis The company also announced an updated label for Ocaliva in the United States  reinforcing appropriate dosing in PBC patients with Child P Class B or C or decompensated cirrhosis 
Our Take
Intercept s fourth quarter results missed expectations as sales of Ocalive declined due to safety issues reported earlier  While the updated label should help the stock turn around  it might be a while before the sales start to recover  First quarter 2018 is expected to be a transitional quarter 
 

 
Intercept s stock has tumbled 57 8  over a year compared with the  s decline of 2 5    The company s stock has been bearing the brunt of the safety guidelines issued regarding the approved drug Ocaliva 
Given the challenges faced by the drug in recent times  the label expansion of OCA will boost the growth prospects 
Per estimates  NASH is expected to surpass hepatitis C as the leading reason for liver transplants in the United States and Europe  NASH market has huge potential and a tentative approval will boost Ocaliva s prospects   However  bigwigs like Novartis AG   NYSE NVS   and Gilead Sciences   NASDAQ GILD   have FXR agonists in phase II or earlier stages of clinical or preclinical development that can be used to treat PBC  NASH and the other liver diseases 
Zacks Rank   Key Pick
Intercept currently carries a Zacks Rank  3  Hold  
A better ranked stock in the healthcare sector is Exelixis   NASDAQ EXEL   which currently carries a Zacks Rank  2  Buy    You can see  
Exelixis  earnings per share estimates increased from 72 cents to 77 cents for 2018 over the last 60 days 
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-02-14,Zacks Investment Research,https://www.investing.com/analysis/intercept-icpt-q4-earnings--sales-lag-on-dull-ocaliva-200290864,200290864
201404,422920,GILD,Celgene  CELG  Q4 Earnings   Sales Beat On Solid Revlimid,opinion,"Celgene Corporation   NASDAQ CELG   reported encouraging fourth quarter 2017 results wherein both earnings and sales topped expectations The company reported adjusted earnings of  2 00 per share which beat the Zacks Consensus Estimate of  1 95  up from  1 61 in the year ago quarter Total revenues grew 16 7  to  3 48 billion in the quarter and beat the Zacks Consensus Estimate of  3 47 billion  Revenues were boosted by consistent performance of the company s key growth driver  Revlimid Celgene Corporation Price  Consensus and EPS Surprise
    Revlimid   A Key CatalystNet product sales increased 17  year over year to  3 48 billion  Net sales of Revlimid came in at  2 2 billion  reflecting 21  year over year growth  The drug performed well in the United States  up 24    Growth in the quarter was driven by increased volume as a result of increases in duration of treatment and market share Net sales of another cancer drug  Abraxane decreased 6  to  251 million as sales declined the United States  Sales of oncology drug  Pomalyst Imnovid  came in at  442 million  up 17   Sales were driven by increased volume due to increases in market share and duration Otezla reported sales of  371 million in the quarter  up 22  All other product sales  including Istodax  Thalomid  Vidaza and an authorized generic version of Vidaza in the United States  totaled  227 million in the quarter  up from  220 million from the year ago quarter Adjusted research and development expenses increased 13 8  to  766 million due to increased spending related to drug discovery and clinical trial activity while adjusted selling  general and administrative expenses decreased 28 9  to  687 million Earlier in the week  Celgene announced that it will acquire Juno Therapeutics  Inc    NASDAQ JUNO   for  87 per share in cash  or a total of approximately  9 billion  net of cash and marketable securities acquired  The former already owns approximately 9 7  of outstanding shares of Juno   Celgene also announced that it will acquire Impact Biomedicines for an upfront amount of  1 1 billion  The acquisition will add a late stage candidate  fedratinib  a highly selective JAK2 kinase inhibitor  to Celgene s pipeline  In December 2017  Celgene and partner bluebird bio   NASDAQ BLUE   presented updated data from the phase I trial evaluating bb2121 in patients with relapsed and or refractory multiple myeloma  RRMM   The candidate was granted Breakthrough Therapy Designation by the FDA and PRIority MEdicines eligibility by the European Medicines Agency  The companies also initiated the KarMMa trial evaluating bb2121 in RRMM was initiated 2017 ResultsSales came in  13 0 billion  up from  11 3 billion in 2016 and beat the Zacks Consensus Estimate of  12 98 billion   Earnings per share came in at  7 44 in 2017  up from  5 94 in 2016 and beat the Zacks Consensus Estimate of  7 37 2018 OutlookCelgene anticipates earnings in the range of  8 70  8 90  The Zacks Consensus Estimate for earnings is  8 78 per share   Net revenues are projected to be in the range of  14 4  14 8 billion  while the Zacks Consensus Estimate for the same is pegged at  14 90 billion Revlimid sales are projected around  9 4 billion  Abraxane sales are estimated to be around  1 billion  Pomalyst s revenues are projected around  1 9 billion  Otezla sales are now projected at  1 5 billion Our TakeCelgene s fourth quarter results were encouraging as the company beat on both sales and earnings  While Revlimid sales were impressive yet again  Abraxane sales declined in the United States  Sales of Otezla have picked up too after a slowdown in the third quarter Celgene s stock has declined 21 4  in the last six months as against the  s loss of 0 5   Shares of the company are up in the pre market trading due to earnings beat  Celgene suffered a series of setbacks over the last few months  The company suffered a setback when a late stage study on its lead cancer drug Revlimid in combination with Rituxan failed  The threat of generic competition is also looming large on Revlimid which loses patent protection in 2022 forcing Celgene to look for acquisitions  The stock was hit earlier after a phase III trial  REVOLVE   CD 002  on pipeline candidate GED 0301 in Crohn s disease and the extension trial  SUSTAIN  CD 004  was discontinued Celgene was on the look out of new deals and acquisitions given a lacklustre 2017 and the announcement of Juno s acquisition was on the same track We note that the slowdown in mature products compelled prominent biotechs to acquire smaller ones with promising pipelines  Gilead Sciences  Inc    NASDAQ GILD   acquired Kite Pharma and subsequently obtained FDA approval of Yescarta  axicabtagene ciloleucel   the latter s chimeric CAR T therapy candidate The CAR T therapy space was in the spotlight in 2017 as the FDA approved the first CAR T therapy  Kymriah for the treatment of patients upto 25 years of age with B cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse stage  Given the immense potential of the therapy  Celgene too wants to go the Gilead way Zacks RankCelgene is a Zacks Rank  4  Sell  stock  You can see   Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-01-24,Zacks Investment Research,https://www.investing.com/analysis/celgene-celg-q4-earnings--sales-beat-on-solid-revlimid-200283625,200283625
201417,422933,GILD,3 Biotech And Pharma Stocks With FDA Catalysts This January,opinion,2017 turned out to be a pretty good year for pharma and biotech stocks where FDA decisions are concerned  The regulatory body approved 46 novel drugs last year  easily surpassing 2016 s total tally of 22 Landmark decisions last year include the approval of a couple of gene based therapies for cancer   Novartis s   NYSE NVS   Kymriah and Gilead Sciences s   NASDAQ GILD   Yescarta  These therapies have the potential to change the way we look at cancer treatments Other key approvals included Lilly s Verzenio  advanced or metastatic breast cancer   Gilead s Vosevi  hepatitis C virus   Puma s Nerlynx  to reduce the risk of breast cancer returning   J J s Tremfya  moderate to severe plaque psoriasis   Regeneron Sanofi s Kevzara  rheumatoid arthritis   Roche s   OTC RHHBY   multiple sclerosis treatment  Ocrevus  Regeneron and Sanofi s   NYSE SNY   eczema treatment  Dupixent  Tesaro s PARP inhibitor  Zejula  and BioMarin s Brineura  treatment of a specific form of Batten disease  among others  Many of these drugs have blockbuster potential With the drug development process being lengthy and time consuming and requiring the utilization of a lot of funds and resources  key pipeline events including data readouts and regulatory updates are of paramount importance and could act as major catalysts  Here is a look at a few important regulatory events scheduled for the month of January Label Expansion for Synergy s Trulance  Biopharma company  Synergy Pharmaceuticals Inc    NASDAQ SGYP    will get to know about the approval status of Trulance for use in adult patients with irritable bowel syndrome with constipation  IBS C  this month  The regulatory body is expected to deliver a decision regarding Trulance s label expansion into this indication on Jan 24  2018  Trulance  the company s first and only commercial product  was approved last year in January for the treatment of adults with chronic idiopathic constipation   CIC    According to information provided by the company  about 33 million adults suffer from CIC while 12 million adults suffer from IBS C in the United States alone  Synergy s shares have declined 63 4  over the last one year Advisory Panel   January PDUFA Date for Aradigm s Linhaliq  Emerging specialty pharmaceutical company  Aradigm Corporation s   NASDAQ ARDM   regulatory application for Linhaliq will be reviewed by an FDA advisory panel  the Antimicrobial Drugs Advisory Committee  on Jan 11  2018  a few days ahead of the PDUFA  Prescription Drug User Fee Act  goal date of Jan 26  2018  Aradigm is looking to get Linhaliq approved for the treatment of non cystic fibrosis bronchiectasis   NCFBE   patients with chronic lung infections with Pseudomonas aeruginosa  According to information provided by Aradigm  there is unmet medical need for NCFBE with more than 150 000 people in the United States and over 200 000 people in Europe being affected by the severe  chronic and rare disease  The company expects that sales for the NCFBE indication could cross  500 million by 2021  Aradigm s shares are up 318 7  over the last one year FDA to Decide on Pediatric Label Expansion for Sucampo s Amitiza  Biopharma company  Sucampo Pharmaceuticals  Inc    NASDAQ SCMP    is awaiting a decision from the FDA for the label expansion of its key marketed drug  Amitiza  The company is looking to get Amitiza approved for use in children aged 6 to 17 years with pediatric functional constipation  With the FDA granting Priority Review designation  a response is expected on Jan 28  2018  Timely approval would make Amitiza the first branded product available for certain pediatric patients that suffer from pediatric functional constipation  We remind investors that Sucampo recently agreed to be acquired by Mallinckrodt  NYSE MNK  in a deal valued at approximately  1 2 billion  The acquisition is expected to close in the first quarter of 2018  Read more    Sucampo s shares are up 32 5  over the last one year Sucampo is a Zacks Rank  2  Buy  stock   you can see  Zacks Editor in Chief Goes  All In  on This StockFull disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ,2018-01-01,Zacks Investment Research,https://www.investing.com/analysis/3-biotech-and-pharma-stocks-with-fda-catalysts-this-january-200277027,200277027
201418,422934,GILD,Celgene To Acquire Impact Biomedicines To Boost Pipeline ,opinion,"Celgene Corporation   NASDAQ CELG   announced that it will acquire Impact Biomedicines for an upfront amount of  1 1 billion Per the terms of agreement  Impact Biomedicines  shareholders will receive contingent payments based on regulatory approval and sales based milestones  The maximum aggregate amount payable for such milestone payments is  1 4 billion   The aggregate tiered sales based milestone payments could total to a maximum of  4 5 billion if global annual net sales exceed  5 0 billion The acquisition will add a late stage candidate  fedratinib  a highly selective JAK2 kinase inhibitor  to Celgene s pipeline   The candidate is being developed for the treatment of myelofibrosis  MF  and polycythemia vera  Fedratinib demonstrated statistically significant improvements in the primary and secondary endpoints of splenic response and total symptom score  respectively in a randomized  placebo controlled  phase III pivotal trial  JAKARTA 1  for treatment na ve MF In addition  a multi center  single arm phase II trial  JAKARTA 2  evaluated fedratinib in MF patients who were found to be resistant or intolerant to Incyte Corporation s   NASDAQ INCY   Jakafi which is another a JAK1 JAK2 inhibitor  Fedratinib demonstrated clinically meaningful improvements in splenic response and total symptom score in this second line setting However  we remind investors that JAKARTA 2 was stopped prematurely as the FDA put a clinical hold on the fedratinib program  The hold was put after potential cases of Wernicke s encephalopathy were reported in eight out of 877 patients receiving one or more doses  less than one percent of treated patients   The FDA withdrew the clinical hold in August 2017  Based on the reported benefit risk profile of fedratinib from the JAKARTA 1 and JAKARTA 2 clinical trials  regulatory applications in MF are planned beginning the middle of 2018 Celgene was on the look out of new deals and acquisitions given a lacklustre 2017 Celgene s stock has declined 20 4  of its value in the last six months compared with the  s loss of 1 9  Celgene suffered a series of setbacks over the last few months  The company suffered a setback last week when a late stage study on its lead cancer drug Revlimid in combination with Rituxan failed The study evaluated Revlimid plus Rituxan  R2  followed by R2 maintenance compared with the standard of care featuring Rituxan plus chemotherapy  R CHOP  R bendamustine or R VN CVP  followed by Rituxan maintenance for previously untreated follicular lymphoma Celgene s key growth engine is Revlimid  In 2016  the drug s worldwide sales increased 20  to  7 0 billion and contributed almost 62 1  of the total revenues  Revlimid  an oral immunomodulatory drug  is currently approved for several indications including MM  myelodysplastic syndromes and mantle cell lymphoma The failure of the study is disappointing  The drug s label expansion would have boosted its sales potential In addition  in October 2017  the company announced a phase III trial  REVOLVE   CD 002  on pipeline candidate GED 0301 in Crohn s disease and the extension trial  SUSTAIN  CD 004  were discontinued following a recommendation from the Data Monitoring Committee  which assessed overall benefit risk during a recent interim futility analysis Meanwhile  the deep  yet persistently slow growth of the psoriatic arthritis and psoriasis markets  especially during the entire third quarter  has led to a weak performance of Otezla  Consequently  the company also reduced its annual guidance  The challenging market conditions were driven by an increasingly restrictive PBM formulary control On a positive note  in August 2017  the company obtained an FDA approval for Idhifa for treatment of relapsed and or refractory acute myeloid leukemia with isocitrate dehydrogenase 2  IDH2  mutation  The drug was developed in partnership with Agios Pharmaceuticals  Inc   NASDAQ AGIO   Big biotechs are looking for strategic acquisitions to bolster their portfolio and pipeline  Gilead Sciences  Inc    NASDAQ GILD   also acquired Kite Pharma in 2017 to boost its portfolio Zacks RankCelgene currently carries a Zacks Rank  3  Hold   You can see   
5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-01-07,Zacks Investment Research,https://www.investing.com/analysis/celgene-to-acquire-impact-biomedicines-to-boost-pipeline-200278503,200278503
201433,422949,GILD,CAR T Stocks In Focus With ASH 2017 Meet  GILD  JUNO   More,opinion,"The CAR T therapy space has remained in investor focus in 2017  courtesy of immense potential  The latest annual conference of the American Society of Hematology  ASH  witnessed pharma big wigs  including Novartis and Gilead reporting data on their CAR T therapy candidates 

The FDA has already approved Swiss giant Novartis AG s   NYSE NVS   breakthrough gene transfer treatment  Kymriah  tisagenlecleucel  for the treatment of patients upto 25 years of age with B cell precursor acute lymphoblastic leukemia  ALL  that is refractory or in second or later relapse stage  Novartis currently carries a Zacks Rank  3  Hold   You can see  
Gilead Sciences  Inc    NASDAQ GILD   acquired Kite Pharma and subsequently obtained FDA approval of Yescarta  axicabtagene ciloleucel   the latter s chimeric CAR T therapy candidate  To further strengthen its position in this space  Gilead Sciences and newly acquired cell therapy subsidiary   Kite Pharma   recently signed an agreement to acquire Cell Design Labs  Inc  for  567 million 
Gilead will also acquire 12 2  Cell Design Labs  shares which are owned by Kite Pharma  Cell Design  is a leading cell based therapy developer through synNotch and Throttle technology platforms  These technological platforms will enhance Gilead s cellular therapy research efforts  The company s lead pre clinical candidate is instrumental in treating multiple myeloma 
Meanwhile  Kite Pharma announced results from the ongoing phase I II ZUMA 3 study of KTE C19  a CD19 CAR T cell therapy for the treatment of adult patients with relapsed or refractory ALL  71  of ALL patients who received a single infusion of KTE C19 achieved complete tumor remission  complete remission  CR  or CR with incomplete hematological recovery   Gilead currently carries a Zacks Rank  3 
Juno Therapeutics  Inc    NASDAQ JUNO   and partner Celgene Corp   NASDAQ CELG  announced additional data from the TRANSCEND study on pipeline candidate JCAR017  lisocabtagene maraleucel  liso cel  in patients with relapsed or refractory  r r  aggressive B cell non Hodgkin lymphoma  Data from the trial showed at dose level 2  74  of patients with the aforementioned indication showed an overall response rate  ORR  and 68  CR rate at three months in core group 
Additionally  50  of patients showed CR at six months  While the data was encouraging  investors expected far better ORR rates leading to a significant decline in Juno s shares  A biologics license application filing is expected to be completed in the second half of 2018 and a tentative approval is expected by 2018 end  Juno currently carries a Zacks Rank  3 
  Inc    NASDAQ BLUE   and partner Celgene also announced results from the ongoing CRB 401 phase I clinical study on investigational anti B cell maturation antigen CAR T cell therapy  bb2121  The data showed ORR of 94  in patients in active dose cohorts  doses above 50 x 106 CAR   T cells  and CR rate of 56  observed in patients in active dose cohorts  bluebird currently carries a Zacks Rank  3 
Meanwhile  Novartis submitted a supplemental Biologics License Application to the FDA for Kymriah suspension for intravenous infusion for the treatment of adult patients with r r diffuse large B cell lymphoma  DLBCL  who are ineligible for autologous stem cell transplant  ASCT   Moreover  in November  the company submitted an application to the European Medicines Agency for Kymriah for the treatment of adult patients with r r DLBCL who are ineligible for ASCT  and for children and young adults with r r B cell ALL 
Kymriah was given Breakthrough Therapy designation for r r DLBCL which  if approved  will be the second indication for Kymriah   The company recently announced results from the pivotal JULIET study which showed sustained complete responses at six months with Kymriah suspension for intravenous infusion  in adult patients with a difficult to treat cancer  r r DLBCL  In the study at six months  30  of patients treated with Kymriah were in complete response  The relapse free probability at six months after first response was 74  
Given the immense potential of the therapy  investors are likely to keep an eye on this space in the days ahead as well 
Investor Alert  Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline 
Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ",2017-12-15,Zacks Investment Research,https://www.investing.com/analysis/car-t-stocks-in-focus-with-ash-2017-meet-gild-juno--more-200273740,200273740
201445,422961,GILD,Novartis Reports Updated Results From Kymriah s JULIET Study	,opinion,"Novartis AG   NYSE NVS   announced updated results from the pivotal JULIET study  It showed sustained complete responses at six months with Kymriah suspension for intravenous infusion  in adult patients with a difficult to treat cancer  relapsed or refractory  r r  diffuse large B cell lymphoma  DLBCL  
Kymriah  tisagenlecleucel   formerly CTL019  is the first chimeric antigen receptor T cell  CAR T  therapy approved   The drug has been developed in collaboration with the University of Pennsylvania  This novel immunocellular therapy and one time treatment uses patient s T cells to fight cancer 
CAR T therapies are developed for individual patients using their own cells  thereby making it different from typical small molecule or biologic therapies 
So far this year  Novartis  shares have gained 15 2   compared with the  s growth of 15 6  

JULIET is the first multi center global registration study for Kymriah in adult patients with r r DLBCL and the second global CAR T cell therapy trial  In the study at six months  30  of patients treated with Kymriah showed complete response  The relapse free probability at six months after first response was 74   Median overall survival was not achieved and the median time from infusion to data cutoff was 5 6 months  
When the patients with DLBCL enrolled for this study  they had to go through multiple rounds of chemotherapy and many had unsuccessful stem cell transplants  leaving them with few options and a poor prognosis  The study showed that Kymriah was able to considerably increase their chance of achieving and maintaining a sustained response without stem cell transplant  thus highlighting its benefit 
Additionally  the study revealed that cytokine release syndrome  CRS  occurred in 58  of the  total patients under treatment while 23  experienced grade 3 4 CRS  15  grade 3  8  grade 4  using the Penn Grading Scale  Also  it showed that 21  of patients experienced any grade neurologic events and 12  of patients had grade 3 4 neurologic adverse events  who were provided supportive care 
In the study  26 patients  26   were infused in the outpatient setting of which 20 patients  77   remained outpatient for three or more days after infusion 43 patients discontinued before infusiondue to rapid progression of their disease or deterioration in their clinical status 
According to the study  only nine out of 147  6 1   enrolled patients could not be infused due to inability to manufacture an adequate dose of CAR T cells 
Novartis submitted a supplemental Biologics License Application  sBLA  to the FDA in October for Kymriah suspension for intravenous infusion  The applicationwas filed for the treatment of adult patients with relapsed or refractory  r r  diffuse large B cell lymphoma  DLBCL  who are ineligible for autologous stem cell transplant  ASCT  
Again in November  the company submitted an application to the European Medicines Agency  EMA  for Kymriah for the treatment of adult patients with r r DLBCL who are ineligible for ASCT and for children as well as young adults with r r B cell ALL 
Of late  Gilead   NASDAQ GILD   also received FDA approval for Yescarta   a CAR T therapy for the treatment of adult patients with relapsed or refractory large B cell lymphoma after two or more lines of systemic therapy  Yescarta is the first CAR T therapy approved by the FDA for this indication 
Another company  bluebird bio  Inc  s   NASDAQ BLUE   anti BCMA CAR T therapy  bb21217  is being evaluated for relapsed refractory multiple myeloma  bb21217 as well as bb2121 are being developed in collaboration with Celgene   NASDAQ CELG   Novartis AG Price

   Zacks Rank 
Novartis carries a Zacks Rank  3  Hold   You can see  
Today s Stocks from Zacks  Hottest Strategies 
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-12-11,Zacks Investment Research,https://www.investing.com/analysis/novartis-reports-updated-results-from-kymriahs-juliet-study-200272308,200272308
201446,422962,GILD,Gilead  GILD  Posts Updated Data On CAR T Therapy Yescarta,opinion,"Gilead Sciences Inc    NASDAQ GILD   announced long term follow up data from a phase II study  evaluating its chimeric antigen receptor T cell  CAR T  therapy  Yescarta  axicabtagene ciloleucel   for treatment of patients with refractory large B cell lymphoma  Detailed results from this study were presented at the Annual Meeting of the American Society of Hematology  ASH  in Atlanta Notably  the drug was added to Gilead s portfolio following the acquisition of Kite Pharma in early October  Subsequently  it received an FDA approval later in the same month for treating refractory aggressive non Hodgkin lymphoma  which includes DLBCL  transformed follicular lymphoma  TFL  and primary mediastinal B cell lymphoma  PMBCL   The drug is also under review in the EU with a tentative approval expected in the first half of 2018 Shares of Gilead have outperformed the  so far this year  The stock has gained 3 6  against the broader industry s 2 6  increase 
The updated data from the ZUMA 1 study showed that the drug with a single infusion of axicabtagene ciloleucel demonstrated an overall response rate  ORR  of 42   including 40  of patients achieving complete remission at a median follow up of 15 4 months  The study was conducted on a total of 108 patients  Notably  the previously reported data from the study showed an overall response rate  ORR  of 72   including 95  of patients achieving complete remission at a median follow up of 7 9 months We remind investors that Novartis   NYSE NVS   has also received an FDA approval for its CAR T therapy  Kymriah  tisagenlecleucel   in August for treatment of patients aged up to 25 years with B cell precursor acute lymphoblastic leukemia  ALL  that is refractory or in second or later stage relapse Additionally  Juno Therapeutics   NASDAQ JUNO   is developing cell based cancer immunotherapies based on its CAR T technologies in partnership with Celgene   NASDAQ CELG   for curing adults with r r aggressive NHL  including r r DLBCL  Hence Gilead is expected to face a fierce competition from these products in the long run Gilead Sciences  Inc  Price

   Zacks RankGilead carries a Zacks Rank  3  Hold   You can see  
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-12-11,Zacks Investment Research,https://www.investing.com/analysis/gilead-gild-posts-updated-data-on-cart-therapy-yescarta-200272306,200272306
201447,422963,GILD,Cancer Space Update  Roche  Pfizer   Regeneron Make Data Presentations,opinion,"The week was marked by a flurry of data presentations by several companies at the 59th annual meeting of the American Society of Hematology held between Dec 9 and Dec 12  The presentations also included new updated data from ongoing clinical studies on different cancer candidates 
The major announcements included Regeneron Pharmaceuticals  Inc  s   NASDAQ REGN   top line data on phase II skin cancer candidate  Roche Holding  SIX ROG  AG s   OTC RHHBY   data on Tecentriq from phase III study in kidney cancer and on Venclexta from another phase III study in chronic lymphocytic leukemia   CLL   
Gilead Sciences Inc    NASDAQ GILD   presented updated data on its CAR T therapy  Yescarta  Novartis AG   NYSE NVS   also announced updated results from a phase III study on its CAR T therapy  Kymriah  Moreover  Pfizer Inc  s   NYSE PFE   PARP inhibitor demonstrated superiority over chemotherapy in a phase III study in breast cancer 
Let s see the news in details 
Regeneron s Cemiplimab Positive in Mid stage Study  Regeneron along with partner Sanofi   NYSE SNY   announced that their checkpoint inhibitor targeting PD 1  cemiplimab  showed an overall response rate   ORR   of 46 3  in advanced cutaneous squamous cell carcinoma  The candidate was evaluated in a phase II study  EMPOWER CSCC 1 
However  the median duration of response hasn t been reached at the data cut off date  The companies plan to file for a rolling Biologics License Application   BLA   based on data from the study   Read more   Regeneron Pharmaceuticals  Inc  Price
 

   Roche Announces Data on Tecentriq and Venclexta  Roche announced  evaluating immuno oncology drug Tecentriq in combination with chemotherapy  Avastin against Pfizer s Sutent for first line treatment of advanced or metastatic renal cell carcinoma  The combination therapy achieved statistically significant and clinically meaningful increase in progression free survival   PFS   compared to Sutent 
Data announced from another phase III study   MURANO   evaluating Venclexta plus Rituxan compared to bendamustine plus Rituxan in patients with relapsed or refractory CLL demonstrated significant reduction in the risk of disease progression or death in Venclexta arm  The MURANO study is being conducted with the aim of converting the current accelerated approval of Venclexta to a full approval   Read more   Roche Holding AG Price
 

   Updates on Two Approved CAR T Therapies  Gilead announced   evaluating its chimeric antigen receptor T cell  CAR T  therapy  Yescarta  The phase II ZUMA 1 study is evaluating the therapy in refractory large B cell lymphoma  Data showed that a single infusion of Yescarta achieved an overall response rate   ORR   of 42  at a median follow up of 15 4 months 
Novartis is evaluating its CAR T therapy  Kymriah  in phase III JULIET study in adult patients with a difficult to treat cancer  relapsed or refractory diffuse large B cell lymphoma Data showed that at six months  30  of patients treated with Kymriah showed complete response  The relapse free probability at six months after first response was 74   Median overall survival was not achieved and the median time from infusion to data cutoff was 5 6 months   Read more   
Apart from these  bluebird bio  Inc    NASDAQ BLUE   and Juno Therapeutics announced additional follow up data on their CAR T therapies  which are in phase I studies  Bluebird s candidate    achieved an objective response of 94  and complete response of 54   The Juno s candidate    showed an ORR and 68  complete response   CR   rate at three months
Pfizer s PARP Inhibitor Superior in Breast Cancer Study  Pfizer is developing its PARP inhibitor  talazaporib  in phase III EMBRACA study in patients with germline BRCA positive breast cancer against chemotherapy  The candidate achieved a significant reduction of 46  in the risk of disease progression as the median PFS was 8 6 months in the talazoparib arm versus 5 6 month in the chemotherapy arm   Read more   Pfizer  Inc  Price
 

   Apart from these news    which is being evaluated in a phase II study in Philadelphia chromosome positive acute lymphoblastic leukemia  Sprycel  following its addition to a chemotherapy regimen  achieved an event free survival rate of 65 5  and an ORR of 91 5  after three years 
Moreover  the  looking for label expansion of Keytruda to include refractory primary mediastinal B cell lymphoma  a type of non Hodgkin lymphoma 
Investor Alert  Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline 
Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ",2017-12-15,Zacks Investment Research,https://www.investing.com/analysis/cancer-space-update-roche-pfizer--regeneron-make-data-presentations-200273722,200273722
201469,422985,GILD,What s In The Cards For PFE  INCY And ACOR In Q3 Earnings ,opinion,The third quarter reporting cycle is witnessing revenue acceleration and a positive revisions trend for Q4 Results from about half of the S P 500 members are already out  As of Oct 27  2017  total earnings for the 272 S P 500 members are up 8 7  from the same period last year on 6 7  higher revenues  with 75 7  and 66 2  surpassing the earnings and revenue estimates  respectively According to the   these 272 S P 500 companies account for 64 2  of the index s total market capitalization  Per the report  total earnings of the S P 500 companies in Q3 are expected to grow 5 4  year over year on 5 5  higher revenues Please note that the broader Medical sector  includes drug  biotech as well as Medical Device companies  is expected to record year over year growth of 4 8  in revenues and 5 2  in earnings in Q3 Among the biotech pharma bigwigs  Merck   Co   Inc    NYSE MRK    Celgene Corporation   NASDAQ CELG    AbbVie Inc  NYSE ABBV    Bristol Myers Squibb Company   NYSE BMY   and Gilead Sciences  Inc    NASDAQ GILD   reported their third quarter results last week   While Merck  Celgene and AbbVie outpaced the Zacks Consensus Estimates for earnings  they lagged the same for revenues  However  Bristol Myers and Gilead surpassed expectations for both earnings and revenues Notably  Bristol Myers and Gilead raised their earnings outlook for 2017 as well  While Merck raised its previously issued adjusted earnings guidance  it upped sales guidance marginally  Abbvie and Celgene also tightened their earnings guidance for 2017 Here we have three biotech pharma companies that are set to report third quarter results on Oct 31 Let s see how things are shaping up for this quarter Pfizer Inc    NYSE PFE   Pfizer  which is scheduled to release earnings before the market opens  delivered a positive earnings surprise of 3 08  in the last quarter  The company s earnings performance has been mixed with the bottom line missing in two of the last four quarters while beating the same in the other two  bringing the average surprise to negative 0 39  For this quarter  Pfizer has an of  0 11  and a Zacks Rank  3  Hold   The Zacks Consensus Estimate is pegged at 65 cents per share  You can uncover the best stocks to buy or sell before they re reported with our  New products like Xeljanz  rheumatoid arthritis  and Ibrance  breast cancer  as well as older products like Lyrica  neuropathic pain  and Eliquis  blood thinner  may contribute to the top line  meaningfully  Meanwhile  sales of blockbuster drug Enbrel will continue to decline in the quarter due to biosimilar competition  The lower sales trend in Prevnar Prevenar 13 vaccines franchise is likely to continue as well  Sales of Viagra are expected to be affected by lower demand   Read More   Our previous article showed that Pfizer was likely to beat on earnings this quarter  However  estimates changed thereafter and we are not certain of a beat this earnings season  Pfizer  Inc  Price and EPS Surprise    Incyte Corporation   NASDAQ INCY  Incyte  which is scheduled to release earnings before the market opens  witnessed a negative earnings surprise of 20  in the last quarter  The company s earnings performance has been mixed so far  having delivered positive surprises in two of the last four quarters and missing in one and estimates unavailable in one  The average earnings surprise over the last four quarters is negative 3 94  The company has an Earnings ESP of  38 64  and a Zacks Rank  3  indicating a likely positive surprise  The Zacks Consensus Estimate is pegged at 6 cents per share  You can see The company s key growth driver  Jakafi  has been performing well and we expect the trend to continue in the to be reported quarter as well  Incyte Corporation Price and EPS Surprise    Acorda Therapeutics  Inc    NASDAQ ACOR  Acorda  which is scheduled to release earnings before the market opens  witnessed a negative earnings surprise of 39 58  last quarter  The company s earnings performance has been disappointing so far  with the company having incurred a negative surprise in each of the last four quarters  The average earnings surprise over the last four quarters is negative 106 91  The company has an Earnings ESP of  5 53  and a Zacks Rank  5  Strong Sell   making the surprise prediction difficult  The Zacks Consensus Estimate is pegged at 66 cents per share As it is we caution against stocks with a Zacks Ranks  4 or 5  Sell rated  going into an earnings announcement  especially when the company is seeing negative estimate revisions We expect investor focus on the refusal to file  RTF  relief for its late stage pipeline candidate  Inbrija  being developed for treatment of patients who are suffering from Parkinson s disease  Acorda Therapeutics  Inc  Price and EPS Surprise    Zacks  Best Private Investment Ideas While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-10-29,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-cards-for-pfe-incy-and-acor-in-q3-earnings-200257048,200257048
201470,422986,GILD,Celyad  Revision Of Clinical Strategy After Responses Seen  ,opinion,"Celyad SA  NASDAQ CYAD  has reported a complete morphological leukaemia free status  MFLS  response in acute myeloid leukaemia  AML  in the NKR CAR T cell THINK study  Spontaneous remission in refractory relapsed AML is extremely rare  so this is a significant result  Importantly  the response was achieved with no toxic preconditioning  CYAD 01 has shown limited toxicities to date  The clinical strategy has been updated to focus on AML and colorectal cancer  Additionally  with the approvals of Yescarta  Gilead Sciences Inc  NASDAQ GILD   at a price of  373k and Kymirah  Novartis  at  475k  we have increased our expected price for NRK CAR T cell therapy to  200k  formerly  150k  The revised strategy and price assumption change moves the indicative value to  103 per share  formerly  51 6 per share 

First  clinical validity  for NKR CAR T cells
Celyad found one AML patient given 3x108 NKR CAR T cells had a complete MLFS response  In effect  it was a near CRi  that is  a complete response with high but not normal blood cell levels  Treatment with NKR CAR T cells has enabled him to move to stem cell transplant  Median survival of relapsed and refractory AML patients is typically less than four months  source Celyad  see AML treatment  ",2017-10-30,Edison,https://www.investing.com/analysis/celyad-revision-of-clinical-strategy-after-responses-seen-200256939,200256939
201471,422987,GILD,Intercept  ICPT  Q3 Loss Narrower Than Expected  Sales Beat ,opinion,"Intercept Pharmaceuticals  Inc    NASDAQ ICPT   reported encouraging results for third quarter 2017  The company posted a loss of  2 89 per share in the third quarter  narrower than the Zacks Consensus Estimate of  3 55 and the year ago loss of  3 59 Intercept Pharmaceuticals  Inc  Price and EPS Surprise
 

   Quarterly revenues were  41 3 million  up significantly from  5 1 million in the year ago quarter and beat the Zacks Consensus Estimate of  35 9 million 
Intercept s stock has declined 43 7  year to date against the  s loss of 1 4    In particular  shares have plunged significantly over the last few days due to safety issues regarding the approved drug Ocaliva 
 Quarter in DetailRevenues from international markets were  4 7 million  In third quarter 2017 Ocaliva recorded  40 9 million of sales  up from 30 4 million recorded in second quarter 2017  Ocaliva was approved in the United States  in combination with ursodeoxycholic  UDCA  for the treatment of primary biliary cholangitis  PBC  in adults with an inadequate response to UDCA  or as monotherapy in adults who are unable to endure UDCA in 2016  The drug was also granted conditional approval by the European Commission Sales from the United States markets came in at  36 2 million  up from  27 9 million recorded in the second quarter as prescriptions continue to grow Research and development expenses increased 29 8  year over year to  45 9 million primarily driven by increases in clinical development programs for OCA and infrastructure to support such programs Selling  general and administrative expenses increased to  61 4 million  up from  52 8 million in the year ago quarter driven by personnel related costs to support commercial and international initiatives and an increase in indirect expenses 2017 Outlook ReiteratedIntercept expects operating expenses to be in the middle of the earlier projected range of  380  420 million in 2017  The company believes that continued commercialization of Ocaliva in PBC in the United States and other markets   In order to streamline operating expenses  Intercept has decided to deprioritize its INT 767 development program Pipeline UpdateOcaliva is being evaluated for other indications including non alcoholic steatohepatitis  NASH  and primary sclerosing cholangitis  PSC  The FDA has earlier approved a redesign of the phase III trial  REGENERATE on Ocaliva for the safety and efficacy in treating NASH patients with liver fibrosis  The company now needs to achieve only one co primary endpoint  either fibrosis improvement or NASH resolution as compared with the earlier target of achieving both  The sample size of the trial has also been reduced to approximately 750 patients or about 250 patients per arm  The company completed enrolment for the interim analysis cohort in the REGENERATE trial  data readout in the first half of 2019  The company also plans to initiate a phase III trial on Ocaliva in NASH patients with cirrhosis in the second half of 2017  Intercept announced trial results from two phase II trials   CONTROL  Combination OCA aNdsTatins for monitoRing Of Lipids  and AESOP for PSC  CONTROL study is being conducted to evaluate the effect of Ocaliva in combination with statin therapy on lipid metabolism in patients with NASH   Results from AESOP revealed that OCA met the primary endpoint of statistically significant reduction in alkaline phosphatase  ALP  while results from CONTROL showed that the company achieved its objective in demonstrating that the lowest available dose of atorvastatin rapidly reverses OCA associated LDL changes to below baseline levels in NASH patients with fibrosis or cirrhosis Our TakeIntercept s third quarter results were encouraging as the company reported a narrower than expected loss and beat on revenues   However  prescription demand softened following the Dear Health Care Provider letter and the FDA safety communication on Ocaliva Recently  some deaths have been reported in PBC patients with moderate or severe hepatic impairment  Child Pugh B or C cirrhosis   The FDA reported 19 deaths due to Ocaliva and stated that the drug may also affect the liver  However  Intercept conducted an analysis and concluded that these patients were prescribed once daily doses of Ocaliva  which is seven times higher than the recommended weekly dose  The analysis was conducted in consultation with the FDA  The company concluded that deaths occurred due to overdosing  Consequently  Intercept issued the Dear Healthcare Provider letter  Thereafter  the FDA issued their own safety communication to reinforce recommended label dosing  Intercept is also working with the FDA on further updates to Ocaliva s label for safety purposes Nevertheless  such side effects will limit the sales potential going forward  On the other hand  NASH market has huge potential and a tentative approval will boost Ocaliva s prospects   However  bigwigs like Novartis AG   NYSE NVS   and Gilead Sciences  Inc    NASDAQ GILD   have FXR agonists in phase II or earlier stages of clinical or preclinical development that can be used to treat PBC  NASH and the other liver diseases 
Zacks Rank   Key Pick
Intercept currently carries a Zacks Rank  3  Hold  
A better ranked stock in the healthcare sector is Exelixis  Inc    NASDAQ EXEL   which currently carries a Zacks Rank  2  Buy    You can see  
Exelixis reported strong results for the third quarter   Earnings per share estimates inched up to 64 cents from 63 cents for 2018  over the last 60 days  The company has delivered positive earnings surprises in the trailing four quarters with an average beat of 572 9  
Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-11-01,Zacks Investment Research,https://www.investing.com/analysis/intercept-icpt-q3-loss-narrower-than-expected-sales-beat-200257967,200257967
201472,422988,GILD,5 Biotech And Pharma Stocks With Key FDA Catalysts This November,opinion,"The FDA  which approved 22 novel drugs last year  has given its approval to 35 drugs so far in 2017 including a key approval in October   Gilead Sciences s   NASDAQ GILD   Yescarta  a cell based gene therapy for the treatment of adult patients with certain types of large B cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment  This makes Yescarta the second gene therapy to gain FDA approval  the first being Novartis AG s   NYSE NVS   Kymriah  Kymriah was approved in late August 2017 for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia   ALL   Other key approvals this year include Lilly s Verzenio  advanced or metastatic breast cancer   Gilead s Vosevi  hepatitis C virus   Puma s Nerlynx  to reduce the risk of breast cancer returning   J J s Tremfya  moderate to severe plaque psoriasis   Regeneron Sanofi s Kevzara  rheumatoid arthritis   Roche s multiple sclerosis treatment  Ocrevus  Regeneron and Sanofi s eczema treatment  Dupixent  Tesaro s PARP inhibitor  Zejula  and BioMarin s Brineura  treatment of a specific form of Batten disease  among others  Quite a few of these drugs have blockbuster potential With the drug development process being lengthy and time consuming and requiring the utilization of a lot of funds and resources  key pipeline events including data readouts and regulatory updates are of paramount importance and could act as major catalysts  Here is a look at a few important regulatory events scheduled for the month of November Keryx s Auryxia under Review for Label Expansion  Keryx Biopharmaceuticals  Inc    NASDAQ KERX    which is focused on developing medicines for renal disease  is seeking FDA approval for the label expansion of Auryxia  The company is looking to get Auryxia approved for the treatment of patients with iron deficiency anemia and non dialysis dependent chronic kidney disease   CKD    A decision should be out on November 6  Approval for this indication would expand the patient population for Auryxia which brought in sales of  24 6 million in the first half of 2017 Keryx s shares are up 2 9  year to date  compared to the  s 2 7  rally 
Label Expansion for Bristol Myers s Sprycel  Bristol Myers Squibb Company   NYSE BMY   is looking to expand the label of its blockbuster drug  Sprycel  so that it can be used for the treatment of children with Ph  chronic phase   CP   chronic myeloid leukemia   CML    The company is also seeking approval for a powder for oral suspension   PFOS   formulation of Sprycel  A response from the FDA for the regulatory application  which is under priority review  is expected on November 9  Label expansion should boost Sprycel sales further   the drug brought in sales of  1 5 billion in the first nine months of 2017 Bristol Myers s shares are up 6 4  year to date  compared to the  s 15 1  rally Bristol Myers is a Zacks Rank  3  Hold  stock   you can see  
Will it be Third Time Lucky for Dynavax s Heplisav B  Dynavax Technologies Corporation   NASDAQ DVAX   is awaiting a response from the FDA for its hepatitis B vaccine  Heplisav B  this month  Earlier this year  the vaccine had got a favorable recommendation  12 1  from the FDA s Vaccines and Related Biological Products Advisory Committee  VRBPAC   With the positive vote  expectations were high that the company would finally gain approval for the vaccine which had previously received two complete response letters  one in November 2016 and the other in February 2013   However  the FDA action date of August 10 was pushed out by three months with the agency asking for more detailed information about the company s proposed post marketing study for the vaccine With the additional information being considered a major amendment to the Biologics License Application   BLA    the FDA is expected to give its response regarding the approval status of the vaccine by November 10  Approval would allow Dynavax to go ahead with its plans to launch the vaccine early next year Dynavax s shares are up 431 7  year to date  compared to the  s 2 7  rally 
Heron s Cinvanti under Review for CINV  Commercial stage biotech company  Heron Therapeutics  Inc    NASDAQ HRTX   is awaiting a decision from the FDA for Cinvanti  which is under review for the prevention of chemotherapy induced nausea and vomiting   CINV    Approval would strengthen Heron s CINV franchise by adding a second  complementary therapeutic agent  The FDA is expected to give its decision on November 12 Heron s shares are up 18 7  year to date while the  recorded a decline of 0 9  
Will Ultragenyx Gain FDA Approval for its First Product  Clinical stage biopharmaceutical company  Ultragenyx Pharmaceutical Inc    NASDAQ RARE   has an FDA action date coming up this month for vestronidase alpha or rhGUS which is under review for mucopolysaccharidosis 7  MPS 7  also known as Sly syndrome  About 200 patients across the world are afflicted by this disease  which is one of the rarest forms of MPS  Currently  there are no approved treatments for MPS 7  Approval for rhGUS on November 16 would transform Ultragenyx into a commercial stage company Ultragenyx s shares are down 31 8  year to date  compared to the  s 2 7  rally 
Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-11-02,Zacks Investment Research,https://www.investing.com/analysis/5-biotech-and-pharma-stocks-with-key-fda-catalysts-this-november-200257874,200257874
201473,422989,GILD,Celgene CAR T Therapy Gets Breakthrough Therapy Designation,opinion,"Celgene Corporation   NASDAQ CELG   and partner bluebird bio  Inc    NASDAQ BLUE   announced that their chimeric antigen receptor T cell  CAR T  therapy candidate  bb2121 targeting b cell maturation antigen  BCMA  in previously treated patients with multiple myeloma obtained Breakthrough Therapy Designation from the FDA The candidate was also granted PRIority MEdicines  PRIME  eligibility by the European Medicines Agency  EMA  Breakthrough Therapy Designation is intended to expedite the development and review of drugs that are intended to treat serious or life threatening conditions while PRIME is a program launched by the EMA to enhance support for the development of medicines that target an unmet medical need We remind investors that Celgene entered into a collaboration agreement with bluebird bio in March 2013 to develop CAR T cell therapies  The collaboration was amended and restated to focus on developing product candidates targeting B cell maturation antigen  BCMA  in June 2015  The lead candidate in this program is bb2121  anti BCMA CAR T program is currently being studied in a phase I trial for the treatment of relapsed refractory multiple myeloma  Both companies are also developing a second anti BCMA CAR T program  bb21217 CAR T uses patient s cells to identify and destroy cancer cells  thereby making it different from other small molecule or biologic therapies  During the treatment  T cells are drawn from a patient s blood  These cells are then reprogrammed in the manufacturing facility to create genetically coded cells to express a chimeric antigen receptor to recognize and fight cancer cells and other B cells expressing a specific antigen The therapy has been in spotlight in 2017  Novartis AG s   NYSE NVS   Kymriah was the first CAR T to get FDA approval in September 2017  Last month  Gilead Sciences  Inc    NASDAQ GILD   also received FDA s approval for Yescarta  axicabtagene ciloleucel   for the treatment of refractory aggressive non Hodgkin lymphoma  which includes DLBCL  transformed follicular lymphoma and primary mediastinal B cell lymphoma While the long term impact of the treatment is yet to be evaluated  the approval opens up new frontiers in the treatment of cancer   Meanwhile  Celgene s stock has fallen 12  in the last six months as against the  s gain of 0 5  Celgene s third quarter results were mixed with the company beating earnings but missing sales estimates  While Revlimid sales were impressive yet again  Otezla sales in the United States were weak which led the management to reduce annual guidance for the drug 
Zacks Rank
Celgene is a Zacks Rank  3  Hold  stock  You can see  
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-11-16,Zacks Investment Research,https://www.investing.com/analysis/celgene-cart-therapy-gets-breakthrough-therapy-designation-200266207,200266207
201488,423004,GILD,Gilead Drug Approval Fuels Interest In CAR T Space  3 Stocks To Consider,opinion,"Interest in the CAR T  chimeric antigen receptor T cells  space continues to build up with the FDA giving its nod to the second CAR T therapy last week  Gilead Sciences s   NASDAQ GILD   Yescarta  a cell based gene therapy  gained approval for the treatment of adult patients with certain types of large B cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment  This makes Yescarta the second gene therapy to gain FDA approval  the first being Novartis AG s   NYSE NVS   Kymriah  Kymriah was approved in late August 2017 for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia   ALL   How Does CAR T Cell Therapy Work CAR T falls under the ambit of cellular immunotherapy which involves using a patient s own immune cells to attack and get rid of harmful disease cells in the body The CAR T approach involves the collection of a patient s T cells  their genetic modification outside the body  the incorporation of specific receptors which target cancer cells and finally  the re infusion of the modified T cells back into the patient There is a lot of enthusiasm for CAR T as studies have shown that it can help achieve durable complete responses in some leukemias and lymphomas  including in patients who have suffered multiple relapses  However  CAR T comes with its own set of challenges including a high level of R D investment as well as safety issues like serious immune toxicity   CRS   or neurotoxicity  In fact  both Kymriah and Yescarta have boxed warnings in their labels for CRS and neurologic toxicities  These treatments will also not come cheap  While Novartis has set a price of  475 000 for Kymriah  the list price for Gilead s Yescarta is  373 000 The FDA s StanceWith the FDA granting back to back approvals to two CAR T treatments  it looks like the regulatory environment might well be encouraging for gene cell therapy candidates   In fact  FDA Commissioner Scott Gottlieb said that the approval of Yescarta shows the continued momentum in this promising new area of medicine  The agency intends to release a comprehensive policy on how it plans to support the development of cell based regenerative medicine CAR T Stocks in FocusGiven the increased focus on this corner of the immuno oncology market and the huge commercial potential for approved treatments in this market  here is a look at 3 companies that are working on CAR T cell treatments Juno Therapeutics  Inc    NASDAQ JUNO    Biopharmaceutical company  Juno  is focused on the development of innovative cellular immunotherapies for the treatment of cancer  Juno s cell based cancer immunotherapies are based on chimeric antigen receptor and high affinity T cell receptor technologies  The company has several cell based candidates in its pipeline targeting a variety of B cell malignancies as well as multiple solid tumors and multiple myeloma Although the company suffered a major setback with the development of its erstwhile lead pipeline candidate due to safety issues  including patient deaths   Juno is now focusing on JCAR017  a next generation CAR T cell product that targets CD19  JCAR017 is currently in a registrational study for non Hodgkin s lymphoma   NHL    The company also has a strong partner in Celgene Corporation   NASDAQ CELG   Juno stock has gained 131 9  year to date  substantially outperforming the 10 2  rally of the  it belongs to 
bluebird bio  Inc    NASDAQ BLUE    bluebird is another clinical stage company working on developing gene therapies for serious genetic diseases and T cell based immunotherapies for cancer  The company s anti BCMA CAR T therapy  bb21217  is being evaluated for relapsed refractory multiple myeloma  bb21217 as well as bb2121 are being developed in collaboration with Celgene bluebird stock has gained 131  year to date  substantially outperforming the 10 2  rally of the  it belongs to 
ZIOPHARM Oncology  Inc    NASDAQ ZIOP    Biotech company ZIOPHARM uses innovative gene expression  control and cell technologies to provide safe  effective and scalable cell  and viral based therapies for cancer and graft versus host disease  ZIOPHARM s immune oncology platform includes CAR T as well as other adoptive cell based approaches While announcing second quarter results  the company had said that within its CAR  T programs  it is continuing with a phase I second generation study of CD19 specific CAR  T for lymphoid malignancies and expects to move third generation CD19 with mbIL15 towards an early stage study evaluating point of care  Plans are also on to commence a phase I study with CD33 specific CAR  T for relapsed refractory acute myeloid leukemia  AML  this year  ZIOPHARM s shares are up 0 9  so far in 2017 
Juno  bluebird and ZIOPHARM are all Zacks Rank  3  Hold  stocks   you can see  In addition to the above three  companies like Bellicum Pharmaceuticals  Inc    NASDAQ BLCM   and Cellectis also have a presence in this area  However  Cellectis  a French  biopharmaceutical company focused on developing immunotherapies based on gene edited allogeneic CAR T cells  UCART   has run into a roadblock with the FDA placing a clinical hold on a couple of early stage studies being conducted on UCART123  The hold came into place after the company reported a death in one of the studies Going forward  we expect investor focus to remain in this corner of the immuno oncology market  In addition to tracking the performance of Kymriah and Yescarta  we believe more deals will be announced in the cell therapy space Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-10-22,Zacks Investment Research,https://www.investing.com/analysis/gilead-drug-approval-fuels-interest-in-cart-space-3-stocks-to-consider-200220365,200220365
201489,423005,GILD,Gilead  GILD  Q3 Earnings And Revenues Sink ,opinion,"Gilead Sciences  Inc    NASDAQ GILD   just released its third quarter 2017 financial results  posting earnings of  2 06 per share and revenues of  6 51 billion  Currently  GILD is a Zacks Rank  3  Hold  and is down over 2 40  to  76 per share in after hours trading shortly after its earnings report was released 
GILD  
Missed earnings estimates  The company posted earnings of  2 06 per share  missing the Zacks Consensus Estimate of  2 09 per share 
Beat revenue estimates  The company saw revenue figures of  6 51 billion  beating our consensus estimate of  6 33 billion 
Gilead Sciences revenues fell over 13  from  7 50 billion in the year ago period  On top of that  the company s earnings tanked over 17  after posting earnings of  2 49 per share in its third quarter of 2016 
The company s third quarter product sales fell from  7 4 billion to  6 4 billion 
Here s a graph that looks at GILD s Price  Consensus and EPS Surprise history Gilead Sciences  Inc  Price  Consensus and EPS Surprise   Gilead Sciences  Inc  is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them  They have a broad based focus on developing and marketing drugs to treat patients with infectious diseases  including viral infections  fungal infections and bacterial infections  and a specialized focus on cancer  They have expertise in liposomal drug delivery technology  a technology that the company uses to develop drugs that are safer  easier for patients to tolerate and more effective 
Check back later for our full analysis on GILD s earnings report 
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-10-26,Zacks Investment Research,https://www.investing.com/analysis/gilead-gild-q3-earnings-and-revenues-sink-200221331,200221331
201511,423027,GILD,Here s Why Bluebird Bio  BLUE  Stock Is Falling Today,opinion,"Shares of Bluebird Bio   NASDAQ BLUE    a major player in the emerging gene therapy and CAR T research markets  slumped more than 6  in morning trading Monday after receiving a key analyst downgrade 
In a note to clients  Morgan Stanley  NYSE MS  downgraded the biotech firm from  Equal weight  to  Underweight  and reiterated its price target of  105 00 per share  That call would represent a 23 5  drop from Friday s close 
Morgan Stanley s Matt Harrison said that he expects shares to underperform  citing headwinds in Bluebird s sickle cell business  Still  the analyst noted that Bluebird s BCMA targeting CAR T candidate does provide some valuation support 
As most biotech investors will know by now  CAR T therapy is an emerging method for treating cancer that includes making genetic changes to a patient s immune T cells and reinjecting them into the body to attack cancer cells 
Bluebird currently has several active clinical and pre clinical programs under its CAR T umbrella  The company s lead CAR T program  bb2121  is a collaboration with biotech giant Celgene   NASDAQ CELG   and has produced encouraging data thus far in its Phase 1 study 
It s been a busy year for the CAR T industry  as several major milestones have been reached  In August  Novartis   NYSE NVS   received approval for its innovative new lymphoblastic leukemia treatment  making it the first approved CAR T therapy in the world 
And earlier that same week  biotech behemoth Gilead Sciences   NASDAQ GILD   announced that it was acquiring Kite Pharma   NASDAQ KITE    another competitor in the CAR T market  Gilead will pay a staggering  11 9 billion for Kite  which is expected to receive approval for its own CAR T therapy in November 
For more on the current state of the CAR T market  check out our  team s exclusive interview with Brad Loncar  the creator of the Loncar Cancer Immunotherapy Index 

Want more stock market analysis from this author  Make sure to follow   on Twitter 
Today s Stocks from Zacks  Hottest Strategies 
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-10-02,Zacks Investment Research,https://www.investing.com/analysis/heres-why-bluebird-bio-blue-stock-is-falling-today-200216455,200216455
201512,423028,GILD,2 Medical Breakthroughs Set To Reward Early Investors,opinion,"This has been called  The Century of Biology  since even before the Human Genome Project was successfully completed in 2003 
But only ten years in  this was the conclusion of Clive Cookson writing in the Financial Times in March of 2010   
 It is clear now that 21st century bioscience has not delivered clinical and other results as quickly as some optimists    or hype merchants    had expected  Medicine and healthcare have changed little over the decade  while the physics based information technology industries have transformed people s lives  
Well  what a difference only five years can make  In the healthcare investing circles I am involved with  we talk daily about two new breakthroughs that sound nearly like science fiction  One is already helping people and the other could only be a few years away from curing inherited disease 
Continued      
                                                                                                      

A medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have been poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline 
The prospects for cures are almost unimaginable  So are the potential profits for early investors 
Zacks just released a Special Report that shows how to take advantage of this trend with 5 stocks to buy now  Deadline to download  Midnight Sunday  October 8 

                                                                                                      
Teaching Your Body to Fight Its Own Cancer
The first big breakthrough of the 21st century is called  immuno oncology  where researchers are learning to teach a person s own immune system to fight his or her cancer 
That s the nefarious thing about cancer  It tricks your body s immune system into not recognizing it  But scientists in university labs and at biotechnology companies big and small have been hard at work on cracking the chemical codes of communication between human T cells  the body s disease warriors  and cancer cells 
One of these  immuno therapies  is called CAR T  a technology which uses chimeric antigen receptors to activate T cells  And one company I ve followed for a while in this space  where we just locked in 70  gains in my Healthcare Innovators portfolio  is Juno Therapeutics  JUNO   Here s how they describe their science   
Juno is focused on revolutionizing medicine by re engaging the body s immune system to treat cancer  Founded on the vision that the use of human T cells as therapeutics will drive one of the next important phases in medicine  we are developing cell based cancer immunotherapies based on our chimeric antigen receptor  CAR  and high affinity T cell receptor  TCR  technologies to genetically engineer T cells to recognize and kill cancer cells  We have shown compelling evidence of tumor shrinkage in clinical trials using multiple cell based product candidates to address refractory B cell lymphomas and leukemias  Longer term  Juno aims to develop our cell based platform to include additional product candidates to address a broad range of cancers and human diseases 
Why is this such a huge discovery  The answer is probably obvious if you or anyone you know has had cancer and gone through surgery  radiation treatment  or chemotherapy  Those  cures  are painful  risky  and don t always work 
To genetically engineer a patient s own T cells to recognize and attack cancer is a revolutionary and most welcome breakthrough in oncology treatment 
While this science is still in its early stages  the clinical results have been inspiring and gaining FDA  fast track  designation to speed the R D process  And speaking of inspired  Gilead Sciences  NASDAQ GILD  is so excited about this frontier that they just plunked down  12 billion for a leading player  Kite Pharma  KITE  
I was also inspired this spring to buy more of these companies  besides JUNO  for my new Healthcare Innovators portfolio 
But the next frontier is one I am equally excited about  yet just beginning to explore for its investment potential as the R D  proof of concept  is still not conclusive for humans 
Gene Editing  Entering the Realm of Fantastic Possibilities
Some people are against genetically modified food  or experiments that alter animal species  But more of us should take an interest in the possibilities of altering human genetic destiny 
While the war to cure cancer in bold new ways using the body s immune system is welcome by most  a quieter revolution has been applying its scientific secrets in a more controversial way to potentially cure inherited diseases 
The breakthrough is called genome editing  Not only will it pay for you to understand this complex and controversial science  especially as you ll be seeing and hearing more news stories and debate about the latest discoveries and achievements  but it could pay us as investors too 
Because whether everyone agrees or not  this science will move forward and many committed researchers will be hot on the trail of curing or preventing disease at the genetic level 
Billions of dollars have already been invested by large pharmaceutical companies and this trend will only grow because the potential outcomes in terms of cures and healthcare cost savings are very sizable 
Genome editing is already being used to modify human blood cells that are then put back into the body to treat conditions including leukemia and AIDS  It could also potentially be used to treat other infections and simple genetic conditions such as muscular dystrophy and hemophilia 
5 Stocks to Ride the Breakthrough
I ve prepared a Zacks Special Report to help you capitalize on this new frontier of medicine 
It s titled Cures and Riches  5 Stocks for the Life Saving  Fortune Building Promise of Gene Editing and you re invited to 
Of course  it s critically important to not simply invest in companies involved with gene editing but to pick the right ones at the right time  For me  5 companies have the best breakout potential in this fast emerging space 
One has 2 product candidates that were recently granted FDA Fast Track designation  Another is developing a potential game changer for cystic fibrosis in addition to its gene editing initiatives  And 3 other stocks offer comparable excitement to early investors 
Please note that the deadline to download this report is midnight Sunday  October 8 

Good Investing 
Kevin Cook
Kevin  Senior Stock Strategist at Zacks  is a leading expert in biotech and medical stocks  He provides commentary and recommendations for Healthcare Innovators and TAZR portfolios  and today is making available his newly released Special Report ",2017-10-06,Zacks Investment Research,https://www.investing.com/analysis/2-medical-breakthroughs-set-to-reward-early-investors-200217492,200217492
201526,423042,GILD,Should Value Investors Consider Gilead Sciences  GILD  Stock ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Gilead Sciences  Inc    NASDAQ GILD   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Gilead Sciences has a trailing twelve months PE ratio of 8 3  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 20 3  If we focus on the long term PE trend  Gilead Sciences  current PE level puts it below its midpoint of 12 6 over the past five years  Moreover  the current level stands significantly lower than the highs for the stock  indicating that it could be a solid entry point Further  the stock s PE compares favorably with the Zacks Medical sector s trailing twelve months PE ratio  which stands at 20 5  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers  We should point out that Gilead Sciences has a forward PE ratio  price relative to this year s earnings  of 9 4  so it is fair to expect an increase in the company s share price in the near future P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  Gilead Sciences has a P S ratio of about 3 8  This is a bit higher than the S P 500 average  which comes in at 3 2 right now  This indicates that the stock is a bit overvalued from this aspect Broad Value OutlookIn aggregate  Gilead Sciences currently has a Value Score of A  putting it into the top 20  of all stocks we cover from this look  This makes Gilead Sciences a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  the P CF ratio  another great indicator of value  for Gilead Sciences is just 6 5  a level that is far lower than the industry average of 23 5  Clearly  GILD is a solid choice on the value front from multiple angles What About the Stock Overall Though Gilead Sciences might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth Score of B and a Momentum Score of A  This gives GILD a Zacks VGM score   or its overarching fundamental grade   of B   You can read more about the Zacks Style Scores  Notably  the company s recent earnings estimates have been quite encouraging  The current quarter and full year have seen three and five estimates go higher in the past sixty days  respectively  The company did not witness any downward revisions in the said time frame This has had a meaningful impact on the consensus estimate as the current quarter consensus estimate has risen by 3 9  in the past two months  while the full year estimate has increased 6 9   You can see the consensus estimate trend and recent price action for the stock in the chart below Gilead Sciences  Inc  Price and Consensus    However  this somewhat bullish trend has likely not yet been reflected in the stock  as we have just a Zacks Rank  3  Hold   which indicates expectations of in line performance in the near term  Nonetheless  the bullish analyst sentiment indicates that the stock s prospects in the near term look good Bottom LineGilead Sciences is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Further  this Zacks Rank  3 company enjoys a solid Zacks Industry Rank  among Top 35  of more than 250 industries   However  the industry has underperformed the broader market over the past two years  This is visible from the chart below So  value investors might want to wait for the broader industry factors to turn favorable  but once that happens  this stock could be a compelling pick 4 Promising Stock Picks to Keep an Eye OnWith news stories about computer hacking and identity theft becoming increasingly commonplace  the cybersecurity industry looks like a promising investment opportunity  But which stocks should you buy  Zacks just released Cybersecurity  An Investor s Guide to Locking Down Profits to help answer this question This new Special Report gives you the information you need to make well informed investment choices in this space  More importantly  it also highlights 4 cybersecurity picks with strong profit potential ,2017-09-18,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-consider-gilead-sciences-gild-stock-200214142,200214142
201527,423043,GILD,Gilead s  GILD  Epclusa Receives Label Expansion In Canada,opinion,"Gilead Sciences Inc    NASDAQ GILD   announced that Health Canada has granted a Notice of Compliance  NOC  for updated label of hepatitis C virus drug  Epclusa 
The drug s label has been expanded to extend the drug s use for patients co infected with HIV 1 
The drug was approved in Canada in July 2016 for the treatment of adults with genotype 1 6 chronic HCV infection without cirrhosis or with compensated cirrhosis  or with decompensated cirrhosis in combination with ribavirin 
We expect the drug s sales to increase with this label expansion as HCV co infection remains a major cause of morbidity in HIV infected individuals 
Last month  Health Canada granted a NOC for single tablet regimen  Vosevi  sofosbuvir 400 mg velpatasvir 100 mg voxilaprevir 100 mg   for chronic HCV infection 
Gilead is known for its presence in the HCV market  courtesy of its blockbuster HCV drugs  Sovaldi and Harvoni  The HCV portfolio received a huge a boost when Epclusa gained approval in both the United States  June 2016  and EU  July 2016  and became the first and only all oral  pan genotypic  STR consisting of Sovaldi and velpatasvir  an NS5A inhibitor   for the treatment of adults with genotype 1 6 chronic HCV infection  The approval of Vosevi is expected to boost Gilead s strong HCV portfolio further 
However  the HCV franchise is under pressure due to competition and pricing issues  We note that Harvoni  Sovaldi and Epclusa  face competition from AbbVie Inc    NYSE ABBV   Viekira Pak and Viekira XR among others  Competition as well as pricing pressure intensified further with the launch of Merck   Co   Inc  s   NYSE MRK   Zepatier 

 
Gilead s stock has gained 17 5  year to date against the  17 3  
Gilead recently announced plans to acquire Kite Pharma  Inc    NASDAQ KITE   to foray in the emerging field of cell therapy  Kite is a pioneer in cell therapy having developed engineered cell therapies that express either a chimeric antigen receptor  CAR  or an engineered T cell receptor  TCR   depending on the type of cancer  The acquisition will diversify Gilead s portfolio and poise the company in a dominant position in cellular therapy space  We note that investors were expecting Gilead to announce an acquisition in the near term given the decline in the once lucrative HCV market due to competitive pressure 
Zacks Rank
Gilead currently carries a Zacks Rank  3  Hold   You can see  
5 Trades Could Profit  Big League  from Trump Policies
If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course  Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-09-22,Zacks Investment Research,https://www.investing.com/analysis/gileads-gild-epclusa-receives-label-expansion-in-canada-200214923,200214923
201539,423055,GILD,6 ETF Picks For September,opinion,"As we exited a lukewarm August and stepped into the final month of Q3  the investing cohort must have shifted its focus to the likely market movement in September  This is especially true given the month s cursed seasonality in the equity market 
September is historically the worst month of the year for stocks  According to   a consensus carried out from 1950 to 2016 has revealed that September ended up offering positive returns in 29 years and negative returns in 38 years  with an average return of negative 0 67   which is worse than any month 
Undesirable financial events like the start of the Great Depression in  or the fall of Lehman Brothers in 2008 all crept up in the month of September  Even this September bears the risk of considerable negative changes to the market in case geopolitical tensions between North Korea and the U S  heighten  and political uncertainty in the United States related to tax reforms and government shutdown escalates 
All these make it more important to pin point ETFs that could safeguard investors from any steep and sudden market swing as well as lead them to some gains 
PowerShares QQQ 
September may be ill reputed in terms of stock returns  but this time the month opened up with a deluge of upbeat data points  First  at the end of August  the Commerce Department released Q2 economic growth data of 3  compared with its earlier estimate of 2 6   This was the best GDP growth since first quarter 2015  read    
And at the start of September  data showed that U S  manufacturing expanded in August at the quickest clip   This calls for growth investing  We are thus bullish on Nasdaq 100 ETF QQQ  Nasdaq Composite has already registered the largest  of the year on signs of economic strength and a bounce in biotech shares 
SPDR S P Biotech  MX XBI  ETF 
Biotech ETFs  especially those with a focus on cancer therapy  staged a great show in August in particular on Gilead s   NASDAQ GILD   buyout announcement of clinical stage biopharmaceutical company Kite Pharma   NASDAQ KITE     Plus  a CAR T treatment     has been approved for use in the United States lately  All these developments in the biotech sphere should bode well for the related ETFs  read    
VanEck Vectors Semiconductor ETF 
The usage of cryptocurrencies like bitcoin  Ethereum and Ripple are on a tear  Following its immense price rise   has also jumped into this area with the launch of its own virtual coin called  WhopperCoin  in Russia  read    
Since mining of cryptocurrencies needs the usage of semiconductors  this part of the technology sector should perform well in September  In any case  semiconductor is the value centric traditional tech area that is likely to have an upper hand in an edgy investing environment  Moreover  the semiconductor space is  rapidly with a number of deals announced lately 
iShares Edge MSCI Multifactor Global ETF 
Since U S  equities have a record of underperformance in the month  investors can have a look at the global ETF  This way  investors can mitigate certain risks  Notably  the global economy is on an upward trajectory  And the fund looks to track the global developed and emerging market large  and mid cap stocks chosen on the basis of value  quality  momentum  and low size scores  read    
WisdomTree Europe Small Cap Dividend ETF  
The Euro zone economic growth has looked up this year  The region grew  sequentially in Q2 following 0 5  expansion in the previous period  Despite this positive sentiment  a rising euro might be a deterrent  So  we have chosen a small cap Europe ETF   DFE   which is less susceptible to a rising euro 
Small caps better reflect the uptick in the domestic economy  And with the benchmark U S  Treasury yield loitering under 2 2   it would be intriguing to go for a higher yielding pick  The fund yields about 2 66  annually 
iShares S P Moderate Allocation Fund 
Finally  we would like to pick a full fledged defensive ETF like AOM  The fund takes a fund of funds approach and is a combination of bonds and global stocks  Equities make up about 45  of the fund followed by 26  government or Treasury bonds  The U S  accounts for about 62  of the portfolio while Japan  5 7   and the U K   4   take the next two spots 
Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2017-09-05,Zacks Investment Research,https://www.investing.com/analysis/6-etf-picks-for-september-200211559,200211559
201540,423056,GILD,Kymriah  First CAR T Therapy Approved  4 Pharma Stocks In Focus,opinion,"Of late  biotechnology and pharmaceutical companies are investing in immuno oncology research therapies as it remains a key area of focus  thanks to its vast growth potential  Last week  the immuno oncology space grabbed investors  attention with the FDA approving Novartis AG s   NYSE NVS   breakthrough gene transfer treatment  Kymriah  tisagenlecleucel  suspension for the treatment of patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia  ALL  that is refractory or in second or later relapse 
Kymriah  formerly CTL019  is the first chimeric antigen receptor T cell  CAR T  therapy approved  A novel immunocellular therapy and one time treatment  Kymriah uses patient s T cells to fight cancer 
While the long term impact of the treatment is yet to be evaluated  the approval opens up new frontiers in the treatment of cancer  To start with  CAR T uses patient s cells to identify and destroy cancer cells  thereby making it different from other small molecule or biologic therapies  During the treatment  T cells are drawn from a patient s blood  These cells are then reprogrammed in the manufacturing facility to create genetically coded cells to express a chimeric antigen receptor to recognize and fight cancer cells and other B cells expressing a specific antigen 
With the approval of Kymriah  investors have started to shift their focus on a number of companies which have been developing their pipeline candidates to remain afloat in the highly competitive environment 
4 Stocks That Warrant a Look
Kite Pharma Inc    NASDAQ KITE   is expected to receive approval for its CAR T therapy axicabtagene ciloleucel  axi cel  shortly  The Biologics License Application for the candidate was submitted in March 2017  The application was gr priority review in the United States and the FDA is expected to give a decision on Nov 29  2017  The candidate is also under review in the EU with a tentative approval expected in 2018  The candidate is being developed for the treatment of refractory aggressive non Hodgkin lymphoma  which includes diffuse large B cell lymphoma  transformed follicular lymphoma and primary mediastinal B cell lymphoma 
Given the likely approval and potential in the space  Gilead Sciences Inc    NASDAQ GILD   has inked a deal to acquire Kite Pharma for  11 9 billion  Kite Pharma s stock has moved up 297 0  year to date  which compares favorably with a 15  increase registered by the   The company presently carries a Zacks Rank  3  Hold   You can see  

Juno Therapeutics  Inc    NASDAQ JUNO   is also developing cell based cancer immunotherapies based on its CAR and high affinity TCR technologies to genetically engineer T cells to recognize and kill cancer cells   The company is currently conducting a phase I trial with JCAR017 in adult r r aggressive NHL  including r r DLBCL  and planning to file an IND in 2017 for a planned phase I II trial with JCAR017 in r r chronic lymphocytic leukemia  CLL   The company expects an approval in 2018  Shares of the company have rallied119 7  year to date  The company currently carries a Zacks Rank  4  Sell  

bluebird bio  Inc    NASDAQ BLUE   in collaboration with Celgene Corporation   NASDAQ CELG   is evaluating bb2121  a CAR T cell product candidate for the treatment of multiple myeloma in a phase I study   The company expects to initiate a phase I study to evaluate the safety and efficacy of bb21217  the next anti BCMA CAR T cell product candidate  Shares of the company have gained 105 0  year to date  The company presently carries a Zacks Rank  3 

ZIOPHARM Oncology  Inc    NASDAQ ZIOP   is developing CAR T cell therapies for advanced lymphoid malignancies  The company is currently enroling patients for an investigator led phase I study using second generation CD19 specific CAR  T cells with a revised CAR structure in patients with advanced lymphoid malignancies  Shares of the company have rallied 18  year to date  The company at present carries a Zacks Rank  3 

One Simple Trading Idea
Since 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars  This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ",2017-09-07,Zacks Investment Research,https://www.investing.com/analysis/kymriah-first-cart-therapy-approved-4-pharma-stocks-in-focus-200212020,200212020
201541,423057,GILD,Here s Where I ll Buy Gilead Sciences,opinion,After a monster surge of over 35  in the last few months  Gilead Sciences  NASDAQ GILD  put in a topping tail on Friday  Topping tails are bearish technical signals alerting investors to likely price reversal  Sure enough  Gilead Sciences fell on Monday  As an investor  I love Gilead Sciences  however the key is what entry price do I want to buy  The answer can be found in the stock chart  Once Gilead Sciences falls back to  76 50  it becomes a strong buy  There is a huge amount of technical support at that price ,2017-09-11,Gareth Soloway,https://www.investing.com/analysis/heres-where-ill-buy-gilead-sciences-200212623,200212623
201557,423073,GILD,Why Novatis   475K CAR T Cancer Treatment Is Actually Cheap,opinion,"The cancer treatment industry is celebrating a massive victory on Wednesday  as Novartis   NYSE NVS   received approval for its innovative new lymphoblastic leukemia treatment  making it the first approved CAR T therapy in the world 
After achieving unprecedented results in patients with this deadly form of cancer  Novartis  new therapy  which will be marketed as  Kymriah   was officially approved by the U S  Food and Drug Administration today 
Kymriah is an example of a CAR T therapy  CAR T is a newly emerging method of treating cancer that includes making genetic changes to a patient s immune T cells and reinjecting them into the body to attack cancer cells 
Unlike traditional medicines and treatments  each CAR T therapy must be individually tailored to a specific patient  For this reason  patients seeking Kymriah will have to travel to one of just 32 locations around the country that can administer the therapy  From there  the harvested cells are sent to a Novartis facility in New Jersey  where they are edited and then sent back 
And the logistics aren t the only thing that s challenging for patients looking to receive Kymriah  Indeed  Novartis has said that just one course of treatment will cost a staggering  475 000 
Nevertheless  the prevailing reaction from the market is that this price tag is actually quite cheap  all things considered  Kymriah left about 83  of trial participants with relapsed acute lymphoblastic leukemia cancer free after just three months 
On top of its effectiveness  Kymriah s initial cost is also quite a bit lower than analysts were expecting  In fact  Wall Street estimates for the therapy s opening price reached as high as  750 000 for just one dose 
For Novartis  this means that Kymriah won t be a massive revenue generator  There are only about 3 100 new cases of acute lymphoblastic leukemia each year  and most of these can be treated with traditional drugs  Nevertheless  this is a monumental achievement for the company 
And while Novartis is the first company in the world to receive regulatory approval for a CAR T treatment  it is hardly the only brand developing these cures  Earlier this week  we learned that biotech behemoth Gilead Sciences   NASDAQ GILD   was planning to acquire CAR T developer Kite Pharma   NASDAQ KITE   for a staggering  11 9 billion  also read    
Kite s lead CAR T candidate  axicabtagene ciloleucel  is currently under review by the FDA  Axicabtagene ciloleucel is expected to be approved as a treatment for aggressive non Hodgkin lymphoma  with a decision coming on or before November 29 
Elsewhere in the biotech space  companies like Juno Therapeutics   NASDAQ JUNO   and Bluebird Bio   NASDAQ BLUE   are working to develop CAR T therapies  Both of these researchers watched their stock prices skyrocket in response to the Kite buyout  as investors speculated that they could also become takeover targets soon 
Kymriah s approval marks the beginning of what could become a monumental moment for biotech investors  but more importantly  it is the first in what will hopefully be a long list of world changing cancer treatments 
Want more stock market analysis from this author  Make sure to follow   on Twitter 
4 Surprising Tech Stocks to Keep an Eye On 
Tech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without 
More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really take off ",2017-08-30,Zacks Investment Research,https://www.investing.com/analysis/why-novatis-475k-cart-cancer-treatment-is-actually-cheap-200210572,200210572
201558,423074,GILD,iFOREX Daily Analysis   August 30  2017,opinion,"On Tuesday the U S  Dollar fell to a new low since January 2015 against major global currencies  following increased geopolitical fears  after North Korea fired a missile over Japan on Monday 
Gold prices gave away some of the gains from Monday after reaching a new high year to date with high volatility in the precious metal amid fears of further escalations on the North Korean peninsula 
Oil traded again lower due to hurricane Harvey pushing demand down for crude oil as a significant amount of oil refinery capacity is impacted by the storm 
U S  equities traded up on Tuesday after positive consumer confidence data and support by resilient technology stocks 
Bitcoin rallied on Tuesday and was finally able to climb over the  4 500 level  Other cryptocurrencies had a calmer day with the Litecoin USD again slightly higher and having its fifth day in a row with a gain  Ripple USD was slightly down from its final level on Tuesday 
On Wednesday we expect the U S  to release the ADP employment report and current GDP figures  The U S  EIA is releasing details about oil and gasoline inventories which will be of special interest due to the disruptions caused by hurricane Harvey  The EU will release its data about the economic sentiment and Germany about its inflation 
EUR USD
The EUR USD  i  sharply rose on Tuesday reaching 1 20719 which was another all time high since January 2015 and temporarily passed the low from July 2012 at 1 20434 with ease before retracing below 1 20 
This new high was partially due to increased geopolitical instability as North Korea dared to fire a ballistic missile over Japanese Territory 
Statistics about consumer confidence in the U S  rose for August to 122 9  which was a significantly above market expectations and helped the Dollar recover 
On Wednesday traders will be looking at economic sentiment data from the EU and the German inflation while waiting for the publication of the U S  GDP figures 

Pivot  1 2035Support  1 1955 1 1915 1 1865Resistance  1 2035 1 2075 1 212
Scenario 1  ort positions below 1 2035 with targets at 1 1955   1 1915 in extension Scenario 2  above 1 2035 look for further upside with 1 2075   1 2120 as targets Comment  the RSI broke below a rising trend line 
Gold
On Tuesday Gold  i  marked again a new high at  1 331 15 since December last year  The rally was however short lived as traders appeared to be taking their profits leading to slight decline from Monday s closing price 
Among other factors for the rebound was the positive consumer confidence data from the U S  which eased investors  worries and led to an out flow from the safe haven asset 
Gold investors will be watching the geopolitical events in far east Asia carefully while waiting for the publication of GDP data from the U S  on Wednesday 

Pivot  1316Support  1300 1292 1285Resistance  1316 1321 1326
Scenario 1  short positions below 1316 00 with targets at 1300 00   1292 00 in extension Scenario 2  above 1316 00 look for further upside with 1321 00   1326 00 as targets Comment  the RSI shows downside momentum 
WTI Oil
Crude oil  i  traded lower for the second day in a row  amid mounting concerns over a decrease in demand for oil in the United States  after hurricane Harvey tore brought devastation to Texas and other southern states  closing down more than 16  of the United States  oil production 
Refineries which are key consumers of crude oil already shut down about 3 million barrel per day refining capacity 
Oil traders will be looking at the publication of the actual oil inventories by the EIA  nergy Information Administration  on Wednesday which will give a first look how the storm actually started to affect stockpiles 

Pivot  46 9Support  45 7 45 35 45Resistance  46 9 47 2 47 5
Scenario 1  short positions below 46 90 with targets at 45 70   45 35 in extension Scenario 2  above 46 90 look for further upside with 47 20   47 50 as targets Comment  the RSI is capped by a declining trend line 
US 500
The major U S  equity indices  i  all closed higher on Tuesday  pushed by bullish technology stocks while as investors shrugged off geopolitical tensions amid upside momentum to some part due to the positive U S  consumer confidence figures 
The move higher was particularly led by tech companies with the US Tech 100  NASDAQ  being up by over 1   Gilead Sciences  NASDAQ GILD  was up 1 41  as market participants continue to vie their plan to purchase Kite Pharma in a positive light 
Investors will be particularly looking at the GDP figures published early in the North American trading session 

Pivot  2438Support  2438 2433 2426Resistance  2449 2455 2460
Scenario 1  long positions above 2438 00 with targets at 2449 00   2455 00 in extension Scenario 2  below 2438 00 look for further downside with 2433 00   2426 00 as targets Comment  the RSI broke above a bearish trend line ",2017-08-30,iFOREX,https://www.investing.com/analysis/iforex-daily-analysis--august-30-2017-200210358,200210358
201559,423075,GILD,The Zacks Analyst Blog Highlights  Gilead Sciences  Kite Pharma  AbbVie s And Novartis AG,opinion,For Immediate ReleaseChicago  IL   August 30  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Gilead Sciences  Inc  NASDAQ   NASDAQ GILD       Kite Pharma  Inc   NASDAQ   NASDAQ KITE       AbbVie s  NYSE   NYSE ABBV      and Novartis AG  NYSE   NYSE NVS       Today  Zacks is promoting its   Buy   stock recommendations    Here are highlights from Tuesday s Analyst Blog  Gilead to Fly High with Kite Pharma AcquisitionBiotech giant Gilead Sciences  Inc   NASDAQ      announced that it will buy Kite Pharma  Inc   NASDAQ      to foray into the emerging field of cell therapy Terms of the Agreement As per the agreement  Gilead will pay  180 00 per share in cash at a transaction valued at approximately  11 9 billion  The price represents a 28  premium over the closing share price of Kite as of Aug 25  2017 The transaction was approved by shareholders of both companies and is expected to close by the fourth quarter of 2017  The acquisition is expected to be neutral to the bottom line by the third year and accretive thereafter Strategic BenefitWe note that Kite is a pioneer in cell therapy having developed engineered cell therapies that express either a chimeric antigen receptor  CAR  or an engineered T cell receptor  TCR   depending on the type of cancer  The most advanced therapy candidate in Kite s pipeline is axicabtagene ciloleucel  axi cel  which is being developed for the treatment of refractory aggressive non Hodgkin lymphoma  which includes diffuse large B cell lymphoma  DLBCL   transformed follicular lymphoma  TFL  and primary mediastinal B cell lymphoma  PMBCL   The Biologics License Application  BLA  for the candidate was submitted in Mar 2017 This CAR T therapy is currently under priority review in the United States and the FDA is expected to give a decision on Nov 29  2017  The candidate is also under review in the EU with a tentative approval expected in 2018  While Kite is prepared for a commercial launch in the United States as manufacturing preparation are complete  the company is currently building infrastructure in Europe  We remind investors that another pipeline candidate in clinical trials in both hematologic cancers and solid tumors is KITE 585  a CAR T therapy candidate that targets BCMA expressed in multiple myeloma Our TakeThe acquisition will diversify Gilead s portfolio and position the company in a dominant position in cellular therapy space We note that investors were expecting Gilead to announce an acquisition in the near term given the decline in the once lucrative hepatitis C  HCV  market due to competitive pressure  Gilead is known for its presence in the HCV market because of its blockbuster HCV drugs  Sovaldi and Harvoni  However  the HCV franchise is under pressure because of competition and pricing issues We note that Harvoni  Sovaldi and Epclusa face competition from AbbVie s  NYSE      Viekira Pak and Viekira XR  among others  Moreover  Gilead was sitting on  21 1 billion of cash and short term marketable securities  Hence  an acquisition announcement was lurking CAR T is manufactured for each individual patient using their own cells thereby making it different from typical small molecule or biologic therapies  During the treatment process  T cells are drawn from a patient s blood  These cells are then reprogrammed in the manufacturing facility to create T cells that are genetically coded to express a chimeric antigen receptor to recognize and fight cancer cells and other Bcells expressing a specific antigen While the deal might look expensive given the premium Gilead paid for Kite  the CAR T space is expected to be revolutionary in treatments for cancer   The CAR T space represents immense potential at this juncture and a potential approval of axi cell will be a significant boost for Gilead s prospects which has dampened of late Gilead s stock has declined 4 3  in the year so far  against the 9 3  Apart from Kite  Novartis AG  NYSE      is another company that is focussed on CAR T treatments   In July  the FDA Oncologic Drugs Advisory Committee  ODAC  unanimously recommended the approval of immunocellular therapy candidate CTL019  tisagenlecleucel  and a decision is expected shortly  September October  CTL019 could become the first CAR T cell therapy if approved  CTL019  an investigational CAR T therapy  is being evaluated for the treatment of relapsed or refractory  r r  pediatric and young adult patients with B cell acute lymphoblastic leukemia  ALL   A potential approval will also open new frontiers in the treatment of cancer by advancing immunocellular therapy for children and young adults with r r B cell ALL On the other hand  shares of Kite were up 28  on the news as the company will immensely benefit from Gilead s dominant position in the biotech space upon an anticipated approval for its lead candidate  In fact  this year so far  Kite Pharma s stock is up 297 1   which compares favorably with a 9 3  increase registered by the  Zacks RankGilead currently carries a Zacks Rank  2  Buy   You can see  Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing and exclusive of fees  it can turn thousands into millions of dollars But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month About Zacks Equity ResearchZacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year Follow us on Twitter  Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ,2017-08-30,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-gilead-sciences-kite-pharma-abbvies-and-novartis-ag-200210441,200210441
201560,423076,GILD,Juno Bluebird Hot Acquisition Targets After Kite Gilead Deal,opinion,Biotech giant Gilead Sciences  Inc  s   NASDAQ GILD    11 8 billion deal to buy CAR T cancer therapy designer  Kite Pharma  Inc    NASDAQ KITE   has made two other leading independent CAR T developers  Juno Therapeutics  Inc    NASDAQ JUNO   and Bluebird Bio  Inc    NASDAQ BLUE   hot takeover targets Terms of the Gilead Kite Pharma DealPer the agreement  Gilead will pay  180 00 per share in cash  The total transaction value is approximately  11 9 billion  The price represents a 28  premium over the closing share price of Kite Pharma as of Aug 25  2017 The transaction was approved by shareholders of both companies and is expected to close by the fourth quarter of 2017 While shares of Gilead have shot up 28   that of Gilead have gone up by almost 3  since the announcement  In fact  so far this year  Kite Pharma s stock is up 296 8 which compares favorably with a 9 7  increase registered by the  Why Kite Pharma                                  Kite Pharma s CAR T therapy axicabtagene ciloleucel for treating aggressive non Hodgkin lymphoma  NHL  is under priority review in the U S  A decision from the FDA is expected on Nov 29  We believe the solid efficacy profile demonstrated by the pivotal ZUMA 1 study of axicabtagene ciloleucel is likely to support the drug s approval this year  In Europe  a regulatory application was filed in July 2017 with an approval and launch expected next year According to the company  the initial market opportunity for axicabtagene ciloleucel includes about 7 400 and 7 000 addressable CAR T patients in the U S  and Europe  respectively  while 7 800 new cases are diagnosed in Japan every year and 25 000 in key urban eastern rural coastal areas of China Meanwhile  other studies with axicabtagene ciloleucel and additional candidates including KITE 585 and KITE 718 are also advancing The acquisition should diversify Gilead s portfolio beyond the struggling HCV franchise and position it to take share in the growing cellular therapy space  The HCV franchise is under pressure because of competition and pricing issues Other CAR T Therapy Makers in FocusCAR T is manufactured for each individual patient using their own cells  thereby making it different from typical small molecule or biologic therapies  During the treatment process  T cells are drawn from a patient s blood  These cells are then reprogrammed in the manufacturing facility to create T cells that are genetically coded to express a chimeric antigen receptor to recognize and fight cancer cells and other Bcells expressing a specific antigen While the deal might look expensive given the premium Gilead paid for Kite  the CAR T space is expected to be revolutionary in treatments for cancer   It represents immense potential at this juncture  thereby attracting the attention of big pharmas It goes without saying that following Kite Pharma s acquisition by Gilead  other small biotechs developing CAR T therapies like Juno and Bluebird may be bought by a larger biotech  probably by Gilead or even their biggest partner Celgene Corporation   NASDAQ CELG   Juno is developing JCAR017 in partnership with Celgene for NHL  utilizing the CAR T cell technology  Data presented in June demonstrated a 50  complete response in patients with relapsed or refractory aggressive cd19  NHL  The company plans to bring JCAR017 to the market for NHL as early as 2018 and for multiple indications by the end of 2019  In fact  shares of Juno are up almost 43  after the Kite Gilead deal was announced on buyout speculation  The company s shares are up 132 4  year to date Bluebird is developing anti BCMA CAR T cell therapy  bb2121  also in collaboration with Celgene  The candidate is only in phase I studies  However  data from an early stage refractory multiple myeloma study on bb2121 presented in June showed that 100  of the 15 evaluable patients in active dose cohorts achieved an objective response  Overall response rate  ORR  across all cohorts  n 18  was 89   The investment community believes that the data  though early stage  bode well for the candidate s future development  Shares of the company are up 66  this year so far Meanwhile  other small biotechs like Tesaro Inc    NASDAQ TSRO    Clovis Oncology Inc    NASDAQ CLVS   and Puma Biotechnology  Inc    NASDAQ PBYI    which have launched innovative cancer treatments recently  are also potential acquisition targets now 4 Surprising Tech Stocks to Keep an Eye On Tech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really take off ,2017-08-30,Zacks Investment Research,https://www.investing.com/analysis/junobluebird-hot-acquisition-targets-after-kitegilead-deal-200210439,200210439
201561,423077,GILD,Novartis  NVS  CAR T Therapy Kymriah Receives FDA Approval ,opinion,"Novartis AG   NYSE NVS   announced that the FDA has approved its breakthrough gene transfer treatment  Kymriah  tisagenlecleucel  suspension for the treatment of patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia  ALL  that is refractory or in second or later relapse Kymriah  formerly CTL019  is the first chimeric antigen receptor T cell  CAR T  therapy approved  A novel immunocellular therapy and one time treatment  Kymriah uses patient s T cells to fight cancer CAR T is manufactured for individual patients using their own cells thereby making it different from typical small molecule or biologic therapies  During the treatment  T cells are drawn from a patient s blood  These cells are then reprogrammed in the manufacturing facility to create genetically coded cells to express a chimeric antigen receptor to recognize and fight cancer cells and other B cells expressing a specific antigen The drug was developed in collaboration with the University of Pennsylvania In addition  the FDA has approved a Risk Evaluation and Mitigation Strategy  REMS  for Kymriah to inform and educate healthcare professionals about the risks that may be associated with Kymriah treatment Meanwhile  Novartis plans to make additional filings for Kymriah in the United Staes and EU later this year for Kymriah for the treatment of adult patients with r r diffuse large B cell lymphoma  DLBCL   In April  the FDA granted Breakthrough Therapy designation to Kymriah based on data from the JULIET study Novartis also teamed up with the United States Centers for Medicare and Medicaid Services  CMS  to improve efficiencies in current regulatory requirements to deliver value based care and ensure access for this specific patient population Kymriah will be manufactured for each individual patient using their own cells at the Novartis Morris Plains  New Jersey facility Our TakeThe approval is a major boost for Novartis given the potential in the CAR T therapy space   The approval opens up new frontiers in the treatment of cancer by advancing immunocellular therapy for children and young adults with r r B cell ALL which comprises approximately 25  of cancer diagnoses among children under 15 years old and is the most common childhood cancer in the United States An approval was in the cards as the FDA Oncologic Drugs Advisory Committee  ODAC  had unanimously recommended the approval of immunocellular therapy in Jul 2017 The approval will also boost Novartis  already strong oncology portfolio which boasts of Afinitor  Exjade  Jakavi  Zykadia  Tasigna  and Jadenu  Novartis is also working on the label expansion of Kymriah Novartis stock has rallied 14 9  in the year so far compared with the  s 11 1  gain Going forward  we expect that the approval of new drugs and label expansion of existing ones will bode well for Novartis even though stiff generic competition for key drugs like Gleevec continues to act as a major deterrent Earlier in the week  biotech giant Gilead Sciences  Inc    NASDAQ GILD   announced that it will buy Kite Pharma  Inc    NASDAQ KITE   to foray into the emerging field of cell therapy  Kite s axicabtagene ciloleucel  axi cel  is being developed for the treatment of refractory aggressive non Hodgkin lymphoma  which includes DLBCL  transformed follicular lymphoma  TFL  and primary mediastinal B cell lymphoma  PMBCL   The Biologics License Application  BLA  for the candidate was submitted in March 2017  This CAR T therapy is currently under priority review in the United States and the FDA is expected to give a decision on Nov 29  2017 Zacks Rank   Key Pick
Novartis currently carries a Zacks Rank  3  Hold   A better ranked stock in the healthcare sector is Aduro Biotech  Inc    NASDAQ ADRO   which carries a Zacks Rank  2  Buy   You can see  Aduro Biotech s loss per share estimates narrowed from  1 46 to  1 32 for 2017 and from  1 41 to  1 24 over the last 30 days  The company delivered positive surprises in two of the trailing four quarters with an average beat of 2 53  One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars  This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ",2017-08-30,Zacks Investment Research,https://www.investing.com/analysis/novartis-nvs-cart-therapy-kymriah-receives-fda-approval-200210800,200210800
201562,423078,GILD,iFOREX Daily Analysis   August 31 2017,opinion,"The U S  dollar continued its recovery from a 2 5 year low on Tuesday  supported by U S  economic data which surpassed economists  expectations 
With a GDP growth at 3  the U S  economy grew at its fastest pace in more than two years  while ADP employment data showed private sector payrolls up by 237 thousands compared to the expectations of only 185 thousands 
Gold further declined slightly after hitting an 11 month high on Tuesday  Oil was further down on Wednesday as EIA inventory figures showed higher than expected inventories of petrol and oil distillates  Combined with uncertainty when refineries in the storm affected south of the U S  would start operating again this led to fears that oil demand will stay down for some time 
Bitcoin USD fell on Wednesday after breaking the  4 500 level upwards and hitting new highs on Tuesday  while still holding prices over  4 500  Etherum continued its rally being now up almost by 20  in the last seven days and is coming close to its all time high from June this year 
On Thursday Germany and the EU is publishing its unemployment statistics  Canada will publish its current GDP data  The U S  is scheduled to release a wealth of economic statistics with figures to be published about personal income  consumer spending  jobless claims  price inflation  purchase manager confidence  PMI   house sales and details from the Federal Reserve s balance sheet 
EUR USD
EUR USD continued its drop from its recent high on Tuesday as U S  economic data reports in payroll and GDP data positively surprised investors 
ADP employment figures surpassed market expectations by over 50 thousands while the GDP growth with 3  surpassed market expectations by 0 2 percentage points 
Consumer price data released on Thursday from the EU and the U S  fill be one of the key points EUR USD traders will be watching 

Pivot  1 195Support  1 1865 1 1825 1 177Resistance  1 195 1 1985 1 203
Scenario 1  short positions below 1 1950 with targets at 1 1865   1 1825 in extension Scenario 2  above 1 1950 look for further upside with 1 1985   1 2030 as targets Comment  the RSI is mixed to bearish 
Gold
Gold extended its losses on Wednesday after an 11 month high on Tuesday  as the U S  dollar significantly reduced its losses from earlier this week as better U S  job and employment growth data reduced the demand for the safe haven commodity 
This economic data led in the eyes of market participant to an increased probability in a rate hike from the U S  Federal Reserve later this year 
U S  employment and inflation data published early in the North American trading session could give further insight in the state of the U S  economy and thus impact the demand for Gold 

Pivot  1316Support  1300 1296 1292Resistance  1316 1321 1326
Scenario 1  short positions below 1316 00 with targets at 1300 00   1296 00 in extension Scenario 2  above 1316 00 look for further upside with 1321 00   1326 00 as targets Comment  the RSI is mixed to bearish 
WTI Oil
Oil traded lower for the fourth day in a row even though according to EIA  Energy Information Administration  statistics the oil stockpiles dropped and surpassed market expectations 
The oil price was pressured by higher than expected stockpiles of processed oil products  distillates and petrol  as this increased worries of continued lower demand from oil processing plants in the U S whose countrywide capacity is already limited due to the effects of the tropical storm in the south east of the country 
Oil traders will be carefully watching the continued effect of hurricane Harvey s effect on the operation of oil rigs and processing plants in the U S 

Pivot  46 6Support  45 7 45 35 45Resistance  46 6 46 9 47 2
Scenario 1  short positions below 46 60 with targets at 45 70   45 35 in extension Scenario 2  above 46 60 look for further upside with 46 90   47 20 as targets Comment  the RSI is mixed with a bearish bias 
US 500
U S  equity indices traded higher on Wednesday  with the exception of the Dow Jones Industrial Average  US 30  which was very slightly down  Positive employment and GDP data from the U S  and strong biotech stocks helped to push the major equity indices in the green numbers 
Gilead Sciences  NASDAQ GILD  was up 7 21  as market participants viewed the announced take over bid for Kite Pharma on Monday with even optimism  Kite Pharma developed with its product  CAR T  a ground breaking new cancer therapy 
U S  consumer spending and jobless data could be determinant published on Thursday could give further insight into the U S  economy and impact equities 

Pivot  2445Support  2445 2438 2433Resistance  2465 2473 2480
Scenario 1  long positions above 2445 00 with targets at 2465 00   2473 00 in extension Scenario 2  below 2445 00 look for further downside with 2438 00   2433 00 as targets Comment  the RSI is bullish and calls for further upside ",2017-08-31,iFOREX,https://www.investing.com/analysis/iforex-daily-analysis--august-312017-200210634,200210634
201576,423092,GILD,Biotech ETFs Soar On Gilead Kite Deal ,opinion,"Gilead Sciences   NASDAQ GILD   showered gains on the biotech ETF world on August 28 by announcing the buyout news of Kite Pharma   NASDAQ KITE   for  11 9 billion  GILD shares gained over 1 2  while KITE shares surged about 28  on the day  responding to the super deal 
Kite Pharma is a clinical stage biopharmaceutical company  focused on the development and commercialization of cancer immunotherapy products  The company is developing a pipeline of eACT based product candidates for the treatment of solid and hematological malignancies 
The deal marks Gilead Sciences  biggest deal for a new cancer treatment that will help the company to look away from its receding sales of medicines for  infections and focus on some budding zones  Gilead said it will be a  180 per share all cash deal 
With this  Gilead will step into the new arena of oncology treatment   known as CAR T   which targets the body s own immune system to fight tumors  As per the source  Kite  doesn t have a treatment on the market yet  is awaiting U S  approval for a drug for non Hodgkin lymphoma  a type of blood cancer  
Since Gilead is yet to see prodigious success itself in cancer research  it had to go for an inorganic expansion to establish its presence in this apparently most wanted area  Needless to say  this megadeal acted as a cornerstone for the entire biotech space  read    
Inside the Participant Stocks  
Gilead has a Zacks Rank  2  Buy  with VGM  Value Growth Momentum  score of C  On the other hand  Kite Pharma has a Zacks Rank  3  Hold  with a VGM score of F  at the time of writing 
In this situation  targeting a basket or ETF approach would be more intriguing than single stock pick plays  First  through ETF ways  investors get to play the overall evolvement of the biotech space and certain downbeat VGM scores of GILD and KITE would not come in the way of investors  optimism 
After all  immune oncology is expected to rule the next era biotech trading  Like yesterday  biotech stocks saw some great trading about two months ago  when Clovis Oncology   NASDAQ CLVS   shares gained about 46 5  following the company s positive cancer drug data  read    
ETF Impact 
Kite Pharma has weights in the range of 4 5  to 6  in funds like ALPS Medical Breakthroughs ETF   SI SBIO    ARK Genomic Revolution Multi Sector ETF   Loncar Cancer Immunotherapy ETF  and PowerShares Dynamic Biotechnology and Genome   The funds gained about 3 8   5 3   6 2  and 2 5   respectively  on August 28  2017  Biotech ETFs like ARKG  Bioshares Biotech Clinical Trial   HM BBC    up 4 0   also hit a 52 week high  see  here  
Investors should note that Gilead Sciences has a considerable focus  in the range of 8  to 10   on VanEck Vectors Biotech ETF   LON BBH   and iShares Nasdaq Biotechnology ETF   which obviously got a spike from the said acquisition news  BBH and IBB were up 1  and 1 9   respectively  on August 28 
Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2017-08-29,Zacks Investment Research,https://www.investing.com/analysis/biotech-etfs-soar-on-gileadkite-deal-200210247,200210247
201577,423093,GILD,Juno Therapeutics  JUNO  Continues Gains After Gilead Kite Acquisition,opinion,Shares of Juno Therapeutics   NASDAQ JUNO   continued to soar on Tuesday  The stock has now gained nearly 40  since the announcement that fellow CAR T cancer therapy designer Kite Pharma   NASDAQ KITE   is being acquired by biotech behemoth Gilead Sciences   NASDAQ GILD    Along with Kite and Bluebird Bio   NASDAQ BLUE    Juno is a leader in the development of CAR T cancer treatments a therapy that includes making genetic changes to a patient s immune T cells and reinjecting them into the body to attack cancer cells  Kite is significantly further in the approval process than Juno and Bluebird  and its lead candidate  axicabtagene ciloleucel  is currently under review by the FDA  Axicabtagene ciloleucel is expected to be approved as a treatment for aggressive non Hodgkin lymphoma  with a decision coming on or before November 29  On Monday  Gilead announced that it was acquiring Kite for  11 9 billion in an all cash deal  The buyout valued Kite at  180 per share  a 29  premium to the company s closing price on Friday  also read       The acquisition of Kite establishes Gilead as a leader in cellular therapy and provides a foundation from which to drive continued innovation for people with advanced cancers   Gilead President and CEO John F  Milligan said in a statement  Of course  the acquisition immediately inspired speculation that Juno and Bluebird would also become takeover targets  With a market cap of just  3 8 billion  Juno would be the cheapest of the three CAR T leaders  however  the company recently took a step back in the approval process  In March  Juno announced that it was discontinuing development of its lead CAR T candidate  which had already reached Phase 2 development   Bluebird s CAR T program  bb2121  is still in Phase 1  but the drug has pretty encouraging data so far  Bluebird s market cap currently sits at about  4 9 billion  Interestingly  both Juno and Bluebird have partnerships with Celgene   NASDAQ CELG    another global biopharma giant  However  Bluebird s partnership only extends to its bb2121 project  so it could a more diversified buyout candidate especially considering that the company has another gene therapy program targeting beta thalassemia and sickle cell disease  Nevertheless  Juno might emerge as the lowest priced CAR T pure play right now  Want to know more about Kite  Read   and listen to the podcast below   Want more stock market analysis from this author  Make sure to follow   on Twitter Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ,2017-08-29,Zacks Investment Research,https://www.investing.com/analysis/juno-therapeutics-juno-continues-gains-after-gileadkite-acquisition-200210235,200210235
201578,423094,GILD,Gilead To Fly High With Kite Pharma Acquisition For  11 9B ,opinion,"Biotech giant Gilead Sciences  Inc    NASDAQ GILD   announced that it will buy Kite Pharma  Inc    NASDAQ KITE   to foray into the emerging field of cell therapy 
Terms of the Agreement 
As per the agreement  Gilead will pay  180 00 per share in cash at a transaction valued at approximately  11 9 billion  The price represents a 28  premium over the closing share price of Kite as of Aug 25  2017 
The transaction was approved by shareholders of both companies and is expected to close by the fourth quarter of 2017  The acquisition is expected to be neutral to the bottom line by the third year and accretive thereafter 
Strategic Benefit
We note that Kite is a pioneer in cell therapy having developed engineered cell therapies that express either a chimeric antigen receptor  CAR  or an engineered T cell receptor  TCR   depending on the type of cancer  The most advanced therapy candidate in Kite s pipeline is axicabtagene ciloleucel  axi cel  which is being developed for the treatment of refractory aggressive non Hodgkin lymphoma  which includes diffuse large B cell lymphoma  DLBCL   transformed follicular lymphoma  TFL  and primary mediastinal B cell lymphoma  PMBCL   The Biologics License Application  BLA  for the candidate was submitted in Mar 2017 
This CAR T therapy is currently under priority review in the United States and the FDA is expected to give a decision on Nov 29  2017  The candidate is also under review in the EU with a tentative approval expected in 2018  While Kite is prepared for a commercial launch in the United States as manufacturing preparation are complete  the company is currently building infrastructure in Europe  We remind investors that another pipeline candidate in clinical trials in both hematologic cancers and solid tumors is KITE 585  a CAR T therapy candidate that targets BCMA expressed in multiple myeloma 
Our Take
The acquisition will diversify Gilead s portfolio and position the company in a dominant position in cellular therapy space 
We note that investors were expecting Gilead to announce an acquisition in the near term given the decline in the once lucrative hepatitis C  HCV  market due to competitive pressure  Gilead is known for its presence in the HCV market because of its blockbuster HCV drugs  Sovaldi and Harvoni  However  the HCV franchise is under pressure because of competition and pricing issues 
We note that Harvoni  Sovaldi and Epclusa face competition from AbbVie s   NYSE ABBV   Viekira Pak and Viekira XR  among others  Moreover  Gilead was sitting on  21 1 billion of cash and short term marketable securities  Hence  an acquisition announcement was lurking 
CAR T is manufactured for each individual patient using their own cells thereby making it different from typical small molecule or biologic therapies  During the treatment process  T cells are drawn from a patient s blood  These cells are then reprogrammed in the manufacturing facility to create T cells that are genetically coded to express a chimeric antigen receptor to recognize and fight cancer cells and other Bcells expressing a specific antigen 
While the deal might look expensive given the premium Gilead paid for Kite  the CAR T space is expected to be revolutionary in treatments for cancer   The CAR T space represents immense potential at this juncture and a potential approval of axi cell will be a significant boost for Gilead s prospects which has dampened of late 
Gilead s stock has declined 4 3  in the year so far  against the 9 3  

Apart from Kite  Novartis AG   NYSE NVS   is another company that is focussed on CAR T treatments   In July  the FDA Oncologic Drugs Advisory Committee  ODAC  unanimously recommended the approval of immunocellular therapy candidate CTL019  tisagenlecleucel  and a decision is expected shortly  September October  
CTL019 could become the first CAR T cell therapy if approved  CTL019  an investigational CAR T therapy  is being evaluated for the treatment of relapsed or refractory  r r  pediatric and young adult patients with B cell acute lymphoblastic leukemia  ALL   A potential approval will also open new frontiers in the treatment of cancer by advancing immunocellular therapy for children and young adults with r r B cell ALL 
On the other hand  shares of Kite were up 28  on the news as the company will immensely benefit from Gilead s dominant position in the biotech space upon an anticipated approval for its lead candidate  In fact  this year so far  Kite Pharma s stock is up 297 1   which compares favorably with a 9 3  increase registered by the  

Zacks Rank
Gilead currently carries a Zacks Rank  2  Buy   You can see  
Zacks  10 Minute Stock Picking Secret
Since 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing and exclusive of fees  it can turn thousands into millions of dollars 
But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ",2017-08-29,Zacks Investment Research,https://www.investing.com/analysis/gilead-to-fly-high-with-kite-pharma-acquisition-for-119b-200210276,200210276
201591,423107,GILD,Are Glaxo s Successful New Drugs Enough To Drive Growth 	,opinion,GlaxoSmithKline plc   NYSE GSK   enjoys a diversified base and presence in different geographical areas  GlaxoSmithKline reshaped its business following the Mar 2015 completion of the three part  inter conditional transaction with Novartis AG   NYSE NVS    Under the deal  Glaxo sold its oncology assets to Novartis and acquired Novartis  Vaccines business  excluding influenza vaccines   Following the completion of the deal  Glaxo now intends to focus on its three core businesses   Pharmaceuticals  Vaccines and Consumer Healthcare The Pharmaceuticals and Vaccines business units of this Brentford  United Kingdom based pharma and consumer giant have performed significantly well  a trend which is likely to continue in the second half of the year Importantly  new products Tivicay and Triumeq  both HIV   Relvar Breo  Anoro  Incruse  Nucala  all respiratory  and Menveo  Bexsero  meningitis vaccines  are all doing well and should continue to perform well and boost revenues significantly  These new products generated 22  of Glaxo s Pharmaceuticals and Vaccine sales in 2016 and 29  in the first half of 2017 Going ahead  Glaxo expects new pharmaceutical and vaccine products including contributions from the yet to be approved Shingrix to deliver sales of  6 billion per annum by 2018  Glaxo is also working on expanding the label of marketed products like Nucala Despite the success of new products  Glaxo believes that its overall performance has been weaker than it would have liked due to some slow starts or missed launches  insufficient R D progress  stiff competition  genericization of some key drugs and pricing pressure along with slowing growth in emerging markets  In particular  pricing dynamics and competitive pressure are hurting sales of its top selling drug  Advair  Meanwhile  Advair is expected to face generic competition in the United States next year  which will further hurt sales Glaxo s shares have underperformed the this year so far  Glaxo s shares are up 5 5  during this period  comparing unfavorably with an increase of 6 4  for the industry To improve its performance  at the second quarter conference call held last month  Glaxo laid out plans to overhaul its R D efforts  New CEO  Emma Walmsley discussed plans to reallocate spending to high priority areas  By 2020  the company plans to terminate  partner or divest about 30 pre clinical and clinical programs and allocate 80  of capital to priority programs in two current areas   Respiratory and HIV infectious   and two potential areas   Oncology and Immuno inflammation Glaxo s promising pipeline candidates  at present  in late stage development or under regulatory review include Shingrix  prevention of shingles   regulatory application filed in both the U S  and the EU   Closed Triple therapy  COPD   regulatory application filed in both the U S  and the EU  asthma   phase III   two drug dolutegravir   rilpivirine regimen  HIV infections   under review in U S  and EU   dolutegravir   lamivudine  HIV infections   phase III  and cabotegravir  HIV prevention  monotherapy    phase III and HIV infection  in two drug regimen with rilpivirine    phase III  Glaxo announced renewed cost savings initiatives  It intends to focus on new business priorities  improve supply chain efficiency  simplify operations  improve procurement savings and reduce administrative costs  The company s extended cost reduction initiatives are expected to lead to additional  1 billion annual cost savings by 2020  The costs saved will be invested to support new product launches  strengthen the R D pipeline and to help mitigate pricing pressure on margins Glaxo carries a Zacks Rank  3  Hold   You can see  Stocks to ConsiderBetter ranked stocks include Gilead Sciences  Inc    NASDAQ GILD   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN    While Regeneron sports a Zacks Rank  1  Strong Buy   Gilead has a Zacks Rank  2  Buy  Regeneron s shares are up 30 4  this year so far  Estimates have risen by 15 2  for 2017 while that for 2018 have gone up by 6 8  over the past 30 days Shares of Gilead have risen 4  so far this year while estimates for 2017 and 2018 have risen by almost 7  and 0 9   respectively  over the past 30 days 4 Surprising Tech Stocks to Keep an Eye on Tech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really takes off ,2017-08-22,Zacks Investment Research,https://www.investing.com/analysis/are-glaxos-successful-new-drugs-enough-to-drive-growth-200208982,200208982
201592,423108,GILD,Pfizer s Ibrance In First Line Combo Breast Cancer Study,opinion,Pfizer  Inc    NYSE PFE   and six international cancer research groups are collaborating on a combination study to explore the use of Ibrance for first line treatment of advanced breast cancer The PATINA phase III study will evaluate Ibrance  a CDK 4 6 inhibitor  in combination with anti HER2 therapy and endocrine therapy versus standard therapy for the first line treatment of HR   HER2  metastatic breast cancer  The first patient in the study was randomized last month   About 500 patients are expected to be recruited worldwide in the study Ibrance is presently marketed for the treatment of HR   HER2  disease in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women  or AstraZeneca plc s   NYSE AZN   Faslodex  fulvestrant  in women whose disease has progressed following endocrine therapy  The drug is presently not approved for use in the HR   HER2  patient population Pfizer s shares have underperformed the  this year so far  Pfizer s shares are up 5 1  during this period comparing unfavorably with an increase of 6 4  for the industry Ibrance plays an instrumental role in driving Pfizer s revenues  The drug recorded sales of  1 53 billion in the first half of 2017  up 63  year over year   Pfizer is also exploring the possibility of expanding the label of its breast cancer drug  Ibrance  into recurrent and subsequent early breast cancer as well as several non breast cancer indications like pancreatic and head and neck cancers Meanwhile  Pfizer boasts a strong oncology pipeline  Its key cancer candidate  Bavencio avelumab got FDA approval for metastatic Merkel cell carcinoma  MCC  in Mar 2017 and for advanced bladder cancer in May  Bavencio is under review in the EU for MCC with a decision expected in the third quarter of 2017  Bavencio is being touted as a significant top line driver for this New York based pharma giant  Another cancer drug  Besponsa  inotuzumab ozogamicin  received FDA approval earlier this month as a monotherapy for the treatment of relapsed or refractory CD22 positive B cell precursor acute lymphoblastic leukemia  ALL   The drug was approved in the EU last month Meanwhile  other cancer candidates include talazoparib  advanced breast cancer  and dacomitinib  advanced lung cancer with EGFR activating mutations  At the Q1 conference call  Pfizer had mentioned that approximately 25 to 30 drug approvals are expected over the next five years  including around 15 products that have blockbuster potential Pfizer carries a Zacks Rank  3  Hold   You can see  Stocks to ConsiderBetter ranked pharma biotech stocks include Gilead Sciences  Inc    NASDAQ GILD   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN    While Regeneron sports a Zacks Rank  1  Gilead has a Zacks Rank  2  Buy  Regeneron s shares up 30 4  this year so far  Estimates have risen 15 2  for 2017 while that for 2018 have gone up by 6 8  over the past 30 days Shares of Gilead have risen 4  so far this year while estimates for 2017 and 2018 have risen almost 7  and 0 9   respectively  over the past 30 days 4 Surprising Tech Stocks to Keep an Eye on Tech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really takes off ,2017-08-22,Zacks Investment Research,https://www.investing.com/analysis/pfizers-ibrance-in-firstline-combo-breast-cancer-study-200209059,200209059
201593,423109,GILD,Roche  RHHBY  Hemophilia A Drug Granted Priority Review ,opinion,"Roche Holding  SIX ROG  AG   OTC RHHBY   announced that the FDA has accepted the company s Biologics License Application  BLA  and granted Priority Review for hemophilia A candidate  emicizumab The FDA has granted emicizumab prophylaxis  preventative  priority review as a once weekly subcutaneous treatment for adults  adolescents and children with hemophilia A with factor VIII inhibitors Priority Review designation from the FDA is generally granted to drugs that have the potential to provide significant improvements in the safety and effectiveness of the treatment  prevention or diagnosis of a serious disease The BLA for emicizumab was based on results from the phase III study  HAVEN 1  in adults and adolescents of 12 years or older  as well as interim results from the phase III study  HAVEN 2 study in children younger than 12 years of age We note that results from HAVEN 1 were published in The New England Journal of Medicine  NEJM  and results from both studies were presented at the 26th International Society on Thrombosis and Haemostasis  ISTH  Congress in July 2017 The FDA is expected to give a decision by Feb 23  2018  We remind investors that the FDA granted Breakthrough Therapy Designation for emicizumab in adults and adolescents with haemophilia A with inhibitors in September 2015 Meanwhile  Roche is evaluating emicizumab in patients with hemophilia A both with and without inhibitors and evaluating less frequent dosing regimens as well Roche s stock has lost 10 1  so far in 2017 against the  s 10 3  gain Along with emicizumab  Roche s hematology portfolio at present consists of MabThera Rituxan  Gazyva Gazyvaro and VenclextaTM VenclyxtoTM in collaboration with AbbVie  Inc   NYSE ABBV   along with a pipeline which has a small molecule antagonist of MDM2  idasanutlin RG7388  and polatuzumab vedotin A few other companies are also developing treatments for hemophilia A  Shire plc   NASDAQ SHPG   also filed an investigational new drug  IND  application with the FDA  seeking approval for recombinant factor VIII  FVIII  gene therapy candidate  SHP654  The drug will be used for the treatment of patients with hemophilia A 
Zacks Rank and Stock to Consider
Roche currently carries a Zacks Rank  3  Hold   A better ranked stock in the health care sector is Gilead Sciences  Inc    NASDAQ GILD    which carries a Zacks Rank  2  Buy   You can see  
Gilead s earnings per share estimates increased from  7 98 to  8 53 for 2017  over the last 30 days  The company delivered positive earnings surprises in three of the trailing four quarters  with an average beat of 8 18  
One Simple Trading Idea
Since 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars 
This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ",2017-08-23,Zacks Investment Research,https://www.investing.com/analysis/roche-rhhby-hemophilia-a-drug-granted-priority-review-200209408,200209408
201594,423110,GILD,Novartis  NVS  Receives EC Approval For Breast Cancer Drug ,opinion,"Novartis AG   NYSE NVS   announced that the European Commission  EC  has approved breast cancer drug Kisqali  ribociclib  The EC approved the drug in combination with an aromatase inhibitor for treatment of postmenopausal women with hormone receptor positive  human epidermal growth factor receptor 2 negative  HR  HER2   locally advanced or metastatic breast cancer as initial endocrine based therapy We remind investors that Kisqali is the first CDK4 6 inhibitor approved in Europe   An approval was in the cards as the Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  gave a positive opinion in June 2017 In March 2017  the FDA also approved Kisqali in combination with any aromatase inhibitor  as a treatment for metastatic breast cancer The drug in combination with letrozole was added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology  NCCN Guidelines  as a category 1 option for HR  HER2 postmenopausal metastatic breast cancer patients Novartis stock has rallied 13 0  in the year so far compared with the  s 11 3  gain Novartis has a strong oncology portfolio of drugs like Afinitor  Exjade  Jakavi  Zykadia  Tasigna  Jadenu and an improved formulation of Exjade The company is making significant progress on its immuno oncology pipeline  The FDA Oncologic Drugs Advisory Committee has unanimously  10 0  recommended the approval of Novartis  immunocellular therapy candidate CTL019  tisagenlecleucel  for the treatment of relapsed or refractory  r r  pediatric and young adult patients with B cell acute lymphoblastic leukemia  ALL   This provided a major boost to Novartis  CTL019 could become the first CAR T cell therapy if approved  A potential approval will also open new frontiers in the treatment of cancer by advancing immunocellular therapy for children and young adults with r r B cell ALL We note that Roche Holding  SIX ROG  AG   OTC RHHBY   is a leading company in breast cancer drugs with a strong portfolio of drugs like Herceptin  Perjeta and Kadcyla 
Zacks Rank   Key Picks
Novartis currently carries a Zacks Rank  3  Hold  
Some better ranked stocks in the healthcare sector include Gilead Sciences  Inc    NASDAQ GILD   and Aduro Biotech  Inc    NASDAQ ADRO    Both the stocks carry a Zacks Rank  2  Buy   You can see  
Gilead s earnings per share estimates increased from  8 31 to  8 75 for 2017  over the last 30 days  The company delivered positive earnings surprises in three of the trailing four quarters  with an average beat of 6 38  
Aduro Biotech s loss per share estimates narrowed from  1 46 to  1 32 for 2017 and from  1 41 to  1 24 over the last 30 days  The company delivered positive surprises in two of the trailing four quarters with an average beat of 2 53  
4 Surprising Tech Stocks to Keep an Eye OnTech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really takes off ",2017-08-24,Zacks Investment Research,https://www.investing.com/analysis/novartis-nvs-receives-ec-approval-for-breast-cancer-drug-200209637,200209637
201595,423111,GILD,Will Endo  ENDP  Continue To Disappoint Investors In 2017 ,opinion,"We issued an updated report on Endo International plc   NASDAQ ENDP   on Aug 24 
Endo  a global specialty pharmaceutical company focused on branded and generic pharmaceuticals  was formed following the acquisition of Paladin Labs 
Revenues from the Generics base business is under significant pressure due to intensifying consortium pricing pressures and additional competitive entrants and product discontinuations as well as discrete factors  including destocking and shifts in purchase timing due to market conditions  Revenues from the segment is projected to decline in the high single to low double digit percentage range in 2017 due to base business sales decline  partially offset by revenues growth in sterile injectables and new launch in alternative dosages which will be partially offset by growth in its sterile injectables and new launch revenues respectively 
Endo s Branded segment continues to be under pressure due to additional competitive entrants as well as a continuous rise in the number of public policy and regulatory actions including the recent CDC guidelines related to opioid prescribing and use and divestiture of Strenda 
In a major setback  Endo withdrew opioid pain medication Opana ER  oxymorphone hydrochloride extended release  from the market following FDA s request in June  In March 2017  the FDA Drug Safety Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees voted in the ratio of 18 to 8 and consented that reformulated Opana ER did not outweigh public health risks 
A few members stated that the benefits are now overshadowed by the continuing public health concerns around the product s misuse  abuse and diversion  In June  the FDA directed the company to remove the drug from the market  The move comes in wake of the widespread opioid abuse epidemic  The drug represented 4  of total 2016 revenues 
International revenues in 2017 is expected to decline in the mid to low 20  range  reflecting the divestiture of Litha and Somar 

Meanwhile  Endo stock has declined 46 7  in the year so far compared to the  s gain of 2 2  during the same period 
The company lowered is revenue guidance range by  70 million and now expects revenues in the range to be  3 38 billion to  3 53 billion  The guidance was lowered due to withdrawal of Opana ER and discontinuation of products associated with recently announced manufacturing restructuring 
Zacks Rank   Key Picks
Endo currently carries a Zacks Rank  5  Strong Sell   Some better ranked stocks in the healthcare sector include Regeneron Pharmaceuticals  Inc    NASDAQ REGN    Gilead Sciences  Inc    NASDAQ GILD   and Aduro Biotech  Inc    NASDAQ ADRO   
While Regeneron sports a Zacks Rank  1  Gilead Sciences and Aduro carry a Zacks Rank  2  Buy   You can see  
Regeneron s earnings per share estimates have increased from  10 52 to  13 81 for 2017 and from  12 10 to  14 54 for 2018 over the last 30 days  The company delivered positive earnings surprises in two of the trailing four quarters  with an average beat of 6 29  
Gilead s earnings per share estimates increased from  7 98 to  8 53 for 2017  over the last 30 days  The company delivered positive earnings surprises in three of the trailing four quarters  with an average beat of 8 18  
Aduro Biotech s loss per share estimates narrowed from  1 46 to  1 32 for 2017 and from  1 41 to  1 24 over the last 30 days  The company delivered positive surprises in two of the trailing four quarters with an average beat of 2 53  
4 Surprising Tech Stocks to Keep an Eye OnTech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without 
More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really takes off ",2017-08-25,Zacks Investment Research,https://www.investing.com/analysis/will-endo-endp-continue-to-disappoint-investors-in-2017-200209669,200209669
201605,423121,GILD,Gilead  GILD  NDA For HIV Combo Regimen Gets Priority Review,opinion,"Gilead Sciences  Inc    NASDAQ GILD   announced that the FDA has granted priority review for the company s New Drug Application  NDA  for an investigational  fixed dose combination of bictegravir  50mg   BIC   a novel investigational integrase strand transfer inhibitor  INSTI   and emtricitabine tenofovir alafenamide  200 25mg   FTC TAF   a dual NRTI backbone  for the treatment of HIV 1 infection The NDA was filed on Jun 12  2017  The FDA has set a target action date under the Prescription Drug User Fee Act  PDUFA  of Feb 12  2018 A marketing application for BIC FTC TAF is also under review in the European Union  and was validated by the European Medicines Agency  EMA  in July A potential approval is expected toboost Gilead s HIV portfoliofurther Gilead is a dominant player in the HIV market with an impressive portfolio for the same The newly launched TAF based products Genvoya  Odefsey and Descovy are performing well with strong adoption in both the U S  and EU  Genvoya has already become the most prescribed regimen for both treatment na ve and switch patients since its launch in Nov 2015  The TAF based regimens now represent 51  of total Gilead HIV prescription volume following the launch of Genvoya and Odefsey and Descovy in 2016  Genvoya is now the company s bestselling HIV product  surpassing both Truvada and Atripla since fourth quarter 2016  Genvoya is now the company s bestselling HIV product with a treatment na ve patient share of 41  Gilead expects use of Truvada for pre exposure prophylaxis  PrEP  to continue boosting sales of HIV franchise going forward  particularly in the U S  Strong uptake for Truvada for use in the pre exposure prophylaxis setting should also boost sales as the company saw a significant uptick in PrEP usage in 2017 with an estimated 136 000 patients using Truvada by the end of the second quarter Meanwhile  Gilead s stock has gained only 1 1  in the year so far  against the  gain of 6 1  The uptake in HIV franchise should help the company combat the persistent decline in HCV franchise due to competitive pressure  The HCV business saw some improvement in the second quarter  The HCV franchise was boosted by the FDA approval of Vosevi  HCV patient starts in the first half were better than expectations but should see a gradual decline in the second half due to increased competition Harvoni  Sovaldi and Epclusa has being facing competition from AbbVie s   NYSE ABBV   Viekira Pak and Viekira XR and Bristol Myers Squibb Company s   NYSE BMY   Daklinza  Competition as well as pricing pressure intensified further with the launch of Merck s   NYSE MRK   Zepatier 
Zacks Rank 
Gilead currently carries a Zacks Rank  2  Buy   You can see  
5 Trades Could Profit  Big League  from Trump Policies
If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-08-13,Zacks Investment Research,https://www.investing.com/analysis/gilead-gild-nda-for-hiv-combo-regimen-gets-priority-review-200207117,200207117
201606,423122,GILD,Mallinckrodt  MNK  Looks Strong On Acthar  Generics Weak,opinion,"We issued an updated report on Mallinckrodt plc   NYSE MNK   on Aug 14 Mallinckrodt develops  manufactures  markets and distributes branded and generic specialty pharmaceutical and biopharmaceutical products and therapies as well as nuclear medicine products The company has been undertaking strategic acquisitions and divestitures to evolve as a high performing specialty pharmaceutical company Acthar Gel  which became part of the company s portfolio following the Questcor acquisition  continues to drive revenues  It is currently approved for 19 indications but marketed for only 9 with a 3  patient penetration rate  Hence  Mallinckrodt is working on boosting Acthar sales in the approved indications including rheumatology and pulmonology as well as underserved patient populations In a bid to expand into the hospital growth platform  Mallinckrodt acquired privately held critical care company Ikaria  which added Inomax  a vasodilator used in conjunction with ventilatory support and other appropriate agents  to its portfolio  Currently  Inomax is Mallinckrodt s second largest product  The company estimates that it is a roughly  400 million business on a global basis The Cadence acquisition added Ofirmev to the company s specialty pharmaceuticals portfolio  thus expanding its pain management franchise  With Ofirmev in its portfolio  Mallinckrodt can target the adjacent acute care hospital market  Penetration rates on available surgical procedures are relatively low and hospitals systems continue to develop recovery standards after surgery protocols  which might benefit products like Ofirmev and enable patients to recover quickly after surgery  Growth of the drug is expected to be driven by expanded patient reach The company aims to focus better on its specialty pharmaceutical business after having sold its Nuclear Imaging business  The company also sold its Intrathecal Therapy business  On the other hand  the acquisition of hemostasis drugs   Recothrom Thrombin topical  recombinant   PreveLeak and Raplixa  fibrin sealant    from The Medicines Co    NASDAQ MDCO   has strengthened its growing hospital portfolio 
However  Therakos sales are down  Although the kit supply issue was resolved in the first quarter  the company underestimated the complexity of the conversion from the XTS to Cellex devices  resulting in lower than anticipated net sales Moreover  these transitional issues are expected to persist in the upcoming quarters The Specialty segment continues to face weakness as various product categories are witnessing stiff competition  which is hurting both their volumes and prices  The company expects double digit declines in revenues from this segment  In addition  continued expected weakness in this segment will adversely impact gross profit margins also Investors interested in the healthcare sector can consider some top ranked stocks like Gilead Sciences  Inc    NASDAQ GILD   and Aduro Biotech  Inc     NASDAQ ADRO   
Zacks  10 Minute Stock Picking SecretSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars 
But here s something even more remarkable  You can master this proven system without going to a single class or seminar  And then you can apply it to your portfolio in as little as 10 minutes a month ",2017-08-14,Zacks Investment Research,https://www.investing.com/analysis/mallinckrodt-mnk-looks-strong-on-acthar-generics-weak-200207315,200207315
201607,423123,GILD,Regeneron s  REGN  RSV Drug Suptavumab Fails NURSERY Trial,opinion,"Regeneron Pharmaceuticals  Inc    NASDAQ REGN   announced disappointing results from a phase III study  NURSERY Pre term on suptavumab  REGN2222   an antibody to respiratory syncytial virus  RSV  
The study was initiated in 2015 and completed enrolling patients in the first quarter of 2017  The double blind  placebo controlled global study enrolled 1 149 healthy pre term infants  Patients were randomized in a 1 1 1 ratio to one of the three study groups  suptavumab 30 mg kg as a single dose  suptavumab 30 mg kg administered as two doses 8 weeks apart  or placebo  Pre term infants in the study had a gestational age of less than 36 weeks and were 6 months old or younger at the beginning of the study 
The study did not meet its primary endpoint of preventing medically attended RSV infections in infants 
The FDA granted Fast Track designation to suptavumab for the prevention of serious lower respiratory tract disease caused by RSV  However  Regeneron plans to discontinue further clinical development of this antibody given the dismal results from the NURSERY study 
We remind investors that the company relies heavily on funding from Sanofi   NYSE SNY   for its immuno oncology research and development programs  However  Sanofi had earlier decided not to continue the co development of fasinumab  suptavumab  and trevogrumab 

Regeneron s stock has gained 28 7  year to date outperforming the  s 7 1  rally  
Meanwhile  Regeneron s second quarter results were impressive as both earnings and sales beat estimates on the back of strong Eylea sales which grabbed additional market share  Regeneron s key growth driver  Eylea  continues to drive revenues and the company is expanding the drug s label for additional indications  The increase in guidance was also encouraging 
Regeneron has co developed Eylea with the HealthCare unit of Bayer  DE BAYGN  AG   OTC BAYRY    The FDA s approval of Dupixent was a major boost to the company s portfolio and the company is working to expand its label Regeneron Pharmaceuticals  Inc  Price and Consensus
 
 
   Zacks Rank                                                                              
Regeneron currently carries a Zacks Rank  1  Strong Buy   Another top ranked stock in the healthcare sector is Gilead Sciences  Inc    NASDAQ GILD   which currently carries a Zacks Rank  2  Buy   You can see  
Gilead s earnings per share estimates increased from  7 93 to  8 53 for 2017  over last 30days following strong results in the second quarter  The company delivered positive earnings surprises in three of the trailing four quarters  with an average beat of 8 18  
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaries   but that should still leave plenty of money for regular investors who make the right trades early ",2017-08-16,Zacks Investment Research,https://www.investing.com/analysis/regenerons-regn-rsv-drug-suptavumab-fails-nursery-trial-200207695,200207695
201608,423124,GILD,Pfizer s  PFE  Besponsa Gets FDA Nod With A Boxed Warning,opinion,Pfizer  Inc    NYSE PFE   announced that its leukemia candidate  Besponsa  inotuzumab ozogamicin  has been approved by the FDA  though with a boxed warning on the label Pfizer s shares were down more than 1  on Thursday  So far this year  Pfizer s shares are up 4 5   comparing unfavorably with an increase of 13 8  for the   Besponsa has been approved as a monotherapy for the treatment of relapsed or refractory CD22 positive B cell precursor acute lymphoblastic leukemia  ALL   The drug was approved in the EU last month The U S  approval was based on data from a pivotal study  INO VATE ALL  which demonstrated that patients treated with Besponsa showed significant improvement in complete response  81  in Besponsa arm versus 29  for chemotherapy   thereby meeting the primary endpoint  The study  however  failed to reach statistical significance in the analysis of overall survival  OS  The median OS in the Besponsa arm was 7 7 months versus 6 2 months for patients treated with chemotherapy Importantly  the U S  label of the drug will include a boxed warning for hepatotoxicity i e  liver damage  including hepatic veno occlusive disease  VOD   The label will also have a warning related to increased risk of non relapse mortality in patients who take the medicine post hematopoietic stem cell transplantation  HSCT  We remind investors that inotuzumab ozogamicin was granted Breakthrough Therapy designation in the U S  for ALL Meanwhile  Pfizer boasts a strong oncology pipeline  Its key cancer candidate  Bavencio avelumab received FDA approval for metastatic Merkel cell carcinoma  MCC  in Mar 2017 and for advanced bladder cancer in May  Bavencio is under review in the EU for MCC with a decision expected in the third quarter of 2017  Bavencio is being touted as a significant top line driver for this New York based pharma giant  Meanwhile  Pfizer is exploring the possibility of expanding the label of its breast cancer drug  Ibrance  into recurrent and subsequent early breast cancer as well as several non breast cancer indications like pancreatic and head and neck cancers Other cancer candidates include talazoparib  advanced breast cancer  and dacomitinib  advanced lung cancer with EGFR activating mutations  At the Q1 conference call  Pfizer had mentioned that approximately 25 to 30 drug approvals are expected over the next five years  These include around 15 products that have blockbuster potential   Pfizer carries a Zacks Rank  3  Hold   You can see  Stocks to ConsiderBetter ranked stocks in the pharma biotech space include Regeneron Pharmaceuticals  Inc    NASDAQ REGN    Sanofi   NYSE SNY   and Gilead Sciences  Inc    NASDAQ GILD    While Regeneron sports a Zacks Rank  1  Strong Buy   Sanofi and Gilead have a Zacks Rank  2  Buy  Regeneron s shares up 26 4  this year so far  Estimates have risen 31 3  for 2017 while that for 2018 have gone up 20 2  inthe past 30 days Shares of Sanofi are up 21 6  year to date while estimates for 2017 and 2018 have risen 3 4  and 0 6   respectively  in the past 30 days Shares of Gilead have risen 2 6  so far this year while estimates for 2017 and 2018 have risen almost 7  and 0 9   respectively  in the past 30 days 4 Surprising Tech Stocks to Keep an Eye on Tech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really takes off ,2017-08-17,Zacks Investment Research,https://www.investing.com/analysis/pfizers-pfe-besponsa-gets-fda-nod-with-a-boxed-warning-200208177,200208177
201609,423125,GILD,Gilead  GILD  HCV Drug Vosevi Receives Approval In Canada,opinion,"Gilead Sciences  Inc    NASDAQ GILD   announced that Health Canada has granted a Notice of Compliance for its single tablet regimen  Vosevi  sofosbuvir 400 mg velpatasvir 100 mg voxilaprevir 100 mg   for the treatment of chronic hepatitis C virus  HCV  infection Vosevi has been approved for the treatment of HCV infection in adults with genotype 1  2  3  4  5 or 6 previously treated with an NS5A inhibitor containing regimen  or with genotype 1  2  3 or 4 previously treated with sofosbuvir containing regimen without an NS5A inhibitor  The drug is already approved in the U S Gilead is known for its presence in the HCV market because of its blockbuster HCV drugs  Sovaldi and Harvoni  The HCV portfolio received a huge a boost when Epclusa gained approval in both the U S   Jun 2016  and EU  Jul 2016  to become the first and only all oral  pan genotypic  STR consisting of Sovaldi and velpatasvir  an NS5A inhibitor   for the treatment of adults with genotype 1 6 chronic HCV infection  The approval of Voseviwill further boost Gilead s strong HCV portfolio However  the HCV franchise is under pressure as a result of competition and pricing issues  We note that Harvoni  Sovaldi and Epclusa  face competition from AbbVie s   NYSE ABBV   Viekira Pak and Viekira XR and Bristol Myers    NYSE BMY   Daklinza among others  Competition as well as pricing pressure intensified further with the launch of Merck s   NYSE MRK   Zepatier  Gilead s stock has moved up 1 0  in the year so far compared with the  gain of 7 3  Meanwhile  the HIV franchise maintains momentum driven by the rapid adoption of TAF based regimens in the U S  and EU  which now represent 51  of total prescription volume  Genvoya is now the company s bestselling HIV product with a treatment na ve patient share of 41   Strong uptake for Truvada for use in the pre exposure prophylaxis setting is expected to further boost sales  However  Gilead will lose exclusivity for Viread in 2017 in some countries outside the U S  which will impact sales Zacks Rank 
Gilead currently carries a Zacks Rank  2  Buy   You can see  4 Surprising Tech Stocks to Keep an Eye onTech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really takes off ",2017-08-17,Zacks Investment Research,https://www.investing.com/analysis/gilead-gild-hcv-drug-vosevi-receives-approval-in-canada-200208151,200208151
201610,423126,GILD,AbbVie s HCV Combo Drug Mavyret Clinches Approval In Canada,opinion,AbbVie Inc    NYSE ABBV   announced that its pan genotypic regimen of glecaprevir pibrentasvir  G P   Mavyret  has been approved of in Canada for treating chronic hepatitis C virus  HCV  infection across all major genotypes  GT1 6  It is important to note that the ribavirin free Mavyret recently gained an approval in  the United States and the EU  The combination medicine is under priority review in Japan for the same indication AbbVie s shares have marginally outperformed the so far this year  The stock has rallied 11 5  compared with the broader industry s increase of 9 8  The approval in Canada was backed by data from nine registration studies in AbbVie s G P clinical development program  The clinical trials were conducted on more than 2 300 patients across major HCV genotypes  Data from these studies showed that eight weeks of treatment with G P achieved 97  cure rates across all major genotypes of chronic HCV Significantly  glecaprevir  GLE  is a potent protease inhibitor while pibrentasvir  PIB  is a new NS5A inhibitor  Glecaprevir was discovered under a collaboration agreement with Enanta Pharmaceuticals   NASDAQ ENTA   for HCV protease inhibitors Per the company s press release  three million Canadians are chronically infected with HCV  More than 10 000 new cases of hepatitis C were reported in 2012 with approximately 40  of patients estimated to be unaware of the disease  Also  while GT1 is the most common genotype in Canada  GT3 is the most difficult to treat and cure  Hence  the drug s approval is expected to provide the company access to a market with huge potential We remind investors that Gilead Sciences  Inc    NASDAQ GILD   launched Epclusa  the first all oral  pan genotypic  single tablet regimen for treating adults with genotype 1 6 HCV infection in the United States and the EU last year  This could lend a strong competition to Mavyret To those not informed  Merck   Co   Inc    NYSE MRK   is also evaluating an all oral triple combination therapy MK 3682B  a mix of MK 3682  grazoprevir and ruzasvir1  for treatment of chronic HCV genotype  GT  infection Pricing pressure in the HCV market is increasing  The company said that it experienced market share loss and price erosion due to competitive dynamics within the HCV arena  This downturn continues this year with Viekira  HCV treatment  sales expected to decline to  1 billion in 2017 AbbVie Inc  Price   Zacks RankAbbVie currently carries a Zacks Rank  3  Hold   You can see  4 Surprising Tech Stocks to Keep an Eye on Tech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really takes off ,2017-08-17,Zacks Investment Research,https://www.investing.com/analysis/abbvies-hcv-combo-drug-mavyret-clinches-approval-in-canada-200208128,200208128
201616,423132,GILD,Mallinckrodt  MNK  Tops Q2 Earnings  Generics Segment Weak ,opinion,"Mallinckrodt Public Limited Company   NYSE MNK   reported second quarter 2017 results wherein earnings beat expectations but sales missed the same 
The company reported adjusted earnings of  1 85 per share in the reported quarter  beating the Zacks Consensus Estimate of  1 73  Earnings were however down from the year ago figure of  2 03 due to continued pricing pressure within the Specialty Generics 
Net sales in the quarter came in at  824 5 million  down 4 9  year over year and missed the Zacks Consensus Estimate of  827 3 million 

Mallinckrodt s stock price has declined 17 9  in the year so far  compared with the  fall of 14  
Quarter in Detail
The company reports results under two segments   Specialty Brands and Specialty Generics 
Sales at the Specialty Brands segment were  594 5 million  up 0 9  from the year ago quarter  Acthar  Mallinckrodt s largest product  garnered sales of  319 4 million  up 7 1   Inomax  its second largest product  generated sales of  125 5 million  up 3 6   Ofirmev sales grew 7 1  year over year to  75 7 million 
Sales of the Therakos immunology platform were  51 2 million  down 2 5   Although the kit supply issue was resolved in the first quarter  the company underestimated the complexity of the conversion from the XTS to Cellex devices  resulting in lower than anticipated net sales  Moreover  these transitional issues are expected to persist in the upcoming quarters 
As expected  weakness in the Specialty Generics segment continues  The segment recorded sales of  216 million  down 18  but better than management s expectation due to the active pharmaceutical ingredients products and controlled substances and other products categories 
Adjusted selling  general and administrative expenses in the reported quarter increased 3 2  to  232 1 million  Meanwhile  research and development expenses declined 7 5  to  69 2 million 
During the second quarter  the company repurchased 2 4 million ordinary shares for  100 7 million under its share repurchase programs  bringing the total repurchased in the first half to 8 million 
2017 Guidance
The company reiterated its earnings guidance of  7 40 to  8 00 for 2017  The Zacks Consensus Estimate for 2017 is  7 53 
 Mallinckrodt PLC Price  Consensus and EPS Surprise
   Our Take
Mallinckrodt s second quarter results were mixed as the company beat on earnings but missed on sales as weaknesses in the generics segment persist  While Acthar sales continue to be strong on the back of increased formulary positions and access for appropriate patients in both the commercial and public environments  sales of Therakos is expected to decline 
The company is currently streamlining its business  The company aims to focus better on its specialty pharmaceutical business after having sold its Nuclear Imaging business  The company also sold its Intrathecal Therapy business  On the other hand  the acquisition of hemostasis drugs   Recothrom Thrombin topical  recombinant   PreveLeak and Raplixa  fibrin sealant    from The Medicines Co    NASDAQ MDCO   has strengthened its growing hospital portfolio 
Shares are down in pre market trading 
Zacks Rank   Key Picks
Mallinckrodt currently carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector are Aduro Biotech  Inc    NASDAQ ADRO   and Gilead Sciences  Inc    NASDAQ GILD    Both the stocks carry a Zacks Rank  2  Buy   You can see  
Gilead s earnings per share estimates increased from  7 92 to  8 53 for 2017  over the last 30 days following strong results in the second quarter  The company delivered positive earnings surprises in three of the trailing four quarters  with an average beat of 8 18  
Aduro Biotech s loss per share estimates narrowed from  1 46 to  1 36 for 2017 over the last 30 days  The company delivered positive earnings surprises in two of the four trailing quarters with an average beat of 2 53  
Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-08-08,Zacks Investment Research,https://www.investing.com/analysis/mallinckrodt-mnk-tops-q2-earnings-generics-segment-weak-200206053,200206053
201617,423133,GILD,Prothena  PRTA  Q2 Loss Narrows As Roche Makes  30M Payment,opinion,"Prothena Corporation plc   NASDAQ PRTA   reported a loss of 46 cents per share in the second quarter of 2017  narrower than the year ago loss of  1 18 and the Zacks Consensus Estimate loss of 89 cents Prothena Corporation PLC Price and EPS Surprise
    Moreover  quarterly revenues came in at  26 8 million  surpassing the Zacks Consensus Estimate of  18 9 million and were up from  0 3 million in the year ago quarter Prothena s stock has moved up 25 4  in the year so far compared with the  s gain of 8 7  Quarter in DetailThe increase in revenue was primarily due to achievement of a clinical milestone from Roche Holding  SIX ROG  AG   OTC RHHBY   of  30 0 million  of which  26 6 million was recognized as collaboration revenue and  3 4 million was recognized as an offset to research and development expenses  R D expenses were  34 0 million  up 5 2  year over year primarily due to higher clinical trial and personnel cost offset in part by lower external expenses for product manufacturing General and administrative expenses were  10 9 million  up 34 2  year over year due to higher personnel costs 2017 OutlookProthena expects net cash from operating and investing activities in the range of  160  170 million  The projected range includes the milestone from Roche earned in the second quarter of 2017 upon initiation of the phase II study of PRX002  The company expects to end 2017 with approximately  375 million in cash  cash equivalents and restricted cash  midpoint  Pipeline UpdatesProthena continues to progress with its pipeline candidates  The company is evaluating its lead candidate NEOD001 in the phase III VITAL Amyloidosis study in newly diagnosed treatment na ve patients with AL amyloidosis and cardiac dysfunction  Enrolment was completed in the VITAL study  The original target enrolment of 236 patients was exceeded and 260 patients have been randomized into the study  Prothena is also evaluating the candidate in a phase IIb study  PRONTO  in previously treated patients with AL amyloidosis and persistent cardiac dysfunction  The company completed enrolment in this study and top line results from the study are expected following the 12 month study period in the second quarter of 2018 Moreover  Prothena is evaluating PRX002  in collaboration with Roche  for the treatment of Parkinson s disease and other related synucleinopathies  The company initiated a phase II study  PASADENA  on PRX002 in patients suffering from Parkinson s disease which triggered a  30 million milestone payment from Roche to Prothena The company expects to report top line data from a phase Ib multiple ascending dose  proof of biology study on PRX003 in patients with psoriasis in Oct 2017 Alongside  Prothena is also working to advance PRX004 in a phase I study in patients with ATTR amyloidosis  The candidate is expected to enter clinic in mid 2018 Our TakeThe narrower than expected loss in the second quarter was encouraging  The company s efforts on developing its pipeline are encouraging  We expect investor focus to remain on further updates from its late stage candidate  NEOD001 Zacks Rank   Key PicksProthena currently carries a Zacks Rank  3  Hold  Some better ranked stocks in the health care sector are Aduro Biotech  Inc    NASDAQ ADRO   and Gilead Sciences  Inc    NASDAQ GILD    Both the stocks carry a Zacks Rank  2  Buy   You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here Aduro Biotech s loss per share estimates narrowed from  1 46 to  1 36 for 2017 over the last 30 days  The company delivered positive earnings surprises in two of the four trailing quarters with an average beat of 2 53  Gilead s earnings per share estimates increased from  7 92 to  8 53 for 2017  over the last 30 days following strong results in the second quarter  The company delivered positive earnings surprises in three of the trailing four quarters  with an average beat of 8 18  More Stock News  Tech Opportunity Worth  386 Billion in 2017From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ",2017-08-08,Zacks Investment Research,https://www.investing.com/analysis/prothena-prta-q2-loss-narrows-as-roche-makes-30m-payment-200206345,200206345
201626,423142,GILD,Gilead  GILD  Shares Pop On Q2 Earnings And Revenue Beats,opinion,"Gilead Sciences    NASDAQ GILD    just released its second quarter financial results  posting non GAAP diluted earnings of  2 56 and revenues of  7 14 billion  Currently  GILD is a Zacks Rank  3  Hold  and is up 2 44  to  76 00 per share in trading shortly after its earnings report was released 
Gilead 
Beat earnings estimates  Gilead reported GAAP diluted earnings of  2 33 per share and non GAAP diluted earnings of  2 56 per share  Adjusting for stock option expenses  the company posted earnings of  2 51 per share  beating the Zacks Consensus Estimate of  2 11 
Beat revenue estimates  The company saw revenue figures of   7 141 billion  crushing our consensus estimate  6 359 billion 
Total product sales came in at  7 05 billion for the quarter  while royalty  contract  and other revenues totaled  95 million  Revenues were down about 6 7  from the prior year quarter 
Antiviral product sales  which include sales of HIV  chronic hepatitis B  HBV   and chronic hepatitis C  HCV  products totaled  6 4 billion  down from  7 1 billion in the same period last year  The slump in this unit was due to lower sales of HCV products  while sales of HIV and HBV products actually grew year over year 
Research and development expenses came in at about  864 million  which was down from  1 48 billion last year 
Gilead updated its full year guidance  The company now expects revenues in the range of  24    25 5 billion  up from its previously announced range of  22 5    24 5 billion 
Here s a graph that looks at Gilead s recent earnings performance Gilead Sciences  Inc  Price  Consensus and EPS Surprise   Gilead Sciences  Inc  is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them  They have a broad based focus on developing and marketing drugs to treat patients with infectious diseases  including viral infections  fungal infections and bacterial infections  and a specialized focus on cancer 
Check back later for our full analysis on GILD s earnings report 
Want more stock market analysis from this author  Make sure to follow   on Twitter 
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaries   but that should still leave plenty of money for regular investors who make the right trades early ",2017-07-26,Zacks Investment Research,https://www.investing.com/analysis/gilead-(gild)-shares-pop-on-q2-earnings-and-revenue-beats-200203756,200203756
201627,423143,GILD,4 Drug Stocks In Focus This World Hepatitis Day ,opinion,"Every year on Jul 28  World Hepatitis Day  WHD  is observed to raise awareness about viral hepatitis  one of the leading causes of death across the world According to the World Health Organization  WHO   viral hepatitis caused 1 34 million deaths across the world in 2015 and many people remain unaware of being infected by the same  While there are five types of hepatitis  A  B  C  D and E   hepatitis B and C are the two main killers with 257 million people living with hepatitis B and 71 million people living with hepatitis C About 90  of people living with hepatitis B and 80  living with hepatitis C are unaware of their status  Hepatitis B and C together account for 80  of liver cancer cases across the world Considering these numbers  it is not a surprise that quite a few pharma and biotech companies are working on bringing innovative treatments in this area to the market  However  challenges in the hepatitis C virus  HCV  market exist in the form of intense competition and pricing pressure   Stocks in FocusHere is a look at some of the key players in the hepatitis B and or C markets Biotech major  Gilead Sciences  Inc    NASDAQ GILD   is perhaps the most well known name in the HCV market  HCV drugs include Harvoni  Sovaldi  Epclusa and the recently approved Vosevi while HBV offerings include Viread and Vemlidy However  the Foster City  CA based company has seen a lot of ups and downs in this market  Gilead s HCV franchise was a major revenue contributor bringing in multi billion dollar sales but increasing competition and pricing pressure resulted in a significant decline in HCV product sales in 2016  Even though Gilead recently raised its 2017 guidance for its HCV franchise  sales are nevertheless expected to witness a significant decline   Gilead launched an educational campaign in 2016 to encourage baby boomers to get tested  According to the company  there has been an 80  increase in HCV antibody screening by baby boomers since the campaign started resulting in an increase in diagnosis as well  The company estimates that about 190 000 people were newly diagnosed with HCV in 2016  up 32  from 2015 Gilead is conducting additional studies on Harvoni as well as Vemlidy and has an early stage HBV candidate in its pipeline  GS 9688  a TLR 8 agonist   Gilead is a Zacks Rank  2  Buy  stock  Year to date  YTD   the company s stock is up 4 7   lagging the 10  rally of the  it belongs to  You can see  

Large cap pharma company  Merck   Co   Inc    NYSE MRK    is another big name in the HCV market  According to information provided by Merck  about 3 5 million people in the U S  have chronic HCV infection  Merck s HCV portfolio comprises Zepatier  which was launched last year  PegIntron and Victrelis  However  the company s HCV franchise is not a major revenue generator  Earlier this year  Merck took a major impairment charge related to an HCV candidate that became a part of its pipeline following the 2014 acquisition of Idenix  The decision was taken based on changes to the product profile  as well as changes to the company s expectations for pricing and the market opportunity  Merck is a Zacks Rank  2 stock  YTD  the company s stock is up 8 2   lagging the 10 7  rally of the  it belongs to 

AbbVie Inc    NYSE ABBV   also has a major presence in the HCV market  The company s HCV products include Viekira Pak and Technivie  AbbVie is currently seeking approval for Maviret  an investigational  pan genotypic regimen of glecaprevir pibrentasvir  G P   The once daily ribavirin free treatment has the potential to provide a faster path to virologic cure for all major HCV genotypes  GT1 6   Maviret represents blockbuster potential and could help AbbVie gain major market share once approved and launched AbbVie is a Zacks Rank  3  Hold  stock  AbbVie stock has gained 14 6  YTD  performing better than the industry it belongs to 
Watertown  MA based Enanta Pharmaceuticals  Inc    NASDAQ ENTA   has a collaboration with AbbVie for its protease inhibitors   paritaprevir and glecaprevir  While paritaprevir is a key compound in AbbVie s direct acting antiviral  DAA  regimen Viekira Pak and its other 3 DAA and 2 DAA treatment regimens currently on the market for HCV  glecaprevir in combination with pibrentasvir  G P  Maviret  is currently under regulatory review  Enanta earns royalties from AbbVie on product sales  Meanwhile  Enanta is also working on developing its HBV pipeline    the focus is currently on core inhibitors with clinical candidate identification planned for 2017 Enanta is a Zacks Rank  3 stock  YTD  Enanta stock has gained 13 6   outperforming the 5 5  rally of the  it belongs to 
Bottom LineThe HCV market will continue to face challenges as more treatments enter the market resulting in increased competition and additional pricing pressure  In fact  HCV drugs have faced immense scrutiny due to their high prices  That said  the market nevertheless represents significant commercial opportunity  As per information provided by Enanta  the market for HCV therapies was worth about  16 billion in 2016  HCV patient starts usually witness a surge following the introduction of new drugs in the market  With a major part of HCV infected people remaining undiagnosed  there remains significant opportunity in this market as awareness increases and newly diagnosed patients seek treatment The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2017-07-28,Zacks Investment Research,https://www.investing.com/analysis/4-drug-stocks-in-focus-this-world-hepatitis-day-200204238,200204238
201628,423144,GILD,5 Undervalued Stocks For The Modern Day Investor,opinion,"Today s market is flooded with great companies to invest in  The following companies fulfill the set parameters to be considered as undervalued  We arrived at this conclusion using the   Every company on this list has been deemed fitting for the cyclical investor to invest as per the Modern Graham technique 
Non cyclical Investors are defined as investors who will make investment decisions without conducting enough research into investments  They will invest in ventures that show signs of the least amount of risk  Cyclical Investors are defined as investors who conduct thorough research into an investment  This research allows them to choose companies that offer a small amount of risk  If a company is fitting to the Non cyclical Investor  it is also acceptable for Cyclical Investors 
Navient Corp  NASDAQ NAVI 
This corporation is suitable for the Cyclical Investor  The Non cyclical Investor will be focused on the deficient earnings the company posted for the decade  The shrinking return history also caught his attention  The Cyclical Investor has no initial concerns  This makes him feel comfortable  and he proceeds with the research 
The corporation is undervalued after posting growth in its earnings which rose from 63 cents in 2012 to an astonishing  2 39 for 2016  This level of growth is ahead of the expected rate of 1 25  annual loss over the next decade  As a result  the ModernGraham model  shows estimates of inherent value above the price  During the assessment period  research into the company showed that it was trading below its Graham Number of  21 98  The company pays out dividends of 64 cents per share for a yield of 4 5   This makes it one of the best dividend paying stocks in the current market 
Gilead Sciences Inc  NASDAQ GILD  
Gilead Sciences is not an acceptable choice for the Non cyclical Investor because he will be put off by the faint current ratio  poor dividend history  and the inflated price book  P B  ratio  The only thing that the Cyclical Investor will concern himself with is the size of debt relative to the value of current assets  These factors seem positive for the Cyclical Investor  and he should feel contented to continue with analysis  The company appears to satisfy characteristics of an undervalued company  This is because of its growing EPSmg that went from  1 61 in 2012 to  8 69 in 2016  The valuation model the returns at an estimate of natural value above the price 
Michael Kors Holdings  NYSE KORS 
Kors Holdings is suitable choice for the Cyclical Investor  The Non cyclical Investor will only notice the inadequate earnings stability over the last decade  the poor return payment history  and the inflated P B ratio  The Cyclical Investor will focus on the lack of bonuses  Because of this  all Cyclical Investors should be okay with continuing with the analysis  As for valuation  the company appears to exhibit signs of being undervalued after posting improved EPSmg rates from 96 cents in 2013 to  4 07 for 2017  This kind of earnings growth is considered to be greater than the market s estimate of annual earnings of 1 92  for the next five to nine years
Linamar Corporation  TO LNR 
Linamar is an acceptable choice for the Cyclical Investor  This is because reason behind this is the Non cyclical Investor will only concentrate on the moderate current ratio and inadequate earnings posted over the last decade  The Cyclical Investor will choose to focus on the level of debt relative to the net value of current assets  From this approach all Cyclical Investors should be satisfied with progressing with their analysis  The company appears to be undervalued after posting positive figures in its EPSmg which rose from  2 22 in 2013 to  6 93 for 2017  The level of earnings growth demonstrated is better than the market s implied estimate  The valuation model returns an estimate of intrinsic value above the price 
LyondellBasell Industries NV  NYSE LYB 
LyondellBasell is suitable for the Cyclical Investor  The Non cyclical Investor is only focused on the insufficient earnings growth posted for the past 10 years and the poor return on investment history  The Cyclical Investor will notice the level of debt versus the net value of current assets  As a result  all Cyclical Investors should feel content proceeding with their analysis 
The company shows signs of being undervalued after posting favorable EPSmg from   939 34 in 2012 to  7 50 in 2016  This level of growth in earnings demonstrated supersedes the market s estimate of 0 5  growth in annual earnings over the next five to eight years  As a result  the valuation model shows estimates of congenital value above the expected price",2017-08-02,dmitry korolev,https://www.investing.com/analysis/5-undervalued-stocks-for-the-modern-day-investor-200204884,200204884
201629,423145,GILD,Regeneron  REGN  Beats On Q2 Earnings   Sales  Raises View,opinion,"Regeneron Pharmaceuticals  Inc    NASDAQ REGN   reported second quarter of 2017 results wherein both earnings and sales beat expectations on the back of strong performance of eye care drug Eylea 

Regeneron s stock has gained 29 9  year to date outperforming the  s 9 9  rally  Shares are up in pre market trading and we expect shares to gain further momentum 
The company reported earnings  including the impact of share based compensation expenses and tax adjustments  of  3 88 per share in the second quarter beating the Zacks Consensus Estimate of  2 67 Regeneron Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
 

   Excluding share based compensation expenses  Regeneron s earnings came in at  4 17 per share  up from  2 82 reported in the year ago quarter 
Total revenue in the second quarter increased 21 2  year over year to  1 47 billion driven by strong sales of eye treatment drug  Eylea  Revenues were above the Zacks Consensus Estimate of  1 36 billion 
We note Regeneron has co developed Eylea with the HealthCare unit of Bayer  DE BAYGN  AG   OTC BAYRY    The company is solely responsible for the U S  sales of the eye drug and is entitled to profits  However  it shares profits and losses equally with Bayer from ex U S  Eylea sales  except in Japan  where the company receives a royalty on net sales 
Quarterly Highlights
Net product sales increased to  924 1 million in the reported quarter  up 10 8  year over year  The majority of sales came from Eylea in the U S    919 million  up 10 6    Sales of Eylea in ex U S  markets were  542 million  up from  486 million reported in the year ago quarter 
Revenues also include Sanofi   NYSE SNY   and Bayer collaboration revenues of  432 million  compared with  355 million in the year ago quarter  Collaboration revenues from Sanofi were  222 1 million in the quarter  compared with  163 4 million a year ago  Praluent recorded global net sales of  46 million in the reported quarter  up from  24 in the year ago quarter   We note Praluent has been co developed in collaboration with Sanofi  Product sales for Praluent are recorded by Sanofi  while
Regeneron shares profits or losses from the commercialization of the drug 
Dupixent sales came in at  29 million  The drug was approved earlier in 2017 for the treatment of adults with moderate to severe atopic dermatitis  AD  
R D expenses decreased 8 9  while selling  general and administrative  SG A  increased 5 1  during the quarter 
2017 Outlook Updated
Based on a strong first half  the company raised its sales guidance for Eylea   In 2017  Regeneron expects U S  Eylea net sales to grow around 10   earlier guidance  growth in single digits   The company now expects adjusted unreimbursed
R D expenses in the range of  925  965 million  down from the earlier guidance of  950  1 025 million 
We note that the European Medicine Agency s Committee for Medicinal Products for Human Use  CHMP  rendered a positive opinion for the marketing authorization of Dupixent  recommending its approval for use in adults with moderate to severe atopic dermatitis who are candidates for systemic therapy in Jul 2017  Meanwhile  a phase III study of Dupixent in pediatric patients  6 11 years of age  with uncontrolled persistent asthma was initiated in second quarter 2017 
In May 2017  the FDA approved Kevzara for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have an inadequate response or intolerance to one or more disease modifying anti rheumatic drugs  DMARDs   The drug was also approved in Europe in Jun 2017 
In Jun 2017  the European Commission granted marketing authorization for Kevzara in combination with methotrexate  MTX  for the treatment of moderately to severely active rheumatoid arthritis in adult patients who have responded inadequately to  or who are intolerant to one or more DMARDs  Kevzara may be used as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate 
Our Take
Regeneron s second quarter results were impressive as both earnings and sales beat estimates driven by strong Eylea sales  The increase in guidance was also encouraging  Dupixent launch in the U S  for moderate to severe atopic dermatitisis progressing well and a potential approval in the EU in the second half of 2017 will further boost sales  Moreover  the company is also looking to expand Dupixent s label in uncontrolled asthma 
Zacks Rank  Key Pick
Regeneron currently carries a Zacks Rank  3  Hold   
A better ranked stock in the healthcare sector is Gilead Sciences  Inc    NASDAQ GILD   which currently carries a Zacks Rank  2  Buy   You can see  
Gilead s earnings per share estimates increased from  7 92 to  8 53 for 2017  over last thirty days following strong results in the second quarter  The company delivered positive earnings surprises in three of the trailing four quarters  with an average beat of 8 18  
More Stock News  Tech Opportunity Worth  386 Billion in 2017
From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without 
Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future  Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ",2017-08-03,Zacks Investment Research,https://www.investing.com/analysis/regeneron-regn-beats-on-q2-earnings--sales-raises-view-200205177,200205177
201630,423146,GILD,Infinity  INFI  Q2 Loss Wider Than Expected  View Intact,opinion,"Infinity Pharmaceuticals  Inc    NASDAQ INFI   reported a loss of 34 cents per share in second quarter 2017  wider than the Zacks Consensus Estimate loss of 22 cents  The company had reported a loss of 12 cents in the year ago quarter Infinity Pharmaceuticals  Inc  Price  Consensus and EPS Surprise

   Since Infinity does not have any approved product in its portfolio  the company earns revenues in the form of royalties  license and milestone payments as well as research and development  R D  support fees paid by its partners 
Infinity did not record any revenues during second quarter 2017  However  it recorded collaboration revenues of  9 5 million in the year ago quarter  related to Infinity s previous collaboration agreement with AbbVie Inc    NYSE ABBV   
Infinity s share price has increased 0 7  year to date compared with the  s gain of 1 0  

Quarter in Detail
In the reported quarter  R D expenses plummeted to  3 9 million from  52 9 million  The decline was mainly related to a decrease in clinical development expenses for duvelisib in addition to the company s 2016 restructuring activities 
General and administrative  G A  expenses were  6 2 million for the reported quarter  down from  15 7 million in the year ago quarter  The decrease was mainly due to the company s 2016 restructuring activities 
2017 Outlook Reiterated
Infinity expects net loss to be in the range of  40  50 million in 2017  The company anticipates ending 2017 with year end cash and cash equivalents and available for sale securities balance in the  40  50 million band  Moreover  Infinity expects that its existing cash and cash equivalents as of Jun 30  2017  should be adequate to fund the company s capital needs into the first quarter 2019 
Pipeline Update
Currently  Infinity is evaluating IPI 549 as a monotherapy and in combination with Bristol Myers Squibb Company s   NYSE BMY   Opdivo  nivolumab  in a phase I study in patients with advanced solid tumors 
The company completed an evaluation of escalating monotherapy doses of IPI 549 ranging from 10   60 mg QD once daily and has determined the 60 mg dose for evaluation in the expansion component of the study  The selection of the mentioned dose was based on pharmacokinetic and pharmacokinetic analyses  which showed that IPI 549 maintained full suppression of PI3K gamma at this dose level 
Further  data from the study also showed that the IPI 549 dosed at 60 mg QD was well tolerated  and no dose limiting toxicities were observed  Subsequently  the monotherapy expansion component of the study is now available for enrolment  The study will evaluate the safety and activity of IPI 549 dosed at 60 QD in approximately 25 patients 
Meanwhile  dose escalation evaluating IPI 549 in combination with Opdivo is currently ongoing  The company plans to initiate the combination expansion component of the study in the second half of 2017 
On the other hand  the company amended its license agreement with Takeda Oncology in Jul 2017 for IPI 549  Per the amended agreement  the company will no longer have an obligation to pay Takeda future royalties on worldwide net sales of selective inhibitors of PI3K gamma  including IPI 549  In lieu  Infinity issued unsecured convertible notes of  6 0 million to Takeda that mature in 2018 and accrues interest at an annual rate of 8  
Our Take
The wider than expected loss in the second quarter was disappointing  Infinity received a huge setback when AbbVie terminated their collaboration agreement for the development and commercialization of duvelisib  Hence  we expect investor focus on pipeline progress in the upcoming quarters 
Zacks Rank   Key Pick
Infinity currently holds a Zacks Rank  3  Hold   
A better ranked stock in the healthcare sector is Gilead Sciences  Inc    NASDAQ GILD   which currently carries a Zacks Rank  2  Buy   You can see  
Gilead s earnings per share estimates increased from  7 92 to  8 53 for 2017  over last 30days following strong results in the second quarter  The company delivered positive earnings surprises in three of the trailing four quarters  with an average beat of 8 18  
Today s Stocks from Zacks  Hottest Strategies 
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-08-04,Zacks Investment Research,https://www.investing.com/analysis/infinity-infi-q2-loss-wider-than-expected-view-intact-200205449,200205449
201640,423156,GILD,HCA Healthcare  HCA  Q2 Earnings  Will It Beat Estimates ,opinion,"HCA Healthcare  Inc    NYSE HCA   is scheduled to report second quarter 2017 results on Jul 25  before the market opens Last quarter  this hospital company posted in line results  It has  however  surpassed earnings estimates in three out of the last four quarters with an average positive surprise of 6 47  Let s see how things are shaping up for this announcement Q2 FlashbackThe company s commercial volumes have been stressed over the past few quarters  It has taken  efforts to build out its local networks and create greater patient access both from an outpatient facilities standpoint and a digital media standpoint to address the issue  We  however  don t expect to see any major improvement in this business in the second quarter Last quarter  the company reported the 12th consecutive quarter of equivalent admission growth for HCA and we expect the trend to continue in the second quarter HCA Healthcare consistently makes capital expenditure for the expansion of services and capacity in its large fast growing urban markets  In 2016  it incurred  2 76 billion in this regard and expects to invest  2 9 billion in 2017  The company has also made a number of acquisitions over the past many years to expedite growth  We believe these investments will generate top line growth by increasing business volumes Share bought back by the company during the to be reported will cushion the bottom line  The company has not paid regular dividend since its IPO in 2011  It prefers share buyback over dividend payment for allocating capital and will maintain its current policy on dividend payouts HCA Holdings  Inc  Price and EPS Surprise   Earnings WhispersOur proven model does not conclusively show that HCA Healthcare is likely to beat on earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank of  1  2 or 3 for this to happen  That is not the case here as you will see below 
Zacks ESP  HCA Holdings has an Earnings ESP of  2 78   This is because the Most Accurate estimate stands at  1 75 per share  below the Zacks Consensus Estimate of  1 80   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  HCA Holdings carries a Zacks Rank  3  Hold   which increases the predictive power of ESP  However  a negative Earnings ESP makes surprise prediction difficult We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks That Warrant a LookHere are some companies in the healthcare sector that you may consider as our model shows that these have the right combination of elements to post an earnings beat this quarter   Gilead Sciences  Inc    NASDAQ GILD   is expected to report second quarter 2017 earnings results on Jul 26  The company has an Earnings ESP of  3 32  and a Zacks Rank  3  You can see    Celgene Corporation   NASDAQ CELG   has an Earnings ESP of  0 62  and a Zacks Rank  3  The company is expected to report second quarter earnings results on Jul 27 Pfizer Inc    NYSE PFE   has an Earnings ESP of  1 54  and a Zacks Rank  3  The company is expected to report second quarter earnings results on Aug 1 
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-07-20,Zacks Investment Research,https://www.investing.com/analysis/hca-healthcare-(hca)-q2-earnings:-will-it-beat-estimates-200202632,200202632
201641,423157,GILD,What To Expect From Keryx  KERX  This Earnings Season ,opinion,Keryx Biopharmaceuticals  Inc    NASDAQ KERX   is expected to report second quarter 2017 results on Jul 27 Last quarter  the company missed expectations by 16 7   In fact  Keryx s performance over the last four quarters has been disappointing  The company reported a wider than expected loss in all the trailing four quarters  with an average negative surprise of 39 32  Keryx s share price has increased 20 6  year to date  outperforming the  11 2  rally Let s see how things are shaping up for the company this quarter Factors Influencing This QuarterApart from license fees  Keryx s top line comprise revenues generated by its only marketed product Auryxia  ferric citrate   Auryxia is approved as tablets to control serum phosphorus levels in patients with chronic kidney disease  CKD  on dialysis Notably  with Auryxia being the only approved product in Keryx s portfolio  the company is entirely dependent on it for growth  Launched in the U S  in late Dec 2014  Auryxia is still in its early stages of commercialization  However  Keryx is working on its commercial efforts for Auryxia  In fact  the company is currently working on gaining formulary status for the drug  In Mar 2017  the nation s largest Medicare Part D plan sponsor added Auryxia to its Medicare Part D plan formularies  With these formulary additions  95  of the patients taking a phosphate binder across Medicare Part D and commercial plans now have unrestricted access to the drug Additionally  it is working on contracting the remaining insurance providers to expand patient access to Auryxia  This should enable more contact with the prescribers  both current physicians and those who have not prescribed Auryxia  yet  Meanwhile  Keryx expanded its field based team to 95 sales representatives  which led to an increase in the number of dialysis patients on Auryxia Moreover  Keryx is working on expanding ferric citrate s  the compound name for Auryxia in additional indications  label to include the treatment of iron deficiency anemia  IDA  in patients with stage III V non dialysis dependent chronic kidney disease indication  NDD CKD  In Mar 2017  the FDA accepted the company s supplemental New Drug Application  sNDA  for Auryxia for review  PDUFA date  Nov 6  2017   If approved for this indication  Auryxia might be the first FDA approved oral medicine to treat IDA in this patient population  We believe a potential approval will significantly boost sales of Auryxia  going forward What Our Model IndicatesOur proven model does not conclusively show an earnings beat for Keryx this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  However  that is not the case here as you will see below Zacks ESP  Keryx s has an Earnings ESP of 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 17 cents You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Keryx s has a Zacks Rank  3  which increases the predictive power of ESP  However  0 00  ESP makes surprise prediction difficult for the quarter Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into an earnings announcement  Keryx Biopharmaceuticals  Inc  Price and EPS Surprise    Stocks to ConsiderHere are some health care stocks that you may want to consider  as our model shows that it has the right combination of elements to post an earnings beat this quarter Agenus Inc    NASDAQ AGEN   has an Earnings ESP of  5 56  and a Zacks Rank  2  The company is expected to release results on Jul 27  You can see  Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  3 32  and a Zacks Rank  3  The company is scheduled to release results on Jul 26 Intercept Pharmaceuticals  Inc    NASDAQ ICPT   has an Earnings ESP of  9 39  and a Zacks Rank  3   The company is expected to release results on Aug 3 Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge  With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research  It s not the one you think ,2017-07-20,Zacks Investment Research,https://www.investing.com/analysis/what-to-expect-from-keryx-(kerx)-this-earnings-season-200202705,200202705
201642,423158,GILD,Biotech Bull Is Back  4 Keys To Play It,opinion,"Since the biotechnology bubble burst in 2015  resulting in a 40  bear market  something has been building that I ve been waiting several quarters for    a resumption of the great  long term bull market 
This week  the Nasdaq Biotechnology Index ETF  IBB  surmounted a closing level that takes back half of its losses  I think we have a lot more room to go  and maybe even new highs eventually 
But the rules are different this time in this second big wave of the bio bull  You can t simply ride the next hot tip or momentum play  Your research and stock selection must have certain discipline  or else you ll get burned 
Here I share 4 keys in my research process and why they are so important 
1  Investment Bank Research
I read dozens of research reports every week from Wall Street s top investment analysts  Now  we all know that these analysts are conflicted from time to time as one side of the company is providing advisory or capital underwriting services for a fee while the  pure research  side is not supposed to be influenced by that business 
But for the most part  there are many good and un conflicted analysts devoted to their research  Many are PhDs in the life sciences or even have medical degrees and they care about the quality of their analysis  Reading their reports every week gives me an edge on understanding the most complicated investing in the world 
And it s how I decided to pull the trigger on Sarepta Therapeutics  SRPT  in May as they tackle a unique disease called Duchenne muscular dystrophy 
2  Big Brother Partnerships
How do you build a billion dollar business in medicine  Sometimes it takes a few hundred million dollars in R D  That s where big Pharma companies come in to help emerging ones with drug pipeline clinical trials that keep the FDA happy  The big firms are constantly looking for exciting new R D  often before it even leaves university labs 
When I see a big company    whether from traditional Pharma or Biotech    team up with a little guy  I know something good is in the pipeline and I start paying more attention to that potential breakthrough  If  big brother  helps get my target through Phase 2 clinical trials with positive results  the stock may already be on the launch pad 
Knowing the long term commitment of partner Sanofi  PA SASY  gave me the conviction to buy Regeneron  REGN  at  366 this year 
More      
                                                                                                      

The healthcare industry is on the cusp of a total transformation  Four unstoppable megatrends look to create exciting gains as their impact unfolds in the days ahead  The companies at the forefront of these trends could ultimately save millions of lives AND put big winners in your investment portfolio in the process 
Zacks has just identified what we consider the best ways to profit from this healthcare revolution and you can see them now  You can also access a new special report highlighting a soon to triple niche in the healthcare sector 
Don t delay  this special opportunity ends at midnight Sunday  July 23 

                                                                                                      
3  Medical Journals  Company Presentations  and KOL Circles
There are many great places that new research can be found and company presentations are some of the best  Company scientists know they can t just  pull the wool  over the eyes of Wall Street analysts  When they publish in peer reviewed academic journals or make presentations at industry conferences  there are just as many doctors in the room as number crunchers 
And those presentations often are placed on company websites where I can see the entire slide deck and watch video recordings  This is a great way to not only understand new science but also to be tuned in to the criticism from scientific peers  You can t really understand an R D thesis unless you can also point out its potential flaws 
This brings up a class of expert known as the KOL  or Key Opinion Leader  In BioPharma especially  there are hundreds of doctors and researchers involved at all levels of drug and disease R D whose opinions are widely respected in the global medical community  For doctors at the front lines taking care of their patients  who don t always have time to stay up to date on the latest research  the view of a KOL can often be an important influence in their decision to try a new treatment option 
The payoff here was greater confidence in my thesis to buy Juno Therapeutics  JUNO  in the low  20s on a low risk high reward bet they will be a game changer in the exciting field of immuno oncology 
4  Institutional Buying and Selling
Lastly  I still like to pay attention to what the big money is doing  There are many fund managers running tens of billions in investment war chests that are ear marked solely for the healthcare field  and some are focused entirely on biotech 
Many of these managers are some of the most serious and disciplined of medical sector investors  So  I pay attention to what they are buying and selling and I don t mind following their money trail if enough of my other criteria are in line 
Gilead Sciences  NASDAQ GILD   GILD  has been a sell for years now  But many have been bottom fishing in the belief that the hepatitis C juggernaut is steps away from finding its next blockbuster acquisition  I thought so too in the mid  60s this year 
Focus on the Long Term Drivers
As I explain often to those who follow my investment research and stock picks  we are pursuing the  megatrends  of healthcare investing  That s why I started a new portfolio this year dedicated to capitalizing on those long term drivers 
This portfolio service  called   gives you something of an inside track as the second wave of the Biotech bull market gets underway 
I have assembled a visionary portfolio of healthcare stocks across various medical sector industries  including 7 more Biotechs besides the four mentioned in this report 
Using the 4 keys of my research process  we are picking powerful assets  brands  and cash flow franchises that will come out on top for strategic healthcare investors 
Now you don t have to dig into medical journals or investment bank reports to pick the most promising healthcare stocks  With Healthcare Innovators  I ll do the research  bring you the most relevant information   in everyday language   and we ll go after exceptional long term gains together 
Plus  if you check out Healthcare Innovators before midnight on Sunday  July 23  you ll get access to a new special report highlighting a flourishing medical niche that is expected to grow from  4 7 billion to  13 1 billion in revenue by 2020 

Good Investing 
Kevin Cook
Kevin  Senior Stock Strategist at Zacks  is a leading expert in biotech and medical stocks  He now provides commentary and recommendations for Zacks  new investment portfolio ",2017-07-21,Zacks Investment Research,https://www.investing.com/analysis/biotech-bull-is-back:-4-keys-to-play-it-200202749,200202749
201651,423167,GILD,The Zacks Analyst Blog Highlights  Merck  Celgene  Gilead Sciences  Seattle Genetics And Vanda Pharmaceuticals,opinion,"For Immediate Release

	Chicago  IL   July 14  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Merck   Co   Inc   NYSE           Celgene Corporation  NASDAQ           Gilead Sciences  NASDAQ GILD   Inc   NASDAQ           Seattle Genetics  Inc   NASDAQ          and Vanda Pharmaceuticals Inc   NASDAQ          

	Today  Zacks is promoting its   Buy   stock recommendations     

Here are highlights from Friday s Analyst Blog  

5 Drug Stocks Poised to Beat Q2 Earnings Estimates 

	The pharma biotech sector has picked up this year after being battered by the drug pricing controversy in 2016  The first half has been pretty strong for companies in the space 

	The NYSE ARCA Pharmaceutical Index has risen almost 9 8  year to date  YTD  after declining almost 10  last year  NASDAQ Biotechnology Index is up 17 7  YTD after sliding 19 1  in 2016 
	The sector does have its share of challenges in the form of rising competition  high profile pipeline setbacks  slowdown in growth of mature products and the loss of exclusivity for certain key drugs  Though the drug pricing issue still prevails  investors  lately  are hoping that steep pricing will not be as damaging as feared previously 
	Nonetheless  strong performance of newer drugs  evolving pipelines  impressive clinical trial results  new drug approvals  continued strong performance of legacy products and rising demand are some of the factors that promise a sustained recovery in the sector 
	Meanwhile  there have been many more FDA drug approvals so far this year than in 2016  A total of 23 drugs have gained FDA approval YTD  beating the total of 22 for the whole of 2016  With acceleration in the drug approval process  more innovation and a surge in new drug approvals are expected 
	Though M A activities and collaborations deals have slowed down this year  chances are that they will pick up in the second half  With President Trump promising a major tax reform that will allow companies to bring back cash held overseas  acquisition activities are expected to pick up pace  Then again  the number of deals will still be less than the pharma industry  as it has been for many years 
	Finally  the Republican administration s vow to  repeal and replace  Obamacare bodes well for the sector s growth How to Pick Likely Q2 Winners
	Given the enormity of the healthcare space  selecting stocks that have the potential to beat estimates could appear to be quite daunting  But our proprietary methodology makes it fairly simple  One way to narrow down the list of choices this earnings season is by looking at stocks that have the combination of a favorable Zacks Rank   Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold    and a positive    More often than not  a positive earnings surprise delivered by a company leads to stock price appreciation 
	Earnings ESP is our proprietary methodology for identifying stocks that have high chances of surprising with their upcoming earnings announcement  It shows the percentage difference between the Most Accurate estimate and the Zacks Consensus Estimate  Our research shows that for stocks with this combination  the chance of a positive earnings surprise is as high as 70   You can uncover the best stocks to buy or sell before they re reported with our   

	Here are five healthcare stocks that are poised to beat estimates in the second quarter according to our methodology 

	Our first pick is healthcare bellwether Merck   Co   Inc   NYSE           This Kenilworth  NJ  based company has an Earnings ESP of  1 15  and a Zacks Rank  2  Buy   You can see   

	The Zacks Consensus Estimate for the second quarter is 87 cents per share  The company has consistently topped earnings expectations  In fact  Merck s earnings surpassed expectations in each of the last four quarters  with an average positive surprise of 4 36  
	Merck is scheduled to report results on Jul 28 
	Our next choice is biotech major  Celgene Corporation  NASDAQ          Carrying a Zacks Rank  3  the stock has an Earnings ESP of  1 86   The Zacks Consensus Estimate for the second quarter is pegged at  1 61 per share  This Summit  NJ based company has a pretty impressive earnings surprise track record  The average earnings surprise over the four trailing quarters is 3 01  
	Celgene is scheduled to announce results on Jul 27 Gilead Sciences  Inc    NASDAQ         too has an impressive track record with the company consistently beating earnings expectations  The company s earnings surpassed estimates in three of the last four quarters  with an average positive surprise of 3 52   It looks poised to beat expectations in the second quarter as well  This Foster City  CA  based company carries a Zacks Rank  3 and has an Earnings ESP of  1 45   The Zacks Consensus Estimate is pegged at  2 07 per share 
	Gilead is scheduled to report results on Jul 26 Seattle Genetics  Inc   NASDAQ          a biotechnology company is another solid bet  This Zacks Rank  3 stock has an Earnings ESP of  9 30   This Bothell  WA based company delivered an average positive earnings surprise of 8 46  over the trailing four quarters 
	Seattle Genetics is scheduled to release results on Jul 27  with the Zacks Consensus Estimate for the second quarter pegged at a loss of 43 cents per share 
	A small biopharmaceutical company Vanda Pharmaceuticals Inc   NASDAQ          makes it to our list of likely outperformers in the second quarter by virtue of its Zacks Rank  3 and an Earnings ESP of  30 0  

	The Zacks Consensus Estimate is pegged at a loss of 20 cents per share  Vanda is expected to report its results on Jul 26 Bottom Line

	Challenges in the form of competitive and pricing pressure will remain in the healthcare sector  However  a number of companies in the space have fared well  Picking some outperformers from the space  backed by a solid Zacks Rank and a positive Earnings ESP  could lead investors to gain this earnings season 

Strong Stocks that Should Be in the News

	Many are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  











	Follow us on Twitter  

	Join us on Facebook  NASDAQ FB   

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2017-07-13,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-merck,-celgene,-gilead-sciences,-seattle-genetics-and-vanda-pharmaceuticals-200201168",200201168
201660,423176,GILD,AbbVie s HCV Combo Drug Gets Positive CHMP Opinion In EU,opinion,AbbVie Inc    NYSE ABBV   announced that the European Committee for Medicinal Products for Human Use  CHMP  of the European Medicines Agency  EMA  has recommended marketing approval of its investigational  pan genotypic regimen of glecaprevir pibrentasvir  G P  The combination medicine is currently under accelerated assessment in the EU and priority review in the U S  and Japan for the treatment of all major chronic hepatitis C virus  HCV  genotypes  genotypes 1 6  with commercialization expected this year The candidate will be marketed by the trade name of Maviret  A decision from the European Commission is expected in the third quarter of 2017 If approved  the G P regimen will provide patients with a shorter duration eight week  once daily  ribavirin free treatment option So far this year  AbbVie s share price has increased 16 1   comparing favorably with a gain of 15  recorded by the Zacks classified industry Coming back to the latest news  Glecaprevir  GLE  is a potent protease inhibitor while pibrentasvir  PIB  is a new NS5A inhibitor  Glecaprevir was discovered under a collaboration agreement between AbbVie and Enanta Pharmaceuticals   NASDAQ ENTA   for HCV protease inhibitors The Marketing Authorization Application  MAA  in the EU was backed by data from eight registration studies in AbbVie s G P clinical development program  The clinical studies were conducted on more than 2 300 patients across major HCV genotypes and special populations in 27 countries  Data from the studies showed that eight weeks of treatment with G P achieved high SVR12 rates across all major genotypes of chronic HCV We remind investors that Gilead Sciences  Inc    NASDAQ GILD   launched Epclusa  the first all oral  pan genotypic  single tablet regimen for the treatment of adults with genotype 1 6 HCV infection  in the U S  and EU last year  This could pose strong competition to AbbVie s next generation HCV combo therapy  if approved Meanwhile  Merck   Co   Inc    NYSE MRK   is also evaluating an all oral triple combination therapy MK 3682B  a combination of MK 3682  grazoprevir and ruzasvir1  for the treatment of chronic HCV genotype  GT  infection  The candidate has also resulted in high SVR12 rates in GT1  GT2 and GT3 infected patients  who received the combination therapy for 12 or 16 weeks AbbVie carries a Zacks Rank  3  Hold   You can see  Sell These Stocks  Now Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These are sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ,2017-06-26,Zacks Investment Research,https://www.investing.com/analysis/abbvie's-hcv-combo-drug-gets-positive-chmp-opinion-in-eu-200197803,200197803
201661,423177,GILD,Galapagos Gilead Begin Phase II Study On Uveitis Candidate,opinion,"Galapagos NV   NASDAQ GLPG   has announced initiation of a new phase II study  evaluating its lead pipeline candidate filgotinib for treatment of adult patients with non infectious uveitis The study will be led by its partner Gilead Sciences  Inc    NASDAQ GILD    Note that  Galapagos had signed a collaboration agreement with Gilead in Dec 2015 to develop and commercialize filgotinib for inflammatory indications Shares of Galapagos have significantly outperformed the Zacks classified  industry so far this year  The stock has rallied 18 7  compared with the broader industry s decline of 2 2  The phase II trial is designed to evaluate the safety and efficacy of filgotinib in patients with active  non infectious uveitis  compared with placebo  The study will be conducted on approximately 110 patients  who will be administered filgotinib or placebo for 52 weeks  The primary outcome of this analysis will be measured by the proportion of subjects failing to respond to treatment by week 24  This trial is an addition to the other ongoing researches on filgotinib We remind investors that in Apr 2017  Galapagos had initiated three new phase II proof of concept studies  evaluating filgotinib in Sjogren s syndrome  ankylosing spondylitis  AS  and psoriatic arthritis  Earlier in Aug 2016  Gilead had initiated a phase III program  FINCH  on filgotinib to heal rheumatoid arthritis  RA  Apart from the FINCH program  Gilead s two more ongoing studies are  phase III assessment of filgotinib for treating Crohn s diseases and a phase II   III study for  curing ulcerative colitis  Both studies had commenced in the third quarter of 2016 Galapagos continues to progress on its cystic fibrosis  CF  candidate GLPG2737 with partner AbbVie Inc    NYSE ABBV    thus effecting a phase I review of the candidate which the company had initiated in Nov 2016  Notably  Galapagos and AbbVie had entered into a global collaboration agreement in Sep 2013  focused on the discovery  worldwide development and commercialization of potentiator and corrector molecules for treatment of CF Going forward  we expect investors  focus to remain on further pipeline updates from the company Galapagos NV Price

   Zacks Rank   Key Picks
Galapagos currently carries a Zacks Rank  3  Hold   A better ranked stock in healthcare sector is Bayer  DE BAYGN  AG   OTC BAYRY    sporting a Zacks Rank  1  Strong Buy   You can see  
Bayer s earnings per share estimates have inched up from  8 85 to  8 93 for 2017 and from  9 53 to  9 61 for 2018  over the last 30 days  The company has delievered positive earnings surprises in three of the four trailing quarters with an average beat of 10 25   Shares of Bayer have soared 23 4  so far this year 
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-07-05,Zacks Investment Research,https://www.investing.com/analysis/galapagos-gilead-begin-phase-ii-study-on-uveitis-candidate-200199331,200199331
201662,423178,GILD,Why I Bought 5 000 Shares Of Cara Therapeutics Stock,opinion,"I bought 5 000 shares of Cara Therapeutics  Inc   NASDAQ CARA  at  12 32 just minutes ago  The reasoning is mostly technical  as the stock chart is hitting major technical support and is extremely oversold  In addition  at such levels and with promising drug candidates  it becomes a possible buyout target for a big player like Gilead Sciences Inc  NASDAQ GILD  and others  In addition  the company is in the pain relief field  Any drug that is not an opioid can make a company extremely valuable considering the epidemic going on in the United States right now 
Please note  I may sell my Cara Therapeutics  Inc  shares at anytime  depending on market technical signals  My general upside target is  15 00 near term ",2017-07-11,Gareth Soloway,"https://www.investing.com/analysis/why-i-bought-5,000-shares-of-cara-therapeutics,-inc-$cara-200200189",200200189
201670,423186,GILD,Gilead  GILD  Submits NDA For HIV Combination Therapy Regimen,opinion,"Gilead Sciences  Inc    NASDAQ GILD   announced that it has submitted a New Drug Application  NDA  to the FDA for an investigational  once daily single tablet regimen containing bictegravir  50 mg   BIC  and emtricitabine tenofovir alafenamide  200 25 mg   FTC TAF  
The regimen is novel experimental integrase strand transfer inhibitor which is being evaluated for the treatment of HIV 1 infection in adults 
The data from the study showed that BIC FTC TAF has demonstrated high rates of virologic suppression and no treatment emergent resistance through 48 weeks in phase III trials among treatment na ve adult patients and among virologically suppressed adult patients who switched regimens 
The NDA is supported by encouraging data four phase III studies in which the regimen met its primary objective of non inferiority  We note that three of the ongoing studies are designed to explore the efficacy and safety of BIC FTC TAF compared with regimens containing GlaxoSmithKline s   NYSE GSK   Tivicay  dolutegravir   50mg   DTG  among treatment na ve patients and virologically suppressed patients switching from an existing antiretroviral regimen 
The fourth study is being conducted among virologically suppressed patients and compares switching to BIC FTC TAF versus on a suppressive regimen of two nucleoside nucleotide reverse transcriptase inhibitors and a boosted protease inhibitor 
Gilead plans to submit a marketing authorization application for the regimen in the European Union in the third quarter of 2017 
Gilead is a dominant player in the HIV market  with an impressive portfolio  The newly launched TAF based products Genvoya  Odefsey and Descovy are performing well  with strong adoption in both the U S  and EU  Genvoya has already become the most prescribed regimen for both treatment na ve and switch patients since its launch in Nov 2015 
Also  Genvoya has been listed as a preferred regimen in several HIV treatment guidelines  The TAF based regimens now represent 42  of total Gilead HIV prescription volume following the launch of Genvoya  Odefsey and Descovy in 2016  Genvoya is now the company s best selling HIV product  surpassing both Truvada and Atripla since fourth quarter 2016 
The uptake in HIV franchise should help the company combat the persistent decline in HCV franchise due to competitive pressure  Competition as well as pricing pressure has intensified further with the launch of Merck s   NYSE MRK   Zepatier 
However  Gilead s HIV products are not only facing generic threats but also steep competition primarily from Tivicay and Triumeq  Meanwhile  Gilead will lose exclusivity for Viread in 2017 in some countries outside the U S  which should impact sales 

Shares of Gilead underperformed the Zacks classified  industry in the last year with the stock losing 21 7  during this period  compared with the industry s decline of 4 9  
Zacks Rank   Key Pick
Gilead currently carries a Zacks Rank  3  Hold  
A top ranked stock in the healthcare sector worth considering is VIVUS  Inc    NASDAQ VVUS   which currently sports a Zacks Rank  1  Strong Buy   You can see  
VIVUS  loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 30 days  The company posted positive earnings surprises in each of the trailing four quarters  with an average beat of 233 69  
Zacks  2017 IPO Watch List 
Before looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-06-13,Zacks Investment Research,https://www.investing.com/analysis/gilead-(gild)-submits-nda-for-hiv-combination-therapy-regimen-200194982,200194982
201671,423187,GILD,Epizyme Provides Positive Interim Data On EZH2 Inhibitor,opinion,Epizyme  Inc    NASDAQ EPZM   announced positive interim data from an ongoing phase II study evaluating pipeline candidate tazemetostat  an oral EZH2 inhibitor  as a monotherapy in patients with relapsed or refractory follicular lymphoma  r rFL  or diffuse large B cell lymphoma  DLBCL  based on their EZH2 mutational status  The data were presented at the International Conference on Malignant Lymphoma  ICML  We remind investors that in the past one year  the candidate has been granted fast track designation for the treatment of patients with DLBCL with EZH2 activating mutations as well as for relapsed or refractory r rFL  either with type EZH2 or EZH2 activating mutations  The candidate also enjoys orphan drug designation for malignant rhabdoid tumors So far this year  Epizyme s shares are up 2 1   This compares unfavorably with the 3 1  increase registered by the Zacks classified  industry during this period The interim data demonstrated that treatment with tazemetostat had clinically meaningful benefit in FL patients as well as promising activity was observed in DLBCL patients  The FL study showed a 92  objective response rate  ORR  for patients with EZH2 activating mutations while almost a quarter of patients with EZH2 wild type achieved ORR  The study in patients with DLBCL with EZH2 mutations showed 29  ORR and is enrolling more patients The company s lead candidate  tazemetostat is also being evaluated both as monotherapy and in combination with other anti cancer agents for various form of non Hodgkin lymphoma  including Roche Holding  SIX ROG  AG s   OTC RHHBY   Tecentriq in DLBCL  The company has an agreement with Eisai Co  Ltd    OTC ESALY   for the development and commercialization of tazemetostat and any other EZH2 product candidates in Japan We note that there are a few treatments available including Roche s Rituxan and Gilead Sciences  Inc  s   NASDAQ GILD   Zydelig and several companies are developing their candidates for treating cancer targeting EZH2 However  we are concerned that the company s pipeline candidates are in early or mid stage studies and commercialization of any product is still years away subject to positive results and subsequent approval by the FDA  Any pipeline setback will have an adverse impact on the company s stock Epizyme  Inc  Price and Consensus   Zacks RankEpizyme carries a Zacks Rank  3  Hold   You can see  3 Stocks to Ride a 588  Revenue ExplosionAt Zacks  we re mostly focused on short term profit cycles  but the hottest of all technology mega trends is starting to take hold   By last year  it was already generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ,2017-06-14,Zacks Investment Research,https://www.investing.com/analysis/epizyme-provides-positive-interim-data-on-ezh2-inhibitor-200195432,200195432
201672,423188,GILD,Is Gilead Sciences A Great Stock For Value Investors ,opinion,"Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Gilead Sciences Inc    NASDAQ GILD   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Gilead Sciences has a trailing twelve months PE ratio of 6 13  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 compares in at about 20 32  If we focus on the stock s long term PE trend  the current level puts Gilead Sciences  current PE ratio below its midpoint over the past five years  with the number remaining stable over the past few months Further  the stock s PE also compares favorably with the Zacks classified Medical   Biomedical and Genetics sector s trailing twelve months PE ratio  which stands at 32 08  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that Gilead Sciences has a forward PE ratio  price relative to this year s earnings  of just 8 25  which is tad higher than the current level  So it is fair to expect an increase in the company s share price in the near term P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  Gilead Sciences has a P S ratio of about 2 94  This is a bit lower than the S P 500 average  which comes in at 3 14 right now  Also  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years If anything  GILD is in the lower end of its range in the time period from a P S metric  suggesting some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  Gilead Sciences currently has a Zacks Value Style Score of  A   putting it into the top 20  of all stocks we cover from this look  This makes Gilead Sciences a solid choice for value investors What About the Stock Overall Though Gilead Sciences might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of  F  and a Momentum score of  F   This gives GILD a Zacks VGM score or its overarching fundamental grade of  C    You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been unfavorable  The current quarter has seen five estimates go lower in the past sixty days  while the full year estimate has seen three up and three down in the same time period This has had a significant impact on the consensus estimate though as the current quarter consensus estimate has decreased by 3 3  in the past two months  while the full year estimate has declined almost 2 4   You can see the consensus estimate trend and recent price action for the stock in the chart below Gilead Sciences  Inc  Price and Consensus
    Despite the bearish analyst sentiments  the stock holds a Zacks Rank  3  Hold  Bottom LineGilead Sciences is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  However  with a sluggish industry rank  among Bottom 36  of more than 250 industries  and a Zacks Rank  3  it is hard to get too excited about this company overall  In fact  over the past two years  the Zacks Medical   Biomedical and Genetics industry has clearly underperformed the broader market  as you can see below So  value investors might want to wait for estimates and analyst sentiment to turn around in this name first  but once that happens  this stock could be a compelling pick 3 Top Picks to Ride the Hottest Tech TrendZacks just released a Special Report to guide you through a space that has already begun to transform our entire economy   Last year  it was generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for those who make the right trades early ",2017-06-15,Zacks Investment Research,https://www.investing.com/analysis/is-gilead-sciences-a-great-stock-for-value-investors-200195634,200195634
201673,423189,GILD,Gilead s  GILD  HBV Drug Vemlidy Receives Approval In Canada ,opinion,"Gilead Sciences Inc    NASDAQ GILD   announced that hepatitis B virus  HBV  drug Vemlidy has been approved in Canada 
Health Canada granted a Notice of Compliance  NOC  for Vemlidy 25mg tablets  a once daily treatment for adults with chronic HBV infection with compensated liver disease 
The approval was supported by positive data from the 48 week data from two international phase 3 studies among treatment na ve and treatment experienced adult patients with chronic HBV infection 
Vemlidy showed antiviral efficacy similar to and at a dose less than one tenth that of Gilead s other HBV drug  Viread  The data also showed that Vemlidy has greater plasma stability and delivers tenofovir to hepatocytes more efficiently compared to Viread  As a result  it can be administered at a lower dose  resulting in less tenofovir in the bloodstream which in turn leads to better renal and bone laboratory safety parameters compared to Viread 
Both studies met their primary endpoint of non inferiority to Viread  The study was based on the percentage of patients with chronic hepatitis B with plasma HBV DNA levels below 29 IU mL at 48 weeks of therapy  Moreover  patients in the Vemlidy arm also experienced numerically higher rates of normalization of blood serum alanine aminotransferase  ALT  levels 
We note that the European Commission granted marketing authorization to Vemlidy in Jan 2017  The drug was also approved by the FDA in Nov 2016  
The approval will strengthen Gilead s HBV portfolio which comprises Viread and Hepsara 
However  Gilead s HBV portfolio faces competition from Bristol Myers Squibb s   NYSE BMY   Baraclude and Novartis    NYSE NVS   Tyzeka Sebivo 
We note that Gilead is a leading player in both the HIV and HCV markets  However  the HCV franchise has been under pressure for a while now due to competitive pressure  This in turn has led to a sharp decline in share price 

Shares of Gilead have underperformed the Zacks classified  industry in the last year  with the stock losing 19 9  during this period  compared with the industry s gain of 2 0  
The HIV franchise of Gilead is performing well and should help the company combat the persistent decline in HCV franchise   
Zacks Rank   Key Pick
Gilead currently carries a Zacks Rank  3  Hold  
A better ranked stock in the healthcare sector worth considering is VIVUS  Inc    NASDAQ VVUS   which currently sports a Zacks Rank  1  Strong Buy   You can see  
VIVUS  loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 30 days  The company posted positive earnings surprises in each of the trailing four quarters  with an average beat of 233 69  
Looking for Stocks with Skyrocketing Upside  
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-06-20,Zacks Investment Research,https://www.investing.com/analysis/gilead's-(gild)-hbv-drug-vemlidy-receives-approval-in-canada-200196382,200196382
201682,423198,GILD,Merck s HIV Drug Gets Positive CHMP Opinion For Higher Dose,opinion,Merck   Co   Inc    NYSE MRK   recently announced that the 600 mg film coated formulation of its marketed drug  Isentress  raltegravir  in combination with other anti retroviral therapies  has received positive opinion from the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP   The drug is meant for the treatment of adults and pediatric patients with HIV 1 infection  weighing at least 40 kg  In such patients   adult or pediatric   the recommended dosage is 1 200 mg  comprising two 600 mg tablets once daily for the treatment of HIV 1 in treatment na ve patients or patients whose virus remains suppressed after treatment with an initial regimen of 400 mg of Isentress twice daily  Presently  Isentress is approved in a 400 mg twice daily formulation for the treatment of HIV 1 infection in adults A final decision on approval is expected in the second half of 2017 We remind the investors that the once daily formulation of Isentress  600 mg tablets  is currently under review in the U S  A decision is expected by May 27  2017 Shares of Merck have outperformed the Zacks classified  industry in the last one year  The stock has gained 16 1  during the period  while the broader industry witnessed an increase of 4 1  Coming back to the latest news  the positive opinion was supported by data from an ongoing phase III pivotal study  ONCEMRK  evaluating the efficacy and safety of Isentress in previously untreated adults with HIV 1 infection  In July last year  Merck announced positive efficacy and safety data from the study  After 48 weeks of treatment  Isentress  given as 2 x 600 mg once daily  was found to be statistically non inferior to the marketed formulation approved dose of Isentress 400 mg twice daily  each in combination therapy with Gilead Sciences Inc  s   NASDAQ GILD   Truvada We note that Isentress faces competitive pressure and is being impacted by slowing growth of the integrase class  Sales of Isentress declined 8  in 2016 and 10  in 2015 Merck   Company  Inc  Price    Zacks Rank   Key PicksMerck currently carries a Zacks Rank  2  Buy   Other top placed stocks in the health care sector include VIVUS  Inc    NASDAQ VVUS   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN    Each of these stocks sports a Zacks Rank  1  Strong Buy   You can see  VIVUS s loss per share estimates narrowed from 50 cents to 39 cents for 2017  over the last 30 days  The company posted positive earnings surprises in all of the four trailing quarters with an average beat of 233 69  Regeneron s earnings per share estimates increased from  10 16 to  10 52 for 2017 and from  10 90 to  12 10  over the last 30 days  The company posted positive earnings surprises in two of the four trailing quarters with an average beat of 0 45  Zacks  2017 IPO Watch ListBefore looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ,2017-05-22,Zacks Investment Research,https://www.investing.com/analysis/merck's-hiv-drug-gets-positive-chmp-opinion-for-higher-dose-200190605,200190605
201683,423199,GILD,Intercept s  ICPT  Liver Drug Ocaliva Approved In Canada ,opinion,"Intercept Pharmaceuticals  Inc    NASDAQ ICPT   announced that Health Canada has granted a conditional approval for Ocaliva  obeticholic acid  for the treatment of primary biliary cholangitis  PBC   when used in combination with ursodeoxycholic acid  UDCA  in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA We remind investors that in May 2016  Intercept received FDA approval for Ocaliva  in combination with UDCA  for the treatment of PBC  In Dec 2016  Ocaliva was approved in the EU for the same indication Intercept s share price movement in the last one year indicates that the stock has underperformed the Zacks classified  industry  The company s shares have lost 20 9  during this period  which compares unfavorably with the industry s 12  fall The initial uptake of Ocaliva has been encouraging and sales of the drug should pick up further in 2017  Approval in other countries will boost sales further Meanwhile  Ocaliva is being evaluated for other indications including non alcoholic steatohepatitis  NASH  and primary sclerosing cholangitis  PSC  The FDA recently approved a redesign of the phase III trial  REGENERATE on Ocaliva for the safety and efficacy in treating NASH patients with liver fibrosis  The company now needs to achieve only one co primary endpoint  either fibrosis improvement or NASH resolution as compared to the earlier target of achieving both  The company plans to complete enrolment for the interim analysis cohort in the REGENERATE trial by mid 2017  data readout in the first half of 2019  Meanwhile  Intercept also initiated a phase II study  CONTROL  Combination OCA aNd sTatins for monitoRing Of Lipids   on OCA  The study is being conducted to evaluate the effect of Ocaliva in combination with statin therapy on lipid metabolism in patients with NASH  Enrollment in the study was completed in the third quarter of 2016  with top line data expected in mid 2017 The company also plans to initiate a phase III trial on Ocaliva in NASH patients with cirrhosis in the second half of 2017  The company will also initiate a phase II trial on another candidate  INT 767  in NASH patients with fibrosis in the second half of 2017 We remind investors that some other companies like Novartis International   NYSE NVS   and Gilead Sciences  Inc    NASDAQ GILD   have FXR agonists in phase II or earlier stages of clinical or preclinical development that could be used to treat PBC  NASH and the other liver diseases 
Zacks Rank   Key Pick
Intercept currently carries a Zacks Rank  4  Sell   A better ranked stock in the healthcare sector is VIVUS  Inc    NASDAQ VVUS   which currently sports a Zacks Rank  1  Strong Buy   You can see  
VIVUS  loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 30 days  The company posted positive earnings surprises in each of the trailing four quarters  with an average beat of 233 69  
Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ",2017-05-28,Zacks Investment Research,https://www.investing.com/analysis/intercept's-(icpt)-liver-drug-ocaliva-approved-in-canada-200191973,200191973
201690,423206,GILD,Gilead  GILD  Misses Q1 Earnings And Revenue Estimates  Stock Drops,opinion,"Gilead Sciences   NASDAQ GILD   just released its first quarter fiscal 2017 financial results  posting earnings of  2 23 per share and revenues of  6 5 billion  GILD is a  2  Buy  on the Zacks Rank  and is down 1 66  to  6 45 per share in trading shortly after its earnings report was released 
Gilead 
Missed earnings estimates  The company reported earnings of  2 23 per share  falling short of the Zacks Consensus Estimate of  2 25 per share  This number excludes 18 cents from non recurring items 
Missed revenue estimates  The company saw revenue figures of  6 5 billion  missing the Zacks Consensus Estimate of  6 66 billion and declining 16 4  year over year 
Gilead reported total product sales of  6 4 billion for Q1  compared to  7 7 billion in the same period in 2016  Antiviral product sales  which include sales of its HIV  chronic hepatitis B  HBV  and chronic hepatitis C  HCV  products  were  5 8 billion for the first quarter 
Regionally  Product sales in Q1 were  4 5 billion in the United States   1 3 billion in Europe  and  661 million in other locations 
The company reiterated its full year 2017 guidance  Gilead expects net product sales in the range of  22 5 billion and  24 5 billion  and product gross margin between 86  and 88   Diluted EPS is forecasted in the range of 84 cents to 91 cents per share 
Here s a graph that looks at Gilead s price  consensus  and EPS surprise Gilead Sciences  Inc  Price  Consensus and EPS Surprise   Gilead Sciences  Inc  is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them  They have a broad based focus on developing and marketing drugs to treat patients with infectious diseases  including viral infections  fungal infections and bacterial infections  and a specialized focus on cancer  They have expertise in liposomal drug delivery technology  a technology that the company uses to develop drugs that are safer  easier for patients to tolerate and more effective 
The Best   Worst of ZacksToday you are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  From 1988 through 2015 this list has averaged a stellar gain of  25  per year  Plus  you may download 220 Zacks Rank  5  Strong Sells   Even though this list holds many stocks that seem to be solid  it has historically performed 6X worse than the market ",2017-05-02,Zacks Investment Research,"https://www.investing.com/analysis/gilead-(gild)-misses-q1-earnings-and-revenue-estimates,-stock-drops-200186620",200186620
201691,423207,GILD,Gilead  GILD  Beats On Q1 Earnings  Revenues Miss Estimates,opinion,"Gilead Sciences  Inc  s   NASDAQ GILD   first quarter 2017 earnings  including the impact of stock based compensation expenses  of  2 20 per share beat the Zacks Consensus Estimate of  2 18  However  earnings were down from  2 98 in the year ago quarter Moreover  total revenue in the reported quarter was  6 5 billion  down 16 5  year over year and missed the Zacks Consensus Estimate of  6 7 billion Shares of Gilead underperformed the Zacks classified  industry in the last one year with the stock losing 19 9  during this period  compared with the industry s decline of 1 4  HCV Franchise Disappoints Again  HIV ImpressesProduct sales came in at  6 4 billion  down 16 9  year over year  The decline was due to lower hepatitis C virus  HCV  sales  partially offset by higher sales across HIV and other therapeutic areas Antiviral product sales  which include Gilead s HIV and liver disease portfolios  came in at  5 8 billion in the reported quarter  down 18 7  HCV product sales  which include Harvoni  Sovaldi and the recently launched Epclusa  were  2 6 billion  down 39 5   The downside was mainly attributed to lower sales of Harvoni and Sovaldi across all major markets  partially offset by sales of Epclusa  launched in 2016  across various locations  Sales in the U S  declined sequentially due to lower Epclusa sales  resulting in lower inventory along with some loss of market share as a result of increased competition Sales of Harvoni declined 54 5  year over year to  1 4 billion in the reported quarter  The decline was mainly due to lower sales in the U S  Further  Sovaldi sales recorded a steep year over year decline of 75 4  to  313 million Epclusa garnered sales of  892 million in the reported quarter  lower than the  1 0 billion in the prior quarter  We note that Epclusa was launched in the U S  and Europe in June and Jul 2016 respectively Meanwhile  HIV and HBV product sales came in at  3 3 billion  up 13 8  year over year  The increase was primarily driven by continuous strong uptake of tenofovir alafenamide  TAF  based products such as Genvoya  which generated sales of  769 million  up from  563 million in the prior quarter  Descovy  which recorded sales of  251 million  up from  149 million in the prior quarter  and Odefsey  which registered sales of  227 million  up from  155 million in the prior quarter HIV treatments like Stribild and Complera Eviplera and Viread sales declined  Atripla sales tanked 33  to  452 million  while Truvada sales fell 20 4  to  714 million Other products like Letairis  Ranexa  AmBisome and Zydelig recorded sales of  211 million  up 20 6     153 million  up 6     92 million  up 6 9   and  35 million  down 28 5    respectively Research   development  R D  expenses declined 26 4  to  931 million due to the  impact of up front collaboration expenses in 2016 related to Gilead s license and collaboration agreement with Galapagos NV and impairment charges related to in process R D  On the other hand  selling  general and administrative  SG A  expenses were up 24  to  850 million due to higher branded prescription drug fee expense Adjusted product gross margin was 88 3   up from 87 2  in the year ago period 2017 Guidance ReiteratedGilead expects net product sales in the range of  22 5  24 5 billion  Non HCV product sales are projected between  15 billion and  15 5 billion  HCV product sales are projected between  7 5 billion and  9 0 billion  Adjusted R D expenses and adjusted SG A expenses are projected in the range of  3 1billion  3 4 billion and  3 1billion  3 4 billion  respectively  Adjusted product gross margin is estimated in the range of 86 88   Earnings per share are projected around 84 cents   91 cents Dividend and Share RepurchaseConcurrently  Gilead declared a cash dividend of 52 cents per share of common stock for second quarter 2017  The dividend is payable on Jun 29 to stockholders of record at the close of business on Jun 16  During the first quarter  the company paid cash dividends of  687 million and repurchased 7 9 million shares of stock for  565 million Gilead Sciences  Inc  Price and Consensus
    Our TakeAlthough the first quarter results beat on earnings  revenues missed expectations  The HCV franchise continues to be under competitive and pricing pressure leading to a massive decline in Harvoni and Sovaldi sales  The company expects that the persistent decline in HCV patient starts will be the primary factor behind the year over year decrease in revenues in 2017 along with increased competition which will impact patient share and pricing  This decline in patient starts is being driven by the evolving profile of patients that are in care  We note that Harvoni  Sovaldi and Epclusa  face competition from AbbVie s   NYSE ABBV   Viekira Pak and Viekira XR and Bristol Myers    NYSE BMY   Daklinza among others  On a positive note  Epclusa s uptake has been encouraging and the drug is now launched in all the five major markets of Europe  Meanwhile  the HIV franchise maintains momentum driven by the rapid adoption of TAF based regimens  The TAF based regimens now represent 42  of total Gilead HIV prescription volume following the launch of Genvoya and the launches of Odefsey and Descovy in 2016  Genvoya is now the company s bestselling HIV product  surpassing both Truvada and Atripla since fourth quarter 2016 Strong uptake for Truvada for use in the pre exposure prophylaxis setting should also boost sales as the company saw a significant uptick in PrEP usage in 2017 with an estimated 125 000 patients using Truvada by the end of the first quarter  However  Gilead will lose exclusivity for Viread in 2017 in some countries outside the U S  which should impact sales 
Zacks Rank   Key Pick 
Gilead currently carries a Zacks Rank  2  Buy     Another well placed stock in the healthcare sector is Infinity Pharmaceuticals  Inc    NASDAQ INFI   which currently carries a Zacks Rank  1  Strong Buy   You can see  
Infinity  loss estimates narrowed to  1 03 from  1 43 for 2017 over the past 60 days  The company recorded a positive earnings surprise in three of the last four quarters  the average being 36 64  Its share price increased 43 7  year to date 
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research  It s not the one you think ",2017-05-02,Zacks Investment Research,"https://www.investing.com/analysis/gilead-(gild)-beats-on-q1-earnings,-revenues-miss-estimates-200186873",200186873
201692,423208,GILD,After Gilead Earnings  Buy These Biotech Stocks,opinion,"Shares of Gilead Sciences   NASDAQ GILD   are down about 2 6  in midday trading Wednesday after the biotech giant s first quarter sales  of analyst estimates yesterday  leaving investors disappointed  The Foster City  California based company  known for its HIV AIDS and hepatitis C treatments  has lost almost 23  in value over the last year 
GILD Earnings
For the first quarter  Gilead posted earnings of  2 23 per share  which came in above the Zacks Consensus Estimate of  2 25 per share  This number excludes 18 cents from non recurring items  Total revenues of  6 5 billion  however  missed the Zacks estimate of  6 66 billion and declined 16 4  year over year 
Gilead reported total product sales of  6 4 billion for Q1  compared to  7 7 billion in the same period in 2016  Antiviral product sales  which include sales of its HIV  chronic hepatitis B  HBV  and chronic hepatitis C  HCV  products  were  5 8 billion for the first quarter 
Breaking its products down  Q1 sales of Truvada  Epclusa  and Solvadi all missed expectations  but sales of Genvoya surpassed Truvada for the first time  coming in at  769 million and beating analysts  projections  Gilead s hepatitis C drug Harvoni also topped expectations 
Gilead also said they had  34 billion in cash and equivalents at the end of the first quarter  Its CFO  Robin Washington  said in the company s earnings release that Gilead is focusing on pursuing external transactions this year  as its last major deal was in April 2016 
Other Biotech Stocks to Consider
Many stocks in the  have recovered from the losses they suffered last year  and despite the risk associated with them think of the many challenges related to drug approvals and the patenting process biotechs remain good options for investors looking for steady growth 
One company to consider is Enzo Biochem  Inc    NYSE ENZ    The company develops  manufactures  and markets products based on molecular biology and genetic engineering techniques to help treat cancer  diabetes  and cardiovascular diseases 
Enzo is a  2  Buy  on the Zacks Rank  which pairs well with its Value score of  B  and Growth score of  A   Its expected earnings growth for the current year is 40   and has an average earnings surprise of 39 17   Enzo has a market cap of roughly  407 million  and the stock has increased over 75  in value over the past one year 
Another stock to look at is Regeneron Pharmaceuticals   NASDAQ REGN    Based in Tarrytown  New York  Regeneron discovers  develops  and commercializes medicines for the treatment of serious medical conditions like eye diseases and colorectal cancer  among others 
The Zacks Rank   2  Buy  stock has beat earnings in three of the past four consecutive quarters  and expects earnings growth of over 72  for the current quarter  Sales are expected to grow 7 7  in the same time frame  earning the company its  A  Growth score  Regeneron is a huge company  with a current market cap of  42 65 billion  and REGN stock has gained just over 4 5  in the past one year 
Stocks that Aren t in the News Yet
You are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  Many of these companies are almost unheard of by the general public and just starting to get noticed by Wall Street 
They have been pinpointed by the Zacks system that nearly tripled the market from 1988 through 2015  with a stellar average gain of  26  per year ",2017-05-03,Zacks Investment Research,"https://www.investing.com/analysis/after-gilead-earnings,-buy-these-biotech-stocks-200186925",200186925
201693,423209,GILD,Gilead Sciences Posts Mixed Q1 Results  ETFs In Focus,opinion,"President Trump s failure to implement the healthcare bill and the blow to his immigration plan were positives for the biotech space  read    
However  there is still high uncertainty surrounding his revamped healthcare bill and its supposed impact on biotech stocks  Gilead Sciences   NASDAQ GILD   released its earnings for the first quarter of 2017  beating the Zacks Consensus Estimate on earnings but missing the same on revenues 
Earnings in Focus
Gilead Sciences reported first quarter 2017  of  2 20 per share  including stock based compensation  on April 26  2017  beating the Zacks Consensus Estimate of  2 18 but down about 26 17  from  2 98 per share reported in the year ago quarter  However  revenues of  6 505 billion missed the consensus estimate of  6 660 billion and were down over 16 50  from  7 794 billion a year ago  read    
Shares lost about 2 5  in after hours trading on Tuesday  May 2  2017  owing to the revenue miss 
Revenues in discussion
Total Antiviral product revenues fell to  5 841 billion from  7 183 billion a year ago 
Other product revenues fell to  536 million from  498 million a year ago 
Royalty  contract and other revenues increased to  128 million from  113 million a year ago 
Outlook
The company expects its 2017 full year net product sales to be in the range of  22 5  24 5 billion  It expects its gross margin to be in the range of 86  88  and effective tax rate to be between 25  and 28  
Let us discuss some ETFs that have a significant exposure to Gilead Sciences 
VanEck Vectors Biotech ETF   LON BBH  
This fund seeks to provide exposure to the biotech industry  It has AUM of  684 5 million and charges a fee of 35 basis points a year  The fund has 10 19  exposure to Gilead Sciences  as of May 2  2017   The fund returned 18 79  in the past one year and 13 65  in the year to date time frame  as of May 2  2017   It currently has a Zacks ETF Rank  3  Hold  with a High risk outlook 
iShares Nasdaq Biotechnology ETF 
This fund has AUM of  8 19 billion and charges a fee of 47 basis points a year  The fund has 7 63  exposure to Gilead Sciences  as of May 2  2017   The fund returned 15 60  in the past one year and 12 39  in the year to date time frame  as of May 2  2017   It currently has a Zacks ETF Rank  3 with a High risk outlook 
PowerShares Dynamic Pharmaceuticals Portfolio ETF   WA PJP  
This fund has AUM of  767 5 million and charges a fee of 57 basis points a year  The fund has 4 97  exposure to Gilead Sciences  as of May 1  2017   The fund lost 0 03  in the past one year but gained 8 71  in the year to date time frame  as of May 2  2017   It currently has a Zacks ETF Rank  3 with a High risk outlook 
Below is a chart comparing the performance of the funds and Gilead Sciences 

Source  Yahoo  NASDAQ YHOO  Finance Want key ETF info delivered straight to your inbox Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2017-05-03,Zacks Investment Research,https://www.investing.com/analysis/gilead-sciences-posts-mixed-q1-results:-etfs-in-focus-200186922,200186922
201702,423218,GILD,Regeneron  REGN  To Post Q1 Earnings  What s In The Cards ,opinion,"Regeneron Pharmaceuticals  Inc    NASDAQ REGN   is scheduled to release first quarter 2017 results on May 4  before the opening bell  The company s performance has been mixed so far  In the last four reported quarters  it surpassed earnings estimates on three occasions and missed the same once  Overall  the company has recorded an average positive earnings surprise of 8 1  

Regeneron s share price movement shows that the stock underperformed the Zacks categorized  industry in the last six months  Specifically  the stock rallied 6 1  during this period  while the industry gained 7 9  
Last quarter  Regeneron missed earnings expectations by 12 75   Let s see how things are shaping up for this quarter 
Factors Influencing This Quarter
Regeneron s key growth driver  Eylea  should continue to contribute to the company s top line growth  Regeneron continued to witness strong sales growth for the eye treatment in both the U S  and ex U S  markets  However  growth for the drug has slowed down and the company expects growth in single digits in 2017  We note that Regeneron has a global development and commercialization agreement with Bayer  DE BAYGN  AG   OTC BAYRY   outside the U S  for Eylea  Product revenues from ex U S  Eylea sales are recorded by Bayer 
The company is working on expanding Eylea s label into diabetic retinopathy in an ongoing phase III study 
Apart from Eylea  investors will remain focused on the performance of the PCSK9 inhibitor  Praluent  The challenge for the PCSK9 inhibitor class continues to be the significant reimbursement hurdle for the physicians  offices and patients which in turn have resulted in a low volume of prescriptions being dispensed   Sales of Praluent have failed to impress so far 
On Feb 8  the United States Court of Appeals for the Federal Circuit stayed the injunction pending appeal  Hence  Regeneron and partner Sanofi   NYSE SNY   will continue marketing  selling  and manufacturing Praluent in the U S  during the appeal process 
During the quarter  the FDA approved its Dupixent  dupilumab  Injection for the treatment of adults with moderate to severe atopic dermatitis  AD   Per the companies  this is the first and only biologic medicine approved for the treatment of adults suffering from AD  Regeneron and Sanofi will launch Dupixent in the U S  at the Wholesale Acquisition Cost  WAC  of  37 000 annually  Pricing will play a key role in the uptake of the drug and we expect management to throw light on the same 
On the first quarter earnings call  focus will be on the company s performance  particularly Eylea and Praluent  The FDA has approved the new supplemental Biologics License Application  sBLA  for a once monthly  every four weeks   300 mg dose of Praluent  alirocumab  Injection for the treatment of adults with high low density lipoprotein  LDL  cholesterol  The approval will expand the drug s dosing options 
Investors are also expected to await updates on the company s pipeline   Earlier in the month  Regeneron and Sanofi announced that the European Medicine Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  has adopted a positive opinion for the marketing authorization of Kevzara  sarilumab   while the FDA has granted Breakthrough Therapy Designation status to its pipeline candidate evinacumab for the treatment of hypercholesterolemia in patients with Homozygous Familial Hypercholesterolemia  HoFH  
Earnings Whispers
Our proven model does not conclusively show that Regeneron is likely to beat earnings estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  However  that is not the case here  as you will see below 
Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at  2 50  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Regeneron currently carries a Zacks Rank  2  Although the company s rank is favorable  the 0 00  ESP makes surprise prediction difficult 
Note  we caution against Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Regeneron Pharmaceuticals  Inc  Price and EPS Surprise
 

   A Stock That Warrants a Look
Here is a health care stock that you may want to consider instead  as our model shows that it has the right combination of elements to post an earnings beat this quarter 
Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  2 77  and a Zacks Rank  3  The company is likely to release results on May 2  You can see  Zacks  Hidden Trades
While we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them   Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-04-28,Zacks Investment Research,https://www.investing.com/analysis/regeneron-(regn)-to-post-q1-earnings:-what's-in-the-cards-200186081,200186081
201703,423219,GILD,What To Expect From Keryx  KERX  Stock This Earnings Season  ,opinion,"Keryx Biopharmaceuticals  Inc    NASDAQ KERX   is expected to report first quarter 2017 results on May 4  Last quarter  the company missed expectations by 18 52   In fact  Keryx s performance over the last four quarters has been disappointing  The company reported a wider than expected loss in three of the trailing four quarters  with an average negative surprise of 35 16  
Keryx s share price has increased 0 7  year to date  while the Zacks classified  industry gained 4 8  Let s see how things are shaping up for the company this quarter 

Factors Influencing This Quarter
Apart from license fees  Keryx s top line comprises revenues generated by its only marketed product Auryxia  ferric citrate   Auryxia is approved as tablets to control serum phosphorus levels in patients with chronic kidney disease  CKD  on dialysis 
Notably  with Auryxia being the only approved product in Keryx s portfolio  the company is entirely dependent on it for growth  Launched in the U S  in late Dec 2014  Auryxia is still in its early stages of commercialization  Insufficient reimbursement and lengthy selling cycles have impacted the ramp up in Auryxia s sales 
However  Keryx is working on its commercial efforts for Auryxia  In fact  the company is currently working on gaining formulary status for the drug  Additionally  it is operating on contracting the remaining insurance providers to expand patient access to Auryxia  This should enable more contact with the prescribers  both current physicians and those who have not prescribed Auryxia yet  The company expanded its field based team to 95 sales representatives 
Moreover  Keryx is working on expanding ferric citrate s  the compound name for Auryxia in additional indications  label to include the treatment of iron deficiency anemia  IDA  in patients with stage III V non dialysis dependent chronic kidney disease indication  NDD CKD   In Mar 2017  the FDA accepted the company s supplemental New Drug Application  sNDA  for Auryxia for review  PDUFA date  Nov 6  2017   If approved for this indication  Auryxia could be the first FDA approved oral medicine to treat IDA in this patient population  A potential approval will significantly boost sales of Auryxia Keryx Biopharmaceuticals  Inc  Price and EPS Surprise
    
What Our Model Indicates
Our proven model does not conclusively show an earnings beat for Keryx this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  However  that is not the case here as you will see below Zacks ESP  Earnings ESP which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate is 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of 18 cents  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Keryx s has a Zacks Rank  3  which increases the predictive power of ESP  However  0 00  ESP makes surprise prediction difficult for the quarter 
Note that we caution against stocks with Zacks Ranks  4 or 5  Sell rated  going into an earnings announcement  especially when the company is seeing a negative estimate revision momentum 
Stocks to Consider
Here are some health care stocks that you may want to consider  as our model shows that it has the right combination of elements to post an earnings beat this quarter 
Fibrogen Inc    NASDAQ FGEN   has an Earnings ESP of  23 81  and a Zacks Rank  3  The company is expected to release results on May 8  You can see  
Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  2 77  and a Zacks Rank  3  The company is scheduled to release results on May 2 
Ultragenyx Pharmaceutical Inc    NASDAQ RARE   has an Earnings ESP of  0 59  and a Zacks Rank  3  The company is expected to release results on May 8 
Zacks  Hidden Trades
While we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-04-28,Zacks Investment Research,https://www.investing.com/analysis/what-to-expect-from-keryx-(kerx)-stock-this-earnings-season-200186078,200186078
201704,423220,GILD,Is Intercept  ICPT  Poised For A Beat This Earnings Season ,opinion,"Intercept Pharmaceuticals  Inc    NASDAQ ICPT   is scheduled to report first quarter 2017 results on May 4  before the market opens 
In the last reported quarter  the company missed expectations by 35 2   Let s see how things are shaping up for this announcement 

Intercept s share price movement in the last six months reveals that the stock underperformed the Zacks classified  industry  The company s shares lost 8 1  during this period  which compares unfavorably with the industry s 7 8  gain 
Surprise History
Intercept s track record has been mixed so far  with the company surpassing expectations in three of the last four quarters  The company has posted an average negative earnings surprise of 2 06  over this period Intercept Pharmaceuticals  Inc  Price and EPS Surprise
 
   Why a Likely Positive Surprise 
Our proven model shows that Intercept is likely to beat estimates this quarter because it has the right combination of two key ingredients  a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  
Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is at  9 13   This is because the Most Accurate estimate is pegged at a loss of  3 38 while the Zacks Consensus Estimate is pegged at a loss of  4 27  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Intercept currently carries a Zacks Rank  3  The combination of Zacks Rank  3 and a positive ESP makes us confident of an earnings beat in the upcoming release 
On the other hand  Sell rated stocks    4 or 5  should never be considered going into an earnings announcement  especially when the company is seeing negative estimate revisions 
Factors at Play
Intercept received a major boost with the FDA approval  in May 2016  of its lead drug  Ocaliva  in combination with ursodeoxycholic  UDCA   for the treatment of primary biliary cholangitis  PBC  in adults with an inadequate response to UDCA or as monotherapy in adults unable to bear with UDCA  Ocaliva generated sales of  4 7 million in the last quarter  In Dec 2016  the European Commission also granted conditional approval to Ocaliva for the same indication 
Meanwhile  Ocaliva is being evaluated for other indications including non alcoholic steatohepatitis  NASH  and primary sclerosing cholangitis  PSC  
Intercept expects operating expenses in the range of  380  420 million in 2017 to support the continued commercialization of Ocaliva in PBC in the United States and other markets  sustained clinical development for OCA in PBC and NASH and the continued advancement of INT 767 and other pipeline programs  The initial uptake of Ocaliva has been encouraging and sales of the drug should pick up further in 2017 
However  sales in the first quarter will be impacted due to higher gross net impact early in the year while patients navigate through the annual change of insurance carriers and benefits  This in turn can cause patients to have their benefits reauthorized and result in a delay in approval 
We expect investors to remain focused on sales ramp up of Ocaliva and pipeline updates on Intercept s first quarter call  The FDA recently approved a redesign of the phase III trial  REGENERATE on Ocaliva for the safety and efficacy in treating NASH patients with liver fibrosis  The company now needs to achieve only one co primary endpoint  either fibrosis improvement or NASH resolution as compared to the earlier target of achieving both 
The sample size of the trial has also been reduced to approximately 750 patients or about 250 patients per arm  The company plans to complete enrolment for the interim analysis cohort in the REGENERATE trial by mid 2017  data readout in 2019  
Meanwhile  Intercept also initiated a phase II study  CONTROL  Combination OCA aNd sTatins for monitoRing Of Lipids   on OCA  The study is being conducted to evaluate the effect of OCA in combination with statin therapy on lipid metabolism in patients with NASH  Enrolment in the study was completed in third quarter 2016  with data expected in 2017 
Stocks That Warrant a LookHere are some health care stocks that you may want to consider  as our model shows that they have the right combination of elements to post an earnings beat this quarter 
Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  2 77  and a Zacks Rank  3 The company is scheduled to release results on May 2   You can see  
The Earnings ESP for Exelixis  Inc    NASDAQ EXEL   is  100  and it carries a Zacks Rank  3  The company is expected to release results on May 1 
Fibrogen Inc    NASDAQ FGEN   has an Earnings ESP of  23 81  and a Zacks Rank  3  The company is likely to release results on May 8 
Zacks  Hidden Trades
While we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them   
Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-04-28,Zacks Investment Research,https://www.investing.com/analysis/is-intercept-(icpt)-poised-for-a-beat-this-earnings-season-200186075,200186075
201705,423221,GILD,What To Expect From Endocyte  ECYT  Stock For Q1 Earnings ,opinion,"Endocyte  Inc   NASDAQ ECYT   is expected to report first quarter 2017 results on May 3  In fact  the company has an impressive track record  having beaten estimates in three of the trailing four quarters and reporting in line results in the remaining quarter  Overall  the company has recorded an average positive surprise of 5 52  
In the last reported quarter  Endocyte missed expectations by 4   Let s see how things are shaping up for this quarter 
Endocyte s share price movement shows that the stock has underperformed the Zacks classified  industry year to date  The stock was down nearly 9 8  as against the industry s gain of approximately 4 9  during the same timeframe 

Factors at Play
Being a biotech company in development stage  Endocyte does not have any approved product in its portfolio  Investors are thus expected to keep an eye on the company s pipeline development  Endocyte s pipeline presently comprises EC1456 and EC1169 
EC1456  second generation folate targeted agent which is being studied as second line treatment for non small cell lung cancer  NSCLC  is identified by the companion imaging agent etarfolatide  The company has initiated the expansion phase of the study on EC1456 in the selected folate receptor positive NSCLC cancer patients 
Patients included in this expansion phase of the trial will receive first line chemotherapy and may also be treated with anti PD 1 therapy  Initially  anti tumor response of the single agent will be evaluated  Positive results from the study would lead to its evaluation as combination therapies in indications like triple negative breast cancer  ovarian cancer and endometrial cancer 
EC1169 is being evaluated in a phase I study for metastatic castration resistant prostate cancer  mCRPC   The company is currently enrolling patients in the expansion phase of the EC1169 trial in up to 50 second line chemotherapy and up to 50 taxane na ve metastatic castrate resistant prostate cancer  mCRPC  patients at a maximum clinical once per week dose of 6 5 mg m2 
Efficacy and safety data from the expansion cohorts for both EC1456 and EC1169 will be reported at medical conferences in the first half of 2017 Endocyte s successful development of targeted small molecule drug conjugates  SMDCs  that are able to penetrate deep into dense solid tumors and have a shorter half life is likely to help the company gain an edge over existing therapies  This biotech company uses its proprietary technology platform to develop various new SMDCs for a range of diseases 
In addition  the company is working on the development of companion imaging agents that help to identify patients most likely to benefit from its product  upon approval  This should help in expanding the market for SMDCs  thereby boosting growth at the company  However  with no approved product in its portfolio at the moment  Endocyte has to depend heavily on its partners for top line growth 
Earnings Whispers
Our proven model does not conclusively show earnings beat for Endocyte this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  But that is not the case here  as you will see below 
Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is 0 00   This is because the Most Accurate estimate is in line with the Zacks Consensus Estimate of a loss of 28 cents  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Endocyte s carries a Zacks Rank  3  which when combined with its 0 00  ESP makes surprise prediction difficult 
Note that we caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Endocyte  Inc  Price and EPS Surprise   Stocks That Warrant a Look
Here are some health care stocks that you may want to consider  as our model shows that they have the right combination of elements to post an earnings beat this quarter Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  2 77  and a Zacks Rank  3  The company is scheduled to release results on May 2  You can see  
Ultragenyx Pharmaceutical Inc    NASDAQ RARE   has an Earnings ESP of  0 59  and a Zacks Rank  3  The company is expected to release results on May 8 Fibrogen Inc    NASDAQ FGEN   has an Earnings ESP of  23 81  and a Zacks Rank  3  The company is expected to release results on May 8 
Sell These Stocks  Now 
Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These are sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ",2017-05-01,Zacks Investment Research,https://www.investing.com/analysis/what-to-expect-from-endocyte-(ecyt)-stock-for-q1-earnings-200186362,200186362
201706,423222,GILD,What s In Store For Zoetis  ZTS  Stock This Earnings Season ,opinion,"Zoetis Inc    NYSE ZTS   is scheduled to report first quarter 2017 results on May 4 before the market opens  In fact  the company has been seen to consistently beat earnings expectations  Zoetis  earnings surpassed expectations in each of the last four quarters  with an average positive surprise of 11 48  
In the last reported quarter  the company topped expectations with a positive earnings surprise of 4 44   Let s see how things are shaping up for this announcement 
Zoetis  share price movement year to date shows that the stock has outperformed the Zacks classified  industry  The stock gained 5 0  compared with industry s gain of 4 9  during this period 

Factors to Consider
Zoetis derives the majority of its revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals  The company continues to strengthen its diverse portfolio of products through lifecycle innovations  strong customer relationships  and access to new markets and technologies 
Notably  the company s companion animal business has been performing well  It expects to see stronger growth from its companion animal portfolio in 2017 driven by its dermatology portfolio  Apoquel and Cytopoint  further penetration of Simparica  and ongoing uptake of new vaccines 
In May 2015  Zoetis had announced comprehensive operational efficiency initiatives that are expected to generate cost savings of more than  300 million by the end of 2017  These initiatives have focused on simplifying its product portfolio through the elimination of approximately 5 000 product stock keeping units  changing its selling approach in certain markets  reducing presence in certain countries  and the sale of exit from 10 manufacturing sites over the long term 
As of December 31  2016  the company has divested or exited three U S  manufacturing sites  two international manufacturing sites  and its 55  ownership share of a Taiwan joint venture  inclusive of its related manufacturing site  The company eliminated about 1 800 positions and additional reductions are expected mainly over the next six months We are positive on Zoetis  acquisitions made so far  In Aug 2016  the company acquired Scandinavian Micro Biodevices   developer and manufacturer of microfluidic  lab on a chip  diagnostic analyzers and tests for veterinary point of care services   in a transaction valued at  80 million  This acquisition has added a suite of specialty test instruments and cartridges to Zoetis  complementary point of care diagnostics portfolio 
Also  the buyout has gained late  and mid stage pipeline candidates that are expected to bring a range of new point of care analyzers and tests to market and contribute to several diagnostic product launches over the next few years in order to help veterinarians better detect  prevent and treat diseases 
In Apr 20 17  Zoetis entered into an agreement with Nexvet Biopharma under which Zoetis  through a wholly owned subsidiary will purchase the later  Nexvet is an innovator in monoclonal antibody therapies for companion animals  The purchase price for the deal is  85 million The acquisition is expected to strengthen Zoetis  pipeline of solutions for chronic pain management in dogs and cats  which represents an area of high need in companion animal health 
However  Zoetis lowered its guidance for 2017 concurrent with its fourth quarter results  Management expects revenue growth to be negatively impacted from product rationalization  especially in the first two quarters of the year  Other headwinds also include disease outbreaks and stiff competition in the animal health space 
Earnings Whispers
Our proven model does not conclusively show earnings beat for Zoetis this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  Unfortunately  that is not the case here  as you will see below 
Zacks ESP  Earnings ESP for Zoetis is  2 04   This is because the Most Accurate estimate is 48 cents  while the Zacks Consensus Estimate is pegged at 49 cents  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Zoetis carries a Zacks Rank  3  which when combined with a negative ESP makes surprise prediction difficult 
Note that we caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Zoetis Inc  Price and EPS Surprise
    Stocks That Warrant a Look
Here are some health care stocks that you may want to consider  as our model shows that they have the right combination of elements to post an earnings beat this quarter Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  2 77  and a Zacks Rank  3  The company is scheduled to release results on May 2  You can see  
Ultragenyx Pharmaceutical Inc    NASDAQ RARE   has an Earnings ESP of  0 59  and a Zacks Rank  3  The company is expected to release results on May 8 Fibrogen Inc    NASDAQ FGEN   has an Earnings ESP of  23 81  and a Zacks Rank  3  The company is expected to release results on May 8 
Sell These Stocks  Now  
Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These are sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 ",2017-05-01,Zacks Investment Research,https://www.investing.com/analysis/what's-in-store-for-zoetis-(zts)-stock-this-earnings-season-200186361,200186361
201707,423223,GILD,Radius Health  RDUS  Q1 Earnings  What s In Store ,opinion,"Radius Health  Inc    NASDAQ RDUS   is scheduled to report first quarter 2017 financial results on May 3 

Radius  shares underperformed the  industry in the last six months  The stock lost 17 6  during this time period as compared to a gain of 10 1  for the industry 
Radius Health has a disappointing track record so far  The company missed estimates in three of the four trailing quarters with a negative average surprise of 5 4  
Let s see how things are shaping up for this quarter 
Factors at Play
Radius Health focuses on the development of therapeutics for the treatment of osteoporosis  oncology and endocrine diseases 
On Apr 28  Radius Health announced that the FDA has approved its lead candidate Tymlos  abaloparatide  injection for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture  multiple risk factors for fracture  or patients who have failed or are intolerant to other available osteoporosis therapy 
Hence  we expect investors to focus on the impending launch during the upcoming earnings call 
The company has been gearing for a potential launch in both the U S and the EU  and has thus increased its headcount  Radius is also looking for a commercialization partner for Tymlos outside the U S  prior to commercial launch  The company also expects to report top line results from the 24 month ACTIVExtend clinical trial in second quarter 2017 
Meanwhile  Raduis is also developing abaloparatide TD for potential use as a short wear time transdermal patch  In Dec 2015  the company initiated a human replicative clinical evaluation to compare the optimized abaloparatide TD patch with its subcutaneous formulation  The company posted positive results from the trial in Sep 2016 
The company is currently focused on completing the manufacturing  scale up  and other required activities needed to initiate a pivotal study to evaluate bioequivalence to abaloparatide SC  The transdermal patch program has the potential to allow physicians who treat osteoporosis but rarely use injectable drugs to expand their practices to include the use of anabolic therapy 
Other candidates in Radius Health s pipeline include RAD1901  in hormone driven and or hormone resistant breast cancer  and vasomotor symptoms in post menopausal women  and RAD140  multiple indications including cancer   During the fourth quarter  Radius Health reported encouraging results of its ongoing phase I studies of RAD1901 in advanced breast cancer 
The company plans to file with regulatory agencies in order to take the next steps for the program in the first half of 2017  which would include the design of a phase II trial  Additionally  it anticipates to report results from its completed phase IIb trial in vasomotor symptoms in the first half of 2017 
Furthermore  the company submitted an investigational new drug application  to the FDA for RAD140  which is a selective androgen receptor modulator  Moving ahead  it expects to commence a first in human phase I study in women with hormone receptor positive breast cancer in 2017 
Research and development expenses are expected to record an upside thanks to pipeline development activities 
Earnings Whispers
Our proven model does not conclusively show that Radius Health is likely to beat estimates this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  But that is not the case here  as you will see below 
Zacks ESP  Earnings ESP for Radius Health is currently pegged at 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at a loss of  1 25  You can uncover the best stocks to buy or sell before they re reported with our 
Zacks Rank  Radius Health has a Zacks Rank  4  Sell   As it is  we caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Radius Health  Inc  Price and EPS Surprise    Stocks to Consider
Here are a few pharma companies that you may consider  as our model shows that they have the right combination of elements to post an earnings beat this quarter 
Intercept Pharmaceuticals  Inc    NASDAQ ICPT   has an Earnings ESP of  9 13  and a Zacks Rank  3   The company is expected to release results on May 4  You can see  
Fibrogen Inc    NASDAQ FGEN   has an Earnings ESP of  23 81  and a Zacks Rank  3  The company is likely to release results on May 8 
Gilead Sciences  Inc      NASDAQ GILD   has an Earnings ESP of  2 77  and a Zacks Rank  3  The company is scheduled to release results on May 2 
Sell These Stocks Now  
Just released  today s 220 Zacks Rank  5 Strong Sells demand urgent attention  If any are lurking in your portfolio or Watch List  they should be removed immediately  These sinister companies because many appear to be sound investments  However  from 1988 through 2016  stocks from our Strong Sell list have actually performed 6X worse than the S P 500 
 ",2017-05-01,Zacks Investment Research,https://www.investing.com/analysis/radius-health-(rdus)-q1-earnings:-what's-in-store-200186360,200186360
201713,423229,GILD,Bristol Myers  BMY  To Post Q1 Earnings  What s In Store ,opinion,"Bristol Myers Squibb Company   NYSE BMY   is scheduled to report first quarter 2017 results on Apr 27  before the opening bell  Last quarter  the company missed earnings estimates by 4 55  
Bristol Myers  stock lost 24 2  in the past year  underperforming the Zacks classified  industry s loss of 2 8  

Bristol Myers has a decent track record so far  The company s earnings beat estimates in three of the four trailing quarters  with an average positive surprise of 7 26   Will Bristol Myers surpass expectations this time as well 
Let s see how things are shaping up for this quarter 
Factors to Impact Q1
Bristol Myers  high profile immuno oncology drug  Opdivo  should continue to drive the company s top line in the to be reported quarter  Opdivo s U S  sales are driven by the melanoma  second line non small cell lung cancer and renal cell carcinoma indications 
Further  recent label expansions into the classical Hodgkin lymphoma and head and neck cancer indications should boost the drug s sales   However  the lung cancer market in the U S became more competitive in 2016 due to the entry of Tecentriq 
Bristol Myers expects the second line lung cancer business to be under competitive pressure  As a result  sales of the drug in the U S is projected be flat in 2017  A potential earlier than expected entry of Merck s   NYSE MRK   Keytruda in combination with chemotherapy will also adversely impact sales  Sales of Opdivo are projected to grow globally 
The virology business is expected to decline significantly in 2017 due to competition from Epclusa  The HIV business continues to face competitive pressure  Particularly  recent launches by other companies in the same space are expected to further impact the Sustiva franchise 
The company trimmed its earnings guidance in Jan 2017 due to the impact of foreign exchange rates and a potential earlier than expected entry of the Keytruda chemo combination in May  The company now expects earnings in the range of  2 70  2 90 per share  
R D expenses are expected to increase in the high single digit range  Marketing  selling and administrative expenses are anticipated to decrease in mid  to high  single digit range  The company expects operating expenses to be roughly flat with 2016 levels through 2020 
On the first quarter earnings call  investors are expected to focus on the company s performance and label expansion efforts  along with updates on business development activities 
Earnings Whispers
Our proven model does not conclusively show that Bristol Myers is likely to beat earnings estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  Unfortunately  that is not the case here  as elaborated below 
Zacks ESP  The Earnings ESP for Bristol Myers is  1 37  since the Most Accurate estimate is 72 cents  lower than the Zacks Consensus Estimate of 73 cents  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Bristol Myers currently carries a Zacks Rank  3 which increases the predictive power of ESP  However  its negative ESP makes it highly unlikely for the stock to beat earnings this quarter  As it is  we caution against Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Bristol Myers Squibb Company Price and EPS Surprise
 
 
   Stocks That Warrant a Look
Here are some health care stocks that you may want to consider  as our model shows that they have the right combination of elements to post an earnings beat this quarter 
Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  2 77  and a Zacks Rank  3  The company is scheduled to release results on May 2  You can see  
Intercept Pharmaceuticals  Inc    NASDAQ ICPT   has an Earnings ESP of  9 13  and a Zacks Rank  3   The company is expected to release results on May 4 
Zacks  Best Private Investment Ideas 
While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public 
Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-04-25,Zacks Investment Research,https://www.investing.com/analysis/bristol-myers-(bmy)-to-post-q1-earnings:-what's-in-store-200185090,200185090
201714,423230,GILD,Exelixis  EXEL  Q1 Earnings  Will The Stock Disappoint ,opinion,"Exelixis  Inc    NASDAQ EXEL   is scheduled to report first quarter 2017 results on May 1  after the market close 
The company surpassed expectations thrice in the four trailing quarters and missed the same once  with an average positive earnings surprise of 360 11  
Exelixis  share price has increased 42 8  year to date compared with the Zacks classified  industry s gain of 1 8  

Factors Likely to Impact Results
Cabometyx tablets  launched in Apr 2016  are experiencing rapid and broad uptake in the market with label expansion opportunities leaving room for an upside  The drug was approved in Apr 2016 for the treatment of patients with advanced renal cell carcinoma 
Exelixis  leading drug Cometriq  the capsule form of cabozantinib  is approved for the treatment of progressive metastatic medullary thyroid cancer  MTC   Moreover  based on positive results from the phase II CABOSUN study on cabozantinib in Oct 2016  the company plans to submit a supplemental New Drug Application  sNDA  for treating first line advanced RCC  The company also plans to build cabozantinib into an entire oncology franchise 
The company expects Cometriq revenues to gradually decline over time as RCC patients come off Cometriq therapy and new patients initiate therapy with Cabometyx  However  successful commercialization of the other marketed drug  Cotellic is expected to boost the top line in the U S  Cotellic is approved in the U S  and EU to be used in combination with Roche Holding s Zelboraf in the U S  for the treatment for patients with BRAF V600E or V600K mutation positive advanced melanoma 
Exelixis has collaborations with other leading pharmaceutical and biotechnology companies such as Bristol Myers Squibb   NYSE BMY    Sanofi  PA SASY  Merck  NYSE MRK  and Daiichi Sankyo for various compounds and programs in its portfolio  These collaborations allow Exelixis to earn milestone payments and royalties that boost its top line 
Earnings Whispers
Our proven model does not conclusively show that Exelixis is likely to beat estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to be able to beat earnings  That is not the case here as you will see below 
Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  200 00  since the Most Accurate stands at a loss of 3 cents while the Zacks Consensus Estimate is pegged at a loss of 1 cent  You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Exelixis carries a Zacks Rank  3  This when combined with a negative ESP makes surprise prediction difficult 
We caution against stocks with a Zacks Rank  4 and  5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Exelixis  Inc  Price and EPS Surprise
   Stocks That Warrant a Look
Here are some health care stocks that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter 
Gilead Sciences  Inc    NASDAQ GILD   is scheduled to report its results on May 2  It has an Earnings ESP of  2 77  and carries a Zacks Rank  3  Hold   You can see  
The Earnings ESP for Paratek Pharmaceuticals  Inc  is  0 83  and it carries a Zacks Rank  3  Hold   The company is scheduled to release results on May 1 
Proteostasis Therapeutics   NASDAQ PTI   has an Earnings ESP of  5 71  and carries a Zacks Rank  2  Buy   It is scheduled to report its results on May 12 
Zacks  Best Private Investment Ideas
While we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public 
Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-04-25,Zacks Investment Research,https://www.investing.com/analysis/exelixis-(exel)-q1-earnings:-will-the-stock-disappoint-200185078,200185078
201715,423231,GILD,What To Expect From Prothena  PRTA  This Earnings Season ,opinion,"Prothena Corporation plc   NASDAQ PRTA   is expected to report first quarter 2017 results early next month 
Last quarter  the company recorded a negative earnings surprise of 13 71   In fact  Prothena s track record has been dismal so far  The company reported a wider than expected loss in all the four trailing quarters  with an average negative surprise of 16 11  
Prothena s share price increased 11 6  in the past one year as against the Zacks classified  industry s gain of 3 2  

Let s see how things are shaping up for this announcement Factors at Play
Prothena s top line primarily comprises collaboration revenues earned through its license  development and commercialization agreements  In fact  the company earns collaboration revenues mainly under its license agreement with Roche Holding  SIX ROG  AG   OTC RHHBY   for PRX002 
We believe  investor focus should remain on pipeline updates by the company as it has no approved product in its portfolio 
PRX002 is currently in phase Ib study in patients with Parkinson s disease  The company expects to initiate a phase II study in patients with Parkinson s disease in 2017 
Other key pipeline candidates include NEOD001 for the treatment of AL amyloidosis and PRX003 for the treatment of inflammatory diseases such as psoriasis and psoriatic arthritis PRX003 is being evaluated in a phase Ib multiple ascending dose study  Interim and full results from the study are expected this year  Currently  the VITAL study on NEOD001 is on track  The company expects to complete enrollment by the second quarter of 2017  Additionally  the company expects top line results from this study in early 2018 Moving ahead  like any other development stage biotechnology company  Prothena is likely to see an increase in research and development expenses due to higher spending on pipelineWhat Does the Zacks Model Unveil 
Our proven model does not conclusively show an earnings beat for Prothena this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  Unfortunately  that is not the case here  as you will see below 
Zacks ESP  Earnings ESP for Prothena is   3 79   because the Most Accurate estimate is  1 37  while the Zacks Consensus Estimate is pegged at a loss of 1 32  You can uncover the best stocks to buy or sell before they re reported with our   
Zacks Rank  Though Prothena s Zacks Rank  3  Sell  increases the predictive power of ESP  its negative ESP makes a surprise prediction difficult   
Note that we caution against stocks with a Zacks Rank  4 or 5  Strong Sell  going into the earnings announcement  especially when the company is seeing negative estimate revisions  Prothena Corporation PLC Price and EPS Surprise   Stocks to Consider
Here are some other health care stocks that you may want to consider  as our model shows that they too have the right combination of elements to post an earnings beat this quarter Fibrogen Inc    NASDAQ FGEN   has an Earnings ESP of  23 81  and a Zacks Rank  3  The company is expected to release results on May 8  You can see  
Gilead Sciences  Inc    NASDAQ GILD   has an Earnings ESP of  2 13  and a Zacks Rank  3  The company is scheduled to release results on May 2 
Looking for Ideas with Even Greater Upside 
Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ",2017-04-26,Zacks Investment Research,https://www.investing.com/analysis/what-to-expect-from-prothena-(prta)-this-earnings-season-200185403,200185403
201716,423232,GILD,The Stock Market Is Up But My Hopes Are Down,opinion,"There is an eight foot broadleaf evergreen directly outside my office door  Normally  I would not give it a second s glance  Recently  however  a hummingbird has been buzzing about the greenery  And with good reason  Two hatchlings have arrived  requiring food as well as warmth 
In spite of my presence  the mother has been expressing an unusual amount of audacity  She does not flinch when I walk near the nest  And when she s out gathering insects to feed her young  she returns to the shrub as if she owns it  My colleague Rob jokingly suggested that we name the siblings  Irrational  and  Exuberance  
The investing public is confident alright  There s no doubt about that  There has never been as much leverage in the market based financial system as there is right now 
Consider margin debt  It is hitting all time records alongside the major stock market averages  And while there s no sure fire way to determine when stock market ascension or brokerage account borrowing will subside  skyrocketing leverage tends to peak at exceptionally inconvenient moments  that is  when the act of borrowing to buy stocks swan dives  bubbly stock prices typically head south for the winter  spring  summer and or fall 

Take a look at the chart above  Leverage as seen in the red line surged in 1999  only to abruptly reverse course by March of 2000  The tech bubble popped in March of 2000   Note  The S P 500 hung in there until August of 2000 before giving way to a two year  six month price evisceration  Similarly  as measured by margin debt increases  investor enthusiasm catapulted higher in 2006  By mid 2007  though  leverage made a hasty retreat  And by October of 2007  stocks cratered  They reached unimaginable lows nineteen harrowing months later 
Some strategists argue that there is nothing irrational or overly exuberant about borrowing the most that one can from his her brokerage account  He she can buy stocks  finance a trip around the globe or even come up with more money for a real estate acquisition  And at these ultra low interest rates  why not 
Here s the problem  When stocks reverse direction  clients receive a  margin call   Either they come up with cash to replenish margin account requirements or they must liquidate holdings  Obviously  they do not have the cash available  between their obligations to mortgages  auto leases and student loans  Not only is household debt to income at an unsustainable 130   but household savings rates at 5  are a fraction of what they were in the 1970s and 1980s 
It follows that forced portfolio liquidation contributes to falling stock prices which  in turn  breeds additional involuntary selling  In other words  while borrowing to buy stocks bolsters higher and higher stock prices for a period  it eventually contributes to a rapid fire descent 
Debt has been the answer for households to maintain their standards of living since the early 1990s  The massive rise in household credit has leveraged families to a point of questionable return  e g   mortgage  auto  education  revolving credit cards  etc   

Unfortunately  that s not the half of it  Get a gander at what one might refer to as Credit Balance  Credit Balance results from subtracting margin debt from Free Credit Cash Accounts and credit balances within margin accounts  What we see is that negative Credit Balances have never been this far out of whack  Not during the tech bubble  And not during the housing collapse  Simply stated  stock market investors are more exuberant than ever before 

Perhaps there are relatively rational reasons for investors to be exceptionally bullish  Low borrowing costs  No obvious sign of an imminent economic recession  Trump tax and regulatory reform  And most glaringly  Tens of trillions of dollars making their way into riskier assets care of globally coordinated central bank intervention 

On the flip side  the notion that there must be an easy to spot catalyst prior to a bearish retreat in prices is false  The Fed may have been raising rates too rapidly leading into the turn of the century  Yet there was nothing in March of 2000 that served as an immediate impetus for the tech wreck that followed 
Here s what I do know   1  Household debt  corporate debt  government debt and investor debt have never been as ugly as right this minute   2  Traditional metrics have rarely pointed to more  than what we are witnessing today   3  Traditional metrics still matter  in spite of    4  Non recession stock bears are common  as are ultra low interest rate bears  meaning neither an expanding economy nor a low rate environment can prevent 20  price declines  and  5  Deficit mindful Republicans are not inclined to  that increases the national debt  let alone a package that seems to favor the wealthiest among us 
As long as valuations and leverage levels push the upper limits of greed  I will continue to maintain a more modest allocation to equity  Stock allocation for my moderate growth and income clients rests at 50   cash and cash equivalents sit closer to 25  for the ability to acquire assets at more attractive price levels 
Is there anything that I would buy in the current environment  I am partial to a few individual companies like Gilead Sciences Inc  NASDAQ GILD   In contrast  it is exceptionally challenging to add to exchange traded stock index funds  ETFs  when few  if any  register as bargains  I crave the ability to buy lower when the crowd is petrified of its own silhouette 
Disclosure Statement  ETF Expert is a web log   blog   that makes the world of ETFs easier to understand  Gary Gordon  MS  CFP is the president of Pacific Park Financial  Inc   a Registered Investment Adviser with the SEC  Gary Gordon  Pacific Park Financial  Inc   and or its clients may hold positions in the ETFs  mutual funds  and or any investment asset mentioned above  The commentary does not constitute individualized investment advice  The opinions offered herein are not personalized recommendations to buy  sell or hold securities  At times  issuers of exchange traded products compensate Pacific Park Financial  Inc  or its subsidiaries for advertising at the ETF Expert website  ETF Expert content is created independently of any advertising relationship ",2017-04-27,Gary Gordon,https://www.investing.com/analysis/extreme-leverage-extreme-valuations-big-time-short-sellers-must-200185467,200185467
201724,423240,GILD,Gilead  GILD  HCV Drugs Gets FDA Nod For Label Expansion,opinion,"Gilead Sciences  Inc    NASDAQ GILD   announced that the FDA approved additional indications for Harvoni  ledipasvir 90 mg sofosbuvir 400 mg  tablets and Sovaldi  sofosbuvir 400 mg  tablets  These drugs can now be used for the treatment of chronic hepatitis C virus  HCV  infection in adolescents without cirrhosis or with compensated cirrhosis  12 years of age and older or weighing at least 35kg 
Shares of Gilead underperformed the Zacks classified  industry in the last one year with the stock losing 30 4  during this period  compared with the industry s decline of 9 5  

 
We remind investors that while Harvoni is already approved for pediatric patients with genotype 1  4  5 or 6 chronic HCV infection  Sovaldi was approved for pediatric patients with genotype 2 or 3 chronic HCV infection in combination with ribavirin 
Hence  the approvals of Sovaldi and Harvoni will benefit patients from interferon free treatment for HCV infection  As per estimates  of the 23 000 46 000 pediatric HCV patients in the U S   most are infected with the virus at birth 
As a result of the approvals  children aging 12 and older in the U S  with genotypes 1 to 6 chronic HCV infection will now have the option of two direct acting antiviral regimens that offer high cure rates and eliminate the need for interferon injections 
However  Gilead s HCV franchise continued to witness slowdown in the fourth quarter of 2016 across key markets including the U S  and Europe  reflecting lower sales of Harvoni and Sovaldi as a result of competitive and pricing pressure  HCV product sales were weaker than expected due to fewer new patient starts for Harvoni and lower revenues per patient 
Higher discounts and payer mix continue to hurt sales  Lower patient starts were also observed in the early launch markets in Germany and France while Spain and Italy continued to experience budgetary constraints  Higher discounts and payer mix continue to impact sales adversely 
Moreover  Harvoni  Sovaldi and Epclusa  face competition from AbbVie s   NYSE ABBV   Viekira Pak and Viekira XR among others 
Zacks Rank   Key Pick
Gilead Sciences currently carries Zacks Rank  5  Strong Sell  
Better ranked stocks in the health care sector are Heska Corp    NASDAQ HSKA   and Retrophin  Inc    NASDAQ RTRX    Both the stocks sport a Zacks Rank  1  Strong Buy  
You can see  
Heska s earnings per share estimates increased from  1 53 to  1 65 for 2017 and from  1 90 to  2 01 for 2018 over the last 30 days  The company posted a positive surprise in three of the four trailing quarters with an average beat of 291 54  
Retrophin s loss per share estimates narrowed from 85 cents to 72 cents for 2017 and from 67 cents to 53 cents for 2018 over the last 60 days  The company posted positive earnings surprises in two of the four trailing quarters  with an average beat of 80 55  
Zacks  Hidden Trades
While we share many recommendations and ideas with the public  certain moves are hidden from everyone but selected members of our portfolio services  Would you like to peek behind the curtain today and view them                                                                                                            
Starting now  for the next month  I invite you to follow all Zacks  private buys and sells in real time from value to momentum   from stocks under  10 to ETF to option movers   from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2017-04-10,Zacks Investment Research,https://www.investing.com/analysis/gilead-(gild)-hcv-drugs-gets-fda-nod-for-label-expansion-200182110,200182110
201725,423241,GILD,See Why I Am Buying Gilead Sciences Here,opinion,"There is something important going on with Gilead Sciences  Inc   NASDAQ GILD   It is likely telling investors the downtrend is nearing an end and significant upside is on the horizon  Based on what I will explain to all investors  I will be buying Gilead Sciences at  65 75   
The basis for my thesis comes from the way the stock has acted over the last two months  Since early February 2017  Gilead Sciences jumped from multi year lows  surging 10  in one week  Over the last 7 weeks  the stock has every so slowly inched back down  This is a major change in character from a stock that usually collapsed sharply in a week and took 7 weeks to inch back up before its next collapse  In other words  the price action is showing institutional  big money  accumulation  In addition  the valuation is very attractive  Analysts continue to strongly believe Gilead Sciences needs to buy some drug companies and I believe the company has heard them  I am sure acquisitions will be on the horizon as Gilead Sciences is sitting on a huge pile of cash ",2017-04-12,Gareth Soloway,https://www.investing.com/analysis/see-why-i-am-buying-gilead-sciences-$gild-here-200182386,200182386
201740,423256,GILD,Galapagos  GLPG  Filgotinib In Phase III For Crohn s Disease,opinion,"Galapagos NV   NASDAQ GLPG   announced that it has dosed the first patient in a phase III study   DIVERSITY   on filgotinib for the treatment of Crohn s disease  This triggered a milestone payment worth  50 million from Gilead Sciences Inc    NASDAQ GILD   The study will evaluate the safety and efficacy of once daily filgotinib  100 mg and 200 mg   compared to placebo  in patients with moderately to severely active Crohn s disease  including those who failed previous biological therapy We remind investors that in Dec 2015  Galapagos signed a collaboration agreement with Gilead for the development and commercialization of filgotinib for inflammatory indications including rheumatoid arthritis  RA   Crohn s disease and ulcerative colitis In Aug 2016  Gilead initiated a phase III program  FINCH  on filgotinib in RA  The FINCH program comprises three studies that will evaluate the safety and efficacy of once daily filgotinib  100 mg and 200 mg  in patients from early stage to biologic experienced Moreover  Gilead expects to start a phase II III study for the treatment of ulcerative colitis later in the quarter Meanwhile  Galapagos continues to progress on its cystic fibrosis programs  with partner AbbVie Inc    NYSE ABBV   conducting several phase I and II studies Going forward  we expect investor focus to remain on further pipeline updates from the company GALAPAGOS  ADR Price
    Currently  Galapagos carries a Zacks Rank  3  Hold  Stock to ConsiderVanda Pharmaceuticals  Inc    NASDAQ VNDA   is a better ranked stock in the health care sector  sporting a Zacks Rank  1  Strong Buy   You can see  Vanda s loss estimates narrowed from 68 cents per share to 56 cents for 2016 over the last 60 days  while its earnings estimates increased from 16 cents per share to 17 cents for 2017  The company posted a positive earnings surprise in three of the last four quarters with an average beat of 56 65   Its share price has surged 80  year to date Zacks  Top Investment Ideas for Long Term ProfitHow would you like to see our best recommendations to help you find today s most promising long term stocks  Starting now  you can look inside our portfolios featuring stocks under  10  income stocks  value investments and more  These picks  which have double and triple digit profit potential  are rarely available to the public  But you can see them now ",2016-11-22,Zacks Investment Research,https://www.investing.com/analysis/galapagos-(glpg)-filgotinib-in-phase-iii-for-crohn's-disease-200166306,200166306
201741,423257,GILD,Gilead Sciences Bucks Biotech Trend,opinion,"While the stock market hit all time highs on Wednesday  the biotechnology sector took a beating  This was on the back of comments from Donald Trump over curbing drug prices  While a majority of biotech stocks were down sharply  there was one that bucked the trend  It has been one of the most beaten down plays in the drug arena  which is why it caught my eye 
The company is Gilead Sciences  Inc   NASDAQ GILD  and the stock actually closed green on the day  This is a major change in character  as Gilead Sciences has notoriously been the weakest biotech stock in the group  This significant eye catching change makes me a buyer on the stock chart here at  72 78  Note the chart below ",2016-12-08,Jenny Rebekka,https://www.investing.com/analysis/this-biotech-is-bucking-the-trend...-200168898,200168898
201749,423265,GILD,Company News For November 03  2016,opinion,"  Shares of Gilead Sciences Inc  NASDAQ GILD      fell 2 1  after reporting third quarter earnings of  2 70 per share  missing the Zacks Consensus Estimate of  2 74



	  Allergan  NYSE AGN pa  plc s    shares slumped 5 4  after posting third quarter earnings per share of  3 32  lower than the Zacks Consensus Estimate of  3 57



	  Shares of Est e Lauder Companies Inc     decreased 5 5  after reporting fiscal first quarter adjusted earnings of  0 84 a share   falling short of the Zacks Consensus Estimate of  0 79



	  Clorox Company s    shares declined 3 2  after posting fiscal first quarter earnings of  1 36 per share  missing the Zacks Consensus Estimate of  1 42",2016-11-02,Zacks Investment Research,"https://www.investing.com/analysis/company-news-for-november-03,-2016-200162532",200162532
201750,423266,GILD,The Zacks Analyst Blog Highlights  Allergan  Gilead Sciences  Pfizer  Regeneron Pharmaceuticals And Lion Biotechnologies,opinion,"For Immediate Release

Chicago  IL   November 04  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Allergan  NYSE AGN pa  plc  NYSE            Gilead Sciences Inc  NASDAQ GILD    NASDAQ            Pfizer Inc   NYSE PFE   NYSE            Regeneron Pharmaceuticals  Inc   NASDAQ           and Lion Biotechnologies  Inc   NASDAQ          

Today  Zacks is promoting its   Buy   stock recommendations    

Here are highlights from Thursday s Analyst Blog  

Drug Stocks to Watch for Earnings on Friday

The bulk of the Q3 earnings season is over  with 364 S P 500 members  as of Nov 2    accounting for 72 6  of the index s total market capitalization   having already reported results  according to the latest  

While total earnings for these index members were up 1 6  from the year ago quarter  revenues were also up 1 6  year over year  The beat ratio was 72 3  for earnings and 54 7  for revenues 
	Notably  the ongoing reporting cycle is on track to be the first quarter of positive earnings growth after five consecutive quarters of earnings decline for the S P 500 index  However  though the third quarter reporting cycle saw numerous positive surprises and stability in current quarter  Q4 2016  estimates in the beginning  these two attributes have started losing ground this week  Positive surprises  particularly on the revenue side  have become harder to come by and Q4 estimates are moving down 

This change was reflected in the results of pharmaceutical companies as well  Though quite a few of the large cap pharma companies posted better than expected third quarter results last week  three large pharma companies that have reported so far this week   Allergan plc s  NYSE            Gilead Sciences Inc   NASDAQ           and Pfizer Inc   NYSE             announced softer than expected Q3 results  While Allergan and Pfizer missed estimates for both earnings and sales  Gilead managed to beat sales expectations marginally but missed earnings estimates 

Two more companies from the healthcare sector are set to report their third quarter results on Nov 4  Let s see how things are shaping up for their respective announcements 

Regeneron Pharmaceuticals  Inc    NASDAQ          

Regeneron posted a positive surprise of 21 97  last reported  The company s performance has been mixed so far  In the last four quarters  it surpassed earnings estimates on two occasions and missed the same twice  Overall  the company has recorded an average negative earnings surprise of 2 04  

Regeneron s key growth driver  Eylea  should continue to perform well in the third quarter of 2016 and contribute meaningfully to the top line  Apart from Eylea  investor focus will remain on the performance of the PCSK9 inhibitor  Praluent   Read More     

The Zacks Consensus Estimate for the quarter is pegged at  2 27 per share  The company has a Zacks Rank  3  Hold  and an  of 0 00   Please check our  that enables you find stocks that are expected to come out with earnings surprises 

Lion Biotechnologies  Inc    NASDAQ          

Last quarter  the company delivered a negative earnings surprise of 21 05   Lion Biotechnologies had a mixed track record over the last four quarters  The company surpassed expectations twice  missed once and delivered in line results in the other quarter  with the average positive earnings surprise being 9 52  

The Zacks Consensus Estimate for the quarter is pegged at a loss of 18 cents per share  The company has an Earnings ESP of 0 00  and a Zacks Rank  3  You can see   

Confidential from Zacks

This week  Zacks researchers have named 7 other stocks that look to break out even sooner than today s Bull of the Day  You can see these time sensitive tickers free  and access additional trades that are not available to the public  

Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks 

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   











Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Media Contact
	Zacks Investment Research

800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-11-03,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-allergan,-gilead-sciences,-pfizer,-regeneron-pharmaceuticals-and-lion-biotechnologies-200162859",200162859
201757,423273,GILD,How Cheap Can Gilead Sciences Get ,opinion,"With the self destruction of Donald Trump s presidential campaign  it seems like the market is pricing in a Hillary Clinton presidential win come November 8th 
In particular  the biotech and major pharmaceutical companies have been smashed over the past half year  with some stocks like Gilead losing almost 30  in this short period of time 
While drops like these may rattle the impatient and fearful investor or trader  we as value investors should be licking our lips for such a tasty opportunity 
The following is what s making me add even more Gilead Sciences  NASDAQ GILD  stock to our long term investing portfolio 
Please note  I am both a long term deep value investor as well as a medium term trader who utilizes the combination of both fundamental  technical and macro analysis to form a view of every investment I make  Doing so I believe leads to  over the long run 
Fundamental Factors  The Bad
Earnings Per Share is forecasted to decline 
Return on Equity  ROE  of over 80  is excellent but is forecast to decline as well 
The biggest risk here is the potential for future government enforced pricing regulations of the pharmaceutical and biotech industry as a whole if Clinton comes into power post November US elections 
The Good
Fair value with intrinsic valuation of  72  80  approx   
Priced at less than six times this year s and next year s earnings  If this isn t cheap  I m not sure what is  The  Clinton fear factor  seems to already be priced in 
Earnings per share  EPS  have been great for the past 5 years 
Long term cash flow relative to reported profits is strong 
Gilead has a long term funding surplus 
Massive cash and investments of over  22 billion dollars on its Balance Sheet 
Consistent big stock buybacks is likely to continue 
Technical Factors  The Bad
Recently broken below the  78 key price support level  with next key price support at  70 
Currently below all 20  50 and 200 day moving averages 
The Good
The stock is oversold on a variety of momentum indicators 
Price is close to its 3 year lows at current price levels 
Other Factors
For longer term investments and trades  I generally like to see who else is on board with me and where the smart money has found its home 
In my opinion  actions always speak louder than words  GILD is held by a lot of smart money managers 
Ronald Muhlenkamp   7 073  of portfolio managed
Jerome Dodson   3 23  of portfolio managed
David Carlson   2 77  of portfolio managed
Zeke Ashton   2 71  of portfolio managed
Samuel Isaly   2 01  of portfolio managed
Conclusion
The dramatic 30  price fall of Gilead Sciences in the past half year has brought the stock back to below fair value for a wonderfully managed bio tech company with plenty of smart money support 
To avoid catching the proverbial falling knife  we ll wait for a buying momentum shift upwards before adding any more Gilead Sciences for our long term portfolio 
With Gilead continuing to buy back their stock in big volumes  thus increasing its own intrinsic value over time  this is definitely not the time to be fearful when such an opportunity exists  The most important bit is to  accordingly and build a position over time and not rush into it  Patience is key ",2016-10-18,Terry Tran,https://www.investing.com/analysis/how-cheap-can-gilead-sciences-(gild)-get-200159372,200159372
201758,423274,GILD,The Best Options Trade For Gilead Sciences  GILD  Earnings ,opinion,"On Tuesday  November 1st  Gilead Sciences  NASDAQ GILD  will release its third quarter earnings results after the bell  The company is a Zacks Rank 5  Strong Sell   and have a Value  Growth  and Momentum score of B 
Dave will look at Gilead Sciences  past earnings  take a look at what is currently going on with the company  and give us his thoughts on their upcoming earnings announcement 
Furthermore  Dave will uncover some potential options trades for investors looking to make a play on Gilead Sciences ahead of earnings 
Gilead Sciences in Focus
Gilead Sciences  Inc  is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them  They have a broad based focus on developing and marketing drugs to treat patients with infectious diseases  including viral infections  fungal infections and bacterial infections  and a specialized focus on cancer  They have expertise in liposomal drug delivery technology  a technology that the company uses to develop drugs that are safer  easier for patients to tolerate and more effective 
Gilead Sciences is expected to  according to the Zacks Consensus Estimate  Last quarter they beat earnings expectations by 0 33  at  3 03 per share  beating estimates of  3 02 a share GILEAD SCIENCES Price  Consensus and EPS Surprise   
Gilead Sciences is trading around  73 a share  and their 52 week high is  110 77 per share  Their average EPS surprise is 1 66  
Bottom Line
How should investors play Gilead Sciences ahead of their earnings report  For insights on the best options trades  then make sure you tune in on our  at 1pm to see his thoughts 
Confidential from ZacksWould you like to access Zacks  2 best trades that are not available to the public  Zacks Executive VP  Steve Reitmeister knows which of our experts has the hottest hand and when key trades are about to be triggered  Today he is prepared to pass the Best of Our Best along to you ",2016-10-31,Zacks Investment Research,https://www.investing.com/analysis/the-best-options-trade-for-gilead-sciences-(gild)-earnings-200161777,200161777
201759,423275,GILD,Your Two Minute Earnings Preview For Gilead  GILD  Stock ,opinion,"Today s quick video takes a closer look at Gilead Sciences  NASDAQ GILD  stock ahead of their earnings report  This biotech giant has been on a rough stretch as of late  erasing some memories of its incredible run a few years ago  The industry rank is pretty promising though  top 40  overall  so some might think there is a bit of hope left for the company heading into the release 
However  if we drill into GILD s fundamentals  it does appear as if more pain could be ahead  The company is expected to see 2017 EPS fall below 2016 figures  while the company just fell into Zacks Rank  5  Strong Sell  territory too 
GILD does have a decent history of living up to expectations in earnings season  but that might not be enough this time around  The outlook will weigh heavily on shares  and this could be a case where we see a beat  but the guidance rules the day for the stock GILEAD SCIENCES Price  Consensus and EPS Surprise   
Gilead reports on November 1st after the bell  and we are looking for earnings of  2 74 share  Make sure to watch the video for a quick guide to GILD heading into the report  but if you want to learn more about trading in earnings season  check out our Zacks Live Trader below for more information ",2016-10-31,Zacks Investment Research,https://www.investing.com/analysis/your-two-minute-earnings-preview-for-gilead-(gild)-stock-200161824,200161824
201760,423276,GILD,Gilead  GILD  Misses Q3 Earnings  Reiterates 2016 Guidance,opinion,"Gilead Sciences Inc    NASDAQ GILD   just released its third quarter fiscal 2016 financial results  posting earnings of  2 70 and revenues of  7 4 billion  GILD is a Zacks Rank  5  Strong Sell   and is up 0 24  to  74 25 per share in after hours trading shortly after its earnings report was released 
Missed earnings estimates  The company reported earnings of  2 70 cents per share  lagging behind the Zacks Consensus Estimate of  2 74 per share  This number excludes 21 cents from non recurring items 
Beat revenue estimates  The company saw revenue figures of  7 4 billion  surpassing our consensus estimate of  7 387 billion but decreasing 9 5  year over year 
Antiviral product sales  which include primarily products in Gilead s HIV and liver disease areas  were  6 8 billion for the third quarter of 2016 compared to  7 7 billionfor the same period in 2015 
Other product sales  which include Letairis   ambrisentan   Ranexa   ranolazine  and AmBisome   amphotericin B liposome for injection   were  564 million for the third quarter of 2016 compared to  509 million for the same period in 2015 
Gilead reiterated its full year 2016 guidance  with revenues expected to be in the range of  29 5 billion to  30 billion 
Here s a graph that looks at Gilead s price  consensus  and EPS surprise GILEAD SCIENCES Price  Consensus and EPS Surprise   Gilead Sciences  Inc  is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them  They have a broad based focus on developing and marketing drugs to treat patients with infectious diseases  including viral infections  fungal infections and bacterial infections  and a specialized focus on cancer  They have expertise in liposomal drug delivery technology  a technology that the company uses to develop drugs that are safer  easier for patients to tolerate and more effective 
Stocks that Aren t in the News Yet
You are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  Many of these companies are almost unheard of by the general public and just starting to get noticed by Wall Street  They have been pinpointed by the Zacks system that nearly tripled the market from 1988 through 2015  with a stellar average gain of  26  per year ",2016-11-01,Zacks Investment Research,"https://www.investing.com/analysis/gilead-(gild)-misses-q3-earnings,-reiterates-2016-guidance-200162098",200162098
201761,423277,GILD,Gilead  GILD  Misses Q3 Earnings Estimates  Retains View,opinion,Gilead Sciences  Inc  s   NASDAQ GILD   third quarter 2016 earnings  including the impact of stock based compensation expenses  of  2 70 per share missed the Zacks Consensus Estimate of  2 74 and were down 15 4  from the year ago quarter figure Moreover  total revenue in the reported quarter came in at  7 5 billion  down 9 6  year over year  Nevertheless  quarterly revenues marginally beat the Zacks Consensus Estimate of  7 4 billion HCV Franchise Disappoints Again  HIV ImpressesProduct sales came in at  7 4 billion  down 9 8  year over year and 3 2  sequentially  The decline was due to lower hepatitis C virus  HCV  sales  partially offset by higher sales across HIV and other therapeutic areas  Sequentially  there was an increase in HIV sales and HCV sales in the U S   and other products  offset by a decline in HCV sales in Japan and Europe Antiviral product sales  which include Gilead s HIV and liver disease portfolios  came in at  6 8 billion in the third quarter of 2016  down 11 2  HCV product sales  which include Harvoni  Sovaldi and the recently launched Epclusa  were  3 3 billion  down 31 3  mainly due to lower sales of Harvoni and Sovaldi HCV product sales in the U S  came in at  2 billion  down 37  year over year  mainly attributable to lower patient starts for Harvoni and lower revenues per patient  This was primarily a result of a higher percentage of sales that were made in more deeply discounted segments  The figure was also down 12  sequentially Total HCV revenue in Europe in the third quarter was  604 million  down 30  year over year and 22  sequentially  This was attributed to lower HCV patient starts in the early launch markets like Germany and France Sales of Harvoni plunged 44 2  year over year to  1 9 billion in the reported quarter  The decline was mainly due to lower sales in the U S   down 57 3  to  1 1 billion  and Europe  down 28 6  to  380 million   Further  Sovaldi sales recorded a year over year decline of 43 7  to  825 million Epclusa garnered sales of  640 million in the reported quarter  significantly higher than  64 million reported in the prior quarter  We note that Epclusa was launched in the U S  and Europe in June and July  respectively Meanwhile  HIV and other antiviral product sales came in at  3 5 billion  up 20 7  year over year and approximately 13  sequentially  The increase was primarily driven by continually strong uptake of tenofovir alafenamide  TAF  based products  Genvoya  which generated sales of  461 million  up from  302 million in the second quarter of 2016  Descovy  which recorded sales of  88 million  up from  61 million in the second quarter of 2016  and Odefsey  which registered sales of  105 million  up from  58 million in the second quarter of 2016 HIV treatments like Stribild  up 21 5  to  621 million   Complera Eviplera  up 14 2  to  411 million  and Viread  up 2  to  303 million  performed well  However  Atripla sales tanked 20 5  to  650 million  while Truvada sales fell 5  to  858 million Other products  that is Letairis  Ranexa  AmBisome and Zydelig recorded sales of  215 million  up 18 8     170 million  up 5 6     91 million  up 3 4   and  39 million  up 8 3    respectively Research   development  R D  expenses  including stock based compensation expenses  were up 35 4  to  1 billion  The increase was primarily due to overall development of the company s clinical studies  including a  200 million milestone expense associated with the acquisition of Nimbus Apollo  Inc Selling  general and administrative  SG A  expenses  including stock based compensation expenses  were down 8 1  to  827 million primarily due to lower branded prescription drug fee expense Adjusted product gross margin was 87 6   down from 89 6  in the year ago period 2016 Guidance ReiteratedGilead maintained its outlook for 2016  The company continues to expect net product sales in the range of  29 5  30 5 billion Adjusted R D expenses and adjusted SG A expenses are still projected in the range of  3 6  3 8 billion and  3 1  3 3 billion  respectively Adjusted product gross margin for 2016 is still predicted in the range of 88 90  Dividend and Share RepurchaseGilead declared its fourth quarter 2016 dividend  The company will pay a quarterly cash dividend of 47 cents per share of common stock on Dec 29  2016  to stockholders of record as of the close of business on Dec 15 During the reported quarter  the company repurchased shares worth  1 billion under its  12 billion 2016 share repurchase program GILEAD SCIENCES Price  Consensus and EPS Surprise    Our TakeGilead s third quarter results were far from encouraging  with the company missing earnings expectations and marginally beating top line estimates  Moreover  both earnings and revenues declined year over year  We expect investors to react negatively to the news  Nevertheless  Gilead has maintained its outlook for 2016  Its HCV franchise has been under competitive and pricing pressure  which led to a disappointing performance  especially the sales decline of both Harvoni and Sovaldi However  Epclusa s uptake has been encouraging  The HIV franchise performed encouragingly as well  thanks to Genvoya  Descovy and Odefsey  The company also revealed quite a few setbacks related to its pipeline on the third quarter call Zacks Rank   Stocks to ConsiderGilead is a Zacks Rank  5  Strong Sell  stock  Investors interested in the health care sector may consider Exelixis  Inc    NASDAQ EXEL    Incyte Corporation   NASDAQ INCY   and Geron Corporation   NASDAQ GERN    While Geron sports a Zacks Rank  1  Strong Buy   Exelixis and Incyte carry a Zacks Rank  2  Buy  You can see  Incyte s earnings estimates for 2016 and 2017 were up a respective 10  and 2 1  over the last 60 days  The company has beaten earnings estimates thrice in the last four quarters with an average surprise of 335 16  Exelixis has an average positive surprise of 9 10  over the trailing four quarters  Its share price has jumped more than 90  year to date  Loss estimates for both 2016 and 2017 have narrowed over the past 60 days Geron has posted a positive earnings surprise in all of the four trailing quarters with an average beat of 20 78  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-11-01,Zacks Investment Research,"https://www.investing.com/analysis/gilead-(gild)-misses-q3-earnings-estimates,-retains-view-200162239",200162239
201781,423297,GILD,GILD  Cheap Dividend Growth Or Value Trap ,opinion,"Gilead Sciences  NASDAQ GILD   the dominant antiviral and hepatitis drug company  is starting to draw a lot of attention from value oriented investors due to its decline of 23  over the past year 
Gilead s stock now trades at a high single digit price to earnings multiple which typically has many bargain hunters salivating  especially in a market where many quality  and  trade at over 20x earnings 
Furthermore  Gilead initiated a dividend in the second quarter of 2015 for the first time since the company s founding in 1987 and now yields 2 4  with strong dividend growth potential 
With a low payout ratio  cheap P E multiple  and a history of phenomenal growth  should  jump on the opportunity to own a stock that has returned nearly 400  over the last decade or are they getting lured into a value trap Business AnalysisGilead Sciences is a global biopharmaceutical company that discovers  develops  and commercializes innovative medicines in areas of unmet medical needs 
Gilead s main focus is on human immunodeficiency virus  HIV   liver diseases such as hepatitis  oncology and inflammations  and cardiovascular and respiratory conditions 
In 2015  they generated sales of  32 6 billion  the most in company history  Their main competitors in the industry include other large global biotechnology and pharmaceutical companies  Their products compete based on efficacy  safety  tolerability  acceptance by doctors  ease of use  insurance coverage  distribution and marketing 
Gilead s main therapeutics are Harvoni  Liver Diseases   Sovaldi  Liver Diseases   Truvada  HIV   Atripla  HIV   Stribild  HIV   Complera Eviplera  HIV   and Viread  Liver Diseases   All of these therapeutics generated sales in excess of one billion dollars in 2015 
Gilead has significant revenue concentration from its main drugs  The company s top ten drugs generated around 97  of their revenue in 2015 with the top three generating around 69  
Furthermore  their top therapeutic  Harvoni  generated sales of about  13 9 billion  or nearly 43  of their total revenue for the year 
It goes without saying that dividend investors need to be very comfortable with the outlook for these drugs to ever consider investing in Gilead Sciences regardless of the attractiveness of the valuation and the current important financial ratios 
The patent protection periods on their top drugs look okay with Harvoni covered until 2030  Sovaldi until 2029  Truvada until 2021  but only 2017 in the European Union   Atripla until 2021  but again only 2017 in the EU   Stribild until 2029  Complera Eviplera until 2022  and Viread until 2018 
Thus  with the benefits of patent protection lasting for at least 4 5 years on their major drugs  and much longer on Harvoni  then why are the shares so cheap today 
It all comes down to the market believing that Gilead s best days are behind the company  After all  it s hard to imagine the company s surge in margins earnings the last few years will be repeated  or possibly even sustained  
As seen below  Gilead s operating margins surged from roughly 40  in fiscal year 2013 to nearly 70  in 2015 thanks to high priced treatments Sovaldi  FDA approval in late 2012  and Harvoni  released in October 2014   Diluted earnings per share increased by a factor of 10 from 2013 to 2015 Source  Simply Safe Dividends
Source  Simply Safe Dividends
Product sales for their HIV and liver disease areas were down 1 3  for the six months ended June 30th  2016  with the decline accelerating in the second quarter for a nearly 6  slump 
Even more concerning  U S  product sales were down 12  year over year in the quarter and HCV product sales were down 33  due to lower revenues per patient as a result of increased rebates  discounts from payer mix  and less new patients starting Harvoni 
Harvoni is a major concern because sales are down over 22  through the first six months of the year  This trend is not getting any better as the sales decline accelerated in the second quarter of 2016 with sales falling nearly 29  from Q2 2015 levels in this key drug 
Furthermore  during the second quarter  Gilead slightly lowered its expectations for full year sales from  30    31 billion to  29 5    30 5 billion  This implies that management expects sales to fallaround 6  year over year from 2015 levels 
Let s dig in a bit further to understand the key drivers of the declining sales 
Here is the CFO  Robin Washington  discussing the trends on the second quarter conference call 
 While we are seeing continued strength in non HCV product sales  given the current trends in payer and patient flow dynamics for HCV  our updated models suggest net product sales will range from being slightly above to slightly below  30 billion for the year The factors contributing to this conclusion include lower HCV revenue per patient as a result of a mix shift towards more heavily discounted payer segment in the U S  and continues with a lower net average price in Europe  a trend toward slowing patient starts in the U S  commercial segment and some earlier launch markets of Europe  a continued gradual trend towards shorter duration and loss of some market share to competition  
These trends are clearly not good for Harvoni  which contributed well over 40  of their 2015 revenue  Sales could continue to fall if the current business trends continue and competition intensifies 
Furthermore  AbbVie and Merck  NYSE MRK  have entered the HCV space with new products  If the competition s new therapies continue to show promise  we would expect sales for Harvoni  and some of their other antiviral products to come under even more pressure 
Overall  there remains a lot of uncertainty surrounding the business  When looking for prospective investments for our Top Dividend Stocks portfolio  we do not like to see such sales concentration in top products because it significantly increases uncertainty and could lead to dividend cuts if a company s financials really deteriorate 
While the biotech industry has numerous appealing qualities  e g  high barriers to entry with steep R D requirements and regulations  products can take 10  years to develop  patent protection and intellectual property result in excellent margins for successful drugs   it s nearly impossible to pick the winners beforehand and predict how new drugs in the pipeline will play out 
Making forecasts is further complicated thanks to healthcare reform changing consumers  insurance policies  public funding issues for some of Gilead s major customers  and increased industry scrutiny over pricing  e g  Harvoni s wholesale cost runs roughly  94 000 for a full treatment  Dividend Safety AnalysisWe analyze 25  years of dividend data and 10  years of fundamental data to understand the safety and growth prospects of a dividend  
Our Dividend Safety Score answers the question   Is the current dividend payment safe   We look at factors such as current and historical EPS and FCF payout ratios  debt levels  free cash flow generation  industry cyclicality  ROIC trends  and more 
Dividend Safety Scores range from 0 to 100  and conservative dividend investors should stick with firms that score at least 60  Since tracking the data  companies cutting their dividends had an average Dividend Safety Score below 20 at the time of their dividend reduction announcements 

We wrote a detailed analysis reviewing how Dividend Safety Scores are calculated  what their track record has been  and how to use them for your portfolio 
Gilead s Dividend Safety Score is 91  which indicates that the dividend is very safe relative to other dividend paying stocks in the market 
Let s investigate the drivers behind this exceptional Safety Score 
Current 2016 forecasts expect Gilead to generate  11 49 in earnings per share  If the company maintains the current dividend  they will pay out about  1 84 per share  This implies a very conservative payout ratio of 16   but up slightly from when they initiated the dividend in 2015 Source  Simply Safe Dividends
Furthermore  the company ended the second quarter of 2016 with  24 6 billion in cash and investments  This means that the company can cover the roughly  2 5 billion dollar 2016 dividend by nearly 10x with just the cash on hand 
However  the company does carry about  22 billion dollars in debt with the majority of it due in the next five years  If the company s business remains stable  we don t expect Gilead to have any difficulty refinancing this debt in coming years 
Overall  we would consider the company to be in excellent financial shape at this time  The largest risk would be the company making a large acquisition that would put the current capital structure at risk 
Here is management discussing capital allocation on the first quarter 2016 earnings conference call 
  I think as we said all along  we look at how we leverage our cash as not only being share repurchases and dividends  but also we consistently look at investing in our core pipeline as well as M A where appropriate  And similar to the amounts that you called out relative to cash  it s actually about a 17  reduction in share count  as I mentioned on the call  We have done a lot of M A as well  And I think we ll continue to do that  as John said  when the right opportunities present themselves  
Since the company sells recession resistant products  the business is not susceptible to the general economic cycle  Rather  as mentioned in the business analysis section  the largest risks to the business and sustainability of the dividend are competition with their HCV product portfolio  payer mix  and patient flow 
Right now the dividend appears to be very safe given the low payout ratios and healthy net cash position 
The key factors dividend investors need to pay attention to going forward to have confidence in the dividend s safety is M A and further erosion of the key anti viral products portfolio Dividend Growth AnalysisOur Growth Score answers the question   How fast is the dividend likely to grow   It considers many of the same fundamental factors as the Safety Score but places more weight on growth centric metrics like sales and earnings growth and payout ratios  Scores of 50 are average  75 or higher is very good  and 25 or lower is considered weak 
Gilead s Dividend Growth Score is 92  which indicates that its dividend growth prospects are very strong 
The main drivers of the fantastic growth score are the low payout ratio  outstanding historical earnings growth  and net cash position 
As detailed above in the Dividend Safety Section  the payout ratio is low   especially compared to other  100 billion dollar market cap stocks in this industry  However  very few companies of this size are so reliant on so few products 
While there is certainly room to move the payout ratio up  we do not believe it would be prudent to move it up to payout ratios of similarly sized companies within the industry given the aforementioned product concentration 
If management is able to skillfully diversify the revenue streams among more and more therapeutics  then we believe the payout ratio can substantially move up over time 
The company s growth in recent history is nothing short of jaw dropping  Sales have gone from  8 4 billion in 2011 to over  32 6 billion in 2015 with EPS increasing from  1 77 to  11 91 Source  Simply Safe Dividends
The main drivers of the growth are from blockbusters in the antiviral portfolio  namely Harvoni  Sovaldi  and Stribild 
These growth rates are clearly not sustainable given the current absolute sales level and the difficulties the company currently faces 
Future growth will come from the pipeline and successful acquisitions 
Gilead spent  3 billion dollars on R D in 2015  a 6  increase over 2014 levels  At the end of 2015 they had 180 active clinical studies  of which 61 were Phase 3 clinical trials  Current promising new medicines include treatments for nonalcoholic steatohepatitis  NASH  and HIV 
Overall  we would expect Gilead to continue to raise the dividend in line with to slightly above EPS growth as long as they are able to stabilize the current product portfolio  successfully introduce new medicines  and maintain a healthy balance sheet 
Management raised the dividend by 10  earlier this year  and future dividend growth will likely be at least in the mid  to high single digits over time ConclusionWhile there is a lot to like about Gilead  including a seemingly cheap valuation and solid positions in difficult to treat diseases  there is a lot of uncertainty in the future of the company  While some high yield dividend stocks  including General Motors  NYSE GM   have a lot of uncertainty  the drivers of that uncertainty are more knowable and easier to analyze 
In the case of Gilead  it is very difficult to have confidence given a number of factors that affect the business including product concentration  pricing initiatives by payers to reduce HCV spending  competitors launching new HCV products  discounts in new commercial payer contracts  and mix shifts in payers  VA  Medicaid  etc  which all can have large impacts on the value of the business 
The very cheap valuation is enticing  but we prefer to invest in businesses we can understand and have strong competitive positions  low customer product concentration  and a narrower range of future outcomes 
Gilead could turn out to be a very good investment at this price  but frankly  the company is outside of our circle of competence and we will not be adding a position to any of our portfolios at this time ",2016-09-09,Brian Bollinger,https://www.investing.com/analysis/gild:-cheap-dividend-growth-or-value-trap-200152807,200152807
201790,423306,GILD,ETFs In Focus On Pfizer s Medivation Acquisition ,opinion,"The biotech giant  Pfizer Inc    NYSE PFE   and Xtandi manufacturer  Medivation  Inc    NASDAQ MDVN   entered into a definitive merger agreement under which Pfizer will  Medivation for  81 50 per share in cash or a total enterprise value of about  14 billion  Pfizer s earnings are expected to get a boost immediately following the completion of the deal     
Pfizer outran other potential buyers like Merck   NYSE MRK    Gilead Sciences   NASDAQ GILD    Celgene   NASDAQ CELG   and Sanofi   NYSE SNY    who were also in the race to acquire Medivation  according to several reports  The company rejected Sanofi s deal to acquire the company at  58 a share in the earlier part of this year  The Pfizer  Medivation deal is likely to have a significant impact on price performances of the two biotech companies and eventually on broader markets 
Is Xtandi the Main Motive Behind the Deal 
The biotech giant is speculated to benefit from the deal  especially in its cancer drugs segment  which is already a significant contributor to its business  The strong potential of Medivation s Xtandi  which is considered one of the leading prostate cancer treating drugs  is likely to boost Pfizer s business  Xtandi emerged as the biggest player in the novel hormonal therapy  NHT  domain with more than half of the market share in the second quarter  the second time in a row  
Strong growth in Xtandi s sales played an important role in boosting revenues during the second quarter  While collaboration related net sales of Xtandi in the U S  surged 11  to  165 1 million for the quarter  Ex U S  revenues soared 60  from the year ago quarter to  41 0 million  It led Medivation s collaboration revenues to jump 18  year on year to  206 2 million  Also  Xtandi is speculated to have the potential to witness strong growth in the near future 
During the second quarter earnings release  David Hung  CEO of Medivation  said   We anticipate a very exciting second half of 2016 for XTANDI as we prepare commercially for the October 22 PDUFA date for a potential U S  label amendment to include head to head data of enzalutamide versus bicalutamide  
Will the Deal Boost Pfizer s Cancer Drug Segment 
The Medivation acquisition  if it goes through  will strengthen Pfizer s cancer franchise  which currently consists of products like Ibrance  Xarelto and Sutent  Pfizer is also working on strengthening its immune oncology pipeline and the Medivation acquisition would be a good strategic fit for the company  Pfizer is already benefitting from strong growth in the oncology segment  read    
During the second quarter  Global Oncology revenues increased 54  to  1 1 billion driven by Xalkori and Ibrance  This was one of the main factors that led the company to post revenues of  13 1 billion in the quarter  increasing 11  from the year ago period  Separately  pipeline candidate talazoparib  an orally available PARP inhibitor  represents significant upside potential  PARP inhibitors are currently being considered to be the next major class of therapeutics in oncology  read    
ETFs in Focus
While the Pfizer Medivation deal is likely to have notable impact on broader stock markets today  ETFs having significant exposure to Pfizer are also poised to be on investors  radar in the days ahead  Hence  we have highlighted four ETFs which have Pfizer as one of their major components and are likely to remain in focus in the post deal period 
iShares US Pharmaceuticals 
This ETF provides exposure to 39 pharma stocks by tracking the Dow Jones U S  Select Pharmaceuticals Index  Pfizer holds the second position among its holdings with an exposure of 8  in the fund  The product has  642 2 million in AUM and charges 44 bps in fees and expense  Volume is moderate as it exchanges about 34 000 shares a day  The fund has gained 9  over the past three months and has a Zacks ETF Rank  2  Buy  with a Medium risk outlook  read    
Health Care Select Sector SPDR ETF  NYSE XLV  
This is by far the most popular and liquid choice in the healthcare space that follows the Health Care Select Sector Index  The product has an AUM of about  13 2 billion and sees solid volume of around 10 million shares a day  The fund charges 14 bps in fees and expenses from investors  The fund holds 59 stocks  Pfizer occupies the second place in terms of holdings with 7 5  share  The fund has gained 6 7  over the past three months and has a Zacks ETF Rank  1  Strong Buy  with a Medium risk outlook  read    
Fidelity MSCI Health Care ETF 
This ETF follows the MSCI USA IMI  LON IMI  Health Care Index and holds a large basket of 350 stocks  Pfizer  at the second spot  has an exposure of 6 5  in the fund  The product has managed to accumulate roughly  635 million in its asset base so far and trades in a moderate volume of nearly 112 000 shares per day  It is very cheap with 8 bps in annual fees  The fund has gained 7 2  over the past three months and has a Zacks ETF Rank  2 with a Medium risk outlook 
Vanguard Health Care ETF 
This ETF provides exposure to 353 stocks by tracking the MSCI US IMI Health Care 25 50 Index  Pfizer holds the second position among its holdings with an exposure of 6 8  in the fund  The product has  5 8 billion in AUM and charges 9 bps in fees and expense  Volume is moderate as it exchanges about 193 000 shares a day  The fund has gained 7 2  over the past three months and has a Zacks ETF Rank  1 with a Medium risk outlook 
Want key ETF info delivered straight to your inbox  
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2016-08-22,Zacks Investment Research,https://www.investing.com/analysis/etfs-in-focus-on-pfizer's-medivation-acquisition-200149367,200149367
201791,423307,GILD,Galapagos  GLPG  Advances RA Drug Filgotinib To Phase III,opinion,"Galapagos NV   NASDAQ GLPG   announced the initiation of a phase III program  FINCH  on filgotinib for the treatment of rheumatoid arthritis  RA  The program will comprise three studies that will evaluate the safety and efficacy of once daily filgotinib  100 mg and 200 mg  in patients with RA  ranging from early stage to biologic experienced FINCH 1  an adalimumab controlled study  will evaluate filgotinib in combination with methotrexate  MTX  in patients who have had inadequate response to MTX  while FINCH 2 will include patients on conventional disease modifying anti rheumatic drugs  cDMARD   who have had an inadequate response to biological treatment  FINCH 3  on the other hand  will enroll MTX na ve patients to evaluate filgotinib in combination with MTX and monotherapy GALAPAGOS  ADR Price
    We note that competition in the RA market is stiff due to the presence of drugs like Acterma  Rayos and Xeljanz among others Galapagos has global partnership with Gilead Sciences  Inc    NASDAQ GILD   for the development and commercialization of filgotinib for inflammatory indications  Under the terms of the agreement  Galapagos will co fund 20  of global development activities  while Gilead will be responsible for manufacturing  worldwide marketing and sales activities Meanwhile  the companies are also preparing to initiate studies on filgotinib in other indications  such as Crohn s disease and ulcerative colitis  in the fourth quarter of 2016 Given that Galapagos has no approved product in its portfolio yet  we expect investor focus to remain on updates pertaining to the development of the candidates in its pipeline Galapagos currently carries a Zacks Rank  2  Buy   A couple of other favorably placed stocks in the health care sector include Actelion Ltd    OTC ALIOF   and ANI Pharmaceuticals  Inc    NASDAQ ANIP    Both the stocks sport a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-08-22,Zacks Investment Research,https://www.investing.com/analysis/galapagos-(glpg)-advances-ra-drug-filgotinib-to-phase-iii-200149625,200149625
201802,423318,GILD,SPY  GOOGL And AMZN Are Moving On Up,opinion," A man is rich in proportion to the number of things he can afford to let alone   Henry David Thoreau
Another solid week for stocks who continued to act just great and as they should in a strong market such as we have right now 
I did have to sell out of Gilead Sciences Inc  NASDAQ GILD  and take a couple dollars per share loss but all my other positions continue to work well 
The good news here is it frees up some capital to put to work in the many new buy setups

SPDR S P 500  NYSE SPY  remains in this horizontal channel which continues to imply higher prices are to come 
I m still long SPY from 202 with a 10  weighting with 215 or so still my stop area ",2016-08-01,Warren Bevan,https://www.investing.com/analysis/googl---amzn-moving-on-up-200145214,200145214
201816,423332,GILD,Gilead  GILD  Stock Falls On Sales Miss And Lower 2016 Revenues Guidance,opinion,"Gilead Sciences Inc    NASDAQ GILD   just released their second quarter fiscal 2016 earnings results  posting earnings of  3 03 per share and revenue of  7 776 billion 
Currently  GILD has a Zacks Rank  2  Buy   but it is subject to change following the release of the company s latest earnings report  Here are 5 key statistics from this just announced report below 
Gilead                                                      
Beat earnings estimates  The company posted  3 03 per share  surpassing our Zacks Consensus Estimate of  3 02   These EPS numbers exclude  0 45 from nonrecurring items 
Missed revenue estimates  The company saw revenue figures of  7 776 billion  missing our estimate of  7 851 billion 
HCV drugs represent Gilead s core revenues source  and sales for the segment were  4 0 billion  which represents a 22 5  decline from the same quarter last year 
Lowered sales guidance for 2016  lowering their revenues forecast from  30 5 billion to  30 billion 
GILD was down  2 58  or 2 91   to  85 97 as of 4 33 PM ET in after hours trading shortly after its earnings report was released 
Here s a graph that looks at Gilead s quarterly revenues over the last five years 
 GILEAD SCIENCES Revenue  Quarterly     
 
Gilead Sciences  Inc  is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them  They have a broad based focus on developing and marketing drugs to treat patients with infectious diseases  including viral infections  fungal infections and bacterial infections  and a specialized focus on cancer  They have expertise in liposomal drug delivery technology  a technology that the company uses to develop drugs that are safer  easier for patients to tolerate and more effective 
Check back later for our full analysis onGilead s secondquarter earnings report ",2016-07-25,Zacks Investment Research,https://www.investing.com/analysis/gilead-(gild)-stock-falls-on-sales-miss-and-lower-2016-revenues-guidance-200144039,200144039
201817,423333,GILD,Will Gilead Earnings Rebound This Quarter ,opinion,"Gilead Sciences  NASDAQ GILD 
Healthcare   Biotechnology   Reports July 25  After Market Closes 
Key Takeaway
The Estimize consensus is looking for earnings per share of  3 06 on  7 9 billion in revenue  4 cents higher than Wall Street on the bottom line and  50 million on the top
Sales of its Hep C medications are facing their biggest obstacle with the emergence of Merck s cheaper drug
Gilead s robust pipeline bodes well moving forward but don t expect them to turn the corner this quarter
Healthcare is one of the most volatile industries today  A single announcement can swing a stock significantly in either direction  Gilead had been on the right side of those swings as earnings continued to rise and top expectations over the past few years  However  a dismal first quarter pushed Gilead off its proverbial pedestal  Expectations for the upcoming quarter have come down considerably in light of the weak Q1 report 
The Estimize consensus is looking for earnings per share of  3 06 on  7 9 billion in revenue  4 cents higher than Wall Street on the bottom line and  50 million on the top  Compared to the year prior  earnings are projected to fall by 3  with sales down as much as 4   Shares are down nearly 27  from year earlier with a majority of those losses coming in the past 3 months 
Gilead rose to prominence on the back of its Hep C and HIV medication  The company is still a dominant presence in both markets but its position has started to wane  Sales for its Hep C medications face its stiffest competition after rival Merck  NYSE MRK  debuts its own drug  Merck s cheaper Hep C drugs has already started to chip away at Gilead s sales  COmbined sales of Harvoni and Sovaldi reported a 6  decline in its first quarter earnings 
With a number of new drugs in the pipeline and the recent approval of its new HCV drug Epclusa  earnings should start stabilize  Epclusa is the first drug that treats all sub types of hepatitis C  which analyst believe could generate  1 8 billion this year  Gilead s pipeline also consists of 7 late stage clinical trials and another 17 phase 2 studies in progress  For now though  investors should expect results similar to the first quarter 

Do you think GILD can beat estimates ",2016-07-25,Estimize,https://www.investing.com/analysis/will-gilead-earnings-rebound-this-quarter-200143865,200143865
201830,423346,GILD,What s In Store For TransUnion  TRU  This Earnings Season ,opinion,"Premium business service company TransUnion   NYSE TRU   is scheduled to release second quarter 2016 results after the closing bell on Jul 26  In the last reported quarter  TransUnion s earnings beat the Zacks Consensus Estimate by a remarkable 20   The average earnings surprise over the last four trailing quarters is 13 41  
Let s see how things are shaping up prior to this announcement 
Factors to Consider
Toward the end of the second quarter  TransUnion acquired Auditz LLC  a healthcare services firm that utilizes sophisticated proprietary technology to help healthcare providers identify and recover payments  Notably  Auditz will bring new capabilities to TransUnion s healthcare business that will prove to be beneficial to its customers and further enhance its competitive strength and market value proposition  Although the acquisition is not likely to make any significant contribution in the to be reported quarter  its impact on attracting potential revenue contribution from other clients is irrefutable 
Also  the company collaborated with FICO and launched FICO Auto Score 9 XT  which utilized TransUnion s CreditVision data  The new score specifically caters to the auto finance marketplace and includes several innovative features like trended data from TransUnion s CreditVision 
During the quarter  TransUnion also entered into a partnership with award winning password manager and leader in online identity management  Dashlane  to create innovative services for its respective customers  The company will focus on credit monitoring  identity and fraud protection  credit information and breaches  TransUnion will also ensure Dashlane expand its distribution through its multiple partner channels in the U S  and globally 
However  TransUnion s revenues are vulnerable to macroeconomic conditions such as interest rates  employment levels  consumer confidence  accessibility of affordable credit and capital  inflation and housing demand  Economic recovery has been weak so far and  consequently  consumer spending has been constrained  Factors like these are likely to limit the company s growth prospects and adversely affect its financials 
TransUnion operates amid stiff competition  Its competitors widely vary according to its business segment  geographical market and the industry vertical that its solutions address  The intense competition restricts the company s pricing power to some degree  All these issues limit its profitability and are a strain on its bottom line 
The company expects second quarter revenues to be in the range of  405 million and  410 million  Adjusted EBITDA for the quarter is likely to be in the range  145 million and  150 million  while adjusted earnings are expected to be between 31 33 cents per share 
TRANSUNION Price and EPS Surprise
   Earnings Whispers
Our proven model does not conclusively state that TransUnion is likely to beat earnings in the upcoming quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  for an earnings beat  This is not the case here as we will see below 
Zacks ESP  Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is currently at 0 00  
Zacks Rank  TransUnion carries a Zacks Rank  3  Though a favorable Zacks Rank increases the predictive power of an earnings beat  a 0 00  ESP makes surprise predictions uncertain 
Note that we caution against Sell rated stocks  Zacks Rank  4 or  5  going into the earnings announcement  especially when the company is seeing negative estimate revisions 
Stocks to Consider
Here are some companies you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter 
American Campus Communities  Inc   NYSE ACC   has an Earnings ESP of  1 89  and a Zacks Rank  2  It is scheduled to report on Jul 25 
The Earnings ESP of Gilead Sciences Inc    NASDAQ GILD   is  6 91  and it has a Zacks Rank  2  The company is expected to report on Jul 25 
AK Steel Holding Corp    NYSE AKS   has an Earnings ESP of  50 00  and a Zacks Rank  2  It is expected to release results on Jul 26 ",2016-07-21,Zacks Investment Research,https://www.investing.com/analysis/what's-in-store-for-transunion-(tru)-this-earnings-season-200143372,200143372
201853,423369,GILD,Gilead s Pan Genotypic HCV Drug Epclusa Gains EU Approval,opinion,"Positive news flowed in at Gilead Sciences Inc    NASDAQ GILD   with the European Commission approving the marketing authorization application for Epclusa  Sovaldi 400 mg velpatasvir 100 mg   the first pan genotypic  single tablet regimen for the treatment of adults with genotype 1 6 chronic hepatitis C virus  HCV  infection  The company s shares inched up 1 3  on the news 
The combination for 12 weeks is approved for the treatment of patients without cirrhosis or with compensated cirrhosis  Child Pugh A  and in combination with ribavirin  RBV  for patients with decompensated cirrhosis  Child Pugh B or C   Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotype 2 and 3  without the need for RBV  Physicians will however have the flexibility to consider the addition of RBV for genotype 3 infected patients with compensated cirrhosis 
EU approval was largely expected as the Committee for Medicinal Products for Human Use had issued a favorable opinion this May  which was adopted following an accelerated review procedure GILEAD SCIENCES Price   We note that Epclusa is Gilead s third sofosbuvir based treatment to gain approval in the EU for the treatment of chronic HCV infection and is expected to complement Gilead s current HCV portfolio consisting of Sovaldi and Harvoni 
We remind investors that Epclusa gained FDA approval for the treatment of adults with genotype 1 6 chronic HCV late last month  We are encouraged by the company s efforts in expanding its HCV franchise  Competition and pricing pressure have already intensified in the HCV market with the entry of a new competitor   Merck   Co  Inc  s   NYSE MRK   Zepatier 
Meanwhile  Gilead is also evaluating a once daily fixed dose combination of Sovaldi velpatasvir plus GS 9857  an experimental NS3 protease inhibitor  in phase III studies  for the treatment of chronic genotype 1 6 HCV 
Gilead is a Zacks Rank  2  Buy  stock  A couple of other favorable stocks in the health care sector are Innoviva  Inc    NASDAQ INVA   and Fibrocell Science  Inc    NASDAQ FCSC    each sporting a Zacks Rank  1  Strong Buy  ",2016-07-10,Zacks Investment Research,https://www.investing.com/analysis/gilead's-pan-genotypic-hcv-drug-epclusa-gains-eu-approval-200141108,200141108
201854,423370,GILD,Ligand  LGND  Signs Deal With Gilead For OmniAb Technology,opinion,Ligand Pharmaceuticals Incorporated   NASDAQ LGND   announced that it has entered into a worldwide license agreement with Gilead Sciences  Inc    NASDAQ GILD    under which the latter will use the OmniRat  OmniMouse and OmniFlic technologies for the discovery of fully human mono  and bispecific antibodies This deal will see Ligand receiving annual access payments  milestone payments and royalties for product developed under the collaboration using an OmniAb antibody  Meanwhile  Gilead will be responsible for all costs related to the programs We remind investors that OmniAb  an antibody generating platform  became part of Ligand s technology portfolio following its Jan 2016 acquisition of OMT  Inc   a privately held company focused on genetic engineering of animals for the generation of human therapeutic antibodies  The acquisition not only diversified Ligand s business by adding OmniAb to its technology portfolio  which consisted of the Captisol  LTP and Selexis technologies  but also created a strong platform to aid the company s search for new licenses and partnerships We note that Ligand has partnerships with several health care companies for its OmniAb platform  Earlier this year  it signed a licensing agreement with Emergent BioSolutions  Inc    NYSE EBS   for the same technology  In addition  the company signed agreements with Tizona Therapeutics  Inc  and ABBA Therapeutics AG Last month  the company announced that it has received  4 million from the expansion of two OmniAb license agreements with Wuxi  One of the extensions relates to expanding access to the OmniAb platform by adding OmniFlic to the current licensee agreement  which is presently limited to OmniRat  The second extension pertains to Wuxi s sub licensing of Chinese rights to an Investigation New Drug  IND  ready antibody discovered through the OmniAb platform Including these payments  revenues for the second quarter of 2016 are anticipated to come in at approximately  19 million Ligand is a Zacks Rank  3  Hold  stock  while Gilead carries a Zacks Rank  2  Buy   Innoviva  Inc    NASDAQ INVA   is a better ranked stock in the health care sector  sporting a Zacks Rank  1 Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-07-10,Zacks Investment Research,https://www.investing.com/analysis/ligand-(lgnd)-signs-deal-with-gilead-for-omniab-technology-200141096,200141096
201855,423371,GILD,Gilead s HCV Drug Epclusa Gets Regulatory Nod In Canada,opinion,Gilead Sciences Inc    NASDAQ GILD   announced that Health Canada has issued a Notice of Compliance to Epclusa  Sovaldi 400 mg velpatasvir 100 mg   the first once daily  pan genotypic single tablet regimen for the treatment of adults with genotype 1 6 chronic hepatitis C virus  HCV  infection The 12 week Sovaldi velpatasvir combination was approved for the treatment of patients without cirrhosis or with compensated cirrhosis and in combination with ribavirin  RBV  for patients with decompensated cirrhosis  Epclusa is also the first single tablet regimen approved for the treatment of HCV genotype 2 and 3  without the need for RBV We remind investors that in Jun 2016  Epclusa was approved in the U S  for the treatment of adults with genotype 1 6 chronic HCV  Last week  the drug gained approval in the EU for the same indication GILEAD SCIENCES Price   Epclusa is Gilead s third sofosbuvir based treatment to gain approval for the treatment of chronic HCV infection We are encouraged by the company s efforts in expanding its HCV franchise  which already boasts two approved drugs   Harvoni and Sovaldi We note that competition in the HCV market is intense with drugs like Viekira Pak  Zepatier  and Olysio crowding the space  Competition and pricing pressure have intensified further with the entry of Merck   Co  Inc  s   NYSE MRK   Zepatier Meanwhile  Gilead is evaluating a once daily fixed dose combination of Sovaldi velpatasvir plus GS 9857  an experimental NS3 protease inhibitor  in phase III studies for the treatment of chronic genotype 1 6 HCV Gilead currently holds a Zacks Rank  2  Buy   A couple of other favorably placed stocks in the health care sector are Merrimack Pharmaceuticals  Inc    NASDAQ MACK   and Innoviva  Inc    NASDAQ INVA    Both stocks sport a Zacks Rank  1  Strong Buy  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-07-14,Zacks Investment Research,https://www.investing.com/analysis/gilead's-hcv-drug-epclusa-gets-regulatory-nod-in-canada-200142170,200142170
201868,423384,GILD,Gilead Presents Favorable Preliminary Bictegravir HIV Data,opinion,"Gilead Sciences Inc    NASDAQ GILD   presented encouraging preliminary data from four pre clinical and phase I studies evaluating its experimental once daily integrase strand transfer inhibitor  INSTI   bictegravir  GS 9883   for the treatment of HIV 1 infection  Data were presented at the American Society of Microbiology Conference 
Results showed that bictegravir demonstrated a favorable pharmacokinetics and resistance profile when compared to currently available INSTIs   Tivicay  dolutegravir   Vitekta  elvitegravir  and Isentress  raltegravir    While bictegravir alone was highly effective against HIV 1 infected target cells  in combination with tenofovir alafenamide  TAF   Emtriva  emtricitabine  and Prezista  darunavir   it was highly synergistic against HIV 1  On the safety front  it was found to be well tolerated with no serious adverse events  AEs  and no discontinuations due to AEs 
We note that a single tablet regimen of bictegravir is currently being evaluated in phase III studies in combination with TAF and Emtriva for the treatment of HIV 1 infection 
HIV is Gilead s one of the primary areas of focus  The company has three other TAF based regimens that recently gained FDA approval for the treatment of HIV 1 infection   Descovy  Odefsey and Genvoya  While Genvoya and Descovy are already approved in the EU  Odefsey is under review in the same 
Gilead is a Zacks Rank  5  Strong Sell  stock  Some better ranked stocks in the health care sector include ANI Pharmaceuticals  Inc    NASDAQ ANIP    Retrophin  Inc    NASDAQ RTRX   and Bristol Myers Squibb Company   NYSE BMY    All three stocks sport a Zacks Rank  1  Strong Buy  ",2016-06-20,Zacks Investment Research,https://www.investing.com/analysis/gilead-presents-favorable-preliminary-bictegravir-hiv-data-200137333,200137333
201869,423385,GILD,Stock Buybacks Up Double Digits In 1st Quarter,opinion,"S P 500 Dow Jones Indices reports first quarter stock buybacks for the S P 500 Index were higher by 12  on a year over year basis  On a quarter over quarter basis buybacks were higher by 10 6   The increase in buyback activity was supported by a quarter over quarter 15 8  increase in as reported earnings  Disappointingly though was the fact QOQ dividend payments declined 3 1   Additionally  the combination of dividends and buybacks equaled  257 65 billion and was in excess of reported earnings of  189 11 billion  This is the six straight quarter buybacks plus dividends exceeded reported earnings  Several highlights from S P s report 

The Health care sector increased 86 1  to  30 6 billion for the quarter  up from the prior quarter s  16 5 billion  as Gilead Sciences  NASDAQ GILD  spent  8 billion  ranking as the 18th largest in S P 500 history  
The Energy sector conducted only minor buybacks   2 1 billion   as it posted a 20 6  decline for the quarter and a 62 9  decline from Q1 2015 
For the ninth consecutive quarter  more than 20  of the S P 500 issues reduced their year over year diluted share count by at least 4   therefore boosting their earnings per share  EPS  by at least 4   The participation rate for significant EPS impact rose to 28 2  for Q1 2016  up from 25 8  in Q4 2015 
Total shareholder return  dividends plus buybacks  set a quarterly record of  257 6 billion in Q1 2016 and a 12 month record of  974 6 billion for the period ending in March 2016 

Howard Silverblatt  Senior Index Analyst at S P Dow Jones Indices  said   The Q4 2015 uptick in buybacks was a surprise to many in the market  but it continued in Q1 2016  The pace of buybacks was partially driven by companies supporting their stock during the opening downturn of the year  which coincidentally started in early February when many earnings lock ups ended  The upswing in both expenditures and participation appears to persist in the market  meaning that the upturn in Q4 was not single shot  Looking at Q2 2016  the share count reduction trend is already baked in  as more than 20  of the issues have reduced their share count by at least 4  from Q2 2015  
Silverblatt also noted in the report cash reserves set a new record and increased 1 6  to  1 347 trillion   Shareholder returns continue to increase  as companies remain awash with cash and have access to low cost financing   especially in Europe and Asia   said Silverblatt   The rate of dividend increases has slowed  as commodity based issues remain a major uncertainty  Given the current cash flow  projections  and an expected slow and measured pace of interest rate increases in the U S  by the FOMC  companies have the ability to increase returns  as they remain under continued pressure from outside investors  
From an investor perspective  at HORAN  we prefer to see companies commit to higher dividend payments versus just an increase in buybacks  Dividends tend to be a more permanent commitment on a company s part and an indication of more consistent expected earnings  growth   where buybacks can be turned off and on at will ",2016-06-27,Blog of HORAN Capital Advisors,https://www.investing.com/analysis/stock-buybacks-up-double-digits-in-first-quarter-200138299,200138299
201870,423386,GILD,Why Is Gilead Sciences  GILD  Stock Gaining Today  ,opinion,"As the global markets continue to deal with the effects of the Brexit  at least one company is bouncing back strong on Tuesday  Gild Sciences   NASDAQ GILD   gained nearly 3 5  in morning trading today following the approval of its new hepatitis C drug 
The Foster City  California based biopharmaceutical company  today that the U S  Food and Drug Administration  FDA  has approved Epclusa  the first all oral  single tablet regimen for the treatment of all six genotypes of the hepatitis C virus  HCV  
 The approval of Epclusa represents an important step forward in the global effort to control and potentially eliminate HCV as it provides a safe  simple and effective cure for the majority of HCV infected patients  regardless of genotype   said Ira Jacobson  MD  an investigator in the Epclusa clinical trials 
The FDA expedited Epclusa s approval process through its Priority Review and Breakthrough Therapy program  which can be applied to potential treatments that offer major advances over existing treatments 
Gilead is already well known for its Hepatitis treatment options  and its existing drugs Harvoni and Sovaldi were responsible for nearly  4 3 billion in revenue last quarter  However  these treatments have been criticized for their high price tags  and they are only effective for patients with the first four genotypes of HCV 
While about 3 2 million people in the United States have HCV  the vast majority of patients have genotypes one and two  with less than 1  of patients contracting genotypes five and six  Nevertheless  Epclusa s simplicity and effectiveness should help give Gilead a leg up on its competition  including AbbVie s   NYSE ABBV   Viekira Pak treatment ",2016-06-28,Zacks Investment Research,https://www.investing.com/analysis/why-is-gilead-sciences-(gild)-stock-gaining-today-200138750,200138750
201871,423387,GILD,The Zacks Analyst Blog Highlights  Gilead  Regulus  AbbVie  The Medicines And GW Pharma,opinion,"For Immediate Release 

Chicago  IL   June 30  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include   Gilead     Regulus     AbbVie     The Medicines Company      and GW Pharma    

Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Wednesday s Analyst Blog  

Biotech Stock Roundup

Gilead    once again showed its expertise in the hepatitis C virus  HCV  segment by gaining FDA approval for yet another drug  Epclusa  However  another company  Regulus      suffered a setback related to its experimental HCV treatment Recap of the Week s Most Important Stories
	1  Gilead got some good news for both its key franchises   HIV and HCV  The company gained European approval for its HIV treatment  Odefsey  the second single tablet regimen containing the Descovy backbone and the third product in the company s new TAF portfolio to gain approval in Europe  Read more     
	Meanwhile  Gilead continues to expand its blockbuster HCV franchise  The company gained FDA approval for Epclusa  the first all oral  pan genotypic  single tablet regimen for the treatment of adults with genotype 1 6 chronic HCV  Epclusa is also approved for use in certain other patient populations  Read more     
	2  Regulus suffered a setback with the company receiving a verbal notice from the FDA placing its IND for experimental HCV treatment  RG 101  on clinical hold  The clinical hold was placed after the company reported a second serious adverse event  SAE  of jaundice in an early stage study  The news led to a 49 3  decline in the company s stock price 
	Meanwhile  AbbVie    decided to terminate its collaboration with Infinity Pharma for the development and commercialization of experimental cancer treatment  duvelisib  Efforts to restructure the partnership proved futile and resulted in global rights to the treatment being returned to Infinity  AbbVie s decision was not exactly unexpected considering top line data from the phase II DYNAMO study  while positive  fell short of expectations 

Meanwhile  Infinity said it will be cutting its workforce by 58  and will close certain studies that were being conducted on duvelisib  The company will explore strategic options for the duvelisib program  and will focus on submitting a NDA in the fourth quarter of 2016 
	3  The Medicines Company    got a boost with its experimental antibiotic  Carbavance  meeting FDA as well as EMA pre specified primary endpoints in a late stage study  TANGO I  in patients with complicated urinary tract infections  cUTI   Plans are on to seek FDA approval early next year  Carbavance is one of the four candidates in the company s pipeline that are estimated to have blockbuster potential  Read more     
	4  GW Pharma s    shares are up on positive data from a late stage study on Epidiolex for the treatment of Lennox Gastaut syndrome  LGS   a rare and severe form of childhood onset epilepsy  Earlier this year  Epidiolex had fared well in another late stage study that was conducted for Dravet syndrome  The company expects to file for FDA approval in the first half of 2017  Read more     

Want the latest recommendations from Zacks Investment Research  Today  you can download7 Best Stocks for the Next 30 Days   

Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks 

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Media Contact

Zacks Investment Research

800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-06-29,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-gilead,-regulus,-abbvie,-the-medicines-and-gw-pharma-200139282",200139282
201883,423399,GILD,Galapagos  RA Drug Filgotinib To Enter Phase III In 3Q16 ,opinion,"Galapagos NV   NASDAQ GLPG   announced that it has successfully concluded the end of phase II discussions with the FDA in the U S  and the European Medicines Agency for the treatment of patients with rheumatoid arthritis  RA   The company also divulged details about the doses for the global phase III program  FINCH  to be conducted on filgotinib for RA 
The FINCH program will comprise three studies that will evaluate the safety and efficacy of once daily filgotinib  100 mg and 200 mg   Dosing is expected to commence in the third quarter of 2016  Moreover  a dedicated male patient testicular safety will be conducted under the phase III FINCH program 
Galapagos noted that the FINCH program will be led by its partner Gilead Sciences Inc    NASDAQ GILD   
We note that competition in the RA market is stiff given the presence of drugs like Acterma  Rayos and Xeljanz among others 
Apart from the FINCH program in RA  Gilead expects to start a phase III study on filgotinib for the treatment of Crohn s diseases and a phase II   III study for the treatment of ulcerative colitis  These studies are also expected to commence in the third quarter of 2016 
Galapagos is a Zacks Rank  3  Hold  stock  A couple of  better ranked stocks in the health care sector are ANI Pharmaceuticals  Inc    NASDAQ ANIP   and Retrophin  Inc    NASDAQ RTRX     each sporting a Zacks Rank  1  Strong Buy  ",2016-05-25,Zacks Investment Research,https://www.investing.com/analysis/galapagos'-ra-drug-filgotinib-to-enter-phase-iii-in-3q16-200132221,200132221
201884,423400,GILD,2 Large Cap Pharmas With PDUFA Catalysts Next Month ,opinion,"It s been a busy year in biotech  and the trend looks set to continue  with a host of FDA decisions set to hit press across the coming six weeks  Here are two large cap pharmaceutical companies with PDUFA dates scheduled during June  which could pick up some upside momentum if the agency gives the drugs in question the green light for commercialization 
Pfizer Inc   NYSE PFE    ALO 02
First up  Pfizer  The pharmaceutical giant submitted a new drug application  NDA  to the FDA early 2015 for its pain management candidate ALO 02  and the agency accepted the submission for review at the end of February  The drug is a reformulation of the current standard of care opioid  oxycodone  designed to deter  or even better  make impossible  abuse of the drug 
Opioid abuse has become an epidemic in the US across the last couple of decades  and costs the US government  annually  As such  abuse deterrent opioids are a particularly hot space in development stage biotech  and a number of companies  large and small  are working to bring their candidates to market  Pfizer is pretty much the leader of the pack with this ALO 02 submission  and as such  if the FDA gives it a nod come PDUFA  could be first to a potentially double digit billion dollar market  
So how does its candidate work  The drug is a combination of the active ingredient  the aforementioned oxycodone  and an opioid receptor agonist called naltrexone  When administered normally  i e  orally  the naltrexone doesn t activate and the oxycodone is released as part of an extended release system 
If it s crushed  however  which is the most common form of abuse preparation  nasal ingestion  dissolving for intravenous administration  etc   the naltrexone gets to work in its aforementioned role as a receptor agonist  The agonization of opioid receptors offsets the impact of the active oxycodone  and renders the drug ineffective 
So that s the science   what did the trials offer up with regard to indication of efficacy  and when will the FDA rule on the drug s future 
The data on which the drug s NDA is based came from two separate phase IIIs  investigating the efficacy of the treatment in patients with cancer pain  The data showed a statistical equivalence of the extended release version of the drug  Pfizer s candidate  to the current SOC IV administration  and the current SOC oral  non abuse deterrent  and so efficacy shouldn t really be a problem when it comes to the agency putting forward its decision 
The real question  and the factor on which the market will base its response to the ruling  will be the labelling  We ve seen some pretty high profile examples of abuse deterrent candidate getting advisory approval this year so far  but not picking up an abuse deterrent label  This failure to get the labelling effectively renders the approval useless  as the pain management market is already crowded  and without a differentiating quality  i e   abuse deterrence  there is no way a new drug can compete  As such  this is the part of the decision on which markets will be focusing 
The date to watch  June 8  2016 
Gilead Sciences  Inc  NASDAQ GILD   SOF VEL
On June 28  the FDA will issue its decision on Gilead s chronic hepatitis C candidate  the combination therapy Sofosbuvir Velpatasvir  The drug picked up priority review at the beginning of this year  and also holds breakthrough designation  meaning initial data is indicative of a substantial improvement in efficacy over the current SOC in this indication  Of course  preliminary data is far from indicative of efficacy at the later stages of development  so it should be taken wit ha pinch of salt as far as forming a speculative  forward bias is concerned 
So  what s the drug  As mentioned  it s a combination therapy with a target indication of hepatitis C  Gilead is regarded as the star player in the hepatitis space already  and with a number of companies currently working on novel therapeutics to target both B and C  is working on bolstering its portfolio through revitalized formulations  in this instance  a combination  of its currently approved portfolio  Sovaldi  which is the trade name for the Sofosbuvir element of this combination  is one of the most expensive drugs in the world  coming I at a little over  84 000 for a 12 week course  and generates in excess of  4 5 billion a quarter for Gilead 
The company is trying to boost its Sovaldi sales through the addition of what s called a pan genotypic NS5A inhibitor  the Velpatasvir side of this submission   which serves to boost the efficacy of the treatment across the 12 week dosing period  in patients that have genotypes of Hep C that would otherwise not be treatable with the single Sovaldi drug  That is  at least  what Gilead is hoping for 
The data on which the NDA is based comes from four phase III trials conducted across the US and Europe  and looks relatively robust  The drug performed well compared to placebo in six separate genotypes of Hep C  and aside from a few discontinuations  managed to hold together a pretty solid safety and tolerability profile 
This doesn t guarantee acceptance by the FDA  and the few discontinuations may warrant further investigation into the safety of the combination therapy  which could lead to a black label warning   but overall things look good for the combination 
The date to watch on this one  as mentioned  is the June 28 PDUFA  There s a chance we will see an advisory panel review   combination therapies  especially when it comes to chronic infections such as Hep C  often undergo an independent review before the FDA has the final word  If so  look to an early June review meeting as a chance to gain insight into the agency s final decision on the drug  One to watch  as it could sure up Gilead s dominance in hepatitis for the next decade if it gets a green light ",2016-05-27,Samuel Rae,https://www.investing.com/analysis/here-are-two-large-cap-pharmas-with-pdufa-catalysts-next-month-200132618,200132618
201885,423401,GILD,Gilead s  GILD  New HCV Drug Epclusa Wins CHMP Backing,opinion,"Gilead Sciences Inc    NASDAQ GILD   announced that the European Medicines Agency s Committee for Medicinal Products for Human Use  CHMP  has rendered a positive opinion in favor of the approval of the company s marketing authorization application for Epclusa 
Gilead is looking to get Epclusa approved for the treatment of adults with all genotypes  1 6  of chronic hepatitis C virus  HCV  infection  Epclusa is an experimental pan genotypic  once daily combination of Gilead s HCV drug Sovaldi  400 mg  and velpatasvir  a pan genotypic NS5A inhibitor  100 mg  
The favorable opinion of the CHMP  which was adopted following an accelerated review procedure  will now be reviewed by the European Commission  With the CHMP issuing a positive opinion  we believe that chances of Epclusa gaining EU approval are pretty high 
We remind investors that Epclusa is currently under priority review in the U S  for the same indication  A response from the FDA is expected by Jun 28 
Epclusa could become the first pan genotypic  all oral  single tablet regimen to gain approval and will complement the company s current HCV portfolio consisting of Sovaldi and Harvoni  Competition and pricing pressure have already intensified in the HCV market with the entry of a new competitor   Merck   Co  Inc  s   NYSE MRK   Zepatier 
Meanwhile  Gilead is also evaluating a once daily fixed dose combination of Sovaldi velpatasvir plus GS 9857  an experimental NS3 protease inhibitor  in phase III studies  for the treatment of chronic genotype 1 6 HCV 
Gilead is a Zacks Rank  3  Hold  stock  A couple of better ranked stocks in the health care sector are ANI Pharmaceuticals  Inc    NASDAQ ANIP   and Retrophin  Inc    NASDAQ RTRX     each sporting a Zacks Rank  1  Strong Buy  ",2016-05-30,Zacks Investment Research,https://www.investing.com/analysis/gilead's-(gild)-new-hcv-drug-epclusa-wins-chmp-backing-200133090,200133090
201886,423402,GILD,Gilead Stock Slowing Sales  Shares Slide,opinion,"Gilead Sciences  NASDAQ GILD 

Shares of GILD have been under pressure over the past month after the stock tested and closed back below its 200 day moving average  Since then  shares have slipped roughly 17  and hovering just above a 2 year low  Can GILD get back on track into the second half of the year or will it be even further off into 2017 
GILD Analyst Expectations
Analysts at Leerink Partners had the following comments on the outlook for GILD 
Gilead s US HCV Price Erosion Seems Likely to Continue Through 2016  Near Term Strong Competitive Position  Volume Only Partially Offsets Discounting  Mix  Market Effects  Given that Gilead has one of the most dominant franchises in recent industry history  GILDs investors and analysts experienced a rude awakening  as apparently did Gilead s management  when the company disclosed softening HCV sales in Q1 2016 based on growing rebates  more government purchases  and shorter treatment duration  Reported total HCV revenue declined by 12  compared to Q4 and by 6  compared to Q1 2015  These results were largely driven by the US   13  QoQ and  40  YoY   where a 13  sequential increase in patient starts could not offset eroding revenue yield per patient  This was consistent with our cautious views on this franchise  but occurred sooner and to a greater degree than we had anticipated 
In todays note  we use Gileads disclosure and commentary and updated IMS data to reestimate HCV product sales for the company for the remaining quarters of 2016  Our longer term forecast of steadily eroding HCV revenue is unchanged  We now forecast Gilead 2016 US HCV revenue of  8 7bn  5  less than our prior  9 2bn estimate  Our revised forecast reflects a 1 3  sequential compounded decline each quarter in realized revenue per start  and a 12  compounded decrease in revenue per Rx  the other approach we use to estimate quarterly sales   These declines are significantly less than the 23  QoQ decrease in realized revenue per start experienced in Q1  assuming that while some of the rebating and contract headwinds in Q1 don t persist in Q2  many others certainly will  Our adjusted total HCV revenue forecast for the company is now 2  above consensus for 2016 and 5  above consensus for 2017
About Gilead Sciences  Inc 
Gilead Sciences  Inc   incorporated on June 22  1987  is a research based biopharmaceutical company  The Company focuses on the discovery  development and commercialization of medicines in areas of unmet medical need  The Company s principal areas of focus include human immunodeficiency virus  HIV   liver diseases  such as chronic hepatitis C virus  HCV  infection and chronic hepatitis B virus  HBV  infection  cardiovascular  hematology oncology and inflammation respiratory 
Its Nimbus Apollo program includes the candidate NDI 010976  a hepatotropic allosteric Acetyl CoA Carboxylase  ACC  inhibitor  and other preclinical ACC inhibitors for the treatment of non alcoholic steatohepatitis  NASH   and for the treatment of hepatocellular carcinoma  HCC  and other diseases  Its Nimbus Apollo program is a Phase II ready clinical program for NDI 010976 and related metabolic and liver diseases ",2016-06-13,Warrior Trading,"https://www.investing.com/analysis/gilead-$gild-stock-slowing-sales,-shares-slide-200135565",200135565
201887,423403,GILD,New Strong Sell Stocks For June 17th,opinion,"Here are 5 stocks added to the Zacks Rank  5  Strong Sell  List today 
     Advanced Drainage Systems  Inc    NYSE WMS   is a manufacturer of thermoplastic corrugated pipe  providing a comprehensive suite of water management products and drainage solutions  The Zacks Consensus Estimate for its current year earnings has been revised 11 2  downward over the last 30 days 
     Advance Auto Parts Inc    NYSE AAP   is a specialty retailer of automotive parts  accessories and maintenance items  The Zacks Consensus Estimate for its current year earnings has declined 10 8  over the last 30 days 
     Ascena Retail Group Inc    NASDAQ ASNA   operates as a national specialty retailer of apparel for women and girls  It has seen the Zacks Consensus Estimate for its current year earnings being revised 10  downward over the last 30 days 
     Community Healthcare Trust Incorporated   NYSE CHCT   is engaged in the acquisition of properties which are leased to hospitals  doctors  healthcare systems or other healthcare service providers  The Zacks Consensus Estimate revision for its current year earnings was a negative 6 7  over the last 30 days 
     Gilead Sciences Inc    NASDAQ GILD   is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them  The Zacks Consensus Estimate for its current year earnings has moved 1 5  lower over the last 30 days View the entire Zacks Rank  5 List ",2016-06-16,Zacks Investment Research,https://www.investing.com/analysis/new-strong-sell-stocks-for-june-17th-200136695,200136695
201894,423410,GILD,Is Gilead Sciences Worth a Buy ,opinion,"A recent fifteen percent fall in most bio tech stocks  including bio tech giant Gilead Sciences  NASDAQ GILD  brings us a great opportunity to profit from 
The following is what has made me add Gilead Sciences to my medium term trading portfolio 
Please note  I am both a long term deep value investor as well as a medium term trader who utilizes the combination of both fundamental  technical and macro analysis to form a view of every investment I make  Doing so I believe leads to low risk and superior market beating returns over the long run 
Fundamental Factors The Bad

Earnings Per Share is forecasted to decline 
Interestingly this is primarily due to the remarkable success of two blockbuster Hepatitis C drugs  Sovaldi and Harvoni which had accounted for over 60  of Gilead s 2015 revenues  and its success in curing their patients has led to fewer patients therefore needing them in the future 
There is also the potential for future Government enforced price regulations of certain drugs due to political pressure  which then affects the whole bio tech industry 

The Good

Intrinsic valuation of  85  90  approx    so GILD is at fair value for a well managed growth company 
Priced at just seven times this year s and next year s earnings  which is cheap 
Earnings per share  EPS  have been great for the past 5 years 
Return on Equity  ROE  of over 80  is excellent but is unsustainable and is forecast to decline 
Long term cash flow relative to reported profits is strong 
Gilead has a long term funding surplus 
Massive cash pile of over  21 billion dollars  even after stock buyback to fund future growth 
Stock buyback likely to continue  even after an  8 billion buy back in the recent quarter 

Technical Factors The Bad

Recently broken below the  86 50 key price support level 
Currently below all 20  50 and 200 day moving averages 

The Good

The stock is oversold on a variety of momentum indicators 
Price is close to its 52 week low and seems to find key support at the  85 price level 

Other FactorsFor longer term investments and trades  I generally like to see who else is on board with me and where the smart money has found its home In my opinion  actions always speak louder than words  Gilead is held by a couple of smart money managers 

Ronald Muhlenkamp   6 63  of portfolio managed
Julian Robertson   5 15  of portfolio managed

ConclusionThe recent 15  price fall in Gilead Sciences has brought the stock back to fair value for a wonderfully managed bio tech company with smart money support 
I have just initiated a new position of Gilead Sciences for our medium term trading portfolio 
This is not the time to be fearful on such a great opportunity which has continued buying back their stock in big volumes at the right price  thus increasing its own intrinsic value over time ",2016-05-12,Terry Tran,https://www.investing.com/analysis/is-gilead-sciences-(gild)-worth-a-buy-200129654,200129654
201902,423418,GILD,Merrimack  MACK  Posts Narrower than Expected Loss In Q1,opinion,Merrimack Pharmaceuticals  Inc    NASDAQ MACK   reported a loss of 33 cents per share in the first quarter of 2016  narrower than both the Zacks Consensus Estimate of 39 cents and the prior quarter loss of 41 cents Quarter in DetailTotal revenue of  21 3 million was slightly lower than  21 4 million reported last quarter but well above the Zacks Consensus Estimate of  15 million In Oct 2015  Merrimack Pharma s first product  Onivyde  gained approval in the U S   in combination with fluorouracil  5 FU  and leucovorin  for the treatment of patients suffering from metastatic adenocarcinoma of the pancreas  who were previously treated with Gemzar based therapy The drug was subsequently launched in the U S  on Oct 26  Onivyde sales in the reported quarter amounted to  10 million  up 133  over the prior quarter  We note that the drug was also added to the National Comprehensive Cancer Network  NCCN  2016 Clinical Practice Guidelines in Oncology as a category I Treatment Option for patients with metastatic pancreatic adenocarcinoma who have previously been treated with Gemzar based therapy Merrimack Pharma earned collaboration revenues of  11 3 million  down 33 8  sequentially Research and development expenses were  32 9 million  down 26 5  due to the completion of various clinical trials in the first quarter of 2016  General and administrative expenses were also down 8  to  17 8 million primarily due to incremental expenses related to the launch of Onivyde last quarter Pipeline UpdateCurrently  Merrimack Pharma is evaluating Onivyde in a phase II study for previously untreated front line metastatic pancreatic cancer  Data from the phase II study are expected in 2017  The company also expects data from three other studies investigating Onivyde in new indications  including pediatric sarcoma  glioma and breast cancer  later in 2016 The company has three more candidates in phase II studies   MM 121 for heregulin positive  locally advanced or metastatic non small cell lung cancer  results expected in 2018 from a phase II study designed to support a potential Biologics License Application to the FDA   MM 302 for HER2 positive metastatic breast cancer  results expected in 2017 from the HERMIONE trial designed to support a potential accelerated approval application to the FDA   and MM 141 for the treatment of patients with front line metastatic pancreatic cancer who have high serum levels of free IGF 1  results expected in 2018   The company recently completed the safety portion and transitioned to part two of the phase II study on MM 141 in patients with front line metastatic pancreatic cancer Outlook ReiteratedMerrimack Pharma continues to expect  46 5 million as net milestones related to Onivyde from Baxalta  Inc    NYSE BXLT   in 2016  Cost of goods sold is estimated to increase as a percentage of revenues as the company sells through the zero cost products that were manufactured prior to receiving FDA approval and therefore  did not have capitalized costs associated with it  Operating expenses are projected between  225 million and  245 million Our TakeMerrimack Pharma reported a narrower than expected loss in the first quarter  The initial uptake of Onivyde is strong and should boost the top line going forward  Inclusion of the drug in the NCCN pathway should prove to be a big boost and accelerate access to the drug Merrimack Pharma carries a Zacks Rank  3  Hold   A couple of well placed stocks in the health care sector are Gilead Sciences   NASDAQ GILD   and Aegerion Pharmaceuticals   NASDAQ AEGR    Both the stocks sport a Zacks Rank  1  Strong Buy  ,2016-05-02,Zacks Investment Research,https://www.investing.com/analysis/merrimack-(mack)-posts-narrower-than-expected-loss-in-q1-200127627,200127627
201903,423419,GILD,Mallinckrodt  MNK  Tops Q2 Earnings And Sales  Ups View,opinion,Mallinckrodt plc   NYSE MNK   reported adjusted earnings of  2 01 per share in the second quarter of fiscal 2016  ended Mar 25  2016   beating the Zacks Consensus Estimate of  1 72  Earnings also increased from the year ago figure of  1 70 Net sales in the quarter came in at  918 million  up 12 1  and above the Zacks Consensus Estimate of  874 million The Quarter in DetailThe company reports results under three segments   Specialty Brands  Specialty Generics and Nuclear Imaging  In Nov 2015  the company sold its contrast media and delivery systems  CMDS  business to Guerbet S A  Following the sale  the Global Medical Imaging segment was renamed Nuclear Imaging Sales at the Specialty Brands segment were  535 million  compared with  334 3 million in the year ago quarter  The increase in net sales was primarily driven by the inclusion of Inomax and Therakos  which generated combined sales of  165 7 million  Acthar sales came in at  248 4 million  up from  228 million a year ago  Ofirmev sales jumped 4 4  year over year to  71 1 million Specialty Generics generated sales of  264 4 million  down 27 1  due to lower sales in various product categories as a result of increased competition Sales at the Nuclear Imaging segment were  102 2 million  compared with  109 5 million in the year ago quarter Research and development expenses were roughly flat at  58 6 million  Selling  general and administrative expenses were  231 2 million  down 25  due to the ongoing restructuring During the quarter  the company repurchased 3 4 million shares under its share repurchase program Earlier  Mallinckrodt had acquired three commercial stage topical hemostasis drugs from The Medicines Company   NASDAQ MDCO     Recothram Thrombin topical  recombinant   PreveLeak and Raplixa  fibrin sealant    in a bid to diversify its pain management franchise and strengthen its growing hospital portfolio Raises GuidanceManagement has lifted its outlook for fiscal 2016 earnings yet again  The company now expects adjusted earnings per share in the range of  8 15  8 50  up from the previous projection of  7 85 to  8 30 Our TakeMallinckrodt s second quarter fiscal 2016 results were impressive  with the company beating both top  and bottom line estimates on the back of solid performance at the Specialty Brands segment  The company s acquire to invest policy is apparently yielding results  as both Inomax and Therakos reported solid demand  along with incremental volume growth of Ofirmev  Consequently  the company raised its annual guidance yet again  encouraged by a strong first half  Moreover  the recent acquisitions should provide accretion to earnings in fiscal 2016 Mallinckrodt carries a Zacks Rank  3  Hold   A couple of better ranked stocks in the health care sector are Gilead Sciences   NASDAQ GILD   and Aegerion Pharmaceuticals   NASDAQ AEGR    Both stocks sport a Zacks Rank  1  Strong Buy  ,2016-05-02,Zacks Investment Research,"https://www.investing.com/analysis/mallinckrodt-(mnk)-tops-q2-earnings-and-sales,-ups-view-200127620",200127620
201904,423420,GILD,SurModics  SRDX  Beats Q2 Earnings   Revenues Estimates,opinion,SurModics  Inc  s   NASDAQ SRDX   reported adjusted earnings of 20 cents per share in the second quarter of fiscal 2016  ended Mar 31  2016   surpassing the Zacks Consensus Estimate of 8 cents  Reported earnings were also higher than the year ago figure of 19 cents  Revenues in the quarter surged 16  to  16 7 million  which included  0 5 million from the acquisition of Creagh Medical  Reported revenues were also above the Zacks Consensus Estimate of  14 7 million Quarter in DetailSurModics reports revenues in two segments   In Vitro Diagnostics  IVD  and Medical Device Products sales surged 44 8  to  8 2 million  reflecting an increase in reagent sales and product sales at the Medical Device and IVD segments  respectively Revenues at the Medical Device segment  which contributes approximately three quarters to the company s total revenue  came in at  11 6 million  up 9 8   Hydrophilic coating royalty revenues dropped 9  to  6 7 million Revenues at the IVD unit surged 32 4  to  5 1 million  The segment benefited from strong sales of stabilization reagents  antigens and BioFX branded products Research and development  R D  expenses were  4 9 million  up 10 6  from the year ago figure General and administrative expenses increased 22 1  to  4 9 million In the quarter  the company initiated the first in human study on the SurVeil drug coated balloon product Fiscal 2016 OutlookSurModics has updated its earnings guidance for fiscal 2016  The company expects earnings per share of 75 85 cents  previous guidance  66 75 cents  Revenues are now expected in the range of  63 million to  66 million  up from the previous guidance of  62  66 million Our TakeWe are impressed by the company s second quarter fiscal 2016 results  wherein it beat on both earnings and revenues  We are also encouraged by the company s recent acquisitions of Creagh Medical and NorMedix Inc   as well as its progress on the SurVeil drug coated balloon platform SurModics carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector are Aegerion Pharmaceuticals  Inc    NASDAQ AEGR    ANI Pharmaceuticals  Inc    NASDAQ ANIP   and Gilead Sciences Inc    NASDAQ GILD    each sporting a Zacks Rank  1  Strong Buy  ,2016-05-03,Zacks Investment Research,https://www.investing.com/analysis/surmodics-(srdx)-beats-q2-earnings---revenues-estimates-200127606,200127606
201912,423428,GILD,Earnings Watch  Can Gilead Maintain Streak ,opinion,"Gilead Sciences  NASDAQ GILD   Healthcare   Biotechnology   Reports April 28  After Market Closes 
Key Takeaway 
The Estimize consensus is calling for earnings per share  3 23 on  8 21 billion in revenue  11 cents higher than Wall Street on the bottom and  130 million on the top
Gilead s recent string of success can be attributed to the strength of its antiviral portfolio
Merck  NYSE MRK  recently launched a cheaper Hepatitis C drug which will put pressure Gilead s margins and sales 
Biopharmaceutical company  Gilead Sciences  is scheduled to report first quarter earnings after the market closes  Gilead has been a hot streak the past 2 fiscal years  beating in 7 of the past 8 reported quarters  Given its track record  it won t be surprising if Gilead posts another win with its Q1 results  The Estimize consensus is calling for earnings per share  3 23 on  8 21 billion in revenue  11 cents higher than Wall Street on the bottom and  130 million on the top  Estimates have been on the move since its last report  Earnings per share estimates have increased 10  with revenue also up 4   Compared to a year earlier  profits are forecasted to rise 10  while sales could increase 8 
Strong earnings have not translated to the market  Gilead stock is down 3  from the prior year and 8  in the past 6 months alone  Fortunately  the stock moves in investors favor throughout earnings season  In the 30 days prior to earnings  shares typically increase 6  and continue to do so through the 30 days following results  
Over the last four quarters Gilead has posted positive earnings surprises of 5 9  on average  and is expected to beat again this Wednesday  Gilead is the market leader in Hepatitis C treatments  with two popular drugs Sovaldi and Harvoni  Their Hep C franchise  along with other antivirals  make up 90  of the company s revenue stream  However  the benefit of these drugs to the bottom line is waning as they have been on the market for a year and half now and are also curative  More competition is set to hit the Hep C market soon  with Merck recently approved to release its rival drug  Merck s treatment imposes a direct threat to Gilead especially since the drug is cheaper than Harvoni 
In order to diversify revenues  Gilead is focusing on growing other core offerings including HIV and Hep B treatments  Newly launched Zydelig  a treatment for three forms of cancer  is performing well and with a number of new drugs already FDA approved  this could lead to strong revenue growth in the near future  In addition to a solid product portfolio  Gilead possess a robust pipeline of potential products  Additional acquisitions and licensing agreements could help Gilead reach these goals  
Do you think GILD can beat estimates ",2016-04-28,Estimize,https://www.investing.com/analysis/will-gileads-run-come-to-an-end-this-quarter-200126779,200126779
201913,423429,GILD,ImmunoGen  IMGN  Posts Wider than Expected Q3 Loss,opinion,ImmunoGen  Inc    NASDAQ IMGN   reported a loss of 37 cents per share in the third quarter of fiscal 2016  wider than both the Zacks Consensus Estimate of a loss of 30 cents and the year ago loss of 25 cents Since ImmunoGen does not have any approved product in its portfolio yet  the company earns revenues in the form of royalties  license and milestone payments  and research and development support fees paid by its partners ImmunoGen reported revenues of  19 7 million in the third quarter of fiscal 2016  up 72 8  from the year ago period  However  revenues missed the Zacks Consensus Estimate of  25 million  The top line included a milestone payment worth  10 million from Bayer AG   OTC BAYRY   for advancing anetumab ravtansine into a phase II study designed for product registration Research and development  R D  expenses increased 40 5  from the year ago quarter to  36 1 million  Likewise  selling  general and administrative  SG A  expenses surged 60  to  11 2 million ImmunoGen continues to progress with its pipeline  Currently  the company is enrolling patients in the phase Ib II study  FORWARD II  on its lead candidate  mirvetuximab soravtansine  for the treatment of FR  positive ovarian cancer  The FORWARD II study is evaluating the candidate in combination with other approved anticancer agents Outlook UpdatedImmunoGen has updated its guidance for fiscal 2016  The company now expects revenues in the  60  70 million band  previous projection   70  80 million   The new guidance includes the effect of changes in the expected timing of partner events Operating expenses  including R D and SG A expenditures  are expected in the range of  180 million to  185 million  previous projection   175 million to  180 million  The company expects net loss of  135  140 million  previously  120  125 million  in fiscal 2016 Our TakeImmunoGen s third quarter results were disappointing with the company reporting a wider than expected loss and missing on revenues  With no approved products in its kitty  we expect investor focus to remain on the development of the company s lead candidate and other pipeline updates ImmunoGen is a Zacks Rank  3  Hold  stock  A couple of better ranked stocks in the health care sector include Aegerion Pharmaceuticals  Inc    NASDAQ AEGR   and Gilead Sciences Inc    NASDAQ GILD    both sporting a Zacks Rank  1  Strong Buy  ,2016-05-01,Zacks Investment Research,https://www.investing.com/analysis/immunogen-(imgn)-posts-wider-than-expected-q3-loss-200127329,200127329
201914,423430,GILD,Novo Nordisk  NVO  Beats On Q1 Earnings  Retains Outlook,opinion,Novo Nordisk  CO NOVOb  A S   NYSE NVO   reported first quarter 2016 earnings of 55 cents per American Depository Receipt  ADR   surpassing the Zacks Consensus Estimate of 53 cents and the year ago figure of 45 cents Quarterly revenues increased 5 5  year over year to  4 billion but were slightly short of the Zacks Consensus Estimate of  4 1 billion  The top line was driven by strong sales in the U S  and international operations  Sales growth was realized in both diabetes care and biopharmaceuticals  with the major contribution coming from Victoza and Norditropin All growth rates mentioned below are on a year over year and in local currency  Quarter in Detail Total sales in the reported quarter climbed 9  driven by sales growth in North America  12   and International Operations  15    The diabetes and obesity care segment recorded sales growth of 7   Modern insulin grew 3  driven by NovoRapid  1    NovoMix  1   and Levemir  9    The company s key drug  Victoza  witnessed sales growth of 15   Sales of Tresiba surged 117  in the reported quarter  Sales in the biopharmaceuticals segment soared 15   Norditropin sales surged 32   while hemophilia sales were up 4   Sales and distribution costs climbed 11  mainly due to costs related to the launch of Tresiba  the continued rollout of Saxenda and NovoEight  and consumer advertising Research and development expenses increased 2  driven by higher research costs related to diabetes and obesity projects  Administration costs increased 9  Pipeline UpdateIn the reported quarter  the company announced encouraging results from phase IIIa studies  SUSTAIN 6 and SUSTAIN 5  on semaglutide  The company expects to file regulatory application for semaglutide in both the U S  and the EU in the fourth quarter of 2016  Meanwhile  the company s Xultophy  the once daily single injection combination of Tresiba and Victoza  is currently under review in the U S  An FDA Advisory Committee meeting is scheduled on May 24 to discuss the New Drug Application  2016 Outlook Novo Nordisk has reiterated its guidance for 2016  The company expects 2016 sales to grow 5 9   reflecting its expectations of a continually strong performance of modern insulins  Tresiba and Victoza  as well as contributions from Saxenda and Xultophy  However  this will be partly offset by the impact of a contract loss in the U S   healthcare reforms  loss of exclusivity for products in hormone replacement therapy  intensifying competition within diabetes and biopharmaceuticals  and macroeconomic conditions in many markets of International Operations as well as China  Novo Nordisk carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector include Aegerion Pharmaceuticals  Inc    NASDAQ AEGR    ANI Pharmaceuticals  Inc    NASDAQ ANIP   and Gilead Sciences Inc    NASDAQ GILD    each sporting a Zacks Rank  1  Strong Buy  ,2016-05-02,Zacks Investment Research,"https://www.investing.com/analysis/novo-nordisk-(nvo)-beats-on-q1-earnings,-retains-outlook-200127298",200127298
201915,423431,GILD,Shire  SHPG  Tops Q1 Earnings  Baxalta Buyout Set For June,opinion,"Shire plc   NASDAQ SHPG   reported first quarter 2016 earnings of  3 19 per American Depositary Share  ADS   up 12  year over year  and comfortably beat the Zacks Consensus Estimate of  3 05 
Revenues surged 15  to  1 7 billion and came in line with the Zacks Consensus Estimate 
Quarter in Detail
Product sales soared 14  to  1 6 billion driven by strong performance of Vyvanse  up 22  to  509 million   Lialda  up 13  to  168 million   Cinryze  up 11  to  164 million   Firazyr  up 39  to  128 million  and Gattex Revestive  up 97  on to  52 million  
Vyvanse is indicated for Attention Deficit Hyperactivity Disorder  ADHD  in patients aged six and above  as well as for moderate to severe binge eating disorder  B E D   in adults  The drug witnessed solid growth in the quarter driven by 10  prescription growth in the U S   which outpaced 7  growth in the ADHD market  Sales of Lialda were strong in the quarter driven by higher demand and price increase in January in the U S  Lialda exited the quarter with a 38 4  market share  representing an increase of more than 2  from 2015 end 
Sales were hurt as Intuniv sales  down 41  to  10 2 million  suffered due to generic competition  Elaprase and Vpriv sales were hampered by currency headwinds due to a strong dollar 
Royalty income surged 26  to  79 2 million  In the reported quarter  adjusted research   development costs were up 14 1  to  211 2 million  while selling  general   administrative expenses increased 13 9  to  439 2 million 
2016 Outlook
Shire continues to expect earnings per ADS to climb 7 10  in 2016  9 13  on a CER basis   The company expects product sales to surge 11 14   including Kalbitor   considering currency impact of 2 3 percentage points 
Shire expects royalties and other revenues to increase 5 10  in 2016 on the back of a benefit from the addition of royalties from Dyax as well as those related to Sensipar 
The full year guidance includes the impact of the recently completed Dyax acquisition  closed on Jan 22  2016   but excludes contributions from its recently announced merger with Baxalta  Inc    NYSE BXLT    which is expected to close in early June 
Pipeline Update
Shire submitted a New Drug Application  NDA  to the FDA for an alternate formulation of Vyvanse as a chewable tablet  Moreover  Shire announced positive top line results from a phase III trial on its ADHD candidate  SHP465  The study was conducted as per the FDA s requirement to evaluate its safety and efficacy in children and adolescents prior to filing a Class 2 resubmission for the drug s approval 
The company s efforts on building an ophthalmology portfolio got a boost when the FDA determined that the resubmission of company s New Drug Application  NDA  for its candidate  lifitegrast  was adequate and assigned a six month review period for the NDA  with a Prescription Drug User Fee Act  PDUFA  date of Jul 22  2016 
Shire is also working on expanding Cinryze s label and conducting a phase III study for the treatment of acute antibody mediated rejection in renal transplant recipients  The company has initiated patient dosing in a phase III trial on the subcutaneous formulation of Cinryze for hereditary angioedema  HAE  attacks in both teenagers and adults  The Dyax acquisition is well on track and SHP643  which was added through the acquisition  has entered into clinical trials for the prophylactic treatment of HAE 
However  the company suffered a setback when preliminary results from a phase II study  CAMEO  on SHP625 for cholestatic liver disease showed no significant reduction from baseline in serum alkaline phosphatase or other liver parameters  Shire plans to analyze data in detail to determine the path forward 
Our Take
Shire currently carries a Zacks Rank  2  Buy   The company s first quarter earnings exceeded expectations on the back of continued strength in Vyvanse  Lialda  Cinrzye and Firazyr  which more than offset the decline in Intuniv sales  Moreover  Shire has a solid presence in the gastrointestinal  neuroscience and rare disease markets 
The impending Baxalta acquisition will diversify its presence in the fields of hematology  immunology and oncology  The company also plans to expand in the transplantation space with maribavir for the treatment of CMV infection and Cinryze for the treatment of antibody mediated rejection 
Meanwhile  the adult ADHD space is one of the largest and fastest growing segments of the market and a potential approval of SHP465 will further strengthen Shire s franchise 
A couple of other well placed stocks in the health care sector are Gilead Sciences   NASDAQ GILD   and Aegerion Pharmaceuticals   NASDAQ AEGR    Both the stocks sport a Zacks Rank  1  Strong Buy  ",2016-05-02,Zacks Investment Research,"https://www.investing.com/analysis/shire-(shpg)-tops-q1-earnings,-baxalta-buyout-set-for-june-200127404",200127404
201925,423441,GILD,Gilead Sciences Still Leading NASDAQ Top Rated Stocks,opinion,"For today s bulletin  we present key metrics for the top picks in the NASDAQ 100  The companies listed below represent the top ten BUY and STRONG BUY stocks within the index  They are presented below according to their one month forecast target prices 
Gilead Sciences  O GILD  is the overall leader and is the only STRONG BUY stock in this list  The components are little changed since the last time we presented the top NASDAQ picks at the beginning of December 

Below is today s data on Skyworks Solutions Inc  O SWKS  
Skyworks Solutions  Inc  is the industry s leading wireless semiconductor company focused on radio frequency  RF  and complete semiconductor system solutions for mobile communications applications 
VALUENGINE RECOMMENDATION  ValuEngine continues its BUY recommendation on SKYWORKS SOLUTN for 2015 12 30  Based on the information we have gathered and our resulting research  we feel that SKYWORKS SOLUTN has the probability to OUTPERFORM average market performance for the next year  The company exhibits ATTRACTIVE Company Size and Sharpe Ratio ",2016-01-01,Steve Hach,https://www.investing.com/analysis/gilead-sciences-still-leading-nasdaq-top-rated-stocks-378398,378398
201926,423442,GILD,Merck s New Hepatitis C Drug Could Threaten Gilead  GILD ,opinion,"Gilead Sciences  Inc   O GILD  Healthcare   Biotechnology   Reports February 2  After Market Closes 
Key Takeaway
This quarter the Estimize consensus is more bullish than Wall Street  calling for EPS of  3 06 and revenue of  8 18 billion
Gilead s recent string of success can be attributed to the strength of its antiviral portfolio
Merck  N MRK  recently launched a cheaper Hepatitis C drug which will put pressure on Gilead s margins and sales
What are you expecting for GILD  
Gilead Sciences  GILD  expects to close an impressive 2015 when it reports 4th quarter earnings February 2  after the bell  The past 4 quarters Gilead posted positive earnings surprises of 5 9  and is expected to beat again this Wednesday 
Gilead is the market leader in Hepatitis C treatment  which has largely contributed to the company s recent success  The drug is expected to strengthen its position and generate meaningful contributions to Gilead s Q4 top line despite increased competition 
This quarter the Estimize consensus is more bullish than Wall Street  calling for EPS of  3 06  8 cents above the Street s consensus  and revenue of  8 18 billion   73 million higher than the sell side  Compared to Q4 2014  this represents a projected YoY increase in EPS and revenue of 26  and 12   respectively  Besides improving its Hep C drug  Harvoni  Gilead is expected to grow its other core offerings including HIV and Hep B treatments 

Coming off a solid string of robust growth  Gilead continues to impress shareholders with a strong portfolio of antivirals  Its Hep C medicine  along with other antivirals account for over 90  of the company s revenue stream 
Fortunately  these drugs have performed well  but Gilead will be faced with roadblocks in the near future  Merck was recently approved to release its rival Hepatitis C drug  Merck s treatment imposes a direct threat to Gilead especially since the drug is cheaper than Harvoni  While Harvoni continues to post impressive sales  the drug is experiencing diminishing returns which will be impacted as competition intensifies 
With the emergence of Merck s new drug  Gilead would be wise to fine tune its other antiviral products outside of its Hep C drugs  Moreover  Gilead is expecting to encounter multiple obstacles in its robust pipeline  That said  pending drug approvals and potential takeovers will provide Gilead with a much needed boost to its top line and portfolio  
Do you think GILD can beat estimates ",2016-02-02,Estimize,https://www.investing.com/analysis/gilead-faces-its-greatest-threat-to-its-hepatitis-c-drug:-how-will-that-382757,382757
201927,423443,GILD,Bonus Stock To Watch  Gilead Sciences  GILD ,opinion,"Here is your Bonus Idea with links to the full Top Ten 
Gilead Sciences  O GILD  accelerated lower from a lower high in October  It finally bounced at the end of January  and has been rising in a channel since  This leaves the question  Will this be a bear flag or a reversal 
The chart shows the momentum rising off of oversold conditions and making a higher high as it approaches the mid line  The MACD is crossed up and rising  These support continued upside  but falls short of strong support  The stock sits over the 20 day SMA for the first time in a couple of months  but all of the SMA are falling 
There is resistance above at 89 50 and 92 50 followed by 96 25 and 97 75 before 100  Support lower comes at 86 15 and 84 followed by 82 25  Short interest low at only 1 5  
Looking at the options open interest shows weekly options  with the February monthly expiring this week  There is extremely high open interest at 92 5 and 93 this week  with large size at 89 as well on the call side  March monthly options show open interest spread from 85 to 110 on the call side and biggest at 85 and 80 on the put side 
Gilead Sciences
Trade Idea 1  Buy the stock on a move over 90 with a stop at 87 25 
Trade Idea 2  Buy the stock with a March 87 5 80 Put Spread   2 00  and selling an April 100 Call  96 cents  
Trade Idea 3  Buy the February March 90 Call Calendar   2 00  
Trade Idea 4  Sell the stock short on a move under 86 with a stop at 90 
Trade Idea 5  Buy the March 11 Expiry 89 Puts for  3 05 
Trade Idea 6  Buy the March 11 expiry 89 85 Put Spread for  1 55 
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday  Heading into the February Operations Expiration Week  the equity markets started with a weak move lower and then consolidation with a promise Friday 
Elsewhere gold looks overdone to the upside and ready for a pullback while crude oil bounces in the downtrend  The US Dollar Index has short term strength in the downturn while US Treasuries may also be overdone to the upside and ready to pullback  The Shanghai Composite comes back after a week off looking to consolidate while Emerging Markets consolidate in their downtrend 
Volatility looks to remain elevated keeping the bias lower for the equity index ETFs N SPY  N IWM and O QQQ  Their charts show possible reversals higher in the downtrend in the short run  but intermediate weakness remains  Use this information as you prepare for the coming week and trad em well 
Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  Please see my Disclaimer page for my full disclaimer ",2016-02-15,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-february-16,-2016:-bonus-idea-384647",384647
201928,423444,GILD,How You Should Trade Biotech Bull Flags,opinion,The most accurate way to invest and trade is to focus on the charts  It gives you the truth without any emotional hype  A bull flag is a bullish pattern of consolidation on a chart  When it appears  the stock price will often move up nicely in the coming days  This bull flag pattern is appearing on multiple big name biotech stocks  Gilead Sciences  Inc  NASDAQ GILD  and Celgene Corporation  NASDAQ CELG   note the charts below ,2016-03-11,Gareth Soloway,https://www.investing.com/analysis/bull-flags-in-biotech-and-how-you-should-trade-them-200121175,200121175
201929,423445,GILD,Biotechs  Safe To Get In The Water  Not So Fast,opinion,"Biotechnology stocks were darlings of the post crisis bull market  with the SPDR S P Biotech Fund  NYSE XBI     an ETF that is equal weighted and thus reflects the performance of the sector s many small companies more than other ETFs    registering a more than 530 percent gain from the 2009 lows to the high in July  2015  The collapse since that high retraced nearly two thirds of the move before beginning to recover in late February 
SPDR S P Biotech ETF  XBI  Retraced 61 8 Percent of Its Rise From the 2009 Low to the 2015 High

Source  Bloomberg
So with that retracement under their belt  should biotechs be a place where investors start bargain hunting  Our simple answer is  No  
Is Biotech Cheap Now  Nope 
It s important to remember that biotech investing    outside the big cap biotechs such as Celgene  NASDAQ CELG  and Gilead  NASDAQ GILD     is simply not based on fundamentals  that is  on a careful and realistic assessment of risks and future earnings  XBI taken as a whole  for example  as of this writing has a price to earnings ratio of 988  based on the past 12 months of earnings    remarkably  there are in fact enough constituents of the index that actually have earnings to drag the average into positive territory   Another commonly used vehicle  the iShares Nasdaq Biotechnology ETF  NASDAQ IBB   which is market capitalization weighted and thus heavier in companies that are actually profitable  comes in at a price to earnings ratio of 72  also based on the last 12 months of earnings   In short  even after a correction of over 60 percent  biotech is still very far from being cheap on a fundamental basis  Thus  it makes little sense to think of biotech as a  beaten down  sector    as if it were like other sectors or markets that have beaten down to a valuation below that supported by their fundamentals  Biotech would have a lot farther to fall before it would join that category 
 We are also skeptical about some of the valuation techniques used for fundamental analysis of biotech stocks which ascribe value based on the purported likelihood of the success of as yet unapproved new drugs  For example  an analyst might judge that a new drug could generate  100 million a year in earnings  and ascribe a 20 percent chance that the drug will be approved    and then factor  20 million in earnings into their model  However  even for capable analysts with doctoral level scientific education  estimating chances of success is at best a matter of educated guesses  And in the example given  the earnings will very likely not be  20 million  but zero or  100 million    a  binary event   So the share price targets that analysts come up with for development  and clinical stage biotech companies should be taken not just with a grain  but with a mountain of salt    or disregarded altogether  except insofar as they are clues as to what other investors are thinking  
What really matters for biotech investing    again  outside the big cap biotechs that have real earnings    is momentum and psychology  and if these are supportive  biotech can make sense for investors  Neither momentum nor psychology is now in play for biotech  If the U S  market does have another push past the old highs  it is not clear that biotechs will remain the anointed leaders of the rally    and as we have been observing since last year  the surrounding macro environment is not one that will support positive psychology for biotech 
Election Year Woes and the Pharma Biotech Whipping Boy
What is that environment  The election season  in which drug prices are a talking point for politicians of all stripes  and drug companies a political punching bag from right and left  Who is going to pass up the political hay that can be made by criticizing drug prices and calling for outright price controls or at the very least Medicare price negotiation  We think no one  The best that can be hoped is that if both nominees agree on the matter  they won t talk about it too much during the campaign  But frankly  that s not likely 
Investment implications   Biotech is down big from its peak last year  with some indices falling almost two thirds  and many stocks having fallen much more  However  that doesn t mean it s cheap  On a fundamental basis  biotechs are still very expensive    especially the small  and mid sized companies  Thus it makes no sense for investors to treat biotech as they would treat sectors or markets that have truly been beaten down below valuation levels supported by their fundamentals  Biotech stocks trade on momentum and psychology  momentum looks unlikely to return  particularly in the face of market psychology shaped by an election campaign in which it s  open season  on drug companies  Even established and profitable biotechs may well languish as the rest of the sector labors under this negative psychology  so for now  we think investors should not be tempted to dip their toes  After the Presidential election  when we know the attitude of the victor towards drug prices  we will know more  After legislation is implemented to cut prices  we will be better able to determine fair valuations for the participants in the industry ",2016-04-01,Tim Shirata,https://www.investing.com/analysis/biotechs:-safe-to-get-in-the-water--not-so-fast-200123595,200123595
201943,423459,GILD,T2108 Update  October 2  2015    Oversold Period Ends And Leaves Behind,opinion," T2108 measures the percentage of stocks trading above their respective 40 day moving averages  DMAs   It helps to identify extremes in market sentiment that are likely to reverse  To learn more about it  see my   You can  on twitter using the  T2108 hashtag  T2108 related trades and other trades are occasionally posted on twitter using   T2107 measures the percentage of stocks trading above their respective 200DMAs 
T2108 Status  27 4 T2107 Status  20 2 VIX Status  20 9  closed on 50DMA General  Short term  Trading Call  Bullish  upside target of 1996 on the S P 500 before overbought conditions finally occur again  See    for more details  Active T2108 periods  Day  1 over 20   ends 4 day oversold period   Day  11 under 30   underperiod   Day  33 under 40   Day  93 under 50   Day  110 under 60   Day  315 under 70 
Commentary In   I came as close as I could to predicting an end to the oversold period  Only the uncertainty of the jobs report prevented me from making the direct prediction  As it turned out  the oversold period indeed ended on Friday  However  the process unfolded in a VERY surprising way 

T2108 ended the day at 27 4   T2108 started LOWER at 18 8  and sank from there as low as 16 2  as part of the fallout from the big miss on the jobs report  The selling ended almost as fast as it began  After about 40 minutes of consolidation  buyers took over for the rest of the day 

The S P 500  SPY  opened poorly in response to the jobs report but buyers quickly took over the trading action 


The end result was a VERY strong close that left Monday s selling  and the start of the oversold period  behind in the dust 
I am not even going to try to explain the sudden change in heart by the market  I WILL note that this surge of buying that reversed Monday s steep selling ends an important retest of August s lows  If buyers can follow through from here  the S P 500  SPY  may have laid the foundation for a double bottom  Getting through October  the last of the seasonally weak months  without further losses or yet another test will firm up this foundation 

Fortunately  I treated the plunge like a fresh drop into oversold territory and loaded up on a new tranche of call options on ProShares Ultra S P500  NYSE SSO   I was taken aback when I reviewed the position later in the day to find a 30  gain  I sold right away  At the close  I locked in my profits on the shares of ProShares Short VIX Short Term Futures  SVXY  that I bought at   This 4 day oversold period delivered yet another validation of the T2108 trading strategy  This time worked even better than the earlier two because it was a more typical run with a duration of 4 days 

The volatility index lost 7 1  on its way to a rest on its 50DMA  If the market pushes further away from oversold conditions  volatility could very quickly complete the reversal of the angst that erupted in Augst 

The volatility index is under pressure again 
The U S  dollar index also experienced a sharp reversal  but it continues to struggle with resistance at its 50DMA  A downtrend is looming overhead as well 

The U S  dollar index has essentially gone nowhere for almost all of 2015  The downtrend from the 12 year high set in March looms larger and larger now 
The dramatic bookends for the week   huge down day on Monday and huge reversal on Friday   helped to generate some very dramatic moves in individual stocks  I review a small sample below 

The iShares MSCI Emerging Markets  EEM  gained 2 7  on the day and surged toward its 50DMA resistance again  My strangle play   out of the money call and put options   is now profitable on the call side  Ironically  this latest round would have been the first time in a very long time where I could have profited from BOTH sides of the trade 

iShares MSCI Emerging Markets  EEM  surges toward 50DMA resistance 
Buyers remain active on the iShares Nasdaq Biotechnology ETF  IBB  as a bottoming process looks more and more likely now  Gilead Sciences Inc   NASDAQ GILD  reversed its big gap down but could barely close flat for the day  I am looking at GILD as a good  catch up  play     

Buyers on the iShares Nasdaq Biotechnology ETF  IBB  print a very strong follow through with a 3 5  gain on high volume 


The 15 minute chart on IBB shows the return of momentum for buyers  Monday s selling increasingly looks like final washout of panic 


Gilead Sciences Inc   GILD  gapped down and struggled just to close even on the day  It now lags the IBB recovery and looks like a good  catch up  play 
On the week  Solar City  SCTY  went from its lowest close since the Flash Crash   and a 2 year low   to a close above   Resistance still looms overhead with the 50DMA 

Solar City  SCTY  recovers from another severe bout of selling but now needs to beat overhead resistance 
SanDisk  NASDAQ SNDK  is a GREAT example of the importance of closing out short positions during oversold conditions  I played SNDK puts off a retest of 50DMA resistance in mid September  I locked in profits on Monday  I was also motivated by the push of SNDK below its lower Bollinger Band  BB  

Sandisk  SNDK  is looking more bullish than it has looked in a very long time  Buyers step up bigtime 
Whole Foods Market  NASDAQ WFM  made a classic  oversold  move by surging 8 5  on the mere rumor of merger and acquisition activity  This looks like a bottoming move given the surge off a retest of the intraday low in August  However  there is a LOT of damage to repair in WFM after two post earnings down gaps and a steep downtrend this year 

Whole Foods Market  WFM  shows a major sign of life 
Speaking of a major oversold market move  Wynn Resorts Ltd   WYNN  soared an incredible 23  after rumors of corporate welfare on the way from the Chinese government to prop up casinos in Macau  I can understand trying to prop up productive activities  but propping up a gambling industry  Something tells me some heavy politicking is at work on that one  I decided to fade this move with put options  Let s see whether the rumors prove to be false in the first place  If TRUE  clearly  there could be a LOT of upside left 

Wynn Resorts Ltd   WYNN  erases seven trading days of losses in a hurry 
Now for some balance  the news was not ALL good  My long term call options on Crocs  Inc   CROX  are pretty much toast  An earnings warning from CROX took the stock down bigtime including some serious follow through selling 

Crocs  CROX  is once again negative for 2015Daily T2108 vs the S P 500
Black line  T2108  measured on the right   Green line  S P 500  for comparative purposes  Red line  T2108 Overbought  70    Blue line  T2108 Oversold  20  
Weekly T2108

Full disclosure  long SVXY shares  long SSO shares  long UVXY put options  long IBB call options  long AAPL put spread and puts  long GILD call options  long WFM call options",2015-10-05,Dr. Duru,"https://www.investing.com/analysis/t2108-update-(october-2,-2015)--oversold-period-ends-and-leaves-behind-267020",267020
201944,423460,GILD,Time To Buy Gilead ,opinion,"Gilead Sciences  NASDAQ GILD  has been dealt an incredibly rough hand over the past three months  However  this great company isn t going to go down in flames  There have been a few issues driving the company downward that in my opinion  are going to be headed for an end relatively soon  Today  we ll talk about what these issues are  why GILD is one of the strongest investments in biotech  and what we can expect to see moving forward 
Issues That Brought Down GILD
There have been two major issues that have been dragging on the curtails of GILD  Here they are   

Market Wide Declines   Throughout the past several months  we ve seen rough times hit the US market  Unfortunately  high valuations  economic conditions around the world  and geopolitical uncertainties have all taken their toll on the United States market  Throughout this time  no stock has been safe  Just about every stock on the market has experienced the declines  including Gilead Sciences 
Hillary Clinton s Comments   Another major issue that hit GILD hard recently was comments made by presidential candidate Hillary Clinton  Hillary Clinton announced that she has plans to end high prices in the medications for the treatment of chronically ill patients  Because Gilead Sciences is the leader in the treatment of hepatitis C  HCV  and focuses heavily on other chronic illnesses  these comments hit home for investors 

Neither Is Likely To Affect GILD In Long Run
While short term declines as a result of market wide resistance and presidential campaign comments are understandable  neither of these issues is likely to affect GILD in the long run  The reality is that the market goes through ups and downs  but the downs don t last very long  In regard to Hillary Clinton s comments  she ll need to will the presidential elections before she s able to effect such a large change  and I simply don t think that s going to happen 
Why GILD Is A Strong Investment Choice

Solid Products   First and foremost  any company is only as strong as its products  When it comes to Gilead Sciences  its product line is absolutely incredible  The company is the current leader in the treatment of HCV  Not to mention  they have been working diligently in the treatments of HIV  HBV  and more  All in all  GILD has proven their abilities with regard to creating effective treatments that take the market by storm 
Proof In The Pudding   While great products are nice to have  we ve learned from MannKind  NASDAQ MNKD  that just having a great product isn t enough  You need to be able to market that product  When it comes to GILD  the proof with regard to marketing ability is already there  They didn t become the leader in HCV for no reason 
Low Valuation   GILD was already trading with an incredibly low PE ratio  However  as a result of the declines we ve seen recently  that PE ratio has fallen even further  This presents an opportunity to get in on a strong stock at an incredible discount 

Legal Disclaimer   The author has no positions in any stocks mentioned  and no plans to initiate any positions within the next 72 hours  The author s wrote this article themselves  and it expresses their own opinions  The author is not receiving compensation for it  other than from CNAFinance   The author has no business relationship with any company whose stock is mentioned in this article ",2015-10-08,CNA Finance,https://www.investing.com/analysis/gilead-sciences-(gild)-stock:-is-now-the-time-to-buy-267559,267559
201945,423461,GILD,Rates And Ranks The NASDAQ 100,opinion,"ValuEngine tracks more than 7000 US equities  ADRs  and foreign stock which trade on US exchanges as well as at 1000 Canadian equities  When EPS estimates are available for a given equity  our model calculates a level of mispricing or valuation percentage for that equity based on earnings estimates and what the stock should be worth if the market were totally rational and efficient  an academic exercise to be sure  but one which allows for useful comparisons between equities  sectors  and industries  Using our Valuation Model  we can currently assign a VE valuation calculation to more than 2800 stocks in our US Universe 
We also use trading data to provide forecast estimates for a variety of time horizons for almost ever equity in our database  Our Buy Sell Hold recommendations are based upon the 1 year forecast return figure  Using valuation and forecast figures  you can rank and rate our covered stocks against each other  to find out  in an objective and systematic way  the most attractive investment targets based on your own risk reward parameters  We re calculate the entire database every trading day  so you are assured that every proprietary valuation and forecast datapoint is as up to date as possible 
We can use our data to track individual stocks  industries  sectors  and indices  For today s bulletin  we present key metrics for the top picks in the Nasdaq 100  The companies listed below represent the top ten STRONG BUY stocks within the index  They are presented below according to their one month forecast target prices 
Gilead Sciences  O GILD  is the overall leader 

Below is today s data on Gilead Sciences  GILD  
Gilead Sciences  Inc  is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them  They have a broad based focus on developing and marketing drugs to treat patients with infectious diseases  including viral infections  fungal infections and bacterial infections  and a specialized focus on cancer  They have expertise in liposomal drug delivery technology  a technology that the company uses to develop drugs that are safer  easier for patients to tolerate and more effective 
VALUENGINE RECOMMENDATION  ValuEngine updated its recommendation from BUY to STRONG BUY for GILEAD SCIENCES on 2015 12 01  Based on the information we have gathered and our resulting research  we feel that GILEAD SCIENCES has the probability to OUTPERFORM average market performance for the next year  The company exhibits ATTRACTIVE Company Size and Sharpe Ratio ",2015-12-03,Steve Hach,https://www.investing.com/analysis/rates-and-ranks-the-nasdaq-374005,374005
201952,423468,GILD,Biotech Stocks To Watch  MNKD  AMRN  GILD,opinion,"MannKind Reports Earnings This Week
MannKind Corporation  NASDAQ MNKD 
MannKind has been one of my favorite stocks to watch  and this week is likely to prove to be a big week for the stock  The reality is that MannKind has been struggling in the market on a poor pre launch of Afrezza  However  that is likely to change  Tomorrow before the market opens  MannKind will be providing its earnings report for the quarter  While I don t think investors will care much about earnings  as we already know that they re not likely to be great  I think that this report may prove to be a catalyst  The reality is that MannKind recently announced that it had tripled its production capacity of Afrezza  With low sales volume  there s got to be a big reason for this move  one that I think is likely to be announced through the earnings report  So  keep your eyes peeled because this has the potential to be a major catalyst 
Amarin Could Have A Very Strong Week This Week
Amarin Corporation plc  ADR   NASDAQ AMRN 
Amarin Corporation had a great day in the market on Friday as a court ruling sent the stock skyrocketing  The case was between Amarin and the FDA in a fight for the disclosure of unapproved affects of Vascepa to physicians  The court ruled that Amarin may disclose unapproved benefits of Vascepa to physicians  leading to a gain of more than 14  in the market  Here s what John F  Thero  CEO of AMRN had to say following the court ruling 

 This lawsuit is based on the principle that better informed physicians will make better treatment decisions for their patients  Many physicians are aware of the efficacy data including in FDA approved labeling for Vascepa but are not aware of efficacy data from the ANCHOR study of Vascepa  FDA has already announced the safety data from both the MARINE and ANCHOR studies in approved Vascepa labeling  Amarin will now be able to communicate efficacy data from ANCHOR and other relevant study results to these physicians and to others in the medical community in the context of appropriate disclaimers  

Considering the reason for the climb  I don t think we ve seen the end of it  So  keep a close eye on AMRN throughout the week for opportunities 
Gilead Sciences  GILD  Is Likely To See Strong Growth
Gilead Sciences  Inc   NASDAQ GILD 
Finally  we have Gilead Sciences  In my opinion  GILD is one of the strongest stocks in biotech  and for good reason  Even in the face of strong competition  the company has proven its ability to maintain control over the HCV market and recently  they ve been given a credit rating of A   However  we saw declines in the stock on Thursday that have brought it down to support followed by relatively flat movement on Friday  Therefore  I m expecting to see strong gains from GILD throughout the week ",2015-08-10,Joshua Rodriguez,"https://www.investing.com/analysis/biotech-stocks-to-watch-this-week:-mannkind-(mnkd),-amarin-(amrn),-gilea-261057",261057
201953,423469,GILD,GILD Breaks Four Support Levels,opinion,Gilead Sciences Inc  NASDAQ GILD  shares managed to break four significant support levels on Friday  Two July local lows and the 100  and 200 day SMA  Bearish outlook ,2015-08-23,Petros Steriotis,https://www.investing.com/analysis/gilead-(gild)-august-24-preview-262514,262514
201954,423470,GILD,Take A Look At Gilead Sciences,opinion,"Gilead Sciences  NASDAQ GILD 
I ve been covering Gilead Sciences for quite some time now  and I m proud that through the ups and downs  I ve maintained my bullish opinion on the stock  The reality is that GILD has one of the most interesting success stories in biotechnology today  and the story keeps getting better  Here s why you may be missing out on an opportunity if this stock is not in your portfolio 
Gilead Sciences Has An Impressive History
First and foremost  Gilead Sciences has an incredible track record  Starting with the hepatitis C market  the company pretty much controls it  Although concerns started to rise earlier this year about GILD s ability to maintain control of the HCV market as AbbVie stepped in  the company proved that they have a stronghold on the market 
It s also important to look at GILD s earnings history  The bottom line is that this company has a strong history of producing incredible earnings reports  According to Street Insider  Gilead Sciences has produced earnings above analyst expectations for 7 out of the last 8 quarters  including the past 3 consecutive quarters  The only miss in the bunch wasn t missed by much 
GILD Is Heavily Undervalued
Another metric I like to pay attention to when choosing stocks to cover is valuation  and when it comes to GILD their valuation is pristine  The reality is that in today s market  it can be difficult to find a stock that isn t overvalued  meaning that good value for your money is hard to come by  However  Gilead Sciences is great in that respect  Currently  a PE ratio under 17 is great  Now  try a PE ratio under 10  According to NASDAQ  Gilead s price to earnings is only 8 55  about half of what investors should be looking for  That insinuates incredible upside potential and one heck of an opportunity 
More Good News Continues To Pop Up
Gilead Sciences also has a knack for producing positive news time and time again  and since news has a tendency of causing moves in the market  that s great for investors  Most recently  the company announced data from it s AMBITION study  AMBITION is a collaboration between GILD and GSK  The study is looking into a combined therapy that combines Letairis and tadalafil in an attempt to treat patients with pulmonary arterial hypertension  New data from the AMBITION study shows that the combined treatment reduced the risk of clinical failure by 50  when compared to Letairis and tadalafil monotherapy  Following the announcement of data  University of California s Emeritus Professor  Lewis J  Rubin  MD   had the following to say 
 The only other published  large scale  event driven study to date in PAH compared an endothelin receptor antagonist to placebo in patients who were either treatment naive or on background therapy  however  all patients in AMBITION received an approved therapy for PAH  Thus  the magnitude of the effect with this combination in comparison to active monotherapy is impressive  particularly in WHO functional calss II patients were we observed nearly an 80 percent reduction in the risk of clinical failure versus monotherapy  
The Bottom Line
The bottom line is that GILD is a great stock  The company has a stronghold on the HCV market  is incredibly effective in the HIV market and is continually finding new medical ailments to tackle  Combining the company s successes with an incredibly low valuation makes this an incredibly strong buy ",2015-08-28,Joshua Rodriguez,https://www.investing.com/analysis/gilead-sciences-(gild)-stock:-dont-miss-this-opportunity-263262,263262
201955,423471,GILD,Ariad Declines Baxalta Offer  Gilead Short Interest Up,opinion,"Ariad Pharmaceuticals Declines Baxalta Offer
Ariad Pharmaceuticals  Inc   NASDAQ ARIA    Baxalta Inc  NYSE BXLT 
One of the biggest conversations in the biotech space has been a discussion with regard to whether or not Baxalta will acquire Ariad Pharmaceuticals  The original offer on the table was  2 billion  However  Ariad Pharmaceuticals declined the offer   and rightfully so  The premium offered was far below what the average expected premium is in the biotech space  However  the company is still in the midst of negotiations  Personally  I would love to see this acquisition happen  but I m not sure it will  Nonetheless  only time will tell what happens next 
Twitter  NYSE TWTR  Investors Await Management News
Twitter Inc  NYSE  TWTR 
Twitter is having a rough day in the market today  However  the declines are likely caused by the market wide declines that we re seeing today  Nonetheless  there is one big piece of news out of Twitter that s expected to surface any time now  The company has been working to find a new CEO for quite some time now after the previous CEO resigned due to his failure to pick up user data  Rumors are surfacing that Jack Dorsey is likely to take the long term position  which I think would be great  Nonetheless  no one knows who will take the position just yet  When the decision is made  we can expect it to act as a positive catalyst  and many experts are expecting this to happen on or around Labor Day  which is less than a week away  So  watch closely as opportunity is likely on its way 
Gilead Sciences  NASDAQ GILD  Short Interest Is Up
Gilead Sciences  Inc   NASDAQ  GILD 
Gilead Sciences is having a rough day in the market as well  however  their declines are beyond current market conditions  Unfortunately  short interest spiked by 16  in the month of August  showing that investors are expecting to see more declines to come  Nonetheless  I still believe that GILD is a great company  They have taken control of the HCV market and maintained that control in the face of strong competition  They are also a major player in the HIV market and are continuing to innovate in the world of medicine  With that said  I think that the short interest has quite a bit to do with overall opinions of the market and  when the market settles  so too will this issue for GILD investors  Nonetheless  expect declines here and there as turbulence continues 
SunEdison Climbs On Insider Buying And Analyst Note
SunEdison Inc  NYSE SUNE 
SunEdison is having an incredible day in the market today  regardless of what is happening elsewhere  First off  Ahmed Chatila  the company s CEO purchased 9 700 shares  Insider buying is important because it shows that insiders have faith in growth  On top of the insider buying  J P  Morgan initiated coverage on the stock with a strong rating as well as a strong target price  The rating offered is  overweight  with a target price at  24  As a result of both of these pieces of news  the stock is up in a big way today  Considering the fact that SUNE is part of a strong emerging market and that the CEO obviously has faith in the company s growth  I m expecting to see more gains ",2015-09-02,Joshua Rodriguez,"https://www.investing.com/analysis/ariad-pharmaceuticals-(aria),-baxalta-(bxlt),-twitter-(twtr),-gilead-263744",263744
201956,423472,GILD,MannKind Up  Immunomedics Climbs,opinion,"MannKind Corporation Is Up  Is There Room Left For More Gains 
MannKind Corporation  NASDAQ MNKD 
MannKind is having an incredible day in the market today  As market turmoil starts to subside  the stock is climbing  currently  2 15  trading at  4 00 per share after a gain of 3 09  so far  While we re likely to see a slight correction bringing the stock down tomorrow  I think that it may finally be time for MNKD to start seeing some real gains  The reality is that concerns about Afrezza are starting to subside  The Direct to Consumer phase is in full swing at the moment and insurers are starting to pick up coverage on the medication  As a result MNKD are likely to see sales climb relatively soon  leading to profits for the company and gains for its stock  With that said  tomorrow we are likely to see dips  In my opinion  buying the dips is likely to prove to be a strong strategy on this stock 
Nanosphere Receives FDA Clearance
Nanosphere  Inc   NASDAQ NSPH 
Nanosphere is having an incredible day in the market today after announcing that they have received 510 k  clearance from the FDA  The clearance surrounds RP Flex  the first test of its kind  The new test features Nanosphere s novelFlex software  a software that allows the 16 viral and bacterial targets identified by RP Flex to be reported as a full multiplex panel or in various user defined subsets  This flexible panel concept addresses varied respiratory testing needs of labs and clinicians with a single comprehensive and cost effective solution  In the RP Flex testing  labs will only be required to pay for the targets that are ordered  ultimately driving down the cost of healthcare  Here s what Paul Granato  Ph D   had to say during the announcement 

 The demand and need for respiratory pathogen testing varies by season  geography  epidemiology and patient demographics  RPFlex is the first respiratory test that provides labs with the flexibility to choose and pay for only the microbial targets applicable to a given patient  which in turn allows them to practice better test stewardship and reduec healthcare costs  

Following the news  NSPH climbed in a big way  Currently  2 23   the stock is trading at  3 00 per share after a gain of 11 11  so far today 
Gilead Sciences Presents A Great Buying Opportunity
Gilead Sciences  Inc   NASDAQ GILD 
Gilead Sciences  in my opinion  is one of the strongest stocks in biotech  After all  the company has complete control over the hepatitis C treatment space  plays a major role in the treatment of HIV and continues to innovate  Another thing that s worth mentioning is that the stock has an incredibly low PE ratio  which means that the stock is incredibly undervalued  On top of the low PE ratio  market wide declines have brought the stock even further down  which is creating quite the buying opportunity  Currently  2 26   GILD is trading at  104 21 per share after a gain of 2 15  so far today  However  don t expect this low price to last  Gains are on their way 
Immunomedics Climbs On Positive Phase 2 Data
Immunomedics  Inc   NASDAQ IMMU 
Immunomedics is having an incredible day in the market after announcing positive phase 2 study data from sacituzumab govitecam  the company s lead investigational drug  Sacituzumab govitecan is an antibody drug conjugate which continues to produce durable responses in patients with metastatic lung cancer who have relapsed or were refractory to their last cancer therapy  Currently  2 30   IMMU is trading at  2 32 per share after a gain of 7 91  so far today ",2015-09-09,Joshua Rodriguez,"https://www.investing.com/analysis/today-in-biotech:-mannkind-(mnkd),-nanosphere-(nsph),-gilead-sciences-264474",264474
201957,423473,GILD,4 Biotech Stocks To Watch Today  MNKD  AEZS  GILD  CTIC,opinion,"MannKind Corporation Starts To See Gains 
MannKind Corporation  NASDAQ MNKD 
MannKind has had tough luck in the market for the past several months  While they have created Afrezza  a key player in medical innovation  the company they contracted for commercialization hasn t been able to get the sales up  However   explaining why sales have been slow and why I believe that sales are likely to pick up relatively soon  To recap  the poor sales had quite a bit to do with no marketing and no insurance coverage  However  these issues are coming to an end  In fact  about 80  of major insurance companies will be covering Afrezza in one way or another relatively soon  On top of that  Sanofi  PARIS SASY  recently started the direct to consumer campaign which is improving consumer awareness  All in all  I believe that MNKD investors will be pleasantly surprised relatively soon 
AEterna Zentaris Is Trading Up On High Volume
AEterna Zentaris Inc   NASDAQ AEZS 
AEZS is having a great day in the market trading on high volume after finding a   According to NASDAQ  the 50 day average volume on the stock has been 15 416 220 shares  However  so far today  2 00  39 940 921 shares have traded hands  Currently  AEZS is trading at  0 10 per share after a gain of 25 58  
Gilead Sciences  NASDAQ GILD  Continues Declining On Hillary Clinton s Comments
Gilead Sciences  Inc 
Gilead Sciences is having a rough day in the market today and has been for the past few trading sessions  The declines on the stock are the   Her plan is to reduce the cost of prescription medications for those suffering from chronic illnesses  However  when you look into the details of the plan  I don t think that it will make it through any voting process  Simply put  a plan like that is likely to halt medical innovation  With that said  while I do believe that GILD is likely to continue declining in the short term  I still believe that this is a strong stock for investors looking for long term gains  Currently  2 04   GILD is trading at  105 44 after a loss of 1 00  so far today 
CTI BioPharma Climbs On NDA Plans
CTI BioPharma Corp  NASDAQ CTIC 
CTI BioPharma is having a great day in the market today after announcing its plans to submit a new drug application to the US Food and Drug Administration  The application will revolve around pacritinib  an investigational oral kinase inhibitor  CTIC plans on submitting the NDA in the fourth quarter of 2015 and will be requesting accelerated approval for the treatment of patients with intermediate and high risk myelofibrosis  As a result of the announcement  CTIC is currently  2 08  trading at  1 56 per share after a gain of 8 33  so far today ",2015-09-24,Joshua Rodriguez,"https://www.investing.com/analysis/biotech-stocks-today:-mannkind-(mnkd),-aeterna-zentaris-(aezs)-266015",266015
201958,423474,GILD,Gilead Sciences Belongs In Your Portfolio,opinion,"In my opinion  Gilead Sciences  NASDAQ GILD  is likely the strongest biotech stock on the market today  They have an incredible story and are offering an even more incredible opportunity  The bottom line here is that GILD is going to grow  and in a big way  Today  we ll talk about why I m so bullish on Gilead Sciences and the opportunity the stock is presenting for investors  So  let s get right to it   
Why My Opinion Of GILD Is A Very Bullish One
Gilead Sciences provides many reasons to be bullish on their stock  To name a few   

Dominance In HCV   First and foremost  Gilead Sciences plays an incredibly dominant role in the hepatitis C treatment arena  Their treatment  Harvoni is currently the leader in the United States  and that s not likely to change any time soon  In fact  even in the face of stiff competition  GILD has maintained their dominant position in the market 
Continued HCV Innovation   While Gilead Sciences is already dominant in the HCV market  that doesn t mean that they ve put an end to innovation  Ultimately  the company wants to continue producing better and better treatments for the ailment  This was proven in their most recent data release  The company released top line results from four studies looking into a new HCV combination drug  The new combination drug relieves the need of phenotype testing in HCV patients  Essentially  it is proving to treat all phenotypes 
Gaining Ground In Other Indications   While Gilead Sciences maintains a stronghold on the hepatitis C market  it is also gaining ground in other areas  The company has promising candidates in both hepatitis B and in HIV 

The Incredible Opportunity GILD Presents
As if the information listed above wasn t enough to get excited about GILD and its potential to grow  the stock is offering quite the opportunity  Currently  GILD is oversold and undervalued  Early in the year  AbbVie  NYSE ABBV  released a hepatitis C drug that would compete with Gilead s  As a result  investors got cold feet and were afraid to push the stock up  Nonetheless  GILD continued to produce incredible earnings  As a result  the PE ratio on the stock fell to below 10 and is still there currently 
More recently  Hillary Clinton made comments that she plans to submit a bill that will reduce the cost of prescription medication for chronically ill patients dramatically  Unfortunately  this would affect the company s bottom line if it happened  However  I don t think that s going to happen  Clinton would have to make it to office before she could submit such a bill  and that would take a miracle at this point thanks to her email scandal 
Nonetheless  the stock declined following Hillary Clinton s statements  bringing it s PMI to 29 5  Anything under 30 shows excessive fear and oversold conditions  It s when great companies meet these conditions that the most hefty discounts are available for investors  and that s exactly the case with GILD 
What Do You Think ",2015-09-30,CNA Finance,https://www.investing.com/analysis/gilead-sciences-(gild):-why-this-stock-should-be-in-your-portfolio-266691,266691
201968,423484,GILD,Biotech Stock To Watch  ANAC  MNKD  GILD  SGYP,opinion,"The US market is off to a great start this week  showing green pretty much across the board  The biotech space is no different  However  there are some gems in biotech that you may want to watch incredibly closely  Here s what I was able to dig up 
Anacor Pharmaceuticals Stock Climbs On Data Release
Anacor Pharmaceuticals Inc  NASDAQ ANAC 
Anacor Pharmaceuticals is up in a big way today after announcing preliminary top line results from two Phase 3 studies of Crisoborole Topical Ointment  The ointment is a novel non steroid anti inflammatory phosphodiesterase 4 inhibitor  It is an experimental treatment designed to treat mid to moderate atopic dermatitis in both children and andults  The data released shows that the studies have both achieved statistically significant results in all endpoints  both primary and secondary  The study also demonstrated a safety profile that is consistent with previous studies  As a result  ANAC is soaring in the market today  currently  12 07  trading at  46 74 per share after a massive gain of 55 24   In a statement  Paul L  Berns  CEO of Anacor Pharmaceuticals had the following to say 

 We are extremely pleased by the top line results from our Phase 3 pivotal studies of crisaborole  We believe there is a significant unmet medical need for a novel non steroid topical anti inflammatory treatment option for the patients who are affected by mild to moderate atopic dermatitis  We also want to extend a special thanks to the clinical investigators who conducted the studies and the patients and their families who volunteered to participate in our studies  We currently plan to file a New Drug Application for crisoborole in the first half of 2016 and  if approved  we believe crisaborole could offer an important treatment option for patients with mid to moderate atopic dermatitis  

Given the reason for the climb today  I don t see any long term downtrends in the near future for ANAC  While we are likely to see a correction after massive gains  I think the overall trend is going to be relatively bullish  So  watch for pull backs as your opportunity to get in on the gains 
MannKind Corporation Is Up As investors Anticipate D2C Phase
MannKind Corporation  NASDAQ MNKD 
MannKind Corporation is having a strong day in the market today as investors anticipate the Direct to Consumer phase for Afrezza  We know that this is just around the corner  However  an exact date hasn t been provided quite yet  However  insider buying shows that it may be closer than we think  It was recently disclosed that the COO of MNKD purchased 20 000 shares in the company at a value of  91 400  Insider buys insinuate confidence from insiders that the stock will grow  and with the Direct to Consumer phase coming soon  there s no reason to think any different  So  keep a close eye on this one as we re likely to see big movement very soon 
Gilead Sciences  NASDAQ GILD  Continues To Climb On Rights To Sell In Japan
Gilead Sciences  Inc 
If you ve followed CNA Finance or my writing just about anywhere else  you know that I m a big fan of Gilead Sciences  The reality is that thanks to uncertainty revolving around competition in the HCV market  the company s stock has been kept at a relatively low price  even when earnings justified growth  However  it seems like GILD is going to see the growth it deserves moving forward  Last week  the company announced that it had received regulatory approval for the sale of Harvoni in Japan  a massive HCV market  As a result  investors have reacted in an overwhelmingly positive way  pushing the stock up  Considering the low valuation on the stock and massive upside potential  I don t see any major downtrends in Gilead s near future  So  keep your eye out for dips as they will likely prove to be incredibly profitable times to buy 
Synergy Pharmaceuticals Is Likely To See Big Gains Soon
Synergy Pharmaceuticals Inc  NASDAQ SGYP 
Synergy Pharmaceuticals has been one of my favorite stocks in biotech to watch recently  The reason revolves around the company s experimental drug known as plecanatide  Last week  the company brought a new member to the board for the commercialization of the drug  showing that a New Drug Application with the FDA isn t far off  Generally  when NDAs are submitted  they prove to be catalysts for the stock  and I m not expecting anything different in this case  So  this is another one to watch closely as its likely to present a strong opportunity for gains 
Do You Know Of Any Others 
Do you know of any other stocks in biotech that are presenting strong opportunities  If so  let us know in the comments below ",2015-07-14,Joshua Rodriguez,https://www.investing.com/analysis/biotech-stock-to-watch-anacor-pharmaceuticals-(anac)-mannkind-corpor-258237,258237
201969,423485,GILD,5 Stocks To Watch,opinion,"Gilead Sciences
Gilead Sciences  NASDAQ GILD  reports its FQ2  15 results on Tuesday after the market close  Both Estimize and Wall Street are predicting a fall in EPS and revenues QoQ  Estimize are forecasting an EPS figure of  2 78 and a revenue target of  7 570B  Wall Street estimates EPS to come in at  2 64 and revenues to be  7 360B 

The success of Gilead over the past 36 months can be attributed to the company s strong revenue growth figures which have blown expectations out of the water consistently over the past 2 years  However  this metric has recently experienced a slowdown and is expected to only further decline  As payers begin to balk at the high price tags of Gilead s Hepatitis C drugs including Sovaldi and Harvoni  sales are expected to be negatively affected 
Despite the potential negatives associated with falling revenue growth  Gilead is in a very strong position in terms of its balance sheet  Gilead has the ability to use its balance sheet to its advantage and potentially acquire desirable businesses in an attempt to bolster growth over the coming years 
Investors will be eager to hear from management with respect to both increasing competition and also their M A strategy moving forward  Investors have become accustomed to Gilead outperforming analyst expectations  therefore if there is a miss on Tuesday  the stock could potentially experience a significant pull back depending on the severity 
Ford Motor Co 
Ford Motor Company  NYSE F  will report its FQ2  15 results before the opening bell on Tuesday and both Estimize and Wall Street are predicting an uptick in revenues and EPS QoQ  The struggles have continued YTD for the car manufacturer with the company posting a negative capital return of  7 16   For FQ2  15  the Estimize community predicts an EPS value of  0 36  just one cent above Wall Street s estimate of  0 35  Dissimilar to EPS  Wall Street actually predict a higher revenue figure of  35 925B compared to Estimize s forecast of  35 886B 

Ford Motors are currently in the process of deploying a substantial amount of capital across the globe in an attempt to expand and boost top line revenue growth  Despite the expected positives associated with its global expansion  Ford is under pressure for a number of reasons including enhanced competition restricting margin expansion  a devalued Russian currency hurting USD denominated earnings  and a weak Eurozone economy continues to hurt sales in the region 
With the recent report from General Motors  NYSE GM  being overwhelmingly positive  market participants are relying on Ford to also post a similar result 
Twitter Inc 
Twitter  NYSE TWTR  will also report its FQ2  15 results after the market close on Tuesday  The Estimize EPS estimate is set at  0 06  a penny above Wall Street s consensus of  0 05  In terms of revenue forecasts  the Estimize community forecast  490 91M compared to Wall Street which predict  487 38M 

Twitter s share price has still not recovered since management announced the FQ1  15 result in which the company reported falling revenues and earnings QoQ  The main concern however drawn from the report was the poor user growth number which resulted in the share price collapsing circa 25  the next day 
Investors will want more guidance on how Twitter s management aim to penetrate the social media advertising market in a more meaningful way  To date  Twitter has continued to lag behind key competitors such Facebook who have much more sophisticated targeting techniques with respect to marketing campaigns  If Twitter can leverage off its user base to create more desirable targeted marketing techniques for advertises  this will ultimately translate to increased revenues in the future 
Facebook Inc 
Facebook  NASDAQ FB  reports its FQ2  15 figures on Wednesday after the closing bell  Year to date  YTD  Facebook s stock has outperformed the NASDAQ with a capital return of 24 08  compared to the index  which has appreciated by 8 54  
For the upcoming quarter  the Estimize community is predicting an EPS figure of  0 49 compared to Wall Street s forecast of  0 47  Estimize also has a higher revenue prediction of  4 028B versus Wall Street s estimate of  4 001B 

Market participants continue to be enthusiastic about Facebook s Instagram business  With over 300M users currently using Instagram  the opportunity for this business segment to deliver strong revenues for Facebook is very real  Advertisers are now able to access data from Facebook profiles in order to fully tailor their advertising campaign depending on each individual  In a world where customized advertising and programmatic advertising buying is becoming integral to the marketing landscape  this offering is highly desirable to advertisers 
With mobile generating circa 73  of all revenues for Facebook  the continuation in innovation of product offerings is critical for the ongoing success of Instagram and Facebook  Investors will be interested to learn more about the upcoming offerings Facebook intends on launching 
LinkedIn Corporation
LinkedIn  NYSE LNKD  reports its FQ2  15 results after the closing bell on Thursday  The Estimize community is predicting an EPS figure of  0 36 and a revenue number of  684 16M  Wall Street analysts however  assume an EPS figure of  0 30 and forecast revenues of  681 56M 

The most important part to LinkedIn s business is clearly its talent solutions segment  This segment was most recently recorded to account for 62  of total revenues for LinkedIn  This particular side of the business focuses on selling products to recruiters  The most important thing for investors heading into the result will be how this segment faired in FQ2  15  With a dramatic 5  fall in YoY growth in FQ1  investors will want to see a better result YoY in FQ2  The sentiment following the report will likely be dictated by the talent solutions segment s performance  investors are advised to watch this number closely and pay attention to management s outlook for this area of the business ",2015-07-27,Estimize,https://www.investing.com/analysis/5-stocks-to-watch-for-this-week-7-27-259634,259634
201970,423486,GILD,Thoughts From Collins Place,opinion," Stability  is working
China almost crossed the line back into the black yesterday and expectations are that the Shanghai and Shenzhen markets will actually register positive prints today  It s a bold call but one I think will be proven right 
It would be remiss to not to point out how much China drove trade yesterday 
Chinese futures plunged at 11 15am AEST on the open  which spooked Asian markets almost immediately 
On the open of the cash markets  however  everything rallied  Japan  Southeast Asia  Australia  Hong Kong and mainland China rallied from 11 30am onwards and did so all the way to the final hour of Chinese trading 
Call it what you will  the aptly named  rescue squad  have made their intentions clear and will continue to support the Chinese markets at any cost 
Yes  the Chinese indices closed down however  strength is seen in the 200 day moving average and further investigations into Monday s price plunge will limit major downswings for the next few weeks 
I have been asking myself this question recently  what effect have the last two months of equity market trade had on the Chinese economy and consumer  The economy is yet to release its retrospective information  August will illustrate how the markets affected the economy  but Chinese consumer numbers are out 
So  is the equity crash having an effect on Chinese consumers  In short  no  The loss of wealth from the collapse of the markets is not hitting the majority of Chinese wealth  Chinese household saving rates are currently the highest in the world at 40   Its nearest rival is Luxembourg at a touch over 10   The China stock market crash is an interesting situation however the net effect on the Chinese people looks minimal at this point 
What else is spiking my interest
US earnings season kicked back into gear   Twitter  NYSE TWTR  is the likely standout on the open with a huge beat on the EPS line  The same can be said for Gilead Sciences  NASDAQ GILD   The hepatitis drug maker has certainly justified the market excitement it has seen in the past six to twelve months and may see solid buying on the open tomorrow 
However  there is a growing sense the US bull market is out of breath  The six and a half year Bull Run in the US is showing signs of fatigue  Here s why 
Only 34  of US stocks are above their 200 day moving average 
Only 54  of stocks are above their 50 day average this year  compared to 64  in 2014 and 73  in 2013  yes  the momentum has been slowing for two years  
Healthcare and consumer discretionary sectors account for all gains in the S P 500 this year  every other sector is in the red 
The transport sector is trading at its largest discount to the market in two years 
57  of S P companies are in a correction  contracted 10  or more  
460 stocks on the NYSE are at 52 week lows 
Yet the S P is up over 3  year to date 
Iron ore is now bouncing   53 45 is the highest level in almost a month  However  both Brazil and Australia have cut export volumes in July as maintenance at terminals kicks in  The longer term outlook shows the taps will be turned back on once July maintenance filters out  I see iron ore averaging US 50 tonne for the remainder of the year 
Ahead of the Australian open
The bounce in the equites and commodities markets overnight should give a pretty positive lead to markets  However  the jump in iron ore was foreshadowed in the Dalian futures market yesterday and the jump in miners may be slightly muted as it might have been priced in yesterday 
There is an interesting pattern emerging in the S P ASX 200  having seen the ASX breaking out of the downtrend from the April top to the June low  The top of the channel has been defended three times in the past week and looks to be a new support level 
This is despite the issues facing China and the weak leads from the States  5550 sees a reasonable amount of buying support and the ASX will cross back into 5600 points today  meaning July will be the first positive trading month for the ASX since February as it would be hard for the market to fall over 150 points in the next two days 
Ahead of the open  the ASX is pointing down 43 points to 5628 
Asian markets opening call 
Price at 8 00am AEDT
Change from the Offical market close 
Percentage Change
Australia 200 cash  ASX 200 
5 628 10
43
0 78 
Japan 225  Nikkei 
20 347 80
19
0 09 
Hong Kong HS 50 cash  Hang Seng 
24 670 70
167
0 68 
China H shares cash
11 238 70
66
0 59 
Singapore Blue Chip cash  NYSE EWS 
367 86
 1
 0 28 
US and Europe Market Calls
Price at 8 00am AEDT
Change Since Australian Market Close
Percentage Change
WALL STREET  cash   Dow 
17 632 00
95
0 54 
US 500  cash   S P 500 
2 094 74
15
0 75 
UK FTSE  cash 
6 586 60
51
0 78 
German DAX  cash 
11 205 70
102
0 92 
Futures Markets
Price at 8 00am AEDT
Change Since Australian Market Close
Percentage Change
Dow Jones Futures  September 
17 552 50
94 50
0 54 
S P Futures  September 
2 088 13
15 00
0 72 
ASX SPI Futures  September 
5 568 00
38 50
0 74 
NKY 225 Futures  September 
20 360 00
10 00
0 05 
Key inputs for the upcoming Australian trading session  Change are from 16 00 AEDT  
Price at 8 00am AEDT
Change Since Australian Market Close
Percentage Change
AUD USD
 0 7333
0 0016
0 22 
USD JPY
 123 560
0 005
0 00 
Rio Tinto  LONDON RIO  Plc  London 
 24 32
0 38
1 60 
BHP Billiton  LONDON BLT  Plc  London 
 11 60
0 30
2 61 
BHP Billiton Ltd  ADR  US   AUD 
 25 52
0 15
0 58 
Gold  spot 
 1 095 46
 1 64
 0 15 
Brent Crude  September 
 52 98
 0 06
 0 10 
Aluminium  London 
1664 5
21 50
1 31 
Copper  London 
5308
111 50
2 15 
Nickel  London 
11280
300 00
2 73 
Zinc  London 
1986
55 00
2 85 
Iron Ore  62 Fe Qingdao 
 53 45
1 10
2 10 
IG provides round the clock CFD trading on currencies  indices and commodities The levels quoted in this email are the latest tradeable price for each market  The net change for each market is referenced from the corresponding tradeable level at yesterday s close of the ASX  These levels are specifically tailored for the Australian trader and take into account the 24hr nature of global markets ",2015-07-29,IG,https://www.investing.com/analysis/thoughts-from-collins-place-259823,259823
201977,423493,GILD,Gilead Sciences Remains Popular Biotech Stock Following Earnings,opinion,"By Sarah Roden
Gilead Sciences  NASDAQ GILD  released first quarter 2015 earnings on April 30  High revenues pointed to the success of Gilead s blockbuster hepatitis C therapies  Sovaldi and Harvoni 
Analysts had estimated that Gilead would post diluted earnings per share of  2 32 for the quarter on a non GAAP basis  but Gilead beat expectations by posting  2 94 per share  This figure nearly doubled from  1 48 in the same quarter of last year  Gilead substantially beat the analyst revenue estimate of  6 89 billion and posted nearly  7 6 billion in quarterly revenue  marking over a 50  year over year increase  Sales derived from Harvoni and Sovaldi totalled more than half of total quarterly revenue at  4 55 billion  Gilead noted that 90 000 patients in the U S  and E U  initiated treatment on Sovaldi or Harvoni  This comes after controversy over the high price tag of the regimes as people protested the  1 000 per pill price tag of Sovaldi 
Looking forward  Gilead provided revised guidance for full year 2015 net product sales between  28 million and  29 million  marking a  2 billion increase from prior guidance  Gilead also declared its first quarterly cash dividend of  0 43 per share of common stock 
Analysts were overwhelmingly bullish on Gilead following the quarterly report 
According to    of Needham reiterated a Buy rating on Gilead following the quarterly report and maintained a price target of  120  Carr noted Harvoni s strong performance  which he expects to continue in the EU and Japan  Carr also commented on GS 5816 testing  a hepatitis C drug in Gilead s pipeline  noting that top line results for the drug are expected in 3Q15 and a New Drug Application should be submitted in 4Q15 
Alan Carr has rated Gilead 15 times since February 2012  earning an 87  success rate recommending the stock with a  51 3  average return per GILD recommendation  Overall  Carr has a 72  success rate recommending stocks with a  39 1  average return per rating Separately   of Barclays maintained an Overweight rating on Gilead following the earnings report with a  125 price target  Meacham noted Harvoni s strong performance and added that Gilead s  strong 1Q performance was differentiated versus large cap biotech peers   Though many analysts are worried about the decreasing market for hepatitis C and pricing competition from other drugs  Meacham acknowledged that while  hep C discounts may increase over 2015  we view the 46  gross to net guidance as a worst case scenario and expect the conversation to increasingly focus on broader patient access   which is just beginning to play out   The analyst assured that Gilead will maintain leadership in hepatitis C therapies  despite competition  Furthermore  Meacham expects  Gilead to continue to innovate and raise the bar in hep C with a pangenotypic regimen and a shorter duration of therapy  
Geoff Meacham has rated Gilead 6 times since September 2012  earning an 83  success rate recommending the stock with a  40 3  average return per GILD recommendation  Overall  Meacham has a 78  success rate recommending stocks with a  29 7  average return per rating On average  the top analyst consensus for Gilead on is Moderate Buy ",2015-05-03,Sarah Roden,https://www.investing.com/analysis/gilead-sciences-remains-a-popular-biotech-stock-following-earnings-250433,250433
201978,423494,GILD,Top Ranked Analysts Are Bullish On Gilead Sciences  Inc   GILD ,opinion,"Gilead Sciences  NASDAQ GILD  has been a favorite among biotech investors due to its successful hepatitis C therapies  Harvoni and Sovaldi  However  the biopharmaceutical company is making headlines again with a new drug for gastric cancer  GS 5745 
GS 5745 is advancing into Phase III testing in the third quarter  prompting RBC Capital analyst  to reiterate an Outperform rating on Gilead with a  120 price target  Yee believes this pipeline advancement is beneficial for Gilead investors because of low expectations for the trial  Furthermore  Yee notes that Gilead s pipeline  is all upside  at this point  He continues   Management is quietly building a pipeline and we predict they ll continue to do more cancer and immuno oncology deals under  5 billion in size and they re looking in EU perhaps using OUS cash  
Michael Yee has rated Gilead 20 times since April 2013  earning an 85  success rate and an  18 6  average return per GILD rating  Overall  Yee has a 70  success rate recommending stocks with a  11 4  average return per rating 
The top analyst consensus on Gilead is Strong Buy thanks to all the bullish ratings that followed the company s first quarter earnings on April 30  Gilead beat expectations for both earnings per share and revenue with more than half of sales coming from Harvoni or Solvadi  Gilead increased their full year 2015 guidance and declared its first quarterly cash dividend 
Nine analysts weighed in on Gilead following earnings with only one bearish rating  All eight analysts who gave bullish ratings on Gilead have consistently high success rates recommending Gilead including analysts from J P  Morgan  Barclays  Piper Jaffray  and others  The eight analysts who gave bullish ratings on Gilead directly after earnings have success rates ranging from 78  to 100  and each of the analysts have rated Gilead at least 5 times 
of Merrill Lynch  the one analyst to issue a Sell rating following Gilead s earnings  has rated Gilead three times with an average loss of 9 3  per GILD rating  Huang is bearish on Gilead due to increasing competition from Merck  NYSE MRK  s hepatitis C drug  He warned that although Merck s pipeline drug may be less effective   they can gain meaningful market share with an aggressive pricing strategy   He also cited concerns regarding the  long term sustainability  of Gilead s hepatitis C and HIV drug sales 
On average  the top analyst consensus for GILD on is Strong Buy ",2015-05-14,Sarah Roden,"https://www.investing.com/analysis/top-ranked-analysts-are-bullish-on-gilead-sciences,-inc.-(gild)-251805",251805
201979,423495,GILD,Support Held And We Are Free To Run Higher Now,opinion," I could not  at any age  be content to take my place by the fireside and simply look on 

Life was meant to be lived  Curiosity must be kept alive  One must never  for whatever reason  turn his back on life   Eleanor RooseveltA much better day than Tuesday today with stocks coming back well and markets also There just wasn t any real panic selling Tuesday which convinced me to hold most of my positions and even add to Gilead Sciences Inc  NASDAQ GILD  at the  110 area at the lower end of its bear flag 

SPDR S P 500  ARCA SPY  bounced superbly off the breakout level at 211 and showed a beauty 2 day reversal but it does need to see a higher close tomorrow to confirm this All in all  great  great action that just tested the breakout area and shook many people out and now we should be free to run higher ",2015-05-28,Warren Bevan,https://www.investing.com/analysis/support-held---we-are-free-to-run-higher-now-253161,253161
201980,423496,GILD,Abzena  A Solid Year In FY15 ,opinion,"Accelerated developmentWe raise our Abzena PLC  LONDON ABZA  valuation to  105m  108p share  following partner Gilead s plans to accelerate the development of antibody GS 5745  with Phase III  gastric cancer  and Phase II III  ulcerative colitis  studies to start in H215  Eight antibodies are currently in clinical development using Abzena s technology  and more are expected to enter the clinic in the next 12 24 months  Abzena could receive small royalties on these products  and others such as antibody drug conjugates  ADCs   which offer the prospect of substantial future revenues 

Gilead leapfrogs GS 5745 from Phase I to Phase IIIIn its Q115 conference call  Gilead Sciences Inc  NASDAQ GILD  announced plans to advance GS 5745  its anti MMP9 antibody  directly from Phase I to Phase III development in gastric cancer  to start Q315   in addition to initiating a Phase II III trial in ulcerative colitis  to start H215   We have increased the probability of success for this asset to 50   from 35    and brought forward the potential launch to 2019  vs 2022   These are primary drivers behind our raised valuation  GS 5745 also recently entered a 175 patient Phase II study in Crohn s disease  and further Phase I trials are ongoing in COPD  rheumatoid arthritis and pancreatic cancer  highlighting its broad potential Technology licenses the key to long term valueGS 5745 is one of eight antibodies currently in clinical development created using Abzena s Composite Human Antibody technology  Gilead s simtuzumab in multiple Phase II trials is another notable partnered candidate   Abzena has also revealed that Annexon Biosciences  pre clinical antibody ANX005 for Huntington s disease was also developed using its technology  Commercialisation of these products could lead to significant long term revenues from small   royalties on sales A solid year in FY15Abzena s FY15 results highlighted solid progress on multiple fronts  129 service projects were completed for  80 customers  while eight new agreements were signed that could lead to milestones royalties in the future  Total group revenues of  5 7m were boosted by a strong H215 result   3 2m vs  2 4m in H115  with two thirds generated from repeat customers  Cash at 31 March 2015 was  15 8m Valuation  Raised to  105m or 108p per shareOur fair value for Abzena has increased to  105m  from  97m  or 108p share  vs 100p   primarily due to the accelerated timelines for Gilead s GS 5745 and higher probability of success  The potential to receive substantial revenues on royalties from licensed antibody ADCs remains key to the long term investment case 
To Read the Entire Report Please Click on the pdf File Below",2015-06-23,Edison,https://www.investing.com/analysis/abzena-fy15-results-partner-255964,255964
201987,423503,GILD,Prescription Data Offers Insight Into Gilead Sciences  Inc  Sales,opinion,By Sarah RodenGilead Sciences  NASDAQ GILD  received new data from IMS Health about the breakdown of its drug prescriptions  Gilead is most known for its hepatitis C medications  Harvoni and Sovaldi IMS prescription data breaks down how many people are receiving which drug prescriptions in more than 15 countries  Robyn Karnauskas  a Deutsche Bank analyst  noted that the IMS predicts an approximate 50  increase in  new starts  for Gilead s hepatitis C drugs in 1Q15 compared to 4Q14  The survey also indicated that the reimbursement process for the drugs is easing  which is integral for most patients considering that Sovaldi s full price tag if  84 000 per treatment course  or  1 000 per pill  The study also indicated that more undiagnosed patients are receiving the treatment they need and this rate will increase in 2015 through 2016 Increases in hepatitis C prescriptions will bolster Sovaldi and Harvoni s sales  In the fourth quarter  Gilead reported that Sovaldi brought in  1 732 billion while Harvoni brought in  2 107 billion  Together  these two hepatitis C drugs make up more than half of Gilead s sales  Gilead s earnings for the first quarter of 2015 are expected to be released at the end of April On April 6  analyst  of Citigroup reiterated a Buy rating on Gilead Sciences with a  120 price target  Werber finds it  unlikely  that Gilead will miss Q1 estimates since  a 30  35  gross net discount is already factored into consensus estimates   Based on his calculations using the IMS script data  Werber believes that HCV sales will be between  3 billion and  4 2 billion for the first quarter  which is higher than both the overall Citi estimate of  2 15 billion and the general consensus of  2 71 billion  Werber believes that Harvoni revenue will come in at  2 3 billion  also higher than both the Citi estimate of  1 5 billion and the general consensus of  1 9 billion  He notes that this data  is likely conservative  because it does  not capture prescriptions in the federal facilities like VA system and prisons  Yaron Werber has rated Gilead 8 times since November 2011  earning a 71  success rate recommending the pharmaceutical company and a  34 5  average return per GILD rating  Overall  Werber has a 75  success rate recommending stocks with an average return of  26 1  per recommendation According to    of Deutsche Bank maintained a Buy rating on Gilead with a price target of  125  After reviewing the IMS prescription data  Karnauskas concluded that  first quarter HCV consensus may be hard to meet but 2015 consensus seems achievable   Though the analyst is bullish about the HCV drugs in the near term  she is  lowering the numbers in out years as the patient pool deplete in our model  Robyn Karnauskas has rated Gilead Sciences 23 times since July 2012  earning a 70  success rate recommending the company with a  22 8  average return per GILD rating  Overall  Karnauskas has a 73  success rate recommending stocks with a  14 8  average return per recommendation On average  the top analyst consensus for Gilead Sciences on is Strong Buy ,2015-04-08,Sarah Roden,"https://www.investing.com/analysis/prescription-data-offers-insight-into-gilead-sciences,-inc.-sales-247728",247728
201988,423504,GILD,Abzena Portfolio Expansion ,opinion,"Portfolio expansionAbzena PLC  LONDON ABZA  has announced that two partners have started clinical studies with antibody candidates developed using Abzena s humanising technology  An undisclosed US major pharma company has initiated a Phase I trial in neurodegenerative conditions and Therapure Innovations has commenced a Phase I study for TBI 304H in chemotherapy induced anaemia  The disclosed clinical stage portfolio now stands at eight candidates  on which Abzena could receive small royalty revenues  which in aggregate may be substantial and highlights the longer term investment case 

Major US pharma partners on boardAbzena now has two major US pharma companies  one undisclosed  the other Gilead Sciences  NASDAQ GILD  with simtuzumab and GS 5745  conducting clinical studies with antibody candidates developed using Abzena s Composite Human Antibody technology  We note also that J J has an option to acquire Vascular Pharma on completion of the Phase II study in diabetic nephropathy with Vascular s anti  V 3 antibody  also developed using Abzena s technology  Abzena could therefore have three major US pharma partners developing four of the eight current candidates Gilead confirms Phase II plans for GS 5745Gilead Sciences Inc  NASDAQ GILD  is Abzena s most notable current partner  with two Phase II assets being developed using Abzena s technology  simtuzumab  anti LOXL2  undergoing Phase II studies for NASH  PSC and IPF  and GS 5745  anti MMP9  poised for Phase II trials in ulcerative colitis  gastric cancer and Crohn s disease  According to clinicaltrials gov a 175 patient Phase II study is now expected to start recruiting patients in April  to test GS 5745 in moderately to severely active Crohn s disease Antibody and ADC services updateAntibody engineering provides important service revenues  so news that the University College London collaboration has delivered a fully humanised antibody  for age related macular degeneration   and that two new agreements with a US biotech have been signed  are positive  Another key offering is the ThioBridge linker technology to develop safer and more effective antibody drug conjugates  ADCs   so the reported increase in the number of ADC collaborations is also significant 
To Read the Entire Report Please Click on the pdf File Below",2015-04-13,Edison,https://www.investing.com/analysis/abzena-portfolio-248172,248172
201989,423505,GILD,Achillion Pharmaceuticals  Hepatitis C Market On Watch ,opinion,"Attacking Hep C via ITHACA and SPARTAAchillion  NASDAQ ACHN  continues to progress its Hep C portfolio though clinical trials with highly encouraging data from its Phase II proxy study with ACH 3102 paving the way for the initiation of more key combination Hep C trials this year  We maintain that Achillion is an attractive candidate for collaboration with a company interested in exploiting the considerable HCV market  but which lacks the in house components necessary for a competitive HCV oral drug 

Triple combi could be epitome of Hep C treatmentsACH 3102 and Gilead  NASDAQ GILD  sofosbuvir showed an SVR12  sustained viral response in 12 weeks  after six weeks of therapy  beating the next best and currently marketed Hep C combination treatment with SVR12 after 8 12 weeks of treatment  The data enable the advancement of Achillion s proprietary drugs into trials supporting the launch of a potent triple cocktail  ACH 3102 ACH 3422 sovaprevir  aiming to reach an SVR12 of less than six weeks  We currently forecast peak sales of  3 4bn for Achillion in Hep C following a triple combination launch in 2018 Hepatitis C market on watchRecently announced heavy discounting of Hep C drugs  as well as high cure rates  have called into question long term market potential in Hep C  However  we expect the sheer size of the market   sales of Hep C treatments tipped  14bn in 2014 and are widely expected to surpass  20bn in the short term   low rates of diagnosis and heavy patient back logs to shore up demand well into the next decade Complementary Factor D enters Phase I this yearAll eyes are on Hep C  although we note Achillion s promising novel Factor D programme with a lead oral compound set to enter the clinic this year  Research thus far has focused on paroxysmal nocturnal hemoglobinuria  PNH   for which the only approved treatment is Alexion s Soliris  2014 sales  2 2bn   which has significant limitations including intravenous administration and a black box warning Valuation   1 85bnOur fair value for Achillion of  1 85bn  adjusted from  1 86bn   15 8 share from  18 5 share   is derived from an NPV analysis of the company s potential triple combination treatment in HCV  forecasting a 2018 launch  The Phase I start of a Factor D compound  targeted for later this year  would trigger inclusion of the programme in our forecasts  adding an estimated risk adjusted  125m to our valuation 
To Read the Entire Report Please Click on the pdf File Below",2015-04-30,Edison,https://www.investing.com/analysis/achillion-pharmaceuticals-250125,250125
201995,423511,GILD,Gilead  Retreats 15  From October All Time Highs,opinion,Gilead Sciences Inc  NASDAQ GILD  has retreated about 15  from the all time high that dates back to October 2014  The trend is neutral as the price has been moving sideways during the last 6 months  around the psychologically critical  100 level  Patience is required for a clarification of the path of lest resistance GILD daily chart  6 months  ,2015-03-15,Petros Steriotis,"https://www.investing.com/analysis/gilead-(gild)-technical-preview-march-16,-2015-244988",244988
201996,423512,GILD,Gilead  Range Bound  Patience Required For More Clarity,opinion,Yesterday s doji candle in the vicinity of  100 is indicative of Gilead Sciences s  NASDAQ GILD  range bound market  Patience is required for clarification of the path of lest resistance GILD daily chart  6 months  ,2015-03-19,Petros Steriotis,"https://www.investing.com/analysis/gilead-(gild)-technical-preview-march-19,-2015-245504",245504
201997,423513,GILD,Analysts Remain Bullish On Gilead Despite Safety Warning,opinion,Gilead Sciences  NASDAQ GILD  issued a new warning about its hepatitis C drugs after discovering a dangerous interaction with amiodarone  a drug that monitors heart rhythm  Consequently  Gilead shares slipped more than 3  on the morning of March 23 On March 20  Gilead sent an alert to healthcare providers after learning about a dangerous interaction between Sovadli and Harvoni  its hepatitis C drugs  and amiodarone  Gilead reported 9 cases of slowed heart rates in patients taking both drugs  The reaction resulted in 1 fatality due to cardiac arrest and 3 patients required pacemakers  The reaction appeared immediately in 6 of the patients  Gilead noted that 7 of the 9 patients were also prescribed beta blockers which also slow the heart rate Harvoni and Sovaldi are Gilead s two highest grossing drugs  Together  the two accounted for more than  3 8 billion in sales in the latest quarter  accounting for a significant amount of the  7 2 billion in total sales Most investors do not seem too flustered by the reaction  Amiodarone is not used widely  it is estimated to be taken by approximately 250 000 to 300 000 patients in the United States at any given time  Gilead does not recommend mixing amiodarone with Harvoni Sovaldi  but if this is the only option the patient must be closely monitored for cardiac abnormalities  Competing hepatitis C drugs  such as AbbVie s Viekira Pak  already carry this warning According to    of William Blair reiterated an Outperform rating on Gilead on March 23  In response to the new health warnings  Sonnier reassured investors that Gilead has extensively evaluated the safety of its hepatitis C drugs and there is  no evidence to suggest there is a safety issue associated with these agents or that Sovaldi Harvoni requires cardiac monitoring outside co administration of amiodarone   The analyst does not think the warning is a dire blow to Gilead because of the  low frequency  utilization of amiodarone  in the U S   as less than 0 5  of patients use the drug  Furthermore  Sonnier reiterates that competing hepatitis C drugs already have this warning on their labels John Sonnier has rated Gilead 4 times since October 2013  earning a 100  success rate recommending the stock and a  22 7  average return per Gilead recommendation  Overall  Sonnier has a 67  success rate recommending stocks with a  23 4  average return per recommendation Separately on March 23  analyst  of Baird reiterated an Outperform rating on the stock with a price target of  126  Skorney does not consider the labeling changes  a major safety event  and he maintains his bullish view  The analyst believes the incident will have  a negligible commercial impact  on Gilead shares and encourages investors to use  any near term stock weakness as a buying opportunity  Brian Skorney has rated Gilead 9 times since August 2012  earning a 71  rate recommending the pharmaceutical company with a  28 7  average return per Gilead rating  Overall  Skorney has a 62  average return recommending stocks with a  18 6  average return per recommendation On average  the top analyst consensus for Gilead Sciences on is Strong Buy ,2015-03-24,Sarah Roden,https://www.investing.com/analysis/analysts-remain-bullish-on-gilead-despite-safety-warning-246092,246092
201998,423514,GILD,Gilead s Hep C Drug Receives Approval in Japan,opinion,Gilead Sciences  NASDAQ GILD  announced on March 26 that Japan s Ministry of Health  Labour  and Welfare approved Sovaldi as a hepatitis C treatment  The approval comes a year and a half after the biotech company filed the New Drug Application  making Sovaldi the first Gilead drug available in Japan  Sovaldi is an attractive treatment option because it is one pill taken once a day for twelve weeks that directly targets the virus Japan offers a large potential market for Sovaldi because the country has one of the highest rates of liver cancer due to hepatitis C of any industrialized country  according to a press release  Gilead Executive Vice President  Norbert Bischofberger  commented   There is a need in Japan for new HCV treatment options that are more effective and better tolerated and we have been pleased to partner with the medical community here in Japan to demonstrate the efficacy and safety of Sovaldi  Although the treatment of hepatitis C has come a long way  Gilead has come under fire for marketing the drugs at a prohibitively expensive price tag  Sovaldi s full price tag is  84 000 per treatment course  or  1 000 per pill  Despite the price tag  Gilead reported total Sovaldi sales of  1 732 billion in the fourth quarter  Sovaldi is Gilead s second highest grossing treatment next to Harvoni  its other hepatitis C treatment which brought in  2 107 billion in sales in the last quarter  Together  Sovaldi and Harvoni make up more than half of Gilead s sales According to    of Maxim Group reiterated a Buy rating on Gilead with a price target of  127 on March 31  The analyst notes   Gilead s stock has been volatile within an unstable Biotechnology marketplace  but we see good news in the Sovaldi approval in Japan  which is in line with our expectations    Kolbert continued that Harvoni  as well as Sovaldi  remain the  key drivers  for the biotech company  He commented   Harvoni has the potential to create real pharmaco economic value  as regimens get shorter and the price goes down to essentially cure HCV   According to Kolbert s model  he is confident that  Gilead can generate significant free cash flow through the end of this decade  Jason Kolbert has rated Gilead 15 times since March 2013  earning a 73  success rate recommending the biotech company with a  16 3  average return per recommendation Overall  the top analyst consensus for Gilead Sciences on  is Strong Buy Kolbert has rated many biopharmaceutical companies such as Medivation Inc  NASDAQ MDVN  and Galena Biopharma Inc  NASDAQ GALE   Kolbert has rated Medivation 10 times since October 2013  earning a 90  success rate recommending the stock with a  44 9  average return per MDVN rating However  Kolbert is not always accurate with his ratings  He has consistently rated Galena a Buy 9 times since March 2014 as the stock price fell  earning a 0  success rate recommending GALE and  25 2  negative success rate recommending the stock  Overall  Kolbert has a 44  success rate recommending stocks with a  9 0  average return per rating To see more recommendations by Jason Kolbert  visit  today ,2015-03-31,Sarah Roden,https://www.investing.com/analysis/gileads-hep-c-drug-receives-approval-in-japan-246887,246887
201999,423515,GILD,More Chop Is Frustrating,opinion," The greatest dreams are always unrealistic   Will SmithThis market stinks We re seeing nothing but chop so I sold some losers today but I m holding my winners so far but who knows how long they will continue to be winners I ve got stops in place and I really don t plan on doing much at all until we breakout one way or another There just hasn t been much acting great since late 2014 Buying breakouts hasn t worked much while buying dips has  but those trades have to be done pretty quickly unfortunately There is nothing like a nicely trending market that you can buy and just watch with minimal maintenance but we ve not got that 

SPDR S P 500  ARCA SPY  is holding the uptrend line which is great and I may look to get long on a move back above 206 60 and then 207 25So many biotech stocks were hit and the charts just need some more time again although some are holding well for now Gilead Sciences Inc  NASDAQ GILD  was one of the best bases I ve seen lately and that chart is busted for now I bought some Advaxis Inc  NASDAQ ADXS  as it s moving out of a decent cup and handle but the way things have gone  chances are it will fall back and fail and I ll be out of it Not much I can do but try  but it hasn t worked a lot lately ",2015-04-02,Warren Bevan,https://www.investing.com/analysis/more-chop-is-frustrating-247103,247103
202000,423516,GILD,Piper Jaffray Sees Potential In UniQure NV And Bristol Myers Squire,opinion,"On Monday  Uniqure NV  NASDAQ QURE  and Bristol Myers Squibb Company  NYSE BMY  announced an exclusive strategic collaboration in which the agreement gives Bristol Myers  exclusive access to uniQure s gene therapy technology platform for multiple targets in cardiovascular diseases   The New York City based pharmaceutical company will make an upfront payment of  50 million to uniQure and an additional  15 million in three months once they collaborate on three more targets  Bristol Myers will have a 4 9  stake in uniQure at a price of  33 84 a share  Before the deal was announced  shares of QURE were trading at  22 
Following news of the partnership  uniQure shares increased 55  and last opened at  34 40  According to BMY s press release  In addition to cardiovascular diseases  the agreement includes the potential for collaboration in other diseases  UniQure will lead  discovery efforts  while BMY will lead  development and regulatory activities  research and development costs   and  commercialization of all products  Glybera  uniQure s leading product candidate  is a gene therapy that treats lipoprotein lipase deficiency  or LPLD  which is a rare genetic disorder than inhibits the breakdown of fatty acids and can cause pancreatitis  Glybera is administered as an injection into a patient s leg in one session  In October 2012  Glybera was granted marketing authorization in the European Union  but it is still in Phase 3 in the United States 
According to    of Piper Jaffray reiterated an overweight rating on uniQure and increased his price target from  35 to  40  Schimmer commented on the significance of uniQure s deal with BMY  noting that it  helps validate QURE s gene therapy platform and baculovirus manufacturing capabilities and highlights the company s leadership in this field   The partnership  he continued   helps takes the pressure off Glybera EU launch and sets up the stock for hemophilia B data in 2H15  
Additionally  Schimmer is optimistic about potential for collaboration on 9 additional targets  He noted that the partnership with Bristol Myers  locks in value for the S100A1 program ahead of CLDN s P2b data in April   S100A1 is a calcium sensor protein that monitors the contracting and relaxing of the heart  It is currently in preclinical development 
Joshua Schimmer has rated many biopharmaceutical stocks in the past  such as GW Pharmaceuticals Plc  NASDAQ GWPH  and Gilead Sciences  NASDAQ GILD   He has rated GW Pharma 7 times since November 2014  earning an 86  success rate recommending the biopharmaceutical company with a  28 5  average return per GWPH rating  Likewise  he consistently rated Gilead a Buy 8 times since February 2011  earning a 75  success rate recommending the stock with a  10 9  average return per GILD rating 
However  Schimmer has not always been accurate recommending stocks in the volatile biotechnology sector  He has rated Pharmacyclics Inc  NASDAQ PCYC  4 times since November 2013 with a 0  success rate recommending PCYC and a average loss of  28 9  per rating 
Overall  Joshua Schimmer has a 63  success rate recommending stocks and a  14 9  average return per recommendation ",2015-04-07,Sarah Roden,https://www.investing.com/analysis/piper-jaffray-sees-potential-in-uniqure-nv-(qure)-and-bristol-myers-squi-247585,247585
202008,423524,GILD,Gilead Sciences Falls 10  After Doubling Drug Discounts For 2015,opinion,Gilead Sciences  NASDAQ    dropped roughly 10  in morning trading on Wednesday  February 4th  following the announcement of its fourth quarter 2014 earnings results the prior evening Although the company s earnings results for the fourth quarter and full year exceeded all expectations  investors were turned off by the amount of discounts Gilead plans to give on its new hepatitis C drugs  Sovaldi and Harvoni  in 2015  The company plans on offering an average discount of 46  on Sovaldi and Harvoni this year  up from 22  in 2014  Investors fear that Gilead s bigger discount is due to increasing competition from AbbVie  NYSE  ABBV   who already has a hepatitis C drug on the market  and Merck   Co   NYSE  MRK  who currently has a hepatitis C treatment in testing However  Gilead President and COO tried to assure investors that the rise in discounts is not because of an increase in competition  stating  I m not at all concerned about future competition that people seem to be concerned about  I think it is a very strong category for us with our profile  Highlights from Gilead s report include earnings of  2 43 per share on a Non GAAP diluted basis  up 341 8  year over year  The company more than doubled in revenue to  7 31 billion  up from  3 12 billion the same quarter a year prior Sales specifically from Sovaldi and Harvoni reached  3 84 billion for the quarter and  12 4 billion for the full year  far exceeding analysts  estimates and marking the best launch for new drugs in history Because of its wildly successful year  Gilead announced plans to start paying a dividend of  0 43 cents a share starting in the second quarter of 2015 Gilead Sciences Chairman and CEO John Martin said of the company s earnings report and dividend plans   The past year was marked by the launch of our first oncology product  second HCV medication  regulatory filings for the next generation HIV medicine  E C F TAF  and a doubling of product revenues relative to 2013  We are entering 2015 with financial strength  a portfolio of 19 marketed products that are addressing significant unmet medical needs and a pipeline for which we expect a number of milestones and data readouts during the coming year Today s announcement reflects the Board of Directors and senior management s confidence in Gilead s future  According to SmarterAnalyst  Piper Jaffray analyst  weighed in on Gilead Sciences on February 4th following the company s fourth quarter earnings  reiterating an Outperform rating on the stock but slashing its price target from  120 to  116  Schimmer noted   While new guidance leaves room for upside  the company also noted a number of obvious factors driving uncertainty in the outlook for Sovaldi Harvoni  Most disappointing to us was the company s continued refusal to help investors gauge prospects for sustainable earnings growth  instead offering some verbal commitment to fund a R D pipeline which we view as undervalued but in need of improvement  While not a favorite stock  we still believe GILD can grind out  10  share appreciation this year  Joshua Schimmer has rated Gilead Sciences 7 times since February 2010  earning an 83  success rate recommending the company and a  20 1  average return per recommendation  Overall  Schimmer has a 66  success rate recommending stocks and a  20 1  average return per recommendation Similarly  J P Morgan analyst  maintained an Overweight rating on Gilead Sciences on February 4th with a price target of  116  as reported on   Kasimov was quick to note the discount increase from 22  to 46   caught just about everyone by surprise   In regards to the increase  the analyst explained  These discounts seem to be largely contingent on increased patient volumes that should help offset the impact in the near term but again call into question the HCV tail  The volume offset is highlighted by 2015 net product sales guidance of  26 27B vs  our previous  26 7B estimate   Furthermore the analyst wrote   Assuming patient volumes do in fact make up for discounts  even if not completely   the bottom line is that GILD s HCV business will still be a significant source of revenue and earnings growth as well as cash flow generation  Cory Kasimov has rated Gilead Sciences 7 times since December 2014  earning a 100  success rate recommending the company and a  7 3  average return per recommendation  Overall  Kasimov has a 60  success rate recommending stocks and a  11 1  average return per recommendation On average  the top analyst consensus for Gilead Sciences on is Strong Buy Disclosure  All recommendations for GILD sourced from TipRanks ,2015-02-05,Carly Forster,https://www.investing.com/analysis/gilead-sciences-falls-10-after-doubling-drug-discounts-for-2015-240966,240966
202009,423525,GILD,Achillion Pharmaceuticals Stock Soars After Successful HepC Drug Trial,opinion,Shares of Achillion Pharmaceuticals  NASDAQ ACHN  jumped almost 20  in trading on February 9th after the company announced positive interim data results for its hepatitis C drug ACH 3102  After six weeks of treatment  the data showed the drug cured 100  of the patients in testing when used in combination with Gilead Sciences  Sovaldi  However  only twelve patients were included in the trial In the Phase 2 trial  the company combined 50 mg of ACH 3102 with 400 mg of Gilead s Sovaldi  which was given to patients with untreated genotype 1 hepatitis C virus Lead Investigator in the Phase 2 study of ACH 3102 and sofosbuvir  Sovaldi  Professor Edward Gane  M D  commented on the results  saying  The ability to further shorten treatment duration to only six weeks and maintain excellent SVR12 rates remains the goal for clinicians and patients  and I am pleased that these Phase 2 results support that goal  The profile of ACH 3102  represents an important and exciting treatment option to shorten treatment duration for patients infected with HCV  The next phase of testing will test whether the treatment has a continued virological response 12 weeks after the completion of treatment and evaluate  four  and six week treatment durations that leverage all of  the company s   hepatitis C  assets including ACH 3102  ACH 3422 and sovaprevir   as stated by Achillion CEO Milind Deshpande  If the results are positive  Achillion Pharmaceuticals ACH 3102 will directly compete with AbbVie s  NYSE ABBV  Viekira Pak  which has proven to cure the virus in twelve weeks  and Gilead Sciences Harvoni  which have proven to cure the virus in eight weeks Cowen   Co  analyst  weighed in on Achillion Pharmaceuticals on February 9th following the company s ACH 3102 Interim Data announcement maintaining an Outperform rating on the stock  according to   The analyst noted   While the number of patients in the Achillion trial is small  the patients do not seem to be particularly easy to treat  Therefore  while the experience is limited  ACH 3102   Sovaldi  have  generated the best data thus far for a two drug regimen  This suggests that ACH 3102 is perhaps the most potent NS5A inhibitor in development or on the market   The analyst added   It is also fair to say that Sovaldi is the major workhorse of the Sovaldi   ACH 3102 regimen  In order to build a wholly owned commercially competitive regimen  Achillion will need a safe and effective nuc  Phil Nadeau has rated Achillion Pharmaceuticals three times since August 2014  earning a 100  success rate recommending the company and a  35 7  average return per recommendation  Overall  Nadeau has a 61  success rate recommending stocks and a  15 0  average return per recommendation Similarly on February 9th  Maxim Group analyst  reiterated a Buy rating on Achillion Pharmaceuticals with a price target of  22  according to   Kolbert noted   As we have stated previously it looks like Achillion has a viable nucleoside   we know they have a viable NS5A  probably best in class   together they equal High SVR s with short treatment duration  With end of year cash   100M  we remain positive and consistent with our very bullish investment thesis  Jason Kolbert has rated Achillion Pharmaceuticals nine times since July 2013  earning a 71  success rate recommending the stock and a  52 5  average return per recommendation  Overall  Kolbert has a 41  success rate recommending stocks and a  3 3  average return per recommendation On average  the top analyst consensus for Achillion Pharmaceuticals on  is Moderate Buy ,2015-02-10,Carly Forster,https://www.investing.com/analysis/achillion-pharmaceuticals-stock-soars-after-successful-hepc-drug-trial-241478,241478
202010,423526,GILD,Abzena  Enables The Development Of More Effective Biological Products ,opinion,"Biological  r evolutionAbzena PLC  LONDON ABZA  offers a range of key services and technologies that enable its customers to develop safer and more effective biological products  This provides stable but growing revenues today  with the potential to generate substantial future revenues from small royalties on successful commercialization of products created with Abzena s technologies  Six candidates are now in clinical development  most notable is Gilead s  NASDAQ GILD  simtuzumab with Phase II trials ongoing for NASH  PSC and IPF  We value Abzena at  95m  97 5p share  on its services royalty mix 

A profitable services business The purchase of Antitope in July 2013 brought in a profitable research services business  FY14 pro forma   5 8m sales 54  GM 22  PM   primarily from major pharma customers accessing its immunogenicity technology platform  A biological product s immunogenicity has implications for safety and efficacy  so accurate  rapid and early assessment  key skills offered by Antitope  is vital to improving clinical success and is increasingly sought after by the regulators  offers significant upside potential Also through Antitope  Abzena offers protein engineering techniques to  humanize  antibodies and reduce immunogenicity  A number of antibodies that utilized this technology are now in clinical development  fully funded by the licencee  Abzena has disclosed six such candidates  with Gilead s simtuzumab the most high profile so far  given its potential across a range of indications  A small royalty on these antibodies would offer potentially significant free cash flow to the group 
To Read the Entire Report Please Click on the pdf File Below",2015-03-02,Edison,https://www.investing.com/analysis/abzena-biological-243550,243550
202022,423538,GILD,Reworking Our Healthcare ETFs,opinion,"My colleague Matthew McAleer and I have examined a transaction that may have altered the valuations of some of our health care positions 
AbbVie Inc  launched a new drug to treat hepatitis C  The other competitor in the hepatitis C treatment space is Gilead Sciences Inc   NASDAQ GILD   Recently  a major pharmaceutical distribution company  Express Scripts Holding Company  NASDAQ ESRX  made a contractual offer to AbbVie for its hepatitis C drug  with a discounted pricing structure 
Here is the issue  Gilead occupied the space  had the treatment  and was the dominant player in the hepatitis C drug treatment arena  AbbVie came in with a competitive product at roughly the same pricing  It was not disruptive with regard to its pricing model  but it presented buyers of these products with two choices  Express Scripts was using Gilead  but they cut a new pricing deal at a discounted rate with AbbVie as a sole source  We do not know what the discount rate is 
The takeaway from this anecdotal event is that pharmaceutical pricing is under pressure  The fact that we have seen one such deal suggests there may be more  Translate that to stock market and ETF strategies  and we can see where this might be going 
Health care ETFs depend on the underlying performance of their component stocks  and those stocks depend on two elements  The first is pricing power  the ability to maintain profit margins on many different components and chemical constructions and approved treatments  Some of these are very highly priced and must now be considered vulnerable 
The second element is that some pharmaceutical companies derive a large fraction of their earnings abroad and face currency translations that could be less than robust due to the strength of the dollar  The combination of the two elements creates some additional risk to earnings and profit margins in this sector 
Cumberland Advisors  response in our US ETF portfolio was to immediately sell  NYSE XPH   SPDR Pharmaceuticals ETF  and  ARCA XLV   Health Care Select Sector SPDR   We are now underweight the health care sector as we watch pricing pressures unfold  We enter 2015 concerned about a sector that had previously delivered stellar stock market returns 
David R  Kotok  Chairman and Chief Investment Officer ",2014-12-26,David Kotok,https://www.investing.com/analysis/reworking-our-healthcare-etfs-236833,236833
202023,423539,GILD,2014 Ends On A High  Bring On 2015,opinion,"As 2014 winds to a close  the year has been interesting for all kinds of reasons  Clearly the most unexpected development in financial markets was the unexpected fall in the price of oil over the back half of the year  Very few prognosticators predicted such an event  let alone those rare birds who actually profited from the rapid market decline of it s various grades  WTI  Brent   Many believed interest rates would finally rise  but this has proved the widow maker trade for those who took the bait  Over the last five years  investors have constantly bet the yield on treasury bonds would gain  especially the ten year duration  Nope  The current rate  2 25   No winners there 
In the equity markets  investors grappled with the threat of a less accommodative Federal Reserve with the ending of QE forever  Much was made of the threat that interest rates would head higher and stocks should fall  Again  nope  Every time equities sold off  it presented a buying opportunity  but only in specific sectors or issues which continued to outperform  From a macroeconomic perspective  the economy picked up steam after a tough first quarter  which has to be attributed to very poor weather  Even better  the price decline of oil has given the average household a shot in the arm with a few extra bucks in their pockets  As consumer spending accounts for such a heavy percentage of the economy  it was not surprising to see third quarter GDP come in at 5   the highest number in 11 years  Clearly  those who thought the economy was poised for persistent stagflation have been in error  I would feel for them  but the negative nabobs of negativity have only provided a constant opportunity over the last five years  Indeed  if you would have listened to them in 2009  and since then  you have missed out on one of the great equity markets of all time  Still  no victory laps for investors as the biggest question now becomes  what will happen in 2015 



Before we think about trying to predict the unpredictable  let s take a look at last weeks major events  In the health care space  Express Scripts  NASDAQ ESRX  signed a deal with AbbVie  NYSE ABBV  to try and displace Gilead  NASDAQ GILD  in the Hepatitis C drug market  Investors saw the deal as a paradigm shift in the biotechnology space  so all the leading performers sold off hard on the thesis the drug providers will no longer have pricing power  Russia s currency stabilized  with some  ahem  help  from the Putin government as it twisted it s bankers arms into helping protect the roughed up ruble  China helped out as well by providing a 24 billion dollar  3 year currency swap  ruble yuan  to assist it s largest trading partner  Do you think the fact that China has committed to buying oil and gas from Russia for the next 20 years has anything to do with the currency swap  No  of course not 



Elsewhere  Christmas came and went and the final week of the holiday shopping season brought out all kinds of estimates as to the relative robustness of retailers results  My own opinion is sellers probably did better than most believe as the crowds I saw in the malls were as large as I have ever witnessed  When you combine lower gas prices  falling unemployment rates  and plenty of holiday specials  both online and off  the urge to spurge dominated most people s thinking at this festive time 



Turning towards 2015  the weekly edition of Barron s gives us a clue on what to expect for the new year  You see  2014 was a year when S P 500 companies spent nearly one Trillion dollars on stock buybacks and dividends for their shareholders  up 24  from 2013  One Trillion  The magnitude of the number is significant because it shows you the earnings power of the largest companies in the world  When enterprises are shrinking the float of outstanding shares year after year  and also rewarding shareholders with increasing payouts  let s just say you want to be a participant in these activities  Will the market post another double digit gain next year  Who knows  and you don t want to base decisions on one statistic  but just remember  one trillion  with a t 



Last  but certainly  not least  I want to thank all of our clients for a fabulous year  It does not matter who you are  money is very important to nearly everyone  and my friends  all clients are friends  and family members are no exception  It is an honor  privilege  and important responsibility to take care of the financial well being of past  present  and future generations  It is nice seeing you benefit from our investing efforts and hope that will be the case for many many years  Finally  thank you for reading the blog this week  Interestingly enough  we had more readers last week than ever before  so welcome back and thanks again for showing an interest in my opinion  I hope you have a great weekend and if you have any questions regarding the column  market  or about Y H   C Investments  please email me at information y hc com
Disclaimer  Y H   C Investments  Yale Bock  and the family of Yale Bock own positions in securities mentioned in the blog post  Investing in stocks can lead to the complete loss of your capital  As always  on any company mentioned here  past performance is not a guarantee of future returns  Investing involves risk of losses on invested capital  One should research any investment and make sure it is suitable with your objectives  risk tolerance  risk profile liquidity considerations  tax situation  and anything else pertinent to your financial situation  Also  the CFA credential in no way implies investment returns will be superior for any charter holder ",2014-12-28,Yale Bock,"https://www.investing.com/analysis/2014-ends-on-a-high,-bring-on-2015-236883",236883
202032,423548,GILD,The Wonder Drug That Will Quadruple Gilead s 3rd Quarter Profits,opinion,"Gilead Sciences  NASDAQ GILD   is set to report earnings for its 3rd quarter of 2014 after the market closes on Tuesday October 28  At the beginning of this year GIlead began selling its new treatment for Hepatitis C  Sovaldi  in one of the most successful drug launches of all time 
In the first 6 months of the year alone Gilead sold over  5 billion worth of Sovaldi  making it the fastest drug to ever reach blockbuster sales status  more than  1 billion   It s on such a trajectory that it could even become the top selling medication of the year in its first year available 
Sovaldi sells for  1000 a pill and helped push Gilead to a colossal earnings beat last quarter  After the close today analysts will be looking to see a strong follow through from Sovaldi  but will also be eager to hear from management about the progress of Gilead s second generation Hepatitis C drug  Harvoni 


Harvoni is a medication that combines Sovaldi with ledipasvir  another drug made by Gilead  Like Sovaldi  Harvoni does not come cheap  A 12 week treatment program runs about  95 000  That s slightly more than the cost of Sovaldi over the same period  but Sovaldi can not used independently  Harvoni provides a cheaper combined treatment than the options which previously existed for Sovaldi 
Gilead just won an FDA approval to sell Harvoni earlier this month  so it won t show up in Q3 earnings  But investors will be looking to management to give a projection on Harvoni and estimate how successful they believe the new substance will be  In the meantime  Sovaldi should have plenty of wind in its sails to carry the company through 3rd quarter earnings 

According to the World Health Organization  roughly 3  of the world s population is living with the Hepatitis C infection  That s why it s no surprise that Sovaldi has been so successful  Last quarter there was a large range of estimates for Gilead on Estimize  signaling uncertainty among investors  Gilead came out and ripped the cover off the ball reporting earnings of  2 36 per share compared to the Estimize consensus of  1 94 while Wall Street was forecasting  1 80 

For the third quarter we are seeing an even larger range of estimates as displayed by the blue box above  That means that investors disagree about whether or not Sovaldi can continue pushing Gilead s earnings higher or if profits will stumble 
One of the interesting things about Gilead is that before the launch of its Hepatisis C drugs revenue growth was hovering around 15  on a year over year basis  On its 2 most recent quarters the pharmaceutical company recorded sales growth of 97  and 146  respectively  This quarter contributing analysts on Estimize except Gilead to up the pace and increase sales by a staggering 159  compared to the same quarter of last year 
Before the launch of Sovaldi profits at Gilead were stable near 50 cents per share each quarter  Since the launch of Sovaldi at the start of the year those numbers have been launched into orbit  This quarter the Estimize community has come to a consensus expectation for Gilead to come 1 penny shy of quadrupling its earnings from the third quarter of last year 
Much like Facebook Inc  NASDAQ FB  which also reports after the close today  Gilead Sciences is a hot stock with sky high expectations to live up to  Sovaldi should net the company huge profits this quarter  and we should learn from management what type of impact to expect from Harvoni over the next 3 months ",2014-10-28,Estimize,https://www.investing.com/analysis/the-wonder-drug-that-will-quadruple-gileads-3rd-quarter-profits-230515,230515
202040,423556,GILD,Casting A Wary Eye On Intercept Pharmaceuticals  Inc ,opinion,"Intercept Pharmaceuticals  Inc   NASDAQ ICPT  may indeed have the  5B blockbluster liver drug that  in hiking its price target on the stock from  425 to  500  Gilead  Gilead Sciences Inc  NASDAQ GILD     Other analysts like Leerink Partners who raised its price target from  270 to  445  and Deutsche Bank  which raised its price target from  395 to  500  may end up being correct 
But on the day after  and announced   the stock experienced a massive fade from the initial euphoria  Moreover  the the initial pop still placed the stock well below the highs of January s amazing euphoria  That euphoria took the stock to and past current price targets  It is like the adrenaline shots are losing their impact 

A wild ride for ICPT
Yesterday  August 12  2014  ICPT gapped up 46  but faded to end the day with  only  a 16 6  gain  If the ICPT story is still golden  there is certainly an amazing upside potential still left here  But the caution of a wary technician has me skeptical 
It is almost never a good sign when a stock sells off and or fades despite unbridled  headline  enthusiasm  Moreover  if the risk of failure has now decreased in ICPT as RBC claims  from 40 to 30  chance of failure   then it seems odd that the stock is trading so far off the initial enthusiasm in January  much less unable to hold today s highs  Contrast today s behavior with January s ability to hold most of the gains from the open AND plow even more buying power into the stock the very next day  both times well above the upper Bollinger  Band  overbought territory  
The failure in March to make new highs  followed by a 1 month loss of 50   followed by churn with a bias lower  finally followed by a  gap and crap  all makes for a high likelihood of buyer exhaustion  The first test comes right away  Buyers must be able to keep the gap from closing and re establish momentum  Otherwise  a resumption of the previous drift lower is in play 
Short interest also caught my eye  The ICPT bears clearly called the stock disastrously wrong as they ramped up positions going into January s announcement  In subsequent months  shares short gradually got cut in half as bears licked their wounds  But oddly enough   as if they could not get enough   bears went right back to work and ramped up positions to fresh highs before pulling back a bit ahead of today s news 

Are these stubborn bears just reckless or are they onto something  
The large swings in ICPT are a trader s dream  whether bullish or bearish  The well behaved technical patterns also provide strong trading potential  For example  note how the break below the 50 day moving average  DMA  confirmed the large swoon the week prior that created a failed retest of all time highs  A classic bearish 1 2 combo  I wish I had been paying attention at the time  The bulls got some relief after ICPT retested the lows from January s pop multiple times and each time bounced until July  After THAT failure  the 200DMA held up support  So while I think bears now hold the upper hand again  they still have a lot to prove when  if   ICPT eventually retests these support levels 
I am definitely not one to short this stock  I do not have that kind of capital to put at risk  I prefer options  The bid ask spread on options are understandably wide  so it may not even be possible to trade this stock  safely  and at a reasonable price  If I could play options  I would go for a spread in order to eliminate a lot of the premium paid for the stock s extremely high  implied  volatility  I would go for something like a  210 200 or  220 200   200 appears to be a reasonable first target if buyer exhaustion eventually leads to a break of current support levels  Bulls looking for new entry points should at least wait to see whether they can get a better deal on a 50DMA retest around  245 
 Note  I would have included a review of insider transactions  but Yahoo  Finance does not have them available at this time  
Disclosure  no positions",2014-08-13,Dr. Duru,"https://www.investing.com/analysis/casting-a-wary-eye-on-intercept-pharmaceuticals,-inc.-222476",222476
202041,423557,GILD,Why Gilead Is The Most Exciting Growth Opportunity In 2014 ,opinion,"Introduction
Earnings drive stock price in the long run and Gilead Sciences Inc  Gilead Sciences Inc  NASDAQ GILD   is entering a remarkable period of what could only be called astounding future earnings growth   This has not gone unnoticed by the market  as the stock price has been on a steady ascent for the past several months  
With this article I will offer a comprehensive fundamental review that I believe supports my view that in spite of its recent price run up  Gilead remains a reasonably valued and exciting opportunity for those investors seeking maximum capital appreciation    However  I will qualify this position by stating that my view is long term   In other words  there is always the possibility that current price may retreat over the short run   But  in the long run earnings determine market price and I believe the future earnings potential of Gilead is clear and well defined 
Short Company Description
The following short business description on Gilead Sciences Inc provided courtesy of S P Capital IQ 
 Gilead Sciences  Inc   a research based biopharmaceutical company  is engaged in the discovery  development  and commercialization of medicines in areas of unmet medical need  The company has operations in North and South America  Europe and Asia Pacific  The company s primary areas of focus include human immunodeficiency virus  HIV   liver diseases such as chronic hepatitis B virus  HBV  infection and chronic hepatitis C virus  HCV  infection  oncology inflammation and serious cardiovascular and respiratory conditions   In the liver diseases area  the company received approval from the U S  Food and Drug Administration  FDA  of new drug application  NDA  for Sovaldi  sofosbuvir 400 mg   Sovaldi is a once daily oral nucleotide analog polymerase inhibitor for the treatment of HCV infection as a component of a combination antiviral treatment regimen  The company also received approval of Tybost  cobicistat  and Vitekta  elvitegravir 85 mg and 150 mg   each a component of Stribild  from the European Commission  In the oncology inflammation area  the company filed for FDA and European Medicines Agency  EMA  marketing approval of idelalisib  formerly GS 1101   an investigational  targeted  oral inhibitor of PI3K delta  for the treatment of patients with refractory indolent non Hodgkin s lymphoma  iNHL  and relapsed chronic lymphocytic leukemia  CLL   The company also continued to advanced research and development pipeline  with approximately 200 active clinical studies in 2013  of which approximately 60 were in Phase 3 clinical trials  
Earnings Operating History
Up through 2013 Gilead was a consistently fast growing biotechnology company averaging 42 9  per annum earnings growth   However  as the following graph reveals  earnings growth had significantly slowed down since 2011   This simultaneously led to a very low valuation   On the other hand  the company s stock price went on a rapid ascent in 2013  perhaps in anticipation of what was soon to come 

The following earnings only FAST Graphs  on Gilead Sciences Inc illustrate the dynamic nature of a company s earnings per share growth over different time periods   Earnings growth is a dynamic calculation that varies when graphed from one timeframe to the next   Consequently  it s important to review several timeframes when evaluating a company s historical earnings growth rate   The following 15 calendar year  10 calendar year  7 calendar year and 5 calendar year graphs illustrate that although Gilead s earnings growth has been consistently high over the years  it became explosive for 2014 and beyond  see earnings growth rates circled in yellow    Note  growth rates include all estimates on the graph whether calendar or fiscal year  
Earnings  Operating  History 15 Year

Earnings Operating History 10 Year

Earnings Operating History 7 Year
 
Earnings Operating History 5 Year

Current 15 Year Earnings and Price Correlated FAST Graph  with Normal P E Ratio 

Current 10 Year Earnings and Price Correlated FAST Graph  with Normal P E Ratio 

The key takeaway from the above earnings and price correlated graphs is that Gilead s quantum leap in earnings growth has not yet been fully credited by the market   Consequently  based on earnings expectations the stock appears to represent a compelling long term investment 
15 Year Historical P E Ratio Trend
The dark blue line reflects the fiscal year end P E ratio for Gilead Sciences Inc since 2008  the right scale on the graph    Clearly we see that Gilead s P E Ratio had been consistently dropping due to lower than average earnings growth  and then began rising again in 2012 and 2013   However  the current explosion in earnings growth has once again brought the P E Ratio on Gilead back into attractive valuation levels  

Performance
Historical performance is functionally related to earnings growth achievement and starting valuation   Consequently  when performance is properly measured  it is imperative that starting valuation be considered in conjunction with earnings  and dividends  if any  growth 
A high beginning valuation will reduce capital appreciation  a low beginning valuation will enhance capital appreciation   When a company s beginning valuation is in alignment with earnings  capital appreciation will be highly correlated with the company s earnings growth rate 
15 Year Performance   From Beginning Undervaluation

 7 Year Performance   From Beginning Undervaluation

Earnings Forecasts
The  Estimated Earnings and Return Calculator  provides several specific future year s earnings forecasts   Specific near term earnings forecasts  varies from two to four years  are provided to include the number of analysts reporting to S P Capital IQ  yellow and green highlights    Additionally  a long term  three to five year  growth rate is also provided  orange highlights    The specific number of analysts offering the long term forecast is found in the FAST FACTS box  orange circle   
Therefore  we highly recommend placing more credence on the near term forecasts because they are likely to be more accurate   Moreover  near term forecasts tend to include a greater number of analysts in the consensus 
The graph below reports consensus earnings of  7 99 for fiscal 2014 according to 26 analysts reporting to S P Capital IQ followed by  9 27 for fiscal 2015 according to 27 analysts and  10 00 for fiscal 2016 according to 23 analysts  These near term forecasts for earnings growth indicate that Gilead is extremely undervalued at current levels 

Earnings Yield
Shareholders in publically traded companies  even though they are passive owners  can expect to be rewarded for their investment in proportion to the company s earnings capacity   Consequently  the earnings yield calculated from current and future  expected  earnings represents an important valuation consideration  
Based on consensus estimates for 2014 s earnings  Gilead offers a current earnings yield of 8 3    However  since investors are always buying the future  the potential for high earnings yield is extremely robust  assuming earnings growth continues 

FUNdamentals   A Deeper Look
Utilizing FUN Graphs  fundamental underlying numbers   the following important fundamental metrics and key ratios are offered to provide a deeper look into the company s financial strength and current valuation 
Balance Sheet Income Statement
The following balance sheet items are offered to reveal the financial health of the company   They include assets per share  atps   cash and equivalents per share  cashps  and common equity or book value per share  ceps  
The following income statement item  revenues per share  revps  is offered to reveal the consistency of revenue growth    

Gross and Net Profit Margins

Return on Assets  Equity and Invested Capital

Key Liquidity Ratios
Liquidity is an important consideration when evaluating a business   The primary liquidity ratio that prudent investors look to is the current ratio  cr  
Additionally  the current ratio  cr  measures the company s ability to retire its short term liabilities  debt and payables  with its short term assets  cash  inventory and receivables    This important ratio is often referred to as the liquidity ratio and is a good indicator of a company s ability to remain a going concern   Gilead s current ratio in the most recent quarter  MRQ  was a very healthy 2 5   
Since many investors are concerned about price volatility  we have included five year beta as an additional key ratio   A beta of one or lower is considered ideal relative to risk   On the other hand  a beta above one may also indicate the potential for above market long term performance 

Additional Key Valuation Ratios
Two important valuation ratios that investors consider are price to book value  pb  and price to sales  ps    When considering both of these valuation ratios  the lower the better  

Key Management Shareholder Friendly Metrics
Many investors consider a company s shareholder friendliness based on its dividend policy and or share buyback policy   A consistent record of paying dividends  and better yet  increasing the dividend are considered positive attributes of management  
However  many companies in the growth phase may consider it more profitable to retain their cash to fund growth   Consequently  the lack of a dividend does not necessarily indicate that management is not shareholder friendly 
Regarding share buybacks  they are considered friendly because they are anti dilutive   However  share buybacks should only be considered shareholder friendly when management is buying back shares when stock price is sound or undervalued 

Summary and Conclusions
Investors are often deterred from investing in a stock when its price reaches an all time high as it recently has in Gilead   However  those same investors often fail to recognize that price and valuation are not the same   In the case of Gilead  its current valuation remains quite attractive in spite of its recent price rise because of 2014 s explosive growth of earnings primarily attributed to the recent approval and sales of Sovaldi   However  there are additional pipeline opportunities that suggest future earnings growth to continue  albeit at lower rates than 2014   Consequently  based on valuation  Gilead appears to be a very attractive growth story for at least the next couple of years   In other words  it s not too late 
Moreover  most of the risks associated with Gilead s future earnings power have been reduced based on recent reports and rulings   The following articles from The Wall Street Journal  Barron s and MarketWatch support this view 



 Disclosure   Long GILD at the time of writing 
Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation ",2014-08-17,Chuck Carnevale,https://www.investing.com/analysis/why-gilead-is-the-most-exciting-growth-opportunity-in-2014-222881,222881
202042,423558,GILD,A Surprisingly Great Day,opinion," Your ultimate success or failure will depend on your ability to ignore the worries of the world long enough to allow your investments to succeed     Peter Lynch

A weak day for markets overall but it could have easily been far worse 
Markets stabilized after the opening gap and then slowly rose 
The good news is our stocks are still doing very well with today s best being GoPro Inc  NASDAQ GPRO  up nearly 11  and Mobileye Nv  NYSE MBLY  up over 7  
Not to take anything away from Merrimack Pharmaceuticals Inc  NASDAQ MACK  up over 4  or Avanir Pharmaceuticals Inc  NASDAQ AVNR  up 2 93  
Tableau Software  NYSE DATA  wasn t as good and United Therapeutics Corporation  NASDAQ UTHR  and Gilead Sciences Inc  NASDAQ GILD  were actually down on the day 
I did buy some Rada Electronics Industries Limited  NASDAQ RADA   a very fast mover and so far it is working but not to a huge degree yet 
I had one of the best weekends of the summer  and do need to catch up on a little beauty rest tonight so I ll try to be as short as possible this evening 
It is so nice to get away from all technology and spend a few day with old a new friends alike in a beautiful setting  It should be done more often 

This remains a complex pattern but it could be now morphing into a downward slanting head and shoulders pattern  the most damaging of all head and shoulder patterns So far it looks like a break below 196 would be the short level if it comes to that but it may not So far the 50 day is holding very nicely on a closing basis which is a must I still do think we have to test the 194 area  or the 100 day average but I just have to play it as it comes and not predict and my stocks are doing very well so that is always my main focus ",2014-09-30,Warren Bevan,https://www.investing.com/analysis/a-surprisingly-great-day-227469,227469
202043,423559,GILD,Twitter Results  Outlook Send Stock Down 12 ,opinion,"After the closing bell  Twitter Inc  NYSE TWTR  reported earnings for Q3  coming in at  0 01 and meeting the Wall Street estimate  the first time it hasn t beat since IPO ing last year  Revenues came in stronger than expected at  361M  above the Estimize consensus of  360 7M and the Wall Street consensus of  351 8M  One very important metric  average Monthly Active Users  MAUs  came in at 284M for the quarter  a 23  increase from Q3 2013  and topping last quarter s record of 271M  This is great sign for the company that hopes building a massive user base will help the profits roll in  Twitter projected that Q4 revs will be in the range of  440M    450M  and full year 2014 revenue will be in the range of  1 365B    1 375B  Despite posting decent results  the company s stock price fell 12  in after hours trading on lower than expected user growth and the fact that the revenue guidance for Q4 predicts 80  y o y growth  the first non triple digit increase in 2 years 
Tomorrow  49 companies from the S P 500 will report Q3 earnings  including highly anticipated results from Facebook Inc  NASDAQ FB  and Gilead Sciences Inc  NASDAQ GILD  
How Are We Doing 
Expectations for S P 500 earnings growth for the third quarter stand at 10 1   Revenues are anticipated to come in with 4 2  growth  All 10 sectors are anticipated to post positive YoY growth on both the earnings and revenue front  

Leaders
Earnings 
Materials  14 0    Notable industry  Metals   Mining  27 9   
Health Care  13 1    Notable industry  Biotechnology  45 5  
Energy  12 7    Notable industry  Oil  Gas   Consumable Fuels  11 8  
Revenues 
Health Care  9 3    Notable industry  Biotech  39 8   
Information Technology  7 3    Notable industry  Internet Software   Services  15 2  
Laggards
Earnings 
Utilities  0 8    Notable industry  Multi  Utilities   2 5   
Telecommunication Services  0 9    All five companies are within Diversified Telecom Services  Only Verizon Communications Inc  NYSE VZ  posted y o y growth 
Revenues 
Energy  0 2    Notable industry  Oil  Gas and Consumable Fuels    0 5   
Materials  2 9    Notable industry  Paper   Forest Products    10 9   
Beat Miss Match
Earnings  215 companies have reported thus far  50  have beaten the Estimize consensus  37  have missed and 13  have met  This is compared to Wall Street estimates  of which 69  of companies have beat on the bottom  line  22  have missed and 8  have met 
Revenue  50  have beaten the Estimize consensus  50  have missed  and 0  have met  For revenues  59  of companies have beat the Wall Street estimate  while 41  have missed ",2014-10-28,Estimize,"https://www.investing.com/analysis/twitter-results,-outlook-send-stock-down-12-230455",230455
202051,423567,GILD,Healthcare Earnings  Sector Deep Dive ,opinion,"Last weekend  in our Weekly Earnings Update  we noted the strength in the S P 500 earnings was coming from Technology and Healthcare  Thanks to Gregg Harrison of Thomson Reuters  T R provided us with some color on the HealthCare sector 
Here is the downloadable  detailing the jump in Healthcare earnings over the last 5 weeks  According to Gregg Harrison  most of the increase is due to Gilead Sciences Inc  NASDAQ GILD   the biotech giant that was on fire last year 
According to our charts  Gilead was up over 100  for calendar 2014  Looking at the fundamentals  when GILD reported earnings on April 22nd  the expectation was for  0 91 in EPS and  3 99 billion in revenues  Actual results were  1 48 and  4 99 billion in revenues for actual upside surprises of 64  and 25  respectively  The stock is still trading below its March 25th high of  84 88 too 
Q1  14 S P 500 earnings are coming in stronger than expected  Our expectation was 3    5   but I m guessing that the 5  ceiling will be exceeded by mid June  14 
Growth stocks have been hit hard this year  Small caps  Consumer Discretionary  Biotech  etc   but looking at  a lot of our names that have reported  like a Facebook   NASDAQ FB    the growth is still there   Long FB ",2014-05-07,Brian Gilmartin,https://www.investing.com/analysis/healthcare-earnings:-sector-deep-dive-211871,211871
202052,423568,GILD,Stocks To Consider As AstraZeneca Rejects Pfizer s Final Offer,opinion,"AstraZeneca  NYSE AZN  announced that it has rejected Pfizer s  NYSE PFE   latest takeover proposal  We note that this is the fourth and final proposal made by Pfizer  AstraZeneca stated that the proposal undervalued the company and would be significantly dilutive to its shareholders  Apart from that  AstraZeneca continued to harbor concerns regarding the transaction structure  low proportion of cash  high proportion of Pfizer shares  and risks related to the proposed inversion structure  Pfizer s intention to redomicile to the UK for tax purposes   AstraZeneca was looking at an offer price of close to  58 85 per share  representing a 10  increase from Pfizer s last offer   53 50 per share   However  Pfizer s final proposal valued AstraZeneca at approximately  55 per share 
Pfizer s Final Proposal
On May 18  2014  Pfizer confirmed an improved takeover proposal  The new proposal values AstraZeneca at  55 00  approximately  92 53  per AstraZeneca share  comprising 1 747 shares in the combined entity and 2 476 pence in cash   As per the final proposal  Pfizer and AstraZeneca shareholders would get 74  and 26  of the combined company  respectively    The latest bid represents a premium of approximately 45  to AstraZeneca s closing price of  37 82 on Apr 17  2014 before the takeover rumors started circulating Our Take We note that AstraZeneca has been struggling with a number of patent expiries  Earnings have also seen a declining trend in the past several quarters  For 2014  the company expects core earnings to decline in the teens  Its acid reflux management drug  Nexium  which generated sales of  3 9 billion in 2013  is set to go off patent in late May this year  We still believe that AstraZeneca is an attractive acquisition target based on its pipeline  product portfolio and presence in a number of countries  The company has a number of immune mediated therapies for cancer in the pipeline  Additionally  a number of products including Forxiga and Xigduo  for type II diabetes  and orphan drug Myalept  complications of leptin deficiency  in addition to diet  in patients with congenital generalized or acquired generalized lipodystrophy  have gained approval in recent quarters  AstraZeneca has been focusing on its late stage pipeline and believes that it has aggregate risk adjusted peak year sales potential of approximately  23 billion  The company expects 2017 revenues to be broadly in line with 2013 levels  From 2017 through 2023  AstraZeneca is targeting strong revenue growth  The company aims to achieve revenues higher than  45 billion by 2023  Meanwhile  earnings growth is expected to be greater than revenue growth  benefiting from operating leverage during this period  If we go by these targets  the company should be poised for a turnaround  AstraZeneca and Pfizer currently hold a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector include Allergan  NYSE AGN  and Gilead Sciences Inc   NASDAQ GILD    Both these companies carry a Zacks Rank  1  Strong Buy  ",2014-05-20,Zacks Investment Research,https://www.investing.com/analysis/stocks-to-consider-as-astrazeneca-rejects-pfizer's-final-offer-213352,213352
202066,423582,GILD,U S  Stocks End Near Flat On Fed Stimulus,opinion,U S  stocks finished near even  giving up gains recorded after the Federal Reserve announced additional stimulus measures   The Fed will add  45 billion in Treasury note purchases to its  40 billion a month purchases of mortgage backed bonds  taking the total monthly purchases up to  85 billion  The Fed also said it would keep official rates near zero so long as the jobless rate remains above 6 5  and inflation remains below 2 5    D C  TalksThe stimulus overshadowed evidence that fiscal cliff negotiations have hit a rough patch  A day after a phone conference with President Barack Obama  House Speaker John Boehner said the president s revenue demand would not pass Congress  Obama has cut his demand for  1 6 trillion in additional revenue from taxing the wealthiest Americans to  1 4 trillion over a decade  Obama s offer is still  600 billion above what Republicans are fighting for   In the pre market session  the Commerce Department reported a 0 9  drop in import prices  mainly due to a decrease in energy costs  Economists expected a decline of 0 5   The price of exports  meanwhile  declined by 0 7    Commodities ended mostly higher  Crude oil for January delivery added 1 1  to close at  86 77 a barrel  Gold for February delivery rose   0 5   to settle at  1 717 90 an ounce on the Comex division of the New York Mercantile Exchange   Here s Where The Markets Stood At Day s EndDow Jones Industrial Average down 2 99   0 02   to 13 245 45S P 500 up 0 64   0 04   to 1 428 48Nasdaq Composite Index down 8 49   0 28   to 3 013 81GLOBAL SENTIMENTNikkei 225 Index up 0 58 Hang Seng Index up 0 80 Shanghai China Composite up 0 40 FTSE 100 Index up 0 34 DAX up 0 31 CAC 40 up 0 02 UPSIDE MOVERS    ACAD  Shares jump after company announced a private placement equity financing through which ACAD will receive gross proceeds of  86 4 million from the sale of its securities     YMI  Surges to new 52 week high of  2 92 after the company and Gilead Sciences  GILD  announced a definitive agreement under which Gilead will acquire YMI for  2 95 per share in cash     SWSH  Company announced that after meeting with the NASDAQ Hearings Panel to review its plan of compliance to complete its public filings  the NASDAQ Stock Market has granted its request to remain listed on NASDAQ  subject to meeting specific conditions for continued listing DOWNSIDE MOVERS    CIE  Stock gets hit after company announces it has priced its registered underwritten public offering of  1 2 billion aggregate principal amount of its 2 625  convertible senior notes due 2019     GEOS  Shares tumble after company reports sequential decline in its earnings and revenues due to its erratic order flow and the timing of shipments which is dictated by its customers     NRF  Shares dip after company priced its previously announced underwritten public offering of 25 million shares of common stock at  6 40 per share   2012 MidnightTrader  Inc  All rights reserved ,2012-12-12,Midnight Trader,https://www.investing.com/analysis/u.s.-stocks-end-near-flat-on-fed-stimulus-147287,147287
202067,423583,GILD,3 Biotech Stocks With Falling Inventory Turnover Ratios,opinion,Screen Criteria  All of the Biotech companies mentioned below have have reported falling inventory turnover ratios  Average Weekly Returns  Average 1 Week Return of All Stocks Mentioned Below   1 22  Average 1 Month Return of All Stocks Mentioned Below  8 23  Analysis of List Alpha  Number of Stocks in This List Generating Excess Return vs  SP500  Beta Adjusted Over Last Week   1 out of 3  33 33   Number of Stocks in This List Generating Excess Return vs  SP500  Beta Adjusted Over Last Month   2 out of 3  66 67   Chart  Distribution of 1 Week Returns For All Stocks Mentioned Below Chart  Distribution of 1 Month Returns For All Stocks Mentioned Below1  Albany Molecular Research Inc   AMRI   Provides contract services to various pharmaceutical and biotechnology companies primarily in the United States  Europe  and Asia  Size of inventory grew by 31 90  during the most recent quarter   33 16M vs   25 14M y y   while revenue only increased by 11 03    55 77M vs   50 23M y y   Inventory  as a percentage of current assets  increased from 22 18  to 30 88  during the most recent quarter  time interval comparison 3 months ending 2012 09 30 to 3 months ending 2011 09 30     2  Gilead Sciences Inc   GILD   Engages in the discovery  development  and commercialization of therapeutics for the treatment of life threatening diseases worldwide  Size of inventory grew by 20 90  during the most recent quarter   1 617 37M vs   1 337 75M y y   while revenue only increased by 14 37    2 426 6M vs   2 121 66M y y   Inventory  as a percentage of current assets  increased from 21 76  to 27 5  during the most recent quarter  time interval comparison 3 months ending 2012 09 30 to 3 months ending 2011 09 30     3  CEL SCI Corp   CVM   Engages in the research and development of drugs and vaccines  Size of inventory grew by  13 29  during the most recent quarter   1 37M vs   1 58M y y   while revenue only increased by  50 0    0 04M vs   0 08M y y   Inventory  as a percentage of current assets  increased from 10 15  to 12 4  during the most recent quarter  time interval comparison 3 months ending 2012 06 30 to 3 months ending 2011 06 30  ,2012-12-14,Contextuall,https://www.investing.com/analysis/3-biotech-stocks-with-falling-inventory-turnover-ratios-147584,147584
202068,423584,GILD,QuickView  Gilead Sciences  ,opinion,Investment summary  Oncology adds diversityGilead s  GILD  investment case is understandably focused on its existing HIV franchise   8 1bn sales in FY12   and burgeoning expectations for its hepC portfolio  However  consensus estimates currently attribute little value to Gilead s oncology portfolio  despite the company spending  1 3bn in the last two years to acquire late stage cancer drugs  We therefore view the successful development of idelalisib  acquired through Calistoga for  600m   simtuzumab  Arresto Biosciences for  225m  and CYT387  YM Biosciences for  510m   as well as further potential oncology targets  as an emerging theme in bolstering and diversifying Gilead s offering CYT387 targets myelofibrosis   Gilead s recently completed  510m acquisition of YM adds a potentially unique JAK1 2 inhibitor for myelofibrosis  MF    Phase I II data from 166 patients has shown comparable spleen response activity to other JAK inhibitors  but      a superior benefit on anaemia and transfusion dependency  With Gilead now in contro l we expect a more aggressive strategy for CYT387  posing a greater threat to Incyte s Jakafi  the only marketed JAK inhibitor in this setting  Gilead plans Phase III studies for CYT387 to start in H213  possibly going head to head with Jakafi  while further development for related myeloproliferative disorders  MDS  PV  ET  is also possible    and could complement simtuzumabCYT387 could also prove to be of benefit in combination with simtuzumab  anti LOXL2 MAb   acquired through the  225m purchase of Arresto in 2010  A 54 patient Phase II study of simtuzumab Jakafi in MF is ongoing and results in Q213 could have a bearing on CYT387 plans  Simtuzumab is also in or about to start Phase IIb trials for pancreatic and colon cancers  as well as liver fibrosis  NASH  PSC and IPF Idelalisib leads the PI3K fieldGilead s third key cancer drug  idelalisib  which is a delta inhibitor  was purchased through Calistoga in 2011 for  600m  including milestones   The product  which now is the most advanced agent in development  is in Phase III studies for CLL and iNHL and is  Valuation  Pipeline success required to underpin  68bn EVGilead s EV of  68bn   2 7bn cash   8 4bn debt  compares to a consensus NPV  EvaluatePharma  of  55bn  but this is derived almost entirely from the marketed HIV franchise and late stage hepC portfolio  Successful cancer drug development would add another dimension to Gilead s investment case and help to underpin its EV To Read the Entire Report Please Click on the pdf File Below ,2013-02-14,Edison,https://www.investing.com/analysis/quickview:-gilead-sciences-155243,155243
202078,423594,GILD,Gilead Sciences Inc  Strong Growth At An Unreasonably Low Price ,opinion,Gilead Sciences Inc  GILD  is an innovative healthcare company with a strong record of historical earnings growth and expectations for above average growth into the future  Nevertheless  Mr  Market seems unwilling to recognize the past and future earnings power of this niche pharmaceutical growth stock  Consequently  the company trades at a single digit PE ratio that we believe significantly undervalues both the company s past and future potential  Therefore  investors seeking high growth at a reasonable level of risk might want to look further into this undervalued growth opportunity Growth stocks are defined as companies with high rates of change of earnings growth of 15  to 20  or better  Growth stocks offer the potential for share prices to rise in lockstep with their profit growth in the long run  Therefore  the PEG ratio formula  price equals growth rate  tends to be the most appropriate formula used to value growth stocks  However  due to the exponential nature of compounding large numbers  PEG ratio forecasts are capped at 40  Because of the higher valuation typically awarded to fast growth  growth stocks offer the potential for greater capital appreciation  On the other hand  they also offer higher risk  First of all  they tend to command much higher than average PE ratios  and second  achieving very high levels of growth is very difficult to sustain  Consequently  forecasting future earnings growth is more important with high growth stocks than any other class of stock  Also  the average growth stock typically ploughs all of its profits back into the company to fund its future growth  instead of paying dividends Gilead Sciences Inc   Large cap Growth at an Attractive PriceGilead Sciences is a biopharmaceutical company that discovers  develops and commercializes innovative therapeutics in areas of unmet medical need  The company s mission is to advance the care of patients suffering from life threatening diseases worldwide  Headquartered in Foster City  California  Gilead has operations in North America  Europe and Asia Pacific     Earnings Determine Market Price   The following earnings and price correlated  clearly illustrates the importance of earnings  The Earnings Growth Rate Line or True Worth  Line  orange line with white triangles  is correlated with the historical stock price line  On graph after graph the lines will move in tandem  If the stock price strays away from the earnings line  over or under   inevitably it will come back to earnings  Here is a link to a live and fully functioning graph on   We suggest running graphs over numerous time frames as part of a more comprehensive fundamental analysis    Gilead Sciences Inc   Historical Earnings  Price  Dividends and Normal PE Since 2004  Performance Table Gilead Sciences IncThe Two Keys to Long Term PerformanceYears of research and experience have taught us that there are two critically important keys to achieving above average  long term shareholder returns at reasonably controlled levels of risk  The first key is earnings growth  or what we like to call the rate of change of earnings growth  The faster a company can grow its business  i e  earnings   the larger the income stream it can produce with which to reward shareholders  This is because of the power of compounding  which Albert Einstein was alleged to have called  the most powerful force on earth   Ultimately  both capital appreciation and dividend income will be a function of a company s ability to grow its profits The second key is valuation  When a company can be purchased at its intrinsic value based on earnings and cash flow generation  the shareholders  rate of return or long term capital appreciation will inevitably correlate to and or equal its earnings growth rate  Overvaluation will lower that rate of return and conversely  undervaluation will increase it  Consequently  paying strict attention to the valuation you pay to buy a stock is a critical component of both greater return and taking lower risk to achieve it  Because  ironically  when you overpay for even the best business  you simultaneously lower your return potential while increasing your risk of achieving the lower return The associated performance results with the earnings and price correlated graph  validates the above discussion regarding the two keys to long term performance  Notice the impact that valuation  black line above or below orange earnings justified valuation line  had on the following performance results  The following graph plots the historically normal PE ratio  the dark blue line  correlated with 10 year Treasury note interest  Notice that the current price earnings ratio on this quality company is as low as it has been since 2004 A further indication of valuation can be seen by examining a company s current price to sales ratio relative to its historical price to sales ratio   The current price to sales ratio for Gilead Sciences Inc is 4 33 which is historically low  Looking to the Future   Extensive research has provided a preponderance of conclusive evidence that future long term returns are a function of two critical determinants    1            The rate of change  growth rate  of the company s earnings   2            The price or valuation you pay to buy those earnings   Forecasting future earnings growth  bought at sound valuations  is the key to safe  sound  and profitable performance    Therefore  it logically follows that measuring performance without simultaneously measuring valuation is a job half done  Gilead Sciences Inc is clearly an industry leading superior business  which based on the consensus estimates from leading analysts  appears to be capable of growing earnings at an above average rate for the foreseeable future  At its current price  which is attractively aligned with its True Worth  valuation  Gilead Sciences Inc represents an opportunity for growth at a reasonable price  The important factor is that Gilead Sciences Inc  with its strong balance sheet and potential for future earnings growth  has real assets and cash flow underpinning its stock price  This solid economic foundation offers shareholders the potential for both a strong margin of safety and an opportunity for outsized future returns    The Estimated Earnings and Return Calculator Tool is a simple yet powerful resource that empowers the user to calculate and run various investing scenarios that generate precise rate of return potentialities  Thinking the investment through to its logical conclusion is an important component towards making sound and prudent commonsense investing decisions    The consensus of 28 leading analysts reporting to Capital IQ forecast Gilead Sciences Inc s long term earnings growth at 17   Gilead Sciences Inc has medium long term debt at 53  of capital  Gilead Sciences Inc is currently trading at a P E of 13 4  which is below the value corridor  defined by the five orange lines  of a maximum P E of 20 4  If the earnings materialize as forecast  Gilead Sciences Inc s True Worth  valuation would be  139 05 at the end of 2017  which would be a 20  annual rate of return from the current price  Earnings Yield EstimatesDiscounted Future Cash Flows   All companies derive their value from the future cash flows  earnings  they are capable of generating for their stake holders over time  Therefore  because Earnings Determine Market Price in the long run  we expect the future earnings of a company to justify the price we pay Since all investments potentially compete with all other investments  it is useful to compare investing in any perspective company to that of a comparable investment in low risk Treasury bonds  Comparing an investment in Gilead Sciences Inc to an equal investment in 10 year Treasury bonds  illustrates that Gilead Sciences Inc s expected earnings would be 9 7 times that of the 10 Year T Bond Interest   See EYE chart below   This is the essence of the importance of proper valuation as a critical investing component Summary   ConclusionsThis report presented essential  fundamentals at a glance  illustrating the past and present valuation based on earnings achievements as reported  Future forecasts for earnings growth are based on the consensus of leading analysts  Although  with just a quick glance you can know a lot about the company  it s imperative that the reader conducts their own due diligence in order to validate whether the consensus estimates seem reasonable or not At its current quotation  Gilead Sciences Inc appears to offer significant upside based on several factors  First of all  the company is trading at a below average PE ratio even though it offers above average growth  Therefore  the aggressive investor could be rewarded with significant PE expansion in addition to above average growth  Furthermore  since the stock is trading art a single digit PE ratio  we believe there is little downside assuming the company s fundamentals do not significant deteriorate  Therefore  this may be an ideal research candidate for the aggressive investor seeking maximum capital appreciation at controlled levels of risk  Disclosure   No position at the time of writing Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation  A comprehensive due diligence effort is recommended ,2012-05-22,F.A.S.T. Graphs,https://www.investing.com/analysis/gilead-sciences-inc:-strong-growth-at-an-unreasonably-low-price-123915,123915
202079,423595,GILD,Gilead Sciences Is Breaking Out Of A 6 Month Consolidation,opinion,Gilead Sciences  Inc  GILD    a large cap bio pharmaceutical company is known for its vast product portfolio for the treatment of human immunodeficiency virus  HIV   After the recent failure of Bristol Myers Squibb s experimental hepatitis C drug INX189 it seems that Gilead becomes a lider in developing an  all oral  combo of Hep C drugs with its promising experimental drug GS7977 After the December January rally  the GILD stock price entered into a 6 month consolidation phase  A pattern formed during this phase resembles a Cup And Handle pattern  blue   Though it doesn t look like an ideal pattern  two breakouts through the previous highs have occurred on increased volume  green arrows  confirming that the consolidation period might be over Following the breakout through the February high the price formed a well defined bullish pennant  magenta   The pennant was stopped at the breakout level and the price moved higher today  A potential price target from a consolidation pattern measured from the depth of the pattern   12  and added to the point of a breakout gives us the 66 area  Now let s take a look at the GILD short term P F chart with the 30 min period and 0 25 pts box  box size is adjusted to intrinsic volatility of the security within a determined time period   Before today s action a Bearish Pattern Reversed with lower lows and lower highs was formed  green lines  on this short term chart  That is how the pennant on the GILD daily chart looks on the short term P F chart  Today the price formed a new column of Xs  light blue boxes  which rose past the previous column of Xs and gave a new short term buy signal  magenta line   My  buy limit  order was triggered and filled upon this signal  Disclaimer  I express only my personal opinion on the market and do not provide any trading or financial advice  see  on my site  ,2012-08-15,Igor Rakhmanov,https://www.investing.com/analysis/gilead-sciences-is-breaking-out-of-a-6-month-consolidation-133021,133021
